data_2kx4_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 2kx4 _Structure_validation_residue.Date_analyzed 2016-10-07 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 25' ' ' THR . . . . . 0.413 ' CB ' ' HB ' ' A' ' 42' ' ' VAL . 11.7 m . . . . . 0 C--O 1.232 0.15 0 CA-C-O 120.765 0.317 . . . . 99.99 111.237 . . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -71.95 122.45 20.85 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.286 -0.415 . . . . 99.99 110.842 -179.836 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 27' ' ' ALA . . . . . 0.52 ' CB ' HG21 ' A' ' 39' ' ' ILE . . . -141.95 162.18 36.13 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.09 -0.505 . . . . 99.99 111.134 179.904 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 21.2 m -129.99 87.95 2.59 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.224 -0.444 . . . . 99.99 111.143 -179.918 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . 0.641 HG21 HG22 ' A' ' 39' ' ' ILE . 2.3 pt -45.15 130.9 1.97 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.277 -0.419 . . . . 99.99 111.08 179.931 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 19.8 m -153.14 97.51 2.19 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.133 -0.485 . . . . 99.99 111.155 179.974 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 8.5 t -135.1 70.86 1.43 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.213 -0.449 . . . . 99.99 110.829 -179.858 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -178.95 167.92 38.47 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.76 -0.733 . . . . 99.99 112.449 179.984 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 4.1 pt-20 -49.12 -23.36 1.22 Allowed 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.828 0.346 . . . . 99.99 110.89 -179.878 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 9.6 tt0 -174.44 94.64 0.08 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.129 -0.487 . . . . 99.99 110.879 -179.938 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -144.9 165.49 27.98 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.992 0.425 . . . . 99.99 110.832 -179.831 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 178.17 87.84 0.07 OUTLIER Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.752 -0.737 . . . . 99.99 112.48 -179.97 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -107.06 -170.67 1.75 Allowed 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.881 0.372 . . . . 99.99 111.087 179.984 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 4.1 p -99.15 120.74 48.9 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.227 -0.442 . . . . 99.99 111.185 179.913 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 39' ' ' ILE . . . . . 0.641 HG22 HG21 ' A' ' 29' ' ' ILE . 0.0 OUTLIER -137.85 148.69 25.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.199 -0.455 . . . . 99.99 111.106 179.951 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 40' ' ' ARG . . . . . 0.402 ' HA ' ' O ' ' A' ' 25' ' ' THR . 18.5 mtt180 -109.66 80.76 1.35 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.189 -0.459 . . . . 99.99 110.887 179.9 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . 0.497 ' H ' ' HB1' ' A' ' 27' ' ' ALA . . . -128.71 148.9 18.21 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.738 -0.744 . . . . 99.99 112.454 -179.928 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 42' ' ' VAL . . . . . 0.504 ' O ' ' HA ' ' A' ' 65' ' ' LEU . 3.4 p -127.16 135.04 64.64 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-O 120.851 0.357 . . . . 99.99 111.102 179.972 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 43' ' ' PHE . . . . . 0.476 ' HA ' ' O ' ' A' ' 64' ' ' SER . 3.2 p90 -92.84 128.2 38.62 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.134 -0.485 . . . . 99.99 110.915 179.945 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 46.8 m-20 -114.88 124.52 51.93 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 116.133 -0.485 . . . . 99.99 110.861 179.944 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--N 1.329 -0.314 0 CA-C-O 121.624 0.726 . . . . 99.99 110.854 179.95 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 63' ' ' PRO . . . . . 0.409 ' O ' ' HA ' ' A' ' 104' ' ' TRP . 54.2 Cg_endo . . . . . 0 C--O 1.231 0.159 0 CA-C-O 120.775 0.24 . . . . 99.99 112.354 . . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 64' ' ' SER . . . . . 0.476 ' O ' ' HA ' ' A' ' 43' ' ' PHE . 2.2 t -106.46 146.8 30.1 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.271 -0.422 . . . . 99.99 110.821 -179.879 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 65' ' ' LEU . . . . . 0.568 ' O ' ' HA ' ' A' ' 102' ' ' HIS . 0.2 OUTLIER -113.36 123.66 50.63 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.07 -0.513 . . . . 99.99 110.899 -179.989 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 15.2 t80 -102.48 110.87 22.94 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.185 -0.461 . . . . 99.99 110.873 179.956 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -140.99 168.73 15.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.193 -0.458 . . . . 99.99 111.237 179.954 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 8.9 ttm180 -98.36 143.18 29.1 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.202 -0.454 . . . . 99.99 110.8 -179.935 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -41.17 -44.51 2.58 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.156 -0.475 . . . . 99.99 111.172 -179.932 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 29.0 m-20 -65.69 -52.64 49.92 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.236 -0.438 . . . . 99.99 110.891 179.888 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 71' ' ' GLU . . . . . . . . . . . . . 2.1 mm-40 -55.0 -39.49 69.1 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.22 -0.445 . . . . 99.99 110.906 -179.947 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 11.1 p -82.6 -22.13 9.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.132 -0.485 . . . . 99.99 111.075 -179.993 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 73' ' ' ARG . . . . . . . . . . . . . 1.5 tmt_? -67.59 -41.52 83.95 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.194 -0.457 . . . . 99.99 110.869 179.984 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 59.1 mt-30 -57.78 -20.45 35.45 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.198 -0.456 . . . . 99.99 110.969 -179.957 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 5.8 mp -104.95 -175.87 2.92 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.199 -0.455 . . . . 99.99 110.899 -179.999 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 76' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -111.76 -179.45 3.7 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.197 -0.456 . . . . 99.99 110.937 179.944 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -81.21 116.25 21.01 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.225 -0.443 . . . . 99.99 110.888 -179.913 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 107.92 20.14 8.61 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.77 -0.729 . . . . 99.99 112.453 -179.991 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -84.41 111.58 19.58 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.881 0.372 . . . . 99.99 110.886 179.996 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 80' ' ' THR . . . . . 0.698 ' HA ' ' HA ' ' A' ' 89' ' ' TRP . 0.0 OUTLIER -86.62 111.6 20.8 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.198 -0.455 . . . . 99.99 111.148 -179.91 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 81' ' ' LEU . . . . . 0.744 ' C ' ' HA ' ' A' ' 87' ' ' ASN . 0.3 OUTLIER -97.22 131.82 43.58 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.194 -0.457 . . . . 99.99 110.921 179.917 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 82' ' ' THR . . . . . 0.747 ' CA ' ' HA ' ' A' ' 87' ' ' ASN . 2.4 t -92.48 101.42 13.87 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.13 -0.486 . . . . 99.99 111.156 179.946 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 83' ' ' ILE . . . . . 0.432 ' CG2' ' CB ' ' A' ' 27' ' ' ALA . 0.1 OUTLIER -137.24 131.84 45.67 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.282 -0.417 . . . . 99.99 111.081 179.979 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 74.9 -53.86 2.56 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.7 -0.762 . . . . 99.99 112.537 179.929 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 85' ' ' GLU . . . . . 0.404 ' C ' ' HG3' ' A' ' 86' ' ' GLU . 84.5 tt0 -117.94 -81.31 0.62 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.766 0.317 . . . . 99.99 110.879 -179.951 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 86' ' ' GLU . . . . . 0.429 ' C ' ' HA ' ' A' ' 82' ' ' THR . 61.7 mt-10 -149.35 161.4 42.13 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.233 -0.439 . . . . 99.99 110.931 -179.903 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 87' ' ' ASN . . . . . 0.747 ' HA ' ' CA ' ' A' ' 82' ' ' THR . 13.0 p30 -51.92 123.99 11.66 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.188 -0.46 . . . . 99.99 110.877 -179.932 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 88' ' ' PHE . . . . . 0.583 ' HB2' HD23 ' A' ' 105' ' ' LEU . 14.3 m-85 -132.2 118.18 19.21 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.184 -0.462 . . . . 99.99 110.869 -179.957 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 89' ' ' TRP . . . . . 0.698 ' HA ' ' HA ' ' A' ' 80' ' ' THR . 64.0 p-90 -82.15 135.35 35.3 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.185 -0.461 . . . . 99.99 110.922 -179.963 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 90' ' ' VAL . . . . . 0.486 ' HA ' ' HB3' ' A' ' 105' ' ' LEU . 0.4 OUTLIER -92.88 139.58 17.8 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.257 -0.429 . . . . 99.99 111.163 179.893 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 91' ' ' ASP . . . . . 0.476 ' CB ' HD11 ' A' ' 103' ' ' LEU . 0.5 OUTLIER -62.71 -71.0 0.17 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.183 -0.462 . . . . 99.99 110.89 179.867 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 92' ' ' ARG . . . . . 0.554 ' O ' ' HG ' ' A' ' 103' ' ' LEU . 7.0 mtm180 -159.9 120.89 3.1 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.172 -0.467 . . . . 99.99 110.894 -179.878 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 93' ' ' VAL . . . . . 0.417 ' HB ' ' CB ' ' A' ' 101' ' ' CYS . 17.4 m -112.51 135.43 51.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.197 -0.456 . . . . 99.99 111.164 179.942 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 2.1 m -130.22 101.62 17.69 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-O 121.661 0.743 . . . . 99.99 110.827 -179.811 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.74 177.27 5.74 Favored 'Trans proline' 0 C--N 1.341 0.155 0 C-N-CA 122.682 2.254 . . . . 99.99 112.319 179.977 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 37.2 t70 . . . . . 0 C--N 1.329 -0.31 0 CA-C-N 116.203 -0.453 . . . . 99.99 110.848 179.928 . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 1.7 m . . . . . 0 C--O 1.232 0.158 0 CA-C-O 120.922 0.392 . . . . 99.99 110.881 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 101' ' ' CYS . . . . . 0.417 ' CB ' ' HB ' ' A' ' 93' ' ' VAL . 0.0 OUTLIER -105.02 148.38 26.82 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.104 -0.498 . . . . 99.99 110.87 -179.996 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 102' ' ' HIS . . . . . 0.568 ' HA ' ' O ' ' A' ' 65' ' ' LEU . 6.7 p80 -157.65 123.69 4.74 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.142 -0.481 . . . . 99.99 110.865 -179.947 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 103' ' ' LEU . . . . . 0.554 ' HG ' ' O ' ' A' ' 92' ' ' ARG . 2.4 tm? -151.53 146.73 26.09 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.256 -0.429 . . . . 99.99 110.959 -180.0 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 104' ' ' TRP . . . . . 0.446 ' N ' ' CD1' ' A' ' 103' ' ' LEU . 30.4 p90 -65.81 110.52 2.87 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.15 -0.477 . . . . 99.99 110.928 179.937 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 105' ' ' LEU . . . . . 0.583 HD23 ' HB2' ' A' ' 88' ' ' PHE . 0.4 OUTLIER -91.23 161.84 14.89 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.169 -0.469 . . . . 99.99 110.944 179.99 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -89.43 159.52 28.5 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.692 -0.766 . . . . 99.99 112.477 179.911 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 107' ' ' ARG . . . . . 0.562 ' HA ' ' CD1' ' A' ' 88' ' ' PHE . 0.4 OUTLIER -69.33 158.47 34.99 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.845 0.355 . . . . 99.99 110.863 -179.83 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -174.56 111.12 0.35 Allowed Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.758 -0.734 . . . . 99.99 112.525 -179.969 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 10.6 t -100.23 132.44 22.6 Favored Pre-proline 0 C--N 1.33 -0.251 0 CA-C-O 121.632 0.729 . . . . 99.99 111.15 -179.961 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 110' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo . . . . . 0 C--N 1.341 0.161 0 C-N-CA 122.718 2.279 . . . . 99.99 112.335 179.955 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 25' ' ' THR . . . . . 0.423 ' O ' ' HA ' ' A' ' 40' ' ' ARG . 9.6 m . . . . . 0 C--O 1.232 0.138 0 CA-C-O 120.816 0.341 . . . . 99.99 111.218 . . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 7.7 m -72.39 122.37 21.08 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.287 -0.415 . . . . 99.99 110.818 -179.833 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 27' ' ' ALA . . . . . 0.522 ' CB ' HG21 ' A' ' 39' ' ' ILE . . . -143.06 162.37 35.7 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.109 -0.496 . . . . 99.99 111.133 179.831 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 28' ' ' THR . . . . . 0.463 ' O ' HG22 ' A' ' 82' ' ' THR . 18.0 m -129.86 88.17 2.63 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.243 -0.435 . . . . 99.99 111.155 -179.846 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . 0.643 HG22 HG22 ' A' ' 39' ' ' ILE . 2.1 pt -43.87 131.08 1.39 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.19 -0.459 . . . . 99.99 111.162 179.978 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 11.3 m -152.98 97.33 2.19 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.229 -0.441 . . . . 99.99 111.183 -179.998 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 86.3 p -135.96 70.79 1.42 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.193 -0.458 . . . . 99.99 110.945 -179.867 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -179.29 167.52 37.65 Favored Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.72 -0.752 . . . . 99.99 112.499 -179.982 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 16.8 pt-20 -48.95 -23.43 1.12 Allowed 'General case' 0 C--N 1.33 -0.283 0 CA-C-O 120.856 0.36 . . . . 99.99 110.885 -179.9 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -174.06 94.63 0.09 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.155 -0.475 . . . . 99.99 110.954 -179.937 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 2.9 m -145.23 165.45 28.35 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.191 -0.459 . . . . 99.99 110.81 -179.783 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 177.8 88.5 0.07 OUTLIER Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.799 -0.715 . . . . 99.99 112.52 -179.923 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -108.43 -170.75 1.73 Allowed 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 120.893 0.378 . . . . 99.99 111.078 179.977 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 64.6 t -98.57 120.23 47.63 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-N 116.211 -0.449 . . . . 99.99 111.146 179.958 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 39' ' ' ILE . . . . . 0.643 HG22 HG22 ' A' ' 29' ' ' ILE . 0.0 OUTLIER -137.08 149.93 26.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.177 -0.465 . . . . 99.99 111.124 179.956 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 40' ' ' ARG . . . . . 0.423 ' HA ' ' O ' ' A' ' 25' ' ' THR . 19.3 mtt85 -109.46 80.47 1.32 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.213 -0.448 . . . . 99.99 110.849 179.934 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . 0.504 ' H ' ' HB2' ' A' ' 27' ' ' ALA . . . -127.47 147.93 17.29 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.797 -0.716 . . . . 99.99 112.527 179.998 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 42' ' ' VAL . . . . . 0.417 ' HB ' ' CB ' ' A' ' 25' ' ' THR . 3.1 p -127.19 138.86 53.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-O 120.851 0.358 . . . . 99.99 111.126 -179.942 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 43' ' ' PHE . . . . . 0.479 ' HA ' ' O ' ' A' ' 64' ' ' SER . 2.8 p90 -101.05 128.71 46.98 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.166 -0.47 . . . . 99.99 110.873 -179.982 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 1.5 t0 -104.38 124.67 49.63 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.106 -0.497 . . . . 99.99 110.835 179.956 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 C--N 1.328 -0.356 0 CA-C-O 121.608 0.718 . . . . 99.99 110.88 179.97 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_endo . . . . . 0 C--O 1.231 0.169 0 CA-C-O 120.779 0.241 . . . . 99.99 112.315 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 64' ' ' SER . . . . . 0.479 ' O ' ' HA ' ' A' ' 43' ' ' PHE . 0.2 OUTLIER -107.02 146.38 31.2 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.228 -0.442 . . . . 99.99 110.894 -179.891 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 65' ' ' LEU . . . . . 0.511 ' HB2' ' HG ' ' A' ' 105' ' ' LEU . 2.7 tm? -114.93 131.48 56.87 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.126 -0.488 . . . . 99.99 110.919 -179.957 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 66' ' ' PHE . . . . . 0.418 ' C ' HG13 ' A' ' 67' ' ' VAL . 1.2 t80 -120.38 106.17 11.59 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.261 -0.427 . . . . 99.99 110.846 179.951 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 67' ' ' VAL . . . . . 0.418 HG13 ' C ' ' A' ' 66' ' ' PHE . 23.2 m -144.69 172.71 5.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.167 -0.469 . . . . 99.99 111.148 179.921 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 1.4 ttt180 -105.62 143.48 33.71 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.128 -0.487 . . . . 99.99 110.896 -179.992 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 69' ' ' THR . . . . . 0.408 ' HB ' ' HG3' ' A' ' 95' ' ' PRO . 0.0 OUTLIER -41.17 -49.4 3.53 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.168 -0.469 . . . . 99.99 111.135 -179.908 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 14.8 t70 -53.39 -51.29 63.01 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.231 -0.44 . . . . 99.99 110.862 179.918 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 71' ' ' GLU . . . . . . . . . . . . . 31.2 mt-10 -53.3 -39.07 63.71 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.164 -0.471 . . . . 99.99 110.905 -179.932 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 3.3 t -78.6 -32.43 16.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.156 -0.474 . . . . 99.99 111.148 179.952 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 73' ' ' ARG . . . . . . . . . . . . . 1.8 tmt_? -57.32 -39.18 75.3 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.149 -0.478 . . . . 99.99 110.841 -179.94 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 39.9 mt-30 -56.22 -22.02 26.86 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.188 -0.46 . . . . 99.99 110.87 -179.897 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 2.3 mp -119.23 -165.29 1.13 Allowed 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.252 -0.431 . . . . 99.99 110.918 -180.0 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 76' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -116.15 171.94 7.49 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.219 -0.446 . . . . 99.99 110.86 179.969 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -62.41 132.05 51.26 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.174 -0.466 . . . . 99.99 110.899 -179.917 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 92.5 18.11 43.03 Favored Glycine 0 N--CA 1.452 -0.252 0 C-N-CA 120.746 -0.74 . . . . 99.99 112.477 179.998 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -74.23 106.33 5.82 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.883 0.373 . . . . 99.99 110.896 -179.976 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 80' ' ' THR . . . . . 0.703 ' HA ' ' HA ' ' A' ' 89' ' ' TRP . 0.6 OUTLIER -85.78 109.14 18.44 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.185 -0.461 . . . . 99.99 111.155 -179.857 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 81' ' ' LEU . . . . . 0.745 ' C ' ' HA ' ' A' ' 87' ' ' ASN . 0.3 OUTLIER -97.07 133.11 42.16 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.188 -0.46 . . . . 99.99 110.9 -179.992 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 82' ' ' THR . . . . . 0.737 ' CA ' ' HA ' ' A' ' 87' ' ' ASN . 9.8 t -93.51 102.27 14.48 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.193 -0.458 . . . . 99.99 111.123 179.949 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 83' ' ' ILE . . . . . 0.43 ' CG2' ' CB ' ' A' ' 27' ' ' ALA . 0.1 OUTLIER -138.46 131.78 40.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.208 -0.451 . . . . 99.99 111.147 179.882 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 74.43 -50.51 2.08 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.663 -0.779 . . . . 99.99 112.548 179.96 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 11.4 mm-40 -119.77 -80.68 0.62 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.831 0.348 . . . . 99.99 110.929 -179.885 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 86' ' ' GLU . . . . . 0.458 ' C ' ' HA ' ' A' ' 82' ' ' THR . 69.0 mt-10 -153.01 161.29 42.71 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.143 -0.48 . . . . 99.99 110.901 -179.908 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 87' ' ' ASN . . . . . 0.745 ' HA ' ' C ' ' A' ' 81' ' ' LEU . 1.6 p30 -49.59 122.15 5.99 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.198 -0.455 . . . . 99.99 110.871 -179.99 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 88' ' ' PHE . . . . . 0.547 ' C ' ' HA ' ' A' ' 80' ' ' THR . 15.9 m-85 -131.83 120.01 22.02 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.196 -0.457 . . . . 99.99 110.859 -179.96 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 89' ' ' TRP . . . . . 0.703 ' HA ' ' HA ' ' A' ' 80' ' ' THR . 59.9 p-90 -83.94 136.79 33.94 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.226 -0.443 . . . . 99.99 110.869 -179.972 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 90' ' ' VAL . . . . . 0.411 ' HA ' ' HB3' ' A' ' 105' ' ' LEU . 10.1 p -86.92 138.75 18.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.246 -0.434 . . . . 99.99 111.074 179.966 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 91' ' ' ASP . . . . . 0.496 ' CB ' HD23 ' A' ' 103' ' ' LEU . 0.7 OUTLIER -70.15 -41.78 73.39 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.177 -0.465 . . . . 99.99 110.76 179.934 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 92' ' ' ARG . . . . . 0.441 ' O ' ' CB ' ' A' ' 103' ' ' LEU . 20.0 tpp180 -160.26 138.59 10.16 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.265 -0.425 . . . . 99.99 110.912 -179.826 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 93' ' ' VAL . . . . . 0.406 ' CB ' ' HB2' ' A' ' 101' ' ' CYS . 0.0 OUTLIER -126.81 111.9 27.41 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.258 -0.428 . . . . 99.99 111.148 179.936 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 4.0 t -127.25 109.35 21.4 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-O 121.694 0.759 . . . . 99.99 110.88 -179.914 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 95' ' ' PRO . . . . . 0.408 ' HG3' ' HB ' ' A' ' 69' ' ' THR . 53.3 Cg_endo -69.77 156.64 62.8 Favored 'Trans proline' 0 C--O 1.232 0.18 0 C-N-CA 122.649 2.232 . . . . 99.99 112.356 179.983 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 44.4 m-20 . . . . . 0 C--N 1.329 -0.322 0 CA-C-N 116.187 -0.46 . . . . 99.99 110.873 179.911 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 C--O 1.232 0.14 0 CA-C-O 120.832 0.349 . . . . 99.99 110.881 . . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 101' ' ' CYS . . . . . 0.406 ' HB2' ' CB ' ' A' ' 93' ' ' VAL . 1.6 p -42.37 142.85 0.71 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.145 -0.479 . . . . 99.99 110.868 -179.99 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 102' ' ' HIS . . . . . 0.484 ' HA ' ' O ' ' A' ' 65' ' ' LEU . 46.1 p-80 -161.2 125.55 3.47 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.188 -0.46 . . . . 99.99 110.87 -179.944 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 103' ' ' LEU . . . . . 0.496 HD23 ' CB ' ' A' ' 91' ' ' ASP . 9.8 tt -152.04 155.85 38.77 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.201 -0.454 . . . . 99.99 110.873 -179.993 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 104' ' ' TRP . . . . . . . . . . . . . 50.2 p-90 -66.23 112.0 3.74 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.136 -0.484 . . . . 99.99 110.981 179.865 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 105' ' ' LEU . . . . . 0.511 ' HG ' ' HB2' ' A' ' 65' ' ' LEU . 0.3 OUTLIER -87.58 162.24 17.29 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.319 -0.4 . . . . 99.99 110.934 -179.983 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -88.36 160.43 30.54 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.724 -0.75 . . . . 99.99 112.53 179.894 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 107' ' ' ARG . . . . . 0.509 ' HA ' ' CD1' ' A' ' 88' ' ' PHE . 2.5 ptm180 -68.89 158.46 34.5 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.799 0.333 . . . . 99.99 110.845 -179.816 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -173.64 106.79 0.23 Allowed Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.694 -0.765 . . . . 99.99 112.436 -179.966 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 8.7 p -91.04 134.01 30.9 Favored Pre-proline 0 C--N 1.33 -0.275 0 CA-C-O 121.644 0.735 . . . . 99.99 111.103 180.0 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 110' ' ' PRO . . . . . 0.505 ' N ' HD22 ' A' ' 87' ' ' ASN . 53.9 Cg_endo . . . . . 0 C--N 1.341 0.153 0 C-N-CA 122.659 2.239 . . . . 99.99 112.358 179.929 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 25' ' ' THR . . . . . . . . . . . . . 85.8 m . . . . . 0 N--CA 1.457 -0.115 0 CA-C-O 120.829 0.347 . . . . 99.99 111.147 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -71.41 123.17 21.76 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.212 -0.449 . . . . 99.99 110.898 -179.861 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 27' ' ' ALA . . . . . 0.549 ' CB ' HG21 ' A' ' 39' ' ' ILE . . . -140.03 162.74 34.5 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.122 -0.49 . . . . 99.99 111.113 179.921 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 16.9 m -129.6 88.54 2.7 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.246 -0.434 . . . . 99.99 111.116 -179.913 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . 0.651 HG22 HG22 ' A' ' 39' ' ' ILE . 2.0 pt -45.12 129.75 1.83 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.385 0 CA-C-N 116.264 -0.425 . . . . 99.99 111.123 179.876 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 7.0 m -152.97 98.53 2.32 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.24 -0.437 . . . . 99.99 111.179 179.917 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 12.1 t -138.38 71.11 1.39 Allowed 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.246 -0.434 . . . . 99.99 110.817 -179.854 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -178.72 168.17 38.99 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.751 -0.738 . . . . 99.99 112.508 179.959 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 15.4 pt-20 -49.38 -23.46 1.49 Allowed 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.781 0.324 . . . . 99.99 110.835 -179.844 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 4.8 tt0 -174.68 94.84 0.08 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.166 -0.47 . . . . 99.99 110.907 -179.916 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 3.3 m -144.97 165.71 27.4 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.214 -0.448 . . . . 99.99 110.891 -179.834 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 178.35 88.21 0.07 OUTLIER Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.811 -0.709 . . . . 99.99 112.505 -179.977 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -109.6 -172.81 2.12 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.849 0.357 . . . . 99.99 111.088 -179.984 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 61.9 t -97.75 121.9 48.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.238 -0.437 . . . . 99.99 111.123 179.962 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 39' ' ' ILE . . . . . 0.651 HG22 HG22 ' A' ' 29' ' ' ILE . 0.0 OUTLIER -137.62 150.12 25.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.126 -0.488 . . . . 99.99 111.157 179.898 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 40' ' ' ARG . . . . . . . . . . . . . 5.4 ttm180 -109.69 80.3 1.3 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.24 -0.436 . . . . 99.99 110.873 179.987 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . 0.5 ' N ' HD13 ' A' ' 39' ' ' ILE . . . -129.18 147.44 17.75 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.774 -0.727 . . . . 99.99 112.46 -179.955 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 42' ' ' VAL . . . . . 0.573 ' O ' ' HA ' ' A' ' 65' ' ' LEU . 2.8 p -126.49 136.59 60.37 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-O 120.845 0.355 . . . . 99.99 111.072 -179.971 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 43' ' ' PHE . . . . . 0.49 ' HA ' ' O ' ' A' ' 64' ' ' SER . 1.3 p90 -93.72 130.77 39.57 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.218 -0.446 . . . . 99.99 110.872 179.96 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 12.6 t70 -117.04 124.76 50.08 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.121 -0.49 . . . . 99.99 110.87 179.956 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 C--N 1.328 -0.327 0 CA-C-O 121.575 0.702 . . . . 99.99 110.877 179.999 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_endo . . . . . 0 C--O 1.232 0.181 0 CA-C-O 120.841 0.267 . . . . 99.99 112.315 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 64' ' ' SER . . . . . 0.49 ' O ' ' HA ' ' A' ' 43' ' ' PHE . 1.5 t -106.32 148.15 28.36 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.222 -0.444 . . . . 99.99 110.915 -179.922 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 65' ' ' LEU . . . . . 0.606 ' O ' ' HA ' ' A' ' 102' ' ' HIS . 0.0 OUTLIER -112.68 140.45 47.44 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.118 -0.492 . . . . 99.99 110.901 179.996 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 17.8 t80 -118.47 107.97 14.45 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.156 -0.475 . . . . 99.99 110.896 179.904 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 4.3 m -141.98 166.79 16.4 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.18 -0.463 . . . . 99.99 111.057 -179.949 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 2.8 ttm180 -103.23 144.19 31.66 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.156 -0.475 . . . . 99.99 110.921 179.984 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 2.0 t -40.32 -47.3 2.48 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.245 -0.434 . . . . 99.99 111.138 -179.92 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 46.8 m-20 -52.97 -62.03 1.92 Allowed 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.224 -0.444 . . . . 99.99 110.859 179.924 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 71' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -53.39 -40.44 65.04 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.235 -0.439 . . . . 99.99 110.903 -179.915 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 14.4 t -69.39 -33.84 59.49 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.125 -0.489 . . . . 99.99 111.12 179.946 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 73' ' ' ARG . . . . . . . . . . . . . 18.9 ttm180 -62.17 -39.89 94.19 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.205 -0.452 . . . . 99.99 110.836 -179.96 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 29.9 mt-30 -55.04 -22.58 16.28 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.219 -0.446 . . . . 99.99 110.874 -179.932 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 4.5 mp -113.03 -168.73 1.36 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.234 -0.439 . . . . 99.99 110.912 -179.969 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 76' ' ' ARG . . . . . . . . . . . . . 11.1 ptp180 -124.12 -178.96 4.24 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.182 -0.463 . . . . 99.99 110.871 179.974 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 4.7 mtp180 -70.05 130.56 42.48 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.155 -0.475 . . . . 99.99 110.926 -179.957 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 92.42 36.47 6.2 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.767 -0.73 . . . . 99.99 112.453 -179.976 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -99.13 105.46 17.55 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.859 0.362 . . . . 99.99 110.926 179.994 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 80' ' ' THR . . . . . 0.728 ' HA ' ' HA ' ' A' ' 89' ' ' TRP . 0.8 OUTLIER -89.61 108.56 19.74 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.199 -0.455 . . . . 99.99 111.102 -179.851 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 81' ' ' LEU . . . . . 0.756 ' C ' ' HA ' ' A' ' 87' ' ' ASN . 0.0 OUTLIER -96.05 135.42 37.85 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.132 -0.485 . . . . 99.99 110.93 179.956 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 82' ' ' THR . . . . . 0.715 ' CA ' ' HA ' ' A' ' 87' ' ' ASN . 8.9 t -94.99 101.64 13.41 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.267 -0.424 . . . . 99.99 111.124 179.958 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 83' ' ' ILE . . . . . 0.444 ' CG2' ' CB ' ' A' ' 27' ' ' ALA . 0.1 OUTLIER -135.58 132.58 51.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.236 -0.438 . . . . 99.99 111.128 179.913 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 73.08 -54.37 1.81 Allowed Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.761 -0.733 . . . . 99.99 112.486 179.936 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 85' ' ' GLU . . . . . 0.403 ' O ' ' HG3' ' A' ' 86' ' ' GLU . 3.0 mm-40 -115.54 -83.18 0.62 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.787 0.327 . . . . 99.99 110.837 -179.829 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 86' ' ' GLU . . . . . 0.403 ' HG3' ' O ' ' A' ' 85' ' ' GLU . 7.6 mp0 -150.02 159.45 44.39 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.195 -0.457 . . . . 99.99 110.883 -179.946 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 87' ' ' ASN . . . . . 0.756 ' HA ' ' C ' ' A' ' 81' ' ' LEU . 0.7 OUTLIER -50.28 124.05 9.66 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.152 -0.476 . . . . 99.99 110.876 -179.868 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 88' ' ' PHE . . . . . 0.568 ' HB2' HD23 ' A' ' 105' ' ' LEU . 15.9 m-85 -131.09 119.61 22.2 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.113 -0.494 . . . . 99.99 110.857 -179.956 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 89' ' ' TRP . . . . . 0.728 ' HA ' ' HA ' ' A' ' 80' ' ' THR . 0.0 OUTLIER -79.23 135.55 36.81 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 116.121 -0.491 . . . . 99.99 110.921 -179.993 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 90' ' ' VAL . . . . . 0.471 ' HA ' ' HB3' ' A' ' 105' ' ' LEU . 3.0 p -91.55 136.08 25.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.207 -0.451 . . . . 99.99 111.161 179.951 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 91' ' ' ASP . . . . . 0.447 ' CB ' HD12 ' A' ' 103' ' ' LEU . 0.8 OUTLIER -63.24 -72.35 0.14 Allowed 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.185 -0.461 . . . . 99.99 110.888 179.926 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 92' ' ' ARG . . . . . 0.556 ' O ' ' HG ' ' A' ' 103' ' ' LEU . 9.0 ptm180 -159.71 122.12 3.43 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.164 -0.471 . . . . 99.99 110.954 -179.936 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 93' ' ' VAL . . . . . 0.455 ' HB ' ' CB ' ' A' ' 101' ' ' CYS . 26.0 m -113.63 136.88 48.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.191 -0.459 . . . . 99.99 111.083 -179.956 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 7.0 t -129.32 100.31 20.31 Favored Pre-proline 0 C--N 1.329 -0.307 0 CA-C-O 121.673 0.749 . . . . 99.99 110.821 -179.84 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.81 169.59 18.62 Favored 'Trans proline' 0 C--N 1.342 0.186 0 C-N-CA 122.629 2.22 . . . . 99.99 112.312 179.958 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 11.7 t0 . . . . . 0 C--N 1.329 -0.302 0 CA-C-N 116.186 -0.461 . . . . 99.99 110.837 179.923 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 46.7 t . . . . . 0 C--O 1.231 0.131 0 CA-C-O 120.791 0.329 . . . . 99.99 110.878 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 101' ' ' CYS . . . . . 0.455 ' CB ' ' HB ' ' A' ' 93' ' ' VAL . 0.0 OUTLIER -110.16 148.54 31.59 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.131 -0.486 . . . . 99.99 110.931 -179.976 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 102' ' ' HIS . . . . . 0.606 ' HA ' ' O ' ' A' ' 65' ' ' LEU . 24.8 p80 -160.37 126.28 4.06 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.225 -0.443 . . . . 99.99 110.953 179.99 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 103' ' ' LEU . . . . . 0.556 ' HG ' ' O ' ' A' ' 92' ' ' ARG . 2.5 tm? -151.22 147.55 27.14 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.272 -0.422 . . . . 99.99 110.926 -179.96 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 104' ' ' TRP . . . . . 0.441 ' N ' ' CD1' ' A' ' 103' ' ' LEU . 22.2 m-90 -63.43 114.45 3.88 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 116.208 -0.451 . . . . 99.99 110.922 179.91 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 105' ' ' LEU . . . . . 0.568 HD23 ' HB2' ' A' ' 88' ' ' PHE . 0.3 OUTLIER -93.7 162.0 14.11 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.255 -0.43 . . . . 99.99 110.912 -179.987 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -88.83 160.63 30.12 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.741 -0.743 . . . . 99.99 112.523 179.878 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 107' ' ' ARG . . . . . 0.558 ' HA ' ' CD1' ' A' ' 88' ' ' PHE . 3.1 ptt85 -67.9 157.31 35.23 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.858 0.361 . . . . 99.99 110.893 -179.887 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -173.97 110.52 0.33 Allowed Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.756 -0.735 . . . . 99.99 112.478 -179.979 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 58.1 t -84.72 134.46 41.92 Favored Pre-proline 0 C--N 1.33 -0.276 0 CA-C-O 121.629 0.728 . . . . 99.99 111.135 -179.988 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 110' ' ' PRO . . . . . . . . . . . . . 52.6 Cg_endo . . . . . 0 C--N 1.341 0.173 0 C-N-CA 122.675 2.25 . . . . 99.99 112.263 -179.971 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 25' ' ' THR . . . . . 0.583 ' O ' ' HA ' ' A' ' 40' ' ' ARG . 60.7 p . . . . . 0 C--O 1.232 0.136 0 CA-C-O 120.785 0.326 . . . . 99.99 111.139 . . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -77.53 121.76 24.32 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.227 -0.442 . . . . 99.99 110.849 -179.822 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 27' ' ' ALA . . . . . 0.582 ' CB ' HG21 ' A' ' 39' ' ' ILE . . . -151.7 161.46 42.64 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.123 -0.489 . . . . 99.99 111.132 179.891 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 11.0 m -130.84 88.87 2.67 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.177 -0.465 . . . . 99.99 111.117 -179.852 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . 0.562 HG12 ' HB ' ' A' ' 39' ' ' ILE . 1.7 pt -43.49 128.75 1.11 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.198 -0.456 . . . . 99.99 111.133 179.902 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 7.1 m -153.76 99.0 2.25 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.199 -0.455 . . . . 99.99 111.148 179.949 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 18.7 t -140.8 72.94 1.4 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.222 -0.444 . . . . 99.99 110.845 -179.84 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -178.53 166.57 36.51 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.72 -0.753 . . . . 99.99 112.512 -179.968 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 10.6 pt-20 -48.96 -23.72 1.23 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.738 0.304 . . . . 99.99 110.873 -179.892 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 4.1 tt0 -174.1 93.5 0.09 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.15 -0.477 . . . . 99.99 110.944 -179.949 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 2.0 m -144.87 165.53 27.87 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.243 -0.435 . . . . 99.99 110.84 -179.791 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -179.86 85.21 0.06 OUTLIER Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.746 -0.74 . . . . 99.99 112.513 179.936 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -106.93 -173.83 2.39 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.886 0.374 . . . . 99.99 111.1 -179.996 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 57.5 t -99.36 124.85 52.92 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.171 -0.468 . . . . 99.99 111.124 179.99 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 39' ' ' ILE . . . . . 0.582 HG21 ' CB ' ' A' ' 27' ' ' ALA . 0.0 OUTLIER -137.15 149.35 26.05 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 116.223 -0.444 . . . . 99.99 111.111 179.97 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 40' ' ' ARG . . . . . 0.583 ' HA ' ' O ' ' A' ' 25' ' ' THR . 0.2 OUTLIER -107.84 82.02 1.59 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.192 -0.458 . . . . 99.99 110.907 179.931 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . 0.535 ' O ' ' HB3' ' A' ' 27' ' ' ALA . . . -141.6 142.75 12.26 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.685 -0.769 . . . . 99.99 112.482 -179.94 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 42' ' ' VAL . . . . . 0.534 ' O ' ' HA ' ' A' ' 65' ' ' LEU . 9.0 p -128.57 141.3 46.91 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-O 120.815 0.34 . . . . 99.99 111.144 -179.939 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 1.8 p90 -90.28 135.88 33.4 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.228 -0.442 . . . . 99.99 110.938 179.964 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 11.4 t70 -126.15 125.27 42.21 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.221 -0.445 . . . . 99.99 110.852 179.99 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 . . . . . 0 C--N 1.329 -0.315 0 CA-C-O 121.619 0.723 . . . . 99.99 110.855 179.943 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo . . . . . 0 C--O 1.23 0.112 0 CA-C-O 120.83 0.263 . . . . 99.99 112.327 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 3.5 t -106.92 142.87 35.85 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.196 -0.456 . . . . 99.99 110.842 -179.839 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 65' ' ' LEU . . . . . 0.534 ' HA ' ' O ' ' A' ' 42' ' ' VAL . 0.0 OUTLIER -114.88 119.76 37.67 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.163 -0.471 . . . . 99.99 110.926 -179.991 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 56.0 t80 -101.76 109.81 21.66 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.226 -0.443 . . . . 99.99 110.85 179.98 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 22.3 m -138.13 169.2 18.9 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.159 -0.473 . . . . 99.99 111.163 179.895 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 1.1 ttp180 -93.43 143.82 25.92 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.191 -0.459 . . . . 99.99 110.919 -179.983 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 2.4 t -45.47 -47.74 13.95 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.241 -0.436 . . . . 99.99 111.039 -179.868 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 30.5 t70 -52.18 -52.84 49.56 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.197 -0.456 . . . . 99.99 110.923 179.928 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 71' ' ' GLU . . . . . . . . . . . . . 66.0 mm-40 -54.41 -39.29 67.16 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.246 -0.434 . . . . 99.99 110.909 -179.947 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 4.4 t -73.49 -38.45 52.7 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.16 -0.473 . . . . 99.99 111.172 179.925 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 73' ' ' ARG . . . . . . . . . . . . . 2.6 tmt_? -55.69 -40.02 71.79 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.187 -0.46 . . . . 99.99 110.907 -179.985 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 41.7 mt-30 -52.64 -25.86 12.0 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.245 -0.434 . . . . 99.99 110.962 -179.995 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 2.5 mp -116.25 -166.64 1.17 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.163 -0.472 . . . . 99.99 110.951 179.942 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 76' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -112.35 -178.67 3.47 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.204 -0.453 . . . . 99.99 110.845 179.925 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -76.05 125.89 29.97 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.184 -0.462 . . . . 99.99 110.925 -179.929 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 99.77 23.94 10.39 Favored Glycine 0 N--CA 1.45 -0.383 0 C-N-CA 120.768 -0.729 . . . . 99.99 112.505 -179.912 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -82.63 109.31 16.7 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.876 0.369 . . . . 99.99 110.916 179.968 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 80' ' ' THR . . . . . 0.721 ' HA ' ' HA ' ' A' ' 89' ' ' TRP . 0.5 OUTLIER -88.37 109.64 20.15 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.209 -0.45 . . . . 99.99 111.16 -179.906 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 81' ' ' LEU . . . . . 0.796 ' C ' ' HA ' ' A' ' 87' ' ' ASN . 0.0 OUTLIER -96.82 134.37 40.21 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 116.227 -0.442 . . . . 99.99 110.956 179.949 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 82' ' ' THR . . . . . 0.727 ' CA ' ' HA ' ' A' ' 87' ' ' ASN . 4.9 t -92.63 101.79 14.21 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.187 -0.461 . . . . 99.99 111.183 179.975 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 83' ' ' ILE . . . . . 0.48 ' CD1' ' O ' ' A' ' 83' ' ' ILE . 0.1 OUTLIER -132.92 130.45 58.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.219 -0.446 . . . . 99.99 111.118 179.975 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 70.42 -62.37 0.83 Allowed Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.749 -0.739 . . . . 99.99 112.458 179.924 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 10.1 tp10 -103.07 -81.83 0.5 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.806 0.336 . . . . 99.99 110.908 -179.891 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 86' ' ' GLU . . . . . 0.43 ' C ' ' HA ' ' A' ' 82' ' ' THR . 95.7 mt-10 -152.91 160.7 43.07 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.143 -0.48 . . . . 99.99 110.923 -179.923 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 87' ' ' ASN . . . . . 0.796 ' HA ' ' C ' ' A' ' 81' ' ' LEU . 1.3 p-10 -51.55 124.64 12.62 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.153 -0.476 . . . . 99.99 110.893 -179.908 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 88' ' ' PHE . . . . . 0.543 ' CD1' ' HA ' ' A' ' 107' ' ' ARG . 15.3 m-85 -132.77 120.27 21.4 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.176 -0.465 . . . . 99.99 110.932 179.999 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 89' ' ' TRP . . . . . 0.721 ' HA ' ' HA ' ' A' ' 80' ' ' THR . 7.1 p90 -80.01 137.0 36.72 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.179 -0.464 . . . . 99.99 111.005 -179.981 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 90' ' ' VAL . . . . . 0.466 ' HA ' ' HB3' ' A' ' 105' ' ' LEU . 7.2 p -89.64 135.97 24.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.318 -0.401 . . . . 99.99 111.161 179.893 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 91' ' ' ASP . . . . . 0.554 ' HB3' HD12 ' A' ' 103' ' ' LEU . 0.0 OUTLIER -64.28 -67.76 0.41 Allowed 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.155 -0.475 . . . . 99.99 110.907 179.891 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 92' ' ' ARG . . . . . 0.631 ' O ' ' HG ' ' A' ' 103' ' ' LEU . 13.3 ttm-85 -162.76 122.26 2.25 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.238 -0.437 . . . . 99.99 110.897 -179.939 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 93' ' ' VAL . . . . . 0.477 ' HB ' ' CB ' ' A' ' 101' ' ' CYS . 22.7 m -117.9 135.42 58.37 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.144 -0.48 . . . . 99.99 111.111 179.966 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 1.1 p -129.36 103.24 18.12 Favored Pre-proline 0 C--N 1.329 -0.285 0 CA-C-O 121.585 0.707 . . . . 99.99 110.856 -179.823 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.76 -176.15 1.39 Allowed 'Trans proline' 0 C--O 1.231 0.142 0 C-N-CA 122.657 2.238 . . . . 99.99 112.31 -179.947 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 66.5 m-20 . . . . . 0 C--N 1.328 -0.332 0 CA-C-N 116.185 -0.461 . . . . 99.99 110.853 179.962 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 1.7 m . . . . . 0 C--O 1.233 0.203 0 CA-C-O 120.89 0.376 . . . . 99.99 110.874 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 101' ' ' CYS . . . . . 0.477 ' CB ' ' HB ' ' A' ' 93' ' ' VAL . 0.0 OUTLIER -106.0 150.02 26.1 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.128 -0.487 . . . . 99.99 110.886 -179.939 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 102' ' ' HIS . . . . . 0.516 ' HA ' ' O ' ' A' ' 65' ' ' LEU . 19.6 p-80 -160.92 123.54 3.19 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.198 -0.456 . . . . 99.99 110.89 -179.951 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 103' ' ' LEU . . . . . 0.631 ' HG ' ' O ' ' A' ' 92' ' ' ARG . 2.1 tm? -152.91 147.67 26.25 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.203 -0.453 . . . . 99.99 110.918 -179.964 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 104' ' ' TRP . . . . . 0.413 ' N ' HD13 ' A' ' 103' ' ' LEU . 30.9 p90 -63.99 117.52 7.15 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 116.178 -0.465 . . . . 99.99 110.891 179.951 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 105' ' ' LEU . . . . . 0.519 HD21 ' HB2' ' A' ' 88' ' ' PHE . 0.3 OUTLIER -94.12 162.92 13.68 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 116.268 -0.424 . . . . 99.99 110.928 179.989 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -88.84 159.74 29.39 Favored Glycine 0 N--CA 1.453 -0.219 0 C-N-CA 120.705 -0.76 . . . . 99.99 112.477 179.9 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 107' ' ' ARG . . . . . 0.543 ' HA ' ' CD1' ' A' ' 88' ' ' PHE . 4.3 ptp180 -66.84 157.29 33.42 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.847 0.356 . . . . 99.99 110.883 -179.882 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -173.1 111.61 0.39 Allowed Glycine 0 N--CA 1.452 -0.272 0 C-N-CA 120.717 -0.754 . . . . 99.99 112.468 -179.916 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 7.2 p -86.42 133.96 39.2 Favored Pre-proline 0 C--N 1.33 -0.264 0 CA-C-O 121.567 0.698 . . . . 99.99 111.157 179.999 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 110' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_endo . . . . . 0 C--O 1.232 0.175 0 C-N-CA 122.635 2.224 . . . . 99.99 112.328 179.987 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 25' ' ' THR . . . . . 0.471 ' O ' ' HA ' ' A' ' 40' ' ' ARG . 1.3 t . . . . . 0 C--O 1.231 0.121 0 CA-C-O 120.746 0.308 . . . . 99.99 111.196 . . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 20.6 p -72.86 123.46 23.44 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.258 -0.428 . . . . 99.99 110.799 -179.811 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 27' ' ' ALA . . . . . 0.514 ' HB1' ' H ' ' A' ' 41' ' ' GLY . . . -146.79 162.83 37.78 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.109 -0.496 . . . . 99.99 111.079 179.882 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 14.4 m -130.69 89.6 2.79 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.164 -0.471 . . . . 99.99 111.183 -179.89 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . 0.628 HG21 HG22 ' A' ' 39' ' ' ILE . 2.2 pt -43.69 134.5 1.21 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.364 0 CA-C-N 116.239 -0.437 . . . . 99.99 111.167 179.936 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 26.7 m -155.29 98.24 1.97 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.183 -0.462 . . . . 99.99 111.104 179.979 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 96.8 p -134.7 70.14 1.45 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.146 -0.479 . . . . 99.99 110.859 -179.868 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -179.27 168.86 39.79 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.733 -0.746 . . . . 99.99 112.476 179.988 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 16.7 pt-20 -48.72 -24.2 1.31 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.731 0.301 . . . . 99.99 110.863 -179.799 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 29.9 tt0 -173.97 95.55 0.1 Allowed 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.14 -0.482 . . . . 99.99 110.956 -179.888 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 2.1 m -144.29 165.07 28.92 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.223 -0.444 . . . . 99.99 110.836 -179.751 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 179.59 89.43 0.08 OUTLIER Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.796 -0.716 . . . . 99.99 112.51 -179.954 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -109.15 -170.71 1.71 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.83 0.348 . . . . 99.99 111.107 179.949 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 51.1 t -98.31 119.89 46.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.133 -0.485 . . . . 99.99 111.161 179.956 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 39' ' ' ILE . . . . . 0.628 HG22 HG21 ' A' ' 29' ' ' ILE . 0.0 OUTLIER -137.72 150.53 25.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.262 -0.426 . . . . 99.99 111.157 179.884 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 40' ' ' ARG . . . . . 0.471 ' HA ' ' O ' ' A' ' 25' ' ' THR . 19.2 mtt-85 -109.56 80.53 1.32 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.2 -0.455 . . . . 99.99 110.893 179.95 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . 0.514 ' H ' ' HB1' ' A' ' 27' ' ' ALA . . . -133.76 141.17 12.48 Favored Glycine 0 N--CA 1.452 -0.252 0 C-N-CA 120.77 -0.729 . . . . 99.99 112.478 -179.911 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 42' ' ' VAL . . . . . 0.407 ' HB ' ' CB ' ' A' ' 25' ' ' THR . 0.4 OUTLIER -124.22 139.01 51.89 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-O 120.818 0.342 . . . . 99.99 111.117 -179.935 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 43' ' ' PHE . . . . . 0.508 ' HA ' ' O ' ' A' ' 64' ' ' SER . 2.4 p90 -96.15 132.21 41.79 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.199 -0.455 . . . . 99.99 110.87 179.981 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 12.9 t70 -114.6 124.29 51.49 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.141 -0.482 . . . . 99.99 110.899 179.918 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--N 1.328 -0.345 0 CA-C-O 121.624 0.726 . . . . 99.99 110.834 -179.97 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo . . . . . 0 C--O 1.231 0.164 0 CA-C-O 120.741 0.226 . . . . 99.99 112.378 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 64' ' ' SER . . . . . 0.508 ' O ' ' HA ' ' A' ' 43' ' ' PHE . 0.5 OUTLIER -105.95 151.21 24.89 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.237 -0.438 . . . . 99.99 110.87 -179.854 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 65' ' ' LEU . . . . . 0.648 ' O ' ' HA ' ' A' ' 102' ' ' HIS . 3.2 tm? -113.52 139.21 49.15 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.119 -0.491 . . . . 99.99 110.951 179.998 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 2.8 t80 -120.54 106.25 11.61 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.235 -0.439 . . . . 99.99 110.923 179.906 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 8.2 p -144.03 161.46 15.59 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 116.144 -0.48 . . . . 99.99 111.124 179.992 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 68' ' ' ARG . . . . . 0.406 ' HG3' HG23 ' A' ' 69' ' ' THR . 7.0 ttm180 -96.09 145.38 25.53 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.148 -0.478 . . . . 99.99 110.878 -179.976 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 69' ' ' THR . . . . . 0.423 ' HB ' ' HG3' ' A' ' 95' ' ' PRO . 3.0 t -40.22 -45.43 2.06 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.227 -0.442 . . . . 99.99 111.209 -179.98 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 4.8 m-20 -65.81 -53.97 33.08 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.191 -0.459 . . . . 99.99 110.91 179.884 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 71' ' ' GLU . . . . . . . . . . . . . 1.1 mp0 -53.74 -39.24 65.14 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.17 -0.468 . . . . 99.99 110.897 -179.964 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 7.2 p -82.63 -24.35 8.73 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.225 -0.443 . . . . 99.99 111.115 179.991 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 73' ' ' ARG . . . . . . . . . . . . . 51.0 ttt180 -63.97 -37.22 86.62 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.16 -0.473 . . . . 99.99 110.887 -179.989 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 15.2 mm-40 -67.62 -10.96 56.85 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.179 -0.464 . . . . 99.99 110.877 -179.95 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 8.7 mp -103.39 -176.4 3.07 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.234 -0.439 . . . . 99.99 110.95 179.995 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 76' ' ' ARG . . . . . . . . . . . . . 16.5 ttm180 -123.64 150.0 44.71 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.231 -0.441 . . . . 99.99 110.873 -179.986 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -50.34 105.43 0.09 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.218 -0.446 . . . . 99.99 110.918 -179.9 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 113.97 16.14 8.1 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.745 -0.741 . . . . 99.99 112.441 -179.974 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -79.88 106.27 11.78 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-O 120.898 0.38 . . . . 99.99 110.852 -179.976 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 80' ' ' THR . . . . . 0.713 ' HA ' ' HA ' ' A' ' 89' ' ' TRP . 0.7 OUTLIER -85.46 110.24 19.03 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.226 -0.443 . . . . 99.99 111.167 -179.929 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 81' ' ' LEU . . . . . 0.74 ' C ' ' HA ' ' A' ' 87' ' ' ASN . 0.3 OUTLIER -96.38 132.2 42.14 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.226 -0.443 . . . . 99.99 110.961 179.955 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 82' ' ' THR . . . . . 0.743 ' CA ' ' HA ' ' A' ' 87' ' ' ASN . 3.4 t -93.82 102.5 14.63 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.205 -0.452 . . . . 99.99 111.18 179.973 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 83' ' ' ILE . . . . . 0.431 ' HB ' ' CB ' ' A' ' 27' ' ' ALA . 0.1 OUTLIER -138.52 131.66 39.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.211 -0.45 . . . . 99.99 111.105 179.966 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 74.59 -53.17 2.39 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.741 -0.742 . . . . 99.99 112.517 179.941 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 85' ' ' GLU . . . . . 0.404 ' O ' ' HG3' ' A' ' 86' ' ' GLU . 4.1 mm-40 -117.76 -82.2 0.63 Allowed 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.834 0.35 . . . . 99.99 110.865 -179.91 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 86' ' ' GLU . . . . . 0.408 ' C ' ' HA ' ' A' ' 82' ' ' THR . 6.9 mp0 -149.7 160.3 43.64 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.163 -0.471 . . . . 99.99 110.92 -179.915 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 87' ' ' ASN . . . . . 0.743 ' HA ' ' CA ' ' A' ' 82' ' ' THR . 1.4 p30 -50.91 123.81 9.95 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.193 -0.458 . . . . 99.99 110.893 -179.913 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 88' ' ' PHE . . . . . 0.539 ' HB2' HD22 ' A' ' 105' ' ' LEU . 14.9 m-85 -131.81 118.32 19.73 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.199 -0.455 . . . . 99.99 110.893 -179.955 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 89' ' ' TRP . . . . . 0.713 ' HA ' ' HA ' ' A' ' 80' ' ' THR . 62.2 p-90 -81.53 135.1 35.59 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.196 -0.456 . . . . 99.99 110.854 -179.963 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 90' ' ' VAL . . . . . 0.471 ' CG2' ' HB3' ' A' ' 103' ' ' LEU . 4.9 p -91.52 136.8 23.38 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.193 -0.458 . . . . 99.99 111.131 179.881 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 91' ' ' ASP . . . . . 0.465 ' CB ' HD12 ' A' ' 103' ' ' LEU . 0.5 OUTLIER -63.06 -72.3 0.14 Allowed 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.219 -0.446 . . . . 99.99 110.919 179.87 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 92' ' ' ARG . . . . . 0.584 ' O ' ' HG ' ' A' ' 103' ' ' LEU . 12.3 ttm-85 -159.17 120.66 3.35 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.185 -0.461 . . . . 99.99 110.861 -179.962 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 93' ' ' VAL . . . . . 0.468 ' HB ' ' CB ' ' A' ' 101' ' ' CYS . 24.4 m -111.8 133.01 58.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.188 -0.46 . . . . 99.99 111.127 179.994 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 94' ' ' SER . . . . . 0.414 ' HA ' ' HD2' ' A' ' 95' ' ' PRO . 11.5 t -125.72 100.29 31.44 Favored Pre-proline 0 C--N 1.329 -0.291 0 CA-C-O 121.692 0.758 . . . . 99.99 110.824 -179.78 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 95' ' ' PRO . . . . . 0.423 ' HG3' ' HB ' ' A' ' 69' ' ' THR . 53.9 Cg_endo -69.79 169.96 17.73 Favored 'Trans proline' 0 C--N 1.343 0.26 0 C-N-CA 122.634 2.222 . . . . 99.99 112.383 179.977 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 8.8 m-20 . . . . . 0 C--N 1.329 -0.32 0 CA-C-N 116.221 -0.445 . . . . 99.99 110.871 179.97 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 28.8 t . . . . . 0 C--O 1.232 0.135 0 CA-C-O 120.785 0.326 . . . . 99.99 110.859 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 101' ' ' CYS . . . . . 0.468 ' CB ' ' HB ' ' A' ' 93' ' ' VAL . 0.0 OUTLIER -108.47 149.77 28.34 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.126 -0.488 . . . . 99.99 110.887 -179.975 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 102' ' ' HIS . . . . . 0.648 ' HA ' ' O ' ' A' ' 65' ' ' LEU . 28.6 p-80 -158.88 125.42 4.64 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.145 -0.48 . . . . 99.99 110.862 179.968 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 103' ' ' LEU . . . . . 0.584 ' HG ' ' O ' ' A' ' 92' ' ' ARG . 2.8 tm? -151.92 148.02 27.28 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.199 -0.455 . . . . 99.99 110.952 -179.955 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 104' ' ' TRP . . . . . 0.429 ' N ' ' CD1' ' A' ' 103' ' ' LEU . 28.0 p90 -64.79 113.69 3.97 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.24 -0.436 . . . . 99.99 110.964 179.839 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 105' ' ' LEU . . . . . 0.539 HD22 ' HB2' ' A' ' 88' ' ' PHE . 0.3 OUTLIER -92.6 162.62 14.11 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.219 -0.446 . . . . 99.99 110.898 179.998 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -89.27 159.16 28.4 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.811 -0.709 . . . . 99.99 112.459 179.92 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 107' ' ' ARG . . . . . 0.528 ' HA ' ' CD1' ' A' ' 88' ' ' PHE . 0.0 OUTLIER -69.74 158.32 35.64 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.852 0.358 . . . . 99.99 110.891 -179.875 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -172.9 109.13 0.29 Allowed Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.715 -0.755 . . . . 99.99 112.442 -179.987 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 7.4 p -92.31 134.34 28.45 Favored Pre-proline 0 C--N 1.329 -0.312 0 CA-C-O 121.604 0.716 . . . . 99.99 111.09 -179.951 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 110' ' ' PRO . . . . . 0.492 ' N ' HD22 ' A' ' 87' ' ' ASN . 53.9 Cg_endo . . . . . 0 C--O 1.232 0.198 0 C-N-CA 122.678 2.252 . . . . 99.99 112.347 179.948 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 25' ' ' THR . . . . . 0.587 ' O ' ' HA ' ' A' ' 40' ' ' ARG . 46.6 p . . . . . 0 N--CA 1.457 -0.1 0 CA-C-O 120.814 0.34 . . . . 99.99 111.172 . . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -76.27 121.77 23.43 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.275 -0.42 . . . . 99.99 110.884 -179.878 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 27' ' ' ALA . . . . . 0.567 ' CB ' HG21 ' A' ' 39' ' ' ILE . . . -151.39 161.12 43.27 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.168 -0.469 . . . . 99.99 111.102 179.877 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 28' ' ' THR . . . . . 0.403 ' O ' HG21 ' A' ' 82' ' ' THR . 16.0 m -131.98 87.99 2.5 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.203 -0.453 . . . . 99.99 111.144 -179.856 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . 0.601 HG23 HG22 ' A' ' 39' ' ' ILE . 2.5 pt -43.23 128.55 1.0 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 CA-C-N 116.189 -0.46 . . . . 99.99 111.171 179.893 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 11.8 m -153.18 101.11 2.52 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.177 -0.465 . . . . 99.99 111.141 -179.998 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 85.2 p -141.09 72.56 1.39 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.217 -0.447 . . . . 99.99 110.879 -179.853 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -178.42 166.91 37.13 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.764 -0.731 . . . . 99.99 112.529 -179.981 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 8.5 pt-20 -49.14 -23.51 1.3 Allowed 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.812 0.339 . . . . 99.99 110.874 -179.915 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -174.47 93.49 0.08 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.192 -0.458 . . . . 99.99 110.971 -179.91 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 1.9 m -145.22 165.34 28.64 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.241 -0.436 . . . . 99.99 110.914 -179.823 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -179.61 86.99 0.07 OUTLIER Glycine 0 N--CA 1.452 -0.273 0 C-N-CA 120.689 -0.767 . . . . 99.99 112.491 -179.999 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -106.23 -173.56 2.33 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.771 0.32 . . . . 99.99 111.184 179.933 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 65.9 t -100.02 122.87 52.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.301 -0.408 . . . . 99.99 111.139 -179.996 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 39' ' ' ILE . . . . . 0.601 HG22 HG23 ' A' ' 29' ' ' ILE . 0.0 OUTLIER -136.88 147.63 27.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.158 -0.473 . . . . 99.99 111.097 179.979 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 40' ' ' ARG . . . . . 0.587 ' HA ' ' O ' ' A' ' 25' ' ' THR . 0.2 OUTLIER -108.8 81.78 1.51 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.166 -0.47 . . . . 99.99 110.913 179.914 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . 0.525 ' O ' ' HB3' ' A' ' 27' ' ' ALA . . . -143.07 141.96 11.0 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.715 -0.755 . . . . 99.99 112.503 -179.989 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 42' ' ' VAL . . . . . 0.464 ' O ' ' HA ' ' A' ' 65' ' ' LEU . 9.8 p -127.8 142.39 43.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-O 120.882 0.373 . . . . 99.99 111.102 -179.904 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 43' ' ' PHE . . . . . 0.434 ' HA ' ' O ' ' A' ' 64' ' ' SER . 1.7 p90 -90.08 137.6 32.21 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.142 -0.481 . . . . 99.99 110.878 -179.969 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 9.9 t70 -123.52 125.0 44.11 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.142 -0.481 . . . . 99.99 110.777 -179.992 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 2.6 p30 . . . . . 0 C--N 1.329 -0.322 0 CA-C-O 121.618 0.723 . . . . 99.99 110.868 179.941 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo . . . . . 0 C--O 1.23 0.123 0 CA-C-O 120.823 0.26 . . . . 99.99 112.298 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 64' ' ' SER . . . . . 0.434 ' O ' ' HA ' ' A' ' 43' ' ' PHE . 8.0 t -105.6 147.04 28.88 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.21 -0.45 . . . . 99.99 110.854 -179.877 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 65' ' ' LEU . . . . . 0.464 ' HA ' ' O ' ' A' ' 42' ' ' VAL . 0.9 OUTLIER -113.62 119.41 37.37 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.141 -0.481 . . . . 99.99 110.932 -179.986 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 6.4 t80 -94.63 111.28 23.05 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.242 -0.435 . . . . 99.99 110.844 179.981 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -141.38 170.49 13.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.096 -0.502 . . . . 99.99 111.197 179.961 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 10.1 ttm180 -100.74 143.86 30.39 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.24 -0.436 . . . . 99.99 110.934 -179.999 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 4.7 t -42.9 -44.61 4.62 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.219 -0.446 . . . . 99.99 111.191 -179.901 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 21.1 t0 -65.67 -46.32 79.56 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.233 -0.44 . . . . 99.99 110.903 179.862 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 71' ' ' GLU . . . . . . . . . . . . . 67.1 mm-40 -53.93 -39.66 66.05 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.116 -0.493 . . . . 99.99 110.928 -179.921 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 19.0 m -86.72 -25.51 6.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.103 -0.498 . . . . 99.99 111.151 179.966 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 73' ' ' ARG . . . . . . . . . . . . . 0.8 OUTLIER -60.0 -41.24 91.67 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.139 -0.482 . . . . 99.99 110.895 -179.999 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 32.3 mt-30 -62.07 -16.59 53.15 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.169 -0.469 . . . . 99.99 110.899 -179.959 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 5.3 mp -108.89 -175.51 2.79 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.246 -0.434 . . . . 99.99 110.85 -179.921 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 76' ' ' ARG . . . . . . . . . . . . . 5.0 ptp85 -115.56 -173.83 2.41 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.135 -0.484 . . . . 99.99 110.934 179.954 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 7.0 ptp180 -79.99 131.38 35.79 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.253 -0.43 . . . . 99.99 110.89 -179.951 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 92.31 25.79 20.33 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.74 -0.743 . . . . 99.99 112.56 -179.924 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -89.24 105.33 17.72 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.911 0.386 . . . . 99.99 110.852 -179.949 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 80' ' ' THR . . . . . 0.757 ' HA ' ' HA ' ' A' ' 89' ' ' TRP . 0.8 OUTLIER -87.28 110.57 20.29 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.196 -0.456 . . . . 99.99 111.101 -179.89 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 81' ' ' LEU . . . . . 0.735 ' C ' ' HA ' ' A' ' 87' ' ' ASN . 0.3 OUTLIER -95.41 131.91 41.04 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.153 -0.476 . . . . 99.99 110.897 179.935 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 82' ' ' THR . . . . . 0.741 ' CA ' ' HA ' ' A' ' 87' ' ' ASN . 5.0 t -94.01 102.03 14.1 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.18 -0.464 . . . . 99.99 111.133 179.932 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 83' ' ' ILE . . . . . 0.487 ' CD1' ' O ' ' A' ' 83' ' ' ILE . 0.1 OUTLIER -132.46 130.26 59.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.184 -0.462 . . . . 99.99 111.116 179.92 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 68.19 -62.73 0.39 Allowed Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.707 -0.758 . . . . 99.99 112.508 179.911 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 29.2 mm-40 -98.66 -83.7 0.41 Allowed 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.766 0.317 . . . . 99.99 110.949 -179.924 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 86' ' ' GLU . . . . . 0.417 ' C ' ' HA ' ' A' ' 82' ' ' THR . 70.1 mt-10 -154.22 160.97 42.09 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.129 -0.487 . . . . 99.99 110.844 -179.96 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 87' ' ' ASN . . . . . 0.741 ' HA ' ' CA ' ' A' ' 82' ' ' THR . 0.8 OUTLIER -50.55 123.73 9.37 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.156 -0.475 . . . . 99.99 110.871 -179.89 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 88' ' ' PHE . . . . . 0.574 ' CD1' ' HA ' ' A' ' 107' ' ' ARG . 15.1 m-85 -131.51 119.48 21.6 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.239 -0.437 . . . . 99.99 110.889 -179.974 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 89' ' ' TRP . . . . . 0.757 ' HA ' ' HA ' ' A' ' 80' ' ' THR . 4.6 p90 -80.12 138.05 36.85 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.166 -0.47 . . . . 99.99 110.856 -179.915 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 90' ' ' VAL . . . . . 0.442 ' HA ' ' HB3' ' A' ' 105' ' ' LEU . 2.2 p -94.59 135.84 27.6 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 116.156 -0.474 . . . . 99.99 111.129 179.942 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 91' ' ' ASP . . . . . 0.447 ' CB ' HD13 ' A' ' 103' ' ' LEU . 0.4 OUTLIER -65.28 -75.25 0.09 Allowed 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.173 -0.467 . . . . 99.99 110.879 179.892 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 92' ' ' ARG . . . . . 0.578 ' O ' ' HG ' ' A' ' 103' ' ' LEU . 0.0 OUTLIER -153.23 117.45 4.87 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.166 -0.47 . . . . 99.99 110.818 -179.944 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 93' ' ' VAL . . . . . 0.491 ' CG2' ' N ' ' A' ' 102' ' ' HIS . 0.3 OUTLIER -111.45 139.82 33.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.171 -0.468 . . . . 99.99 111.173 179.906 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 1.4 p -140.78 103.94 6.32 Favored Pre-proline 0 C--N 1.329 -0.293 0 CA-C-O 121.713 0.768 . . . . 99.99 110.857 -179.807 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_endo -69.68 173.61 10.65 Favored 'Trans proline' 0 C--N 1.342 0.199 0 C-N-CA 122.729 2.286 . . . . 99.99 112.365 179.908 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 21.2 m-20 . . . . . 0 C--N 1.328 -0.337 0 CA-C-N 116.197 -0.456 . . . . 99.99 110.854 179.95 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 1.5 m . . . . . 0 C--O 1.232 0.176 0 CA-C-O 120.775 0.321 . . . . 99.99 110.831 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 101' ' ' CYS . . . . . 0.4 ' HB3' HG11 ' A' ' 93' ' ' VAL . 0.0 OUTLIER -122.95 154.43 38.39 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.212 -0.449 . . . . 99.99 110.839 -179.954 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 102' ' ' HIS . . . . . 0.491 ' N ' ' CG2' ' A' ' 93' ' ' VAL . 13.5 p80 -156.94 123.34 4.96 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.161 -0.472 . . . . 99.99 110.853 -179.972 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 103' ' ' LEU . . . . . 0.578 ' HG ' ' O ' ' A' ' 92' ' ' ARG . 3.4 tm? -148.25 144.57 27.74 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.211 -0.45 . . . . 99.99 110.856 -179.916 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 104' ' ' TRP . . . . . . . . . . . . . 4.2 m-90 -69.29 108.54 3.72 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.225 -0.443 . . . . 99.99 110.924 179.831 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 105' ' ' LEU . . . . . 0.523 HD21 ' HB2' ' A' ' 88' ' ' PHE . 0.3 OUTLIER -89.6 161.8 15.97 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.266 -0.424 . . . . 99.99 110.985 179.945 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -89.69 159.92 28.5 Favored Glycine 0 N--CA 1.45 -0.379 0 C-N-CA 120.713 -0.756 . . . . 99.99 112.537 179.891 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 107' ' ' ARG . . . . . 0.574 ' HA ' ' CD1' ' A' ' 88' ' ' PHE . 0.1 OUTLIER -68.94 157.55 36.46 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.88 0.372 . . . . 99.99 110.832 -179.807 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -172.05 112.38 0.44 Allowed Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.78 -0.724 . . . . 99.99 112.538 -179.998 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 7.3 p -85.56 133.78 41.35 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-O 121.599 0.714 . . . . 99.99 111.176 -179.975 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 110' ' ' PRO . . . . . . . . . . . . . 54.8 Cg_endo . . . . . 0 C--O 1.233 0.232 0 C-N-CA 122.693 2.262 . . . . 99.99 112.394 179.9 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 25' ' ' THR . . . . . 0.538 ' O ' ' HA ' ' A' ' 40' ' ' ARG . 0.0 OUTLIER . . . . . 0 N--CA 1.458 -0.072 0 CA-C-O 120.867 0.365 . . . . 99.99 111.09 . . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -75.09 123.33 25.03 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.112 -0.495 . . . . 99.99 110.838 -179.856 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 27' ' ' ALA . . . . . 0.497 ' CB ' HG21 ' A' ' 39' ' ' ILE . . . -145.13 163.21 35.02 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.15 -0.477 . . . . 99.99 111.056 179.894 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 19.1 m -130.46 87.2 2.47 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.173 -0.467 . . . . 99.99 111.164 -179.874 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . 0.629 HG21 HG22 ' A' ' 39' ' ' ILE . 2.2 pt -44.27 132.15 1.55 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.213 -0.448 . . . . 99.99 111.161 179.926 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 23.4 m -153.89 101.17 2.42 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.183 -0.462 . . . . 99.99 111.176 179.983 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 1.8 t -137.12 71.04 1.4 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.265 -0.425 . . . . 99.99 110.843 -179.856 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -179.4 168.1 38.51 Favored Glycine 0 N--CA 1.45 -0.422 0 C-N-CA 120.72 -0.752 . . . . 99.99 112.458 -179.968 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 6.7 pt-20 -49.24 -23.4 1.33 Allowed 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.793 0.33 . . . . 99.99 110.894 -179.896 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 3.5 tt0 -174.69 94.93 0.08 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.12 -0.491 . . . . 99.99 110.971 -179.97 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -145.11 165.33 28.59 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.232 -0.44 . . . . 99.99 110.801 -179.789 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -179.22 88.86 0.07 OUTLIER Glycine 0 N--CA 1.452 -0.254 0 C-N-CA 120.723 -0.751 . . . . 99.99 112.449 179.995 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -106.26 -172.45 2.09 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.798 0.332 . . . . 99.99 111.116 179.942 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 23.5 t -99.66 120.01 48.47 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.232 -0.44 . . . . 99.99 111.117 179.998 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 39' ' ' ILE . . . . . 0.629 HG22 HG21 ' A' ' 29' ' ' ILE . 0.0 OUTLIER -137.28 151.03 26.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.227 -0.442 . . . . 99.99 111.177 179.918 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 40' ' ' ARG . . . . . 0.538 ' HA ' ' O ' ' A' ' 25' ' ' THR . 28.0 mmt180 -112.87 82.03 1.59 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.193 -0.458 . . . . 99.99 110.845 179.988 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . 0.486 ' H ' ' HB3' ' A' ' 27' ' ' ALA . . . -140.18 138.21 8.92 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.794 -0.717 . . . . 99.99 112.451 -179.966 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 42' ' ' VAL . . . . . 0.469 ' HB ' ' OG1' ' A' ' 25' ' ' THR . 1.7 p -123.59 137.81 55.53 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-O 120.817 0.341 . . . . 99.99 111.17 179.943 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 2.1 p90 -93.22 137.82 32.19 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.198 -0.455 . . . . 99.99 110.88 -179.91 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 3.4 t70 -117.96 125.43 50.41 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.147 -0.479 . . . . 99.99 110.853 179.986 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 1.2 p30 . . . . . 0 C--N 1.329 -0.323 0 CA-C-O 121.548 0.69 . . . . 99.99 110.913 179.951 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo . . . . . 0 N--CA 1.465 -0.149 0 CA-C-O 120.776 0.24 . . . . 99.99 112.326 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 1.3 t -111.29 138.29 47.94 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.211 -0.45 . . . . 99.99 110.834 -179.863 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 65' ' ' LEU . . . . . 0.46 ' HB2' ' CD2' ' A' ' 105' ' ' LEU . 1.7 tm? -117.1 135.67 53.57 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.19 -0.459 . . . . 99.99 110.962 -179.974 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 35.7 t80 -117.94 110.28 17.53 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.244 -0.435 . . . . 99.99 110.87 179.966 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 24.1 m -140.13 168.12 17.85 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.092 -0.504 . . . . 99.99 111.11 179.993 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 1.5 ptm180 -102.83 146.18 28.66 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.191 -0.459 . . . . 99.99 110.859 179.982 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 69' ' ' THR . . . . . 0.411 ' HB ' ' HG3' ' A' ' 95' ' ' PRO . 0.2 OUTLIER -37.75 -60.96 0.67 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.153 -0.476 . . . . 99.99 111.139 -179.895 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 3.4 m-20 -46.11 -43.92 15.24 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.198 -0.455 . . . . 99.99 110.887 179.886 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 71' ' ' GLU . . . . . . . . . . . . . 8.7 tp10 -59.77 -42.81 94.15 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.198 -0.456 . . . . 99.99 110.858 -179.873 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 14.3 p -87.27 -3.86 9.38 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.172 -0.467 . . . . 99.99 111.106 -179.978 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 73' ' ' ARG . . . . . . . . . . . . . 57.6 ttt180 -85.27 -41.93 15.11 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.165 -0.47 . . . . 99.99 110.884 -179.965 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 71.8 mt-30 -53.26 -25.25 13.74 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.188 -0.46 . . . . 99.99 110.907 -179.944 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 3.9 mp -107.74 -169.63 1.56 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.204 -0.453 . . . . 99.99 110.956 179.963 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 76' ' ' ARG . . . . . . . . . . . . . 8.5 ttp180 -116.6 136.84 52.64 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.212 -0.449 . . . . 99.99 110.85 179.978 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -47.34 102.01 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.211 -0.45 . . . . 99.99 110.884 -179.899 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 133.19 25.73 0.64 Allowed Glycine 0 N--CA 1.453 -0.231 0 C-N-CA 120.701 -0.762 . . . . 99.99 112.427 -179.967 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 5.4 p-10 -114.13 119.84 38.48 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.871 0.367 . . . . 99.99 110.91 179.963 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 80' ' ' THR . . . . . 0.671 ' HA ' ' CA ' ' A' ' 89' ' ' TRP . 13.6 p -83.11 123.05 29.14 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.195 -0.457 . . . . 99.99 111.123 -179.825 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 81' ' ' LEU . . . . . 0.783 ' C ' ' HA ' ' A' ' 87' ' ' ASN . 0.2 OUTLIER -94.37 124.47 38.42 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.243 -0.435 . . . . 99.99 110.921 179.956 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 82' ' ' THR . . . . . 0.796 ' N ' ' HA ' ' A' ' 87' ' ' ASN . 3.5 t -91.47 104.42 16.93 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.214 -0.448 . . . . 99.99 111.164 179.947 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 83' ' ' ILE . . . . . 0.466 ' CD1' ' O ' ' A' ' 83' ' ' ILE . 0.1 OUTLIER -141.17 126.45 18.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.177 -0.465 . . . . 99.99 111.062 179.97 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 74.36 -52.74 2.27 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.692 -0.766 . . . . 99.99 112.495 179.908 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 8.1 tp10 -112.91 -82.73 0.59 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.809 0.338 . . . . 99.99 110.903 -179.896 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 86' ' ' GLU . . . . . 0.469 ' C ' ' HA ' ' A' ' 82' ' ' THR . 86.9 mt-10 -152.17 160.86 43.31 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.171 -0.468 . . . . 99.99 110.884 -179.937 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 87' ' ' ASN . . . . . 0.796 ' HA ' ' N ' ' A' ' 82' ' ' THR . 9.2 p30 -51.32 121.66 6.6 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.168 -0.469 . . . . 99.99 110.938 -179.949 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 88' ' ' PHE . . . . . 0.565 ' HB2' HD23 ' A' ' 105' ' ' LEU . 15.9 m-85 -132.16 121.36 23.61 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.172 -0.467 . . . . 99.99 110.938 -179.958 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 89' ' ' TRP . . . . . 0.671 ' CA ' ' HA ' ' A' ' 80' ' ' THR . 3.7 t-105 -81.38 130.53 35.07 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.14 -0.482 . . . . 99.99 110.906 -179.923 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 90' ' ' VAL . . . . . 0.505 ' O ' ' CH2' ' A' ' 89' ' ' TRP . 6.1 p -80.93 114.58 22.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.215 -0.448 . . . . 99.99 111.172 179.912 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 91' ' ' ASP . . . . . 0.43 ' CB ' HD11 ' A' ' 103' ' ' LEU . 0.2 OUTLIER -41.9 -65.21 0.48 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.208 -0.451 . . . . 99.99 110.945 179.953 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 92' ' ' ARG . . . . . 0.472 ' O ' ' HG ' ' A' ' 103' ' ' LEU . 69.5 ttt180 -160.15 125.65 4.03 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.197 -0.456 . . . . 99.99 110.902 -179.967 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 93' ' ' VAL . . . . . 0.458 ' HB ' ' HB2' ' A' ' 101' ' ' CYS . 0.0 OUTLIER -115.49 111.55 36.12 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 116.203 -0.453 . . . . 99.99 111.135 179.954 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 94' ' ' SER . . . . . 0.44 ' C ' ' HB3' ' A' ' 101' ' ' CYS . 4.4 p -105.8 106.16 55.61 Favored Pre-proline 0 C--N 1.33 -0.255 0 CA-C-O 121.666 0.746 . . . . 99.99 110.833 -179.78 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 95' ' ' PRO . . . . . 0.411 ' HG3' ' HB ' ' A' ' 69' ' ' THR . 53.3 Cg_endo -69.83 159.19 54.28 Favored 'Trans proline' 0 C--N 1.341 0.18 0 C-N-CA 122.633 2.222 . . . . 99.99 112.363 179.984 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 4.5 m-20 . . . . . 0 C--N 1.329 -0.32 0 CA-C-N 116.23 -0.441 . . . . 99.99 110.884 179.982 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 2.0 p . . . . . 0 C--O 1.233 0.194 0 CA-C-O 120.831 0.348 . . . . 99.99 110.861 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 101' ' ' CYS . . . . . 0.458 ' HB2' ' HB ' ' A' ' 93' ' ' VAL . 0.3 OUTLIER -129.21 167.47 17.6 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.168 -0.469 . . . . 99.99 110.898 -179.95 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 102' ' ' HIS . . . . . 0.411 ' HA ' ' O ' ' A' ' 65' ' ' LEU . 37.0 p-80 -167.41 128.28 1.5 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.137 -0.483 . . . . 99.99 110.842 -179.928 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 103' ' ' LEU . . . . . 0.472 ' HG ' ' O ' ' A' ' 92' ' ' ARG . 2.5 tm? -150.19 147.17 27.38 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.181 -0.463 . . . . 99.99 110.938 -179.928 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 104' ' ' TRP . . . . . . . . . . . . . 29.7 p90 -63.92 118.25 8.15 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.261 -0.427 . . . . 99.99 110.95 179.893 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 105' ' ' LEU . . . . . 0.565 HD23 ' HB2' ' A' ' 88' ' ' PHE . 0.2 OUTLIER -88.45 163.58 15.89 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 116.245 -0.434 . . . . 99.99 110.924 -179.998 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -88.15 160.26 30.66 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.751 -0.737 . . . . 99.99 112.523 179.919 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 107' ' ' ARG . . . . . 0.474 ' HA ' ' CD1' ' A' ' 88' ' ' PHE . 0.7 OUTLIER -66.17 157.5 31.14 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.864 0.364 . . . . 99.99 110.923 -179.941 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -176.58 108.16 0.25 Allowed Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.733 -0.746 . . . . 99.99 112.425 179.984 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 10.8 p -100.06 133.6 21.46 Favored Pre-proline 0 C--N 1.329 -0.296 0 CA-C-O 121.543 0.687 . . . . 99.99 111.091 -179.938 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 110' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo . . . . . 0 C--O 1.23 0.123 0 C-N-CA 122.652 2.235 . . . . 99.99 112.319 179.934 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 25' ' ' THR . . . . . 0.424 ' CB ' ' HB ' ' A' ' 42' ' ' VAL . 8.4 m . . . . . 0 N--CA 1.457 -0.107 0 CA-C-O 120.742 0.306 . . . . 99.99 111.192 . . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -72.5 122.08 20.71 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.207 -0.451 . . . . 99.99 110.866 -179.855 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 27' ' ' ALA . . . . . 0.544 ' CB ' HG21 ' A' ' 39' ' ' ILE . . . -142.05 162.29 35.86 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.047 -0.524 . . . . 99.99 111.119 179.89 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 16.9 m -129.23 88.65 2.73 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.242 -0.436 . . . . 99.99 111.184 -179.883 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . 0.63 HG23 HG22 ' A' ' 39' ' ' ILE . 1.8 pt -44.64 130.99 1.7 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.218 -0.446 . . . . 99.99 111.135 179.917 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 7.3 m -153.73 97.98 2.16 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.167 -0.47 . . . . 99.99 111.15 179.934 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 87.1 p -137.76 70.92 1.39 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.229 -0.441 . . . . 99.99 110.921 -179.858 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -178.61 167.52 38.01 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.779 -0.724 . . . . 99.99 112.511 -179.924 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 3.6 pt-20 -49.45 -23.01 1.34 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.798 0.332 . . . . 99.99 110.851 -179.935 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -174.6 94.22 0.08 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.228 -0.442 . . . . 99.99 110.919 -179.913 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 3.1 m -144.71 165.77 27.12 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.161 -0.472 . . . . 99.99 110.821 -179.81 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 178.6 87.6 0.07 OUTLIER Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.78 -0.724 . . . . 99.99 112.497 -179.975 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -109.03 -172.49 2.06 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.904 0.383 . . . . 99.99 111.078 179.983 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 4.0 p -97.97 123.04 50.22 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.209 -0.451 . . . . 99.99 111.12 179.969 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 39' ' ' ILE . . . . . 0.63 HG22 HG23 ' A' ' 29' ' ' ILE . 0.0 OUTLIER -138.53 149.9 24.1 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.137 -0.483 . . . . 99.99 111.165 179.906 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 40' ' ' ARG . . . . . 0.401 ' HA ' ' O ' ' A' ' 25' ' ' THR . 6.6 mtm-85 -109.1 80.05 1.28 Allowed 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.159 -0.473 . . . . 99.99 110.879 -179.962 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . 0.501 ' N ' HD13 ' A' ' 39' ' ' ILE . . . -128.38 148.78 18.03 Favored Glycine 0 N--CA 1.45 -0.374 0 C-N-CA 120.814 -0.708 . . . . 99.99 112.577 -179.937 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 42' ' ' VAL . . . . . 0.424 ' HB ' ' CB ' ' A' ' 25' ' ' THR . 3.4 p -127.53 138.79 53.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-O 120.837 0.351 . . . . 99.99 111.148 -179.986 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 43' ' ' PHE . . . . . 0.503 ' HA ' ' O ' ' A' ' 64' ' ' SER . 2.5 p90 -98.36 128.76 44.92 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.175 -0.466 . . . . 99.99 110.887 -179.966 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -107.75 124.0 49.38 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.12 -0.491 . . . . 99.99 110.812 180.0 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 C--N 1.329 -0.315 0 CA-C-O 121.61 0.719 . . . . 99.99 110.854 179.976 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo . . . . . 0 C--O 1.231 0.15 0 CA-C-O 120.81 0.254 . . . . 99.99 112.359 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 64' ' ' SER . . . . . 0.503 ' O ' ' HA ' ' A' ' 43' ' ' PHE . 0.1 OUTLIER -106.54 148.39 28.29 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.203 -0.453 . . . . 99.99 110.865 -179.832 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 65' ' ' LEU . . . . . 0.495 ' HB2' ' CD2' ' A' ' 105' ' ' LEU . 2.8 tm? -114.55 129.29 56.65 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.134 -0.484 . . . . 99.99 110.924 -179.96 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 66' ' ' PHE . . . . . 0.4 ' C ' HG13 ' A' ' 67' ' ' VAL . 1.7 t80 -119.03 105.68 11.67 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.257 -0.428 . . . . 99.99 110.889 179.937 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 67' ' ' VAL . . . . . 0.4 HG13 ' C ' ' A' ' 66' ' ' PHE . 33.7 m -141.04 172.51 10.85 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-N 116.148 -0.478 . . . . 99.99 111.126 -179.968 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 1.1 ptp180 -109.23 144.47 37.3 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.194 -0.457 . . . . 99.99 110.849 -179.986 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 69' ' ' THR . . . . . 0.521 ' O ' ' N ' ' A' ' 73' ' ' ARG . 0.0 OUTLIER -38.01 -56.88 1.1 Allowed 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.202 -0.454 . . . . 99.99 111.189 -179.927 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 7.8 t70 -44.28 -59.43 2.38 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.155 -0.475 . . . . 99.99 110.865 179.908 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 71' ' ' GLU . . . . . . . . . . . . . 1.2 tm-20 -59.35 -42.1 90.74 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.217 -0.447 . . . . 99.99 110.92 -179.966 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 72' ' ' VAL . . . . . 0.442 HG12 ' O ' ' A' ' 69' ' ' THR . 0.3 OUTLIER -82.98 4.42 2.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.117 -0.492 . . . . 99.99 111.073 -179.948 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 73' ' ' ARG . . . . . 0.521 ' N ' ' O ' ' A' ' 69' ' ' THR . 16.1 ttt180 -98.31 -37.98 9.44 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.168 -0.469 . . . . 99.99 110.86 -179.993 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 48.7 mt-30 -65.67 -12.36 52.85 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.252 -0.431 . . . . 99.99 110.956 -179.978 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 3.1 mp -107.99 -174.46 2.53 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.157 -0.474 . . . . 99.99 110.877 -179.964 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 76' ' ' ARG . . . . . . . . . . . . . 10.5 ptp180 -117.91 154.37 32.02 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.164 -0.471 . . . . 99.99 110.941 179.965 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 3.7 ptt180 -51.21 131.91 28.15 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.24 -0.436 . . . . 99.99 110.87 -179.909 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 86.77 42.97 6.21 Favored Glycine 0 N--CA 1.452 -0.24 0 C-N-CA 120.735 -0.745 . . . . 99.99 112.397 179.944 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -103.43 110.74 22.88 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.909 0.385 . . . . 99.99 110.85 -179.963 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 80' ' ' THR . . . . . 0.72 ' HA ' ' HA ' ' A' ' 89' ' ' TRP . 0.0 OUTLIER -88.62 108.59 19.52 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.119 -0.491 . . . . 99.99 111.209 -179.886 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 81' ' ' LEU . . . . . 0.775 ' C ' ' HA ' ' A' ' 87' ' ' ASN . 0.0 OUTLIER -98.18 135.24 40.12 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.272 -0.422 . . . . 99.99 110.928 -179.986 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 82' ' ' THR . . . . . 0.695 ' N ' ' HA ' ' A' ' 87' ' ' ASN . 8.0 t -93.63 101.59 13.75 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.204 -0.453 . . . . 99.99 111.145 179.968 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 83' ' ' ILE . . . . . 0.443 ' CG2' ' CB ' ' A' ' 27' ' ' ALA . 0.1 OUTLIER -136.18 131.11 48.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.22 -0.446 . . . . 99.99 111.184 179.861 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 73.0 -54.59 1.78 Allowed Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.785 -0.722 . . . . 99.99 112.507 179.936 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 10.7 mm-40 -113.55 -80.65 0.59 Allowed 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 120.86 0.362 . . . . 99.99 110.875 -179.922 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 86' ' ' GLU . . . . . 0.463 ' C ' ' HA ' ' A' ' 82' ' ' THR . 96.1 mt-10 -154.54 161.06 41.82 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 116.159 -0.473 . . . . 99.99 110.823 -179.939 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 87' ' ' ASN . . . . . 0.775 ' HA ' ' C ' ' A' ' 81' ' ' LEU . 1.6 p-10 -50.7 121.98 6.63 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.156 -0.474 . . . . 99.99 110.921 -179.957 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 88' ' ' PHE . . . . . 0.539 ' C ' ' HA ' ' A' ' 80' ' ' THR . 14.7 m-85 -131.08 120.86 24.02 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.155 -0.475 . . . . 99.99 110.903 -179.972 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 89' ' ' TRP . . . . . 0.72 ' HA ' ' HA ' ' A' ' 80' ' ' THR . 0.9 OUTLIER -80.11 135.77 36.39 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.12 -0.491 . . . . 99.99 110.913 -179.951 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 90' ' ' VAL . . . . . 0.448 ' HA ' ' HB3' ' A' ' 105' ' ' LEU . 0.3 OUTLIER -92.58 138.23 20.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.264 -0.426 . . . . 99.99 111.101 179.925 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 91' ' ' ASP . . . . . 0.437 ' CB ' HD13 ' A' ' 103' ' ' LEU . 0.5 OUTLIER -65.61 -71.19 0.2 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.186 -0.461 . . . . 99.99 110.85 179.935 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 92' ' ' ARG . . . . . 0.511 ' O ' ' HG ' ' A' ' 103' ' ' LEU . 0.0 OUTLIER -152.58 120.89 6.3 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.251 -0.432 . . . . 99.99 110.838 -179.882 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 93' ' ' VAL . . . . . 0.568 ' HB ' ' HB2' ' A' ' 101' ' ' CYS . 8.8 m -121.45 137.28 55.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.254 -0.43 . . . . 99.99 111.121 179.928 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 12.6 t -137.14 128.4 16.44 Favored Pre-proline 0 C--N 1.328 -0.337 0 CA-C-O 121.714 0.769 . . . . 99.99 110.862 -179.856 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 95' ' ' PRO . . . . . 0.469 ' HG3' ' HB ' ' A' ' 69' ' ' THR . 53.2 Cg_endo -69.85 160.51 49.42 Favored 'Trans proline' 0 C--N 1.342 0.198 0 C-N-CA 122.681 2.254 . . . . 99.99 112.322 -179.946 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 9.4 t0 . . . . . 0 C--N 1.329 -0.307 0 CA-C-N 116.256 -0.429 . . . . 99.99 110.844 179.945 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 20.1 t . . . . . 0 C--O 1.232 0.153 0 CA-C-O 120.91 0.386 . . . . 99.99 110.842 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 101' ' ' CYS . . . . . 0.568 ' HB2' ' HB ' ' A' ' 93' ' ' VAL . 19.6 p -47.23 142.31 3.98 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.16 -0.473 . . . . 99.99 110.882 -179.98 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 102' ' ' HIS . . . . . 0.429 ' HA ' ' O ' ' A' ' 65' ' ' LEU . 43.4 p-80 -159.97 129.38 5.2 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.241 -0.436 . . . . 99.99 110.836 -179.934 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 103' ' ' LEU . . . . . 0.511 ' HG ' ' O ' ' A' ' 92' ' ' ARG . 2.8 tm? -150.8 148.4 28.45 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 116.239 -0.437 . . . . 99.99 110.943 -179.998 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 104' ' ' TRP . . . . . . . . . . . . . 56.3 p-90 -64.34 118.02 8.08 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.174 -0.466 . . . . 99.99 110.855 179.946 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 105' ' ' LEU . . . . . 0.502 HD21 ' HB2' ' A' ' 88' ' ' PHE . 0.4 OUTLIER -93.92 162.8 13.76 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.266 -0.425 . . . . 99.99 110.866 179.978 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -91.0 160.39 27.26 Favored Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.712 -0.756 . . . . 99.99 112.498 179.892 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 107' ' ' ARG . . . . . 0.532 ' HA ' ' CD1' ' A' ' 88' ' ' PHE . 0.0 OUTLIER -65.73 157.39 30.31 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.856 0.36 . . . . 99.99 110.925 -179.895 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -173.1 110.18 0.33 Allowed Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.644 -0.789 . . . . 99.99 112.454 179.984 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 7.1 p -84.19 133.89 44.38 Favored Pre-proline 0 C--N 1.33 -0.28 0 CA-C-O 121.687 0.756 . . . . 99.99 111.084 -179.93 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 110' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo . . . . . 0 C--N 1.342 0.222 0 C-N-CA 122.644 2.229 . . . . 99.99 112.328 179.928 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 25' ' ' THR . . . . . 0.481 ' HB ' HG21 ' A' ' 42' ' ' VAL . 98.6 m . . . . . 0 C--O 1.231 0.081 0 CA-C-O 120.804 0.335 . . . . 99.99 111.107 . . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 3.0 p -70.81 123.5 22.11 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.173 -0.467 . . . . 99.99 110.823 -179.844 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 27' ' ' ALA . . . . . 0.54 ' CB ' HG21 ' A' ' 39' ' ' ILE . . . -135.24 162.42 32.61 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.074 -0.512 . . . . 99.99 111.104 179.884 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 21.7 m -129.33 85.8 2.36 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.216 -0.447 . . . . 99.99 111.09 -179.902 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . 0.666 HG22 HG22 ' A' ' 39' ' ' ILE . 1.9 pt -44.92 126.93 1.3 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.182 -0.463 . . . . 99.99 111.137 179.884 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 17.6 m -151.93 97.87 2.39 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.119 -0.491 . . . . 99.99 111.143 -179.983 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 5.1 t -136.5 70.53 1.41 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.161 -0.472 . . . . 99.99 110.913 -179.853 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -178.88 168.8 39.92 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.771 -0.728 . . . . 99.99 112.536 -179.93 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 5.8 pt-20 -49.31 -23.25 1.33 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.809 0.338 . . . . 99.99 110.9 -179.906 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -174.76 95.29 0.08 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.204 -0.453 . . . . 99.99 110.913 -179.908 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 2.3 m -145.24 165.41 28.46 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.148 -0.478 . . . . 99.99 110.84 -179.794 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 176.36 88.42 0.07 OUTLIER Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 120.756 -0.735 . . . . 99.99 112.515 -179.988 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -108.11 -170.53 1.7 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.809 0.337 . . . . 99.99 111.161 179.994 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 4.4 p -99.03 119.64 47.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.293 -0.412 . . . . 99.99 111.112 179.983 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 39' ' ' ILE . . . . . 0.666 HG22 HG22 ' A' ' 29' ' ' ILE . 0.0 OUTLIER -139.1 151.56 23.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.059 -0.518 . . . . 99.99 111.096 179.938 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 40' ' ' ARG . . . . . . . . . . . . . 1.4 ptp85 -113.59 82.86 1.75 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.191 -0.459 . . . . 99.99 110.879 179.964 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . 0.464 ' H ' ' HB2' ' A' ' 27' ' ' ALA . . . -111.92 146.46 18.0 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.723 -0.751 . . . . 99.99 112.436 -179.923 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 42' ' ' VAL . . . . . 0.56 ' O ' ' HA ' ' A' ' 65' ' ' LEU . 2.2 t -124.58 112.57 32.68 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-O 120.882 0.372 . . . . 99.99 111.08 -179.937 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 43' ' ' PHE . . . . . 0.515 ' HA ' ' O ' ' A' ' 64' ' ' SER . 2.4 p90 -87.29 131.38 34.26 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.141 -0.481 . . . . 99.99 110.89 -179.976 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 2.8 t70 -129.78 125.34 35.56 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.129 -0.487 . . . . 99.99 110.811 -179.965 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 2.5 p-10 . . . . . 0 C--N 1.33 -0.276 0 CA-C-O 121.567 0.698 . . . . 99.99 110.862 -179.928 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo . . . . . 0 C--O 1.231 0.17 0 CA-C-O 120.753 0.23 . . . . 99.99 112.37 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 64' ' ' SER . . . . . 0.515 ' O ' ' HA ' ' A' ' 43' ' ' PHE . 1.3 t -106.19 142.51 35.77 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.259 -0.428 . . . . 99.99 110.906 -179.816 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 65' ' ' LEU . . . . . 0.56 ' HA ' ' O ' ' A' ' 42' ' ' VAL . 0.4 OUTLIER -110.75 123.72 50.59 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.178 -0.464 . . . . 99.99 110.942 179.982 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -94.05 111.83 23.59 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.23 -0.441 . . . . 99.99 110.924 179.961 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -140.92 167.28 17.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.227 -0.442 . . . . 99.99 111.109 -179.998 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 3.5 ttp85 -96.84 132.42 42.6 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.174 -0.466 . . . . 99.99 110.91 -179.952 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 69' ' ' THR . . . . . 0.417 ' O ' HG12 ' A' ' 72' ' ' VAL . 1.4 m -44.67 -36.81 3.29 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.246 -0.433 . . . . 99.99 111.126 -179.825 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 33.2 t0 -59.02 -71.88 0.11 Allowed 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.199 -0.455 . . . . 99.99 110.872 179.868 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 71' ' ' GLU . . . . . . . . . . . . . 3.1 pt-20 -56.37 -37.73 70.45 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.176 -0.466 . . . . 99.99 110.875 -179.849 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 72' ' ' VAL . . . . . 0.417 HG12 ' O ' ' A' ' 69' ' ' THR . 0.4 OUTLIER -68.74 -25.39 30.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.157 -0.474 . . . . 99.99 111.148 179.982 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 73' ' ' ARG . . . . . . . . . . . . . 24.7 ttm-85 -75.9 -39.3 56.62 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.107 -0.497 . . . . 99.99 110.869 -179.996 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 12.4 mt-30 -54.73 -29.09 52.59 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.214 -0.448 . . . . 99.99 110.895 -179.936 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 3.4 mp -87.26 -175.82 5.43 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.182 -0.463 . . . . 99.99 110.944 -179.973 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 76' ' ' ARG . . . . . . . . . . . . . 6.8 ttt-85 -109.47 139.33 44.59 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.192 -0.458 . . . . 99.99 110.866 179.962 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 3.3 ptt85 -48.65 108.31 0.17 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.224 -0.443 . . . . 99.99 110.844 -179.92 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 119.55 9.96 8.15 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.663 -0.78 . . . . 99.99 112.536 -179.932 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -73.09 109.12 6.38 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.945 0.402 . . . . 99.99 110.914 -179.994 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 80' ' ' THR . . . . . 0.701 ' HA ' ' HA ' ' A' ' 89' ' ' TRP . 0.0 OUTLIER -85.51 110.34 19.13 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.17 -0.468 . . . . 99.99 111.118 -179.828 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 81' ' ' LEU . . . . . 0.746 ' C ' ' HA ' ' A' ' 87' ' ' ASN . 0.3 OUTLIER -97.63 132.43 43.29 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.222 -0.445 . . . . 99.99 110.887 179.97 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 82' ' ' THR . . . . . 0.76 ' CA ' ' HA ' ' A' ' 87' ' ' ASN . 6.7 t -91.57 102.35 15.0 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.189 -0.46 . . . . 99.99 111.139 179.925 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 83' ' ' ILE . . . . . 0.45 ' CG2' ' CB ' ' A' ' 27' ' ' ALA . 0.1 OUTLIER -139.24 131.2 35.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.223 -0.444 . . . . 99.99 111.119 179.923 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 76.74 -51.67 3.1 Favored Glycine 0 N--CA 1.452 -0.264 0 C-N-CA 120.715 -0.755 . . . . 99.99 112.471 179.9 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 6.7 tp10 -121.37 -77.83 0.59 Allowed 'General case' 0 C--N 1.331 -0.229 0 CA-C-O 120.818 0.342 . . . . 99.99 110.876 -179.876 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 86' ' ' GLU . . . . . 0.476 ' C ' ' HA ' ' A' ' 82' ' ' THR . 98.8 mt-10 -152.76 162.29 41.46 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.12 -0.491 . . . . 99.99 110.923 -179.977 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 87' ' ' ASN . . . . . 0.76 ' HA ' ' CA ' ' A' ' 82' ' ' THR . 2.4 p30 -51.5 122.02 7.31 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.183 -0.462 . . . . 99.99 110.899 -179.975 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 88' ' ' PHE . . . . . 0.588 ' HB2' HD23 ' A' ' 105' ' ' LEU . 13.9 m-85 -131.77 119.4 21.23 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.184 -0.462 . . . . 99.99 110.935 179.95 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 89' ' ' TRP . . . . . 0.701 ' HA ' ' HA ' ' A' ' 80' ' ' THR . 65.4 p-90 -82.21 132.87 35.23 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.164 -0.471 . . . . 99.99 110.96 179.983 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 90' ' ' VAL . . . . . 0.506 ' HA ' ' HB3' ' A' ' 105' ' ' LEU . 4.0 p -95.39 139.11 19.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.231 -0.441 . . . . 99.99 111.156 179.92 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 1.9 t70 -58.84 -73.82 0.08 Allowed 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.208 -0.451 . . . . 99.99 110.877 179.959 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 8.2 ttt180 -170.15 121.39 0.64 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.215 -0.448 . . . . 99.99 110.898 -179.908 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 93' ' ' VAL . . . . . 0.536 ' HB ' ' HB3' ' A' ' 101' ' ' CYS . 2.6 m -104.83 139.0 27.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.217 -0.447 . . . . 99.99 111.176 179.917 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 12.1 t -130.1 96.53 25.18 Favored Pre-proline 0 C--N 1.33 -0.278 0 CA-C-O 121.577 0.703 . . . . 99.99 110.826 -179.766 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 52.6 Cg_endo -69.8 -167.39 0.22 Allowed 'Trans proline' 0 C--N 1.341 0.152 0 C-N-CA 122.655 2.237 . . . . 99.99 112.319 179.97 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 5.8 t0 . . . . . 0 C--N 1.328 -0.345 0 CA-C-N 116.226 -0.443 . . . . 99.99 110.871 179.971 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 12.0 t . . . . . 0 C--O 1.232 0.168 0 CA-C-O 120.809 0.338 . . . . 99.99 110.774 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 101' ' ' CYS . . . . . 0.536 ' HB3' ' HB ' ' A' ' 93' ' ' VAL . 1.8 t -132.12 -172.83 2.98 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.185 -0.462 . . . . 99.99 110.849 -179.955 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 102' ' ' HIS . . . . . . . . . . . . . 2.6 p-80 -169.53 138.91 1.99 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.183 -0.462 . . . . 99.99 110.91 -179.933 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 103' ' ' LEU . . . . . . . . . . . . . 6.2 tt -139.26 155.79 47.51 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.267 -0.424 . . . . 99.99 110.945 -179.943 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 104' ' ' TRP . . . . . . . . . . . . . 48.4 p-90 -64.21 110.27 2.15 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 116.18 -0.464 . . . . 99.99 110.871 179.92 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 105' ' ' LEU . . . . . 0.588 HD23 ' HB2' ' A' ' 88' ' ' PHE . 0.4 OUTLIER -91.24 163.05 14.38 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.218 -0.446 . . . . 99.99 110.958 179.957 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -89.13 157.64 27.21 Favored Glycine 0 N--CA 1.452 -0.266 0 C-N-CA 120.732 -0.747 . . . . 99.99 112.456 179.888 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 107' ' ' ARG . . . . . 0.506 ' HA ' ' CD1' ' A' ' 88' ' ' PHE . 65.5 ttp85 -69.99 156.91 38.43 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.784 0.326 . . . . 99.99 110.895 -179.856 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -169.77 108.15 0.29 Allowed Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.736 -0.745 . . . . 99.99 112.549 179.999 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 7.3 p -90.14 134.16 32.08 Favored Pre-proline 0 C--N 1.329 -0.295 0 CA-C-O 121.566 0.698 . . . . 99.99 111.121 -179.906 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 110' ' ' PRO . . . . . 0.471 ' N ' HD22 ' A' ' 87' ' ' ASN . 53.2 Cg_endo . . . . . 0 C--O 1.232 0.217 0 C-N-CA 122.737 2.291 . . . . 99.99 112.308 179.995 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 25' ' ' THR . . . . . 0.601 ' O ' ' HA ' ' A' ' 40' ' ' ARG . 69.8 p . . . . . 0 N--CA 1.456 -0.14 0 CA-C-O 120.737 0.303 . . . . 99.99 111.156 . . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -76.3 122.47 24.48 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.268 -0.424 . . . . 99.99 110.838 -179.838 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 27' ' ' ALA . . . . . 0.581 ' CB ' HG21 ' A' ' 39' ' ' ILE . . . -151.56 161.78 42.1 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.184 -0.462 . . . . 99.99 111.104 179.882 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 12.9 m -131.46 89.74 2.76 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.215 -0.448 . . . . 99.99 111.167 -179.97 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . 0.552 HG23 HG22 ' A' ' 39' ' ' ILE . 2.1 pt -44.22 130.23 1.48 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 116.186 -0.461 . . . . 99.99 111.12 179.932 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 9.1 m -153.61 99.26 2.3 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.218 -0.447 . . . . 99.99 111.137 179.924 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 8.1 t -139.34 72.41 1.4 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.184 -0.462 . . . . 99.99 110.856 -179.819 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -178.96 166.95 36.9 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.796 -0.716 . . . . 99.99 112.512 179.999 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 17.1 pt-20 -49.24 -23.58 1.41 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.743 0.306 . . . . 99.99 110.829 -179.901 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 1.1 mt-30 -174.4 93.65 0.08 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.193 -0.458 . . . . 99.99 110.948 -179.829 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 3.2 m -145.95 165.71 28.16 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.196 -0.456 . . . . 99.99 110.885 -179.793 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 179.46 86.97 0.07 OUTLIER Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.788 -0.72 . . . . 99.99 112.542 -179.966 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -105.79 -171.82 1.98 Allowed 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.81 0.338 . . . . 99.99 111.056 -179.955 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 73.5 t -99.74 122.79 52.0 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.15 -0.477 . . . . 99.99 111.131 -179.985 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 39' ' ' ILE . . . . . 0.581 HG21 ' CB ' ' A' ' 27' ' ' ALA . 0.0 OUTLIER -136.82 150.24 26.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.189 -0.459 . . . . 99.99 111.093 179.882 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 40' ' ' ARG . . . . . 0.601 ' HA ' ' O ' ' A' ' 25' ' ' THR . 10.1 mmt-85 -110.82 82.23 1.56 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.17 -0.468 . . . . 99.99 110.88 179.987 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . 0.486 ' O ' ' HB2' ' A' ' 27' ' ' ALA . . . -141.5 142.95 12.49 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.78 -0.724 . . . . 99.99 112.485 -179.965 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 42' ' ' VAL . . . . . 0.49 ' O ' ' HA ' ' A' ' 65' ' ' LEU . 8.8 p -127.46 142.34 43.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-O 120.912 0.387 . . . . 99.99 111.091 -179.95 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 43' ' ' PHE . . . . . 0.413 ' HA ' ' O ' ' A' ' 64' ' ' SER . 2.0 p90 -90.05 135.19 33.8 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.205 -0.452 . . . . 99.99 110.937 179.905 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 11.5 t0 -120.17 125.23 47.68 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.134 -0.485 . . . . 99.99 110.869 179.965 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--N 1.328 -0.339 0 CA-C-O 121.646 0.736 . . . . 99.99 110.854 179.988 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo . . . . . 0 C--O 1.231 0.156 0 CA-C-O 120.74 0.225 . . . . 99.99 112.337 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 64' ' ' SER . . . . . 0.413 ' O ' ' HA ' ' A' ' 43' ' ' PHE . 1.1 t -110.7 144.42 39.66 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.214 -0.448 . . . . 99.99 110.817 -179.798 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 65' ' ' LEU . . . . . 0.49 ' HA ' ' O ' ' A' ' 42' ' ' VAL . 0.0 OUTLIER -112.97 123.39 50.22 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.142 -0.481 . . . . 99.99 110.869 -179.943 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 15.3 t80 -102.88 110.31 22.18 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.235 -0.439 . . . . 99.99 110.972 179.857 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 28.0 m -141.16 172.09 11.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.135 -0.484 . . . . 99.99 111.089 -179.93 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 68' ' ' ARG . . . . . 0.424 ' HG2' ' H ' ' A' ' 71' ' ' GLU . 0.9 OUTLIER -104.95 142.19 35.22 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.126 -0.488 . . . . 99.99 110.885 179.989 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 69' ' ' THR . . . . . 0.445 ' O ' ' N ' ' A' ' 73' ' ' ARG . 0.1 OUTLIER -36.03 -69.59 0.1 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.18 -0.464 . . . . 99.99 111.128 -179.91 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 30.9 t70 -44.06 -50.24 8.5 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.183 -0.462 . . . . 99.99 110.922 179.917 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 71' ' ' GLU . . . . . 0.424 ' H ' ' HG2' ' A' ' 68' ' ' ARG . 7.4 tp10 -55.49 -40.69 72.02 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.199 -0.455 . . . . 99.99 110.978 -179.976 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 6.1 p -101.09 16.55 4.25 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.244 0 CA-C-N 116.134 -0.485 . . . . 99.99 111.052 179.998 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 73' ' ' ARG . . . . . 0.445 ' N ' ' O ' ' A' ' 69' ' ' THR . 0.6 OUTLIER -103.58 -32.19 9.55 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.18 -0.464 . . . . 99.99 110.87 -179.95 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -64.57 -23.46 67.28 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.143 -0.481 . . . . 99.99 110.983 -179.936 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 75' ' ' LEU . . . . . 0.496 ' CD2' ' C ' ' A' ' 75' ' ' LEU . 0.0 OUTLIER -103.99 -177.56 3.4 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.149 -0.478 . . . . 99.99 110.888 179.968 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 76' ' ' ARG . . . . . . . . . . . . . 33.4 ttt180 -97.35 146.55 25.05 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.162 -0.472 . . . . 99.99 110.85 179.977 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 5.6 ptm180 -51.79 154.89 1.87 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.203 -0.453 . . . . 99.99 110.848 -179.919 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 72.46 18.9 78.66 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.734 -0.746 . . . . 99.99 112.538 -179.943 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 58.5 t0 -76.5 115.18 16.01 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.866 0.365 . . . . 99.99 110.81 -179.95 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 80' ' ' THR . . . . . 0.703 ' HA ' ' HA ' ' A' ' 89' ' ' TRP . 0.0 OUTLIER -88.15 109.1 19.63 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.148 -0.478 . . . . 99.99 111.197 -179.957 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 81' ' ' LEU . . . . . 0.774 ' C ' ' HA ' ' A' ' 87' ' ' ASN . 0.0 OUTLIER -97.24 134.46 40.51 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.246 -0.433 . . . . 99.99 110.943 179.93 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 82' ' ' THR . . . . . 0.71 ' CA ' ' HA ' ' A' ' 87' ' ' ASN . 5.0 t -92.77 101.36 13.74 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.186 -0.461 . . . . 99.99 111.112 179.981 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 83' ' ' ILE . . . . . 0.482 ' CD1' ' O ' ' A' ' 83' ' ' ILE . 0.1 OUTLIER -132.99 130.66 58.61 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 116.246 -0.434 . . . . 99.99 111.111 179.938 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 71.97 -57.92 1.41 Allowed Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.721 -0.752 . . . . 99.99 112.502 179.931 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 7.6 tp10 -109.54 -82.37 0.57 Allowed 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.838 0.352 . . . . 99.99 110.893 -179.92 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 86' ' ' GLU . . . . . 0.452 ' C ' ' HA ' ' A' ' 82' ' ' THR . 5.8 mm-40 -151.09 162.02 41.64 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.162 -0.472 . . . . 99.99 110.896 -179.955 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 87' ' ' ASN . . . . . 0.774 ' HA ' ' C ' ' A' ' 81' ' ' LEU . 12.1 p30 -51.43 125.31 14.09 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.14 -0.482 . . . . 99.99 110.9 -179.933 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 88' ' ' PHE . . . . . 0.594 ' CD1' ' HA ' ' A' ' 107' ' ' ARG . 15.3 m-85 -132.55 118.5 19.3 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.166 -0.47 . . . . 99.99 110.846 -179.958 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 89' ' ' TRP . . . . . 0.703 ' HA ' ' HA ' ' A' ' 80' ' ' THR . 53.9 p-90 -82.62 136.3 34.83 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.12 -0.491 . . . . 99.99 110.91 -179.976 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 90' ' ' VAL . . . . . 0.484 ' HA ' ' HB3' ' A' ' 105' ' ' LEU . 4.5 p -93.36 139.6 17.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.197 -0.456 . . . . 99.99 111.158 179.915 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -62.71 -63.77 1.12 Allowed 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.157 -0.474 . . . . 99.99 110.869 179.933 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 92' ' ' ARG . . . . . 0.448 ' H ' HD22 ' A' ' 103' ' ' LEU . 11.5 mtm180 -159.2 123.9 4.06 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.145 -0.479 . . . . 99.99 110.858 -179.869 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 93' ' ' VAL . . . . . 0.598 ' HB ' ' HB2' ' A' ' 101' ' ' CYS . 18.6 m -123.37 136.01 61.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.155 -0.475 . . . . 99.99 111.086 179.985 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 21.0 m -136.36 130.45 18.14 Favored Pre-proline 0 C--N 1.33 -0.244 0 CA-C-O 121.618 0.723 . . . . 99.99 110.854 -179.855 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 95' ' ' PRO . . . . . 0.411 ' HG3' ' HB ' ' A' ' 69' ' ' THR . 53.8 Cg_endo -69.75 155.55 65.7 Favored 'Trans proline' 0 C--O 1.232 0.178 0 C-N-CA 122.667 2.244 . . . . 99.99 112.385 179.931 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 14.1 t0 . . . . . 0 C--N 1.328 -0.34 0 CA-C-N 116.198 -0.455 . . . . 99.99 110.914 179.909 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 3.3 m . . . . . 0 C--O 1.232 0.163 0 CA-C-O 120.8 0.333 . . . . 99.99 110.845 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 101' ' ' CYS . . . . . 0.598 ' HB2' ' HB ' ' A' ' 93' ' ' VAL . 25.4 p -47.3 132.66 12.82 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.144 -0.48 . . . . 99.99 110.939 179.996 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 102' ' ' HIS . . . . . . . . . . . . . 1.7 p80 -163.28 130.3 3.45 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.221 -0.445 . . . . 99.99 110.887 -179.968 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 103' ' ' LEU . . . . . 0.448 HD22 ' H ' ' A' ' 92' ' ' ARG . 7.1 tt -147.78 157.1 43.38 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.211 -0.449 . . . . 99.99 110.942 179.978 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 104' ' ' TRP . . . . . . . . . . . . . 8.4 m-90 -64.0 110.08 2.02 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.195 -0.457 . . . . 99.99 110.939 179.898 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 105' ' ' LEU . . . . . 0.535 HD22 ' HB2' ' A' ' 88' ' ' PHE . 0.3 OUTLIER -88.75 163.06 15.9 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.231 -0.44 . . . . 99.99 110.922 179.986 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -92.41 161.37 26.26 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.749 -0.738 . . . . 99.99 112.455 179.956 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 107' ' ' ARG . . . . . 0.594 ' HA ' ' CD1' ' A' ' 88' ' ' PHE . 4.8 ptt180 -68.07 158.57 32.7 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.835 0.35 . . . . 99.99 110.841 -179.832 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -171.49 112.38 0.44 Allowed Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.673 -0.775 . . . . 99.99 112.469 -179.998 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 7.2 p -101.3 134.09 20.52 Favored Pre-proline 0 C--N 1.328 -0.332 0 CA-C-O 121.619 0.723 . . . . 99.99 111.157 179.999 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 110' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo . . . . . 0 C--O 1.232 0.199 0 C-N-CA 122.731 2.288 . . . . 99.99 112.321 179.956 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--O 1.231 0.115 0 CA-C-O 120.766 0.317 . . . . 99.99 110.887 . . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -156.36 178.35 10.41 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.22 -0.446 . . . . 99.99 111.151 179.833 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 3' ' ' ASP . . . . . . . . . . . . . 9.3 m-20 -159.6 -178.56 7.19 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.234 -0.439 . . . . 99.99 110.837 -179.997 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 4' ' ' PHE . . . . . . . . . . . . . 3.8 t80 -170.12 161.03 8.36 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.173 -0.467 . . . . 99.99 110.892 -179.878 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 8.5 m-20 -157.9 -177.25 6.43 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.154 -0.476 . . . . 99.99 110.838 179.933 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 6' ' ' ASN . . . . . . . . . . . . . 24.4 t30 -151.68 173.7 14.38 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.15 -0.477 . . . . 99.99 110.82 -179.903 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 7' ' ' LEU . . . . . . . . . . . . . 3.4 pp -171.81 -176.87 1.83 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.168 -0.469 . . . . 99.99 110.926 179.945 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 8' ' ' PHE . . . . . . . . . . . . . 30.6 p90 -140.33 178.54 7.22 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.16 -0.473 . . . . 99.99 110.884 179.9 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 4.0 m-20 -164.04 179.14 7.16 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.146 -0.479 . . . . 99.99 110.834 179.979 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -132.85 -173.18 3.11 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.148 -0.478 . . . . 99.99 111.092 179.967 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -149.15 133.15 17.15 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.206 -0.452 . . . . 99.99 111.078 179.953 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -132.68 -153.68 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.141 -0.481 . . . . 99.99 111.175 179.927 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -144.37 144.42 31.42 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.261 -0.427 . . . . 99.99 111.135 179.824 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 22.3 mmm180 -145.45 -176.85 5.28 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.262 -0.426 . . . . 99.99 110.875 -179.936 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -124.79 -172.47 2.58 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.187 -0.461 . . . . 99.99 111.029 179.95 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 8.8 t0 -140.43 176.53 8.7 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.136 -0.484 . . . . 99.99 110.842 -179.996 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -175.02 176.3 2.15 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.192 -0.458 . . . . 99.99 110.971 -179.91 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 1.1 p -139.59 150.39 44.96 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.189 -0.46 . . . . 99.99 111.142 -179.919 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 45.0 mm -140.12 103.59 1.65 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.251 -0.432 . . . . 99.99 111.081 179.953 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 20' ' ' ARG . . . . . . . . . . . . . 5.4 tmm_? -167.47 132.61 1.97 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.179 -0.464 . . . . 99.99 110.863 179.963 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 155.89 92.19 0.09 OUTLIER Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.721 -0.752 . . . . 99.99 112.45 -179.97 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 22' ' ' TYR . . . . . . . . . . . . . 72.7 t80 -150.09 93.93 2.08 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.921 0.391 . . . . 99.99 110.91 -179.883 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 23' ' ' MET . . . . . . . . . . . . . 11.1 ttm -134.37 -55.8 0.85 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.08 -0.509 . . . . 99.99 110.921 179.913 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -112.19 -112.39 3.21 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.699 -0.763 . . . . 99.99 112.473 -179.999 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 25' ' ' THR . . . . . 0.413 ' CB ' ' HB ' ' A' ' 42' ' ' VAL . 11.7 m -98.65 137.41 37.33 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.765 0.317 . . . . 99.99 111.237 -179.913 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -71.95 122.45 20.85 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.286 -0.415 . . . . 99.99 110.842 -179.836 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 27' ' ' ALA . . . . . 0.52 ' CB ' HG21 ' A' ' 39' ' ' ILE . . . -141.95 162.18 36.13 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.09 -0.505 . . . . 99.99 111.134 179.904 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 21.2 m -129.99 87.95 2.59 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.224 -0.444 . . . . 99.99 111.143 -179.918 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . 0.641 HG21 HG22 ' A' ' 39' ' ' ILE . 2.3 pt -45.15 130.9 1.97 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.277 -0.419 . . . . 99.99 111.08 179.931 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 19.8 m -153.14 97.51 2.19 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.133 -0.485 . . . . 99.99 111.155 179.974 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 8.5 t -135.1 70.86 1.43 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.213 -0.449 . . . . 99.99 110.829 -179.858 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -178.95 167.92 38.47 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.76 -0.733 . . . . 99.99 112.449 179.984 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 4.1 pt-20 -49.12 -23.36 1.22 Allowed 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.828 0.346 . . . . 99.99 110.89 -179.878 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 9.6 tt0 -174.44 94.64 0.08 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.129 -0.487 . . . . 99.99 110.879 -179.938 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -144.9 165.49 27.98 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.992 0.425 . . . . 99.99 110.832 -179.831 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 178.17 87.84 0.07 OUTLIER Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.752 -0.737 . . . . 99.99 112.48 -179.97 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -107.06 -170.67 1.75 Allowed 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.881 0.372 . . . . 99.99 111.087 179.984 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 4.1 p -99.15 120.74 48.9 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.227 -0.442 . . . . 99.99 111.185 179.913 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 39' ' ' ILE . . . . . 0.641 HG22 HG21 ' A' ' 29' ' ' ILE . 0.0 OUTLIER -137.85 148.69 25.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.199 -0.455 . . . . 99.99 111.106 179.951 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 40' ' ' ARG . . . . . 0.402 ' HA ' ' O ' ' A' ' 25' ' ' THR . 18.5 mtt180 -109.66 80.76 1.35 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.189 -0.459 . . . . 99.99 110.887 179.9 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . 0.497 ' H ' ' HB1' ' A' ' 27' ' ' ALA . . . -128.71 148.9 18.21 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.738 -0.744 . . . . 99.99 112.454 -179.928 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 42' ' ' VAL . . . . . 0.504 ' O ' ' HA ' ' A' ' 65' ' ' LEU . 3.4 p -127.16 135.04 64.64 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-O 120.851 0.357 . . . . 99.99 111.102 179.972 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 43' ' ' PHE . . . . . 0.476 ' HA ' ' O ' ' A' ' 64' ' ' SER . 3.2 p90 -92.84 128.2 38.62 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.134 -0.485 . . . . 99.99 110.915 179.945 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 46.8 m-20 -114.88 124.52 51.93 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 116.133 -0.485 . . . . 99.99 110.861 179.944 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -105.63 153.0 40.19 Favored Pre-proline 0 C--N 1.329 -0.314 0 CA-C-O 121.624 0.726 . . . . 99.99 110.854 179.95 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 46' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.78 -41.31 4.36 Favored 'Trans proline' 0 C--N 1.342 0.186 0 C-N-CA 122.636 2.224 . . . . 99.99 112.355 179.991 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 28.9 tt0 -169.74 103.97 0.33 Allowed 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.225 -0.443 . . . . 99.99 110.898 179.989 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 4.0 t-20 -51.57 -30.5 21.06 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.213 -0.449 . . . . 99.99 110.861 -179.853 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 28.6 mt -88.69 100.16 10.18 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.192 -0.458 . . . . 99.99 111.104 179.911 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 1.4 t -153.83 147.3 24.99 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.149 -0.478 . . . . 99.99 110.864 -179.923 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 7.6 m-85 -148.72 178.62 8.49 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.13 -0.487 . . . . 99.99 110.854 -179.82 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -125.96 -75.79 0.59 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.105 -0.498 . . . . 99.99 111.043 179.875 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 147.13 39.91 0.04 OUTLIER Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.764 -0.731 . . . . 99.99 112.457 -179.921 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 54' ' ' GLN . . . . . . . . . . . . . 42.8 mt-30 53.26 29.55 8.69 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.818 0.342 . . . . 99.99 110.914 -179.866 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -103.96 -65.75 0.7 Allowed Glycine 0 N--CA 1.452 -0.271 0 C-N-CA 120.752 -0.737 . . . . 99.99 112.434 -179.946 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 43.8 t -68.17 147.18 12.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-O 120.79 0.329 . . . . 99.99 111.126 -179.916 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 15.6 ptm180 -94.95 -31.34 13.69 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.126 -0.488 . . . . 99.99 110.871 -179.961 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 7.1 p -134.44 126.89 49.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.209 -0.45 . . . . 99.99 111.142 179.972 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 2.6 tt0 -104.81 172.56 6.72 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.165 -0.47 . . . . 99.99 110.885 -179.981 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -131.83 131.99 6.54 Favored Glycine 0 N--CA 1.452 -0.262 0 C-N-CA 120.706 -0.759 . . . . 99.99 112.496 -179.991 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 1.7 p -148.11 123.64 10.41 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.885 0.374 . . . . 99.99 110.888 -179.77 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 16.7 p -133.01 97.81 16.39 Favored Pre-proline 0 C--N 1.329 -0.322 0 CA-C-O 121.689 0.757 . . . . 99.99 110.84 -179.796 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 63' ' ' PRO . . . . . 0.409 ' O ' ' HA ' ' A' ' 104' ' ' TRP . 54.2 Cg_endo -69.76 -178.46 2.35 Favored 'Trans proline' 0 C--N 1.341 0.183 0 C-N-CA 122.684 2.256 . . . . 99.99 112.354 179.975 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 64' ' ' SER . . . . . 0.476 ' O ' ' HA ' ' A' ' 43' ' ' PHE . 2.2 t -106.46 146.8 30.1 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.271 -0.422 . . . . 99.99 110.821 -179.879 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 65' ' ' LEU . . . . . 0.568 ' O ' ' HA ' ' A' ' 102' ' ' HIS . 0.2 OUTLIER -113.36 123.66 50.63 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.07 -0.513 . . . . 99.99 110.899 -179.989 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 15.2 t80 -102.48 110.87 22.94 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.185 -0.461 . . . . 99.99 110.873 179.956 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -140.99 168.73 15.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.193 -0.458 . . . . 99.99 111.237 179.954 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 68' ' ' ARG . . . . . 0.424 ' HG3' ' HA3' ' A' ' 99' ' ' GLY . 8.9 ttm180 -98.36 143.18 29.1 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.202 -0.454 . . . . 99.99 110.8 -179.935 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -41.17 -44.51 2.58 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.156 -0.475 . . . . 99.99 111.172 -179.932 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 29.0 m-20 -65.69 -52.64 49.92 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.236 -0.438 . . . . 99.99 110.891 179.888 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 71' ' ' GLU . . . . . . . . . . . . . 2.1 mm-40 -55.0 -39.49 69.1 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.22 -0.445 . . . . 99.99 110.906 -179.947 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 11.1 p -82.6 -22.13 9.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.132 -0.485 . . . . 99.99 111.075 -179.993 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 73' ' ' ARG . . . . . . . . . . . . . 1.5 tmt_? -67.59 -41.52 83.95 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.194 -0.457 . . . . 99.99 110.869 179.984 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 59.1 mt-30 -57.78 -20.45 35.45 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.198 -0.456 . . . . 99.99 110.969 -179.957 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 5.8 mp -104.95 -175.87 2.92 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.199 -0.455 . . . . 99.99 110.899 -179.999 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 76' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -111.76 -179.45 3.7 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.197 -0.456 . . . . 99.99 110.937 179.944 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -81.21 116.25 21.01 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.225 -0.443 . . . . 99.99 110.888 -179.913 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 107.92 20.14 8.61 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.77 -0.729 . . . . 99.99 112.453 -179.991 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -84.41 111.58 19.58 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.881 0.372 . . . . 99.99 110.886 179.996 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 80' ' ' THR . . . . . 0.698 ' HA ' ' HA ' ' A' ' 89' ' ' TRP . 0.0 OUTLIER -86.62 111.6 20.8 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.198 -0.455 . . . . 99.99 111.148 -179.91 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 81' ' ' LEU . . . . . 0.744 ' C ' ' HA ' ' A' ' 87' ' ' ASN . 0.3 OUTLIER -97.22 131.82 43.58 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.194 -0.457 . . . . 99.99 110.921 179.917 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 82' ' ' THR . . . . . 0.747 ' CA ' ' HA ' ' A' ' 87' ' ' ASN . 2.4 t -92.48 101.42 13.87 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.13 -0.486 . . . . 99.99 111.156 179.946 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 83' ' ' ILE . . . . . 0.432 ' CG2' ' CB ' ' A' ' 27' ' ' ALA . 0.1 OUTLIER -137.24 131.84 45.67 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.282 -0.417 . . . . 99.99 111.081 179.979 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 74.9 -53.86 2.56 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.7 -0.762 . . . . 99.99 112.537 179.929 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . 0.404 ' C ' ' HG3' ' A' ' 86' ' ' GLU . 84.5 tt0 -117.94 -81.31 0.62 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.766 0.317 . . . . 99.99 110.879 -179.951 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 86' ' ' GLU . . . . . 0.429 ' C ' ' HA ' ' A' ' 82' ' ' THR . 61.7 mt-10 -149.35 161.4 42.13 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.233 -0.439 . . . . 99.99 110.931 -179.903 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 87' ' ' ASN . . . . . 0.747 ' HA ' ' CA ' ' A' ' 82' ' ' THR . 13.0 p30 -51.92 123.99 11.66 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.188 -0.46 . . . . 99.99 110.877 -179.932 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 88' ' ' PHE . . . . . 0.583 ' HB2' HD23 ' A' ' 105' ' ' LEU . 14.3 m-85 -132.2 118.18 19.21 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.184 -0.462 . . . . 99.99 110.869 -179.957 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 89' ' ' TRP . . . . . 0.698 ' HA ' ' HA ' ' A' ' 80' ' ' THR . 64.0 p-90 -82.15 135.35 35.3 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.185 -0.461 . . . . 99.99 110.922 -179.963 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 90' ' ' VAL . . . . . 0.486 ' HA ' ' HB3' ' A' ' 105' ' ' LEU . 0.4 OUTLIER -92.88 139.58 17.8 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.257 -0.429 . . . . 99.99 111.163 179.893 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 91' ' ' ASP . . . . . 0.476 ' CB ' HD11 ' A' ' 103' ' ' LEU . 0.5 OUTLIER -62.71 -71.0 0.17 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.183 -0.462 . . . . 99.99 110.89 179.867 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 92' ' ' ARG . . . . . 0.554 ' O ' ' HG ' ' A' ' 103' ' ' LEU . 7.0 mtm180 -159.9 120.89 3.1 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.172 -0.467 . . . . 99.99 110.894 -179.878 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 93' ' ' VAL . . . . . 0.417 ' HB ' ' CB ' ' A' ' 101' ' ' CYS . 17.4 m -112.51 135.43 51.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.197 -0.456 . . . . 99.99 111.164 179.942 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 2.1 m -130.22 101.62 17.69 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-O 121.661 0.743 . . . . 99.99 110.827 -179.811 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.74 177.27 5.74 Favored 'Trans proline' 0 C--N 1.341 0.155 0 C-N-CA 122.682 2.254 . . . . 99.99 112.319 179.977 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 37.2 t70 -121.21 -31.82 4.03 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.203 -0.453 . . . . 99.99 110.848 179.928 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 5.8 t70 177.96 134.64 0.07 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.244 -0.435 . . . . 99.99 110.781 -179.942 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 75.53 41.55 29.52 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.692 -0.766 . . . . 99.99 112.45 -179.994 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 99' ' ' GLY . . . . . 0.424 ' HA3' ' HG3' ' A' ' 68' ' ' ARG . . . 42.7 74.31 0.19 Allowed Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.723 -0.751 . . . . 99.99 112.533 -179.901 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 1.7 m -131.66 76.98 1.74 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.922 0.392 . . . . 99.99 110.881 -179.748 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 101' ' ' CYS . . . . . 0.417 ' CB ' ' HB ' ' A' ' 93' ' ' VAL . 0.0 OUTLIER -105.02 148.38 26.82 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.104 -0.498 . . . . 99.99 110.87 -179.996 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 102' ' ' HIS . . . . . 0.568 ' HA ' ' O ' ' A' ' 65' ' ' LEU . 6.7 p80 -157.65 123.69 4.74 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.142 -0.481 . . . . 99.99 110.865 -179.947 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 103' ' ' LEU . . . . . 0.554 ' HG ' ' O ' ' A' ' 92' ' ' ARG . 2.4 tm? -151.53 146.73 26.09 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.256 -0.429 . . . . 99.99 110.959 -180.0 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 104' ' ' TRP . . . . . 0.446 ' N ' ' CD1' ' A' ' 103' ' ' LEU . 30.4 p90 -65.81 110.52 2.87 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.15 -0.477 . . . . 99.99 110.928 179.937 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 105' ' ' LEU . . . . . 0.583 HD23 ' HB2' ' A' ' 88' ' ' PHE . 0.4 OUTLIER -91.23 161.84 14.89 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.169 -0.469 . . . . 99.99 110.944 179.99 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -89.43 159.52 28.5 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.692 -0.766 . . . . 99.99 112.477 179.911 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 107' ' ' ARG . . . . . 0.562 ' HA ' ' CD1' ' A' ' 88' ' ' PHE . 0.4 OUTLIER -69.33 158.47 34.99 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.845 0.355 . . . . 99.99 110.863 -179.83 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -174.56 111.12 0.35 Allowed Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.758 -0.734 . . . . 99.99 112.525 -179.969 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 10.6 t -100.23 132.44 22.6 Favored Pre-proline 0 C--N 1.33 -0.251 0 CA-C-O 121.632 0.729 . . . . 99.99 111.15 -179.961 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 110' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.7 168.2 22.17 Favored 'Trans proline' 0 C--N 1.341 0.161 0 C-N-CA 122.718 2.279 . . . . 99.99 112.335 179.955 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 111' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.77 -8.01 22.51 Favored 'Trans proline' 0 C--N 1.341 0.149 0 C-N-CA 122.661 2.241 . . . . 99.99 112.318 179.905 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -59.31 161.54 5.46 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.221 -0.445 . . . . 99.99 111.128 179.87 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 19.7 m -93.26 124.24 45.63 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.244 -0.435 . . . . 99.99 111.134 179.941 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 114' ' ' ASN . . . . . . . . . . . . . 6.0 t-20 -128.35 146.13 50.86 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.168 -0.469 . . . . 99.99 110.919 179.99 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -82.56 133.46 35.19 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.155 -0.475 . . . . 99.99 110.901 -179.95 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 116' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -106.71 138.1 43.51 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.201 -0.454 . . . . 99.99 110.919 -179.904 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 1.6 tpm_? . . . . . 0 C--N 1.329 -0.299 0 CA-C-N 116.239 -0.437 . . . . 99.99 110.823 -179.857 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 6.8 ttp . . . . . 0 C--O 1.231 0.082 0 CA-C-O 120.829 0.347 . . . . 99.99 110.928 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -174.71 176.08 2.33 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.199 -0.455 . . . . 99.99 111.101 179.866 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 3' ' ' ASP . . . . . . . . . . . . . 3.0 p-10 -174.96 170.15 3.29 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.178 -0.464 . . . . 99.99 110.822 -179.983 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 4' ' ' PHE . . . . . . . . . . . . . 10.3 m-85 -160.74 177.58 10.31 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.267 -0.424 . . . . 99.99 110.9 -179.959 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -174.98 178.07 1.85 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.149 -0.478 . . . . 99.99 110.912 179.983 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 6' ' ' ASN . . . . . . . . . . . . . 18.0 m-80 -161.63 173.4 14.78 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.245 -0.434 . . . . 99.99 110.89 -179.94 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 7' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -164.48 172.08 13.79 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.157 -0.474 . . . . 99.99 110.967 179.927 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 8' ' ' PHE . . . . . . . . . . . . . 25.6 p90 -174.36 150.12 1.43 Allowed 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.185 -0.462 . . . . 99.99 110.915 -179.984 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 3.9 m-20 -153.86 157.07 38.76 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.192 -0.458 . . . . 99.99 110.842 179.978 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -175.39 158.54 2.32 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.152 -0.476 . . . . 99.99 111.061 179.893 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -70.33 173.93 6.24 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.177 -0.465 . . . . 99.99 111.082 179.967 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 32.5 mt -54.3 -74.99 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.239 -0.437 . . . . 99.99 111.144 -179.999 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . 52.64 49.69 19.81 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.14 -0.482 . . . . 99.99 111.118 179.786 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 3.3 tpm_? -55.02 105.0 0.13 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.297 -0.41 . . . . 99.99 110.914 -179.926 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -172.7 170.09 4.8 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.208 -0.451 . . . . 99.99 111.062 179.907 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 2.0 t70 -61.96 173.76 1.01 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.142 -0.481 . . . . 99.99 110.815 -179.929 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 3.7 tt0 -136.45 171.45 14.47 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.192 -0.458 . . . . 99.99 110.899 -179.886 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -154.93 178.03 10.64 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.213 -0.448 . . . . 99.99 111.231 -179.932 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 4.1 tp -160.38 110.86 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.263 -0.426 . . . . 99.99 111.11 179.907 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 20' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -145.93 -176.23 5.06 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.13 -0.487 . . . . 99.99 110.839 179.931 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 141.52 87.72 0.11 Allowed Glycine 0 N--CA 1.452 -0.264 0 C-N-CA 120.685 -0.769 . . . . 99.99 112.471 179.972 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 22' ' ' TYR . . . . . . . . . . . . . 56.8 m-85 -153.93 -175.9 5.6 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.885 0.374 . . . . 99.99 110.913 -179.818 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 23' ' ' MET . . . . . . . . . . . . . 1.8 ptt? -61.11 -172.19 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.129 -0.487 . . . . 99.99 110.844 179.892 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 59.42 -159.56 20.04 Favored Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 120.756 -0.735 . . . . 99.99 112.474 -179.967 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 25' ' ' THR . . . . . 0.423 ' O ' ' HA ' ' A' ' 40' ' ' ARG . 9.6 m -97.89 137.77 36.23 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.816 0.341 . . . . 99.99 111.218 -179.943 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 7.7 m -72.39 122.37 21.08 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.287 -0.415 . . . . 99.99 110.818 -179.833 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 27' ' ' ALA . . . . . 0.522 ' CB ' HG21 ' A' ' 39' ' ' ILE . . . -143.06 162.37 35.7 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.109 -0.496 . . . . 99.99 111.133 179.831 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 28' ' ' THR . . . . . 0.463 ' O ' HG22 ' A' ' 82' ' ' THR . 18.0 m -129.86 88.17 2.63 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.243 -0.435 . . . . 99.99 111.155 -179.846 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . 0.643 HG22 HG22 ' A' ' 39' ' ' ILE . 2.1 pt -43.87 131.08 1.39 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.19 -0.459 . . . . 99.99 111.162 179.978 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 11.3 m -152.98 97.33 2.19 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.229 -0.441 . . . . 99.99 111.183 -179.998 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 86.3 p -135.96 70.79 1.42 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.193 -0.458 . . . . 99.99 110.945 -179.867 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -179.29 167.52 37.65 Favored Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.72 -0.752 . . . . 99.99 112.499 -179.982 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 16.8 pt-20 -48.95 -23.43 1.12 Allowed 'General case' 0 C--N 1.33 -0.283 0 CA-C-O 120.856 0.36 . . . . 99.99 110.885 -179.9 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -174.06 94.63 0.09 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.155 -0.475 . . . . 99.99 110.954 -179.937 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 2.9 m -145.23 165.45 28.35 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.191 -0.459 . . . . 99.99 110.81 -179.783 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 177.8 88.5 0.07 OUTLIER Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.799 -0.715 . . . . 99.99 112.52 -179.923 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -108.43 -170.75 1.73 Allowed 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 120.893 0.378 . . . . 99.99 111.078 179.977 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 64.6 t -98.57 120.23 47.63 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-N 116.211 -0.449 . . . . 99.99 111.146 179.958 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 39' ' ' ILE . . . . . 0.643 HG22 HG22 ' A' ' 29' ' ' ILE . 0.0 OUTLIER -137.08 149.93 26.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.177 -0.465 . . . . 99.99 111.124 179.956 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 40' ' ' ARG . . . . . 0.423 ' HA ' ' O ' ' A' ' 25' ' ' THR . 19.3 mtt85 -109.46 80.47 1.32 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.213 -0.448 . . . . 99.99 110.849 179.934 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . 0.504 ' H ' ' HB2' ' A' ' 27' ' ' ALA . . . -127.47 147.93 17.29 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.797 -0.716 . . . . 99.99 112.527 179.998 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 42' ' ' VAL . . . . . 0.417 ' HB ' ' CB ' ' A' ' 25' ' ' THR . 3.1 p -127.19 138.86 53.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-O 120.851 0.358 . . . . 99.99 111.126 -179.942 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 43' ' ' PHE . . . . . 0.479 ' HA ' ' O ' ' A' ' 64' ' ' SER . 2.8 p90 -101.05 128.71 46.98 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.166 -0.47 . . . . 99.99 110.873 -179.982 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 1.5 t0 -104.38 124.67 49.63 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.106 -0.497 . . . . 99.99 110.835 179.956 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -114.1 105.79 53.85 Favored Pre-proline 0 C--N 1.328 -0.356 0 CA-C-O 121.608 0.718 . . . . 99.99 110.88 179.97 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 46' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.76 -46.3 1.27 Allowed 'Trans proline' 0 C--N 1.34 0.107 0 C-N-CA 122.678 2.252 . . . . 99.99 112.346 -179.979 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 1.9 tp10 -158.76 95.83 1.33 Allowed 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.155 -0.475 . . . . 99.99 110.868 -179.993 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 48.2 t30 -69.88 88.79 0.57 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.141 -0.481 . . . . 99.99 110.928 -179.988 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 10.4 tp -173.2 136.99 0.24 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.146 -0.479 . . . . 99.99 111.108 179.974 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 11.2 p -95.48 120.37 35.61 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.132 -0.486 . . . . 99.99 110.881 -179.933 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 10.8 m-85 -66.88 -74.34 0.11 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.118 -0.492 . . . . 99.99 110.971 -179.878 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -178.04 -179.85 0.78 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.175 -0.466 . . . . 99.99 111.058 179.915 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 178.32 136.29 2.51 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.763 -0.732 . . . . 99.99 112.533 -179.986 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 54' ' ' GLN . . . . . . . . . . . . . 9.7 pt20 -166.01 158.15 14.38 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.888 0.375 . . . . 99.99 110.886 -179.911 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 66.37 -91.61 0.17 Allowed Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.684 -0.769 . . . . 99.99 112.456 -179.976 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 80.0 t -111.34 111.6 36.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-O 120.868 0.366 . . . . 99.99 111.084 -179.921 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -102.4 102.33 12.65 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.156 -0.475 . . . . 99.99 110.856 -179.939 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 6.8 p -128.32 23.72 2.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.201 -0.454 . . . . 99.99 111.103 -179.964 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 3.8 tp10 -120.46 141.3 50.3 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.154 -0.476 . . . . 99.99 110.903 179.948 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -135.13 142.92 14.41 Favored Glycine 0 N--CA 1.452 -0.246 0 C-N-CA 120.744 -0.741 . . . . 99.99 112.478 -179.91 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 2.5 m -131.88 112.67 12.65 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.884 0.373 . . . . 99.99 110.848 -179.798 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -131.0 160.17 68.11 Favored Pre-proline 0 C--N 1.329 -0.295 0 CA-C-O 121.67 0.748 . . . . 99.99 110.836 -179.792 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_endo -69.76 -179.25 2.78 Favored 'Trans proline' 0 C--O 1.231 0.169 0 C-N-CA 122.754 2.303 . . . . 99.99 112.315 179.987 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 64' ' ' SER . . . . . 0.479 ' O ' ' HA ' ' A' ' 43' ' ' PHE . 0.2 OUTLIER -107.02 146.38 31.2 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.228 -0.442 . . . . 99.99 110.894 -179.891 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 65' ' ' LEU . . . . . 0.511 ' HB2' ' HG ' ' A' ' 105' ' ' LEU . 2.7 tm? -114.93 131.48 56.87 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.126 -0.488 . . . . 99.99 110.919 -179.957 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 66' ' ' PHE . . . . . 0.418 ' C ' HG13 ' A' ' 67' ' ' VAL . 1.2 t80 -120.38 106.17 11.59 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.261 -0.427 . . . . 99.99 110.846 179.951 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 67' ' ' VAL . . . . . 0.418 HG13 ' C ' ' A' ' 66' ' ' PHE . 23.2 m -144.69 172.71 5.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.167 -0.469 . . . . 99.99 111.148 179.921 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 1.4 ttt180 -105.62 143.48 33.71 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.128 -0.487 . . . . 99.99 110.896 -179.992 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 69' ' ' THR . . . . . 0.408 ' HB ' ' HG3' ' A' ' 95' ' ' PRO . 0.0 OUTLIER -41.17 -49.4 3.53 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.168 -0.469 . . . . 99.99 111.135 -179.908 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 14.8 t70 -53.39 -51.29 63.01 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.231 -0.44 . . . . 99.99 110.862 179.918 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 71' ' ' GLU . . . . . . . . . . . . . 31.2 mt-10 -53.3 -39.07 63.71 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.164 -0.471 . . . . 99.99 110.905 -179.932 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 3.3 t -78.6 -32.43 16.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.156 -0.474 . . . . 99.99 111.148 179.952 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 73' ' ' ARG . . . . . . . . . . . . . 1.8 tmt_? -57.32 -39.18 75.3 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.149 -0.478 . . . . 99.99 110.841 -179.94 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 39.9 mt-30 -56.22 -22.02 26.86 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.188 -0.46 . . . . 99.99 110.87 -179.897 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 2.3 mp -119.23 -165.29 1.13 Allowed 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.252 -0.431 . . . . 99.99 110.918 -180.0 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 76' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -116.15 171.94 7.49 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.219 -0.446 . . . . 99.99 110.86 179.969 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -62.41 132.05 51.26 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.174 -0.466 . . . . 99.99 110.899 -179.917 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 92.5 18.11 43.03 Favored Glycine 0 N--CA 1.452 -0.252 0 C-N-CA 120.746 -0.74 . . . . 99.99 112.477 179.998 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -74.23 106.33 5.82 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.883 0.373 . . . . 99.99 110.896 -179.976 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 80' ' ' THR . . . . . 0.703 ' HA ' ' HA ' ' A' ' 89' ' ' TRP . 0.6 OUTLIER -85.78 109.14 18.44 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.185 -0.461 . . . . 99.99 111.155 -179.857 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 81' ' ' LEU . . . . . 0.745 ' C ' ' HA ' ' A' ' 87' ' ' ASN . 0.3 OUTLIER -97.07 133.11 42.16 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.188 -0.46 . . . . 99.99 110.9 -179.992 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 82' ' ' THR . . . . . 0.737 ' CA ' ' HA ' ' A' ' 87' ' ' ASN . 9.8 t -93.51 102.27 14.48 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.193 -0.458 . . . . 99.99 111.123 179.949 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 83' ' ' ILE . . . . . 0.43 ' CG2' ' CB ' ' A' ' 27' ' ' ALA . 0.1 OUTLIER -138.46 131.78 40.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.208 -0.451 . . . . 99.99 111.147 179.882 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 74.43 -50.51 2.08 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.663 -0.779 . . . . 99.99 112.548 179.96 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 11.4 mm-40 -119.77 -80.68 0.62 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.831 0.348 . . . . 99.99 110.929 -179.885 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 86' ' ' GLU . . . . . 0.458 ' C ' ' HA ' ' A' ' 82' ' ' THR . 69.0 mt-10 -153.01 161.29 42.71 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.143 -0.48 . . . . 99.99 110.901 -179.908 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 87' ' ' ASN . . . . . 0.745 ' HA ' ' C ' ' A' ' 81' ' ' LEU . 1.6 p30 -49.59 122.15 5.99 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.198 -0.455 . . . . 99.99 110.871 -179.99 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 88' ' ' PHE . . . . . 0.547 ' C ' ' HA ' ' A' ' 80' ' ' THR . 15.9 m-85 -131.83 120.01 22.02 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.196 -0.457 . . . . 99.99 110.859 -179.96 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 89' ' ' TRP . . . . . 0.703 ' HA ' ' HA ' ' A' ' 80' ' ' THR . 59.9 p-90 -83.94 136.79 33.94 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.226 -0.443 . . . . 99.99 110.869 -179.972 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 90' ' ' VAL . . . . . 0.411 ' HA ' ' HB3' ' A' ' 105' ' ' LEU . 10.1 p -86.92 138.75 18.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.246 -0.434 . . . . 99.99 111.074 179.966 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 91' ' ' ASP . . . . . 0.496 ' CB ' HD23 ' A' ' 103' ' ' LEU . 0.7 OUTLIER -70.15 -41.78 73.39 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.177 -0.465 . . . . 99.99 110.76 179.934 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 92' ' ' ARG . . . . . 0.441 ' O ' ' CB ' ' A' ' 103' ' ' LEU . 20.0 tpp180 -160.26 138.59 10.16 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.265 -0.425 . . . . 99.99 110.912 -179.826 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 93' ' ' VAL . . . . . 0.406 ' CB ' ' HB2' ' A' ' 101' ' ' CYS . 0.0 OUTLIER -126.81 111.9 27.41 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.258 -0.428 . . . . 99.99 111.148 179.936 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 4.0 t -127.25 109.35 21.4 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-O 121.694 0.759 . . . . 99.99 110.88 -179.914 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 95' ' ' PRO . . . . . 0.408 ' HG3' ' HB ' ' A' ' 69' ' ' THR . 53.3 Cg_endo -69.77 156.64 62.8 Favored 'Trans proline' 0 C--O 1.232 0.18 0 C-N-CA 122.649 2.232 . . . . 99.99 112.356 179.983 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 44.4 m-20 -113.67 -24.55 9.14 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.187 -0.46 . . . . 99.99 110.873 179.911 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 3.6 t0 179.04 92.46 0.02 OUTLIER 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 116.229 -0.441 . . . . 99.99 110.9 179.992 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 87.21 58.9 1.81 Allowed Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.705 -0.76 . . . . 99.99 112.491 180.0 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . 42.7 81.68 0.03 OUTLIER Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.764 -0.731 . . . . 99.99 112.478 -179.873 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -127.53 6.55 6.27 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.832 0.349 . . . . 99.99 110.881 -179.81 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 101' ' ' CYS . . . . . 0.406 ' HB2' ' CB ' ' A' ' 93' ' ' VAL . 1.6 p -42.37 142.85 0.71 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.145 -0.479 . . . . 99.99 110.868 -179.99 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 102' ' ' HIS . . . . . 0.484 ' HA ' ' O ' ' A' ' 65' ' ' LEU . 46.1 p-80 -161.2 125.55 3.47 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.188 -0.46 . . . . 99.99 110.87 -179.944 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 103' ' ' LEU . . . . . 0.496 HD23 ' CB ' ' A' ' 91' ' ' ASP . 9.8 tt -152.04 155.85 38.77 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.201 -0.454 . . . . 99.99 110.873 -179.993 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 104' ' ' TRP . . . . . . . . . . . . . 50.2 p-90 -66.23 112.0 3.74 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.136 -0.484 . . . . 99.99 110.981 179.865 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 105' ' ' LEU . . . . . 0.511 ' HG ' ' HB2' ' A' ' 65' ' ' LEU . 0.3 OUTLIER -87.58 162.24 17.29 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.319 -0.4 . . . . 99.99 110.934 -179.983 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -88.36 160.43 30.54 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.724 -0.75 . . . . 99.99 112.53 179.894 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 107' ' ' ARG . . . . . 0.509 ' HA ' ' CD1' ' A' ' 88' ' ' PHE . 2.5 ptm180 -68.89 158.46 34.5 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.799 0.333 . . . . 99.99 110.845 -179.816 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -173.64 106.79 0.23 Allowed Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.694 -0.765 . . . . 99.99 112.436 -179.966 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 8.7 p -91.04 134.01 30.9 Favored Pre-proline 0 C--N 1.33 -0.275 0 CA-C-O 121.644 0.735 . . . . 99.99 111.103 180.0 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 110' ' ' PRO . . . . . 0.505 ' N ' HD22 ' A' ' 87' ' ' ASN . 53.9 Cg_endo -69.75 167.84 23.27 Favored 'Trans proline' 0 C--N 1.341 0.153 0 C-N-CA 122.659 2.239 . . . . 99.99 112.358 179.929 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 111' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.7 -48.64 0.69 Allowed 'Trans proline' 0 C--N 1.341 0.174 0 C-N-CA 122.714 2.276 . . . . 99.99 112.374 179.939 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -109.85 160.98 15.9 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.247 -0.433 . . . . 99.99 111.114 179.881 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 13.6 p -93.63 138.67 19.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.243 -0.435 . . . . 99.99 111.146 179.969 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 114' ' ' ASN . . . . . . . . . . . . . 2.2 p30 -128.4 146.21 50.85 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.247 -0.433 . . . . 99.99 110.934 179.965 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -82.22 103.19 11.63 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.121 -0.491 . . . . 99.99 110.889 -179.953 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 116' ' ' ARG . . . . . . . . . . . . . 16.9 mmm180 -95.44 132.61 40.33 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.24 -0.437 . . . . 99.99 110.843 -179.894 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 8.5 ttt-85 . . . . . 0 C--N 1.33 -0.278 0 CA-C-N 116.241 -0.436 . . . . 99.99 110.884 -179.921 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 29.4 mmm . . . . . 0 C--O 1.231 0.091 0 CA-C-O 120.732 0.301 . . . . 99.99 110.873 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -174.1 -178.66 1.52 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.205 -0.452 . . . . 99.99 111.089 179.976 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 3' ' ' ASP . . . . . . . . . . . . . 3.0 t0 59.75 57.56 3.13 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.185 -0.461 . . . . 99.99 110.901 179.968 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 4' ' ' PHE . . . . . . . . . . . . . 12.3 t80 -72.82 162.09 29.92 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.153 -0.476 . . . . 99.99 110.887 -179.881 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 1.8 t70 -140.14 169.1 18.31 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.238 -0.437 . . . . 99.99 110.944 179.946 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 6' ' ' ASN . . . . . . . . . . . . . 24.7 m120 -133.29 -175.52 3.83 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.244 -0.435 . . . . 99.99 110.897 -179.895 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 7' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -107.73 -179.13 3.82 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.254 -0.43 . . . . 99.99 110.904 179.918 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 8' ' ' PHE . . . . . . . . . . . . . 10.6 p90 -167.14 -175.05 2.83 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.16 -0.473 . . . . 99.99 110.921 179.923 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 6.5 t0 -104.16 171.44 7.34 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.185 -0.461 . . . . 99.99 110.879 -179.996 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -113.86 -170.41 1.7 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.186 -0.461 . . . . 99.99 111.064 -179.98 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -111.16 177.58 4.62 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.262 -0.426 . . . . 99.99 111.111 179.934 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 4.0 mp -140.07 73.65 0.24 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.242 -0.436 . . . . 99.99 111.153 179.989 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -153.01 146.72 25.17 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.174 -0.466 . . . . 99.99 111.052 179.881 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -128.39 176.45 7.71 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.2 -0.454 . . . . 99.99 110.835 -179.902 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -154.35 -171.02 3.72 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.172 -0.467 . . . . 99.99 111.067 179.985 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 16.5 p-10 -62.0 -171.49 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.195 -0.457 . . . . 99.99 110.862 -179.99 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 4.8 pt-20 -142.38 176.84 8.69 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.189 -0.459 . . . . 99.99 110.9 -179.906 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 1.4 p -148.98 175.56 11.19 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.141 -0.481 . . . . 99.99 111.174 -179.924 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 59.5 mt -131.05 96.72 2.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.258 -0.428 . . . . 99.99 111.119 179.872 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 20' ' ' ARG . . . . . . . . . . . . . 14.7 ptt180 -176.83 -179.08 0.91 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.182 -0.463 . . . . 99.99 110.845 179.94 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -176.36 -172.24 40.87 Favored Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.706 -0.759 . . . . 99.99 112.482 -179.997 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 22' ' ' TYR . . . . . . . . . . . . . 0.4 OUTLIER -164.08 -169.65 1.9 Allowed 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 120.843 0.354 . . . . 99.99 110.96 -179.844 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 23' ' ' MET . . . . . . . . . . . . . 33.0 mmt -82.34 148.93 28.02 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.112 -0.494 . . . . 99.99 110.913 179.867 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 171.29 -121.94 0.93 Allowed Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.78 -0.724 . . . . 99.99 112.479 -179.972 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 25' ' ' THR . . . . . . . . . . . . . 85.8 m -122.24 133.29 54.71 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.829 0.347 . . . . 99.99 111.147 -179.858 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -71.41 123.17 21.76 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.212 -0.449 . . . . 99.99 110.898 -179.861 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 27' ' ' ALA . . . . . 0.549 ' CB ' HG21 ' A' ' 39' ' ' ILE . . . -140.03 162.74 34.5 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.122 -0.49 . . . . 99.99 111.113 179.921 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 16.9 m -129.6 88.54 2.7 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.246 -0.434 . . . . 99.99 111.116 -179.913 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . 0.651 HG22 HG22 ' A' ' 39' ' ' ILE . 2.0 pt -45.12 129.75 1.83 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.385 0 CA-C-N 116.264 -0.425 . . . . 99.99 111.123 179.876 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 7.0 m -152.97 98.53 2.32 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.24 -0.437 . . . . 99.99 111.179 179.917 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 12.1 t -138.38 71.11 1.39 Allowed 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.246 -0.434 . . . . 99.99 110.817 -179.854 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -178.72 168.17 38.99 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.751 -0.738 . . . . 99.99 112.508 179.959 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 15.4 pt-20 -49.38 -23.46 1.49 Allowed 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.781 0.324 . . . . 99.99 110.835 -179.844 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 4.8 tt0 -174.68 94.84 0.08 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.166 -0.47 . . . . 99.99 110.907 -179.916 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 3.3 m -144.97 165.71 27.4 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.214 -0.448 . . . . 99.99 110.891 -179.834 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 178.35 88.21 0.07 OUTLIER Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.811 -0.709 . . . . 99.99 112.505 -179.977 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -109.6 -172.81 2.12 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.849 0.357 . . . . 99.99 111.088 -179.984 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 61.9 t -97.75 121.9 48.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.238 -0.437 . . . . 99.99 111.123 179.962 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 39' ' ' ILE . . . . . 0.651 HG22 HG22 ' A' ' 29' ' ' ILE . 0.0 OUTLIER -137.62 150.12 25.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.126 -0.488 . . . . 99.99 111.157 179.898 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 40' ' ' ARG . . . . . . . . . . . . . 5.4 ttm180 -109.69 80.3 1.3 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.24 -0.436 . . . . 99.99 110.873 179.987 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . 0.5 ' N ' HD13 ' A' ' 39' ' ' ILE . . . -129.18 147.44 17.75 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.774 -0.727 . . . . 99.99 112.46 -179.955 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 42' ' ' VAL . . . . . 0.573 ' O ' ' HA ' ' A' ' 65' ' ' LEU . 2.8 p -126.49 136.59 60.37 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-O 120.845 0.355 . . . . 99.99 111.072 -179.971 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 43' ' ' PHE . . . . . 0.49 ' HA ' ' O ' ' A' ' 64' ' ' SER . 1.3 p90 -93.72 130.77 39.57 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.218 -0.446 . . . . 99.99 110.872 179.96 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 12.6 t70 -117.04 124.76 50.08 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.121 -0.49 . . . . 99.99 110.87 179.956 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -122.51 149.94 56.59 Favored Pre-proline 0 C--N 1.328 -0.327 0 CA-C-O 121.575 0.702 . . . . 99.99 110.877 179.999 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 46' ' ' PRO . . . . . . . . . . . . . 52.5 Cg_endo -69.93 -39.03 6.65 Favored 'Trans proline' 0 C--O 1.232 0.186 0 C-N-CA 122.689 2.259 . . . . 99.99 112.297 -179.94 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 17.1 tt0 -161.76 95.92 1.01 Allowed 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.29 -0.414 . . . . 99.99 110.891 179.96 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 19.8 t-20 -52.47 106.84 0.17 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.116 -0.493 . . . . 99.99 110.908 -179.913 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 26.0 mm -70.03 149.96 10.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.117 -0.492 . . . . 99.99 111.143 179.942 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 20.4 t -112.15 131.39 55.48 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.241 -0.436 . . . . 99.99 110.776 -179.855 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 45.7 p90 -75.35 177.28 6.71 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.11 -0.495 . . . . 99.99 110.964 -179.934 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -111.27 -67.22 1.01 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.137 -0.483 . . . . 99.99 111.133 179.854 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -170.26 -116.16 0.37 Allowed Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.797 -0.716 . . . . 99.99 112.574 -179.993 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 54' ' ' GLN . . . . . . . . . . . . . 5.2 tt0 -82.56 57.93 3.96 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.872 0.368 . . . . 99.99 110.952 -179.959 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -164.91 100.69 0.18 Allowed Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.665 -0.778 . . . . 99.99 112.46 -179.993 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 39.2 t -63.31 124.58 18.22 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-O 120.758 0.313 . . . . 99.99 111.213 -179.998 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -59.88 -23.0 63.09 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.204 -0.453 . . . . 99.99 110.884 -179.936 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 21.0 t 64.31 63.16 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-N 116.19 -0.459 . . . . 99.99 111.122 179.955 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 46.4 tt0 -170.37 147.51 3.04 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.122 -0.49 . . . . 99.99 110.891 -179.992 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -145.98 120.72 1.36 Allowed Glycine 0 N--CA 1.45 -0.433 0 C-N-CA 120.786 -0.721 . . . . 99.99 112.499 -179.923 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 1.7 t -89.95 155.4 19.14 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.869 0.366 . . . . 99.99 110.907 -179.758 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 1.9 p -106.14 97.72 16.7 Favored Pre-proline 0 C--N 1.33 -0.267 0 CA-C-O 121.669 0.747 . . . . 99.99 110.886 -179.804 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_endo -69.78 -178.0 2.15 Favored 'Trans proline' 0 C--N 1.342 0.198 0 C-N-CA 122.679 2.253 . . . . 99.99 112.315 -179.988 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 64' ' ' SER . . . . . 0.49 ' O ' ' HA ' ' A' ' 43' ' ' PHE . 1.5 t -106.32 148.15 28.36 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.222 -0.444 . . . . 99.99 110.915 -179.922 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 65' ' ' LEU . . . . . 0.606 ' O ' ' HA ' ' A' ' 102' ' ' HIS . 0.0 OUTLIER -112.68 140.45 47.44 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.118 -0.492 . . . . 99.99 110.901 179.996 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 17.8 t80 -118.47 107.97 14.45 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.156 -0.475 . . . . 99.99 110.896 179.904 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 4.3 m -141.98 166.79 16.4 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.18 -0.463 . . . . 99.99 111.057 -179.949 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 68' ' ' ARG . . . . . 0.414 ' HG3' ' HA2' ' A' ' 99' ' ' GLY . 2.8 ttm180 -103.23 144.19 31.66 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.156 -0.475 . . . . 99.99 110.921 179.984 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 2.0 t -40.32 -47.3 2.48 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.245 -0.434 . . . . 99.99 111.138 -179.92 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 46.8 m-20 -52.97 -62.03 1.92 Allowed 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.224 -0.444 . . . . 99.99 110.859 179.924 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 71' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -53.39 -40.44 65.04 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.235 -0.439 . . . . 99.99 110.903 -179.915 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 14.4 t -69.39 -33.84 59.49 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.125 -0.489 . . . . 99.99 111.12 179.946 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 73' ' ' ARG . . . . . . . . . . . . . 18.9 ttm180 -62.17 -39.89 94.19 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.205 -0.452 . . . . 99.99 110.836 -179.96 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 29.9 mt-30 -55.04 -22.58 16.28 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.219 -0.446 . . . . 99.99 110.874 -179.932 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 4.5 mp -113.03 -168.73 1.36 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.234 -0.439 . . . . 99.99 110.912 -179.969 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 76' ' ' ARG . . . . . . . . . . . . . 11.1 ptp180 -124.12 -178.96 4.24 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.182 -0.463 . . . . 99.99 110.871 179.974 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 4.7 mtp180 -70.05 130.56 42.48 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.155 -0.475 . . . . 99.99 110.926 -179.957 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 92.42 36.47 6.2 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.767 -0.73 . . . . 99.99 112.453 -179.976 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -99.13 105.46 17.55 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.859 0.362 . . . . 99.99 110.926 179.994 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 80' ' ' THR . . . . . 0.728 ' HA ' ' HA ' ' A' ' 89' ' ' TRP . 0.8 OUTLIER -89.61 108.56 19.74 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.199 -0.455 . . . . 99.99 111.102 -179.851 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 81' ' ' LEU . . . . . 0.756 ' C ' ' HA ' ' A' ' 87' ' ' ASN . 0.0 OUTLIER -96.05 135.42 37.85 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.132 -0.485 . . . . 99.99 110.93 179.956 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 82' ' ' THR . . . . . 0.715 ' CA ' ' HA ' ' A' ' 87' ' ' ASN . 8.9 t -94.99 101.64 13.41 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.267 -0.424 . . . . 99.99 111.124 179.958 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 83' ' ' ILE . . . . . 0.444 ' CG2' ' CB ' ' A' ' 27' ' ' ALA . 0.1 OUTLIER -135.58 132.58 51.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.236 -0.438 . . . . 99.99 111.128 179.913 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 73.08 -54.37 1.81 Allowed Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.761 -0.733 . . . . 99.99 112.486 179.936 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . 0.403 ' O ' ' HG3' ' A' ' 86' ' ' GLU . 3.0 mm-40 -115.54 -83.18 0.62 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.787 0.327 . . . . 99.99 110.837 -179.829 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 86' ' ' GLU . . . . . 0.403 ' HG3' ' O ' ' A' ' 85' ' ' GLU . 7.6 mp0 -150.02 159.45 44.39 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.195 -0.457 . . . . 99.99 110.883 -179.946 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 87' ' ' ASN . . . . . 0.756 ' HA ' ' C ' ' A' ' 81' ' ' LEU . 0.7 OUTLIER -50.28 124.05 9.66 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.152 -0.476 . . . . 99.99 110.876 -179.868 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 88' ' ' PHE . . . . . 0.568 ' HB2' HD23 ' A' ' 105' ' ' LEU . 15.9 m-85 -131.09 119.61 22.2 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.113 -0.494 . . . . 99.99 110.857 -179.956 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 89' ' ' TRP . . . . . 0.728 ' HA ' ' HA ' ' A' ' 80' ' ' THR . 0.0 OUTLIER -79.23 135.55 36.81 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 116.121 -0.491 . . . . 99.99 110.921 -179.993 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 90' ' ' VAL . . . . . 0.471 ' HA ' ' HB3' ' A' ' 105' ' ' LEU . 3.0 p -91.55 136.08 25.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.207 -0.451 . . . . 99.99 111.161 179.951 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 91' ' ' ASP . . . . . 0.447 ' CB ' HD12 ' A' ' 103' ' ' LEU . 0.8 OUTLIER -63.24 -72.35 0.14 Allowed 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.185 -0.461 . . . . 99.99 110.888 179.926 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 92' ' ' ARG . . . . . 0.556 ' O ' ' HG ' ' A' ' 103' ' ' LEU . 9.0 ptm180 -159.71 122.12 3.43 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.164 -0.471 . . . . 99.99 110.954 -179.936 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 93' ' ' VAL . . . . . 0.455 ' HB ' ' CB ' ' A' ' 101' ' ' CYS . 26.0 m -113.63 136.88 48.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.191 -0.459 . . . . 99.99 111.083 -179.956 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 7.0 t -129.32 100.31 20.31 Favored Pre-proline 0 C--N 1.329 -0.307 0 CA-C-O 121.673 0.749 . . . . 99.99 110.821 -179.84 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.81 169.59 18.62 Favored 'Trans proline' 0 C--N 1.342 0.186 0 C-N-CA 122.629 2.22 . . . . 99.99 112.312 179.958 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 11.7 t0 -129.64 1.58 4.96 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.186 -0.461 . . . . 99.99 110.837 179.923 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 4.5 p30 -139.27 29.29 2.22 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.196 -0.457 . . . . 99.99 110.859 179.98 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 51.04 55.95 16.42 Favored Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.759 -0.734 . . . . 99.99 112.469 -179.953 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 99' ' ' GLY . . . . . 0.414 ' HA2' ' HG3' ' A' ' 68' ' ' ARG . . . 145.05 35.21 0.07 OUTLIER Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.655 -0.783 . . . . 99.99 112.495 -179.904 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 46.7 t -151.61 71.31 0.98 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.791 0.329 . . . . 99.99 110.878 -179.675 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 101' ' ' CYS . . . . . 0.455 ' CB ' ' HB ' ' A' ' 93' ' ' VAL . 0.0 OUTLIER -110.16 148.54 31.59 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.131 -0.486 . . . . 99.99 110.931 -179.976 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 102' ' ' HIS . . . . . 0.606 ' HA ' ' O ' ' A' ' 65' ' ' LEU . 24.8 p80 -160.37 126.28 4.06 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.225 -0.443 . . . . 99.99 110.953 179.99 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 103' ' ' LEU . . . . . 0.556 ' HG ' ' O ' ' A' ' 92' ' ' ARG . 2.5 tm? -151.22 147.55 27.14 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.272 -0.422 . . . . 99.99 110.926 -179.96 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 104' ' ' TRP . . . . . 0.441 ' N ' ' CD1' ' A' ' 103' ' ' LEU . 22.2 m-90 -63.43 114.45 3.88 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 116.208 -0.451 . . . . 99.99 110.922 179.91 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 105' ' ' LEU . . . . . 0.568 HD23 ' HB2' ' A' ' 88' ' ' PHE . 0.3 OUTLIER -93.7 162.0 14.11 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.255 -0.43 . . . . 99.99 110.912 -179.987 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -88.83 160.63 30.12 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.741 -0.743 . . . . 99.99 112.523 179.878 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 107' ' ' ARG . . . . . 0.558 ' HA ' ' CD1' ' A' ' 88' ' ' PHE . 3.1 ptt85 -67.9 157.31 35.23 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.858 0.361 . . . . 99.99 110.893 -179.887 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -173.97 110.52 0.33 Allowed Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.756 -0.735 . . . . 99.99 112.478 -179.979 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 58.1 t -84.72 134.46 41.92 Favored Pre-proline 0 C--N 1.33 -0.276 0 CA-C-O 121.629 0.728 . . . . 99.99 111.135 -179.988 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 110' ' ' PRO . . . . . . . . . . . . . 52.6 Cg_endo -69.85 170.0 17.71 Favored 'Trans proline' 0 C--N 1.341 0.173 0 C-N-CA 122.675 2.25 . . . . 99.99 112.263 -179.971 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 111' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.77 -4.47 14.11 Favored 'Trans proline' 0 C--N 1.342 0.232 0 C-N-CA 122.697 2.265 . . . . 99.99 112.289 -179.98 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -58.16 162.16 3.68 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.246 -0.434 . . . . 99.99 111.082 179.899 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 5.3 p -91.81 119.62 39.49 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 CA-C-N 116.165 -0.471 . . . . 99.99 111.117 -179.984 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 114' ' ' ASN . . . . . . . . . . . . . 5.5 t30 -128.75 146.82 50.79 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.145 -0.479 . . . . 99.99 110.863 179.974 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 5.2 mmt180 -81.66 101.95 10.38 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.141 -0.481 . . . . 99.99 110.881 -179.985 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 116' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -116.3 139.5 50.32 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.198 -0.455 . . . . 99.99 110.811 -179.918 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 3.3 mtt180 . . . . . 0 C--N 1.329 -0.295 0 CA-C-N 116.186 -0.461 . . . . 99.99 110.852 -179.898 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 12.0 mmt . . . . . 0 N--CA 1.458 -0.04 0 CA-C-O 120.78 0.324 . . . . 99.99 110.861 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -171.69 173.68 4.53 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.226 -0.443 . . . . 99.99 111.101 179.941 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 3' ' ' ASP . . . . . . . . . . . . . 3.7 p-10 -161.11 179.84 8.08 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.202 -0.454 . . . . 99.99 110.841 179.977 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 4' ' ' PHE . . . . . . . . . . . . . 51.1 p90 -174.26 156.38 2.57 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.157 -0.474 . . . . 99.99 110.857 -179.907 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 3.7 m-20 -142.81 153.09 42.89 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.159 -0.473 . . . . 99.99 110.894 179.993 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 6' ' ' ASN . . . . . . . . . . . . . 3.5 p-10 -138.24 111.73 8.13 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.239 -0.437 . . . . 99.99 110.87 -179.916 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 7' ' ' LEU . . . . . . . . . . . . . 3.5 mm? -51.5 163.35 0.28 Allowed 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.106 -0.497 . . . . 99.99 110.835 179.99 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 8' ' ' PHE . . . . . . . . . . . . . 67.4 m-85 -125.9 115.01 19.28 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.152 -0.477 . . . . 99.99 110.876 179.966 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 9.1 m-20 -71.01 83.45 0.68 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.17 -0.468 . . . . 99.99 110.886 179.966 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -114.89 148.47 38.58 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.13 -0.486 . . . . 99.99 111.064 179.99 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -79.31 104.34 9.86 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.251 -0.431 . . . . 99.99 111.133 179.925 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 29.9 mt -123.83 64.9 0.29 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.356 0 CA-C-N 116.229 -0.441 . . . . 99.99 111.161 179.96 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -171.32 124.63 0.61 Allowed 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.177 -0.465 . . . . 99.99 111.093 179.835 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 9.7 mpt_? -92.87 62.0 3.61 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.151 -0.477 . . . . 99.99 110.876 -179.884 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -134.63 -176.33 4.19 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.11 -0.496 . . . . 99.99 111.077 179.996 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 11.2 p-10 -104.52 112.38 25.42 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.192 -0.458 . . . . 99.99 110.88 179.984 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 5.5 pt-20 -134.04 158.65 43.01 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.21 -0.45 . . . . 99.99 110.966 -179.962 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -156.81 173.99 16.15 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.193 -0.458 . . . . 99.99 111.165 -179.912 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 8.5 tt -134.29 109.71 12.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.241 -0.436 . . . . 99.99 111.115 179.914 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 20' ' ' ARG . . . . . . . . . . . . . 52.5 mtp180 -96.14 143.8 26.94 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.117 -0.492 . . . . 99.99 110.836 -179.989 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 161.37 118.45 0.48 Allowed Glycine 0 C--N 1.33 0.238 0 C-N-CA 120.728 -0.748 . . . . 99.99 112.416 -179.983 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 22' ' ' TYR . . . . . . . . . . . . . 0.5 OUTLIER -136.16 -53.39 0.74 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.849 0.356 . . . . 99.99 110.873 -179.822 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 23' ' ' MET . . . . . . . . . . . . . 2.3 tpt -80.71 -59.73 2.57 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.156 -0.475 . . . . 99.99 110.869 179.916 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 126.53 -17.53 6.5 Favored Glycine 0 N--CA 1.452 -0.279 0 C-N-CA 120.685 -0.769 . . . . 99.99 112.482 -179.935 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 25' ' ' THR . . . . . 0.583 ' O ' ' HA ' ' A' ' 40' ' ' ARG . 60.7 p -94.42 107.49 19.46 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.785 0.326 . . . . 99.99 111.139 -179.85 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -77.53 121.76 24.32 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.227 -0.442 . . . . 99.99 110.849 -179.822 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 27' ' ' ALA . . . . . 0.582 ' CB ' HG21 ' A' ' 39' ' ' ILE . . . -151.7 161.46 42.64 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.123 -0.489 . . . . 99.99 111.132 179.891 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 11.0 m -130.84 88.87 2.67 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.177 -0.465 . . . . 99.99 111.117 -179.852 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . 0.562 HG12 ' HB ' ' A' ' 39' ' ' ILE . 1.7 pt -43.49 128.75 1.11 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.198 -0.456 . . . . 99.99 111.133 179.902 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 7.1 m -153.76 99.0 2.25 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.199 -0.455 . . . . 99.99 111.148 179.949 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 18.7 t -140.8 72.94 1.4 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.222 -0.444 . . . . 99.99 110.845 -179.84 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -178.53 166.57 36.51 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.72 -0.753 . . . . 99.99 112.512 -179.968 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 10.6 pt-20 -48.96 -23.72 1.23 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.738 0.304 . . . . 99.99 110.873 -179.892 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 4.1 tt0 -174.1 93.5 0.09 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.15 -0.477 . . . . 99.99 110.944 -179.949 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 2.0 m -144.87 165.53 27.87 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.243 -0.435 . . . . 99.99 110.84 -179.791 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -179.86 85.21 0.06 OUTLIER Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.746 -0.74 . . . . 99.99 112.513 179.936 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -106.93 -173.83 2.39 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.886 0.374 . . . . 99.99 111.1 -179.996 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 57.5 t -99.36 124.85 52.92 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.171 -0.468 . . . . 99.99 111.124 179.99 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 39' ' ' ILE . . . . . 0.582 HG21 ' CB ' ' A' ' 27' ' ' ALA . 0.0 OUTLIER -137.15 149.35 26.05 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 116.223 -0.444 . . . . 99.99 111.111 179.97 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 40' ' ' ARG . . . . . 0.583 ' HA ' ' O ' ' A' ' 25' ' ' THR . 0.2 OUTLIER -107.84 82.02 1.59 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.192 -0.458 . . . . 99.99 110.907 179.931 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . 0.535 ' O ' ' HB3' ' A' ' 27' ' ' ALA . . . -141.6 142.75 12.26 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.685 -0.769 . . . . 99.99 112.482 -179.94 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 42' ' ' VAL . . . . . 0.534 ' O ' ' HA ' ' A' ' 65' ' ' LEU . 9.0 p -128.57 141.3 46.91 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-O 120.815 0.34 . . . . 99.99 111.144 -179.939 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 1.8 p90 -90.28 135.88 33.4 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.228 -0.442 . . . . 99.99 110.938 179.964 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 11.4 t70 -126.15 125.27 42.21 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.221 -0.445 . . . . 99.99 110.852 179.99 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -101.17 153.27 37.88 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-O 121.619 0.723 . . . . 99.99 110.855 179.943 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 46' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_endo -69.73 -48.15 0.79 Allowed 'Trans proline' 0 C--N 1.341 0.158 0 C-N-CA 122.715 2.277 . . . . 99.99 112.334 179.991 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 25.0 tt0 -178.86 105.91 0.04 OUTLIER 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.247 -0.433 . . . . 99.99 110.881 -179.95 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 11.2 t30 -51.86 105.35 0.11 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.228 -0.442 . . . . 99.99 110.883 -179.936 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 10.1 tp -72.25 143.48 14.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.145 -0.48 . . . . 99.99 111.139 179.923 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 3.0 t -107.79 -170.61 1.72 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.157 -0.474 . . . . 99.99 110.904 -179.917 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 43.9 t80 -52.54 158.41 1.27 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.165 -0.47 . . . . 99.99 110.912 -179.865 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -123.46 -74.48 0.61 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.159 -0.473 . . . . 99.99 111.099 179.907 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 111.8 38.83 1.37 Allowed Glycine 0 N--CA 1.452 -0.249 0 C-N-CA 120.723 -0.751 . . . . 99.99 112.437 -179.985 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 54' ' ' GLN . . . . . . . . . . . . . 24.8 mt-30 -126.1 -37.77 2.22 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.927 0.394 . . . . 99.99 110.948 -179.919 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 120.33 19.39 3.88 Favored Glycine 0 N--CA 1.452 -0.272 0 C-N-CA 120.674 -0.774 . . . . 99.99 112.502 -179.938 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 22.3 t -137.33 92.28 0.88 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-O 120.839 0.352 . . . . 99.99 111.097 -179.857 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 8.8 mpt_? -57.68 170.66 0.55 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.208 -0.451 . . . . 99.99 110.797 -179.968 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 11.2 p -51.63 147.06 1.6 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.136 -0.484 . . . . 99.99 111.124 179.978 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -80.27 -75.18 0.27 Allowed 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.174 -0.467 . . . . 99.99 110.886 179.99 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -150.14 149.19 21.05 Favored Glycine 0 N--CA 1.452 -0.267 0 C-N-CA 120.677 -0.773 . . . . 99.99 112.477 -179.945 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -124.48 125.42 44.21 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.853 0.358 . . . . 99.99 110.855 -179.732 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 89.3 p -129.19 97.88 24.85 Favored Pre-proline 0 C--N 1.328 -0.328 0 CA-C-O 121.666 0.746 . . . . 99.99 110.895 -179.886 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.74 166.18 28.44 Favored 'Trans proline' 0 C--N 1.341 0.162 0 C-N-CA 122.638 2.225 . . . . 99.99 112.327 -179.994 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 3.5 t -106.92 142.87 35.85 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.196 -0.456 . . . . 99.99 110.842 -179.839 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 65' ' ' LEU . . . . . 0.534 ' HA ' ' O ' ' A' ' 42' ' ' VAL . 0.0 OUTLIER -114.88 119.76 37.67 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.163 -0.471 . . . . 99.99 110.926 -179.991 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 56.0 t80 -101.76 109.81 21.66 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.226 -0.443 . . . . 99.99 110.85 179.98 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 22.3 m -138.13 169.2 18.9 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.159 -0.473 . . . . 99.99 111.163 179.895 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 1.1 ttp180 -93.43 143.82 25.92 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.191 -0.459 . . . . 99.99 110.919 -179.983 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 2.4 t -45.47 -47.74 13.95 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.241 -0.436 . . . . 99.99 111.039 -179.868 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 30.5 t70 -52.18 -52.84 49.56 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.197 -0.456 . . . . 99.99 110.923 179.928 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 71' ' ' GLU . . . . . . . . . . . . . 66.0 mm-40 -54.41 -39.29 67.16 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.246 -0.434 . . . . 99.99 110.909 -179.947 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 4.4 t -73.49 -38.45 52.7 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.16 -0.473 . . . . 99.99 111.172 179.925 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 73' ' ' ARG . . . . . . . . . . . . . 2.6 tmt_? -55.69 -40.02 71.79 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.187 -0.46 . . . . 99.99 110.907 -179.985 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 41.7 mt-30 -52.64 -25.86 12.0 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.245 -0.434 . . . . 99.99 110.962 -179.995 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 2.5 mp -116.25 -166.64 1.17 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.163 -0.472 . . . . 99.99 110.951 179.942 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 76' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -112.35 -178.67 3.47 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.204 -0.453 . . . . 99.99 110.845 179.925 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -76.05 125.89 29.97 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.184 -0.462 . . . . 99.99 110.925 -179.929 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 99.77 23.94 10.39 Favored Glycine 0 N--CA 1.45 -0.383 0 C-N-CA 120.768 -0.729 . . . . 99.99 112.505 -179.912 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -82.63 109.31 16.7 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.876 0.369 . . . . 99.99 110.916 179.968 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 80' ' ' THR . . . . . 0.721 ' HA ' ' HA ' ' A' ' 89' ' ' TRP . 0.5 OUTLIER -88.37 109.64 20.15 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.209 -0.45 . . . . 99.99 111.16 -179.906 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 81' ' ' LEU . . . . . 0.796 ' C ' ' HA ' ' A' ' 87' ' ' ASN . 0.0 OUTLIER -96.82 134.37 40.21 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 116.227 -0.442 . . . . 99.99 110.956 179.949 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 82' ' ' THR . . . . . 0.727 ' CA ' ' HA ' ' A' ' 87' ' ' ASN . 4.9 t -92.63 101.79 14.21 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.187 -0.461 . . . . 99.99 111.183 179.975 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 83' ' ' ILE . . . . . 0.48 ' CD1' ' O ' ' A' ' 83' ' ' ILE . 0.1 OUTLIER -132.92 130.45 58.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.219 -0.446 . . . . 99.99 111.118 179.975 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 70.42 -62.37 0.83 Allowed Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.749 -0.739 . . . . 99.99 112.458 179.924 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 10.1 tp10 -103.07 -81.83 0.5 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.806 0.336 . . . . 99.99 110.908 -179.891 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 86' ' ' GLU . . . . . 0.43 ' C ' ' HA ' ' A' ' 82' ' ' THR . 95.7 mt-10 -152.91 160.7 43.07 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.143 -0.48 . . . . 99.99 110.923 -179.923 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 87' ' ' ASN . . . . . 0.796 ' HA ' ' C ' ' A' ' 81' ' ' LEU . 1.3 p-10 -51.55 124.64 12.62 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.153 -0.476 . . . . 99.99 110.893 -179.908 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 88' ' ' PHE . . . . . 0.543 ' CD1' ' HA ' ' A' ' 107' ' ' ARG . 15.3 m-85 -132.77 120.27 21.4 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.176 -0.465 . . . . 99.99 110.932 179.999 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 89' ' ' TRP . . . . . 0.721 ' HA ' ' HA ' ' A' ' 80' ' ' THR . 7.1 p90 -80.01 137.0 36.72 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.179 -0.464 . . . . 99.99 111.005 -179.981 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 90' ' ' VAL . . . . . 0.466 ' HA ' ' HB3' ' A' ' 105' ' ' LEU . 7.2 p -89.64 135.97 24.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.318 -0.401 . . . . 99.99 111.161 179.893 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 91' ' ' ASP . . . . . 0.554 ' HB3' HD12 ' A' ' 103' ' ' LEU . 0.0 OUTLIER -64.28 -67.76 0.41 Allowed 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.155 -0.475 . . . . 99.99 110.907 179.891 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 92' ' ' ARG . . . . . 0.631 ' O ' ' HG ' ' A' ' 103' ' ' LEU . 13.3 ttm-85 -162.76 122.26 2.25 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.238 -0.437 . . . . 99.99 110.897 -179.939 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 93' ' ' VAL . . . . . 0.477 ' HB ' ' CB ' ' A' ' 101' ' ' CYS . 22.7 m -117.9 135.42 58.37 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.144 -0.48 . . . . 99.99 111.111 179.966 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 1.1 p -129.36 103.24 18.12 Favored Pre-proline 0 C--N 1.329 -0.285 0 CA-C-O 121.585 0.707 . . . . 99.99 110.856 -179.823 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.76 -176.15 1.39 Allowed 'Trans proline' 0 C--O 1.231 0.142 0 C-N-CA 122.657 2.238 . . . . 99.99 112.31 -179.947 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 66.5 m-20 -124.66 -36.25 2.62 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.185 -0.461 . . . . 99.99 110.853 179.962 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 4.5 t70 177.7 117.65 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.199 -0.455 . . . . 99.99 110.858 179.959 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 93.22 39.74 5.02 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.724 -0.75 . . . . 99.99 112.516 -179.894 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . 46.62 68.4 1.12 Allowed Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.699 -0.762 . . . . 99.99 112.5 -179.889 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 1.7 m -125.29 71.67 1.21 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.89 0.376 . . . . 99.99 110.874 -179.755 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 101' ' ' CYS . . . . . 0.477 ' CB ' ' HB ' ' A' ' 93' ' ' VAL . 0.0 OUTLIER -106.0 150.02 26.1 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.128 -0.487 . . . . 99.99 110.886 -179.939 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 102' ' ' HIS . . . . . 0.516 ' HA ' ' O ' ' A' ' 65' ' ' LEU . 19.6 p-80 -160.92 123.54 3.19 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.198 -0.456 . . . . 99.99 110.89 -179.951 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 103' ' ' LEU . . . . . 0.631 ' HG ' ' O ' ' A' ' 92' ' ' ARG . 2.1 tm? -152.91 147.67 26.25 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.203 -0.453 . . . . 99.99 110.918 -179.964 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 104' ' ' TRP . . . . . 0.413 ' N ' HD13 ' A' ' 103' ' ' LEU . 30.9 p90 -63.99 117.52 7.15 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 116.178 -0.465 . . . . 99.99 110.891 179.951 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 105' ' ' LEU . . . . . 0.519 HD21 ' HB2' ' A' ' 88' ' ' PHE . 0.3 OUTLIER -94.12 162.92 13.68 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 116.268 -0.424 . . . . 99.99 110.928 179.989 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -88.84 159.74 29.39 Favored Glycine 0 N--CA 1.453 -0.219 0 C-N-CA 120.705 -0.76 . . . . 99.99 112.477 179.9 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 107' ' ' ARG . . . . . 0.543 ' HA ' ' CD1' ' A' ' 88' ' ' PHE . 4.3 ptp180 -66.84 157.29 33.42 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.847 0.356 . . . . 99.99 110.883 -179.882 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -173.1 111.61 0.39 Allowed Glycine 0 N--CA 1.452 -0.272 0 C-N-CA 120.717 -0.754 . . . . 99.99 112.468 -179.916 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 7.2 p -86.42 133.96 39.2 Favored Pre-proline 0 C--N 1.33 -0.264 0 CA-C-O 121.567 0.698 . . . . 99.99 111.157 179.999 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 110' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_endo -69.76 167.53 24.17 Favored 'Trans proline' 0 C--O 1.232 0.175 0 C-N-CA 122.635 2.224 . . . . 99.99 112.328 179.987 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 111' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.8 -18.08 37.04 Favored 'Trans proline' 0 C--N 1.342 0.201 0 C-N-CA 122.685 2.256 . . . . 99.99 112.312 179.963 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -75.42 138.33 41.61 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.221 -0.445 . . . . 99.99 111.068 179.955 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 8.4 p -125.04 139.03 52.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.207 -0.451 . . . . 99.99 111.111 -179.951 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 114' ' ' ASN . . . . . . . . . . . . . 16.7 t30 -107.29 122.94 47.57 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.169 -0.469 . . . . 99.99 110.95 179.986 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 3.2 ptm180 -107.65 140.47 40.63 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.207 -0.452 . . . . 99.99 110.929 -179.992 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 116' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -114.47 135.37 54.18 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.221 -0.445 . . . . 99.99 110.894 -179.886 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 3.9 tmm_? . . . . . 0 C--N 1.329 -0.296 0 CA-C-N 116.156 -0.475 . . . . 99.99 110.894 -179.883 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 2.0 mpt? . . . . . 0 C--O 1.23 0.065 0 CA-C-O 120.824 0.345 . . . . 99.99 110.857 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -166.25 163.26 17.74 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.196 -0.456 . . . . 99.99 111.123 179.961 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 3' ' ' ASP . . . . . . . . . . . . . 14.7 m-20 -137.57 -178.64 5.32 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.305 -0.407 . . . . 99.99 110.886 179.914 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 4' ' ' PHE . . . . . . . . . . . . . 66.2 m-85 -152.04 -175.72 5.36 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.194 -0.457 . . . . 99.99 110.862 -179.915 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 6.4 t0 -162.81 177.59 9.17 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.152 -0.476 . . . . 99.99 110.89 -179.985 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 6' ' ' ASN . . . . . . . . . . . . . 2.2 p30 -152.83 176.02 12.26 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.156 -0.475 . . . . 99.99 110.89 -179.898 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 7' ' ' LEU . . . . . . . . . . . . . 4.8 mp -127.15 -67.63 0.83 Allowed 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.178 -0.465 . . . . 99.99 110.976 179.948 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 8' ' ' PHE . . . . . . . . . . . . . 8.2 m-85 57.17 51.74 9.89 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.192 -0.458 . . . . 99.99 110.922 179.92 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 77.1 m-20 -75.23 -175.05 2.54 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.166 -0.47 . . . . 99.99 110.866 179.984 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -150.39 177.28 10.13 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.138 -0.483 . . . . 99.99 111.074 179.921 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -160.11 177.8 10.32 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.171 -0.468 . . . . 99.99 111.099 -179.993 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -132.25 -154.67 0.14 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.23 -0.441 . . . . 99.99 111.139 -179.98 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -173.68 178.34 2.29 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.194 -0.457 . . . . 99.99 111.081 179.842 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -155.85 -176.33 5.9 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.158 -0.474 . . . . 99.99 110.861 -179.944 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -138.18 179.1 6.65 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.16 -0.473 . . . . 99.99 111.159 179.882 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 21.9 m-20 -153.28 -174.05 4.8 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.246 -0.434 . . . . 99.99 110.879 179.969 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 49.6 mt-10 -125.11 177.66 5.97 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.157 -0.474 . . . . 99.99 110.83 -179.853 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -129.39 171.34 12.62 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.132 -0.485 . . . . 99.99 111.144 -179.986 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 61.5 mt -144.41 110.38 1.3 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.168 -0.469 . . . . 99.99 111.116 179.971 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 20' ' ' ARG . . . . . . . . . . . . . 25.5 mtp180 -98.91 179.06 4.76 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.163 -0.471 . . . . 99.99 110.837 179.974 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 120.61 120.31 2.76 Favored Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.748 -0.739 . . . . 99.99 112.499 -179.967 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 22' ' ' TYR . . . . . . . . . . . . . 52.7 t80 -162.24 107.0 1.2 Allowed 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.897 0.379 . . . . 99.99 110.973 -179.796 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 23' ' ' MET . . . . . . . . . . . . . 0.9 OUTLIER -175.02 145.31 0.8 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.113 -0.494 . . . . 99.99 110.845 179.939 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 102.76 -128.29 9.49 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.73 -0.748 . . . . 99.99 112.435 179.942 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 25' ' ' THR . . . . . 0.471 ' O ' ' HA ' ' A' ' 40' ' ' ARG . 1.3 t -111.67 111.71 22.89 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.746 0.308 . . . . 99.99 111.196 -179.828 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 20.6 p -72.86 123.46 23.44 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.258 -0.428 . . . . 99.99 110.799 -179.811 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 27' ' ' ALA . . . . . 0.514 ' HB1' ' H ' ' A' ' 41' ' ' GLY . . . -146.79 162.83 37.78 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.109 -0.496 . . . . 99.99 111.079 179.882 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 14.4 m -130.69 89.6 2.79 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.164 -0.471 . . . . 99.99 111.183 -179.89 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . 0.628 HG21 HG22 ' A' ' 39' ' ' ILE . 2.2 pt -43.69 134.5 1.21 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.364 0 CA-C-N 116.239 -0.437 . . . . 99.99 111.167 179.936 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 26.7 m -155.29 98.24 1.97 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.183 -0.462 . . . . 99.99 111.104 179.979 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 96.8 p -134.7 70.14 1.45 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.146 -0.479 . . . . 99.99 110.859 -179.868 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -179.27 168.86 39.79 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.733 -0.746 . . . . 99.99 112.476 179.988 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 16.7 pt-20 -48.72 -24.2 1.31 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.731 0.301 . . . . 99.99 110.863 -179.799 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 29.9 tt0 -173.97 95.55 0.1 Allowed 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.14 -0.482 . . . . 99.99 110.956 -179.888 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 2.1 m -144.29 165.07 28.92 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.223 -0.444 . . . . 99.99 110.836 -179.751 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 179.59 89.43 0.08 OUTLIER Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.796 -0.716 . . . . 99.99 112.51 -179.954 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -109.15 -170.71 1.71 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.83 0.348 . . . . 99.99 111.107 179.949 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 51.1 t -98.31 119.89 46.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.133 -0.485 . . . . 99.99 111.161 179.956 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 39' ' ' ILE . . . . . 0.628 HG22 HG21 ' A' ' 29' ' ' ILE . 0.0 OUTLIER -137.72 150.53 25.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.262 -0.426 . . . . 99.99 111.157 179.884 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 40' ' ' ARG . . . . . 0.471 ' HA ' ' O ' ' A' ' 25' ' ' THR . 19.2 mtt-85 -109.56 80.53 1.32 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.2 -0.455 . . . . 99.99 110.893 179.95 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . 0.514 ' H ' ' HB1' ' A' ' 27' ' ' ALA . . . -133.76 141.17 12.48 Favored Glycine 0 N--CA 1.452 -0.252 0 C-N-CA 120.77 -0.729 . . . . 99.99 112.478 -179.911 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 42' ' ' VAL . . . . . 0.407 ' HB ' ' CB ' ' A' ' 25' ' ' THR . 0.4 OUTLIER -124.22 139.01 51.89 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-O 120.818 0.342 . . . . 99.99 111.117 -179.935 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 43' ' ' PHE . . . . . 0.508 ' HA ' ' O ' ' A' ' 64' ' ' SER . 2.4 p90 -96.15 132.21 41.79 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.199 -0.455 . . . . 99.99 110.87 179.981 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 12.9 t70 -114.6 124.29 51.49 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.141 -0.482 . . . . 99.99 110.899 179.918 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -105.62 153.09 40.13 Favored Pre-proline 0 C--N 1.328 -0.345 0 CA-C-O 121.624 0.726 . . . . 99.99 110.834 -179.97 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 46' ' ' PRO . . . . . . . . . . . . . 54.9 Cg_endo -69.71 -36.21 11.35 Favored 'Trans proline' 0 C--N 1.342 0.187 0 C-N-CA 122.699 2.266 . . . . 99.99 112.379 179.96 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 38.5 mt-10 -59.67 -20.44 56.21 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.221 -0.445 . . . . 99.99 110.894 -179.984 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 10.4 m-20 -76.52 64.34 2.19 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.158 -0.474 . . . . 99.99 110.847 -179.943 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 9.6 pt -143.22 -40.42 0.17 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.215 -0.448 . . . . 99.99 111.135 179.899 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 13.1 m -82.78 -169.85 2.7 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.132 -0.485 . . . . 99.99 110.927 -179.946 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 7.9 m-85 -95.59 40.65 1.11 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.123 -0.489 . . . . 99.99 110.883 -179.878 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -167.97 143.65 3.84 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.105 -0.498 . . . . 99.99 111.14 179.798 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -159.34 88.19 0.11 Allowed Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.692 -0.766 . . . . 99.99 112.466 -179.952 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 54' ' ' GLN . . . . . . . . . . . . . 16.2 tt0 -174.94 109.82 0.12 Allowed 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.822 0.344 . . . . 99.99 110.948 -179.918 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 169.2 81.9 0.05 OUTLIER Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.827 -0.702 . . . . 99.99 112.541 -179.962 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 46.3 t -93.42 87.18 2.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-O 120.792 0.329 . . . . 99.99 111.136 -179.971 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 30.8 mtt180 -105.93 71.23 0.89 Allowed 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.17 -0.468 . . . . 99.99 110.862 -179.972 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 12.6 p 39.78 38.02 0.21 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.143 -0.481 . . . . 99.99 111.121 179.953 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 9.0 tt0 -92.59 156.7 16.94 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.194 -0.457 . . . . 99.99 110.877 -179.992 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -129.23 128.72 5.87 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.762 -0.732 . . . . 99.99 112.533 -179.972 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -147.38 153.41 39.6 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.882 0.372 . . . . 99.99 110.804 -179.718 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 1.1 m -106.04 97.63 16.19 Favored Pre-proline 0 C--N 1.329 -0.325 0 CA-C-O 121.611 0.719 . . . . 99.99 110.878 -179.838 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.78 -177.96 2.13 Favored 'Trans proline' 0 C--O 1.231 0.164 0 C-N-CA 122.636 2.224 . . . . 99.99 112.378 179.958 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 64' ' ' SER . . . . . 0.508 ' O ' ' HA ' ' A' ' 43' ' ' PHE . 0.5 OUTLIER -105.95 151.21 24.89 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.237 -0.438 . . . . 99.99 110.87 -179.854 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 65' ' ' LEU . . . . . 0.648 ' O ' ' HA ' ' A' ' 102' ' ' HIS . 3.2 tm? -113.52 139.21 49.15 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.119 -0.491 . . . . 99.99 110.951 179.998 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 2.8 t80 -120.54 106.25 11.61 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.235 -0.439 . . . . 99.99 110.923 179.906 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 8.2 p -144.03 161.46 15.59 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 116.144 -0.48 . . . . 99.99 111.124 179.992 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 68' ' ' ARG . . . . . 0.486 ' HG3' ' HA2' ' A' ' 99' ' ' GLY . 7.0 ttm180 -96.09 145.38 25.53 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.148 -0.478 . . . . 99.99 110.878 -179.976 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 69' ' ' THR . . . . . 0.423 ' HB ' ' HG3' ' A' ' 95' ' ' PRO . 3.0 t -40.22 -45.43 2.06 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.227 -0.442 . . . . 99.99 111.209 -179.98 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 4.8 m-20 -65.81 -53.97 33.08 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.191 -0.459 . . . . 99.99 110.91 179.884 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 71' ' ' GLU . . . . . . . . . . . . . 1.1 mp0 -53.74 -39.24 65.14 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.17 -0.468 . . . . 99.99 110.897 -179.964 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 7.2 p -82.63 -24.35 8.73 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.225 -0.443 . . . . 99.99 111.115 179.991 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 73' ' ' ARG . . . . . . . . . . . . . 51.0 ttt180 -63.97 -37.22 86.62 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.16 -0.473 . . . . 99.99 110.887 -179.989 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 15.2 mm-40 -67.62 -10.96 56.85 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.179 -0.464 . . . . 99.99 110.877 -179.95 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 8.7 mp -103.39 -176.4 3.07 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.234 -0.439 . . . . 99.99 110.95 179.995 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 76' ' ' ARG . . . . . . . . . . . . . 16.5 ttm180 -123.64 150.0 44.71 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.231 -0.441 . . . . 99.99 110.873 -179.986 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -50.34 105.43 0.09 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.218 -0.446 . . . . 99.99 110.918 -179.9 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 113.97 16.14 8.1 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.745 -0.741 . . . . 99.99 112.441 -179.974 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -79.88 106.27 11.78 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-O 120.898 0.38 . . . . 99.99 110.852 -179.976 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 80' ' ' THR . . . . . 0.713 ' HA ' ' HA ' ' A' ' 89' ' ' TRP . 0.7 OUTLIER -85.46 110.24 19.03 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.226 -0.443 . . . . 99.99 111.167 -179.929 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 81' ' ' LEU . . . . . 0.74 ' C ' ' HA ' ' A' ' 87' ' ' ASN . 0.3 OUTLIER -96.38 132.2 42.14 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.226 -0.443 . . . . 99.99 110.961 179.955 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 82' ' ' THR . . . . . 0.743 ' CA ' ' HA ' ' A' ' 87' ' ' ASN . 3.4 t -93.82 102.5 14.63 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.205 -0.452 . . . . 99.99 111.18 179.973 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 83' ' ' ILE . . . . . 0.431 ' HB ' ' CB ' ' A' ' 27' ' ' ALA . 0.1 OUTLIER -138.52 131.66 39.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.211 -0.45 . . . . 99.99 111.105 179.966 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 74.59 -53.17 2.39 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.741 -0.742 . . . . 99.99 112.517 179.941 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . 0.404 ' O ' ' HG3' ' A' ' 86' ' ' GLU . 4.1 mm-40 -117.76 -82.2 0.63 Allowed 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.834 0.35 . . . . 99.99 110.865 -179.91 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 86' ' ' GLU . . . . . 0.408 ' C ' ' HA ' ' A' ' 82' ' ' THR . 6.9 mp0 -149.7 160.3 43.64 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.163 -0.471 . . . . 99.99 110.92 -179.915 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 87' ' ' ASN . . . . . 0.743 ' HA ' ' CA ' ' A' ' 82' ' ' THR . 1.4 p30 -50.91 123.81 9.95 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.193 -0.458 . . . . 99.99 110.893 -179.913 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 88' ' ' PHE . . . . . 0.539 ' HB2' HD22 ' A' ' 105' ' ' LEU . 14.9 m-85 -131.81 118.32 19.73 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.199 -0.455 . . . . 99.99 110.893 -179.955 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 89' ' ' TRP . . . . . 0.713 ' HA ' ' HA ' ' A' ' 80' ' ' THR . 62.2 p-90 -81.53 135.1 35.59 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.196 -0.456 . . . . 99.99 110.854 -179.963 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 90' ' ' VAL . . . . . 0.471 ' CG2' ' HB3' ' A' ' 103' ' ' LEU . 4.9 p -91.52 136.8 23.38 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.193 -0.458 . . . . 99.99 111.131 179.881 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 91' ' ' ASP . . . . . 0.465 ' CB ' HD12 ' A' ' 103' ' ' LEU . 0.5 OUTLIER -63.06 -72.3 0.14 Allowed 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.219 -0.446 . . . . 99.99 110.919 179.87 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 92' ' ' ARG . . . . . 0.584 ' O ' ' HG ' ' A' ' 103' ' ' LEU . 12.3 ttm-85 -159.17 120.66 3.35 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.185 -0.461 . . . . 99.99 110.861 -179.962 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 93' ' ' VAL . . . . . 0.468 ' HB ' ' CB ' ' A' ' 101' ' ' CYS . 24.4 m -111.8 133.01 58.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.188 -0.46 . . . . 99.99 111.127 179.994 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 94' ' ' SER . . . . . 0.414 ' HA ' ' HD2' ' A' ' 95' ' ' PRO . 11.5 t -125.72 100.29 31.44 Favored Pre-proline 0 C--N 1.329 -0.291 0 CA-C-O 121.692 0.758 . . . . 99.99 110.824 -179.78 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 95' ' ' PRO . . . . . 0.423 ' HG3' ' HB ' ' A' ' 69' ' ' THR . 53.9 Cg_endo -69.79 169.96 17.73 Favored 'Trans proline' 0 C--N 1.343 0.26 0 C-N-CA 122.634 2.222 . . . . 99.99 112.383 179.977 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 8.8 m-20 -131.68 4.74 4.25 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.221 -0.445 . . . . 99.99 110.871 179.97 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 12.1 t0 -140.95 30.45 1.82 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.13 -0.486 . . . . 99.99 110.918 179.957 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 49.27 60.21 6.4 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.701 -0.762 . . . . 99.99 112.442 -179.957 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 99' ' ' GLY . . . . . 0.486 ' HA2' ' HG3' ' A' ' 68' ' ' ARG . . . 138.42 35.13 0.17 Allowed Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.712 -0.756 . . . . 99.99 112.462 -179.964 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 28.8 t -152.22 72.12 0.98 Allowed 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 120.785 0.326 . . . . 99.99 110.859 -179.747 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 101' ' ' CYS . . . . . 0.468 ' CB ' ' HB ' ' A' ' 93' ' ' VAL . 0.0 OUTLIER -108.47 149.77 28.34 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.126 -0.488 . . . . 99.99 110.887 -179.975 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 102' ' ' HIS . . . . . 0.648 ' HA ' ' O ' ' A' ' 65' ' ' LEU . 28.6 p-80 -158.88 125.42 4.64 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.145 -0.48 . . . . 99.99 110.862 179.968 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 103' ' ' LEU . . . . . 0.584 ' HG ' ' O ' ' A' ' 92' ' ' ARG . 2.8 tm? -151.92 148.02 27.28 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.199 -0.455 . . . . 99.99 110.952 -179.955 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 104' ' ' TRP . . . . . 0.429 ' N ' ' CD1' ' A' ' 103' ' ' LEU . 28.0 p90 -64.79 113.69 3.97 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.24 -0.436 . . . . 99.99 110.964 179.839 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 105' ' ' LEU . . . . . 0.539 HD22 ' HB2' ' A' ' 88' ' ' PHE . 0.3 OUTLIER -92.6 162.62 14.11 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.219 -0.446 . . . . 99.99 110.898 179.998 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -89.27 159.16 28.4 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.811 -0.709 . . . . 99.99 112.459 179.92 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 107' ' ' ARG . . . . . 0.528 ' HA ' ' CD1' ' A' ' 88' ' ' PHE . 0.0 OUTLIER -69.74 158.32 35.64 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.852 0.358 . . . . 99.99 110.891 -179.875 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -172.9 109.13 0.29 Allowed Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.715 -0.755 . . . . 99.99 112.442 -179.987 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 7.4 p -92.31 134.34 28.45 Favored Pre-proline 0 C--N 1.329 -0.312 0 CA-C-O 121.604 0.716 . . . . 99.99 111.09 -179.951 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 110' ' ' PRO . . . . . 0.492 ' N ' HD22 ' A' ' 87' ' ' ASN . 53.9 Cg_endo -69.75 168.34 21.83 Favored 'Trans proline' 0 C--O 1.232 0.198 0 C-N-CA 122.678 2.252 . . . . 99.99 112.347 179.948 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 111' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.79 -8.39 23.48 Favored 'Trans proline' 0 C--N 1.341 0.164 0 C-N-CA 122.723 2.282 . . . . 99.99 112.304 179.967 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -60.81 161.39 8.11 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.249 -0.432 . . . . 99.99 111.144 179.86 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 5.6 p -93.08 119.86 41.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.168 -0.469 . . . . 99.99 111.129 179.999 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 114' ' ' ASN . . . . . . . . . . . . . 1.6 m-80 -129.11 145.88 51.19 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.217 -0.447 . . . . 99.99 110.884 -179.993 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -83.49 125.96 32.28 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.13 -0.487 . . . . 99.99 110.824 -179.935 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 116' ' ' ARG . . . . . . . . . . . . . 6.9 ptp85 -115.01 138.21 51.12 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.172 -0.467 . . . . 99.99 110.924 -179.956 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 46.0 ttt180 . . . . . 0 C--N 1.329 -0.29 0 CA-C-N 116.202 -0.454 . . . . 99.99 110.86 -179.891 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 27.1 mtt . . . . . 0 C--O 1.231 0.088 0 CA-C-O 120.779 0.324 . . . . 99.99 110.91 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . 62.5 53.79 2.61 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.323 -0.399 . . . . 99.99 111.07 179.901 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 3' ' ' ASP . . . . . . . . . . . . . 11.1 t70 -121.84 149.46 43.33 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.207 -0.452 . . . . 99.99 110.8 -179.977 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 4' ' ' PHE . . . . . . . . . . . . . 31.4 m-85 -153.0 178.98 9.11 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.181 -0.463 . . . . 99.99 110.938 -179.968 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 5.7 m-20 -160.63 178.96 8.97 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 116.147 -0.479 . . . . 99.99 110.906 -179.975 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 6' ' ' ASN . . . . . . . . . . . . . 30.8 t30 -159.34 171.57 19.55 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.213 -0.448 . . . . 99.99 110.868 -179.918 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 7' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -164.85 178.7 6.99 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.138 -0.483 . . . . 99.99 110.864 179.954 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 8' ' ' PHE . . . . . . . . . . . . . 45.6 m-85 -139.73 -178.65 5.51 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.156 -0.474 . . . . 99.99 110.856 179.979 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 3.3 t70 -175.96 177.43 1.63 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.165 -0.471 . . . . 99.99 110.834 179.932 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -154.79 177.55 11.14 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.238 -0.437 . . . . 99.99 111.149 179.98 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -125.16 -72.33 0.67 Allowed 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.243 -0.435 . . . . 99.99 111.042 179.972 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 41.9 mt 59.96 71.64 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.268 -0.424 . . . . 99.99 111.102 -179.993 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -150.87 168.88 23.13 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.194 -0.457 . . . . 99.99 111.108 179.832 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 22.6 mmm180 -139.71 -176.01 4.41 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.272 -0.422 . . . . 99.99 110.871 -179.855 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -145.0 -172.48 3.85 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.165 -0.47 . . . . 99.99 111.048 179.918 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 1.8 p-10 -152.48 -174.04 4.76 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.171 -0.468 . . . . 99.99 110.861 179.933 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -146.68 176.94 9.47 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.212 -0.449 . . . . 99.99 110.883 -179.942 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -159.71 151.09 19.81 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.108 -0.496 . . . . 99.99 111.136 -179.932 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 38.7 mm -136.92 103.73 3.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.196 -0.456 . . . . 99.99 111.09 179.93 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 20' ' ' ARG . . . . . . . . . . . . . 8.4 ttm-85 -137.14 167.88 20.7 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.148 -0.478 . . . . 99.99 110.886 179.943 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -107.25 -125.13 5.32 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.696 -0.764 . . . . 99.99 112.478 -179.947 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 22' ' ' TYR . . . . . . . . . . . . . 33.7 p90 -165.69 134.34 3.17 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.894 0.378 . . . . 99.99 110.901 -179.786 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 23' ' ' MET . . . . . . . . . . . . . 2.6 ptt? -169.14 156.41 7.1 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.112 -0.495 . . . . 99.99 110.903 179.85 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 75.7 -99.2 1.22 Allowed Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.761 -0.733 . . . . 99.99 112.451 179.985 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 25' ' ' THR . . . . . 0.587 ' O ' ' HA ' ' A' ' 40' ' ' ARG . 46.6 p -99.51 108.19 20.56 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.814 0.34 . . . . 99.99 111.172 -179.905 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -76.27 121.77 23.43 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.275 -0.42 . . . . 99.99 110.884 -179.878 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 27' ' ' ALA . . . . . 0.567 ' CB ' HG21 ' A' ' 39' ' ' ILE . . . -151.39 161.12 43.27 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.168 -0.469 . . . . 99.99 111.102 179.877 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 28' ' ' THR . . . . . 0.403 ' O ' HG21 ' A' ' 82' ' ' THR . 16.0 m -131.98 87.99 2.5 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.203 -0.453 . . . . 99.99 111.144 -179.856 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . 0.601 HG23 HG22 ' A' ' 39' ' ' ILE . 2.5 pt -43.23 128.55 1.0 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 CA-C-N 116.189 -0.46 . . . . 99.99 111.171 179.893 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 11.8 m -153.18 101.11 2.52 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.177 -0.465 . . . . 99.99 111.141 -179.998 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 85.2 p -141.09 72.56 1.39 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.217 -0.447 . . . . 99.99 110.879 -179.853 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -178.42 166.91 37.13 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.764 -0.731 . . . . 99.99 112.529 -179.981 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 8.5 pt-20 -49.14 -23.51 1.3 Allowed 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.812 0.339 . . . . 99.99 110.874 -179.915 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -174.47 93.49 0.08 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.192 -0.458 . . . . 99.99 110.971 -179.91 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 1.9 m -145.22 165.34 28.64 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.241 -0.436 . . . . 99.99 110.914 -179.823 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -179.61 86.99 0.07 OUTLIER Glycine 0 N--CA 1.452 -0.273 0 C-N-CA 120.689 -0.767 . . . . 99.99 112.491 -179.999 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -106.23 -173.56 2.33 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.771 0.32 . . . . 99.99 111.184 179.933 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 65.9 t -100.02 122.87 52.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.301 -0.408 . . . . 99.99 111.139 -179.996 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 39' ' ' ILE . . . . . 0.601 HG22 HG23 ' A' ' 29' ' ' ILE . 0.0 OUTLIER -136.88 147.63 27.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.158 -0.473 . . . . 99.99 111.097 179.979 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 40' ' ' ARG . . . . . 0.587 ' HA ' ' O ' ' A' ' 25' ' ' THR . 0.2 OUTLIER -108.8 81.78 1.51 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.166 -0.47 . . . . 99.99 110.913 179.914 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . 0.525 ' O ' ' HB3' ' A' ' 27' ' ' ALA . . . -143.07 141.96 11.0 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.715 -0.755 . . . . 99.99 112.503 -179.989 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 42' ' ' VAL . . . . . 0.464 ' O ' ' HA ' ' A' ' 65' ' ' LEU . 9.8 p -127.8 142.39 43.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-O 120.882 0.373 . . . . 99.99 111.102 -179.904 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 43' ' ' PHE . . . . . 0.434 ' HA ' ' O ' ' A' ' 64' ' ' SER . 1.7 p90 -90.08 137.6 32.21 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.142 -0.481 . . . . 99.99 110.878 -179.969 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 9.9 t70 -123.52 125.0 44.11 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.142 -0.481 . . . . 99.99 110.777 -179.992 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 2.6 p30 -120.15 153.06 55.34 Favored Pre-proline 0 C--N 1.329 -0.322 0 CA-C-O 121.618 0.723 . . . . 99.99 110.868 179.941 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 46' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.73 -37.63 8.99 Favored 'Trans proline' 0 C--N 1.34 0.121 0 C-N-CA 122.725 2.283 . . . . 99.99 112.308 -179.958 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 3.7 tt0 -146.16 89.08 1.84 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.255 -0.43 . . . . 99.99 110.877 -179.938 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 18.4 p-10 -54.96 161.89 1.48 Allowed 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.136 -0.483 . . . . 99.99 110.89 -179.907 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 52.9 mt -52.13 140.02 7.87 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.202 -0.454 . . . . 99.99 111.138 179.956 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 54.4 p -124.02 61.6 1.1 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.158 -0.473 . . . . 99.99 110.863 -179.883 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 36.2 m-85 -156.7 175.98 13.33 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.131 -0.486 . . . . 99.99 110.917 -179.868 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -57.1 113.69 1.82 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.106 -0.497 . . . . 99.99 111.119 179.875 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -81.05 -138.74 2.36 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.704 -0.76 . . . . 99.99 112.465 -179.927 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 54' ' ' GLN . . . . . . . . . . . . . 11.8 mm-40 62.87 25.71 15.21 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.907 0.384 . . . . 99.99 110.955 -179.849 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 128.57 53.09 0.12 Allowed Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.726 -0.749 . . . . 99.99 112.507 -179.947 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 11.1 p -115.88 151.36 17.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-O 120.832 0.349 . . . . 99.99 111.083 -179.926 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 52.9 mtp180 -75.22 -177.06 3.3 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.143 -0.48 . . . . 99.99 110.909 179.995 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 58.1 t -137.38 143.54 34.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.19 -0.459 . . . . 99.99 111.117 179.948 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 11.9 mt-10 -75.07 -171.13 1.28 Allowed 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.117 -0.492 . . . . 99.99 110.939 -179.981 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -91.33 100.27 2.66 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.746 -0.74 . . . . 99.99 112.481 -179.952 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -150.14 152.88 35.4 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.852 0.358 . . . . 99.99 110.861 -179.704 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 62' ' ' SER . . . . . 0.402 ' HA ' ' HD2' ' A' ' 63' ' ' PRO . 0.3 OUTLIER -120.35 97.52 48.94 Favored Pre-proline 0 C--N 1.33 -0.277 0 CA-C-O 121.689 0.757 . . . . 99.99 110.882 -179.852 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 63' ' ' PRO . . . . . 0.402 ' HD2' ' HA ' ' A' ' 62' ' ' SER . 53.5 Cg_endo -69.78 171.22 14.89 Favored 'Trans proline' 0 C--N 1.341 0.164 0 C-N-CA 122.722 2.281 . . . . 99.99 112.298 -179.985 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 64' ' ' SER . . . . . 0.434 ' O ' ' HA ' ' A' ' 43' ' ' PHE . 8.0 t -105.6 147.04 28.88 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.21 -0.45 . . . . 99.99 110.854 -179.877 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 65' ' ' LEU . . . . . 0.464 ' HA ' ' O ' ' A' ' 42' ' ' VAL . 0.9 OUTLIER -113.62 119.41 37.37 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.141 -0.481 . . . . 99.99 110.932 -179.986 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 6.4 t80 -94.63 111.28 23.05 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.242 -0.435 . . . . 99.99 110.844 179.981 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -141.38 170.49 13.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.096 -0.502 . . . . 99.99 111.197 179.961 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 10.1 ttm180 -100.74 143.86 30.39 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.24 -0.436 . . . . 99.99 110.934 -179.999 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 4.7 t -42.9 -44.61 4.62 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.219 -0.446 . . . . 99.99 111.191 -179.901 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 21.1 t0 -65.67 -46.32 79.56 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.233 -0.44 . . . . 99.99 110.903 179.862 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 71' ' ' GLU . . . . . . . . . . . . . 67.1 mm-40 -53.93 -39.66 66.05 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.116 -0.493 . . . . 99.99 110.928 -179.921 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 19.0 m -86.72 -25.51 6.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.103 -0.498 . . . . 99.99 111.151 179.966 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 73' ' ' ARG . . . . . . . . . . . . . 0.8 OUTLIER -60.0 -41.24 91.67 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.139 -0.482 . . . . 99.99 110.895 -179.999 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 32.3 mt-30 -62.07 -16.59 53.15 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.169 -0.469 . . . . 99.99 110.899 -179.959 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 5.3 mp -108.89 -175.51 2.79 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.246 -0.434 . . . . 99.99 110.85 -179.921 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 76' ' ' ARG . . . . . . . . . . . . . 5.0 ptp85 -115.56 -173.83 2.41 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.135 -0.484 . . . . 99.99 110.934 179.954 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 7.0 ptp180 -79.99 131.38 35.79 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.253 -0.43 . . . . 99.99 110.89 -179.951 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 92.31 25.79 20.33 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.74 -0.743 . . . . 99.99 112.56 -179.924 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -89.24 105.33 17.72 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.911 0.386 . . . . 99.99 110.852 -179.949 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 80' ' ' THR . . . . . 0.757 ' HA ' ' HA ' ' A' ' 89' ' ' TRP . 0.8 OUTLIER -87.28 110.57 20.29 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.196 -0.456 . . . . 99.99 111.101 -179.89 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 81' ' ' LEU . . . . . 0.735 ' C ' ' HA ' ' A' ' 87' ' ' ASN . 0.3 OUTLIER -95.41 131.91 41.04 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.153 -0.476 . . . . 99.99 110.897 179.935 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 82' ' ' THR . . . . . 0.741 ' CA ' ' HA ' ' A' ' 87' ' ' ASN . 5.0 t -94.01 102.03 14.1 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.18 -0.464 . . . . 99.99 111.133 179.932 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 83' ' ' ILE . . . . . 0.487 ' CD1' ' O ' ' A' ' 83' ' ' ILE . 0.1 OUTLIER -132.46 130.26 59.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.184 -0.462 . . . . 99.99 111.116 179.92 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 68.19 -62.73 0.39 Allowed Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.707 -0.758 . . . . 99.99 112.508 179.911 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 29.2 mm-40 -98.66 -83.7 0.41 Allowed 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.766 0.317 . . . . 99.99 110.949 -179.924 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 86' ' ' GLU . . . . . 0.417 ' C ' ' HA ' ' A' ' 82' ' ' THR . 70.1 mt-10 -154.22 160.97 42.09 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.129 -0.487 . . . . 99.99 110.844 -179.96 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 87' ' ' ASN . . . . . 0.741 ' HA ' ' CA ' ' A' ' 82' ' ' THR . 0.8 OUTLIER -50.55 123.73 9.37 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.156 -0.475 . . . . 99.99 110.871 -179.89 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 88' ' ' PHE . . . . . 0.574 ' CD1' ' HA ' ' A' ' 107' ' ' ARG . 15.1 m-85 -131.51 119.48 21.6 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.239 -0.437 . . . . 99.99 110.889 -179.974 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 89' ' ' TRP . . . . . 0.757 ' HA ' ' HA ' ' A' ' 80' ' ' THR . 4.6 p90 -80.12 138.05 36.85 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.166 -0.47 . . . . 99.99 110.856 -179.915 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 90' ' ' VAL . . . . . 0.442 ' HA ' ' HB3' ' A' ' 105' ' ' LEU . 2.2 p -94.59 135.84 27.6 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 116.156 -0.474 . . . . 99.99 111.129 179.942 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 91' ' ' ASP . . . . . 0.447 ' CB ' HD13 ' A' ' 103' ' ' LEU . 0.4 OUTLIER -65.28 -75.25 0.09 Allowed 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.173 -0.467 . . . . 99.99 110.879 179.892 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 92' ' ' ARG . . . . . 0.578 ' O ' ' HG ' ' A' ' 103' ' ' LEU . 0.0 OUTLIER -153.23 117.45 4.87 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.166 -0.47 . . . . 99.99 110.818 -179.944 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 93' ' ' VAL . . . . . 0.491 ' CG2' ' N ' ' A' ' 102' ' ' HIS . 0.3 OUTLIER -111.45 139.82 33.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.171 -0.468 . . . . 99.99 111.173 179.906 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 1.4 p -140.78 103.94 6.32 Favored Pre-proline 0 C--N 1.329 -0.293 0 CA-C-O 121.713 0.768 . . . . 99.99 110.857 -179.807 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_endo -69.68 173.61 10.65 Favored 'Trans proline' 0 C--N 1.342 0.199 0 C-N-CA 122.729 2.286 . . . . 99.99 112.365 179.908 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 21.2 m-20 -107.26 -6.28 17.34 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.197 -0.456 . . . . 99.99 110.854 179.95 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 46.5 p-10 -151.78 32.81 0.55 Allowed 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.236 -0.438 . . . . 99.99 110.906 179.981 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 45.25 68.8 0.88 Allowed Glycine 0 N--CA 1.452 -0.235 0 C-N-CA 120.696 -0.764 . . . . 99.99 112.437 -179.97 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . 173.08 -28.13 0.09 OUTLIER Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.74 -0.743 . . . . 99.99 112.467 179.991 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 1.5 m -122.04 101.03 7.3 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.775 0.321 . . . . 99.99 110.831 -179.741 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 101' ' ' CYS . . . . . 0.4 ' HB3' HG11 ' A' ' 93' ' ' VAL . 0.0 OUTLIER -122.95 154.43 38.39 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.212 -0.449 . . . . 99.99 110.839 -179.954 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 102' ' ' HIS . . . . . 0.491 ' N ' ' CG2' ' A' ' 93' ' ' VAL . 13.5 p80 -156.94 123.34 4.96 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.161 -0.472 . . . . 99.99 110.853 -179.972 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 103' ' ' LEU . . . . . 0.578 ' HG ' ' O ' ' A' ' 92' ' ' ARG . 3.4 tm? -148.25 144.57 27.74 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.211 -0.45 . . . . 99.99 110.856 -179.916 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 104' ' ' TRP . . . . . . . . . . . . . 4.2 m-90 -69.29 108.54 3.72 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.225 -0.443 . . . . 99.99 110.924 179.831 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 105' ' ' LEU . . . . . 0.523 HD21 ' HB2' ' A' ' 88' ' ' PHE . 0.3 OUTLIER -89.6 161.8 15.97 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.266 -0.424 . . . . 99.99 110.985 179.945 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -89.69 159.92 28.5 Favored Glycine 0 N--CA 1.45 -0.379 0 C-N-CA 120.713 -0.756 . . . . 99.99 112.537 179.891 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 107' ' ' ARG . . . . . 0.574 ' HA ' ' CD1' ' A' ' 88' ' ' PHE . 0.1 OUTLIER -68.94 157.55 36.46 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.88 0.372 . . . . 99.99 110.832 -179.807 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -172.05 112.38 0.44 Allowed Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.78 -0.724 . . . . 99.99 112.538 -179.998 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 7.3 p -85.56 133.78 41.35 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-O 121.599 0.714 . . . . 99.99 111.176 -179.975 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 110' ' ' PRO . . . . . . . . . . . . . 54.8 Cg_endo -69.63 168.14 22.26 Favored 'Trans proline' 0 C--O 1.233 0.232 0 C-N-CA 122.693 2.262 . . . . 99.99 112.394 179.9 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 111' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.77 -8.48 23.7 Favored 'Trans proline' 0 C--O 1.231 0.174 0 C-N-CA 122.708 2.272 . . . . 99.99 112.365 179.896 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -59.15 161.22 5.47 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.244 -0.435 . . . . 99.99 111.156 179.769 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 17.2 m -92.97 122.0 44.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.278 -0.419 . . . . 99.99 111.135 179.97 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 114' ' ' ASN . . . . . . . . . . . . . 1.5 m-80 -128.67 146.15 50.95 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.097 -0.501 . . . . 99.99 110.896 179.985 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 6.4 mtp180 -82.46 112.6 19.54 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.159 -0.473 . . . . 99.99 110.804 -179.897 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 116' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -111.79 138.0 48.96 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.159 -0.473 . . . . 99.99 110.889 -179.912 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 C--N 1.328 -0.326 0 CA-C-N 116.173 -0.467 . . . . 99.99 110.873 -179.909 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 10.6 ttp . . . . . 0 C--O 1.23 0.049 0 CA-C-O 120.794 0.33 . . . . 99.99 110.931 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -172.7 158.98 4.18 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.162 -0.472 . . . . 99.99 111.094 179.885 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 3' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -154.57 122.75 5.98 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.262 -0.426 . . . . 99.99 110.867 179.937 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 4' ' ' PHE . . . . . . . . . . . . . 36.8 p90 -141.54 147.56 37.94 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.123 -0.489 . . . . 99.99 110.89 -179.909 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 5.4 m-20 -136.64 151.72 49.62 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.156 -0.475 . . . . 99.99 110.863 -179.968 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 6' ' ' ASN . . . . . . . . . . . . . 64.4 m-80 -101.06 -70.48 0.74 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.239 -0.437 . . . . 99.99 110.916 -179.951 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 7' ' ' LEU . . . . . . . . . . . . . 20.3 mt -101.34 109.66 21.54 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.143 -0.48 . . . . 99.99 110.932 179.91 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 8' ' ' PHE . . . . . . . . . . . . . 10.4 m-85 -63.93 -30.58 71.65 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.172 -0.467 . . . . 99.99 110.899 179.881 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 28.5 t70 -165.95 104.2 0.67 Allowed 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.184 -0.462 . . . . 99.99 110.885 179.994 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -127.39 108.72 11.08 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.232 -0.44 . . . . 99.99 111.07 179.978 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -71.04 97.68 1.5 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.23 -0.441 . . . . 99.99 111.139 179.899 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 32.0 mt -121.82 63.95 0.26 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.21 -0.45 . . . . 99.99 111.102 -179.981 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -175.54 104.82 0.08 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.113 -0.494 . . . . 99.99 111.106 179.786 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 61.4 ttt180 -71.84 125.94 28.46 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.171 -0.468 . . . . 99.99 110.828 -179.88 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -75.53 74.14 2.56 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.152 -0.476 . . . . 99.99 111.078 179.941 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 10.5 p-10 -137.2 58.48 1.71 Allowed 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.17 -0.468 . . . . 99.99 110.83 -179.983 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 10.1 tt0 61.74 52.66 3.44 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.217 -0.447 . . . . 99.99 110.908 -179.91 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 43.0 p -62.17 -176.69 0.1 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.135 -0.484 . . . . 99.99 111.158 -179.882 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 9.5 mt 64.98 46.02 0.17 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.261 -0.427 . . . . 99.99 111.143 179.941 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 20' ' ' ARG . . . . . . . . . . . . . 3.9 ttt180 -106.17 -62.99 1.31 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.172 -0.467 . . . . 99.99 110.855 180.0 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 82.87 176.39 51.47 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.678 -0.772 . . . . 99.99 112.454 -179.957 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 22' ' ' TYR . . . . . . . . . . . . . 20.3 p90 -177.78 123.37 0.12 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.89 0.376 . . . . 99.99 110.905 -179.839 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 23' ' ' MET . . . . . . . . . . . . . 4.2 mmt -150.97 145.21 25.42 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.126 -0.488 . . . . 99.99 110.833 179.883 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 74.51 -99.51 1.11 Allowed Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.711 -0.757 . . . . 99.99 112.519 -179.952 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 25' ' ' THR . . . . . 0.538 ' O ' ' HA ' ' A' ' 40' ' ' ARG . 0.0 OUTLIER -122.22 111.88 17.49 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.867 0.365 . . . . 99.99 111.09 -179.889 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -75.09 123.33 25.03 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.112 -0.495 . . . . 99.99 110.838 -179.856 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 27' ' ' ALA . . . . . 0.497 ' CB ' HG21 ' A' ' 39' ' ' ILE . . . -145.13 163.21 35.02 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.15 -0.477 . . . . 99.99 111.056 179.894 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 19.1 m -130.46 87.2 2.47 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.173 -0.467 . . . . 99.99 111.164 -179.874 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . 0.629 HG21 HG22 ' A' ' 39' ' ' ILE . 2.2 pt -44.27 132.15 1.55 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.213 -0.448 . . . . 99.99 111.161 179.926 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 23.4 m -153.89 101.17 2.42 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.183 -0.462 . . . . 99.99 111.176 179.983 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 1.8 t -137.12 71.04 1.4 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.265 -0.425 . . . . 99.99 110.843 -179.856 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -179.4 168.1 38.51 Favored Glycine 0 N--CA 1.45 -0.422 0 C-N-CA 120.72 -0.752 . . . . 99.99 112.458 -179.968 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 6.7 pt-20 -49.24 -23.4 1.33 Allowed 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.793 0.33 . . . . 99.99 110.894 -179.896 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 3.5 tt0 -174.69 94.93 0.08 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.12 -0.491 . . . . 99.99 110.971 -179.97 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -145.11 165.33 28.59 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.232 -0.44 . . . . 99.99 110.801 -179.789 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -179.22 88.86 0.07 OUTLIER Glycine 0 N--CA 1.452 -0.254 0 C-N-CA 120.723 -0.751 . . . . 99.99 112.449 179.995 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -106.26 -172.45 2.09 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.798 0.332 . . . . 99.99 111.116 179.942 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 23.5 t -99.66 120.01 48.47 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.232 -0.44 . . . . 99.99 111.117 179.998 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 39' ' ' ILE . . . . . 0.629 HG22 HG21 ' A' ' 29' ' ' ILE . 0.0 OUTLIER -137.28 151.03 26.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.227 -0.442 . . . . 99.99 111.177 179.918 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 40' ' ' ARG . . . . . 0.538 ' HA ' ' O ' ' A' ' 25' ' ' THR . 28.0 mmt180 -112.87 82.03 1.59 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.193 -0.458 . . . . 99.99 110.845 179.988 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . 0.486 ' H ' ' HB3' ' A' ' 27' ' ' ALA . . . -140.18 138.21 8.92 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.794 -0.717 . . . . 99.99 112.451 -179.966 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 42' ' ' VAL . . . . . 0.469 ' HB ' ' OG1' ' A' ' 25' ' ' THR . 1.7 p -123.59 137.81 55.53 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-O 120.817 0.341 . . . . 99.99 111.17 179.943 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 2.1 p90 -93.22 137.82 32.19 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.198 -0.455 . . . . 99.99 110.88 -179.91 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 3.4 t70 -117.96 125.43 50.41 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.147 -0.479 . . . . 99.99 110.853 179.986 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 45' ' ' ASP . . . . . 0.412 ' HA ' ' HD2' ' A' ' 46' ' ' PRO . 1.2 p30 -109.63 106.2 58.13 Favored Pre-proline 0 C--N 1.329 -0.323 0 CA-C-O 121.548 0.69 . . . . 99.99 110.913 179.951 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 46' ' ' PRO . . . . . 0.412 ' HD2' ' HA ' ' A' ' 45' ' ' ASP . 53.9 Cg_endo -69.81 -37.74 8.63 Favored 'Trans proline' 0 C--O 1.231 0.126 0 C-N-CA 122.673 2.248 . . . . 99.99 112.335 -179.949 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 35.8 mt-10 -133.98 84.03 2.09 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.296 -0.411 . . . . 99.99 110.917 179.999 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 28.4 m-80 -59.21 164.77 2.96 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.171 -0.468 . . . . 99.99 110.932 -179.963 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 7.3 tt -98.11 23.17 1.08 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.373 0 CA-C-N 116.187 -0.461 . . . . 99.99 111.129 179.948 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -69.02 100.1 1.18 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.162 -0.472 . . . . 99.99 110.837 -179.923 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 8.4 t80 -164.97 158.3 16.9 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.11 -0.495 . . . . 99.99 110.878 -179.858 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -116.95 116.13 26.8 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.086 -0.507 . . . . 99.99 111.102 179.838 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 112.11 71.07 0.59 Allowed Glycine 0 N--CA 1.452 -0.257 0 C-N-CA 120.791 -0.718 . . . . 99.99 112.487 -179.913 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 54' ' ' GLN . . . . . . . . . . . . . 5.2 pm0 -163.28 142.54 8.49 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.884 0.373 . . . . 99.99 110.885 -179.915 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -177.33 31.81 0.08 OUTLIER Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.78 -0.724 . . . . 99.99 112.523 -179.991 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 25.0 t -89.3 -67.23 0.77 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-O 120.855 0.36 . . . . 99.99 111.085 -179.899 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -176.94 122.14 0.13 Allowed 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.194 -0.457 . . . . 99.99 110.874 -179.94 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 11.3 p -51.71 132.28 13.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.258 -0.428 . . . . 99.99 111.097 179.986 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 1.3 mt-10 -81.7 -74.7 0.32 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.196 -0.456 . . . . 99.99 110.904 -179.999 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -149.99 136.1 5.55 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.747 -0.74 . . . . 99.99 112.476 -179.974 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 22.3 m -145.13 105.51 4.08 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.87 0.367 . . . . 99.99 110.883 -179.811 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -147.99 97.82 3.87 Favored Pre-proline 0 C--N 1.329 -0.289 0 CA-C-O 121.661 0.744 . . . . 99.99 110.822 -179.766 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.78 175.77 7.67 Favored 'Trans proline' 0 C--N 1.342 0.199 0 C-N-CA 122.727 2.285 . . . . 99.99 112.326 179.986 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 1.3 t -111.29 138.29 47.94 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.211 -0.45 . . . . 99.99 110.834 -179.863 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 65' ' ' LEU . . . . . 0.46 ' HB2' ' CD2' ' A' ' 105' ' ' LEU . 1.7 tm? -117.1 135.67 53.57 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.19 -0.459 . . . . 99.99 110.962 -179.974 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 35.7 t80 -117.94 110.28 17.53 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.244 -0.435 . . . . 99.99 110.87 179.966 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 24.1 m -140.13 168.12 17.85 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.092 -0.504 . . . . 99.99 111.11 179.993 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 1.5 ptm180 -102.83 146.18 28.66 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.191 -0.459 . . . . 99.99 110.859 179.982 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 69' ' ' THR . . . . . 0.411 ' HB ' ' HG3' ' A' ' 95' ' ' PRO . 0.2 OUTLIER -37.75 -60.96 0.67 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.153 -0.476 . . . . 99.99 111.139 -179.895 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 3.4 m-20 -46.11 -43.92 15.24 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.198 -0.455 . . . . 99.99 110.887 179.886 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 71' ' ' GLU . . . . . . . . . . . . . 8.7 tp10 -59.77 -42.81 94.15 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.198 -0.456 . . . . 99.99 110.858 -179.873 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 14.3 p -87.27 -3.86 9.38 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.172 -0.467 . . . . 99.99 111.106 -179.978 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 73' ' ' ARG . . . . . . . . . . . . . 57.6 ttt180 -85.27 -41.93 15.11 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.165 -0.47 . . . . 99.99 110.884 -179.965 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 71.8 mt-30 -53.26 -25.25 13.74 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.188 -0.46 . . . . 99.99 110.907 -179.944 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 3.9 mp -107.74 -169.63 1.56 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.204 -0.453 . . . . 99.99 110.956 179.963 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 76' ' ' ARG . . . . . . . . . . . . . 8.5 ttp180 -116.6 136.84 52.64 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.212 -0.449 . . . . 99.99 110.85 179.978 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -47.34 102.01 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.211 -0.45 . . . . 99.99 110.884 -179.899 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 133.19 25.73 0.64 Allowed Glycine 0 N--CA 1.453 -0.231 0 C-N-CA 120.701 -0.762 . . . . 99.99 112.427 -179.967 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 5.4 p-10 -114.13 119.84 38.48 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.871 0.367 . . . . 99.99 110.91 179.963 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 80' ' ' THR . . . . . 0.671 ' HA ' ' CA ' ' A' ' 89' ' ' TRP . 13.6 p -83.11 123.05 29.14 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.195 -0.457 . . . . 99.99 111.123 -179.825 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 81' ' ' LEU . . . . . 0.783 ' C ' ' HA ' ' A' ' 87' ' ' ASN . 0.2 OUTLIER -94.37 124.47 38.42 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.243 -0.435 . . . . 99.99 110.921 179.956 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 82' ' ' THR . . . . . 0.796 ' N ' ' HA ' ' A' ' 87' ' ' ASN . 3.5 t -91.47 104.42 16.93 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.214 -0.448 . . . . 99.99 111.164 179.947 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 83' ' ' ILE . . . . . 0.466 ' CD1' ' O ' ' A' ' 83' ' ' ILE . 0.1 OUTLIER -141.17 126.45 18.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.177 -0.465 . . . . 99.99 111.062 179.97 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 74.36 -52.74 2.27 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.692 -0.766 . . . . 99.99 112.495 179.908 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 8.1 tp10 -112.91 -82.73 0.59 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.809 0.338 . . . . 99.99 110.903 -179.896 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 86' ' ' GLU . . . . . 0.469 ' C ' ' HA ' ' A' ' 82' ' ' THR . 86.9 mt-10 -152.17 160.86 43.31 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.171 -0.468 . . . . 99.99 110.884 -179.937 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 87' ' ' ASN . . . . . 0.796 ' HA ' ' N ' ' A' ' 82' ' ' THR . 9.2 p30 -51.32 121.66 6.6 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.168 -0.469 . . . . 99.99 110.938 -179.949 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 88' ' ' PHE . . . . . 0.565 ' HB2' HD23 ' A' ' 105' ' ' LEU . 15.9 m-85 -132.16 121.36 23.61 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.172 -0.467 . . . . 99.99 110.938 -179.958 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 89' ' ' TRP . . . . . 0.671 ' CA ' ' HA ' ' A' ' 80' ' ' THR . 3.7 t-105 -81.38 130.53 35.07 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.14 -0.482 . . . . 99.99 110.906 -179.923 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 90' ' ' VAL . . . . . 0.505 ' O ' ' CH2' ' A' ' 89' ' ' TRP . 6.1 p -80.93 114.58 22.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.215 -0.448 . . . . 99.99 111.172 179.912 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 91' ' ' ASP . . . . . 0.43 ' CB ' HD11 ' A' ' 103' ' ' LEU . 0.2 OUTLIER -41.9 -65.21 0.48 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.208 -0.451 . . . . 99.99 110.945 179.953 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 92' ' ' ARG . . . . . 0.472 ' O ' ' HG ' ' A' ' 103' ' ' LEU . 69.5 ttt180 -160.15 125.65 4.03 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.197 -0.456 . . . . 99.99 110.902 -179.967 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 93' ' ' VAL . . . . . 0.458 ' HB ' ' HB2' ' A' ' 101' ' ' CYS . 0.0 OUTLIER -115.49 111.55 36.12 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 116.203 -0.453 . . . . 99.99 111.135 179.954 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 94' ' ' SER . . . . . 0.44 ' C ' ' HB3' ' A' ' 101' ' ' CYS . 4.4 p -105.8 106.16 55.61 Favored Pre-proline 0 C--N 1.33 -0.255 0 CA-C-O 121.666 0.746 . . . . 99.99 110.833 -179.78 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 95' ' ' PRO . . . . . 0.411 ' HG3' ' HB ' ' A' ' 69' ' ' THR . 53.3 Cg_endo -69.83 159.19 54.28 Favored 'Trans proline' 0 C--N 1.341 0.18 0 C-N-CA 122.633 2.222 . . . . 99.99 112.363 179.984 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 4.5 m-20 -123.14 -3.3 8.53 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.23 -0.441 . . . . 99.99 110.884 179.982 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 14.9 t70 -145.54 40.81 1.21 Allowed 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.148 -0.478 . . . . 99.99 110.955 179.992 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 51.02 60.95 6.57 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.713 -0.756 . . . . 99.99 112.47 -179.922 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . 124.21 46.58 0.25 Allowed Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.697 -0.763 . . . . 99.99 112.438 -179.948 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 2.0 p -159.74 77.61 0.68 Allowed 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 120.831 0.348 . . . . 99.99 110.861 -179.736 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 101' ' ' CYS . . . . . 0.458 ' HB2' ' HB ' ' A' ' 93' ' ' VAL . 0.3 OUTLIER -129.21 167.47 17.6 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.168 -0.469 . . . . 99.99 110.898 -179.95 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 102' ' ' HIS . . . . . 0.411 ' HA ' ' O ' ' A' ' 65' ' ' LEU . 37.0 p-80 -167.41 128.28 1.5 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.137 -0.483 . . . . 99.99 110.842 -179.928 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 103' ' ' LEU . . . . . 0.472 ' HG ' ' O ' ' A' ' 92' ' ' ARG . 2.5 tm? -150.19 147.17 27.38 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.181 -0.463 . . . . 99.99 110.938 -179.928 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 104' ' ' TRP . . . . . . . . . . . . . 29.7 p90 -63.92 118.25 8.15 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.261 -0.427 . . . . 99.99 110.95 179.893 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 105' ' ' LEU . . . . . 0.565 HD23 ' HB2' ' A' ' 88' ' ' PHE . 0.2 OUTLIER -88.45 163.58 15.89 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 116.245 -0.434 . . . . 99.99 110.924 -179.998 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -88.15 160.26 30.66 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.751 -0.737 . . . . 99.99 112.523 179.919 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 107' ' ' ARG . . . . . 0.474 ' HA ' ' CD1' ' A' ' 88' ' ' PHE . 0.7 OUTLIER -66.17 157.5 31.14 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.864 0.364 . . . . 99.99 110.923 -179.941 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -176.58 108.16 0.25 Allowed Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.733 -0.746 . . . . 99.99 112.425 179.984 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 10.8 p -100.06 133.6 21.46 Favored Pre-proline 0 C--N 1.329 -0.296 0 CA-C-O 121.543 0.687 . . . . 99.99 111.091 -179.938 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 110' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.75 167.62 23.9 Favored 'Trans proline' 0 C--O 1.23 0.123 0 C-N-CA 122.652 2.235 . . . . 99.99 112.319 179.934 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 111' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.8 -15.41 36.94 Favored 'Trans proline' 0 C--N 1.342 0.214 0 C-N-CA 122.672 2.248 . . . . 99.99 112.284 179.993 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -117.97 121.25 40.17 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.198 -0.455 . . . . 99.99 111.079 179.881 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 7.4 m -118.61 129.14 75.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.166 -0.47 . . . . 99.99 111.055 -179.957 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 114' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -128.31 118.99 24.21 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.151 -0.477 . . . . 99.99 110.884 179.976 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 5.5 ptm180 -112.12 130.44 55.89 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-N 116.126 -0.488 . . . . 99.99 110.837 -179.93 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 116' ' ' ARG . . . . . . . . . . . . . 12.3 ptp180 -114.2 137.81 51.29 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.167 -0.47 . . . . 99.99 110.899 -179.913 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 C--N 1.329 -0.307 0 CA-C-N 116.24 -0.436 . . . . 99.99 110.89 -179.981 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 19.8 ptt? . . . . . 0 C--O 1.231 0.1 0 CA-C-O 120.831 0.348 . . . . 99.99 110.919 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -119.84 -45.42 2.49 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.237 -0.438 . . . . 99.99 111.096 179.948 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 3' ' ' ASP . . . . . . . . . . . . . 22.5 t70 -52.37 144.71 12.52 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.22 -0.446 . . . . 99.99 110.791 -179.978 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 4' ' ' PHE . . . . . . . . . . . . . 12.1 m-85 -114.89 -73.57 0.65 Allowed 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.147 -0.478 . . . . 99.99 110.916 -179.927 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 3.9 m-20 -166.33 119.79 1.09 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.104 -0.498 . . . . 99.99 110.892 179.955 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 6' ' ' ASN . . . . . . . . . . . . . 4.4 t-20 -176.92 133.43 0.19 Allowed 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.227 -0.442 . . . . 99.99 110.858 -179.842 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 7' ' ' LEU . . . . . . . . . . . . . 5.1 mp -124.37 -72.97 0.65 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.215 -0.448 . . . . 99.99 110.938 179.931 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 8' ' ' PHE . . . . . . . . . . . . . 3.7 m-85 -163.26 178.27 8.32 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.211 -0.45 . . . . 99.99 110.924 179.898 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 4.4 m-20 -122.13 -176.69 3.41 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.162 -0.472 . . . . 99.99 110.846 179.98 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -144.27 177.36 8.67 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.198 -0.455 . . . . 99.99 111.095 179.967 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -136.74 150.63 48.51 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.193 -0.458 . . . . 99.99 111.066 179.915 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 26.6 mm -133.69 69.37 0.33 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.237 -0.438 . . . . 99.99 111.097 -179.993 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -147.54 142.25 26.69 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.19 -0.459 . . . . 99.99 111.128 179.77 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 1.8 tpt180 -175.34 117.07 0.16 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.222 -0.445 . . . . 99.99 110.849 -179.946 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -177.68 138.86 0.22 Allowed 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.233 -0.44 . . . . 99.99 111.1 179.895 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 6.1 p-10 -174.29 169.44 3.84 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.21 -0.45 . . . . 99.99 110.967 179.963 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 9.9 mp0 -114.19 -174.06 2.4 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.247 -0.433 . . . . 99.99 110.913 -179.917 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 94.1 m -88.84 -72.97 0.52 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.171 -0.468 . . . . 99.99 111.128 -179.906 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 31.5 mt 54.82 77.42 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.229 -0.441 . . . . 99.99 111.166 179.945 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 20' ' ' ARG . . . . . . . . . . . . . 9.6 tpt180 -71.54 149.15 46.0 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.136 -0.484 . . . . 99.99 110.879 179.971 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -158.23 -162.34 11.73 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.787 -0.72 . . . . 99.99 112.548 -179.945 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 22' ' ' TYR . . . . . . . . . . . . . 34.7 t80 -158.92 -45.92 0.06 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.869 0.366 . . . . 99.99 110.907 -179.843 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 23' ' ' MET . . . . . . . . . . . . . 9.4 ptt? -52.1 145.93 9.66 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.171 -0.468 . . . . 99.99 110.856 179.953 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 103.75 -156.61 17.6 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.696 -0.764 . . . . 99.99 112.496 179.998 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 25' ' ' THR . . . . . 0.424 ' CB ' ' HB ' ' A' ' 42' ' ' VAL . 8.4 m -110.69 137.69 48.03 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.742 0.306 . . . . 99.99 111.192 -179.911 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -72.5 122.08 20.71 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.207 -0.451 . . . . 99.99 110.866 -179.855 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 27' ' ' ALA . . . . . 0.544 ' CB ' HG21 ' A' ' 39' ' ' ILE . . . -142.05 162.29 35.86 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.047 -0.524 . . . . 99.99 111.119 179.89 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 16.9 m -129.23 88.65 2.73 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.242 -0.436 . . . . 99.99 111.184 -179.883 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . 0.63 HG23 HG22 ' A' ' 39' ' ' ILE . 1.8 pt -44.64 130.99 1.7 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.218 -0.446 . . . . 99.99 111.135 179.917 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 7.3 m -153.73 97.98 2.16 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.167 -0.47 . . . . 99.99 111.15 179.934 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 87.1 p -137.76 70.92 1.39 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.229 -0.441 . . . . 99.99 110.921 -179.858 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -178.61 167.52 38.01 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.779 -0.724 . . . . 99.99 112.511 -179.924 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 3.6 pt-20 -49.45 -23.01 1.34 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.798 0.332 . . . . 99.99 110.851 -179.935 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -174.6 94.22 0.08 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.228 -0.442 . . . . 99.99 110.919 -179.913 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 3.1 m -144.71 165.77 27.12 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.161 -0.472 . . . . 99.99 110.821 -179.81 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 178.6 87.6 0.07 OUTLIER Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.78 -0.724 . . . . 99.99 112.497 -179.975 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -109.03 -172.49 2.06 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.904 0.383 . . . . 99.99 111.078 179.983 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 4.0 p -97.97 123.04 50.22 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.209 -0.451 . . . . 99.99 111.12 179.969 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 39' ' ' ILE . . . . . 0.63 HG22 HG23 ' A' ' 29' ' ' ILE . 0.0 OUTLIER -138.53 149.9 24.1 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.137 -0.483 . . . . 99.99 111.165 179.906 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 40' ' ' ARG . . . . . 0.401 ' HA ' ' O ' ' A' ' 25' ' ' THR . 6.6 mtm-85 -109.1 80.05 1.28 Allowed 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.159 -0.473 . . . . 99.99 110.879 -179.962 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . 0.501 ' N ' HD13 ' A' ' 39' ' ' ILE . . . -128.38 148.78 18.03 Favored Glycine 0 N--CA 1.45 -0.374 0 C-N-CA 120.814 -0.708 . . . . 99.99 112.577 -179.937 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 42' ' ' VAL . . . . . 0.424 ' HB ' ' CB ' ' A' ' 25' ' ' THR . 3.4 p -127.53 138.79 53.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-O 120.837 0.351 . . . . 99.99 111.148 -179.986 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 43' ' ' PHE . . . . . 0.503 ' HA ' ' O ' ' A' ' 64' ' ' SER . 2.5 p90 -98.36 128.76 44.92 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.175 -0.466 . . . . 99.99 110.887 -179.966 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -107.75 124.0 49.38 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.12 -0.491 . . . . 99.99 110.812 180.0 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -120.33 106.13 40.89 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-O 121.61 0.719 . . . . 99.99 110.854 179.976 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 46' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.73 -41.64 4.14 Favored 'Trans proline' 0 C--N 1.343 0.238 0 C-N-CA 122.582 2.188 . . . . 99.99 112.415 179.987 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 20.7 mt-10 -146.78 89.95 1.87 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.227 -0.442 . . . . 99.99 110.904 -179.992 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 2.2 t-20 -62.84 99.74 0.17 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.123 -0.489 . . . . 99.99 110.894 -179.963 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 4.9 pt -148.96 179.82 0.63 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.207 -0.451 . . . . 99.99 111.136 179.929 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -122.36 154.72 37.3 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.145 -0.479 . . . . 99.99 110.823 -179.91 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 9.3 m-85 -127.28 -72.89 0.62 Allowed 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.086 -0.506 . . . . 99.99 110.951 -179.848 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -52.73 169.56 0.09 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.057 -0.52 . . . . 99.99 111.137 179.835 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -152.34 -113.63 0.56 Allowed Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.685 -0.769 . . . . 99.99 112.463 -179.951 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 54' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -53.83 147.26 12.26 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.796 0.331 . . . . 99.99 110.891 -179.888 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 78.23 -59.31 3.99 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.736 -0.745 . . . . 99.99 112.514 -179.971 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 43.4 t -53.84 147.41 2.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-O 120.856 0.36 . . . . 99.99 111.079 -179.93 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 22.0 ptt180 -90.38 -32.83 16.29 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.104 -0.498 . . . . 99.99 110.838 -179.931 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 38.4 t -144.0 138.64 24.73 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.206 -0.452 . . . . 99.99 111.101 -179.979 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 6.6 pt-20 -54.38 173.51 0.07 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.12 -0.491 . . . . 99.99 110.934 179.983 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -100.0 100.95 2.27 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.717 -0.754 . . . . 99.99 112.475 -179.947 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 1.4 m -148.03 129.73 15.09 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.859 0.361 . . . . 99.99 110.911 -179.768 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 1.1 t -137.06 97.59 10.82 Favored Pre-proline 0 C--N 1.328 -0.332 0 CA-C-O 121.626 0.727 . . . . 99.99 110.831 -179.755 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.78 -172.9 0.63 Allowed 'Trans proline' 0 C--O 1.231 0.15 0 C-N-CA 122.613 2.209 . . . . 99.99 112.359 179.946 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 64' ' ' SER . . . . . 0.503 ' O ' ' HA ' ' A' ' 43' ' ' PHE . 0.1 OUTLIER -106.54 148.39 28.29 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.203 -0.453 . . . . 99.99 110.865 -179.832 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 65' ' ' LEU . . . . . 0.495 ' HB2' ' CD2' ' A' ' 105' ' ' LEU . 2.8 tm? -114.55 129.29 56.65 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.134 -0.484 . . . . 99.99 110.924 -179.96 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 66' ' ' PHE . . . . . 0.4 ' C ' HG13 ' A' ' 67' ' ' VAL . 1.7 t80 -119.03 105.68 11.67 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.257 -0.428 . . . . 99.99 110.889 179.937 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 67' ' ' VAL . . . . . 0.4 HG13 ' C ' ' A' ' 66' ' ' PHE . 33.7 m -141.04 172.51 10.85 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-N 116.148 -0.478 . . . . 99.99 111.126 -179.968 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 1.1 ptp180 -109.23 144.47 37.3 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.194 -0.457 . . . . 99.99 110.849 -179.986 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 69' ' ' THR . . . . . 0.521 ' O ' ' N ' ' A' ' 73' ' ' ARG . 0.0 OUTLIER -38.01 -56.88 1.1 Allowed 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.202 -0.454 . . . . 99.99 111.189 -179.927 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 7.8 t70 -44.28 -59.43 2.38 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.155 -0.475 . . . . 99.99 110.865 179.908 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 71' ' ' GLU . . . . . . . . . . . . . 1.2 tm-20 -59.35 -42.1 90.74 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.217 -0.447 . . . . 99.99 110.92 -179.966 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 72' ' ' VAL . . . . . 0.442 HG12 ' O ' ' A' ' 69' ' ' THR . 0.3 OUTLIER -82.98 4.42 2.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.117 -0.492 . . . . 99.99 111.073 -179.948 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 73' ' ' ARG . . . . . 0.521 ' N ' ' O ' ' A' ' 69' ' ' THR . 16.1 ttt180 -98.31 -37.98 9.44 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.168 -0.469 . . . . 99.99 110.86 -179.993 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 48.7 mt-30 -65.67 -12.36 52.85 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.252 -0.431 . . . . 99.99 110.956 -179.978 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 3.1 mp -107.99 -174.46 2.53 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.157 -0.474 . . . . 99.99 110.877 -179.964 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 76' ' ' ARG . . . . . . . . . . . . . 10.5 ptp180 -117.91 154.37 32.02 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.164 -0.471 . . . . 99.99 110.941 179.965 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 3.7 ptt180 -51.21 131.91 28.15 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.24 -0.436 . . . . 99.99 110.87 -179.909 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 86.77 42.97 6.21 Favored Glycine 0 N--CA 1.452 -0.24 0 C-N-CA 120.735 -0.745 . . . . 99.99 112.397 179.944 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -103.43 110.74 22.88 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.909 0.385 . . . . 99.99 110.85 -179.963 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 80' ' ' THR . . . . . 0.72 ' HA ' ' HA ' ' A' ' 89' ' ' TRP . 0.0 OUTLIER -88.62 108.59 19.52 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.119 -0.491 . . . . 99.99 111.209 -179.886 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 81' ' ' LEU . . . . . 0.775 ' C ' ' HA ' ' A' ' 87' ' ' ASN . 0.0 OUTLIER -98.18 135.24 40.12 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.272 -0.422 . . . . 99.99 110.928 -179.986 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 82' ' ' THR . . . . . 0.695 ' N ' ' HA ' ' A' ' 87' ' ' ASN . 8.0 t -93.63 101.59 13.75 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.204 -0.453 . . . . 99.99 111.145 179.968 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 83' ' ' ILE . . . . . 0.443 ' CG2' ' CB ' ' A' ' 27' ' ' ALA . 0.1 OUTLIER -136.18 131.11 48.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.22 -0.446 . . . . 99.99 111.184 179.861 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 73.0 -54.59 1.78 Allowed Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.785 -0.722 . . . . 99.99 112.507 179.936 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 10.7 mm-40 -113.55 -80.65 0.59 Allowed 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 120.86 0.362 . . . . 99.99 110.875 -179.922 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 86' ' ' GLU . . . . . 0.463 ' C ' ' HA ' ' A' ' 82' ' ' THR . 96.1 mt-10 -154.54 161.06 41.82 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 116.159 -0.473 . . . . 99.99 110.823 -179.939 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 87' ' ' ASN . . . . . 0.775 ' HA ' ' C ' ' A' ' 81' ' ' LEU . 1.6 p-10 -50.7 121.98 6.63 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.156 -0.474 . . . . 99.99 110.921 -179.957 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 88' ' ' PHE . . . . . 0.539 ' C ' ' HA ' ' A' ' 80' ' ' THR . 14.7 m-85 -131.08 120.86 24.02 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.155 -0.475 . . . . 99.99 110.903 -179.972 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 89' ' ' TRP . . . . . 0.72 ' HA ' ' HA ' ' A' ' 80' ' ' THR . 0.9 OUTLIER -80.11 135.77 36.39 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.12 -0.491 . . . . 99.99 110.913 -179.951 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 90' ' ' VAL . . . . . 0.448 ' HA ' ' HB3' ' A' ' 105' ' ' LEU . 0.3 OUTLIER -92.58 138.23 20.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.264 -0.426 . . . . 99.99 111.101 179.925 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 91' ' ' ASP . . . . . 0.437 ' CB ' HD13 ' A' ' 103' ' ' LEU . 0.5 OUTLIER -65.61 -71.19 0.2 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.186 -0.461 . . . . 99.99 110.85 179.935 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 92' ' ' ARG . . . . . 0.511 ' O ' ' HG ' ' A' ' 103' ' ' LEU . 0.0 OUTLIER -152.58 120.89 6.3 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.251 -0.432 . . . . 99.99 110.838 -179.882 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 93' ' ' VAL . . . . . 0.568 ' HB ' ' HB2' ' A' ' 101' ' ' CYS . 8.8 m -121.45 137.28 55.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.254 -0.43 . . . . 99.99 111.121 179.928 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 12.6 t -137.14 128.4 16.44 Favored Pre-proline 0 C--N 1.328 -0.337 0 CA-C-O 121.714 0.769 . . . . 99.99 110.862 -179.856 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 95' ' ' PRO . . . . . 0.469 ' HG3' ' HB ' ' A' ' 69' ' ' THR . 53.2 Cg_endo -69.85 160.51 49.42 Favored 'Trans proline' 0 C--N 1.342 0.198 0 C-N-CA 122.681 2.254 . . . . 99.99 112.322 -179.946 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 9.4 t0 -118.23 -25.35 6.64 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.256 -0.429 . . . . 99.99 110.844 179.945 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER 177.9 85.5 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.277 -0.419 . . . . 99.99 110.909 -179.96 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 99.71 55.42 1.01 Allowed Glycine 0 N--CA 1.452 -0.267 0 C-N-CA 120.726 -0.75 . . . . 99.99 112.508 -179.959 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . 40.29 77.53 0.07 OUTLIER Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.769 -0.729 . . . . 99.99 112.461 -179.918 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 20.1 t -125.81 12.12 7.87 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.91 0.386 . . . . 99.99 110.842 -179.745 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 101' ' ' CYS . . . . . 0.568 ' HB2' ' HB ' ' A' ' 93' ' ' VAL . 19.6 p -47.23 142.31 3.98 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.16 -0.473 . . . . 99.99 110.882 -179.98 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 102' ' ' HIS . . . . . 0.429 ' HA ' ' O ' ' A' ' 65' ' ' LEU . 43.4 p-80 -159.97 129.38 5.2 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.241 -0.436 . . . . 99.99 110.836 -179.934 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 103' ' ' LEU . . . . . 0.511 ' HG ' ' O ' ' A' ' 92' ' ' ARG . 2.8 tm? -150.8 148.4 28.45 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 116.239 -0.437 . . . . 99.99 110.943 -179.998 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 104' ' ' TRP . . . . . . . . . . . . . 56.3 p-90 -64.34 118.02 8.08 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.174 -0.466 . . . . 99.99 110.855 179.946 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 105' ' ' LEU . . . . . 0.502 HD21 ' HB2' ' A' ' 88' ' ' PHE . 0.4 OUTLIER -93.92 162.8 13.76 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.266 -0.425 . . . . 99.99 110.866 179.978 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -91.0 160.39 27.26 Favored Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.712 -0.756 . . . . 99.99 112.498 179.892 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 107' ' ' ARG . . . . . 0.532 ' HA ' ' CD1' ' A' ' 88' ' ' PHE . 0.0 OUTLIER -65.73 157.39 30.31 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.856 0.36 . . . . 99.99 110.925 -179.895 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -173.1 110.18 0.33 Allowed Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.644 -0.789 . . . . 99.99 112.454 179.984 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 7.1 p -84.19 133.89 44.38 Favored Pre-proline 0 C--N 1.33 -0.28 0 CA-C-O 121.687 0.756 . . . . 99.99 111.084 -179.93 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 110' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.68 168.22 22.08 Favored 'Trans proline' 0 C--N 1.342 0.222 0 C-N-CA 122.644 2.229 . . . . 99.99 112.328 179.928 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 111' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.77 -8.94 24.87 Favored 'Trans proline' 0 C--N 1.342 0.189 0 C-N-CA 122.66 2.24 . . . . 99.99 112.358 179.905 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -59.67 161.08 6.49 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.231 -0.44 . . . . 99.99 111.072 179.891 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 6.4 p -93.69 124.2 46.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.209 -0.45 . . . . 99.99 111.073 -179.986 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 114' ' ' ASN . . . . . . . . . . . . . 2.6 m-20 -128.71 145.54 51.14 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.132 -0.485 . . . . 99.99 110.849 179.994 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 13.3 mtt180 -82.91 103.31 12.28 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.109 -0.496 . . . . 99.99 110.9 179.983 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 116' ' ' ARG . . . . . . . . . . . . . 2.7 mmp_? -115.24 138.1 51.31 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.171 -0.468 . . . . 99.99 110.804 -179.85 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 15.7 tpt180 . . . . . 0 C--N 1.329 -0.293 0 CA-C-N 116.173 -0.467 . . . . 99.99 110.866 -179.922 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 1.3 mpt? . . . . . 0 C--O 1.231 0.09 0 CA-C-O 120.749 0.309 . . . . 99.99 110.86 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . 52.9 47.04 25.54 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.218 -0.447 . . . . 99.99 111.122 179.939 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 3' ' ' ASP . . . . . . . . . . . . . 6.2 p-10 -117.11 150.13 39.19 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.176 -0.465 . . . . 99.99 110.881 179.968 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 4' ' ' PHE . . . . . . . . . . . . . 47.7 t80 -170.42 150.77 3.56 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.233 -0.44 . . . . 99.99 110.886 -179.913 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 33.5 m-20 -153.74 157.24 39.18 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.162 -0.472 . . . . 99.99 110.864 -179.988 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 6' ' ' ASN . . . . . . . . . . . . . 6.7 p30 -173.76 141.2 0.81 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.242 -0.435 . . . . 99.99 110.921 -179.92 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 7' ' ' LEU . . . . . . . . . . . . . 20.1 mt -107.33 171.39 7.41 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.173 -0.467 . . . . 99.99 110.957 179.941 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 8' ' ' PHE . . . . . . . . . . . . . 11.9 t80 -129.64 58.06 1.65 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.207 -0.451 . . . . 99.99 110.94 179.934 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 3.0 m-20 -118.74 127.06 53.2 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.141 -0.481 . . . . 99.99 110.892 179.992 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -68.55 133.53 48.69 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.253 -0.431 . . . . 99.99 111.057 179.946 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -164.05 164.39 23.0 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.172 -0.467 . . . . 99.99 111.086 179.942 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 3.4 mp -125.31 64.76 0.3 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.244 -0.434 . . . . 99.99 111.188 179.901 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -145.87 56.44 1.2 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.173 -0.467 . . . . 99.99 111.095 179.847 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 31.8 mmm-85 -104.72 -179.53 3.97 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.27 -0.423 . . . . 99.99 110.866 -179.902 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -171.01 130.67 0.78 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.179 -0.464 . . . . 99.99 111.057 179.903 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 4.3 p-10 -93.58 47.4 1.23 Allowed 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.179 -0.464 . . . . 99.99 110.874 -179.988 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 6.8 mm-40 -117.83 -172.27 2.21 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.202 -0.454 . . . . 99.99 110.875 -179.848 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 39.7 p -74.04 -178.35 3.29 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.143 -0.481 . . . . 99.99 111.135 -179.923 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 2.7 pt -114.35 74.36 0.39 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.242 -0.435 . . . . 99.99 111.065 179.933 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 20' ' ' ARG . . . . . . . . . . . . . 9.0 tpp180 -110.06 -64.28 1.28 Allowed 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.157 -0.474 . . . . 99.99 110.88 179.924 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -71.36 140.5 30.92 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.755 -0.736 . . . . 99.99 112.494 -179.965 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 22' ' ' TYR . . . . . . . . . . . . . 5.9 t80 -121.7 -67.47 0.96 Allowed 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.842 0.353 . . . . 99.99 110.923 -179.824 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 23' ' ' MET . . . . . . . . . . . . . 10.4 ptm -175.81 173.48 2.32 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.147 -0.478 . . . . 99.99 110.899 179.888 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 138.59 -142.95 13.6 Favored Glycine 0 N--CA 1.452 -0.239 0 C-N-CA 120.727 -0.749 . . . . 99.99 112.448 -179.973 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 25' ' ' THR . . . . . 0.481 ' HB ' HG21 ' A' ' 42' ' ' VAL . 98.6 m -96.74 126.7 42.09 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.804 0.335 . . . . 99.99 111.107 -179.815 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 3.0 p -70.81 123.5 22.11 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.173 -0.467 . . . . 99.99 110.823 -179.844 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 27' ' ' ALA . . . . . 0.54 ' CB ' HG21 ' A' ' 39' ' ' ILE . . . -135.24 162.42 32.61 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.074 -0.512 . . . . 99.99 111.104 179.884 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 21.7 m -129.33 85.8 2.36 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.216 -0.447 . . . . 99.99 111.09 -179.902 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . 0.666 HG22 HG22 ' A' ' 39' ' ' ILE . 1.9 pt -44.92 126.93 1.3 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.182 -0.463 . . . . 99.99 111.137 179.884 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 17.6 m -151.93 97.87 2.39 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.119 -0.491 . . . . 99.99 111.143 -179.983 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 5.1 t -136.5 70.53 1.41 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.161 -0.472 . . . . 99.99 110.913 -179.853 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -178.88 168.8 39.92 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.771 -0.728 . . . . 99.99 112.536 -179.93 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 5.8 pt-20 -49.31 -23.25 1.33 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.809 0.338 . . . . 99.99 110.9 -179.906 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -174.76 95.29 0.08 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.204 -0.453 . . . . 99.99 110.913 -179.908 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 2.3 m -145.24 165.41 28.46 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.148 -0.478 . . . . 99.99 110.84 -179.794 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 176.36 88.42 0.07 OUTLIER Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 120.756 -0.735 . . . . 99.99 112.515 -179.988 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -108.11 -170.53 1.7 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.809 0.337 . . . . 99.99 111.161 179.994 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 4.4 p -99.03 119.64 47.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.293 -0.412 . . . . 99.99 111.112 179.983 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 39' ' ' ILE . . . . . 0.666 HG22 HG22 ' A' ' 29' ' ' ILE . 0.0 OUTLIER -139.1 151.56 23.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.059 -0.518 . . . . 99.99 111.096 179.938 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 40' ' ' ARG . . . . . . . . . . . . . 1.4 ptp85 -113.59 82.86 1.75 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.191 -0.459 . . . . 99.99 110.879 179.964 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . 0.464 ' H ' ' HB2' ' A' ' 27' ' ' ALA . . . -111.92 146.46 18.0 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.723 -0.751 . . . . 99.99 112.436 -179.923 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 42' ' ' VAL . . . . . 0.56 ' O ' ' HA ' ' A' ' 65' ' ' LEU . 2.2 t -124.58 112.57 32.68 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-O 120.882 0.372 . . . . 99.99 111.08 -179.937 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 43' ' ' PHE . . . . . 0.515 ' HA ' ' O ' ' A' ' 64' ' ' SER . 2.4 p90 -87.29 131.38 34.26 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.141 -0.481 . . . . 99.99 110.89 -179.976 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 2.8 t70 -129.78 125.34 35.56 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.129 -0.487 . . . . 99.99 110.811 -179.965 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 2.5 p-10 -102.46 152.97 38.43 Favored Pre-proline 0 C--N 1.33 -0.276 0 CA-C-O 121.567 0.698 . . . . 99.99 110.862 -179.928 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 46' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.89 -37.89 8.25 Favored 'Trans proline' 0 C--N 1.341 0.161 0 C-N-CA 122.724 2.283 . . . . 99.99 112.307 -179.907 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 1.2 mp0 -91.92 64.98 4.81 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.249 -0.432 . . . . 99.99 110.887 179.97 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 2.8 t30 -92.78 124.86 37.08 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.107 -0.497 . . . . 99.99 110.959 179.98 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 12.6 tt -146.98 137.81 17.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.194 -0.457 . . . . 99.99 111.163 179.91 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 2.8 p 46.29 39.36 6.19 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.191 -0.459 . . . . 99.99 110.831 -179.893 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 15.9 p90 -55.15 -27.75 47.78 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.151 -0.477 . . . . 99.99 110.969 -179.951 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -97.35 41.31 1.12 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.099 -0.5 . . . . 99.99 111.135 179.872 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -147.18 -86.37 0.06 OUTLIER Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.8 -0.714 . . . . 99.99 112.486 -179.903 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 54' ' ' GLN . . . . . . . . . . . . . 3.8 tt0 -176.11 126.75 0.21 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.783 0.325 . . . . 99.99 110.918 -179.945 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -144.3 89.97 0.16 Allowed Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.706 -0.759 . . . . 99.99 112.539 -179.963 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 21.8 t -85.71 71.52 0.79 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 CA-C-O 120.798 0.333 . . . . 99.99 111.104 -179.922 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 29.3 ptt-85 -177.17 145.24 0.45 Allowed 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.194 -0.457 . . . . 99.99 110.909 179.962 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 74.7 t -148.04 144.68 19.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.16 -0.473 . . . . 99.99 111.162 179.95 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 11.2 mt-10 -113.01 -171.78 1.93 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.122 -0.49 . . . . 99.99 110.937 179.976 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -90.09 100.42 2.67 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.75 -0.738 . . . . 99.99 112.447 -179.92 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -149.83 159.24 44.52 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.846 0.355 . . . . 99.99 110.881 -179.815 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 62' ' ' SER . . . . . 0.4 ' HA ' ' HD2' ' A' ' 63' ' ' PRO . 1.1 p -105.82 97.31 14.66 Favored Pre-proline 0 C--N 1.33 -0.277 0 CA-C-O 121.613 0.721 . . . . 99.99 110.858 -179.774 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 63' ' ' PRO . . . . . 0.4 ' HD2' ' HA ' ' A' ' 62' ' ' SER . 54.1 Cg_endo -69.82 169.41 19.05 Favored 'Trans proline' 0 C--N 1.342 0.207 0 C-N-CA 122.706 2.271 . . . . 99.99 112.37 179.984 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 64' ' ' SER . . . . . 0.515 ' O ' ' HA ' ' A' ' 43' ' ' PHE . 1.3 t -106.19 142.51 35.77 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.259 -0.428 . . . . 99.99 110.906 -179.816 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 65' ' ' LEU . . . . . 0.56 ' HA ' ' O ' ' A' ' 42' ' ' VAL . 0.4 OUTLIER -110.75 123.72 50.59 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.178 -0.464 . . . . 99.99 110.942 179.982 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -94.05 111.83 23.59 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.23 -0.441 . . . . 99.99 110.924 179.961 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -140.92 167.28 17.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.227 -0.442 . . . . 99.99 111.109 -179.998 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 3.5 ttp85 -96.84 132.42 42.6 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.174 -0.466 . . . . 99.99 110.91 -179.952 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 69' ' ' THR . . . . . 0.417 ' O ' HG12 ' A' ' 72' ' ' VAL . 1.4 m -44.67 -36.81 3.29 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.246 -0.433 . . . . 99.99 111.126 -179.825 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 33.2 t0 -59.02 -71.88 0.11 Allowed 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.199 -0.455 . . . . 99.99 110.872 179.868 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 71' ' ' GLU . . . . . . . . . . . . . 3.1 pt-20 -56.37 -37.73 70.45 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.176 -0.466 . . . . 99.99 110.875 -179.849 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 72' ' ' VAL . . . . . 0.417 HG12 ' O ' ' A' ' 69' ' ' THR . 0.4 OUTLIER -68.74 -25.39 30.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.157 -0.474 . . . . 99.99 111.148 179.982 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 73' ' ' ARG . . . . . . . . . . . . . 24.7 ttm-85 -75.9 -39.3 56.62 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.107 -0.497 . . . . 99.99 110.869 -179.996 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 12.4 mt-30 -54.73 -29.09 52.59 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.214 -0.448 . . . . 99.99 110.895 -179.936 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 3.4 mp -87.26 -175.82 5.43 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.182 -0.463 . . . . 99.99 110.944 -179.973 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 76' ' ' ARG . . . . . . . . . . . . . 6.8 ttt-85 -109.47 139.33 44.59 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.192 -0.458 . . . . 99.99 110.866 179.962 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 3.3 ptt85 -48.65 108.31 0.17 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.224 -0.443 . . . . 99.99 110.844 -179.92 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 119.55 9.96 8.15 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.663 -0.78 . . . . 99.99 112.536 -179.932 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -73.09 109.12 6.38 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.945 0.402 . . . . 99.99 110.914 -179.994 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 80' ' ' THR . . . . . 0.701 ' HA ' ' HA ' ' A' ' 89' ' ' TRP . 0.0 OUTLIER -85.51 110.34 19.13 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.17 -0.468 . . . . 99.99 111.118 -179.828 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 81' ' ' LEU . . . . . 0.746 ' C ' ' HA ' ' A' ' 87' ' ' ASN . 0.3 OUTLIER -97.63 132.43 43.29 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.222 -0.445 . . . . 99.99 110.887 179.97 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 82' ' ' THR . . . . . 0.76 ' CA ' ' HA ' ' A' ' 87' ' ' ASN . 6.7 t -91.57 102.35 15.0 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.189 -0.46 . . . . 99.99 111.139 179.925 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 83' ' ' ILE . . . . . 0.45 ' CG2' ' CB ' ' A' ' 27' ' ' ALA . 0.1 OUTLIER -139.24 131.2 35.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.223 -0.444 . . . . 99.99 111.119 179.923 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 76.74 -51.67 3.1 Favored Glycine 0 N--CA 1.452 -0.264 0 C-N-CA 120.715 -0.755 . . . . 99.99 112.471 179.9 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 6.7 tp10 -121.37 -77.83 0.59 Allowed 'General case' 0 C--N 1.331 -0.229 0 CA-C-O 120.818 0.342 . . . . 99.99 110.876 -179.876 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 86' ' ' GLU . . . . . 0.476 ' C ' ' HA ' ' A' ' 82' ' ' THR . 98.8 mt-10 -152.76 162.29 41.46 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.12 -0.491 . . . . 99.99 110.923 -179.977 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 87' ' ' ASN . . . . . 0.76 ' HA ' ' CA ' ' A' ' 82' ' ' THR . 2.4 p30 -51.5 122.02 7.31 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.183 -0.462 . . . . 99.99 110.899 -179.975 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 88' ' ' PHE . . . . . 0.588 ' HB2' HD23 ' A' ' 105' ' ' LEU . 13.9 m-85 -131.77 119.4 21.23 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.184 -0.462 . . . . 99.99 110.935 179.95 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 89' ' ' TRP . . . . . 0.701 ' HA ' ' HA ' ' A' ' 80' ' ' THR . 65.4 p-90 -82.21 132.87 35.23 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.164 -0.471 . . . . 99.99 110.96 179.983 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 90' ' ' VAL . . . . . 0.506 ' HA ' ' HB3' ' A' ' 105' ' ' LEU . 4.0 p -95.39 139.11 19.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.231 -0.441 . . . . 99.99 111.156 179.92 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 1.9 t70 -58.84 -73.82 0.08 Allowed 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.208 -0.451 . . . . 99.99 110.877 179.959 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 92' ' ' ARG . . . . . . . . . . . . . 8.2 ttt180 -170.15 121.39 0.64 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.215 -0.448 . . . . 99.99 110.898 -179.908 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 93' ' ' VAL . . . . . 0.536 ' HB ' ' HB3' ' A' ' 101' ' ' CYS . 2.6 m -104.83 139.0 27.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.217 -0.447 . . . . 99.99 111.176 179.917 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 12.1 t -130.1 96.53 25.18 Favored Pre-proline 0 C--N 1.33 -0.278 0 CA-C-O 121.577 0.703 . . . . 99.99 110.826 -179.766 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 52.6 Cg_endo -69.8 -167.39 0.22 Allowed 'Trans proline' 0 C--N 1.341 0.152 0 C-N-CA 122.655 2.237 . . . . 99.99 112.319 179.97 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 5.8 t0 -135.57 5.99 3.21 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.226 -0.443 . . . . 99.99 110.871 179.971 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 8.7 t70 -159.56 105.46 1.65 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.224 -0.444 . . . . 99.99 110.795 -179.946 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 63.39 -90.03 0.07 OUTLIER Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.768 -0.73 . . . . 99.99 112.515 -179.996 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -163.57 87.81 0.1 Allowed Glycine 0 N--CA 1.45 -0.38 0 C-N-CA 120.752 -0.737 . . . . 99.99 112.511 -179.961 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 12.0 t -155.07 79.22 1.05 Allowed 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.809 0.338 . . . . 99.99 110.774 -179.71 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 101' ' ' CYS . . . . . 0.536 ' HB3' ' HB ' ' A' ' 93' ' ' VAL . 1.8 t -132.12 -172.83 2.98 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.185 -0.462 . . . . 99.99 110.849 -179.955 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 102' ' ' HIS . . . . . . . . . . . . . 2.6 p-80 -169.53 138.91 1.99 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.183 -0.462 . . . . 99.99 110.91 -179.933 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 103' ' ' LEU . . . . . . . . . . . . . 6.2 tt -139.26 155.79 47.51 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.267 -0.424 . . . . 99.99 110.945 -179.943 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 104' ' ' TRP . . . . . . . . . . . . . 48.4 p-90 -64.21 110.27 2.15 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 116.18 -0.464 . . . . 99.99 110.871 179.92 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 105' ' ' LEU . . . . . 0.588 HD23 ' HB2' ' A' ' 88' ' ' PHE . 0.4 OUTLIER -91.24 163.05 14.38 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.218 -0.446 . . . . 99.99 110.958 179.957 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -89.13 157.64 27.21 Favored Glycine 0 N--CA 1.452 -0.266 0 C-N-CA 120.732 -0.747 . . . . 99.99 112.456 179.888 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 107' ' ' ARG . . . . . 0.506 ' HA ' ' CD1' ' A' ' 88' ' ' PHE . 65.5 ttp85 -69.99 156.91 38.43 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.784 0.326 . . . . 99.99 110.895 -179.856 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -169.77 108.15 0.29 Allowed Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.736 -0.745 . . . . 99.99 112.549 179.999 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 7.3 p -90.14 134.16 32.08 Favored Pre-proline 0 C--N 1.329 -0.295 0 CA-C-O 121.566 0.698 . . . . 99.99 111.121 -179.906 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 110' ' ' PRO . . . . . 0.471 ' N ' HD22 ' A' ' 87' ' ' ASN . 53.2 Cg_endo -69.76 169.65 18.42 Favored 'Trans proline' 0 C--O 1.232 0.217 0 C-N-CA 122.737 2.291 . . . . 99.99 112.308 179.995 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 111' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.73 -8.9 24.78 Favored 'Trans proline' 0 C--N 1.342 0.197 0 C-N-CA 122.727 2.285 . . . . 99.99 112.355 179.923 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -102.67 102.29 12.47 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.216 -0.447 . . . . 99.99 111.126 179.868 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 32.0 m -130.5 140.11 49.62 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.182 -0.463 . . . . 99.99 111.11 179.985 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 114' ' ' ASN . . . . . . . . . . . . . 7.3 t-20 -100.31 113.16 25.65 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.158 -0.474 . . . . 99.99 110.858 179.986 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 14.1 mtm180 -113.09 147.97 36.22 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.155 -0.475 . . . . 99.99 110.848 -179.998 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 116' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -115.12 138.14 51.23 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.19 -0.459 . . . . 99.99 110.907 -179.948 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 12.2 ptm180 . . . . . 0 C--N 1.328 -0.33 0 CA-C-N 116.24 -0.436 . . . . 99.99 110.8 -179.865 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 13.9 mtt . . . . . 0 C--O 1.23 0.041 0 CA-C-O 120.755 0.312 . . . . 99.99 110.889 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -95.36 131.5 41.4 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.168 -0.469 . . . . 99.99 111.097 179.897 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 3' ' ' ASP . . . . . . . . . . . . . 24.9 t70 -120.01 -33.94 3.83 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 116.274 -0.421 . . . . 99.99 110.845 179.931 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 4' ' ' PHE . . . . . . . . . . . . . 41.9 t80 -128.17 141.05 51.59 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.26 -0.427 . . . . 99.99 110.836 -179.874 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 17.0 m-20 -138.0 179.34 6.49 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.134 -0.484 . . . . 99.99 110.86 179.928 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 6' ' ' ASN . . . . . . . . . . . . . 7.6 t-20 -164.38 163.54 22.36 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.191 -0.459 . . . . 99.99 110.83 -179.894 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 7' ' ' LEU . . . . . . . . . . . . . 2.1 mp -144.61 -174.93 4.46 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.097 -0.501 . . . . 99.99 110.999 179.942 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 8' ' ' PHE . . . . . . . . . . . . . 2.7 t80 -159.95 175.37 13.11 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.247 -0.433 . . . . 99.99 110.894 179.924 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 5.9 t0 -109.27 -179.72 3.92 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.199 -0.455 . . . . 99.99 110.867 179.999 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -144.83 -170.9 3.51 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.229 -0.442 . . . . 99.99 111.1 179.984 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -94.43 156.69 16.36 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.231 -0.44 . . . . 99.99 111.154 179.854 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 3.8 mp -139.64 73.16 0.25 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.233 -0.439 . . . . 99.99 111.166 179.991 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -151.04 159.43 44.54 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.219 -0.446 . . . . 99.99 111.088 179.865 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 6.8 ttp180 -171.01 179.25 3.15 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.194 -0.457 . . . . 99.99 110.844 -179.893 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -137.62 -174.88 3.89 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.149 -0.478 . . . . 99.99 111.056 179.933 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -162.64 -178.15 6.02 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.156 -0.474 . . . . 99.99 110.846 179.948 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 13.3 tp10 -104.14 139.63 38.93 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.248 -0.433 . . . . 99.99 110.883 -179.861 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -54.07 169.28 0.17 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.213 -0.448 . . . . 99.99 111.097 -179.932 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 14.4 mm -118.99 0.35 8.0 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.166 -0.47 . . . . 99.99 111.107 179.862 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 20' ' ' ARG . . . . . . . . . . . . . 24.9 mtt-85 61.0 95.78 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.197 -0.456 . . . . 99.99 110.907 179.949 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 157.96 123.8 0.76 Allowed Glycine 0 N--CA 1.452 -0.262 0 C-N-CA 120.751 -0.738 . . . . 99.99 112.489 -179.908 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 22' ' ' TYR . . . . . . . . . . . . . 7.6 p90 -178.76 140.25 0.18 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.915 0.388 . . . . 99.99 110.87 -179.849 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 23' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -179.25 136.92 0.13 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.07 -0.514 . . . . 99.99 110.853 179.854 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 130.53 -91.53 0.3 Allowed Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.674 -0.774 . . . . 99.99 112.489 -179.954 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 25' ' ' THR . . . . . 0.601 ' O ' ' HA ' ' A' ' 40' ' ' ARG . 69.8 p -93.23 108.69 20.27 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.737 0.303 . . . . 99.99 111.156 -179.884 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -76.3 122.47 24.48 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.268 -0.424 . . . . 99.99 110.838 -179.838 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 27' ' ' ALA . . . . . 0.581 ' CB ' HG21 ' A' ' 39' ' ' ILE . . . -151.56 161.78 42.1 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.184 -0.462 . . . . 99.99 111.104 179.882 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 28' ' ' THR . . . . . . . . . . . . . 12.9 m -131.46 89.74 2.76 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.215 -0.448 . . . . 99.99 111.167 -179.97 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . 0.552 HG23 HG22 ' A' ' 39' ' ' ILE . 2.1 pt -44.22 130.23 1.48 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 116.186 -0.461 . . . . 99.99 111.12 179.932 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 30' ' ' THR . . . . . . . . . . . . . 9.1 m -153.61 99.26 2.3 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.218 -0.447 . . . . 99.99 111.137 179.924 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 8.1 t -139.34 72.41 1.4 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.184 -0.462 . . . . 99.99 110.856 -179.819 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -178.96 166.95 36.9 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.796 -0.716 . . . . 99.99 112.512 179.999 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 17.1 pt-20 -49.24 -23.58 1.41 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.743 0.306 . . . . 99.99 110.829 -179.901 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 1.1 mt-30 -174.4 93.65 0.08 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.193 -0.458 . . . . 99.99 110.948 -179.829 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 3.2 m -145.95 165.71 28.16 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.196 -0.456 . . . . 99.99 110.885 -179.793 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 179.46 86.97 0.07 OUTLIER Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.788 -0.72 . . . . 99.99 112.542 -179.966 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 37' ' ' ALA . . . . . . . . . . . . . . . -105.79 -171.82 1.98 Allowed 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.81 0.338 . . . . 99.99 111.056 -179.955 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 73.5 t -99.74 122.79 52.0 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.15 -0.477 . . . . 99.99 111.131 -179.985 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 39' ' ' ILE . . . . . 0.581 HG21 ' CB ' ' A' ' 27' ' ' ALA . 0.0 OUTLIER -136.82 150.24 26.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.189 -0.459 . . . . 99.99 111.093 179.882 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 40' ' ' ARG . . . . . 0.601 ' HA ' ' O ' ' A' ' 25' ' ' THR . 10.1 mmt-85 -110.82 82.23 1.56 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.17 -0.468 . . . . 99.99 110.88 179.987 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . 0.486 ' O ' ' HB2' ' A' ' 27' ' ' ALA . . . -141.5 142.95 12.49 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.78 -0.724 . . . . 99.99 112.485 -179.965 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 42' ' ' VAL . . . . . 0.49 ' O ' ' HA ' ' A' ' 65' ' ' LEU . 8.8 p -127.46 142.34 43.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-O 120.912 0.387 . . . . 99.99 111.091 -179.95 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 43' ' ' PHE . . . . . 0.413 ' HA ' ' O ' ' A' ' 64' ' ' SER . 2.0 p90 -90.05 135.19 33.8 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.205 -0.452 . . . . 99.99 110.937 179.905 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 11.5 t0 -120.17 125.23 47.68 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.134 -0.485 . . . . 99.99 110.869 179.965 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -101.59 153.64 37.76 Favored Pre-proline 0 C--N 1.328 -0.339 0 CA-C-O 121.646 0.736 . . . . 99.99 110.854 179.988 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 46' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.78 -35.76 11.98 Favored 'Trans proline' 0 C--N 1.341 0.172 0 C-N-CA 122.629 2.22 . . . . 99.99 112.337 -179.905 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 40.1 tt0 63.92 57.93 1.28 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.204 -0.453 . . . . 99.99 110.807 179.966 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -146.8 -169.77 3.37 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.143 -0.48 . . . . 99.99 110.939 179.996 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 1.3 pp -140.17 22.3 0.55 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.19 -0.459 . . . . 99.99 111.084 179.9 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 11.0 t -77.06 108.17 9.94 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.201 -0.454 . . . . 99.99 110.856 -179.938 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 4.3 m-85 -160.88 178.56 9.29 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.112 -0.495 . . . . 99.99 110.865 -179.912 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -152.0 172.85 15.64 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.108 -0.496 . . . . 99.99 111.073 179.874 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 131.22 -171.73 20.97 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.746 -0.74 . . . . 99.99 112.523 -179.94 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 54' ' ' GLN . . . . . . . . . . . . . 4.7 mp0 -80.07 -43.11 22.37 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.874 0.369 . . . . 99.99 110.975 -179.911 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 114.19 -32.11 6.11 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.719 -0.753 . . . . 99.99 112.508 -179.98 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 48.1 t -52.58 -36.71 22.84 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-O 120.863 0.363 . . . . 99.99 111.178 179.953 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 23.2 mtm180 -104.78 162.13 13.57 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.146 -0.479 . . . . 99.99 110.889 -179.974 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 24.9 t -135.55 144.82 32.81 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.194 -0.457 . . . . 99.99 111.131 179.944 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 3.4 tt0 -112.0 -179.53 3.71 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.217 -0.447 . . . . 99.99 110.864 179.999 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -110.3 155.45 16.09 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.743 -0.741 . . . . 99.99 112.429 -179.909 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 29.7 t -91.65 149.94 21.39 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.861 0.362 . . . . 99.99 110.834 -179.705 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 37.2 m -126.58 97.35 33.76 Favored Pre-proline 0 C--N 1.328 -0.33 0 CA-C-O 121.667 0.746 . . . . 99.99 110.829 -179.832 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.81 179.99 3.33 Favored 'Trans proline' 0 C--N 1.341 0.181 0 C-N-CA 122.689 2.26 . . . . 99.99 112.337 179.993 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 64' ' ' SER . . . . . 0.413 ' O ' ' HA ' ' A' ' 43' ' ' PHE . 1.1 t -110.7 144.42 39.66 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.214 -0.448 . . . . 99.99 110.817 -179.798 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 65' ' ' LEU . . . . . 0.49 ' HA ' ' O ' ' A' ' 42' ' ' VAL . 0.0 OUTLIER -112.97 123.39 50.22 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.142 -0.481 . . . . 99.99 110.869 -179.943 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 15.3 t80 -102.88 110.31 22.18 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.235 -0.439 . . . . 99.99 110.972 179.857 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 67' ' ' VAL . . . . . . . . . . . . . 28.0 m -141.16 172.09 11.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.135 -0.484 . . . . 99.99 111.089 -179.93 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 68' ' ' ARG . . . . . 0.424 ' HG2' ' H ' ' A' ' 71' ' ' GLU . 0.9 OUTLIER -104.95 142.19 35.22 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.126 -0.488 . . . . 99.99 110.885 179.989 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 69' ' ' THR . . . . . 0.445 ' O ' ' N ' ' A' ' 73' ' ' ARG . 0.1 OUTLIER -36.03 -69.59 0.1 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.18 -0.464 . . . . 99.99 111.128 -179.91 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 30.9 t70 -44.06 -50.24 8.5 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.183 -0.462 . . . . 99.99 110.922 179.917 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 71' ' ' GLU . . . . . 0.424 ' H ' ' HG2' ' A' ' 68' ' ' ARG . 7.4 tp10 -55.49 -40.69 72.02 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.199 -0.455 . . . . 99.99 110.978 -179.976 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 6.1 p -101.09 16.55 4.25 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.244 0 CA-C-N 116.134 -0.485 . . . . 99.99 111.052 179.998 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 73' ' ' ARG . . . . . 0.445 ' N ' ' O ' ' A' ' 69' ' ' THR . 0.6 OUTLIER -103.58 -32.19 9.55 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.18 -0.464 . . . . 99.99 110.87 -179.95 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -64.57 -23.46 67.28 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.143 -0.481 . . . . 99.99 110.983 -179.936 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 75' ' ' LEU . . . . . 0.496 ' CD2' ' C ' ' A' ' 75' ' ' LEU . 0.0 OUTLIER -103.99 -177.56 3.4 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.149 -0.478 . . . . 99.99 110.888 179.968 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 76' ' ' ARG . . . . . . . . . . . . . 33.4 ttt180 -97.35 146.55 25.05 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.162 -0.472 . . . . 99.99 110.85 179.977 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 5.6 ptm180 -51.79 154.89 1.87 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.203 -0.453 . . . . 99.99 110.848 -179.919 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 72.46 18.9 78.66 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.734 -0.746 . . . . 99.99 112.538 -179.943 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 58.5 t0 -76.5 115.18 16.01 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.866 0.365 . . . . 99.99 110.81 -179.95 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 80' ' ' THR . . . . . 0.703 ' HA ' ' HA ' ' A' ' 89' ' ' TRP . 0.0 OUTLIER -88.15 109.1 19.63 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.148 -0.478 . . . . 99.99 111.197 -179.957 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 81' ' ' LEU . . . . . 0.774 ' C ' ' HA ' ' A' ' 87' ' ' ASN . 0.0 OUTLIER -97.24 134.46 40.51 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.246 -0.433 . . . . 99.99 110.943 179.93 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 82' ' ' THR . . . . . 0.71 ' CA ' ' HA ' ' A' ' 87' ' ' ASN . 5.0 t -92.77 101.36 13.74 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.186 -0.461 . . . . 99.99 111.112 179.981 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 83' ' ' ILE . . . . . 0.482 ' CD1' ' O ' ' A' ' 83' ' ' ILE . 0.1 OUTLIER -132.99 130.66 58.61 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 116.246 -0.434 . . . . 99.99 111.111 179.938 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 71.97 -57.92 1.41 Allowed Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.721 -0.752 . . . . 99.99 112.502 179.931 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 7.6 tp10 -109.54 -82.37 0.57 Allowed 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.838 0.352 . . . . 99.99 110.893 -179.92 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 86' ' ' GLU . . . . . 0.452 ' C ' ' HA ' ' A' ' 82' ' ' THR . 5.8 mm-40 -151.09 162.02 41.64 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.162 -0.472 . . . . 99.99 110.896 -179.955 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 87' ' ' ASN . . . . . 0.774 ' HA ' ' C ' ' A' ' 81' ' ' LEU . 12.1 p30 -51.43 125.31 14.09 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.14 -0.482 . . . . 99.99 110.9 -179.933 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 88' ' ' PHE . . . . . 0.594 ' CD1' ' HA ' ' A' ' 107' ' ' ARG . 15.3 m-85 -132.55 118.5 19.3 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.166 -0.47 . . . . 99.99 110.846 -179.958 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 89' ' ' TRP . . . . . 0.703 ' HA ' ' HA ' ' A' ' 80' ' ' THR . 53.9 p-90 -82.62 136.3 34.83 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.12 -0.491 . . . . 99.99 110.91 -179.976 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 90' ' ' VAL . . . . . 0.484 ' HA ' ' HB3' ' A' ' 105' ' ' LEU . 4.5 p -93.36 139.6 17.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.197 -0.456 . . . . 99.99 111.158 179.915 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -62.71 -63.77 1.12 Allowed 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.157 -0.474 . . . . 99.99 110.869 179.933 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 92' ' ' ARG . . . . . 0.448 ' H ' HD22 ' A' ' 103' ' ' LEU . 11.5 mtm180 -159.2 123.9 4.06 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.145 -0.479 . . . . 99.99 110.858 -179.869 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 93' ' ' VAL . . . . . 0.598 ' HB ' ' HB2' ' A' ' 101' ' ' CYS . 18.6 m -123.37 136.01 61.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.155 -0.475 . . . . 99.99 111.086 179.985 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 21.0 m -136.36 130.45 18.14 Favored Pre-proline 0 C--N 1.33 -0.244 0 CA-C-O 121.618 0.723 . . . . 99.99 110.854 -179.855 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 95' ' ' PRO . . . . . 0.411 ' HG3' ' HB ' ' A' ' 69' ' ' THR . 53.8 Cg_endo -69.75 155.55 65.7 Favored 'Trans proline' 0 C--O 1.232 0.178 0 C-N-CA 122.667 2.244 . . . . 99.99 112.385 179.931 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 14.1 t0 -117.31 -24.62 7.35 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.198 -0.455 . . . . 99.99 110.914 179.909 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 20.1 t70 -179.77 76.27 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.197 -0.456 . . . . 99.99 110.835 -179.976 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 98' ' ' GLY . . . . . 0.419 ' O ' ' C ' ' A' ' 99' ' ' GLY . . . 103.59 64.93 0.7 Allowed Glycine 0 N--CA 1.452 -0.263 0 C-N-CA 120.701 -0.761 . . . . 99.99 112.504 -179.921 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 99' ' ' GLY . . . . . 0.419 ' C ' ' O ' ' A' ' 98' ' ' GLY . . . 36.69 75.18 0.08 OUTLIER Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.79 -0.719 . . . . 99.99 112.434 -179.928 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 3.3 m -119.93 5.96 10.89 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 120.8 0.333 . . . . 99.99 110.845 -179.759 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 101' ' ' CYS . . . . . 0.598 ' HB2' ' HB ' ' A' ' 93' ' ' VAL . 25.4 p -47.3 132.66 12.82 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.144 -0.48 . . . . 99.99 110.939 179.996 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 102' ' ' HIS . . . . . . . . . . . . . 1.7 p80 -163.28 130.3 3.45 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.221 -0.445 . . . . 99.99 110.887 -179.968 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 103' ' ' LEU . . . . . 0.448 HD22 ' H ' ' A' ' 92' ' ' ARG . 7.1 tt -147.78 157.1 43.38 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.211 -0.449 . . . . 99.99 110.942 179.978 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 104' ' ' TRP . . . . . . . . . . . . . 8.4 m-90 -64.0 110.08 2.02 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.195 -0.457 . . . . 99.99 110.939 179.898 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 105' ' ' LEU . . . . . 0.535 HD22 ' HB2' ' A' ' 88' ' ' PHE . 0.3 OUTLIER -88.75 163.06 15.9 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.231 -0.44 . . . . 99.99 110.922 179.986 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -92.41 161.37 26.26 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.749 -0.738 . . . . 99.99 112.455 179.956 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 107' ' ' ARG . . . . . 0.594 ' HA ' ' CD1' ' A' ' 88' ' ' PHE . 4.8 ptt180 -68.07 158.57 32.7 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.835 0.35 . . . . 99.99 110.841 -179.832 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -171.49 112.38 0.44 Allowed Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.673 -0.775 . . . . 99.99 112.469 -179.998 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 109' ' ' VAL . . . . . . . . . . . . . 7.2 p -101.3 134.09 20.52 Favored Pre-proline 0 C--N 1.328 -0.332 0 CA-C-O 121.619 0.723 . . . . 99.99 111.157 179.999 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 110' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.76 167.89 23.13 Favored 'Trans proline' 0 C--O 1.232 0.199 0 C-N-CA 122.731 2.288 . . . . 99.99 112.321 179.956 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 111' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.76 -8.23 23.08 Favored 'Trans proline' 0 C--N 1.342 0.19 0 C-N-CA 122.717 2.278 . . . . 99.99 112.321 179.912 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -61.94 161.01 11.23 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.262 -0.426 . . . . 99.99 111.064 179.929 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 33.8 t -93.84 127.99 45.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.176 -0.465 . . . . 99.99 111.215 179.934 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 114' ' ' ASN . . . . . . . . . . . . . 6.5 m-20 -127.83 145.79 50.82 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.275 -0.42 . . . . 99.99 110.942 -179.987 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -83.78 103.25 12.92 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.162 -0.472 . . . . 99.99 110.895 -179.986 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 116' ' ' ARG . . . . . . . . . . . . . 19.3 mmt85 -115.34 114.37 25.05 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.15 -0.477 . . . . 99.99 110.799 -179.858 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 11.9 ptp180 . . . . . 0 C--N 1.33 -0.277 0 CA-C-N 116.172 -0.467 . . . . 99.99 110.883 -179.966 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 25' ' ' THR . . . . . 0.485 HG21 HG23 ' A' ' 42' ' ' VAL . 11.7 m . . . . . 0 C--O 1.232 0.15 0 CA-C-O 120.765 0.317 . . . . 60.23 111.237 . . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -71.95 122.45 20.85 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.286 -0.415 . . . . 74.12 110.842 -179.836 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 27' ' ' ALA . . . . . 0.81 ' HB3' HG23 ' A' ' 39' ' ' ILE . . . -141.95 162.18 36.13 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.09 -0.505 . . . . 73.02 111.134 179.904 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 28' ' ' THR . . . . . 0.464 HG22 ' O ' ' A' ' 28' ' ' THR . 21.2 m -129.99 87.95 2.59 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.224 -0.444 . . . . 73.24 111.143 -179.918 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 29' ' ' ILE . . . . . 0.858 HG21 HD21 ' A' ' 75' ' ' LEU . 2.3 pt -45.15 130.9 1.97 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.277 -0.419 . . . . 75.42 111.08 179.931 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 30' ' ' THR . . . . . 0.667 HG23 ' O ' ' A' ' 35' ' ' SER . 19.8 m -153.14 97.51 2.19 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.133 -0.485 . . . . 74.12 111.155 179.974 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 31' ' ' SER . . . . . 0.402 ' OG ' HG22 ' A' ' 80' ' ' THR . 8.5 t -135.1 70.86 1.43 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.213 -0.449 . . . . 61.23 110.829 -179.858 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -178.95 167.92 38.47 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.76 -0.733 . . . . 72.11 112.449 179.984 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 4.1 pt-20 -49.12 -23.36 1.22 Allowed 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.828 0.346 . . . . 64.41 110.89 -179.878 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 9.6 tt0 -174.44 94.64 0.08 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.129 -0.487 . . . . 71.3 110.879 -179.938 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 35' ' ' SER . . . . . 0.667 ' O ' HG23 ' A' ' 30' ' ' THR . 0.1 OUTLIER -144.9 165.49 27.98 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.992 0.425 . . . . 55.32 110.832 -179.831 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 178.17 87.84 0.07 OUTLIER Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.752 -0.737 . . . . 61.32 112.48 -179.97 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 37' ' ' ALA . . . . . 0.601 ' HB3' ' CD1' ' A' ' 29' ' ' ILE . . . -107.06 -170.67 1.75 Allowed 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.881 0.372 . . . . 63.42 111.087 179.984 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 4.1 p -99.15 120.74 48.9 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.227 -0.442 . . . . 74.22 111.185 179.913 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 39' ' ' ILE . . . . . 0.81 HG23 ' HB3' ' A' ' 27' ' ' ALA . 0.0 OUTLIER -137.85 148.69 25.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.199 -0.455 . . . . 74.1 111.106 179.951 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 40' ' ' ARG . . . . . 0.575 ' O ' HG12 ' A' ' 67' ' ' VAL . 18.5 mtt180 -109.66 80.76 1.35 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.189 -0.459 . . . . 70.22 110.887 179.9 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 41' ' ' GLY . . . . . 0.479 ' N ' HD13 ' A' ' 39' ' ' ILE . . . -128.71 148.9 18.21 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.738 -0.744 . . . . 72.52 112.454 -179.928 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 42' ' ' VAL . . . . . 0.664 HG12 ' HB3' ' A' ' 66' ' ' PHE . 3.4 p -127.16 135.04 64.64 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-O 120.851 0.357 . . . . 73.22 111.102 179.972 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 43' ' ' PHE . . . . . 0.58 ' H ' HD11 ' A' ' 83' ' ' ILE . 3.2 p90 -92.84 128.2 38.62 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.134 -0.485 . . . . 73.14 110.915 179.945 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 46.8 m-20 -114.88 124.52 51.93 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 116.133 -0.485 . . . . 64.13 110.861 179.944 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--N 1.329 -0.314 0 CA-C-O 121.624 0.726 . . . . 63.24 110.854 179.95 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 63' ' ' PRO . . . . . 0.536 ' HG2' HD11 ' A' ' 105' ' ' LEU . 54.2 Cg_endo . . . . . 0 C--O 1.231 0.159 0 CA-C-O 120.775 0.24 . . . . 64.21 112.354 . . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 64' ' ' SER . . . . . 0.488 ' O ' ' HA ' ' A' ' 43' ' ' PHE . 2.2 t -106.46 146.8 30.1 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.271 -0.422 . . . . 74.44 110.821 -179.879 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 65' ' ' LEU . . . . . 0.788 HD11 HG13 ' A' ' 67' ' ' VAL . 0.2 OUTLIER -113.36 123.66 50.63 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.07 -0.513 . . . . 54.13 110.899 -179.989 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 66' ' ' PHE . . . . . 0.664 ' HB3' HG12 ' A' ' 42' ' ' VAL . 15.2 t80 -102.48 110.87 22.94 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.185 -0.461 . . . . 72.14 110.873 179.956 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 67' ' ' VAL . . . . . 0.788 HG13 HD11 ' A' ' 65' ' ' LEU . 0.3 OUTLIER -140.99 168.73 15.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.193 -0.458 . . . . 52.41 111.237 179.954 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 8.9 ttm180 -98.36 143.18 29.1 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.202 -0.454 . . . . 73.52 110.8 -179.935 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 69' ' ' THR . . . . . 0.421 ' HB ' ' HG3' ' A' ' 95' ' ' PRO . 0.0 OUTLIER -41.17 -44.51 2.58 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.156 -0.475 . . . . 74.41 111.172 -179.932 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 29.0 m-20 -65.69 -52.64 49.92 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.236 -0.438 . . . . 70.51 110.891 179.888 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 71' ' ' GLU . . . . . . . . . . . . . 2.1 mm-40 -55.0 -39.49 69.1 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.22 -0.445 . . . . 73.11 110.906 -179.947 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 11.1 p -82.6 -22.13 9.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.132 -0.485 . . . . 63.43 111.075 -179.993 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 73' ' ' ARG . . . . . . . . . . . . . 1.5 tmt_? -67.59 -41.52 83.95 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.194 -0.457 . . . . 75.23 110.869 179.984 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 59.1 mt-30 -57.78 -20.45 35.45 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.198 -0.456 . . . . 71.12 110.969 -179.957 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 75' ' ' LEU . . . . . 0.858 HD21 HG21 ' A' ' 29' ' ' ILE . 5.8 mp -104.95 -175.87 2.92 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.199 -0.455 . . . . 73.43 110.899 -179.999 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 76' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -111.76 -179.45 3.7 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.197 -0.456 . . . . 75.24 110.937 179.944 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -81.21 116.25 21.01 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.225 -0.443 . . . . 71.15 110.888 -179.913 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 107.92 20.14 8.61 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.77 -0.729 . . . . 70.23 112.453 -179.991 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 79' ' ' ASP . . . . . 0.409 ' OD2' HD23 ' A' ' 75' ' ' LEU . 0.2 OUTLIER -84.41 111.58 19.58 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.881 0.372 . . . . 74.23 110.886 179.996 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 80' ' ' THR . . . . . 0.711 ' HA ' ' HA ' ' A' ' 89' ' ' TRP . 0.0 OUTLIER -86.62 111.6 20.8 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.198 -0.455 . . . . 71.14 111.148 -179.91 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 81' ' ' LEU . . . . . 0.755 ' C ' ' HA ' ' A' ' 87' ' ' ASN . 0.3 OUTLIER -97.22 131.82 43.58 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.194 -0.457 . . . . 64.43 110.921 179.917 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 82' ' ' THR . . . . . 0.748 ' CA ' ' HA ' ' A' ' 87' ' ' ASN . 2.4 t -92.48 101.42 13.87 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.13 -0.486 . . . . 61.15 111.156 179.946 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 83' ' ' ILE . . . . . 0.713 ' CG2' HD12 ' A' ' 81' ' ' LEU . 0.1 OUTLIER -137.24 131.84 45.67 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.282 -0.417 . . . . 73.34 111.081 179.979 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 74.9 -53.86 2.56 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.7 -0.762 . . . . 65.25 112.537 179.929 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 85' ' ' GLU . . . . . 0.41 ' C ' ' HG3' ' A' ' 86' ' ' GLU . 84.5 tt0 -117.94 -81.31 0.62 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.766 0.317 . . . . 73.34 110.879 -179.951 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 86' ' ' GLU . . . . . 0.695 ' OE1' HG22 ' A' ' 109' ' ' VAL . 61.7 mt-10 -149.35 161.4 42.13 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.233 -0.439 . . . . 73.23 110.931 -179.903 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 87' ' ' ASN . . . . . 0.755 ' HA ' ' C ' ' A' ' 81' ' ' LEU . 13.0 p30 -51.92 123.99 11.66 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.188 -0.46 . . . . 70.12 110.877 -179.932 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 88' ' ' PHE . . . . . 0.795 ' HB3' HD13 ' A' ' 105' ' ' LEU . 14.3 m-85 -132.2 118.18 19.21 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.184 -0.462 . . . . 73.52 110.869 -179.957 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 89' ' ' TRP . . . . . 0.711 ' HA ' ' HA ' ' A' ' 80' ' ' THR . 64.0 p-90 -82.15 135.35 35.3 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.185 -0.461 . . . . 74.34 110.922 -179.963 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 90' ' ' VAL . . . . . 0.731 ' HB ' HD23 ' A' ' 65' ' ' LEU . 0.4 OUTLIER -92.88 139.58 17.8 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.257 -0.429 . . . . 71.24 111.163 179.893 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -62.71 -71.0 0.17 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.183 -0.462 . . . . 74.32 110.89 179.867 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 92' ' ' ARG . . . . . 0.569 ' O ' ' HG ' ' A' ' 103' ' ' LEU . 7.0 mtm180 -159.9 120.89 3.1 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.172 -0.467 . . . . 54.31 110.894 -179.878 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 93' ' ' VAL . . . . . 0.758 HG12 ' HB2' ' A' ' 103' ' ' LEU . 17.4 m -112.51 135.43 51.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.197 -0.456 . . . . 75.04 111.164 179.942 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 2.1 m -130.22 101.62 17.69 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-O 121.661 0.743 . . . . 72.34 110.827 -179.811 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 95' ' ' PRO . . . . . 0.421 ' HG3' ' HB ' ' A' ' 69' ' ' THR . 54.0 Cg_endo -69.74 177.27 5.74 Favored 'Trans proline' 0 C--N 1.341 0.155 0 C-N-CA 122.682 2.254 . . . . 73.22 112.319 179.977 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 37.2 t70 . . . . . 0 C--N 1.329 -0.31 0 CA-C-N 116.203 -0.453 . . . . 74.12 110.848 179.928 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 1.7 m . . . . . 0 C--O 1.232 0.158 0 CA-C-O 120.922 0.392 . . . . 44.42 110.881 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 101' ' ' CYS . . . . . 0.425 ' CB ' ' HB ' ' A' ' 93' ' ' VAL . 0.0 OUTLIER -105.02 148.38 26.82 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.104 -0.498 . . . . 72.13 110.87 -179.996 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 102' ' ' HIS . . . . . 0.579 ' HA ' ' O ' ' A' ' 65' ' ' LEU . 6.7 p80 -157.65 123.69 4.74 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.142 -0.481 . . . . 64.53 110.865 -179.947 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 103' ' ' LEU . . . . . 0.931 HD13 ' N ' ' A' ' 104' ' ' TRP . 2.4 tm? -151.53 146.73 26.09 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.256 -0.429 . . . . 55.14 110.959 -180.0 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 104' ' ' TRP . . . . . 0.931 ' N ' HD13 ' A' ' 103' ' ' LEU . 30.4 p90 -65.81 110.52 2.87 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.15 -0.477 . . . . 73.11 110.928 179.937 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 105' ' ' LEU . . . . . 0.795 HD13 ' HB3' ' A' ' 88' ' ' PHE . 0.4 OUTLIER -91.23 161.84 14.89 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.169 -0.469 . . . . 72.42 110.944 179.99 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -89.43 159.52 28.5 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.692 -0.766 . . . . 61.04 112.477 179.911 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 107' ' ' ARG . . . . . 0.574 ' HA ' ' CD1' ' A' ' 88' ' ' PHE . 0.4 OUTLIER -69.33 158.47 34.99 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.845 0.355 . . . . 73.33 110.863 -179.83 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -174.56 111.12 0.35 Allowed Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.758 -0.734 . . . . 60.14 112.525 -179.969 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 109' ' ' VAL . . . . . 0.695 HG22 ' OE1' ' A' ' 86' ' ' GLU . 10.6 t -100.23 132.44 22.6 Favored Pre-proline 0 C--N 1.33 -0.251 0 CA-C-O 121.632 0.729 . . . . 64.42 111.15 -179.961 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 110' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo . . . . . 0 C--N 1.341 0.161 0 C-N-CA 122.718 2.279 . . . . 64.1 112.335 179.955 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 25' ' ' THR . . . . . 0.49 HG21 HG23 ' A' ' 42' ' ' VAL . 9.6 m . . . . . 0 C--O 1.232 0.138 0 CA-C-O 120.816 0.341 . . . . 72.33 111.218 . . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 7.7 m -72.39 122.37 21.08 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.287 -0.415 . . . . 74.51 110.818 -179.833 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 27' ' ' ALA . . . . . 0.816 ' HB3' HG23 ' A' ' 39' ' ' ILE . . . -143.06 162.37 35.7 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.109 -0.496 . . . . 75.11 111.133 179.831 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 28' ' ' THR . . . . . 0.49 HG22 ' O ' ' A' ' 28' ' ' THR . 18.0 m -129.86 88.17 2.63 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.243 -0.435 . . . . 43.33 111.155 -179.846 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 29' ' ' ILE . . . . . 0.766 HG23 ' CB ' ' A' ' 39' ' ' ILE . 2.1 pt -43.87 131.08 1.39 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.19 -0.459 . . . . 71.11 111.162 179.978 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 30' ' ' THR . . . . . 0.698 HG23 ' O ' ' A' ' 35' ' ' SER . 11.3 m -152.98 97.33 2.19 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.229 -0.441 . . . . 53.11 111.183 -179.998 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 86.3 p -135.96 70.79 1.42 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.193 -0.458 . . . . 71.34 110.945 -179.867 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -179.29 167.52 37.65 Favored Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.72 -0.752 . . . . 71.22 112.499 -179.982 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 16.8 pt-20 -48.95 -23.43 1.12 Allowed 'General case' 0 C--N 1.33 -0.283 0 CA-C-O 120.856 0.36 . . . . 73.33 110.885 -179.9 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -174.06 94.63 0.09 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.155 -0.475 . . . . 41.33 110.954 -179.937 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 35' ' ' SER . . . . . 0.698 ' O ' HG23 ' A' ' 30' ' ' THR . 2.9 m -145.23 165.45 28.35 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.191 -0.459 . . . . 70.41 110.81 -179.783 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 177.8 88.5 0.07 OUTLIER Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.799 -0.715 . . . . 74.4 112.52 -179.923 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 37' ' ' ALA . . . . . 0.648 ' HB3' ' CD1' ' A' ' 29' ' ' ILE . . . -108.43 -170.75 1.73 Allowed 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 120.893 0.378 . . . . 53.51 111.078 179.977 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 64.6 t -98.57 120.23 47.63 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-N 116.211 -0.449 . . . . 72.11 111.146 179.958 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 39' ' ' ILE . . . . . 0.816 HG23 ' HB3' ' A' ' 27' ' ' ALA . 0.0 OUTLIER -137.08 149.93 26.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.177 -0.465 . . . . 71.3 111.124 179.956 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 40' ' ' ARG . . . . . 0.434 ' HA ' ' O ' ' A' ' 25' ' ' THR . 19.3 mtt85 -109.46 80.47 1.32 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.213 -0.448 . . . . 73.53 110.849 179.934 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 41' ' ' GLY . . . . . 0.591 ' HA2' HG12 ' A' ' 67' ' ' VAL . . . -127.47 147.93 17.29 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.797 -0.716 . . . . 74.42 112.527 179.998 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 42' ' ' VAL . . . . . 0.56 HG12 ' CB ' ' A' ' 66' ' ' PHE . 3.1 p -127.19 138.86 53.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-O 120.851 0.358 . . . . 72.41 111.126 -179.942 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 43' ' ' PHE . . . . . 0.51 ' H ' HD11 ' A' ' 83' ' ' ILE . 2.8 p90 -101.05 128.71 46.98 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.166 -0.47 . . . . 73.13 110.873 -179.982 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 1.5 t0 -104.38 124.67 49.63 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.106 -0.497 . . . . 75.13 110.835 179.956 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 C--N 1.328 -0.356 0 CA-C-O 121.608 0.718 . . . . 73.42 110.88 179.97 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_endo . . . . . 0 C--O 1.231 0.169 0 CA-C-O 120.779 0.241 . . . . 72.32 112.315 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 64' ' ' SER . . . . . 0.492 ' O ' ' HA ' ' A' ' 43' ' ' PHE . 0.2 OUTLIER -107.02 146.38 31.2 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.228 -0.442 . . . . 43.53 110.894 -179.891 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 65' ' ' LEU . . . . . 0.55 HD11 ' CG1' ' A' ' 67' ' ' VAL . 2.7 tm? -114.93 131.48 56.87 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.126 -0.488 . . . . 74.24 110.919 -179.957 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 66' ' ' PHE . . . . . 0.56 ' CB ' HG12 ' A' ' 42' ' ' VAL . 1.2 t80 -120.38 106.17 11.59 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.261 -0.427 . . . . 73.24 110.846 179.951 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 67' ' ' VAL . . . . . 0.591 HG12 ' HA2' ' A' ' 41' ' ' GLY . 23.2 m -144.69 172.71 5.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.167 -0.469 . . . . 75.24 111.148 179.921 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 1.4 ttt180 -105.62 143.48 33.71 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.128 -0.487 . . . . 72.12 110.896 -179.992 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 69' ' ' THR . . . . . 0.415 ' HB ' ' HG3' ' A' ' 95' ' ' PRO . 0.0 OUTLIER -41.17 -49.4 3.53 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.168 -0.469 . . . . 72.33 111.135 -179.908 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 14.8 t70 -53.39 -51.29 63.01 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.231 -0.44 . . . . 74.4 110.862 179.918 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 71' ' ' GLU . . . . . . . . . . . . . 31.2 mt-10 -53.3 -39.07 63.71 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.164 -0.471 . . . . 64.22 110.905 -179.932 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 72' ' ' VAL . . . . . 0.838 HG11 HG21 ' A' ' 93' ' ' VAL . 3.3 t -78.6 -32.43 16.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.156 -0.474 . . . . 74.05 111.148 179.952 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 73' ' ' ARG . . . . . . . . . . . . . 1.8 tmt_? -57.32 -39.18 75.3 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.149 -0.478 . . . . 63.11 110.841 -179.94 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 39.9 mt-30 -56.22 -22.02 26.86 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.188 -0.46 . . . . 63.25 110.87 -179.897 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 75' ' ' LEU . . . . . 0.784 HD22 ' CG ' ' A' ' 79' ' ' ASP . 2.3 mp -119.23 -165.29 1.13 Allowed 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.252 -0.431 . . . . 54.05 110.918 -180.0 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 76' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -116.15 171.94 7.49 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.219 -0.446 . . . . 73.23 110.86 179.969 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -62.41 132.05 51.26 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.174 -0.466 . . . . 75.25 110.899 -179.917 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 92.5 18.11 43.03 Favored Glycine 0 N--CA 1.452 -0.252 0 C-N-CA 120.746 -0.74 . . . . 70.23 112.477 179.998 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 79' ' ' ASP . . . . . 0.784 ' CG ' HD22 ' A' ' 75' ' ' LEU . 0.1 OUTLIER -74.23 106.33 5.82 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.883 0.373 . . . . 74.34 110.896 -179.976 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 80' ' ' THR . . . . . 0.718 ' HA ' ' HA ' ' A' ' 89' ' ' TRP . 0.6 OUTLIER -85.78 109.14 18.44 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.185 -0.461 . . . . 72.22 111.155 -179.857 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 81' ' ' LEU . . . . . 0.756 ' C ' ' HA ' ' A' ' 87' ' ' ASN . 0.3 OUTLIER -97.07 133.11 42.16 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.188 -0.46 . . . . 71.24 110.9 -179.992 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 82' ' ' THR . . . . . 0.741 ' CA ' ' HA ' ' A' ' 87' ' ' ASN . 9.8 t -93.51 102.27 14.48 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.193 -0.458 . . . . 73.32 111.123 179.949 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 83' ' ' ILE . . . . . 0.734 ' CG2' HD12 ' A' ' 81' ' ' LEU . 0.1 OUTLIER -138.46 131.78 40.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.208 -0.451 . . . . 64.45 111.147 179.882 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 74.43 -50.51 2.08 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.663 -0.779 . . . . 55.43 112.548 179.96 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 11.4 mm-40 -119.77 -80.68 0.62 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.831 0.348 . . . . 74.12 110.929 -179.885 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 86' ' ' GLU . . . . . 0.458 ' C ' ' HA ' ' A' ' 82' ' ' THR . 69.0 mt-10 -153.01 161.29 42.71 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.143 -0.48 . . . . 72.11 110.901 -179.908 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 87' ' ' ASN . . . . . 0.756 ' HA ' ' C ' ' A' ' 81' ' ' LEU . 2.1 p-10 -49.59 122.15 5.99 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.198 -0.455 . . . . 75.12 110.871 -179.99 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 88' ' ' PHE . . . . . 0.857 ' HB2' HD22 ' A' ' 105' ' ' LEU . 15.9 m-85 -131.83 120.01 22.02 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.196 -0.457 . . . . 74.41 110.859 -179.96 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 89' ' ' TRP . . . . . 0.718 ' HA ' ' HA ' ' A' ' 80' ' ' THR . 59.9 p-90 -83.94 136.79 33.94 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.226 -0.443 . . . . 65.01 110.869 -179.972 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 90' ' ' VAL . . . . . 0.556 HG21 HG13 ' A' ' 93' ' ' VAL . 10.1 p -86.92 138.75 18.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.246 -0.434 . . . . 70.42 111.074 179.966 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 91' ' ' ASP . . . . . 0.416 ' H ' HD22 ' A' ' 103' ' ' LEU . 0.7 OUTLIER -70.15 -41.78 73.39 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.177 -0.465 . . . . 61.11 110.76 179.934 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 92' ' ' ARG . . . . . 0.508 ' HB3' HD13 ' A' ' 103' ' ' LEU . 20.0 tpp180 -160.26 138.59 10.16 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.265 -0.425 . . . . 62.53 110.912 -179.826 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 93' ' ' VAL . . . . . 0.838 HG21 HG11 ' A' ' 72' ' ' VAL . 0.0 OUTLIER -126.81 111.9 27.41 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.258 -0.428 . . . . 52.32 111.148 179.936 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 4.0 t -127.25 109.35 21.4 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-O 121.694 0.759 . . . . 64.25 110.88 -179.914 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 95' ' ' PRO . . . . . 0.415 ' HG3' ' HB ' ' A' ' 69' ' ' THR . 53.3 Cg_endo -69.77 156.64 62.8 Favored 'Trans proline' 0 C--O 1.232 0.18 0 C-N-CA 122.649 2.232 . . . . 55.24 112.356 179.983 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 44.4 m-20 . . . . . 0 C--N 1.329 -0.322 0 CA-C-N 116.187 -0.46 . . . . 74.42 110.873 179.911 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 C--O 1.232 0.14 0 CA-C-O 120.832 0.349 . . . . 73.1 110.881 . . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 101' ' ' CYS . . . . . 0.406 ' HB2' ' CB ' ' A' ' 93' ' ' VAL . 1.6 p -42.37 142.85 0.71 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.145 -0.479 . . . . 73.31 110.868 -179.99 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 102' ' ' HIS . . . . . 0.491 ' HA ' ' O ' ' A' ' 65' ' ' LEU . 46.1 p-80 -161.2 125.55 3.47 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.188 -0.46 . . . . 65.21 110.87 -179.944 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 103' ' ' LEU . . . . . 0.571 HD23 ' N ' ' A' ' 104' ' ' TRP . 9.8 tt -152.04 155.85 38.77 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.201 -0.454 . . . . 71.3 110.873 -179.993 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 104' ' ' TRP . . . . . 0.571 ' N ' HD23 ' A' ' 103' ' ' LEU . 50.2 p-90 -66.23 112.0 3.74 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.136 -0.484 . . . . 74.42 110.981 179.865 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 105' ' ' LEU . . . . . 0.857 HD22 ' HB2' ' A' ' 88' ' ' PHE . 0.3 OUTLIER -87.58 162.24 17.29 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.319 -0.4 . . . . 74.32 110.934 -179.983 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -88.36 160.43 30.54 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.724 -0.75 . . . . 62.0 112.53 179.894 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 107' ' ' ARG . . . . . 0.52 ' HA ' ' CD1' ' A' ' 88' ' ' PHE . 2.5 ptm180 -68.89 158.46 34.5 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.799 0.333 . . . . 64.41 110.845 -179.816 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -173.64 106.79 0.23 Allowed Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.694 -0.765 . . . . 45.2 112.436 -179.966 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 109' ' ' VAL . . . . . 0.443 HG23 ' HD2' ' A' ' 110' ' ' PRO . 8.7 p -91.04 134.01 30.9 Favored Pre-proline 0 C--N 1.33 -0.275 0 CA-C-O 121.644 0.735 . . . . 64.35 111.103 180.0 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 110' ' ' PRO . . . . . 0.443 ' HD2' HG23 ' A' ' 109' ' ' VAL . 53.9 Cg_endo . . . . . 0 C--N 1.341 0.153 0 C-N-CA 122.659 2.239 . . . . 74.12 112.358 179.929 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 25' ' ' THR . . . . . 0.718 HG21 HG23 ' A' ' 42' ' ' VAL . 85.8 m . . . . . 0 N--CA 1.457 -0.115 0 CA-C-O 120.829 0.347 . . . . 61.22 111.147 . . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -71.41 123.17 21.76 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.212 -0.449 . . . . 75.31 110.898 -179.861 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 27' ' ' ALA . . . . . 0.827 ' HB3' HG23 ' A' ' 39' ' ' ILE . . . -140.03 162.74 34.5 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.122 -0.49 . . . . 63.0 111.113 179.921 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 28' ' ' THR . . . . . 0.501 HG22 ' O ' ' A' ' 28' ' ' THR . 16.9 m -129.6 88.54 2.7 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.246 -0.434 . . . . 73.21 111.116 -179.913 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 29' ' ' ILE . . . . . 0.766 HG23 ' CB ' ' A' ' 39' ' ' ILE . 2.0 pt -45.12 129.75 1.83 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.385 0 CA-C-N 116.264 -0.425 . . . . 75.51 111.123 179.876 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 30' ' ' THR . . . . . 0.711 HG23 ' O ' ' A' ' 35' ' ' SER . 7.0 m -152.97 98.53 2.32 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.24 -0.437 . . . . 74.05 111.179 179.917 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 31' ' ' SER . . . . . 0.441 ' OG ' HG22 ' A' ' 80' ' ' THR . 12.1 t -138.38 71.11 1.39 Allowed 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.246 -0.434 . . . . 71.44 110.817 -179.854 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -178.72 168.17 38.99 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.751 -0.738 . . . . 74.23 112.508 179.959 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 15.4 pt-20 -49.38 -23.46 1.49 Allowed 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.781 0.324 . . . . 53.42 110.835 -179.844 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 4.8 tt0 -174.68 94.84 0.08 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.166 -0.47 . . . . 52.13 110.907 -179.916 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 35' ' ' SER . . . . . 0.711 ' O ' HG23 ' A' ' 30' ' ' THR . 3.3 m -144.97 165.71 27.4 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.214 -0.448 . . . . 70.14 110.891 -179.834 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 178.35 88.21 0.07 OUTLIER Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.811 -0.709 . . . . 63.42 112.505 -179.977 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 37' ' ' ALA . . . . . 0.666 ' HB3' ' CD1' ' A' ' 29' ' ' ILE . . . -109.6 -172.81 2.12 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.849 0.357 . . . . 44.03 111.088 -179.984 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 61.9 t -97.75 121.9 48.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.238 -0.437 . . . . 62.4 111.123 179.962 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 39' ' ' ILE . . . . . 0.827 HG23 ' HB3' ' A' ' 27' ' ' ALA . 0.0 OUTLIER -137.62 150.12 25.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.126 -0.488 . . . . 74.32 111.157 179.898 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 40' ' ' ARG . . . . . 0.657 ' O ' HG12 ' A' ' 67' ' ' VAL . 5.4 ttm180 -109.69 80.3 1.3 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.24 -0.436 . . . . 73.0 110.873 179.987 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 41' ' ' GLY . . . . . 0.499 ' N ' HD13 ' A' ' 39' ' ' ILE . . . -129.18 147.44 17.75 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.774 -0.727 . . . . 74.14 112.46 -179.955 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 42' ' ' VAL . . . . . 0.718 HG23 HG21 ' A' ' 25' ' ' THR . 2.8 p -126.49 136.59 60.37 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-O 120.845 0.355 . . . . 74.12 111.072 -179.971 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 43' ' ' PHE . . . . . 0.658 ' H ' HD11 ' A' ' 83' ' ' ILE . 1.3 p90 -93.72 130.77 39.57 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.218 -0.446 . . . . 73.12 110.872 179.96 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 12.6 t70 -117.04 124.76 50.08 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.121 -0.49 . . . . 61.12 110.87 179.956 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 C--N 1.328 -0.327 0 CA-C-O 121.575 0.702 . . . . 73.33 110.877 179.999 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_endo . . . . . 0 C--O 1.232 0.181 0 CA-C-O 120.841 0.267 . . . . 55.25 112.315 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 64' ' ' SER . . . . . 0.502 ' O ' ' HA ' ' A' ' 43' ' ' PHE . 1.5 t -106.32 148.15 28.36 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.222 -0.444 . . . . 62.24 110.915 -179.922 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 65' ' ' LEU . . . . . 0.666 ' O ' HD23 ' A' ' 65' ' ' LEU . 0.0 OUTLIER -112.68 140.45 47.44 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.118 -0.492 . . . . 63.01 110.901 179.996 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 66' ' ' PHE . . . . . 0.63 ' HB3' HG12 ' A' ' 42' ' ' VAL . 17.8 t80 -118.47 107.97 14.45 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.156 -0.475 . . . . 70.55 110.896 179.904 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 67' ' ' VAL . . . . . 0.657 HG12 ' O ' ' A' ' 40' ' ' ARG . 4.3 m -141.98 166.79 16.4 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.18 -0.463 . . . . 75.54 111.057 -179.949 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 68' ' ' ARG . . . . . 0.619 ' O ' HG23 ' A' ' 72' ' ' VAL . 2.8 ttm180 -103.23 144.19 31.66 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.156 -0.475 . . . . 72.15 110.921 179.984 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 69' ' ' THR . . . . . 0.403 ' HB ' ' HG3' ' A' ' 95' ' ' PRO . 2.0 t -40.32 -47.3 2.48 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.245 -0.434 . . . . 73.0 111.138 -179.92 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 46.8 m-20 -52.97 -62.03 1.92 Allowed 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.224 -0.444 . . . . 72.4 110.859 179.924 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 71' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -53.39 -40.44 65.04 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.235 -0.439 . . . . 64.44 110.903 -179.915 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 72' ' ' VAL . . . . . 0.619 HG23 ' O ' ' A' ' 68' ' ' ARG . 14.4 t -69.39 -33.84 59.49 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.125 -0.489 . . . . 70.52 111.12 179.946 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 73' ' ' ARG . . . . . . . . . . . . . 18.9 ttm180 -62.17 -39.89 94.19 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.205 -0.452 . . . . 73.05 110.836 -179.96 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 29.9 mt-30 -55.04 -22.58 16.28 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.219 -0.446 . . . . 72.12 110.874 -179.932 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 75' ' ' LEU . . . . . 0.511 HD21 HG21 ' A' ' 29' ' ' ILE . 4.5 mp -113.03 -168.73 1.36 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.234 -0.439 . . . . 73.41 110.912 -179.969 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 76' ' ' ARG . . . . . . . . . . . . . 11.1 ptp180 -124.12 -178.96 4.24 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.182 -0.463 . . . . 74.22 110.871 179.974 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 4.7 mtp180 -70.05 130.56 42.48 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.155 -0.475 . . . . 74.33 110.926 -179.957 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 78' ' ' GLY . . . . . 0.401 ' HA2' ' CD1' ' A' ' 89' ' ' TRP . . . 92.42 36.47 6.2 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.767 -0.73 . . . . 33.52 112.453 -179.976 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 79' ' ' ASP . . . . . 0.486 ' OD1' HD23 ' A' ' 75' ' ' LEU . 0.6 OUTLIER -99.13 105.46 17.55 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.859 0.362 . . . . 71.15 110.926 179.994 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 80' ' ' THR . . . . . 0.742 ' HA ' ' HA ' ' A' ' 89' ' ' TRP . 0.8 OUTLIER -89.61 108.56 19.74 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.199 -0.455 . . . . 70.44 111.102 -179.851 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 81' ' ' LEU . . . . . 0.768 ' C ' ' HA ' ' A' ' 87' ' ' ASN . 0.0 OUTLIER -96.05 135.42 37.85 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.132 -0.485 . . . . 71.24 110.93 179.956 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 82' ' ' THR . . . . . 0.714 ' CA ' ' HA ' ' A' ' 87' ' ' ASN . 8.9 t -94.99 101.64 13.41 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.267 -0.424 . . . . 73.45 111.124 179.958 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 83' ' ' ILE . . . . . 0.732 HD13 ' O ' ' A' ' 83' ' ' ILE . 0.1 OUTLIER -135.58 132.58 51.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.236 -0.438 . . . . 73.14 111.128 179.913 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 73.08 -54.37 1.81 Allowed Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.761 -0.733 . . . . 65.53 112.486 179.936 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 3.0 mm-40 -115.54 -83.18 0.62 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.787 0.327 . . . . 54.43 110.837 -179.829 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 7.6 mp0 -150.02 159.45 44.39 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.195 -0.457 . . . . 61.43 110.883 -179.946 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 87' ' ' ASN . . . . . 0.768 ' HA ' ' C ' ' A' ' 81' ' ' LEU . 0.7 OUTLIER -50.28 124.05 9.66 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.152 -0.476 . . . . 63.13 110.876 -179.868 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 88' ' ' PHE . . . . . 0.748 ' HB3' HD13 ' A' ' 105' ' ' LEU . 15.9 m-85 -131.09 119.61 22.2 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.113 -0.494 . . . . 73.55 110.857 -179.956 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 89' ' ' TRP . . . . . 0.742 ' HA ' ' HA ' ' A' ' 80' ' ' THR . 0.0 OUTLIER -79.23 135.55 36.81 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 116.121 -0.491 . . . . 72.01 110.921 -179.993 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 90' ' ' VAL . . . . . 0.682 HG21 HG13 ' A' ' 93' ' ' VAL . 3.0 p -91.55 136.08 25.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.207 -0.451 . . . . 72.34 111.161 179.951 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -63.24 -72.35 0.14 Allowed 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.185 -0.461 . . . . 71.21 110.888 179.926 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 92' ' ' ARG . . . . . 0.569 ' O ' ' HG ' ' A' ' 103' ' ' LEU . 9.0 ptm180 -159.71 122.12 3.43 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.164 -0.471 . . . . 74.32 110.954 -179.936 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 93' ' ' VAL . . . . . 0.699 HG12 ' HB2' ' A' ' 103' ' ' LEU . 26.0 m -113.63 136.88 48.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.191 -0.459 . . . . 72.42 111.083 -179.956 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 94' ' ' SER . . . . . 0.423 ' HA ' ' HD2' ' A' ' 95' ' ' PRO . 7.0 t -129.32 100.31 20.31 Favored Pre-proline 0 C--N 1.329 -0.307 0 CA-C-O 121.673 0.749 . . . . 41.05 110.821 -179.84 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 95' ' ' PRO . . . . . 0.423 ' HD2' ' HA ' ' A' ' 94' ' ' SER . 53.5 Cg_endo -69.81 169.59 18.62 Favored 'Trans proline' 0 C--N 1.342 0.186 0 C-N-CA 122.629 2.22 . . . . 75.43 112.312 179.958 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 11.7 t0 . . . . . 0 C--N 1.329 -0.302 0 CA-C-N 116.186 -0.461 . . . . 75.2 110.837 179.923 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 46.7 t . . . . . 0 C--O 1.231 0.131 0 CA-C-O 120.791 0.329 . . . . 73.53 110.878 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 101' ' ' CYS . . . . . 0.463 ' CB ' ' HB ' ' A' ' 93' ' ' VAL . 0.0 OUTLIER -110.16 148.54 31.59 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.131 -0.486 . . . . 75.21 110.931 -179.976 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 102' ' ' HIS . . . . . 0.613 ' HA ' ' O ' ' A' ' 65' ' ' LEU . 24.8 p80 -160.37 126.28 4.06 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.225 -0.443 . . . . 64.24 110.953 179.99 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 103' ' ' LEU . . . . . 0.926 HD13 ' N ' ' A' ' 104' ' ' TRP . 2.5 tm? -151.22 147.55 27.14 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.272 -0.422 . . . . 62.45 110.926 -179.96 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 104' ' ' TRP . . . . . 0.926 ' N ' HD13 ' A' ' 103' ' ' LEU . 22.2 m-90 -63.43 114.45 3.88 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 116.208 -0.451 . . . . 71.24 110.922 179.91 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 105' ' ' LEU . . . . . 0.748 HD13 ' HB3' ' A' ' 88' ' ' PHE . 0.3 OUTLIER -93.7 162.0 14.11 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.255 -0.43 . . . . 63.22 110.912 -179.987 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -88.83 160.63 30.12 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.741 -0.743 . . . . 75.5 112.523 179.878 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 107' ' ' ARG . . . . . 0.57 ' HA ' ' CD1' ' A' ' 88' ' ' PHE . 3.1 ptt85 -67.9 157.31 35.23 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.858 0.361 . . . . 74.24 110.893 -179.887 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -173.97 110.52 0.33 Allowed Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.756 -0.735 . . . . 72.14 112.478 -179.979 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 109' ' ' VAL . . . . . 0.475 HG13 ' HD2' ' A' ' 110' ' ' PRO . 58.1 t -84.72 134.46 41.92 Favored Pre-proline 0 C--N 1.33 -0.276 0 CA-C-O 121.629 0.728 . . . . 72.4 111.135 -179.988 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 110' ' ' PRO . . . . . 0.475 ' HD2' HG13 ' A' ' 109' ' ' VAL . 52.6 Cg_endo . . . . . 0 C--N 1.341 0.173 0 C-N-CA 122.675 2.25 . . . . 63.15 112.263 -179.971 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 25' ' ' THR . . . . . 0.594 ' O ' ' HA ' ' A' ' 40' ' ' ARG . 60.7 p . . . . . 0 C--O 1.232 0.136 0 CA-C-O 120.785 0.326 . . . . 74.32 111.139 . . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -77.53 121.76 24.32 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.227 -0.442 . . . . 62.44 110.849 -179.822 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 27' ' ' ALA . . . . . 0.793 ' HB3' HG23 ' A' ' 39' ' ' ILE . . . -151.7 161.46 42.64 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.123 -0.489 . . . . 63.51 111.132 179.891 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 28' ' ' THR . . . . . 0.537 HG22 ' O ' ' A' ' 28' ' ' THR . 11.0 m -130.84 88.87 2.67 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.177 -0.465 . . . . 75.24 111.117 -179.852 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 29' ' ' ILE . . . . . 0.798 HG23 ' CB ' ' A' ' 39' ' ' ILE . 1.7 pt -43.49 128.75 1.11 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.198 -0.456 . . . . 72.43 111.133 179.902 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 30' ' ' THR . . . . . 0.688 HG23 ' O ' ' A' ' 35' ' ' SER . 7.1 m -153.76 99.0 2.25 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.199 -0.455 . . . . 70.31 111.148 179.949 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 18.7 t -140.8 72.94 1.4 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.222 -0.444 . . . . 62.43 110.845 -179.84 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -178.53 166.57 36.51 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.72 -0.753 . . . . 70.14 112.512 -179.968 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 10.6 pt-20 -48.96 -23.72 1.23 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.738 0.304 . . . . 74.11 110.873 -179.892 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 4.1 tt0 -174.1 93.5 0.09 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.15 -0.477 . . . . 62.41 110.944 -179.949 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 35' ' ' SER . . . . . 0.688 ' O ' HG23 ' A' ' 30' ' ' THR . 2.0 m -144.87 165.53 27.87 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.243 -0.435 . . . . 73.51 110.84 -179.791 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -179.86 85.21 0.06 OUTLIER Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.746 -0.74 . . . . 74.31 112.513 179.936 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 37' ' ' ALA . . . . . 0.619 ' HB3' ' CD1' ' A' ' 29' ' ' ILE . . . -106.93 -173.83 2.39 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.886 0.374 . . . . 54.05 111.1 -179.996 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 57.5 t -99.36 124.85 52.92 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.171 -0.468 . . . . 74.04 111.124 179.99 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 39' ' ' ILE . . . . . 0.798 ' CB ' HG23 ' A' ' 29' ' ' ILE . 0.0 OUTLIER -137.15 149.35 26.05 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 116.223 -0.444 . . . . 73.24 111.111 179.97 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 40' ' ' ARG . . . . . 0.665 ' O ' HG12 ' A' ' 67' ' ' VAL . 0.2 OUTLIER -107.84 82.02 1.59 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.192 -0.458 . . . . 74.33 110.907 179.931 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 41' ' ' GLY . . . . . 0.608 ' O ' ' HB2' ' A' ' 27' ' ' ALA . . . -141.6 142.75 12.26 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.685 -0.769 . . . . 43.24 112.482 -179.94 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 42' ' ' VAL . . . . . 0.545 ' O ' ' HA ' ' A' ' 65' ' ' LEU . 9.0 p -128.57 141.3 46.91 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-O 120.815 0.34 . . . . 74.43 111.144 -179.939 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 43' ' ' PHE . . . . . 0.784 ' H ' HD11 ' A' ' 83' ' ' ILE . 1.8 p90 -90.28 135.88 33.4 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.228 -0.442 . . . . 73.24 110.938 179.964 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 11.4 t70 -126.15 125.27 42.21 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.221 -0.445 . . . . 71.14 110.852 179.99 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 . . . . . 0 C--N 1.329 -0.315 0 CA-C-O 121.619 0.723 . . . . 75.32 110.855 179.943 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo . . . . . 0 C--O 1.23 0.112 0 CA-C-O 120.83 0.263 . . . . 71.05 112.327 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 3.5 t -106.92 142.87 35.85 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.196 -0.456 . . . . 75.22 110.842 -179.839 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 65' ' ' LEU . . . . . 0.613 ' O ' HD23 ' A' ' 65' ' ' LEU . 0.0 OUTLIER -114.88 119.76 37.67 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.163 -0.471 . . . . 60.25 110.926 -179.991 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 56.0 t80 -101.76 109.81 21.66 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.226 -0.443 . . . . 54.24 110.85 179.98 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 67' ' ' VAL . . . . . 0.665 HG12 ' O ' ' A' ' 40' ' ' ARG . 22.3 m -138.13 169.2 18.9 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.159 -0.473 . . . . 64.43 111.163 179.895 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 68' ' ' ARG . . . . . 0.469 ' O ' HG23 ' A' ' 72' ' ' VAL . 1.1 ttp180 -93.43 143.82 25.92 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.191 -0.459 . . . . 64.22 110.919 -179.983 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 69' ' ' THR . . . . . 0.411 HG23 ' N ' ' A' ' 70' ' ' ASP . 2.4 t -45.47 -47.74 13.95 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.241 -0.436 . . . . 74.53 111.039 -179.868 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 70' ' ' ASP . . . . . 0.411 ' N ' HG23 ' A' ' 69' ' ' THR . 30.5 t70 -52.18 -52.84 49.56 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.197 -0.456 . . . . 75.13 110.923 179.928 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 71' ' ' GLU . . . . . . . . . . . . . 66.0 mm-40 -54.41 -39.29 67.16 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.246 -0.434 . . . . 75.24 110.909 -179.947 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 72' ' ' VAL . . . . . 0.469 HG23 ' O ' ' A' ' 68' ' ' ARG . 4.4 t -73.49 -38.45 52.7 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.16 -0.473 . . . . 74.22 111.172 179.925 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 73' ' ' ARG . . . . . . . . . . . . . 2.6 tmt_? -55.69 -40.02 71.79 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.187 -0.46 . . . . 74.12 110.907 -179.985 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 41.7 mt-30 -52.64 -25.86 12.0 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.245 -0.434 . . . . 71.24 110.962 -179.995 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 75' ' ' LEU . . . . . 0.496 HD21 ' CD1' ' A' ' 29' ' ' ILE . 2.5 mp -116.25 -166.64 1.17 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.163 -0.472 . . . . 62.3 110.951 179.942 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 76' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -112.35 -178.67 3.47 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.204 -0.453 . . . . 74.34 110.845 179.925 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -76.05 125.89 29.97 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.184 -0.462 . . . . 72.31 110.925 -179.929 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 99.77 23.94 10.39 Favored Glycine 0 N--CA 1.45 -0.383 0 C-N-CA 120.768 -0.729 . . . . 34.42 112.505 -179.912 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -82.63 109.31 16.7 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.876 0.369 . . . . 73.02 110.916 179.968 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 80' ' ' THR . . . . . 0.737 ' HA ' ' HA ' ' A' ' 89' ' ' TRP . 0.5 OUTLIER -88.37 109.64 20.15 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.209 -0.45 . . . . 71.34 111.16 -179.906 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 81' ' ' LEU . . . . . 0.806 ' C ' ' HA ' ' A' ' 87' ' ' ASN . 0.0 OUTLIER -96.82 134.37 40.21 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 116.227 -0.442 . . . . 55.44 110.956 179.949 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 82' ' ' THR . . . . . 0.729 ' CA ' ' HA ' ' A' ' 87' ' ' ASN . 4.9 t -92.63 101.79 14.21 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.187 -0.461 . . . . 72.12 111.183 179.975 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 83' ' ' ILE . . . . . 0.784 HD11 ' H ' ' A' ' 43' ' ' PHE . 0.1 OUTLIER -132.92 130.45 58.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.219 -0.446 . . . . 74.12 111.118 179.975 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 70.42 -62.37 0.83 Allowed Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.749 -0.739 . . . . 75.03 112.458 179.924 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 10.1 tp10 -103.07 -81.83 0.5 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.806 0.336 . . . . 75.45 110.908 -179.891 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 86' ' ' GLU . . . . . 0.427 ' C ' ' HA ' ' A' ' 82' ' ' THR . 95.7 mt-10 -152.91 160.7 43.07 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.143 -0.48 . . . . 73.43 110.923 -179.923 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 87' ' ' ASN . . . . . 0.806 ' HA ' ' C ' ' A' ' 81' ' ' LEU . 1.3 p-10 -51.55 124.64 12.62 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.153 -0.476 . . . . 60.32 110.893 -179.908 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 88' ' ' PHE . . . . . 0.634 ' HB2' HD22 ' A' ' 105' ' ' LEU . 15.3 m-85 -132.77 120.27 21.4 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.176 -0.465 . . . . 74.42 110.932 179.999 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 89' ' ' TRP . . . . . 0.737 ' HA ' ' HA ' ' A' ' 80' ' ' THR . 7.1 p90 -80.01 137.0 36.72 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.179 -0.464 . . . . 64.43 111.005 -179.981 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 90' ' ' VAL . . . . . 0.569 HG21 ' CG1' ' A' ' 93' ' ' VAL . 7.2 p -89.64 135.97 24.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.318 -0.401 . . . . 62.44 111.161 179.893 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 91' ' ' ASP . . . . . 0.422 ' HB3' HD12 ' A' ' 103' ' ' LEU . 0.0 OUTLIER -64.28 -67.76 0.41 Allowed 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.155 -0.475 . . . . 73.2 110.907 179.891 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 92' ' ' ARG . . . . . 0.646 ' O ' ' HG ' ' A' ' 103' ' ' LEU . 13.3 ttm-85 -162.76 122.26 2.25 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.238 -0.437 . . . . 75.24 110.897 -179.939 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 93' ' ' VAL . . . . . 0.741 HG12 ' HB2' ' A' ' 103' ' ' LEU . 22.7 m -117.9 135.42 58.37 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.144 -0.48 . . . . 73.13 111.111 179.966 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 94' ' ' SER . . . . . 0.425 ' HA ' ' HD2' ' A' ' 95' ' ' PRO . 1.1 p -129.36 103.24 18.12 Favored Pre-proline 0 C--N 1.329 -0.285 0 CA-C-O 121.585 0.707 . . . . 65.45 110.856 -179.823 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 95' ' ' PRO . . . . . 0.425 ' HD2' ' HA ' ' A' ' 94' ' ' SER . 53.6 Cg_endo -69.76 -176.15 1.39 Allowed 'Trans proline' 0 C--O 1.231 0.142 0 C-N-CA 122.657 2.238 . . . . 74.3 112.31 -179.947 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 66.5 m-20 . . . . . 0 C--N 1.328 -0.332 0 CA-C-N 116.185 -0.461 . . . . 74.42 110.853 179.962 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 1.7 m . . . . . 0 C--O 1.233 0.203 0 CA-C-O 120.89 0.376 . . . . 74.25 110.874 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 101' ' ' CYS . . . . . 0.485 ' CB ' ' HB ' ' A' ' 93' ' ' VAL . 0.0 OUTLIER -106.0 150.02 26.1 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.128 -0.487 . . . . 65.52 110.886 -179.939 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 102' ' ' HIS . . . . . 0.526 ' HA ' ' O ' ' A' ' 65' ' ' LEU . 19.6 p-80 -160.92 123.54 3.19 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.198 -0.456 . . . . 74.11 110.89 -179.951 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 103' ' ' LEU . . . . . 0.841 HD13 ' N ' ' A' ' 104' ' ' TRP . 2.1 tm? -152.91 147.67 26.25 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.203 -0.453 . . . . 73.15 110.918 -179.964 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 104' ' ' TRP . . . . . 0.841 ' N ' HD13 ' A' ' 103' ' ' LEU . 30.9 p90 -63.99 117.52 7.15 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 116.178 -0.465 . . . . 74.21 110.891 179.951 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 105' ' ' LEU . . . . . 0.634 HD22 ' HB2' ' A' ' 88' ' ' PHE . 0.3 OUTLIER -94.12 162.92 13.68 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 116.268 -0.424 . . . . 71.44 110.928 179.989 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -88.84 159.74 29.39 Favored Glycine 0 N--CA 1.453 -0.219 0 C-N-CA 120.705 -0.76 . . . . 61.33 112.477 179.9 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 107' ' ' ARG . . . . . 0.554 ' HA ' ' CD1' ' A' ' 88' ' ' PHE . 4.3 ptp180 -66.84 157.29 33.42 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.847 0.356 . . . . 74.13 110.883 -179.882 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -173.1 111.61 0.39 Allowed Glycine 0 N--CA 1.452 -0.272 0 C-N-CA 120.717 -0.754 . . . . 42.4 112.468 -179.916 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 109' ' ' VAL . . . . . 0.448 HG23 ' HD2' ' A' ' 110' ' ' PRO . 7.2 p -86.42 133.96 39.2 Favored Pre-proline 0 C--N 1.33 -0.264 0 CA-C-O 121.567 0.698 . . . . 64.44 111.157 179.999 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 110' ' ' PRO . . . . . 0.448 ' HD2' HG23 ' A' ' 109' ' ' VAL . 53.1 Cg_endo . . . . . 0 C--O 1.232 0.175 0 C-N-CA 122.635 2.224 . . . . 72.32 112.328 179.987 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 25' ' ' THR . . . . . 0.482 ' O ' ' HA ' ' A' ' 40' ' ' ARG . 1.3 t . . . . . 0 C--O 1.231 0.121 0 CA-C-O 120.746 0.308 . . . . 70.32 111.196 . . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 20.6 p -72.86 123.46 23.44 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.258 -0.428 . . . . 63.2 110.799 -179.811 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 27' ' ' ALA . . . . . 0.783 ' HB3' HG23 ' A' ' 39' ' ' ILE . . . -146.79 162.83 37.78 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.109 -0.496 . . . . 63.11 111.079 179.882 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 28' ' ' THR . . . . . 0.505 HG22 ' O ' ' A' ' 28' ' ' THR . 14.4 m -130.69 89.6 2.79 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.164 -0.471 . . . . 75.31 111.183 -179.89 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 29' ' ' ILE . . . . . 0.856 HG21 HD21 ' A' ' 75' ' ' LEU . 2.2 pt -43.69 134.5 1.21 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.364 0 CA-C-N 116.239 -0.437 . . . . 72.52 111.167 179.936 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 30' ' ' THR . . . . . 0.593 HG23 ' O ' ' A' ' 35' ' ' SER . 26.7 m -155.29 98.24 1.97 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.183 -0.462 . . . . 72.12 111.104 179.979 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 96.8 p -134.7 70.14 1.45 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.146 -0.479 . . . . 71.43 110.859 -179.868 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -179.27 168.86 39.79 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.733 -0.746 . . . . 74.11 112.476 179.988 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 16.7 pt-20 -48.72 -24.2 1.31 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.731 0.301 . . . . 74.32 110.863 -179.799 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 29.9 tt0 -173.97 95.55 0.1 Allowed 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.14 -0.482 . . . . 64.31 110.956 -179.888 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 35' ' ' SER . . . . . 0.593 ' O ' HG23 ' A' ' 30' ' ' THR . 2.1 m -144.29 165.07 28.92 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.223 -0.444 . . . . 73.34 110.836 -179.751 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 179.59 89.43 0.08 OUTLIER Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.796 -0.716 . . . . 72.41 112.51 -179.954 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 37' ' ' ALA . . . . . 0.642 ' HB3' ' CD1' ' A' ' 29' ' ' ILE . . . -109.15 -170.71 1.71 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.83 0.348 . . . . 53.44 111.107 179.949 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 51.1 t -98.31 119.89 46.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.133 -0.485 . . . . 75.54 111.161 179.956 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 39' ' ' ILE . . . . . 0.787 HD12 HD13 ' A' ' 81' ' ' LEU . 0.0 OUTLIER -137.72 150.53 25.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.262 -0.426 . . . . 71.1 111.157 179.884 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 40' ' ' ARG . . . . . 0.482 ' HA ' ' O ' ' A' ' 25' ' ' THR . 19.2 mtt-85 -109.56 80.53 1.32 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.2 -0.455 . . . . 75.32 110.893 179.95 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 41' ' ' GLY . . . . . 0.437 ' N ' HD13 ' A' ' 39' ' ' ILE . . . -133.76 141.17 12.48 Favored Glycine 0 N--CA 1.452 -0.252 0 C-N-CA 120.77 -0.729 . . . . 42.43 112.478 -179.911 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 42' ' ' VAL . . . . . 0.445 HG23 ' OG1' ' A' ' 25' ' ' THR . 0.4 OUTLIER -124.22 139.01 51.89 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-O 120.818 0.342 . . . . 73.2 111.117 -179.935 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 43' ' ' PHE . . . . . 0.536 ' H ' HD11 ' A' ' 83' ' ' ILE . 2.4 p90 -96.15 132.21 41.79 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.199 -0.455 . . . . 54.1 110.87 179.981 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 12.9 t70 -114.6 124.29 51.49 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.141 -0.482 . . . . 52.33 110.899 179.918 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--N 1.328 -0.345 0 CA-C-O 121.624 0.726 . . . . 65.43 110.834 -179.97 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 63' ' ' PRO . . . . . 0.408 ' HG2' HD11 ' A' ' 105' ' ' LEU . 53.9 Cg_endo . . . . . 0 C--O 1.231 0.164 0 CA-C-O 120.741 0.226 . . . . 73.33 112.378 . . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 64' ' ' SER . . . . . 0.52 ' O ' ' HA ' ' A' ' 43' ' ' PHE . 0.5 OUTLIER -105.95 151.21 24.89 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.237 -0.438 . . . . 74.35 110.87 -179.854 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 65' ' ' LEU . . . . . 0.78 HD21 HD11 ' A' ' 81' ' ' LEU . 3.2 tm? -113.52 139.21 49.15 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.119 -0.491 . . . . 64.12 110.951 179.998 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 66' ' ' PHE . . . . . 0.697 ' N ' HD13 ' A' ' 65' ' ' LEU . 2.8 t80 -120.54 106.25 11.61 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.235 -0.439 . . . . 74.31 110.923 179.906 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 67' ' ' VAL . . . . . 0.477 HG22 ' N ' ' A' ' 68' ' ' ARG . 8.2 p -144.03 161.46 15.59 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 116.144 -0.48 . . . . 70.43 111.124 179.992 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 68' ' ' ARG . . . . . 0.477 ' N ' HG22 ' A' ' 67' ' ' VAL . 7.0 ttm180 -96.09 145.38 25.53 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.148 -0.478 . . . . 62.34 110.878 -179.976 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 69' ' ' THR . . . . . 0.459 ' HB ' ' HG3' ' A' ' 95' ' ' PRO . 3.0 t -40.22 -45.43 2.06 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.227 -0.442 . . . . 74.22 111.209 -179.98 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 70' ' ' ASP . . . . . 0.407 ' N ' HG23 ' A' ' 69' ' ' THR . 4.8 m-20 -65.81 -53.97 33.08 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.191 -0.459 . . . . 72.24 110.91 179.884 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 71' ' ' GLU . . . . . 0.484 ' O ' HD13 ' A' ' 75' ' ' LEU . 1.1 mp0 -53.74 -39.24 65.14 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.17 -0.468 . . . . 70.13 110.897 -179.964 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 7.2 p -82.63 -24.35 8.73 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.225 -0.443 . . . . 71.43 111.115 179.991 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 73' ' ' ARG . . . . . . . . . . . . . 51.0 ttt180 -63.97 -37.22 86.62 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.16 -0.473 . . . . 63.45 110.887 -179.989 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 15.2 mm-40 -67.62 -10.96 56.85 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.179 -0.464 . . . . 71.31 110.877 -179.95 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 75' ' ' LEU . . . . . 0.856 HD21 HG21 ' A' ' 29' ' ' ILE . 8.7 mp -103.39 -176.4 3.07 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.234 -0.439 . . . . 64.33 110.95 179.995 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 76' ' ' ARG . . . . . . . . . . . . . 16.5 ttm180 -123.64 150.0 44.71 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.231 -0.441 . . . . 61.2 110.873 -179.986 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -50.34 105.43 0.09 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.218 -0.446 . . . . 61.53 110.918 -179.9 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 113.97 16.14 8.1 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.745 -0.741 . . . . 64.55 112.441 -179.974 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 79' ' ' ASP . . . . . 0.73 ' HB3' HD23 ' A' ' 75' ' ' LEU . 0.4 OUTLIER -79.88 106.27 11.78 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-O 120.898 0.38 . . . . 73.12 110.852 -179.976 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 80' ' ' THR . . . . . 0.728 ' HA ' ' HA ' ' A' ' 89' ' ' TRP . 0.7 OUTLIER -85.46 110.24 19.03 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.226 -0.443 . . . . 21.43 111.167 -179.929 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 81' ' ' LEU . . . . . 0.787 HD13 HD12 ' A' ' 39' ' ' ILE . 0.3 OUTLIER -96.38 132.2 42.14 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.226 -0.443 . . . . 71.51 110.961 179.955 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 82' ' ' THR . . . . . 0.743 ' CA ' ' HA ' ' A' ' 87' ' ' ASN . 3.4 t -93.82 102.5 14.63 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.205 -0.452 . . . . 72.1 111.18 179.973 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 83' ' ' ILE . . . . . 0.722 ' CG2' HD12 ' A' ' 81' ' ' LEU . 0.1 OUTLIER -138.52 131.66 39.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.211 -0.45 . . . . 73.43 111.105 179.966 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 74.59 -53.17 2.39 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.741 -0.742 . . . . 65.42 112.517 179.941 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 4.1 mm-40 -117.76 -82.2 0.63 Allowed 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.834 0.35 . . . . 74.23 110.865 -179.91 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 86' ' ' GLU . . . . . 0.404 ' HB2' ' CE1' ' A' ' 88' ' ' PHE . 6.9 mp0 -149.7 160.3 43.64 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.163 -0.471 . . . . 75.34 110.92 -179.915 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 87' ' ' ASN . . . . . 0.751 ' HA ' ' C ' ' A' ' 81' ' ' LEU . 1.9 p-10 -50.91 123.81 9.95 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.193 -0.458 . . . . 73.04 110.893 -179.913 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 88' ' ' PHE . . . . . 0.779 ' HB2' HD22 ' A' ' 105' ' ' LEU . 14.9 m-85 -131.81 118.32 19.73 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.199 -0.455 . . . . 74.13 110.893 -179.955 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 89' ' ' TRP . . . . . 0.728 ' HA ' ' HA ' ' A' ' 80' ' ' THR . 62.2 p-90 -81.53 135.1 35.59 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.196 -0.456 . . . . 65.3 110.854 -179.963 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 90' ' ' VAL . . . . . 0.48 ' HA ' ' HB3' ' A' ' 105' ' ' LEU . 4.9 p -91.52 136.8 23.38 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.193 -0.458 . . . . 74.41 111.131 179.881 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -63.06 -72.3 0.14 Allowed 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.219 -0.446 . . . . 71.42 110.919 179.87 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 92' ' ' ARG . . . . . 0.597 ' O ' ' HG ' ' A' ' 103' ' ' LEU . 12.3 ttm-85 -159.17 120.66 3.35 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.185 -0.461 . . . . 72.04 110.861 -179.962 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 93' ' ' VAL . . . . . 0.645 HG12 ' HB2' ' A' ' 103' ' ' LEU . 24.4 m -111.8 133.01 58.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.188 -0.46 . . . . 73.3 111.127 179.994 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 94' ' ' SER . . . . . 0.442 ' HA ' ' HD2' ' A' ' 95' ' ' PRO . 11.5 t -125.72 100.29 31.44 Favored Pre-proline 0 C--N 1.329 -0.291 0 CA-C-O 121.692 0.758 . . . . 75.12 110.824 -179.78 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 95' ' ' PRO . . . . . 0.459 ' HG3' ' HB ' ' A' ' 69' ' ' THR . 53.9 Cg_endo -69.79 169.96 17.73 Favored 'Trans proline' 0 C--N 1.343 0.26 0 C-N-CA 122.634 2.222 . . . . 75.32 112.383 179.977 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 8.8 m-20 . . . . . 0 C--N 1.329 -0.32 0 CA-C-N 116.221 -0.445 . . . . 74.45 110.871 179.97 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 28.8 t . . . . . 0 C--O 1.232 0.135 0 CA-C-O 120.785 0.326 . . . . 74.41 110.859 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 101' ' ' CYS . . . . . 0.475 ' CB ' ' HB ' ' A' ' 93' ' ' VAL . 0.0 OUTLIER -108.47 149.77 28.34 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.126 -0.488 . . . . 75.23 110.887 -179.975 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 102' ' ' HIS . . . . . 0.656 ' HA ' ' O ' ' A' ' 65' ' ' LEU . 28.6 p-80 -158.88 125.42 4.64 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.145 -0.48 . . . . 71.44 110.862 179.968 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 103' ' ' LEU . . . . . 0.923 HD13 ' N ' ' A' ' 104' ' ' TRP . 2.8 tm? -151.92 148.02 27.28 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.199 -0.455 . . . . 53.54 110.952 -179.955 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 104' ' ' TRP . . . . . 0.923 ' N ' HD13 ' A' ' 103' ' ' LEU . 28.0 p90 -64.79 113.69 3.97 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.24 -0.436 . . . . 73.25 110.964 179.839 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 105' ' ' LEU . . . . . 0.779 HD22 ' HB2' ' A' ' 88' ' ' PHE . 0.3 OUTLIER -92.6 162.62 14.11 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.219 -0.446 . . . . 65.34 110.898 179.998 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -89.27 159.16 28.4 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.811 -0.709 . . . . 61.24 112.459 179.92 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 107' ' ' ARG . . . . . 0.539 ' HA ' ' CD1' ' A' ' 88' ' ' PHE . 0.0 OUTLIER -69.74 158.32 35.64 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.852 0.358 . . . . 53.52 110.891 -179.875 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -172.9 109.13 0.29 Allowed Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.715 -0.755 . . . . 41.12 112.442 -179.987 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 109' ' ' VAL . . . . . 0.487 HG23 ' HD2' ' A' ' 110' ' ' PRO . 7.4 p -92.31 134.34 28.45 Favored Pre-proline 0 C--N 1.329 -0.312 0 CA-C-O 121.604 0.716 . . . . 71.51 111.09 -179.951 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 110' ' ' PRO . . . . . 0.487 ' HD2' HG23 ' A' ' 109' ' ' VAL . 53.9 Cg_endo . . . . . 0 C--O 1.232 0.198 0 C-N-CA 122.678 2.252 . . . . 70.25 112.347 179.948 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 25' ' ' THR . . . . . 0.597 ' O ' ' HA ' ' A' ' 40' ' ' ARG . 46.6 p . . . . . 0 N--CA 1.457 -0.1 0 CA-C-O 120.814 0.34 . . . . 53.11 111.172 . . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -76.27 121.77 23.43 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.275 -0.42 . . . . 45.01 110.884 -179.878 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 27' ' ' ALA . . . . . 0.798 ' HB3' HG23 ' A' ' 39' ' ' ILE . . . -151.39 161.12 43.27 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.168 -0.469 . . . . 73.32 111.102 179.877 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 28' ' ' THR . . . . . 0.529 HG22 ' O ' ' A' ' 28' ' ' THR . 16.0 m -131.98 87.99 2.5 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.203 -0.453 . . . . 74.34 111.144 -179.856 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 29' ' ' ILE . . . . . 0.778 HG23 ' CB ' ' A' ' 39' ' ' ILE . 2.5 pt -43.23 128.55 1.0 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 CA-C-N 116.189 -0.46 . . . . 71.45 111.171 179.893 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 30' ' ' THR . . . . . 0.687 HG23 ' O ' ' A' ' 35' ' ' SER . 11.8 m -153.18 101.11 2.52 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.177 -0.465 . . . . 75.42 111.141 -179.998 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 85.2 p -141.09 72.56 1.39 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.217 -0.447 . . . . 73.32 110.879 -179.853 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -178.42 166.91 37.13 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.764 -0.731 . . . . 61.43 112.529 -179.981 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 8.5 pt-20 -49.14 -23.51 1.3 Allowed 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.812 0.339 . . . . 70.13 110.874 -179.915 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -174.47 93.49 0.08 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.192 -0.458 . . . . 72.52 110.971 -179.91 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 35' ' ' SER . . . . . 0.687 ' O ' HG23 ' A' ' 30' ' ' THR . 1.9 m -145.22 165.34 28.64 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.241 -0.436 . . . . 75.12 110.914 -179.823 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -179.61 86.99 0.07 OUTLIER Glycine 0 N--CA 1.452 -0.273 0 C-N-CA 120.689 -0.767 . . . . 71.05 112.491 -179.999 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 37' ' ' ALA . . . . . 0.631 ' HB3' ' CD1' ' A' ' 29' ' ' ILE . . . -106.23 -173.56 2.33 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.771 0.32 . . . . 73.43 111.184 179.933 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 65.9 t -100.02 122.87 52.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.301 -0.408 . . . . 63.4 111.139 -179.996 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 39' ' ' ILE . . . . . 0.798 HG23 ' HB3' ' A' ' 27' ' ' ALA . 0.0 OUTLIER -136.88 147.63 27.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.158 -0.473 . . . . 71.13 111.097 179.979 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 40' ' ' ARG . . . . . 0.691 ' O ' HG12 ' A' ' 67' ' ' VAL . 0.2 OUTLIER -108.8 81.78 1.51 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.166 -0.47 . . . . 72.13 110.913 179.914 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 41' ' ' GLY . . . . . 0.594 ' O ' ' HB2' ' A' ' 27' ' ' ALA . . . -143.07 141.96 11.0 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.715 -0.755 . . . . 75.2 112.503 -179.989 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 42' ' ' VAL . . . . . 0.533 HG12 HG21 ' A' ' 25' ' ' THR . 9.8 p -127.8 142.39 43.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-O 120.882 0.373 . . . . 70.31 111.102 -179.904 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 43' ' ' PHE . . . . . 0.769 ' H ' HD11 ' A' ' 83' ' ' ILE . 1.7 p90 -90.08 137.6 32.21 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.142 -0.481 . . . . 62.42 110.878 -179.969 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 9.9 t70 -123.52 125.0 44.11 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.142 -0.481 . . . . 72.14 110.777 -179.992 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 2.6 p30 . . . . . 0 C--N 1.329 -0.322 0 CA-C-O 121.618 0.723 . . . . 65.54 110.868 179.941 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo . . . . . 0 C--O 1.23 0.123 0 CA-C-O 120.823 0.26 . . . . 75.42 112.298 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 64' ' ' SER . . . . . 0.444 ' O ' ' HA ' ' A' ' 43' ' ' PHE . 8.0 t -105.6 147.04 28.88 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.21 -0.45 . . . . 63.24 110.854 -179.877 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 65' ' ' LEU . . . . . 0.94 HD11 HG13 ' A' ' 67' ' ' VAL . 0.9 OUTLIER -113.62 119.41 37.37 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.141 -0.481 . . . . 75.02 110.932 -179.986 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 66' ' ' PHE . . . . . 0.433 ' N ' HD12 ' A' ' 65' ' ' LEU . 6.4 t80 -94.63 111.28 23.05 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.242 -0.435 . . . . 73.2 110.844 179.981 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 67' ' ' VAL . . . . . 0.94 HG13 HD11 ' A' ' 65' ' ' LEU . 0.8 OUTLIER -141.38 170.49 13.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.096 -0.502 . . . . 72.32 111.197 179.961 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 10.1 ttm180 -100.74 143.86 30.39 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.24 -0.436 . . . . 60.3 110.934 -179.999 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 69' ' ' THR . . . . . 0.421 HG23 ' N ' ' A' ' 70' ' ' ASP . 4.7 t -42.9 -44.61 4.62 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.219 -0.446 . . . . 65.43 111.191 -179.901 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 70' ' ' ASP . . . . . 0.421 ' N ' HG23 ' A' ' 69' ' ' THR . 21.1 t0 -65.67 -46.32 79.56 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.233 -0.44 . . . . 71.51 110.903 179.862 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 71' ' ' GLU . . . . . . . . . . . . . 67.1 mm-40 -53.93 -39.66 66.05 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.116 -0.493 . . . . 72.42 110.928 -179.921 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 19.0 m -86.72 -25.51 6.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.103 -0.498 . . . . 72.12 111.151 179.966 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 73' ' ' ARG . . . . . . . . . . . . . 0.8 OUTLIER -60.0 -41.24 91.67 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.139 -0.482 . . . . 64.21 110.895 -179.999 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 32.3 mt-30 -62.07 -16.59 53.15 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.169 -0.469 . . . . 73.35 110.899 -179.959 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 75' ' ' LEU . . . . . 0.648 HD21 HG21 ' A' ' 29' ' ' ILE . 5.3 mp -108.89 -175.51 2.79 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.246 -0.434 . . . . 73.13 110.85 -179.921 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 76' ' ' ARG . . . . . . . . . . . . . 5.0 ptp85 -115.56 -173.83 2.41 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.135 -0.484 . . . . 71.2 110.934 179.954 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 7.0 ptp180 -79.99 131.38 35.79 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.253 -0.43 . . . . 64.0 110.89 -179.951 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 92.31 25.79 20.33 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.74 -0.743 . . . . 71.14 112.56 -179.924 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -89.24 105.33 17.72 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.911 0.386 . . . . 75.12 110.852 -179.949 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 80' ' ' THR . . . . . 0.776 ' HA ' ' HA ' ' A' ' 89' ' ' TRP . 0.8 OUTLIER -87.28 110.57 20.29 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.196 -0.456 . . . . 41.34 111.101 -179.89 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 81' ' ' LEU . . . . . 0.777 HD13 HD12 ' A' ' 39' ' ' ILE . 0.3 OUTLIER -95.41 131.91 41.04 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.153 -0.476 . . . . 75.23 110.897 179.935 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 82' ' ' THR . . . . . 0.741 ' CA ' ' HA ' ' A' ' 87' ' ' ASN . 5.0 t -94.01 102.03 14.1 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.18 -0.464 . . . . 74.12 111.133 179.932 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 83' ' ' ILE . . . . . 0.769 HD11 ' H ' ' A' ' 43' ' ' PHE . 0.1 OUTLIER -132.46 130.26 59.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.184 -0.462 . . . . 73.42 111.116 179.92 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 68.19 -62.73 0.39 Allowed Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.707 -0.758 . . . . 73.24 112.508 179.911 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 85' ' ' GLU . . . . . 0.404 ' N ' ' O ' ' A' ' 83' ' ' ILE . 29.2 mm-40 -98.66 -83.7 0.41 Allowed 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.766 0.317 . . . . 65.44 110.949 -179.924 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 86' ' ' GLU . . . . . 0.414 ' C ' ' HA ' ' A' ' 82' ' ' THR . 70.1 mt-10 -154.22 160.97 42.09 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.129 -0.487 . . . . 52.15 110.844 -179.96 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 87' ' ' ASN . . . . . 0.747 ' HA ' ' C ' ' A' ' 81' ' ' LEU . 0.8 OUTLIER -50.55 123.73 9.37 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.156 -0.475 . . . . 73.35 110.871 -179.89 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 88' ' ' PHE . . . . . 0.784 ' HB2' HD22 ' A' ' 105' ' ' LEU . 15.1 m-85 -131.51 119.48 21.6 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.239 -0.437 . . . . 73.14 110.889 -179.974 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 89' ' ' TRP . . . . . 0.776 ' HA ' ' HA ' ' A' ' 80' ' ' THR . 4.6 p90 -80.12 138.05 36.85 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.166 -0.47 . . . . 72.15 110.856 -179.915 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 90' ' ' VAL . . . . . 0.552 HG23 HD12 ' A' ' 103' ' ' LEU . 2.2 p -94.59 135.84 27.6 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 116.156 -0.474 . . . . 63.13 111.129 179.942 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -65.28 -75.25 0.09 Allowed 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.173 -0.467 . . . . 72.12 110.879 179.892 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 92' ' ' ARG . . . . . 0.587 ' O ' ' HG ' ' A' ' 103' ' ' LEU . 0.0 OUTLIER -153.23 117.45 4.87 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.166 -0.47 . . . . 75.13 110.818 -179.944 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 93' ' ' VAL . . . . . 0.491 ' CG2' ' N ' ' A' ' 102' ' ' HIS . 0.3 OUTLIER -111.45 139.82 33.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.171 -0.468 . . . . 72.44 111.173 179.906 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 1.4 p -140.78 103.94 6.32 Favored Pre-proline 0 C--N 1.329 -0.293 0 CA-C-O 121.713 0.768 . . . . 53.11 110.857 -179.807 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 95' ' ' PRO . . . . . 0.418 ' HG3' ' HB ' ' A' ' 69' ' ' THR . 54.4 Cg_endo -69.68 173.61 10.65 Favored 'Trans proline' 0 C--N 1.342 0.199 0 C-N-CA 122.729 2.286 . . . . 75.32 112.365 179.908 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 21.2 m-20 . . . . . 0 C--N 1.328 -0.337 0 CA-C-N 116.197 -0.456 . . . . 74.02 110.854 179.95 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 1.5 m . . . . . 0 C--O 1.232 0.176 0 CA-C-O 120.775 0.321 . . . . 74.53 110.831 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 101' ' ' CYS . . . . . 0.433 ' HB3' HG22 ' A' ' 93' ' ' VAL . 0.0 OUTLIER -122.95 154.43 38.39 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.212 -0.449 . . . . 75.22 110.839 -179.954 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 102' ' ' HIS . . . . . 0.491 ' N ' ' CG2' ' A' ' 93' ' ' VAL . 13.5 p80 -156.94 123.34 4.96 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.161 -0.472 . . . . 74.23 110.853 -179.972 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 103' ' ' LEU . . . . . 0.814 HD13 ' N ' ' A' ' 104' ' ' TRP . 3.4 tm? -148.25 144.57 27.74 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.211 -0.45 . . . . 75.32 110.856 -179.916 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 104' ' ' TRP . . . . . 0.814 ' N ' HD13 ' A' ' 103' ' ' LEU . 4.2 m-90 -69.29 108.54 3.72 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.225 -0.443 . . . . 62.33 110.924 179.831 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 105' ' ' LEU . . . . . 0.784 HD22 ' HB2' ' A' ' 88' ' ' PHE . 0.3 OUTLIER -89.6 161.8 15.97 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.266 -0.424 . . . . 73.1 110.985 179.945 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -89.69 159.92 28.5 Favored Glycine 0 N--CA 1.45 -0.379 0 C-N-CA 120.713 -0.756 . . . . 53.21 112.537 179.891 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 107' ' ' ARG . . . . . 0.585 ' HA ' ' CD1' ' A' ' 88' ' ' PHE . 0.1 OUTLIER -68.94 157.55 36.46 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.88 0.372 . . . . 73.34 110.832 -179.807 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -172.05 112.38 0.44 Allowed Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.78 -0.724 . . . . 73.55 112.538 -179.998 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 109' ' ' VAL . . . . . 0.454 HG23 ' HD2' ' A' ' 110' ' ' PRO . 7.3 p -85.56 133.78 41.35 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-O 121.599 0.714 . . . . 71.52 111.176 -179.975 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 110' ' ' PRO . . . . . 0.454 ' HD2' HG23 ' A' ' 109' ' ' VAL . 54.8 Cg_endo . . . . . 0 C--O 1.233 0.232 0 C-N-CA 122.693 2.262 . . . . 72.55 112.394 179.9 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 25' ' ' THR . . . . . 0.547 ' O ' ' HA ' ' A' ' 40' ' ' ARG . 0.0 OUTLIER . . . . . 0 N--CA 1.458 -0.072 0 CA-C-O 120.867 0.365 . . . . 73.12 111.09 . . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -75.09 123.33 25.03 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.112 -0.495 . . . . 70.21 110.838 -179.856 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 27' ' ' ALA . . . . . 0.832 ' HB3' HG23 ' A' ' 39' ' ' ILE . . . -145.13 163.21 35.02 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.15 -0.477 . . . . 53.12 111.056 179.894 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 28' ' ' THR . . . . . 0.501 HG22 ' O ' ' A' ' 28' ' ' THR . 19.1 m -130.46 87.2 2.47 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.173 -0.467 . . . . 62.05 111.164 -179.874 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 29' ' ' ILE . . . . . 0.744 HG23 ' CB ' ' A' ' 39' ' ' ILE . 2.2 pt -44.27 132.15 1.55 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.213 -0.448 . . . . 71.21 111.161 179.926 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 30' ' ' THR . . . . . 0.636 HG23 ' O ' ' A' ' 35' ' ' SER . 23.4 m -153.89 101.17 2.42 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.183 -0.462 . . . . 64.14 111.176 179.983 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 1.8 t -137.12 71.04 1.4 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.265 -0.425 . . . . 71.21 110.843 -179.856 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -179.4 168.1 38.51 Favored Glycine 0 N--CA 1.45 -0.422 0 C-N-CA 120.72 -0.752 . . . . 54.23 112.458 -179.968 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 6.7 pt-20 -49.24 -23.4 1.33 Allowed 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.793 0.33 . . . . 74.45 110.894 -179.896 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 3.5 tt0 -174.69 94.93 0.08 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.12 -0.491 . . . . 65.31 110.971 -179.97 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 35' ' ' SER . . . . . 0.636 ' O ' HG23 ' A' ' 30' ' ' THR . 0.1 OUTLIER -145.11 165.33 28.59 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.232 -0.44 . . . . 52.14 110.801 -179.789 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -179.22 88.86 0.07 OUTLIER Glycine 0 N--CA 1.452 -0.254 0 C-N-CA 120.723 -0.751 . . . . 44.24 112.449 179.995 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 37' ' ' ALA . . . . . 0.649 ' HB3' ' CD1' ' A' ' 29' ' ' ILE . . . -106.26 -172.45 2.09 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.798 0.332 . . . . 54.33 111.116 179.942 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 23.5 t -99.66 120.01 48.47 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.232 -0.44 . . . . 71.23 111.117 179.998 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 39' ' ' ILE . . . . . 0.832 HG23 ' HB3' ' A' ' 27' ' ' ALA . 0.0 OUTLIER -137.28 151.03 26.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.227 -0.442 . . . . 73.03 111.177 179.918 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 40' ' ' ARG . . . . . 0.598 ' O ' HG12 ' A' ' 67' ' ' VAL . 28.0 mmt180 -112.87 82.03 1.59 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.193 -0.458 . . . . 72.2 110.845 179.988 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 41' ' ' GLY . . . . . 0.51 ' HA3' HD21 ' A' ' 65' ' ' LEU . . . -140.18 138.21 8.92 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.794 -0.717 . . . . 72.01 112.451 -179.966 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 42' ' ' VAL . . . . . 0.517 HG12 HG21 ' A' ' 25' ' ' THR . 1.7 p -123.59 137.81 55.53 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-O 120.817 0.341 . . . . 64.42 111.17 179.943 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 43' ' ' PHE . . . . . 0.58 ' H ' HD11 ' A' ' 83' ' ' ILE . 2.1 p90 -93.22 137.82 32.19 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.198 -0.455 . . . . 74.51 110.88 -179.91 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 3.4 t70 -117.96 125.43 50.41 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.147 -0.479 . . . . 64.31 110.853 179.986 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 1.2 p30 . . . . . 0 C--N 1.329 -0.323 0 CA-C-O 121.548 0.69 . . . . 71.54 110.913 179.951 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo . . . . . 0 N--CA 1.465 -0.149 0 CA-C-O 120.776 0.24 . . . . 72.1 112.326 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 1.3 t -111.29 138.29 47.94 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.211 -0.45 . . . . 75.21 110.834 -179.863 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 65' ' ' LEU . . . . . 0.781 HD11 HG13 ' A' ' 67' ' ' VAL . 1.7 tm? -117.1 135.67 53.57 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.19 -0.459 . . . . 74.21 110.962 -179.974 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 66' ' ' PHE . . . . . 0.664 ' N ' HD22 ' A' ' 65' ' ' LEU . 35.7 t80 -117.94 110.28 17.53 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.244 -0.435 . . . . 74.24 110.87 179.966 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 67' ' ' VAL . . . . . 0.781 HG13 HD11 ' A' ' 65' ' ' LEU . 24.1 m -140.13 168.12 17.85 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.092 -0.504 . . . . 71.15 111.11 179.993 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 68' ' ' ARG . . . . . 0.436 ' HG2' ' H ' ' A' ' 71' ' ' GLU . 1.5 ptm180 -102.83 146.18 28.66 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.191 -0.459 . . . . 73.23 110.859 179.982 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 69' ' ' THR . . . . . 0.432 ' HB ' ' HG3' ' A' ' 95' ' ' PRO . 0.2 OUTLIER -37.75 -60.96 0.67 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.153 -0.476 . . . . 73.4 111.139 -179.895 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 3.4 m-20 -46.11 -43.92 15.24 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.198 -0.455 . . . . 70.1 110.887 179.886 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 71' ' ' GLU . . . . . 0.436 ' H ' ' HG2' ' A' ' 68' ' ' ARG . 8.7 tp10 -59.77 -42.81 94.15 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.198 -0.456 . . . . 72.5 110.858 -179.873 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 72' ' ' VAL . . . . . 0.503 HG22 ' O ' ' A' ' 72' ' ' VAL . 14.3 p -87.27 -3.86 9.38 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.172 -0.467 . . . . 73.11 111.106 -179.978 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 73' ' ' ARG . . . . . . . . . . . . . 57.6 ttt180 -85.27 -41.93 15.11 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.165 -0.47 . . . . 70.22 110.884 -179.965 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 71.8 mt-30 -53.26 -25.25 13.74 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.188 -0.46 . . . . 71.55 110.907 -179.944 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 75' ' ' LEU . . . . . 0.74 HD21 ' CD1' ' A' ' 29' ' ' ILE . 3.9 mp -107.74 -169.63 1.56 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.204 -0.453 . . . . 72.53 110.956 179.963 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 76' ' ' ARG . . . . . . . . . . . . . 8.5 ttp180 -116.6 136.84 52.64 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.212 -0.449 . . . . 72.14 110.85 179.978 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -47.34 102.01 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.211 -0.45 . . . . 72.15 110.884 -179.899 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 133.19 25.73 0.64 Allowed Glycine 0 N--CA 1.453 -0.231 0 C-N-CA 120.701 -0.762 . . . . 74.33 112.427 -179.967 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 79' ' ' ASP . . . . . 0.724 ' OD2' HD22 ' A' ' 75' ' ' LEU . 5.4 p-10 -114.13 119.84 38.48 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.871 0.367 . . . . 55.42 110.91 179.963 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 80' ' ' THR . . . . . 0.831 HG22 ' HB3' ' A' ' 89' ' ' TRP . 13.6 p -83.11 123.05 29.14 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.195 -0.457 . . . . 71.22 111.123 -179.825 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 81' ' ' LEU . . . . . 0.794 ' C ' ' HA ' ' A' ' 87' ' ' ASN . 0.2 OUTLIER -94.37 124.47 38.42 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.243 -0.435 . . . . 61.22 110.921 179.956 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 82' ' ' THR . . . . . 0.802 ' N ' ' HA ' ' A' ' 87' ' ' ASN . 3.5 t -91.47 104.42 16.93 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.214 -0.448 . . . . 74.44 111.164 179.947 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 83' ' ' ILE . . . . . 0.725 HD13 ' O ' ' A' ' 83' ' ' ILE . 0.1 OUTLIER -141.17 126.45 18.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.177 -0.465 . . . . 72.25 111.062 179.97 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 74.36 -52.74 2.27 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.692 -0.766 . . . . 65.0 112.495 179.908 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 8.1 tp10 -112.91 -82.73 0.59 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.809 0.338 . . . . 74.13 110.903 -179.896 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 86' ' ' GLU . . . . . 0.468 ' C ' ' HA ' ' A' ' 82' ' ' THR . 86.9 mt-10 -152.17 160.86 43.31 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.171 -0.468 . . . . 74.14 110.884 -179.937 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 87' ' ' ASN . . . . . 0.802 ' HA ' ' N ' ' A' ' 82' ' ' THR . 9.2 p30 -51.32 121.66 6.6 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.168 -0.469 . . . . 64.33 110.938 -179.949 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 88' ' ' PHE . . . . . 0.661 ' HB2' HD22 ' A' ' 105' ' ' LEU . 15.9 m-85 -132.16 121.36 23.61 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.172 -0.467 . . . . 74.14 110.938 -179.958 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 89' ' ' TRP . . . . . 0.831 ' HB3' HG22 ' A' ' 80' ' ' THR . 3.7 t-105 -81.38 130.53 35.07 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.14 -0.482 . . . . 70.12 110.906 -179.923 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 90' ' ' VAL . . . . . 0.505 ' O ' ' CH2' ' A' ' 89' ' ' TRP . 6.1 p -80.93 114.58 22.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.215 -0.448 . . . . 72.21 111.172 179.912 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -41.9 -65.21 0.48 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.208 -0.451 . . . . 52.51 110.945 179.953 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 92' ' ' ARG . . . . . 0.488 ' O ' ' HG ' ' A' ' 103' ' ' LEU . 69.5 ttt180 -160.15 125.65 4.03 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.197 -0.456 . . . . 71.31 110.902 -179.967 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 93' ' ' VAL . . . . . 0.507 HG12 ' N ' ' A' ' 102' ' ' HIS . 0.0 OUTLIER -115.49 111.55 36.12 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 116.203 -0.453 . . . . 75.23 111.135 179.954 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 94' ' ' SER . . . . . 0.451 ' C ' ' HB3' ' A' ' 101' ' ' CYS . 4.4 p -105.8 106.16 55.61 Favored Pre-proline 0 C--N 1.33 -0.255 0 CA-C-O 121.666 0.746 . . . . 73.12 110.833 -179.78 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 95' ' ' PRO . . . . . 0.432 ' HG3' ' HB ' ' A' ' 69' ' ' THR . 53.3 Cg_endo -69.83 159.19 54.28 Favored 'Trans proline' 0 C--N 1.341 0.18 0 C-N-CA 122.633 2.222 . . . . 65.2 112.363 179.984 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 4.5 m-20 . . . . . 0 C--N 1.329 -0.32 0 CA-C-N 116.23 -0.441 . . . . 64.51 110.884 179.982 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 2.0 p . . . . . 0 C--O 1.233 0.194 0 CA-C-O 120.831 0.348 . . . . 70.41 110.861 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 101' ' ' CYS . . . . . 0.451 ' HB3' ' C ' ' A' ' 94' ' ' SER . 0.3 OUTLIER -129.21 167.47 17.6 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.168 -0.469 . . . . 73.24 110.898 -179.95 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 102' ' ' HIS . . . . . 0.507 ' N ' HG12 ' A' ' 93' ' ' VAL . 37.0 p-80 -167.41 128.28 1.5 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.137 -0.483 . . . . 74.0 110.842 -179.928 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 103' ' ' LEU . . . . . 0.824 HD13 ' N ' ' A' ' 104' ' ' TRP . 2.5 tm? -150.19 147.17 27.38 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.181 -0.463 . . . . 71.14 110.938 -179.928 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 104' ' ' TRP . . . . . 0.824 ' N ' HD13 ' A' ' 103' ' ' LEU . 29.7 p90 -63.92 118.25 8.15 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.261 -0.427 . . . . 71.31 110.95 179.893 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 105' ' ' LEU . . . . . 0.661 HD22 ' HB2' ' A' ' 88' ' ' PHE . 0.2 OUTLIER -88.45 163.58 15.89 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 116.245 -0.434 . . . . 72.2 110.924 -179.998 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -88.15 160.26 30.66 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.751 -0.737 . . . . 74.42 112.523 179.919 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 107' ' ' ARG . . . . . 0.486 ' HA ' ' CD1' ' A' ' 88' ' ' PHE . 0.7 OUTLIER -66.17 157.5 31.14 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.864 0.364 . . . . 74.42 110.923 -179.941 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -176.58 108.16 0.25 Allowed Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.733 -0.746 . . . . 74.24 112.425 179.984 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 109' ' ' VAL . . . . . 0.416 HG23 ' HD2' ' A' ' 110' ' ' PRO . 10.8 p -100.06 133.6 21.46 Favored Pre-proline 0 C--N 1.329 -0.296 0 CA-C-O 121.543 0.687 . . . . 53.25 111.091 -179.938 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 110' ' ' PRO . . . . . 0.416 ' HD2' HG23 ' A' ' 109' ' ' VAL . 54.0 Cg_endo . . . . . 0 C--O 1.23 0.123 0 C-N-CA 122.652 2.235 . . . . 75.31 112.319 179.934 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 25' ' ' THR . . . . . 0.496 HG21 HG23 ' A' ' 42' ' ' VAL . 8.4 m . . . . . 0 N--CA 1.457 -0.107 0 CA-C-O 120.742 0.306 . . . . 71.21 111.192 . . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -72.5 122.08 20.71 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.207 -0.451 . . . . 50.25 110.866 -179.855 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 27' ' ' ALA . . . . . 0.823 ' HB3' HG23 ' A' ' 39' ' ' ILE . . . -142.05 162.29 35.86 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.047 -0.524 . . . . 42.21 111.119 179.89 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 28' ' ' THR . . . . . 0.505 HG22 ' O ' ' A' ' 28' ' ' THR . 16.9 m -129.23 88.65 2.73 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.242 -0.436 . . . . 74.44 111.184 -179.883 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 29' ' ' ILE . . . . . 0.764 HG23 ' CB ' ' A' ' 39' ' ' ILE . 1.8 pt -44.64 130.99 1.7 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.218 -0.446 . . . . 74.45 111.135 179.917 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 30' ' ' THR . . . . . 0.695 HG23 ' O ' ' A' ' 35' ' ' SER . 7.3 m -153.73 97.98 2.16 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.167 -0.47 . . . . 71.12 111.15 179.934 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 87.1 p -137.76 70.92 1.39 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.229 -0.441 . . . . 63.2 110.921 -179.858 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -178.61 167.52 38.01 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.779 -0.724 . . . . 55.2 112.511 -179.924 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 3.6 pt-20 -49.45 -23.01 1.34 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.798 0.332 . . . . 71.22 110.851 -179.935 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -174.6 94.22 0.08 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.228 -0.442 . . . . 75.22 110.919 -179.913 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 35' ' ' SER . . . . . 0.695 ' O ' HG23 ' A' ' 30' ' ' THR . 3.1 m -144.71 165.77 27.12 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.161 -0.472 . . . . 72.51 110.821 -179.81 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 178.6 87.6 0.07 OUTLIER Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.78 -0.724 . . . . 75.41 112.497 -179.975 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 37' ' ' ALA . . . . . 0.676 ' HB3' ' CD1' ' A' ' 29' ' ' ILE . . . -109.03 -172.49 2.06 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.904 0.383 . . . . 74.42 111.078 179.983 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 4.0 p -97.97 123.04 50.22 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.209 -0.451 . . . . 72.34 111.12 179.969 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 39' ' ' ILE . . . . . 0.823 HG23 ' HB3' ' A' ' 27' ' ' ALA . 0.0 OUTLIER -138.53 149.9 24.1 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.137 -0.483 . . . . 65.31 111.165 179.906 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 40' ' ' ARG . . . . . 0.548 ' O ' HG12 ' A' ' 67' ' ' VAL . 6.6 mtm-85 -109.1 80.05 1.28 Allowed 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.159 -0.473 . . . . 72.43 110.879 -179.962 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 41' ' ' GLY . . . . . 0.52 ' HA2' HG12 ' A' ' 67' ' ' VAL . . . -128.38 148.78 18.03 Favored Glycine 0 N--CA 1.45 -0.374 0 C-N-CA 120.814 -0.708 . . . . 70.23 112.577 -179.937 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 42' ' ' VAL . . . . . 0.573 HG12 ' CB ' ' A' ' 66' ' ' PHE . 3.4 p -127.53 138.79 53.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-O 120.837 0.351 . . . . 72.44 111.148 -179.986 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 43' ' ' PHE . . . . . 0.613 ' H ' HD11 ' A' ' 83' ' ' ILE . 2.5 p90 -98.36 128.76 44.92 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.175 -0.466 . . . . 61.14 110.887 -179.966 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -107.75 124.0 49.38 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.12 -0.491 . . . . 74.43 110.812 180.0 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 C--N 1.329 -0.315 0 CA-C-O 121.61 0.719 . . . . 61.42 110.854 179.976 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo . . . . . 0 C--O 1.231 0.15 0 CA-C-O 120.81 0.254 . . . . 73.12 112.359 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 64' ' ' SER . . . . . 0.516 ' O ' ' HA ' ' A' ' 43' ' ' PHE . 0.1 OUTLIER -106.54 148.39 28.29 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.203 -0.453 . . . . 65.13 110.865 -179.832 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 65' ' ' LEU . . . . . 0.558 HD11 ' CG1' ' A' ' 67' ' ' VAL . 2.8 tm? -114.55 129.29 56.65 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.134 -0.484 . . . . 75.01 110.924 -179.96 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 66' ' ' PHE . . . . . 0.573 ' CB ' HG12 ' A' ' 42' ' ' VAL . 1.7 t80 -119.03 105.68 11.67 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.257 -0.428 . . . . 74.21 110.889 179.937 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 67' ' ' VAL . . . . . 0.558 ' CG1' HD11 ' A' ' 65' ' ' LEU . 33.7 m -141.04 172.51 10.85 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-N 116.148 -0.478 . . . . 74.04 111.126 -179.968 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 68' ' ' ARG . . . . . 0.447 ' HG2' ' H ' ' A' ' 71' ' ' GLU . 1.1 ptp180 -109.23 144.47 37.3 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.194 -0.457 . . . . 64.4 110.849 -179.986 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 69' ' ' THR . . . . . 0.651 ' HA ' HG12 ' A' ' 72' ' ' VAL . 0.0 OUTLIER -38.01 -56.88 1.1 Allowed 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.202 -0.454 . . . . 73.14 111.189 -179.927 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 70' ' ' ASP . . . . . 0.46 ' H ' HG23 ' A' ' 69' ' ' THR . 7.8 t70 -44.28 -59.43 2.38 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.155 -0.475 . . . . 70.21 110.865 179.908 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 71' ' ' GLU . . . . . 0.447 ' H ' ' HG2' ' A' ' 68' ' ' ARG . 1.2 tm-20 -59.35 -42.1 90.74 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.217 -0.447 . . . . 74.22 110.92 -179.966 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 72' ' ' VAL . . . . . 0.651 HG12 ' HA ' ' A' ' 69' ' ' THR . 0.3 OUTLIER -82.98 4.42 2.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.117 -0.492 . . . . 74.13 111.073 -179.948 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 73' ' ' ARG . . . . . 0.521 ' N ' ' O ' ' A' ' 69' ' ' THR . 16.1 ttt180 -98.31 -37.98 9.44 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.168 -0.469 . . . . 75.14 110.86 -179.993 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 48.7 mt-30 -65.67 -12.36 52.85 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.252 -0.431 . . . . 74.4 110.956 -179.978 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 75' ' ' LEU . . . . . 0.651 HD21 HG21 ' A' ' 29' ' ' ILE . 3.1 mp -107.99 -174.46 2.53 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.157 -0.474 . . . . 70.11 110.877 -179.964 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 76' ' ' ARG . . . . . . . . . . . . . 10.5 ptp180 -117.91 154.37 32.02 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.164 -0.471 . . . . 75.34 110.941 179.965 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 3.7 ptt180 -51.21 131.91 28.15 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.24 -0.436 . . . . 70.03 110.87 -179.909 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 86.77 42.97 6.21 Favored Glycine 0 N--CA 1.452 -0.24 0 C-N-CA 120.735 -0.745 . . . . 60.23 112.397 179.944 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -103.43 110.74 22.88 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.909 0.385 . . . . 74.01 110.85 -179.963 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 80' ' ' THR . . . . . 0.733 ' HA ' ' HA ' ' A' ' 89' ' ' TRP . 0.0 OUTLIER -88.62 108.59 19.52 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.119 -0.491 . . . . 62.12 111.209 -179.886 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 81' ' ' LEU . . . . . 0.787 ' C ' ' HA ' ' A' ' 87' ' ' ASN . 0.0 OUTLIER -98.18 135.24 40.12 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.272 -0.422 . . . . 71.21 110.928 -179.986 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 82' ' ' THR . . . . . 0.7 ' N ' ' HA ' ' A' ' 87' ' ' ASN . 8.0 t -93.63 101.59 13.75 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.204 -0.453 . . . . 63.4 111.145 179.968 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 83' ' ' ILE . . . . . 0.714 HD13 ' O ' ' A' ' 83' ' ' ILE . 0.1 OUTLIER -136.18 131.11 48.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.22 -0.446 . . . . 75.01 111.184 179.861 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 73.0 -54.59 1.78 Allowed Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.785 -0.722 . . . . 64.14 112.507 179.936 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 10.7 mm-40 -113.55 -80.65 0.59 Allowed 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 120.86 0.362 . . . . 64.4 110.875 -179.922 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 86' ' ' GLU . . . . . 0.46 ' C ' ' HA ' ' A' ' 82' ' ' THR . 96.1 mt-10 -154.54 161.06 41.82 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 116.159 -0.473 . . . . 64.42 110.823 -179.939 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 87' ' ' ASN . . . . . 0.787 ' HA ' ' C ' ' A' ' 81' ' ' LEU . 1.6 p-10 -50.7 121.98 6.63 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.156 -0.474 . . . . 74.5 110.921 -179.957 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 88' ' ' PHE . . . . . 0.747 ' CB ' HD13 ' A' ' 105' ' ' LEU . 14.7 m-85 -131.08 120.86 24.02 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.155 -0.475 . . . . 75.14 110.903 -179.972 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 89' ' ' TRP . . . . . 0.733 ' HA ' ' HA ' ' A' ' 80' ' ' THR . 0.9 OUTLIER -80.11 135.77 36.39 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.12 -0.491 . . . . 64.12 110.913 -179.951 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 90' ' ' VAL . . . . . 0.464 ' HA ' ' HB3' ' A' ' 105' ' ' LEU . 0.3 OUTLIER -92.58 138.23 20.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.264 -0.426 . . . . 71.01 111.101 179.925 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -65.61 -71.19 0.2 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.186 -0.461 . . . . 75.21 110.85 179.935 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 92' ' ' ARG . . . . . 0.526 ' O ' ' HG ' ' A' ' 103' ' ' LEU . 0.0 OUTLIER -152.58 120.89 6.3 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.251 -0.432 . . . . 74.24 110.838 -179.882 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 93' ' ' VAL . . . . . 0.617 HG12 ' CB ' ' A' ' 103' ' ' LEU . 8.8 m -121.45 137.28 55.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.254 -0.43 . . . . 65.14 111.121 179.928 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 12.6 t -137.14 128.4 16.44 Favored Pre-proline 0 C--N 1.328 -0.337 0 CA-C-O 121.714 0.769 . . . . 73.01 110.862 -179.856 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 95' ' ' PRO . . . . . 0.479 ' HG3' ' HB ' ' A' ' 69' ' ' THR . 53.2 Cg_endo -69.85 160.51 49.42 Favored 'Trans proline' 0 C--N 1.342 0.198 0 C-N-CA 122.681 2.254 . . . . 71.31 112.322 -179.946 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 9.4 t0 . . . . . 0 C--N 1.329 -0.307 0 CA-C-N 116.256 -0.429 . . . . 74.34 110.844 179.945 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 20.1 t . . . . . 0 C--O 1.232 0.153 0 CA-C-O 120.91 0.386 . . . . 75.14 110.842 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 101' ' ' CYS . . . . . 0.571 ' HB2' ' HB ' ' A' ' 93' ' ' VAL . 19.6 p -47.23 142.31 3.98 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.16 -0.473 . . . . 73.45 110.882 -179.98 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 102' ' ' HIS . . . . . 0.437 ' HA ' ' O ' ' A' ' 65' ' ' LEU . 43.4 p-80 -159.97 129.38 5.2 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.241 -0.436 . . . . 75.43 110.836 -179.934 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 103' ' ' LEU . . . . . 0.874 HD13 ' N ' ' A' ' 104' ' ' TRP . 2.8 tm? -150.8 148.4 28.45 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 116.239 -0.437 . . . . 72.24 110.943 -179.998 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 104' ' ' TRP . . . . . 0.874 ' N ' HD13 ' A' ' 103' ' ' LEU . 56.3 p-90 -64.34 118.02 8.08 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.174 -0.466 . . . . 64.3 110.855 179.946 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 105' ' ' LEU . . . . . 0.747 HD13 ' CB ' ' A' ' 88' ' ' PHE . 0.4 OUTLIER -93.92 162.8 13.76 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.266 -0.425 . . . . 71.42 110.866 179.978 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -91.0 160.39 27.26 Favored Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.712 -0.756 . . . . 65.44 112.498 179.892 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 107' ' ' ARG . . . . . 0.544 ' HA ' ' CD1' ' A' ' 88' ' ' PHE . 0.0 OUTLIER -65.73 157.39 30.31 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.856 0.36 . . . . 74.43 110.925 -179.895 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -173.1 110.18 0.33 Allowed Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.644 -0.789 . . . . 32.31 112.454 179.984 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 109' ' ' VAL . . . . . 0.453 HG23 ' HD2' ' A' ' 110' ' ' PRO . 7.1 p -84.19 133.89 44.38 Favored Pre-proline 0 C--N 1.33 -0.28 0 CA-C-O 121.687 0.756 . . . . 74.1 111.084 -179.93 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 110' ' ' PRO . . . . . 0.453 ' HD2' HG23 ' A' ' 109' ' ' VAL . 53.8 Cg_endo . . . . . 0 C--N 1.342 0.222 0 C-N-CA 122.644 2.229 . . . . 61.33 112.328 179.928 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 25' ' ' THR . . . . . 0.821 ' HB ' HG22 ' A' ' 42' ' ' VAL . 98.6 m . . . . . 0 C--O 1.231 0.081 0 CA-C-O 120.804 0.335 . . . . 65.13 111.107 . . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 3.0 p -70.81 123.5 22.11 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.173 -0.467 . . . . 75.4 110.823 -179.844 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 27' ' ' ALA . . . . . 0.84 ' HB3' HG23 ' A' ' 39' ' ' ILE . . . -135.24 162.42 32.61 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.074 -0.512 . . . . 63.51 111.104 179.884 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 28' ' ' THR . . . . . 0.503 HG22 ' O ' ' A' ' 28' ' ' THR . 21.7 m -129.33 85.8 2.36 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.216 -0.447 . . . . 73.22 111.09 -179.902 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 29' ' ' ILE . . . . . 0.682 HG23 HG21 ' A' ' 39' ' ' ILE . 1.9 pt -44.92 126.93 1.3 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.182 -0.463 . . . . 73.44 111.137 179.884 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 30' ' ' THR . . . . . 0.669 HG23 ' O ' ' A' ' 35' ' ' SER . 17.6 m -151.93 97.87 2.39 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.119 -0.491 . . . . 74.42 111.143 -179.983 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 31' ' ' SER . . . . . 0.517 ' OG ' HG22 ' A' ' 80' ' ' THR . 5.1 t -136.5 70.53 1.41 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.161 -0.472 . . . . 73.54 110.913 -179.853 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -178.88 168.8 39.92 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.771 -0.728 . . . . 74.42 112.536 -179.93 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 5.8 pt-20 -49.31 -23.25 1.33 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.809 0.338 . . . . 64.03 110.9 -179.906 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -174.76 95.29 0.08 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.204 -0.453 . . . . 53.23 110.913 -179.908 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 35' ' ' SER . . . . . 0.669 ' O ' HG23 ' A' ' 30' ' ' THR . 2.3 m -145.24 165.41 28.46 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.148 -0.478 . . . . 72.15 110.84 -179.794 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 176.36 88.42 0.07 OUTLIER Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 120.756 -0.735 . . . . 44.13 112.515 -179.988 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 37' ' ' ALA . . . . . 0.667 ' HB3' ' CD1' ' A' ' 29' ' ' ILE . . . -108.11 -170.53 1.7 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.809 0.337 . . . . 73.35 111.161 179.994 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 38' ' ' VAL . . . . . 0.413 ' O ' HG13 ' A' ' 38' ' ' VAL . 4.4 p -99.03 119.64 47.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.293 -0.412 . . . . 41.14 111.112 179.983 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 39' ' ' ILE . . . . . 0.84 HG23 ' HB3' ' A' ' 27' ' ' ALA . 0.0 OUTLIER -139.1 151.56 23.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.059 -0.518 . . . . 73.33 111.096 179.938 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 40' ' ' ARG . . . . . . . . . . . . . 1.4 ptp85 -113.59 82.86 1.75 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.191 -0.459 . . . . 75.04 110.879 179.964 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 41' ' ' GLY . . . . . 0.434 ' N ' HD13 ' A' ' 39' ' ' ILE . . . -111.92 146.46 18.0 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.723 -0.751 . . . . 61.44 112.436 -179.923 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 42' ' ' VAL . . . . . 0.821 HG22 ' HB ' ' A' ' 25' ' ' THR . 2.2 t -124.58 112.57 32.68 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-O 120.882 0.372 . . . . 72.41 111.08 -179.937 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 43' ' ' PHE . . . . . 0.526 ' HA ' ' O ' ' A' ' 64' ' ' SER . 2.4 p90 -87.29 131.38 34.26 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.141 -0.481 . . . . 74.12 110.89 -179.976 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 2.8 t70 -129.78 125.34 35.56 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.129 -0.487 . . . . 74.12 110.811 -179.965 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 2.5 p-10 . . . . . 0 C--N 1.33 -0.276 0 CA-C-O 121.567 0.698 . . . . 64.14 110.862 -179.928 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo . . . . . 0 C--O 1.231 0.17 0 CA-C-O 120.753 0.23 . . . . 45.22 112.37 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 64' ' ' SER . . . . . 0.526 ' O ' ' HA ' ' A' ' 43' ' ' PHE . 1.3 t -106.19 142.51 35.77 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.259 -0.428 . . . . 71.12 110.906 -179.816 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 65' ' ' LEU . . . . . 1.031 HD11 HG13 ' A' ' 67' ' ' VAL . 0.4 OUTLIER -110.75 123.72 50.59 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.178 -0.464 . . . . 52.12 110.942 179.982 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 66' ' ' PHE . . . . . 0.571 ' N ' HD12 ' A' ' 65' ' ' LEU . 0.2 OUTLIER -94.05 111.83 23.59 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.23 -0.441 . . . . 74.34 110.924 179.961 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 67' ' ' VAL . . . . . 1.031 HG13 HD11 ' A' ' 65' ' ' LEU . 0.4 OUTLIER -140.92 167.28 17.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.227 -0.442 . . . . 64.35 111.109 -179.998 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 68' ' ' ARG . . . . . 0.4 ' HB3' ' HG2' ' A' ' 71' ' ' GLU . 3.5 ttp85 -96.84 132.42 42.6 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.174 -0.466 . . . . 71.23 110.91 -179.952 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 69' ' ' THR . . . . . 0.414 ' O ' HG12 ' A' ' 72' ' ' VAL . 1.4 m -44.67 -36.81 3.29 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.246 -0.433 . . . . 74.03 111.126 -179.825 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 33.2 t0 -59.02 -71.88 0.11 Allowed 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.199 -0.455 . . . . 71.52 110.872 179.868 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 71' ' ' GLU . . . . . 0.473 ' O ' HD12 ' A' ' 75' ' ' LEU . 3.1 pt-20 -56.37 -37.73 70.45 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.176 -0.466 . . . . 51.13 110.875 -179.849 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 72' ' ' VAL . . . . . 0.414 HG12 ' O ' ' A' ' 69' ' ' THR . 0.4 OUTLIER -68.74 -25.39 30.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.157 -0.474 . . . . 71.0 111.148 179.982 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 73' ' ' ARG . . . . . . . . . . . . . 24.7 ttm-85 -75.9 -39.3 56.62 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.107 -0.497 . . . . 71.35 110.869 -179.996 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 12.4 mt-30 -54.73 -29.09 52.59 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.214 -0.448 . . . . 62.5 110.895 -179.936 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 75' ' ' LEU . . . . . 0.517 HD23 ' CG ' ' A' ' 79' ' ' ASP . 3.4 mp -87.26 -175.82 5.43 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.182 -0.463 . . . . 72.53 110.944 -179.973 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 76' ' ' ARG . . . . . . . . . . . . . 6.8 ttt-85 -109.47 139.33 44.59 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.192 -0.458 . . . . 74.43 110.866 179.962 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 3.3 ptt85 -48.65 108.31 0.17 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.224 -0.443 . . . . 74.32 110.844 -179.92 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 119.55 9.96 8.15 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.663 -0.78 . . . . 63.33 112.536 -179.932 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 79' ' ' ASP . . . . . 0.517 ' CG ' HD23 ' A' ' 75' ' ' LEU . 0.4 OUTLIER -73.09 109.12 6.38 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.945 0.402 . . . . 72.11 110.914 -179.994 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 80' ' ' THR . . . . . 0.716 ' HA ' ' HA ' ' A' ' 89' ' ' TRP . 0.0 OUTLIER -85.51 110.34 19.13 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.17 -0.468 . . . . 74.45 111.118 -179.828 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 81' ' ' LEU . . . . . 0.758 ' C ' ' HA ' ' A' ' 87' ' ' ASN . 0.3 OUTLIER -97.63 132.43 43.29 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.222 -0.445 . . . . 71.42 110.887 179.97 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 82' ' ' THR . . . . . 0.762 ' CA ' ' HA ' ' A' ' 87' ' ' ASN . 6.7 t -91.57 102.35 15.0 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.189 -0.46 . . . . 73.41 111.139 179.925 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 83' ' ' ILE . . . . . 0.733 ' CG2' HD12 ' A' ' 81' ' ' LEU . 0.1 OUTLIER -139.24 131.2 35.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.223 -0.444 . . . . 74.31 111.119 179.923 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 76.74 -51.67 3.1 Favored Glycine 0 N--CA 1.452 -0.264 0 C-N-CA 120.715 -0.755 . . . . 40.34 112.471 179.9 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 6.7 tp10 -121.37 -77.83 0.59 Allowed 'General case' 0 C--N 1.331 -0.229 0 CA-C-O 120.818 0.342 . . . . 62.54 110.876 -179.876 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 86' ' ' GLU . . . . . 0.472 ' C ' ' HA ' ' A' ' 82' ' ' THR . 98.8 mt-10 -152.76 162.29 41.46 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.12 -0.491 . . . . 73.22 110.923 -179.977 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 87' ' ' ASN . . . . . 0.762 ' HA ' ' CA ' ' A' ' 82' ' ' THR . 2.6 p-10 -51.5 122.02 7.31 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.183 -0.462 . . . . 73.41 110.899 -179.975 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 88' ' ' PHE . . . . . 0.776 ' HB2' HD22 ' A' ' 105' ' ' LEU . 13.9 m-85 -131.77 119.4 21.23 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.184 -0.462 . . . . 70.55 110.935 179.95 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 89' ' ' TRP . . . . . 0.716 ' HA ' ' HA ' ' A' ' 80' ' ' THR . 65.4 p-90 -82.21 132.87 35.23 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.164 -0.471 . . . . 71.31 110.96 179.983 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 90' ' ' VAL . . . . . 0.515 ' HA ' ' HB3' ' A' ' 105' ' ' LEU . 4.0 p -95.39 139.11 19.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.231 -0.441 . . . . 75.31 111.156 179.92 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 91' ' ' ASP . . . . . 0.476 ' HB2' HD21 ' A' ' 103' ' ' LEU . 1.9 t70 -58.84 -73.82 0.08 Allowed 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.208 -0.451 . . . . 63.44 110.877 179.959 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 92' ' ' ARG . . . . . 0.684 ' O ' HD13 ' A' ' 103' ' ' LEU . 8.2 ttt180 -170.15 121.39 0.64 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.215 -0.448 . . . . 73.21 110.898 -179.908 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 93' ' ' VAL . . . . . 0.532 ' HB ' ' HB3' ' A' ' 101' ' ' CYS . 2.6 m -104.83 139.0 27.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.217 -0.447 . . . . 72.41 111.176 179.917 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 12.1 t -130.1 96.53 25.18 Favored Pre-proline 0 C--N 1.33 -0.278 0 CA-C-O 121.577 0.703 . . . . 63.52 110.826 -179.766 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 52.6 Cg_endo -69.8 -167.39 0.22 Allowed 'Trans proline' 0 C--N 1.341 0.152 0 C-N-CA 122.655 2.237 . . . . 72.03 112.319 179.97 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 5.8 t0 . . . . . 0 C--N 1.328 -0.345 0 CA-C-N 116.226 -0.443 . . . . 70.01 110.871 179.971 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 12.0 t . . . . . 0 C--O 1.232 0.168 0 CA-C-O 120.809 0.338 . . . . 72.44 110.774 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 101' ' ' CYS . . . . . 0.532 ' HB3' ' HB ' ' A' ' 93' ' ' VAL . 1.8 t -132.12 -172.83 2.98 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.185 -0.462 . . . . 54.4 110.849 -179.955 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 102' ' ' HIS . . . . . 0.408 ' HB3' ' HA ' ' A' ' 66' ' ' PHE . 0.3 OUTLIER -169.53 138.91 1.99 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.183 -0.462 . . . . 73.12 110.91 -179.933 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 103' ' ' LEU . . . . . 0.684 HD13 ' O ' ' A' ' 92' ' ' ARG . 6.2 tt -139.26 155.79 47.51 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.267 -0.424 . . . . 61.1 110.945 -179.943 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 104' ' ' TRP . . . . . 0.451 ' O ' HD23 ' A' ' 103' ' ' LEU . 48.4 p-90 -64.21 110.27 2.15 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 116.18 -0.464 . . . . 65.12 110.871 179.92 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 105' ' ' LEU . . . . . 0.776 HD22 ' HB2' ' A' ' 88' ' ' PHE . 0.4 OUTLIER -91.24 163.05 14.38 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.218 -0.446 . . . . 65.24 110.958 179.957 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -89.13 157.64 27.21 Favored Glycine 0 N--CA 1.452 -0.266 0 C-N-CA 120.732 -0.747 . . . . 74.42 112.456 179.888 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 107' ' ' ARG . . . . . 0.516 ' HA ' ' CD1' ' A' ' 88' ' ' PHE . 65.5 ttp85 -69.99 156.91 38.43 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.784 0.326 . . . . 75.03 110.895 -179.856 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -169.77 108.15 0.29 Allowed Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.736 -0.745 . . . . 43.23 112.549 179.999 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 109' ' ' VAL . . . . . 0.471 HG23 ' HD2' ' A' ' 110' ' ' PRO . 7.3 p -90.14 134.16 32.08 Favored Pre-proline 0 C--N 1.329 -0.295 0 CA-C-O 121.566 0.698 . . . . 72.15 111.121 -179.906 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 110' ' ' PRO . . . . . 0.471 ' HD2' HG23 ' A' ' 109' ' ' VAL . 53.2 Cg_endo . . . . . 0 C--O 1.232 0.217 0 C-N-CA 122.737 2.291 . . . . 72.54 112.308 179.995 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 25' ' ' THR . . . . . 0.611 ' O ' ' HA ' ' A' ' 40' ' ' ARG . 69.8 p . . . . . 0 N--CA 1.456 -0.14 0 CA-C-O 120.737 0.303 . . . . 74.2 111.156 . . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -76.3 122.47 24.48 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.268 -0.424 . . . . 54.42 110.838 -179.838 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 27' ' ' ALA . . . . . 0.788 ' HB3' HG23 ' A' ' 39' ' ' ILE . . . -151.56 161.78 42.1 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.184 -0.462 . . . . 74.13 111.104 179.882 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 28' ' ' THR . . . . . 0.514 HG22 ' O ' ' A' ' 28' ' ' THR . 12.9 m -131.46 89.74 2.76 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.215 -0.448 . . . . 71.21 111.167 -179.97 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 29' ' ' ILE . . . . . 0.792 HG23 ' CB ' ' A' ' 39' ' ' ILE . 2.1 pt -44.22 130.23 1.48 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 116.186 -0.461 . . . . 73.11 111.12 179.932 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 30' ' ' THR . . . . . 0.716 HG23 ' O ' ' A' ' 35' ' ' SER . 9.1 m -153.61 99.26 2.3 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.218 -0.447 . . . . 75.55 111.137 179.924 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 8.1 t -139.34 72.41 1.4 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.184 -0.462 . . . . 64.31 110.856 -179.819 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -178.96 166.95 36.9 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.796 -0.716 . . . . 73.05 112.512 179.999 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 17.1 pt-20 -49.24 -23.58 1.41 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.743 0.306 . . . . 70.41 110.829 -179.901 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 1.1 mt-30 -174.4 93.65 0.08 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.193 -0.458 . . . . 62.54 110.948 -179.829 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 35' ' ' SER . . . . . 0.716 ' O ' HG23 ' A' ' 30' ' ' THR . 3.2 m -145.95 165.71 28.16 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.196 -0.456 . . . . 72.43 110.885 -179.793 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 179.46 86.97 0.07 OUTLIER Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.788 -0.72 . . . . 55.21 112.542 -179.966 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 37' ' ' ALA . . . . . 0.657 ' HB3' ' CD1' ' A' ' 29' ' ' ILE . . . -105.79 -171.82 1.98 Allowed 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.81 0.338 . . . . 53.51 111.056 -179.955 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 73.5 t -99.74 122.79 52.0 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.15 -0.477 . . . . 73.51 111.131 -179.985 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 39' ' ' ILE . . . . . 0.792 ' CB ' HG23 ' A' ' 29' ' ' ILE . 0.0 OUTLIER -136.82 150.24 26.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.189 -0.459 . . . . 75.03 111.093 179.882 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 40' ' ' ARG . . . . . 0.701 ' O ' HG12 ' A' ' 67' ' ' VAL . 10.1 mmt-85 -110.82 82.23 1.56 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.17 -0.468 . . . . 63.51 110.88 179.987 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 41' ' ' GLY . . . . . 0.546 ' O ' ' HB2' ' A' ' 27' ' ' ALA . . . -141.5 142.95 12.49 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.78 -0.724 . . . . 72.15 112.485 -179.965 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 42' ' ' VAL . . . . . 0.515 HG12 HG21 ' A' ' 25' ' ' THR . 8.8 p -127.46 142.34 43.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-O 120.912 0.387 . . . . 71.41 111.091 -179.95 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 43' ' ' PHE . . . . . 0.743 ' H ' HD11 ' A' ' 83' ' ' ILE . 2.0 p90 -90.05 135.19 33.8 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.205 -0.452 . . . . 55.52 110.937 179.905 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 11.5 t0 -120.17 125.23 47.68 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.134 -0.485 . . . . 74.01 110.869 179.965 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--N 1.328 -0.339 0 CA-C-O 121.646 0.736 . . . . 70.01 110.854 179.988 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo . . . . . 0 C--O 1.231 0.156 0 CA-C-O 120.74 0.225 . . . . 61.34 112.337 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 64' ' ' SER . . . . . 0.426 ' O ' ' HA ' ' A' ' 43' ' ' PHE . 1.1 t -110.7 144.42 39.66 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.214 -0.448 . . . . 63.05 110.817 -179.798 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 65' ' ' LEU . . . . . 0.627 ' O ' HD23 ' A' ' 65' ' ' LEU . 0.0 OUTLIER -112.97 123.39 50.22 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.142 -0.481 . . . . 72.45 110.869 -179.943 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 66' ' ' PHE . . . . . 0.426 ' HA ' ' HB3' ' A' ' 102' ' ' HIS . 15.3 t80 -102.88 110.31 22.18 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.235 -0.439 . . . . 73.22 110.972 179.857 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 67' ' ' VAL . . . . . 0.701 HG12 ' O ' ' A' ' 40' ' ' ARG . 28.0 m -141.16 172.09 11.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.135 -0.484 . . . . 64.0 111.089 -179.93 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 68' ' ' ARG . . . . . 0.483 ' HG2' ' H ' ' A' ' 71' ' ' GLU . 0.9 OUTLIER -104.95 142.19 35.22 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.126 -0.488 . . . . 71.3 110.885 179.989 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 69' ' ' THR . . . . . 0.463 HG23 ' H ' ' A' ' 70' ' ' ASP . 0.1 OUTLIER -36.03 -69.59 0.1 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.18 -0.464 . . . . 42.41 111.128 -179.91 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 70' ' ' ASP . . . . . 0.463 ' H ' HG23 ' A' ' 69' ' ' THR . 30.9 t70 -44.06 -50.24 8.5 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.183 -0.462 . . . . 73.21 110.922 179.917 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 71' ' ' GLU . . . . . 0.483 ' H ' ' HG2' ' A' ' 68' ' ' ARG . 7.4 tp10 -55.49 -40.69 72.02 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.199 -0.455 . . . . 54.13 110.978 -179.976 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 72' ' ' VAL . . . . . 0.766 ' HA ' HD11 ' A' ' 75' ' ' LEU . 6.1 p -101.09 16.55 4.25 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.244 0 CA-C-N 116.134 -0.485 . . . . 71.41 111.052 179.998 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 73' ' ' ARG . . . . . 0.445 ' N ' ' O ' ' A' ' 69' ' ' THR . 0.6 OUTLIER -103.58 -32.19 9.55 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.18 -0.464 . . . . 72.24 110.87 -179.95 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -64.57 -23.46 67.28 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.143 -0.481 . . . . 75.32 110.983 -179.936 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 75' ' ' LEU . . . . . 0.766 HD11 ' HA ' ' A' ' 72' ' ' VAL . 0.0 OUTLIER -103.99 -177.56 3.4 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.149 -0.478 . . . . 54.12 110.888 179.968 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 76' ' ' ARG . . . . . . . . . . . . . 33.4 ttt180 -97.35 146.55 25.05 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.162 -0.472 . . . . 75.42 110.85 179.977 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 5.6 ptm180 -51.79 154.89 1.87 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.203 -0.453 . . . . 72.23 110.848 -179.919 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 72.46 18.9 78.66 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.734 -0.746 . . . . 32.43 112.538 -179.943 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 58.5 t0 -76.5 115.18 16.01 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.866 0.365 . . . . 63.03 110.81 -179.95 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 80' ' ' THR . . . . . 0.715 ' HA ' ' HA ' ' A' ' 89' ' ' TRP . 0.0 OUTLIER -88.15 109.1 19.63 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.148 -0.478 . . . . 75.25 111.197 -179.957 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 81' ' ' LEU . . . . . 0.785 ' C ' ' HA ' ' A' ' 87' ' ' ASN . 0.0 OUTLIER -97.24 134.46 40.51 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.246 -0.433 . . . . 63.42 110.943 179.93 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 82' ' ' THR . . . . . 0.71 ' CA ' ' HA ' ' A' ' 87' ' ' ASN . 5.0 t -92.77 101.36 13.74 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.186 -0.461 . . . . 74.41 111.112 179.981 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 83' ' ' ILE . . . . . 0.782 HD13 ' O ' ' A' ' 83' ' ' ILE . 0.1 OUTLIER -132.99 130.66 58.61 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 116.246 -0.434 . . . . 72.03 111.111 179.938 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 71.97 -57.92 1.41 Allowed Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.721 -0.752 . . . . 74.44 112.502 179.931 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 7.6 tp10 -109.54 -82.37 0.57 Allowed 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.838 0.352 . . . . 71.13 110.893 -179.92 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 86' ' ' GLU . . . . . 0.448 ' C ' ' HA ' ' A' ' 82' ' ' THR . 5.8 mm-40 -151.09 162.02 41.64 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.162 -0.472 . . . . 64.22 110.896 -179.955 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 87' ' ' ASN . . . . . 0.785 ' HA ' ' C ' ' A' ' 81' ' ' LEU . 12.1 p30 -51.43 125.31 14.09 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.14 -0.482 . . . . 73.31 110.9 -179.933 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 88' ' ' PHE . . . . . 0.682 ' HB2' HD22 ' A' ' 105' ' ' LEU . 15.3 m-85 -132.55 118.5 19.3 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.166 -0.47 . . . . 73.2 110.846 -179.958 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 89' ' ' TRP . . . . . 0.715 ' HA ' ' HA ' ' A' ' 80' ' ' THR . 53.9 p-90 -82.62 136.3 34.83 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.12 -0.491 . . . . 74.42 110.91 -179.976 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 90' ' ' VAL . . . . . 0.679 HG21 ' CG1' ' A' ' 93' ' ' VAL . 4.5 p -93.36 139.6 17.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.197 -0.456 . . . . 72.44 111.158 179.915 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 91' ' ' ASP . . . . . 0.412 ' HB2' HD21 ' A' ' 103' ' ' LEU . 0.2 OUTLIER -62.71 -63.77 1.12 Allowed 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.157 -0.474 . . . . 55.33 110.869 179.933 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 92' ' ' ARG . . . . . 0.67 ' O ' HD13 ' A' ' 103' ' ' LEU . 11.5 mtm180 -159.2 123.9 4.06 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.145 -0.479 . . . . 73.13 110.858 -179.869 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 93' ' ' VAL . . . . . 0.679 ' CG1' HG21 ' A' ' 90' ' ' VAL . 18.6 m -123.37 136.01 61.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.155 -0.475 . . . . 73.14 111.086 179.985 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 21.0 m -136.36 130.45 18.14 Favored Pre-proline 0 C--N 1.33 -0.244 0 CA-C-O 121.618 0.723 . . . . 74.12 110.854 -179.855 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 95' ' ' PRO . . . . . 0.421 ' HG3' ' HB ' ' A' ' 69' ' ' THR . 53.8 Cg_endo -69.75 155.55 65.7 Favored 'Trans proline' 0 C--O 1.232 0.178 0 C-N-CA 122.667 2.244 . . . . 71.42 112.385 179.931 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 14.1 t0 . . . . . 0 C--N 1.328 -0.34 0 CA-C-N 116.198 -0.455 . . . . 54.05 110.914 179.909 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 3.3 m . . . . . 0 C--O 1.232 0.163 0 CA-C-O 120.8 0.333 . . . . 71.12 110.845 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 101' ' ' CYS . . . . . 0.592 ' HB2' ' HB ' ' A' ' 93' ' ' VAL . 25.4 p -47.3 132.66 12.82 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.144 -0.48 . . . . 62.15 110.939 179.996 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 102' ' ' HIS . . . . . 0.426 ' HB3' ' HA ' ' A' ' 66' ' ' PHE . 1.7 p80 -163.28 130.3 3.45 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.221 -0.445 . . . . 71.22 110.887 -179.968 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 103' ' ' LEU . . . . . 0.67 HD13 ' O ' ' A' ' 92' ' ' ARG . 7.1 tt -147.78 157.1 43.38 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.211 -0.449 . . . . 75.34 110.942 179.978 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 104' ' ' TRP . . . . . 0.509 ' O ' HD23 ' A' ' 103' ' ' LEU . 8.4 m-90 -64.0 110.08 2.02 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.195 -0.457 . . . . 75.31 110.939 179.898 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 105' ' ' LEU . . . . . 0.682 HD22 ' HB2' ' A' ' 88' ' ' PHE . 0.3 OUTLIER -88.75 163.06 15.9 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.231 -0.44 . . . . 63.54 110.922 179.986 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -92.41 161.37 26.26 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.749 -0.738 . . . . 54.43 112.455 179.956 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 107' ' ' ARG . . . . . 0.606 ' HA ' ' CD1' ' A' ' 88' ' ' PHE . 4.8 ptt180 -68.07 158.57 32.7 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.835 0.35 . . . . 73.31 110.841 -179.832 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -171.49 112.38 0.44 Allowed Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.673 -0.775 . . . . 52.41 112.469 -179.998 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 109' ' ' VAL . . . . . 0.455 HG23 ' HD2' ' A' ' 110' ' ' PRO . 7.2 p -101.3 134.09 20.52 Favored Pre-proline 0 C--N 1.328 -0.332 0 CA-C-O 121.619 0.723 . . . . 71.5 111.157 179.999 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 110' ' ' PRO . . . . . 0.455 ' HD2' HG23 ' A' ' 109' ' ' VAL . 53.7 Cg_endo . . . . . 0 C--O 1.232 0.199 0 C-N-CA 122.731 2.288 . . . . 64.53 112.321 179.956 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--O 1.231 0.115 0 CA-C-O 120.766 0.317 . . . . 72.21 110.887 . . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -156.36 178.35 10.41 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.22 -0.446 . . . . 60.41 111.151 179.833 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 3' ' ' ASP . . . . . . . . . . . . . 9.3 m-20 -159.6 -178.56 7.19 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.234 -0.439 . . . . 72.32 110.837 -179.997 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 4' ' ' PHE . . . . . . . . . . . . . 3.8 t80 -170.12 161.03 8.36 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.173 -0.467 . . . . 72.33 110.892 -179.878 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 8.5 m-20 -157.9 -177.25 6.43 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.154 -0.476 . . . . 72.32 110.838 179.933 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 6' ' ' ASN . . . . . . . . . . . . . 24.4 t30 -151.68 173.7 14.38 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.15 -0.477 . . . . 74.23 110.82 -179.903 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 7' ' ' LEU . . . . . 0.403 HD12 ' C ' ' A' ' 7' ' ' LEU . 3.4 pp -171.81 -176.87 1.83 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.168 -0.469 . . . . 55.02 110.926 179.945 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 8' ' ' PHE . . . . . . . . . . . . . 30.6 p90 -140.33 178.54 7.22 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.16 -0.473 . . . . 74.43 110.884 179.9 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 4.0 m-20 -164.04 179.14 7.16 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.146 -0.479 . . . . 50.15 110.834 179.979 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -132.85 -173.18 3.11 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.148 -0.478 . . . . 74.34 111.092 179.967 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -149.15 133.15 17.15 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.206 -0.452 . . . . 61.44 111.078 179.953 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -132.68 -153.68 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.141 -0.481 . . . . 62.34 111.175 179.927 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -144.37 144.42 31.42 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.261 -0.427 . . . . 73.43 111.135 179.824 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 22.3 mmm180 -145.45 -176.85 5.28 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.262 -0.426 . . . . 73.04 110.875 -179.936 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -124.79 -172.47 2.58 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.187 -0.461 . . . . 74.11 111.029 179.95 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 8.8 t0 -140.43 176.53 8.7 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.136 -0.484 . . . . 54.4 110.842 -179.996 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -175.02 176.3 2.15 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.192 -0.458 . . . . 75.33 110.971 -179.91 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 18' ' ' THR . . . . . 0.523 ' O ' HD13 ' A' ' 19' ' ' ILE . 1.1 p -139.59 150.39 44.96 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.189 -0.46 . . . . 63.12 111.142 -179.919 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 19' ' ' ILE . . . . . 0.523 HD13 ' O ' ' A' ' 18' ' ' THR . 45.0 mm -140.12 103.59 1.65 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.251 -0.432 . . . . 55.23 111.081 179.953 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 20' ' ' ARG . . . . . . . . . . . . . 5.4 tmm_? -167.47 132.61 1.97 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.179 -0.464 . . . . 72.22 110.863 179.963 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 155.89 92.19 0.09 OUTLIER Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.721 -0.752 . . . . 75.21 112.45 -179.97 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 22' ' ' TYR . . . . . . . . . . . . . 72.7 t80 -150.09 93.93 2.08 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.921 0.391 . . . . 63.01 110.91 -179.883 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 23' ' ' MET . . . . . . . . . . . . . 11.1 ttm -134.37 -55.8 0.85 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.08 -0.509 . . . . 75.32 110.921 179.913 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -112.19 -112.39 3.21 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.699 -0.763 . . . . 73.41 112.473 -179.999 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 25' ' ' THR . . . . . 0.485 HG21 HG23 ' A' ' 42' ' ' VAL . 11.7 m -98.65 137.41 37.33 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.765 0.317 . . . . 60.23 111.237 -179.913 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -71.95 122.45 20.85 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.286 -0.415 . . . . 74.12 110.842 -179.836 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 27' ' ' ALA . . . . . 0.81 ' HB3' HG23 ' A' ' 39' ' ' ILE . . . -141.95 162.18 36.13 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.09 -0.505 . . . . 73.02 111.134 179.904 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 28' ' ' THR . . . . . 0.464 HG22 ' O ' ' A' ' 28' ' ' THR . 21.2 m -129.99 87.95 2.59 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.224 -0.444 . . . . 73.24 111.143 -179.918 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 29' ' ' ILE . . . . . 0.858 HG21 HD21 ' A' ' 75' ' ' LEU . 2.3 pt -45.15 130.9 1.97 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.277 -0.419 . . . . 75.42 111.08 179.931 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 30' ' ' THR . . . . . 0.667 HG23 ' O ' ' A' ' 35' ' ' SER . 19.8 m -153.14 97.51 2.19 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.133 -0.485 . . . . 74.12 111.155 179.974 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 31' ' ' SER . . . . . 0.402 ' OG ' HG22 ' A' ' 80' ' ' THR . 8.5 t -135.1 70.86 1.43 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.213 -0.449 . . . . 61.23 110.829 -179.858 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -178.95 167.92 38.47 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.76 -0.733 . . . . 72.11 112.449 179.984 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 4.1 pt-20 -49.12 -23.36 1.22 Allowed 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.828 0.346 . . . . 64.41 110.89 -179.878 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 9.6 tt0 -174.44 94.64 0.08 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.129 -0.487 . . . . 71.3 110.879 -179.938 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 35' ' ' SER . . . . . 0.667 ' O ' HG23 ' A' ' 30' ' ' THR . 0.1 OUTLIER -144.9 165.49 27.98 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.992 0.425 . . . . 55.32 110.832 -179.831 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 178.17 87.84 0.07 OUTLIER Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.752 -0.737 . . . . 61.32 112.48 -179.97 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 37' ' ' ALA . . . . . 0.601 ' HB3' ' CD1' ' A' ' 29' ' ' ILE . . . -107.06 -170.67 1.75 Allowed 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.881 0.372 . . . . 63.42 111.087 179.984 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 4.1 p -99.15 120.74 48.9 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.227 -0.442 . . . . 74.22 111.185 179.913 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 39' ' ' ILE . . . . . 0.81 HG23 ' HB3' ' A' ' 27' ' ' ALA . 0.0 OUTLIER -137.85 148.69 25.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.199 -0.455 . . . . 74.1 111.106 179.951 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 40' ' ' ARG . . . . . 0.575 ' O ' HG12 ' A' ' 67' ' ' VAL . 18.5 mtt180 -109.66 80.76 1.35 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.189 -0.459 . . . . 70.22 110.887 179.9 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 41' ' ' GLY . . . . . 0.479 ' N ' HD13 ' A' ' 39' ' ' ILE . . . -128.71 148.9 18.21 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.738 -0.744 . . . . 72.52 112.454 -179.928 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 42' ' ' VAL . . . . . 0.664 HG12 ' HB3' ' A' ' 66' ' ' PHE . 3.4 p -127.16 135.04 64.64 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-O 120.851 0.357 . . . . 73.22 111.102 179.972 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 43' ' ' PHE . . . . . 0.58 ' H ' HD11 ' A' ' 83' ' ' ILE . 3.2 p90 -92.84 128.2 38.62 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.134 -0.485 . . . . 73.14 110.915 179.945 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 46.8 m-20 -114.88 124.52 51.93 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 116.133 -0.485 . . . . 64.13 110.861 179.944 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -105.63 153.0 40.19 Favored Pre-proline 0 C--N 1.329 -0.314 0 CA-C-O 121.624 0.726 . . . . 63.24 110.854 179.95 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 46' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.78 -41.31 4.36 Favored 'Trans proline' 0 C--N 1.342 0.186 0 C-N-CA 122.636 2.224 . . . . 54.33 112.355 179.991 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 28.9 tt0 -169.74 103.97 0.33 Allowed 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.225 -0.443 . . . . 70.42 110.898 179.989 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 4.0 t-20 -51.57 -30.5 21.06 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.213 -0.449 . . . . 74.23 110.861 -179.853 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 28.6 mt -88.69 100.16 10.18 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.192 -0.458 . . . . 54.12 111.104 179.911 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 1.4 t -153.83 147.3 24.99 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.149 -0.478 . . . . 75.35 110.864 -179.923 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 7.6 m-85 -148.72 178.62 8.49 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.13 -0.487 . . . . 74.44 110.854 -179.82 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -125.96 -75.79 0.59 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.105 -0.498 . . . . 72.2 111.043 179.875 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 147.13 39.91 0.04 OUTLIER Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.764 -0.731 . . . . 54.44 112.457 -179.921 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 54' ' ' GLN . . . . . . . . . . . . . 42.8 mt-30 53.26 29.55 8.69 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.818 0.342 . . . . 73.34 110.914 -179.866 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -103.96 -65.75 0.7 Allowed Glycine 0 N--CA 1.452 -0.271 0 C-N-CA 120.752 -0.737 . . . . 73.24 112.434 -179.946 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 43.8 t -68.17 147.18 12.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-O 120.79 0.329 . . . . 72.2 111.126 -179.916 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 15.6 ptm180 -94.95 -31.34 13.69 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.126 -0.488 . . . . 65.04 110.871 -179.961 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 7.1 p -134.44 126.89 49.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.209 -0.45 . . . . 74.43 111.142 179.972 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 2.6 tt0 -104.81 172.56 6.72 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.165 -0.47 . . . . 72.14 110.885 -179.981 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -131.83 131.99 6.54 Favored Glycine 0 N--CA 1.452 -0.262 0 C-N-CA 120.706 -0.759 . . . . 32.03 112.496 -179.991 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 1.7 p -148.11 123.64 10.41 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.885 0.374 . . . . 41.44 110.888 -179.77 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 62' ' ' SER . . . . . 0.409 ' HA ' ' HD2' ' A' ' 63' ' ' PRO . 16.7 p -133.01 97.81 16.39 Favored Pre-proline 0 C--N 1.329 -0.322 0 CA-C-O 121.689 0.757 . . . . 45.42 110.84 -179.796 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 63' ' ' PRO . . . . . 0.536 ' HG2' HD11 ' A' ' 105' ' ' LEU . 54.2 Cg_endo -69.76 -178.46 2.35 Favored 'Trans proline' 0 C--N 1.341 0.183 0 C-N-CA 122.684 2.256 . . . . 64.21 112.354 179.975 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 64' ' ' SER . . . . . 0.488 ' O ' ' HA ' ' A' ' 43' ' ' PHE . 2.2 t -106.46 146.8 30.1 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.271 -0.422 . . . . 74.44 110.821 -179.879 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 65' ' ' LEU . . . . . 0.788 HD11 HG13 ' A' ' 67' ' ' VAL . 0.2 OUTLIER -113.36 123.66 50.63 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.07 -0.513 . . . . 54.13 110.899 -179.989 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 66' ' ' PHE . . . . . 0.664 ' HB3' HG12 ' A' ' 42' ' ' VAL . 15.2 t80 -102.48 110.87 22.94 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.185 -0.461 . . . . 72.14 110.873 179.956 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 67' ' ' VAL . . . . . 0.788 HG13 HD11 ' A' ' 65' ' ' LEU . 0.3 OUTLIER -140.99 168.73 15.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.193 -0.458 . . . . 52.41 111.237 179.954 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 68' ' ' ARG . . . . . 0.427 ' HG3' ' HA3' ' A' ' 99' ' ' GLY . 8.9 ttm180 -98.36 143.18 29.1 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.202 -0.454 . . . . 73.52 110.8 -179.935 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 69' ' ' THR . . . . . 0.722 HG22 ' HA2' ' A' ' 99' ' ' GLY . 0.0 OUTLIER -41.17 -44.51 2.58 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.156 -0.475 . . . . 74.41 111.172 -179.932 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 29.0 m-20 -65.69 -52.64 49.92 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.236 -0.438 . . . . 70.51 110.891 179.888 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 71' ' ' GLU . . . . . . . . . . . . . 2.1 mm-40 -55.0 -39.49 69.1 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.22 -0.445 . . . . 73.11 110.906 -179.947 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 11.1 p -82.6 -22.13 9.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.132 -0.485 . . . . 63.43 111.075 -179.993 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 73' ' ' ARG . . . . . . . . . . . . . 1.5 tmt_? -67.59 -41.52 83.95 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.194 -0.457 . . . . 75.23 110.869 179.984 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 59.1 mt-30 -57.78 -20.45 35.45 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.198 -0.456 . . . . 71.12 110.969 -179.957 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 75' ' ' LEU . . . . . 0.858 HD21 HG21 ' A' ' 29' ' ' ILE . 5.8 mp -104.95 -175.87 2.92 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.199 -0.455 . . . . 73.43 110.899 -179.999 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 76' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -111.76 -179.45 3.7 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.197 -0.456 . . . . 75.24 110.937 179.944 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -81.21 116.25 21.01 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.225 -0.443 . . . . 71.15 110.888 -179.913 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 107.92 20.14 8.61 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.77 -0.729 . . . . 70.23 112.453 -179.991 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 79' ' ' ASP . . . . . 0.409 ' OD2' HD23 ' A' ' 75' ' ' LEU . 0.2 OUTLIER -84.41 111.58 19.58 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.881 0.372 . . . . 74.23 110.886 179.996 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 80' ' ' THR . . . . . 0.711 ' HA ' ' HA ' ' A' ' 89' ' ' TRP . 0.0 OUTLIER -86.62 111.6 20.8 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.198 -0.455 . . . . 71.14 111.148 -179.91 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 81' ' ' LEU . . . . . 0.755 ' C ' ' HA ' ' A' ' 87' ' ' ASN . 0.3 OUTLIER -97.22 131.82 43.58 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.194 -0.457 . . . . 64.43 110.921 179.917 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 82' ' ' THR . . . . . 0.748 ' CA ' ' HA ' ' A' ' 87' ' ' ASN . 2.4 t -92.48 101.42 13.87 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.13 -0.486 . . . . 61.15 111.156 179.946 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 83' ' ' ILE . . . . . 0.713 ' CG2' HD12 ' A' ' 81' ' ' LEU . 0.1 OUTLIER -137.24 131.84 45.67 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.282 -0.417 . . . . 73.34 111.081 179.979 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 74.9 -53.86 2.56 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.7 -0.762 . . . . 65.25 112.537 179.929 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 85' ' ' GLU . . . . . 0.41 ' C ' ' HG3' ' A' ' 86' ' ' GLU . 84.5 tt0 -117.94 -81.31 0.62 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.766 0.317 . . . . 73.34 110.879 -179.951 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 86' ' ' GLU . . . . . 0.695 ' OE1' HG22 ' A' ' 109' ' ' VAL . 61.7 mt-10 -149.35 161.4 42.13 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.233 -0.439 . . . . 73.23 110.931 -179.903 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 87' ' ' ASN . . . . . 0.755 ' HA ' ' C ' ' A' ' 81' ' ' LEU . 13.0 p30 -51.92 123.99 11.66 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.188 -0.46 . . . . 70.12 110.877 -179.932 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 88' ' ' PHE . . . . . 0.795 ' HB3' HD13 ' A' ' 105' ' ' LEU . 14.3 m-85 -132.2 118.18 19.21 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.184 -0.462 . . . . 73.52 110.869 -179.957 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 89' ' ' TRP . . . . . 0.711 ' HA ' ' HA ' ' A' ' 80' ' ' THR . 64.0 p-90 -82.15 135.35 35.3 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.185 -0.461 . . . . 74.34 110.922 -179.963 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 90' ' ' VAL . . . . . 0.731 ' HB ' HD23 ' A' ' 65' ' ' LEU . 0.4 OUTLIER -92.88 139.58 17.8 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.257 -0.429 . . . . 71.24 111.163 179.893 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -62.71 -71.0 0.17 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.183 -0.462 . . . . 74.32 110.89 179.867 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 92' ' ' ARG . . . . . 0.569 ' O ' ' HG ' ' A' ' 103' ' ' LEU . 7.0 mtm180 -159.9 120.89 3.1 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.172 -0.467 . . . . 54.31 110.894 -179.878 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 93' ' ' VAL . . . . . 0.758 HG12 ' HB2' ' A' ' 103' ' ' LEU . 17.4 m -112.51 135.43 51.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.197 -0.456 . . . . 75.04 111.164 179.942 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 2.1 m -130.22 101.62 17.69 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-O 121.661 0.743 . . . . 72.34 110.827 -179.811 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 95' ' ' PRO . . . . . 0.421 ' HG3' ' HB ' ' A' ' 69' ' ' THR . 54.0 Cg_endo -69.74 177.27 5.74 Favored 'Trans proline' 0 C--N 1.341 0.155 0 C-N-CA 122.682 2.254 . . . . 73.22 112.319 179.977 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 37.2 t70 -121.21 -31.82 4.03 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.203 -0.453 . . . . 74.12 110.848 179.928 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 5.8 t70 177.96 134.64 0.07 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.244 -0.435 . . . . 74.42 110.781 -179.942 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 75.53 41.55 29.52 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.692 -0.766 . . . . 74.13 112.45 -179.994 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 99' ' ' GLY . . . . . 0.722 ' HA2' HG22 ' A' ' 69' ' ' THR . . . 42.7 74.31 0.19 Allowed Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.723 -0.751 . . . . 73.0 112.533 -179.901 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 1.7 m -131.66 76.98 1.74 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.922 0.392 . . . . 44.42 110.881 -179.748 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 101' ' ' CYS . . . . . 0.425 ' CB ' ' HB ' ' A' ' 93' ' ' VAL . 0.0 OUTLIER -105.02 148.38 26.82 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.104 -0.498 . . . . 72.13 110.87 -179.996 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 102' ' ' HIS . . . . . 0.579 ' HA ' ' O ' ' A' ' 65' ' ' LEU . 6.7 p80 -157.65 123.69 4.74 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.142 -0.481 . . . . 64.53 110.865 -179.947 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 103' ' ' LEU . . . . . 0.931 HD13 ' N ' ' A' ' 104' ' ' TRP . 2.4 tm? -151.53 146.73 26.09 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.256 -0.429 . . . . 55.14 110.959 -180.0 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 104' ' ' TRP . . . . . 0.931 ' N ' HD13 ' A' ' 103' ' ' LEU . 30.4 p90 -65.81 110.52 2.87 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.15 -0.477 . . . . 73.11 110.928 179.937 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 105' ' ' LEU . . . . . 0.795 HD13 ' HB3' ' A' ' 88' ' ' PHE . 0.4 OUTLIER -91.23 161.84 14.89 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.169 -0.469 . . . . 72.42 110.944 179.99 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -89.43 159.52 28.5 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.692 -0.766 . . . . 61.04 112.477 179.911 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 107' ' ' ARG . . . . . 0.574 ' HA ' ' CD1' ' A' ' 88' ' ' PHE . 0.4 OUTLIER -69.33 158.47 34.99 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.845 0.355 . . . . 73.33 110.863 -179.83 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -174.56 111.12 0.35 Allowed Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.758 -0.734 . . . . 60.14 112.525 -179.969 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 109' ' ' VAL . . . . . 0.695 HG22 ' OE1' ' A' ' 86' ' ' GLU . 10.6 t -100.23 132.44 22.6 Favored Pre-proline 0 C--N 1.33 -0.251 0 CA-C-O 121.632 0.729 . . . . 64.42 111.15 -179.961 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 110' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.7 168.2 22.17 Favored 'Trans proline' 0 C--N 1.341 0.161 0 C-N-CA 122.718 2.279 . . . . 64.1 112.335 179.955 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 111' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.77 -8.01 22.51 Favored 'Trans proline' 0 C--N 1.341 0.149 0 C-N-CA 122.661 2.241 . . . . 75.23 112.318 179.905 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -59.31 161.54 5.46 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.221 -0.445 . . . . 44.41 111.128 179.87 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 19.7 m -93.26 124.24 45.63 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.244 -0.435 . . . . 74.54 111.134 179.941 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 114' ' ' ASN . . . . . . . . . . . . . 6.0 t-20 -128.35 146.13 50.86 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.168 -0.469 . . . . 74.41 110.919 179.99 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -82.56 133.46 35.19 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.155 -0.475 . . . . 75.42 110.901 -179.95 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 116' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -106.71 138.1 43.51 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.201 -0.454 . . . . 75.54 110.919 -179.904 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 1.6 tpm_? . . . . . 0 C--N 1.329 -0.299 0 CA-C-N 116.239 -0.437 . . . . 73.34 110.823 -179.857 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 6.8 ttp . . . . . 0 C--O 1.231 0.082 0 CA-C-O 120.829 0.347 . . . . 63.41 110.928 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -174.71 176.08 2.33 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.199 -0.455 . . . . 53.24 111.101 179.866 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 3' ' ' ASP . . . . . . . . . . . . . 3.0 p-10 -174.96 170.15 3.29 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.178 -0.464 . . . . 64.25 110.822 -179.983 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 4' ' ' PHE . . . . . . . . . . . . . 10.3 m-85 -160.74 177.58 10.31 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.267 -0.424 . . . . 41.23 110.9 -179.959 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -174.98 178.07 1.85 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.149 -0.478 . . . . 63.44 110.912 179.983 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 6' ' ' ASN . . . . . . . . . . . . . 18.0 m-80 -161.63 173.4 14.78 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.245 -0.434 . . . . 62.51 110.89 -179.94 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 7' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -164.48 172.08 13.79 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.157 -0.474 . . . . 52.23 110.967 179.927 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 8' ' ' PHE . . . . . . . . . . . . . 25.6 p90 -174.36 150.12 1.43 Allowed 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.185 -0.462 . . . . 72.41 110.915 -179.984 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 3.9 m-20 -153.86 157.07 38.76 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.192 -0.458 . . . . 53.14 110.842 179.978 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -175.39 158.54 2.32 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.152 -0.476 . . . . 73.55 111.061 179.893 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -70.33 173.93 6.24 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.177 -0.465 . . . . 51.32 111.082 179.967 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 32.5 mt -54.3 -74.99 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.239 -0.437 . . . . 63.24 111.144 -179.999 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . 52.64 49.69 19.81 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.14 -0.482 . . . . 61.43 111.118 179.786 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 3.3 tpm_? -55.02 105.0 0.13 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.297 -0.41 . . . . 74.42 110.914 -179.926 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -172.7 170.09 4.8 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.208 -0.451 . . . . 53.24 111.062 179.907 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 2.0 t70 -61.96 173.76 1.01 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.142 -0.481 . . . . 72.11 110.815 -179.929 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 3.7 tt0 -136.45 171.45 14.47 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.192 -0.458 . . . . 61.33 110.899 -179.886 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -154.93 178.03 10.64 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.213 -0.448 . . . . 75.33 111.231 -179.932 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 19' ' ' ILE . . . . . 0.457 ' O ' HG23 ' A' ' 19' ' ' ILE . 4.1 tp -160.38 110.86 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.263 -0.426 . . . . 74.24 111.11 179.907 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 20' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -145.93 -176.23 5.06 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.13 -0.487 . . . . 74.13 110.839 179.931 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 141.52 87.72 0.11 Allowed Glycine 0 N--CA 1.452 -0.264 0 C-N-CA 120.685 -0.769 . . . . 62.32 112.471 179.972 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 22' ' ' TYR . . . . . . . . . . . . . 56.8 m-85 -153.93 -175.9 5.6 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.885 0.374 . . . . 70.33 110.913 -179.818 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 23' ' ' MET . . . . . . . . . . . . . 1.8 ptt? -61.11 -172.19 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.129 -0.487 . . . . 61.0 110.844 179.892 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 59.42 -159.56 20.04 Favored Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 120.756 -0.735 . . . . 72.21 112.474 -179.967 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 25' ' ' THR . . . . . 0.49 HG21 HG23 ' A' ' 42' ' ' VAL . 9.6 m -97.89 137.77 36.23 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.816 0.341 . . . . 72.33 111.218 -179.943 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 7.7 m -72.39 122.37 21.08 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.287 -0.415 . . . . 74.51 110.818 -179.833 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 27' ' ' ALA . . . . . 0.816 ' HB3' HG23 ' A' ' 39' ' ' ILE . . . -143.06 162.37 35.7 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.109 -0.496 . . . . 75.11 111.133 179.831 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 28' ' ' THR . . . . . 0.49 HG22 ' O ' ' A' ' 28' ' ' THR . 18.0 m -129.86 88.17 2.63 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.243 -0.435 . . . . 43.33 111.155 -179.846 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 29' ' ' ILE . . . . . 0.766 HG23 ' CB ' ' A' ' 39' ' ' ILE . 2.1 pt -43.87 131.08 1.39 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.19 -0.459 . . . . 71.11 111.162 179.978 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 30' ' ' THR . . . . . 0.698 HG23 ' O ' ' A' ' 35' ' ' SER . 11.3 m -152.98 97.33 2.19 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.229 -0.441 . . . . 53.11 111.183 -179.998 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 86.3 p -135.96 70.79 1.42 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.193 -0.458 . . . . 71.34 110.945 -179.867 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -179.29 167.52 37.65 Favored Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.72 -0.752 . . . . 71.22 112.499 -179.982 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 16.8 pt-20 -48.95 -23.43 1.12 Allowed 'General case' 0 C--N 1.33 -0.283 0 CA-C-O 120.856 0.36 . . . . 73.33 110.885 -179.9 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -174.06 94.63 0.09 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.155 -0.475 . . . . 41.33 110.954 -179.937 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 35' ' ' SER . . . . . 0.698 ' O ' HG23 ' A' ' 30' ' ' THR . 2.9 m -145.23 165.45 28.35 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.191 -0.459 . . . . 70.41 110.81 -179.783 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 177.8 88.5 0.07 OUTLIER Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.799 -0.715 . . . . 74.4 112.52 -179.923 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 37' ' ' ALA . . . . . 0.648 ' HB3' ' CD1' ' A' ' 29' ' ' ILE . . . -108.43 -170.75 1.73 Allowed 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 120.893 0.378 . . . . 53.51 111.078 179.977 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 64.6 t -98.57 120.23 47.63 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-N 116.211 -0.449 . . . . 72.11 111.146 179.958 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 39' ' ' ILE . . . . . 0.816 HG23 ' HB3' ' A' ' 27' ' ' ALA . 0.0 OUTLIER -137.08 149.93 26.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.177 -0.465 . . . . 71.3 111.124 179.956 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 40' ' ' ARG . . . . . 0.434 ' HA ' ' O ' ' A' ' 25' ' ' THR . 19.3 mtt85 -109.46 80.47 1.32 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.213 -0.448 . . . . 73.53 110.849 179.934 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 41' ' ' GLY . . . . . 0.591 ' HA2' HG12 ' A' ' 67' ' ' VAL . . . -127.47 147.93 17.29 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.797 -0.716 . . . . 74.42 112.527 179.998 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 42' ' ' VAL . . . . . 0.56 HG12 ' CB ' ' A' ' 66' ' ' PHE . 3.1 p -127.19 138.86 53.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-O 120.851 0.358 . . . . 72.41 111.126 -179.942 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 43' ' ' PHE . . . . . 0.51 ' H ' HD11 ' A' ' 83' ' ' ILE . 2.8 p90 -101.05 128.71 46.98 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.166 -0.47 . . . . 73.13 110.873 -179.982 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 1.5 t0 -104.38 124.67 49.63 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.106 -0.497 . . . . 75.13 110.835 179.956 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 45' ' ' ASP . . . . . 0.415 ' HA ' ' HD2' ' A' ' 46' ' ' PRO . 0.4 OUTLIER -114.1 105.79 53.85 Favored Pre-proline 0 C--N 1.328 -0.356 0 CA-C-O 121.608 0.718 . . . . 73.42 110.88 179.97 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 46' ' ' PRO . . . . . 0.415 ' HD2' ' HA ' ' A' ' 45' ' ' ASP . 53.2 Cg_endo -69.76 -46.3 1.27 Allowed 'Trans proline' 0 C--N 1.34 0.107 0 C-N-CA 122.678 2.252 . . . . 72.54 112.346 -179.979 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 1.9 tp10 -158.76 95.83 1.33 Allowed 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.155 -0.475 . . . . 71.24 110.868 -179.993 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 48.2 t30 -69.88 88.79 0.57 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.141 -0.481 . . . . 64.34 110.928 -179.988 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 10.4 tp -173.2 136.99 0.24 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.146 -0.479 . . . . 63.23 111.108 179.974 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 11.2 p -95.48 120.37 35.61 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.132 -0.486 . . . . 74.2 110.881 -179.933 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 10.8 m-85 -66.88 -74.34 0.11 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.118 -0.492 . . . . 65.05 110.971 -179.878 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -178.04 -179.85 0.78 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.175 -0.466 . . . . 72.41 111.058 179.915 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 178.32 136.29 2.51 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.763 -0.732 . . . . 35.34 112.533 -179.986 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 54' ' ' GLN . . . . . . . . . . . . . 9.7 pt20 -166.01 158.15 14.38 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.888 0.375 . . . . 65.34 110.886 -179.911 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 66.37 -91.61 0.17 Allowed Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.684 -0.769 . . . . 53.42 112.456 -179.976 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 80.0 t -111.34 111.6 36.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-O 120.868 0.366 . . . . 72.31 111.084 -179.921 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -102.4 102.33 12.65 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.156 -0.475 . . . . 73.25 110.856 -179.939 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 58' ' ' VAL . . . . . 0.44 HG22 ' O ' ' A' ' 58' ' ' VAL . 6.8 p -128.32 23.72 2.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.201 -0.454 . . . . 75.51 111.103 -179.964 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 3.8 tp10 -120.46 141.3 50.3 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.154 -0.476 . . . . 64.54 110.903 179.948 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -135.13 142.92 14.41 Favored Glycine 0 N--CA 1.452 -0.246 0 C-N-CA 120.744 -0.741 . . . . 74.12 112.478 -179.91 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 2.5 m -131.88 112.67 12.65 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.884 0.373 . . . . 53.34 110.848 -179.798 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -131.0 160.17 68.11 Favored Pre-proline 0 C--N 1.329 -0.295 0 CA-C-O 121.67 0.748 . . . . 55.42 110.836 -179.792 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_endo -69.76 -179.25 2.78 Favored 'Trans proline' 0 C--O 1.231 0.169 0 C-N-CA 122.754 2.303 . . . . 72.32 112.315 179.987 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 64' ' ' SER . . . . . 0.492 ' O ' ' HA ' ' A' ' 43' ' ' PHE . 0.2 OUTLIER -107.02 146.38 31.2 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.228 -0.442 . . . . 43.53 110.894 -179.891 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 65' ' ' LEU . . . . . 0.55 HD11 ' CG1' ' A' ' 67' ' ' VAL . 2.7 tm? -114.93 131.48 56.87 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.126 -0.488 . . . . 74.24 110.919 -179.957 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 66' ' ' PHE . . . . . 0.56 ' CB ' HG12 ' A' ' 42' ' ' VAL . 1.2 t80 -120.38 106.17 11.59 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.261 -0.427 . . . . 73.24 110.846 179.951 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 67' ' ' VAL . . . . . 0.591 HG12 ' HA2' ' A' ' 41' ' ' GLY . 23.2 m -144.69 172.71 5.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.167 -0.469 . . . . 75.24 111.148 179.921 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 1.4 ttt180 -105.62 143.48 33.71 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.128 -0.487 . . . . 72.12 110.896 -179.992 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 69' ' ' THR . . . . . 0.672 HG22 ' HA2' ' A' ' 99' ' ' GLY . 0.0 OUTLIER -41.17 -49.4 3.53 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.168 -0.469 . . . . 72.33 111.135 -179.908 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 14.8 t70 -53.39 -51.29 63.01 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.231 -0.44 . . . . 74.4 110.862 179.918 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 71' ' ' GLU . . . . . . . . . . . . . 31.2 mt-10 -53.3 -39.07 63.71 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.164 -0.471 . . . . 64.22 110.905 -179.932 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 72' ' ' VAL . . . . . 0.838 HG11 HG21 ' A' ' 93' ' ' VAL . 3.3 t -78.6 -32.43 16.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.156 -0.474 . . . . 74.05 111.148 179.952 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 73' ' ' ARG . . . . . . . . . . . . . 1.8 tmt_? -57.32 -39.18 75.3 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.149 -0.478 . . . . 63.11 110.841 -179.94 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 39.9 mt-30 -56.22 -22.02 26.86 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.188 -0.46 . . . . 63.25 110.87 -179.897 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 75' ' ' LEU . . . . . 0.784 HD22 ' CG ' ' A' ' 79' ' ' ASP . 2.3 mp -119.23 -165.29 1.13 Allowed 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.252 -0.431 . . . . 54.05 110.918 -180.0 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 76' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -116.15 171.94 7.49 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.219 -0.446 . . . . 73.23 110.86 179.969 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -62.41 132.05 51.26 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.174 -0.466 . . . . 75.25 110.899 -179.917 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 92.5 18.11 43.03 Favored Glycine 0 N--CA 1.452 -0.252 0 C-N-CA 120.746 -0.74 . . . . 70.23 112.477 179.998 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 79' ' ' ASP . . . . . 0.784 ' CG ' HD22 ' A' ' 75' ' ' LEU . 0.1 OUTLIER -74.23 106.33 5.82 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.883 0.373 . . . . 74.34 110.896 -179.976 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 80' ' ' THR . . . . . 0.718 ' HA ' ' HA ' ' A' ' 89' ' ' TRP . 0.6 OUTLIER -85.78 109.14 18.44 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.185 -0.461 . . . . 72.22 111.155 -179.857 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 81' ' ' LEU . . . . . 0.756 ' C ' ' HA ' ' A' ' 87' ' ' ASN . 0.3 OUTLIER -97.07 133.11 42.16 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.188 -0.46 . . . . 71.24 110.9 -179.992 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 82' ' ' THR . . . . . 0.741 ' CA ' ' HA ' ' A' ' 87' ' ' ASN . 9.8 t -93.51 102.27 14.48 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.193 -0.458 . . . . 73.32 111.123 179.949 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 83' ' ' ILE . . . . . 0.734 ' CG2' HD12 ' A' ' 81' ' ' LEU . 0.1 OUTLIER -138.46 131.78 40.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.208 -0.451 . . . . 64.45 111.147 179.882 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 74.43 -50.51 2.08 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.663 -0.779 . . . . 55.43 112.548 179.96 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 11.4 mm-40 -119.77 -80.68 0.62 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.831 0.348 . . . . 74.12 110.929 -179.885 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 86' ' ' GLU . . . . . 0.458 ' C ' ' HA ' ' A' ' 82' ' ' THR . 69.0 mt-10 -153.01 161.29 42.71 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.143 -0.48 . . . . 72.11 110.901 -179.908 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 87' ' ' ASN . . . . . 0.756 ' HA ' ' C ' ' A' ' 81' ' ' LEU . 2.1 p-10 -49.59 122.15 5.99 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.198 -0.455 . . . . 75.12 110.871 -179.99 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 88' ' ' PHE . . . . . 0.857 ' HB2' HD22 ' A' ' 105' ' ' LEU . 15.9 m-85 -131.83 120.01 22.02 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.196 -0.457 . . . . 74.41 110.859 -179.96 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 89' ' ' TRP . . . . . 0.718 ' HA ' ' HA ' ' A' ' 80' ' ' THR . 59.9 p-90 -83.94 136.79 33.94 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.226 -0.443 . . . . 65.01 110.869 -179.972 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 90' ' ' VAL . . . . . 0.556 HG21 HG13 ' A' ' 93' ' ' VAL . 10.1 p -86.92 138.75 18.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.246 -0.434 . . . . 70.42 111.074 179.966 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 91' ' ' ASP . . . . . 0.416 ' H ' HD22 ' A' ' 103' ' ' LEU . 0.7 OUTLIER -70.15 -41.78 73.39 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.177 -0.465 . . . . 61.11 110.76 179.934 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 92' ' ' ARG . . . . . 0.508 ' HB3' HD13 ' A' ' 103' ' ' LEU . 20.0 tpp180 -160.26 138.59 10.16 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.265 -0.425 . . . . 62.53 110.912 -179.826 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 93' ' ' VAL . . . . . 0.838 HG21 HG11 ' A' ' 72' ' ' VAL . 0.0 OUTLIER -126.81 111.9 27.41 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.258 -0.428 . . . . 52.32 111.148 179.936 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 4.0 t -127.25 109.35 21.4 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-O 121.694 0.759 . . . . 64.25 110.88 -179.914 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 95' ' ' PRO . . . . . 0.415 ' HG3' ' HB ' ' A' ' 69' ' ' THR . 53.3 Cg_endo -69.77 156.64 62.8 Favored 'Trans proline' 0 C--O 1.232 0.18 0 C-N-CA 122.649 2.232 . . . . 55.24 112.356 179.983 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 44.4 m-20 -113.67 -24.55 9.14 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.187 -0.46 . . . . 74.42 110.873 179.911 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 3.6 t0 179.04 92.46 0.02 OUTLIER 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 116.229 -0.441 . . . . 72.42 110.9 179.992 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 87.21 58.9 1.81 Allowed Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.705 -0.76 . . . . 75.43 112.491 180.0 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 99' ' ' GLY . . . . . 0.672 ' HA2' HG22 ' A' ' 69' ' ' THR . . . 42.7 81.68 0.03 OUTLIER Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.764 -0.731 . . . . 50.32 112.478 -179.873 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -127.53 6.55 6.27 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.832 0.349 . . . . 73.1 110.881 -179.81 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 101' ' ' CYS . . . . . 0.406 ' HB2' ' CB ' ' A' ' 93' ' ' VAL . 1.6 p -42.37 142.85 0.71 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.145 -0.479 . . . . 73.31 110.868 -179.99 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 102' ' ' HIS . . . . . 0.491 ' HA ' ' O ' ' A' ' 65' ' ' LEU . 46.1 p-80 -161.2 125.55 3.47 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.188 -0.46 . . . . 65.21 110.87 -179.944 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 103' ' ' LEU . . . . . 0.571 HD23 ' N ' ' A' ' 104' ' ' TRP . 9.8 tt -152.04 155.85 38.77 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.201 -0.454 . . . . 71.3 110.873 -179.993 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 104' ' ' TRP . . . . . 0.571 ' N ' HD23 ' A' ' 103' ' ' LEU . 50.2 p-90 -66.23 112.0 3.74 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.136 -0.484 . . . . 74.42 110.981 179.865 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 105' ' ' LEU . . . . . 0.857 HD22 ' HB2' ' A' ' 88' ' ' PHE . 0.3 OUTLIER -87.58 162.24 17.29 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.319 -0.4 . . . . 74.32 110.934 -179.983 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -88.36 160.43 30.54 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.724 -0.75 . . . . 62.0 112.53 179.894 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 107' ' ' ARG . . . . . 0.52 ' HA ' ' CD1' ' A' ' 88' ' ' PHE . 2.5 ptm180 -68.89 158.46 34.5 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.799 0.333 . . . . 64.41 110.845 -179.816 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -173.64 106.79 0.23 Allowed Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.694 -0.765 . . . . 45.2 112.436 -179.966 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 109' ' ' VAL . . . . . 0.443 HG23 ' HD2' ' A' ' 110' ' ' PRO . 8.7 p -91.04 134.01 30.9 Favored Pre-proline 0 C--N 1.33 -0.275 0 CA-C-O 121.644 0.735 . . . . 64.35 111.103 180.0 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 110' ' ' PRO . . . . . 0.443 ' HD2' HG23 ' A' ' 109' ' ' VAL . 53.9 Cg_endo -69.75 167.84 23.27 Favored 'Trans proline' 0 C--N 1.341 0.153 0 C-N-CA 122.659 2.239 . . . . 74.12 112.358 179.929 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 111' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.7 -48.64 0.69 Allowed 'Trans proline' 0 C--N 1.341 0.174 0 C-N-CA 122.714 2.276 . . . . 71.31 112.374 179.939 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -109.85 160.98 15.9 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.247 -0.433 . . . . 71.35 111.114 179.881 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 13.6 p -93.63 138.67 19.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.243 -0.435 . . . . 64.14 111.146 179.969 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 114' ' ' ASN . . . . . . . . . . . . . 2.2 p30 -128.4 146.21 50.85 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.247 -0.433 . . . . 73.12 110.934 179.965 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -82.22 103.19 11.63 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.121 -0.491 . . . . 65.23 110.889 -179.953 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 116' ' ' ARG . . . . . . . . . . . . . 16.9 mmm180 -95.44 132.61 40.33 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.24 -0.437 . . . . 63.15 110.843 -179.894 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 8.5 ttt-85 . . . . . 0 C--N 1.33 -0.278 0 CA-C-N 116.241 -0.436 . . . . 74.51 110.884 -179.921 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 29.4 mmm . . . . . 0 C--O 1.231 0.091 0 CA-C-O 120.732 0.301 . . . . 75.31 110.873 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -174.1 -178.66 1.52 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.205 -0.452 . . . . 64.13 111.089 179.976 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 3' ' ' ASP . . . . . . . . . . . . . 3.0 t0 59.75 57.56 3.13 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.185 -0.461 . . . . 74.35 110.901 179.968 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 4' ' ' PHE . . . . . . . . . . . . . 12.3 t80 -72.82 162.09 29.92 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.153 -0.476 . . . . 73.11 110.887 -179.881 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 1.8 t70 -140.14 169.1 18.31 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.238 -0.437 . . . . 75.25 110.944 179.946 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 6' ' ' ASN . . . . . . . . . . . . . 24.7 m120 -133.29 -175.52 3.83 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.244 -0.435 . . . . 65.3 110.897 -179.895 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 7' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -107.73 -179.13 3.82 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.254 -0.43 . . . . 75.23 110.904 179.918 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 8' ' ' PHE . . . . . . . . . . . . . 10.6 p90 -167.14 -175.05 2.83 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.16 -0.473 . . . . 53.25 110.921 179.923 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 6.5 t0 -104.16 171.44 7.34 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.185 -0.461 . . . . 73.32 110.879 -179.996 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 10' ' ' ALA . . . . . 0.468 ' HB2' ' CE2' ' A' ' 89' ' ' TRP . . . -113.86 -170.41 1.7 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.186 -0.461 . . . . 70.21 111.064 -179.98 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -111.16 177.58 4.62 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.262 -0.426 . . . . 62.43 111.111 179.934 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 4.0 mp -140.07 73.65 0.24 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.242 -0.436 . . . . 62.34 111.153 179.989 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 13' ' ' ALA . . . . . 0.47 ' HB3' ' HD3' ' A' ' 77' ' ' ARG . . . -153.01 146.72 25.17 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.174 -0.466 . . . . 53.41 111.052 179.881 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -128.39 176.45 7.71 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.2 -0.454 . . . . 73.25 110.835 -179.902 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -154.35 -171.02 3.72 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.172 -0.467 . . . . 75.52 111.067 179.985 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 16.5 p-10 -62.0 -171.49 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.195 -0.457 . . . . 73.1 110.862 -179.99 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 4.8 pt-20 -142.38 176.84 8.69 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.189 -0.459 . . . . 62.32 110.9 -179.906 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 18' ' ' THR . . . . . 0.595 HG21 ' NH2' ' A' ' 20' ' ' ARG . 1.4 p -148.98 175.56 11.19 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.141 -0.481 . . . . 65.44 111.174 -179.924 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 59.5 mt -131.05 96.72 2.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.258 -0.428 . . . . 62.3 111.119 179.872 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 20' ' ' ARG . . . . . 0.595 ' NH2' HG21 ' A' ' 18' ' ' THR . 14.7 ptt180 -176.83 -179.08 0.91 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.182 -0.463 . . . . 72.43 110.845 179.94 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -176.36 -172.24 40.87 Favored Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.706 -0.759 . . . . 44.44 112.482 -179.997 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 22' ' ' TYR . . . . . . . . . . . . . 0.4 OUTLIER -164.08 -169.65 1.9 Allowed 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 120.843 0.354 . . . . 73.13 110.96 -179.844 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 23' ' ' MET . . . . . . . . . . . . . 33.0 mmt -82.34 148.93 28.02 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.112 -0.494 . . . . 73.01 110.913 179.867 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 171.29 -121.94 0.93 Allowed Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.78 -0.724 . . . . 70.5 112.479 -179.972 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 25' ' ' THR . . . . . 0.718 HG21 HG23 ' A' ' 42' ' ' VAL . 85.8 m -122.24 133.29 54.71 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.829 0.347 . . . . 61.22 111.147 -179.858 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -71.41 123.17 21.76 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.212 -0.449 . . . . 75.31 110.898 -179.861 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 27' ' ' ALA . . . . . 0.827 ' HB3' HG23 ' A' ' 39' ' ' ILE . . . -140.03 162.74 34.5 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.122 -0.49 . . . . 63.0 111.113 179.921 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 28' ' ' THR . . . . . 0.501 HG22 ' O ' ' A' ' 28' ' ' THR . 16.9 m -129.6 88.54 2.7 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.246 -0.434 . . . . 73.21 111.116 -179.913 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 29' ' ' ILE . . . . . 0.766 HG23 ' CB ' ' A' ' 39' ' ' ILE . 2.0 pt -45.12 129.75 1.83 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.385 0 CA-C-N 116.264 -0.425 . . . . 75.51 111.123 179.876 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 30' ' ' THR . . . . . 0.711 HG23 ' O ' ' A' ' 35' ' ' SER . 7.0 m -152.97 98.53 2.32 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.24 -0.437 . . . . 74.05 111.179 179.917 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 31' ' ' SER . . . . . 0.441 ' OG ' HG22 ' A' ' 80' ' ' THR . 12.1 t -138.38 71.11 1.39 Allowed 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.246 -0.434 . . . . 71.44 110.817 -179.854 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -178.72 168.17 38.99 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.751 -0.738 . . . . 74.23 112.508 179.959 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 15.4 pt-20 -49.38 -23.46 1.49 Allowed 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.781 0.324 . . . . 53.42 110.835 -179.844 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 4.8 tt0 -174.68 94.84 0.08 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.166 -0.47 . . . . 52.13 110.907 -179.916 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 35' ' ' SER . . . . . 0.711 ' O ' HG23 ' A' ' 30' ' ' THR . 3.3 m -144.97 165.71 27.4 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.214 -0.448 . . . . 70.14 110.891 -179.834 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 178.35 88.21 0.07 OUTLIER Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.811 -0.709 . . . . 63.42 112.505 -179.977 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 37' ' ' ALA . . . . . 0.666 ' HB3' ' CD1' ' A' ' 29' ' ' ILE . . . -109.6 -172.81 2.12 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.849 0.357 . . . . 44.03 111.088 -179.984 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 61.9 t -97.75 121.9 48.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.238 -0.437 . . . . 62.4 111.123 179.962 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 39' ' ' ILE . . . . . 0.827 HG23 ' HB3' ' A' ' 27' ' ' ALA . 0.0 OUTLIER -137.62 150.12 25.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.126 -0.488 . . . . 74.32 111.157 179.898 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 40' ' ' ARG . . . . . 0.657 ' O ' HG12 ' A' ' 67' ' ' VAL . 5.4 ttm180 -109.69 80.3 1.3 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.24 -0.436 . . . . 73.0 110.873 179.987 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 41' ' ' GLY . . . . . 0.499 ' N ' HD13 ' A' ' 39' ' ' ILE . . . -129.18 147.44 17.75 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.774 -0.727 . . . . 74.14 112.46 -179.955 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 42' ' ' VAL . . . . . 0.718 HG23 HG21 ' A' ' 25' ' ' THR . 2.8 p -126.49 136.59 60.37 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-O 120.845 0.355 . . . . 74.12 111.072 -179.971 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 43' ' ' PHE . . . . . 0.658 ' H ' HD11 ' A' ' 83' ' ' ILE . 1.3 p90 -93.72 130.77 39.57 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.218 -0.446 . . . . 73.12 110.872 179.96 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 12.6 t70 -117.04 124.76 50.08 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.121 -0.49 . . . . 61.12 110.87 179.956 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -122.51 149.94 56.59 Favored Pre-proline 0 C--N 1.328 -0.327 0 CA-C-O 121.575 0.702 . . . . 73.33 110.877 179.999 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 46' ' ' PRO . . . . . . . . . . . . . 52.5 Cg_endo -69.93 -39.03 6.65 Favored 'Trans proline' 0 C--O 1.232 0.186 0 C-N-CA 122.689 2.259 . . . . 73.5 112.297 -179.94 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 17.1 tt0 -161.76 95.92 1.01 Allowed 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.29 -0.414 . . . . 73.14 110.891 179.96 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 19.8 t-20 -52.47 106.84 0.17 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.116 -0.493 . . . . 73.24 110.908 -179.913 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 26.0 mm -70.03 149.96 10.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.117 -0.492 . . . . 72.13 111.143 179.942 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 20.4 t -112.15 131.39 55.48 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.241 -0.436 . . . . 72.4 110.776 -179.855 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 45.7 p90 -75.35 177.28 6.71 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.11 -0.495 . . . . 62.34 110.964 -179.934 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -111.27 -67.22 1.01 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.137 -0.483 . . . . 75.55 111.133 179.854 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -170.26 -116.16 0.37 Allowed Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.797 -0.716 . . . . 65.43 112.574 -179.993 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 54' ' ' GLN . . . . . . . . . . . . . 5.2 tt0 -82.56 57.93 3.96 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.872 0.368 . . . . 72.41 110.952 -179.959 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -164.91 100.69 0.18 Allowed Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.665 -0.778 . . . . 50.02 112.46 -179.993 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 56' ' ' VAL . . . . . 0.71 HG12 ' H ' ' A' ' 58' ' ' VAL . 39.2 t -63.31 124.58 18.22 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-O 120.758 0.313 . . . . 61.33 111.213 -179.998 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -59.88 -23.0 63.09 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.204 -0.453 . . . . 64.23 110.884 -179.936 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 58' ' ' VAL . . . . . 0.71 ' H ' HG12 ' A' ' 56' ' ' VAL . 21.0 t 64.31 63.16 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-N 116.19 -0.459 . . . . 71.13 111.122 179.955 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 46.4 tt0 -170.37 147.51 3.04 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.122 -0.49 . . . . 74.22 110.891 -179.992 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -145.98 120.72 1.36 Allowed Glycine 0 N--CA 1.45 -0.433 0 C-N-CA 120.786 -0.721 . . . . 71.24 112.499 -179.923 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 1.7 t -89.95 155.4 19.14 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.869 0.366 . . . . 41.44 110.907 -179.758 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 62' ' ' SER . . . . . 0.413 ' HA ' ' HD2' ' A' ' 63' ' ' PRO . 1.9 p -106.14 97.72 16.7 Favored Pre-proline 0 C--N 1.33 -0.267 0 CA-C-O 121.669 0.747 . . . . 73.52 110.886 -179.804 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 63' ' ' PRO . . . . . 0.413 ' HD2' ' HA ' ' A' ' 62' ' ' SER . 53.1 Cg_endo -69.78 -178.0 2.15 Favored 'Trans proline' 0 C--N 1.342 0.198 0 C-N-CA 122.679 2.253 . . . . 55.25 112.315 -179.988 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 64' ' ' SER . . . . . 0.502 ' O ' ' HA ' ' A' ' 43' ' ' PHE . 1.5 t -106.32 148.15 28.36 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.222 -0.444 . . . . 62.24 110.915 -179.922 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 65' ' ' LEU . . . . . 0.666 ' O ' HD23 ' A' ' 65' ' ' LEU . 0.0 OUTLIER -112.68 140.45 47.44 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.118 -0.492 . . . . 63.01 110.901 179.996 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 66' ' ' PHE . . . . . 0.63 ' HB3' HG12 ' A' ' 42' ' ' VAL . 17.8 t80 -118.47 107.97 14.45 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.156 -0.475 . . . . 70.55 110.896 179.904 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 67' ' ' VAL . . . . . 0.657 HG12 ' O ' ' A' ' 40' ' ' ARG . 4.3 m -141.98 166.79 16.4 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.18 -0.463 . . . . 75.54 111.057 -179.949 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 68' ' ' ARG . . . . . 0.619 ' O ' HG23 ' A' ' 72' ' ' VAL . 2.8 ttm180 -103.23 144.19 31.66 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.156 -0.475 . . . . 72.15 110.921 179.984 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 69' ' ' THR . . . . . 0.403 ' HB ' ' HG3' ' A' ' 95' ' ' PRO . 2.0 t -40.32 -47.3 2.48 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.245 -0.434 . . . . 73.0 111.138 -179.92 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 46.8 m-20 -52.97 -62.03 1.92 Allowed 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.224 -0.444 . . . . 72.4 110.859 179.924 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 71' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -53.39 -40.44 65.04 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.235 -0.439 . . . . 64.44 110.903 -179.915 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 72' ' ' VAL . . . . . 0.619 HG23 ' O ' ' A' ' 68' ' ' ARG . 14.4 t -69.39 -33.84 59.49 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.125 -0.489 . . . . 70.52 111.12 179.946 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 73' ' ' ARG . . . . . . . . . . . . . 18.9 ttm180 -62.17 -39.89 94.19 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.205 -0.452 . . . . 73.05 110.836 -179.96 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 29.9 mt-30 -55.04 -22.58 16.28 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.219 -0.446 . . . . 72.12 110.874 -179.932 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 75' ' ' LEU . . . . . 0.511 HD21 HG21 ' A' ' 29' ' ' ILE . 4.5 mp -113.03 -168.73 1.36 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.234 -0.439 . . . . 73.41 110.912 -179.969 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 76' ' ' ARG . . . . . . . . . . . . . 11.1 ptp180 -124.12 -178.96 4.24 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.182 -0.463 . . . . 74.22 110.871 179.974 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 77' ' ' ARG . . . . . 0.47 ' HD3' ' HB3' ' A' ' 13' ' ' ALA . 4.7 mtp180 -70.05 130.56 42.48 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.155 -0.475 . . . . 74.33 110.926 -179.957 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 78' ' ' GLY . . . . . 0.401 ' HA2' ' CD1' ' A' ' 89' ' ' TRP . . . 92.42 36.47 6.2 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.767 -0.73 . . . . 33.52 112.453 -179.976 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 79' ' ' ASP . . . . . 0.486 ' OD1' HD23 ' A' ' 75' ' ' LEU . 0.6 OUTLIER -99.13 105.46 17.55 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.859 0.362 . . . . 71.15 110.926 179.994 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 80' ' ' THR . . . . . 0.742 ' HA ' ' HA ' ' A' ' 89' ' ' TRP . 0.8 OUTLIER -89.61 108.56 19.74 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.199 -0.455 . . . . 70.44 111.102 -179.851 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 81' ' ' LEU . . . . . 0.768 ' C ' ' HA ' ' A' ' 87' ' ' ASN . 0.0 OUTLIER -96.05 135.42 37.85 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.132 -0.485 . . . . 71.24 110.93 179.956 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 82' ' ' THR . . . . . 0.714 ' CA ' ' HA ' ' A' ' 87' ' ' ASN . 8.9 t -94.99 101.64 13.41 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.267 -0.424 . . . . 73.45 111.124 179.958 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 83' ' ' ILE . . . . . 0.732 HD13 ' O ' ' A' ' 83' ' ' ILE . 0.1 OUTLIER -135.58 132.58 51.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.236 -0.438 . . . . 73.14 111.128 179.913 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 73.08 -54.37 1.81 Allowed Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.761 -0.733 . . . . 65.53 112.486 179.936 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 3.0 mm-40 -115.54 -83.18 0.62 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.787 0.327 . . . . 54.43 110.837 -179.829 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 7.6 mp0 -150.02 159.45 44.39 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.195 -0.457 . . . . 61.43 110.883 -179.946 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 87' ' ' ASN . . . . . 0.768 ' HA ' ' C ' ' A' ' 81' ' ' LEU . 0.7 OUTLIER -50.28 124.05 9.66 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.152 -0.476 . . . . 63.13 110.876 -179.868 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 88' ' ' PHE . . . . . 0.748 ' HB3' HD13 ' A' ' 105' ' ' LEU . 15.9 m-85 -131.09 119.61 22.2 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.113 -0.494 . . . . 73.55 110.857 -179.956 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 89' ' ' TRP . . . . . 0.742 ' HA ' ' HA ' ' A' ' 80' ' ' THR . 0.0 OUTLIER -79.23 135.55 36.81 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 116.121 -0.491 . . . . 72.01 110.921 -179.993 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 90' ' ' VAL . . . . . 0.682 HG21 HG13 ' A' ' 93' ' ' VAL . 3.0 p -91.55 136.08 25.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.207 -0.451 . . . . 72.34 111.161 179.951 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -63.24 -72.35 0.14 Allowed 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.185 -0.461 . . . . 71.21 110.888 179.926 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 92' ' ' ARG . . . . . 0.569 ' O ' ' HG ' ' A' ' 103' ' ' LEU . 9.0 ptm180 -159.71 122.12 3.43 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.164 -0.471 . . . . 74.32 110.954 -179.936 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 93' ' ' VAL . . . . . 0.699 HG12 ' HB2' ' A' ' 103' ' ' LEU . 26.0 m -113.63 136.88 48.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.191 -0.459 . . . . 72.42 111.083 -179.956 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 94' ' ' SER . . . . . 0.423 ' HA ' ' HD2' ' A' ' 95' ' ' PRO . 7.0 t -129.32 100.31 20.31 Favored Pre-proline 0 C--N 1.329 -0.307 0 CA-C-O 121.673 0.749 . . . . 41.05 110.821 -179.84 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 95' ' ' PRO . . . . . 0.423 ' HD2' ' HA ' ' A' ' 94' ' ' SER . 53.5 Cg_endo -69.81 169.59 18.62 Favored 'Trans proline' 0 C--N 1.342 0.186 0 C-N-CA 122.629 2.22 . . . . 75.43 112.312 179.958 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 11.7 t0 -129.64 1.58 4.96 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.186 -0.461 . . . . 75.2 110.837 179.923 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 4.5 p30 -139.27 29.29 2.22 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.196 -0.457 . . . . 72.01 110.859 179.98 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 51.04 55.95 16.42 Favored Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.759 -0.734 . . . . 53.4 112.469 -179.953 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 99' ' ' GLY . . . . . 0.426 ' HA2' ' HG3' ' A' ' 68' ' ' ARG . . . 145.05 35.21 0.07 OUTLIER Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.655 -0.783 . . . . 72.21 112.495 -179.904 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 46.7 t -151.61 71.31 0.98 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.791 0.329 . . . . 73.53 110.878 -179.675 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 101' ' ' CYS . . . . . 0.463 ' CB ' ' HB ' ' A' ' 93' ' ' VAL . 0.0 OUTLIER -110.16 148.54 31.59 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.131 -0.486 . . . . 75.21 110.931 -179.976 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 102' ' ' HIS . . . . . 0.613 ' HA ' ' O ' ' A' ' 65' ' ' LEU . 24.8 p80 -160.37 126.28 4.06 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.225 -0.443 . . . . 64.24 110.953 179.99 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 103' ' ' LEU . . . . . 0.926 HD13 ' N ' ' A' ' 104' ' ' TRP . 2.5 tm? -151.22 147.55 27.14 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.272 -0.422 . . . . 62.45 110.926 -179.96 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 104' ' ' TRP . . . . . 0.926 ' N ' HD13 ' A' ' 103' ' ' LEU . 22.2 m-90 -63.43 114.45 3.88 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 116.208 -0.451 . . . . 71.24 110.922 179.91 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 105' ' ' LEU . . . . . 0.748 HD13 ' HB3' ' A' ' 88' ' ' PHE . 0.3 OUTLIER -93.7 162.0 14.11 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.255 -0.43 . . . . 63.22 110.912 -179.987 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -88.83 160.63 30.12 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.741 -0.743 . . . . 75.5 112.523 179.878 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 107' ' ' ARG . . . . . 0.57 ' HA ' ' CD1' ' A' ' 88' ' ' PHE . 3.1 ptt85 -67.9 157.31 35.23 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.858 0.361 . . . . 74.24 110.893 -179.887 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -173.97 110.52 0.33 Allowed Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.756 -0.735 . . . . 72.14 112.478 -179.979 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 109' ' ' VAL . . . . . 0.475 HG13 ' HD2' ' A' ' 110' ' ' PRO . 58.1 t -84.72 134.46 41.92 Favored Pre-proline 0 C--N 1.33 -0.276 0 CA-C-O 121.629 0.728 . . . . 72.4 111.135 -179.988 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 110' ' ' PRO . . . . . 0.475 ' HD2' HG13 ' A' ' 109' ' ' VAL . 52.6 Cg_endo -69.85 170.0 17.71 Favored 'Trans proline' 0 C--N 1.341 0.173 0 C-N-CA 122.675 2.25 . . . . 63.15 112.263 -179.971 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 111' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.77 -4.47 14.11 Favored 'Trans proline' 0 C--N 1.342 0.232 0 C-N-CA 122.697 2.265 . . . . 72.02 112.289 -179.98 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -58.16 162.16 3.68 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.246 -0.434 . . . . 40.22 111.082 179.899 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 113' ' ' VAL . . . . . 0.422 ' O ' HG13 ' A' ' 113' ' ' VAL . 5.3 p -91.81 119.62 39.49 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 CA-C-N 116.165 -0.471 . . . . 70.25 111.117 -179.984 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 114' ' ' ASN . . . . . . . . . . . . . 5.5 t30 -128.75 146.82 50.79 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.145 -0.479 . . . . 71.34 110.863 179.974 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 5.2 mmt180 -81.66 101.95 10.38 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.141 -0.481 . . . . 74.25 110.881 -179.985 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 116' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -116.3 139.5 50.32 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.198 -0.455 . . . . 71.42 110.811 -179.918 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 3.3 mtt180 . . . . . 0 C--N 1.329 -0.295 0 CA-C-N 116.186 -0.461 . . . . 74.54 110.852 -179.898 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 12.0 mmt . . . . . 0 N--CA 1.458 -0.04 0 CA-C-O 120.78 0.324 . . . . 64.32 110.861 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -171.69 173.68 4.53 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.226 -0.443 . . . . 54.31 111.101 179.941 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 3' ' ' ASP . . . . . . . . . . . . . 3.7 p-10 -161.11 179.84 8.08 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.202 -0.454 . . . . 72.32 110.841 179.977 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 4' ' ' PHE . . . . . . . . . . . . . 51.1 p90 -174.26 156.38 2.57 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.157 -0.474 . . . . 75.24 110.857 -179.907 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 3.7 m-20 -142.81 153.09 42.89 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.159 -0.473 . . . . 74.43 110.894 179.993 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 6' ' ' ASN . . . . . . . . . . . . . 3.5 p-10 -138.24 111.73 8.13 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.239 -0.437 . . . . 72.12 110.87 -179.916 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 7' ' ' LEU . . . . . . . . . . . . . 3.5 mm? -51.5 163.35 0.28 Allowed 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.106 -0.497 . . . . 53.25 110.835 179.99 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 8' ' ' PHE . . . . . . . . . . . . . 67.4 m-85 -125.9 115.01 19.28 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.152 -0.477 . . . . 62.42 110.876 179.966 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 9.1 m-20 -71.01 83.45 0.68 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.17 -0.468 . . . . 60.51 110.886 179.966 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -114.89 148.47 38.58 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.13 -0.486 . . . . 72.43 111.064 179.99 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -79.31 104.34 9.86 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.251 -0.431 . . . . 62.23 111.133 179.925 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 29.9 mt -123.83 64.9 0.29 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.356 0 CA-C-N 116.229 -0.441 . . . . 71.51 111.161 179.96 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -171.32 124.63 0.61 Allowed 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.177 -0.465 . . . . 64.31 111.093 179.835 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 9.7 mpt_? -92.87 62.0 3.61 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.151 -0.477 . . . . 72.21 110.876 -179.884 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -134.63 -176.33 4.19 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.11 -0.496 . . . . 71.34 111.077 179.996 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 11.2 p-10 -104.52 112.38 25.42 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.192 -0.458 . . . . 72.14 110.88 179.984 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 5.5 pt-20 -134.04 158.65 43.01 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.21 -0.45 . . . . 75.42 110.966 -179.962 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -156.81 173.99 16.15 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.193 -0.458 . . . . 73.1 111.165 -179.912 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 19' ' ' ILE . . . . . 0.442 ' O ' HG23 ' A' ' 19' ' ' ILE . 8.5 tt -134.29 109.71 12.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.241 -0.436 . . . . 65.53 111.115 179.914 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 20' ' ' ARG . . . . . 0.508 HH12 HG21 ' A' ' 38' ' ' VAL . 52.5 mtp180 -96.14 143.8 26.94 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.117 -0.492 . . . . 70.32 110.836 -179.989 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 161.37 118.45 0.48 Allowed Glycine 0 C--N 1.33 0.238 0 C-N-CA 120.728 -0.748 . . . . 50.15 112.416 -179.983 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 22' ' ' TYR . . . . . . . . . . . . . 0.5 OUTLIER -136.16 -53.39 0.74 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.849 0.356 . . . . 74.42 110.873 -179.822 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 23' ' ' MET . . . . . . . . . . . . . 2.3 tpt -80.71 -59.73 2.57 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.156 -0.475 . . . . 73.32 110.869 179.916 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 126.53 -17.53 6.5 Favored Glycine 0 N--CA 1.452 -0.279 0 C-N-CA 120.685 -0.769 . . . . 51.35 112.482 -179.935 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 25' ' ' THR . . . . . 0.594 ' O ' ' HA ' ' A' ' 40' ' ' ARG . 60.7 p -94.42 107.49 19.46 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.785 0.326 . . . . 74.32 111.139 -179.85 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -77.53 121.76 24.32 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.227 -0.442 . . . . 62.44 110.849 -179.822 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 27' ' ' ALA . . . . . 0.793 ' HB3' HG23 ' A' ' 39' ' ' ILE . . . -151.7 161.46 42.64 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.123 -0.489 . . . . 63.51 111.132 179.891 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 28' ' ' THR . . . . . 0.537 HG22 ' O ' ' A' ' 28' ' ' THR . 11.0 m -130.84 88.87 2.67 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.177 -0.465 . . . . 75.24 111.117 -179.852 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 29' ' ' ILE . . . . . 0.798 HG23 ' CB ' ' A' ' 39' ' ' ILE . 1.7 pt -43.49 128.75 1.11 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.198 -0.456 . . . . 72.43 111.133 179.902 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 30' ' ' THR . . . . . 0.688 HG23 ' O ' ' A' ' 35' ' ' SER . 7.1 m -153.76 99.0 2.25 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.199 -0.455 . . . . 70.31 111.148 179.949 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 18.7 t -140.8 72.94 1.4 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.222 -0.444 . . . . 62.43 110.845 -179.84 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -178.53 166.57 36.51 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.72 -0.753 . . . . 70.14 112.512 -179.968 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 10.6 pt-20 -48.96 -23.72 1.23 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.738 0.304 . . . . 74.11 110.873 -179.892 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 4.1 tt0 -174.1 93.5 0.09 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.15 -0.477 . . . . 62.41 110.944 -179.949 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 35' ' ' SER . . . . . 0.688 ' O ' HG23 ' A' ' 30' ' ' THR . 2.0 m -144.87 165.53 27.87 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.243 -0.435 . . . . 73.51 110.84 -179.791 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -179.86 85.21 0.06 OUTLIER Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.746 -0.74 . . . . 74.31 112.513 179.936 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 37' ' ' ALA . . . . . 0.619 ' HB3' ' CD1' ' A' ' 29' ' ' ILE . . . -106.93 -173.83 2.39 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.886 0.374 . . . . 54.05 111.1 -179.996 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 38' ' ' VAL . . . . . 0.508 HG21 HH12 ' A' ' 20' ' ' ARG . 57.5 t -99.36 124.85 52.92 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.171 -0.468 . . . . 74.04 111.124 179.99 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 39' ' ' ILE . . . . . 0.798 ' CB ' HG23 ' A' ' 29' ' ' ILE . 0.0 OUTLIER -137.15 149.35 26.05 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 116.223 -0.444 . . . . 73.24 111.111 179.97 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 40' ' ' ARG . . . . . 0.665 ' O ' HG12 ' A' ' 67' ' ' VAL . 0.2 OUTLIER -107.84 82.02 1.59 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.192 -0.458 . . . . 74.33 110.907 179.931 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 41' ' ' GLY . . . . . 0.608 ' O ' ' HB2' ' A' ' 27' ' ' ALA . . . -141.6 142.75 12.26 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.685 -0.769 . . . . 43.24 112.482 -179.94 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 42' ' ' VAL . . . . . 0.545 ' O ' ' HA ' ' A' ' 65' ' ' LEU . 9.0 p -128.57 141.3 46.91 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-O 120.815 0.34 . . . . 74.43 111.144 -179.939 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 43' ' ' PHE . . . . . 0.784 ' H ' HD11 ' A' ' 83' ' ' ILE . 1.8 p90 -90.28 135.88 33.4 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.228 -0.442 . . . . 73.24 110.938 179.964 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 11.4 t70 -126.15 125.27 42.21 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.221 -0.445 . . . . 71.14 110.852 179.99 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -101.17 153.27 37.88 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-O 121.619 0.723 . . . . 75.32 110.855 179.943 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 46' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_endo -69.73 -48.15 0.79 Allowed 'Trans proline' 0 C--N 1.341 0.158 0 C-N-CA 122.715 2.277 . . . . 63.32 112.334 179.991 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 25.0 tt0 -178.86 105.91 0.04 OUTLIER 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.247 -0.433 . . . . 74.33 110.881 -179.95 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 11.2 t30 -51.86 105.35 0.11 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.228 -0.442 . . . . 73.14 110.883 -179.936 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 10.1 tp -72.25 143.48 14.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.145 -0.48 . . . . 63.42 111.139 179.923 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 3.0 t -107.79 -170.61 1.72 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.157 -0.474 . . . . 75.44 110.904 -179.917 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 43.9 t80 -52.54 158.41 1.27 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.165 -0.47 . . . . 74.25 110.912 -179.865 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -123.46 -74.48 0.61 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.159 -0.473 . . . . 55.32 111.099 179.907 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 111.8 38.83 1.37 Allowed Glycine 0 N--CA 1.452 -0.249 0 C-N-CA 120.723 -0.751 . . . . 62.44 112.437 -179.985 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 54' ' ' GLN . . . . . . . . . . . . . 24.8 mt-30 -126.1 -37.77 2.22 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.927 0.394 . . . . 61.41 110.948 -179.919 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 120.33 19.39 3.88 Favored Glycine 0 N--CA 1.452 -0.272 0 C-N-CA 120.674 -0.774 . . . . 74.44 112.502 -179.938 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 22.3 t -137.33 92.28 0.88 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-O 120.839 0.352 . . . . 70.25 111.097 -179.857 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 8.8 mpt_? -57.68 170.66 0.55 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.208 -0.451 . . . . 74.03 110.797 -179.968 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 11.2 p -51.63 147.06 1.6 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.136 -0.484 . . . . 71.02 111.124 179.978 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -80.27 -75.18 0.27 Allowed 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.174 -0.467 . . . . 65.1 110.886 179.99 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -150.14 149.19 21.05 Favored Glycine 0 N--CA 1.452 -0.267 0 C-N-CA 120.677 -0.773 . . . . 33.23 112.477 -179.945 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -124.48 125.42 44.21 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.853 0.358 . . . . 74.52 110.855 -179.732 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 89.3 p -129.19 97.88 24.85 Favored Pre-proline 0 C--N 1.328 -0.328 0 CA-C-O 121.666 0.746 . . . . 73.23 110.895 -179.886 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.74 166.18 28.44 Favored 'Trans proline' 0 C--N 1.341 0.162 0 C-N-CA 122.638 2.225 . . . . 71.05 112.327 -179.994 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 3.5 t -106.92 142.87 35.85 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.196 -0.456 . . . . 75.22 110.842 -179.839 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 65' ' ' LEU . . . . . 0.613 ' O ' HD23 ' A' ' 65' ' ' LEU . 0.0 OUTLIER -114.88 119.76 37.67 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.163 -0.471 . . . . 60.25 110.926 -179.991 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 56.0 t80 -101.76 109.81 21.66 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.226 -0.443 . . . . 54.24 110.85 179.98 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 67' ' ' VAL . . . . . 0.665 HG12 ' O ' ' A' ' 40' ' ' ARG . 22.3 m -138.13 169.2 18.9 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.159 -0.473 . . . . 64.43 111.163 179.895 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 68' ' ' ARG . . . . . 0.469 ' O ' HG23 ' A' ' 72' ' ' VAL . 1.1 ttp180 -93.43 143.82 25.92 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.191 -0.459 . . . . 64.22 110.919 -179.983 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 69' ' ' THR . . . . . 0.442 HG22 ' HA2' ' A' ' 99' ' ' GLY . 2.4 t -45.47 -47.74 13.95 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.241 -0.436 . . . . 74.53 111.039 -179.868 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 70' ' ' ASP . . . . . 0.411 ' N ' HG23 ' A' ' 69' ' ' THR . 30.5 t70 -52.18 -52.84 49.56 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.197 -0.456 . . . . 75.13 110.923 179.928 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 71' ' ' GLU . . . . . . . . . . . . . 66.0 mm-40 -54.41 -39.29 67.16 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.246 -0.434 . . . . 75.24 110.909 -179.947 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 72' ' ' VAL . . . . . 0.469 HG23 ' O ' ' A' ' 68' ' ' ARG . 4.4 t -73.49 -38.45 52.7 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.16 -0.473 . . . . 74.22 111.172 179.925 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 73' ' ' ARG . . . . . . . . . . . . . 2.6 tmt_? -55.69 -40.02 71.79 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.187 -0.46 . . . . 74.12 110.907 -179.985 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 41.7 mt-30 -52.64 -25.86 12.0 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.245 -0.434 . . . . 71.24 110.962 -179.995 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 75' ' ' LEU . . . . . 0.496 HD21 ' CD1' ' A' ' 29' ' ' ILE . 2.5 mp -116.25 -166.64 1.17 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.163 -0.472 . . . . 62.3 110.951 179.942 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 76' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -112.35 -178.67 3.47 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.204 -0.453 . . . . 74.34 110.845 179.925 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -76.05 125.89 29.97 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.184 -0.462 . . . . 72.31 110.925 -179.929 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 99.77 23.94 10.39 Favored Glycine 0 N--CA 1.45 -0.383 0 C-N-CA 120.768 -0.729 . . . . 34.42 112.505 -179.912 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -82.63 109.31 16.7 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.876 0.369 . . . . 73.02 110.916 179.968 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 80' ' ' THR . . . . . 0.737 ' HA ' ' HA ' ' A' ' 89' ' ' TRP . 0.5 OUTLIER -88.37 109.64 20.15 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.209 -0.45 . . . . 71.34 111.16 -179.906 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 81' ' ' LEU . . . . . 0.806 ' C ' ' HA ' ' A' ' 87' ' ' ASN . 0.0 OUTLIER -96.82 134.37 40.21 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 116.227 -0.442 . . . . 55.44 110.956 179.949 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 82' ' ' THR . . . . . 0.729 ' CA ' ' HA ' ' A' ' 87' ' ' ASN . 4.9 t -92.63 101.79 14.21 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.187 -0.461 . . . . 72.12 111.183 179.975 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 83' ' ' ILE . . . . . 0.784 HD11 ' H ' ' A' ' 43' ' ' PHE . 0.1 OUTLIER -132.92 130.45 58.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.219 -0.446 . . . . 74.12 111.118 179.975 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 70.42 -62.37 0.83 Allowed Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.749 -0.739 . . . . 75.03 112.458 179.924 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 10.1 tp10 -103.07 -81.83 0.5 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.806 0.336 . . . . 75.45 110.908 -179.891 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 86' ' ' GLU . . . . . 0.427 ' C ' ' HA ' ' A' ' 82' ' ' THR . 95.7 mt-10 -152.91 160.7 43.07 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.143 -0.48 . . . . 73.43 110.923 -179.923 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 87' ' ' ASN . . . . . 0.806 ' HA ' ' C ' ' A' ' 81' ' ' LEU . 1.3 p-10 -51.55 124.64 12.62 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.153 -0.476 . . . . 60.32 110.893 -179.908 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 88' ' ' PHE . . . . . 0.634 ' HB2' HD22 ' A' ' 105' ' ' LEU . 15.3 m-85 -132.77 120.27 21.4 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.176 -0.465 . . . . 74.42 110.932 179.999 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 89' ' ' TRP . . . . . 0.737 ' HA ' ' HA ' ' A' ' 80' ' ' THR . 7.1 p90 -80.01 137.0 36.72 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.179 -0.464 . . . . 64.43 111.005 -179.981 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 90' ' ' VAL . . . . . 0.569 HG21 ' CG1' ' A' ' 93' ' ' VAL . 7.2 p -89.64 135.97 24.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.318 -0.401 . . . . 62.44 111.161 179.893 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 91' ' ' ASP . . . . . 0.422 ' HB3' HD12 ' A' ' 103' ' ' LEU . 0.0 OUTLIER -64.28 -67.76 0.41 Allowed 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.155 -0.475 . . . . 73.2 110.907 179.891 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 92' ' ' ARG . . . . . 0.646 ' O ' ' HG ' ' A' ' 103' ' ' LEU . 13.3 ttm-85 -162.76 122.26 2.25 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.238 -0.437 . . . . 75.24 110.897 -179.939 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 93' ' ' VAL . . . . . 0.741 HG12 ' HB2' ' A' ' 103' ' ' LEU . 22.7 m -117.9 135.42 58.37 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.144 -0.48 . . . . 73.13 111.111 179.966 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 94' ' ' SER . . . . . 0.425 ' HA ' ' HD2' ' A' ' 95' ' ' PRO . 1.1 p -129.36 103.24 18.12 Favored Pre-proline 0 C--N 1.329 -0.285 0 CA-C-O 121.585 0.707 . . . . 65.45 110.856 -179.823 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 95' ' ' PRO . . . . . 0.425 ' HD2' ' HA ' ' A' ' 94' ' ' SER . 53.6 Cg_endo -69.76 -176.15 1.39 Allowed 'Trans proline' 0 C--O 1.231 0.142 0 C-N-CA 122.657 2.238 . . . . 74.3 112.31 -179.947 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 66.5 m-20 -124.66 -36.25 2.62 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.185 -0.461 . . . . 74.42 110.853 179.962 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 4.5 t70 177.7 117.65 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.199 -0.455 . . . . 72.14 110.858 179.959 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 93.22 39.74 5.02 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.724 -0.75 . . . . 61.15 112.516 -179.894 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 99' ' ' GLY . . . . . 0.442 ' HA2' HG22 ' A' ' 69' ' ' THR . . . 46.62 68.4 1.12 Allowed Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.699 -0.762 . . . . 74.15 112.5 -179.889 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 1.7 m -125.29 71.67 1.21 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.89 0.376 . . . . 74.25 110.874 -179.755 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 101' ' ' CYS . . . . . 0.485 ' CB ' ' HB ' ' A' ' 93' ' ' VAL . 0.0 OUTLIER -106.0 150.02 26.1 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.128 -0.487 . . . . 65.52 110.886 -179.939 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 102' ' ' HIS . . . . . 0.526 ' HA ' ' O ' ' A' ' 65' ' ' LEU . 19.6 p-80 -160.92 123.54 3.19 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.198 -0.456 . . . . 74.11 110.89 -179.951 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 103' ' ' LEU . . . . . 0.841 HD13 ' N ' ' A' ' 104' ' ' TRP . 2.1 tm? -152.91 147.67 26.25 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.203 -0.453 . . . . 73.15 110.918 -179.964 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 104' ' ' TRP . . . . . 0.841 ' N ' HD13 ' A' ' 103' ' ' LEU . 30.9 p90 -63.99 117.52 7.15 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 116.178 -0.465 . . . . 74.21 110.891 179.951 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 105' ' ' LEU . . . . . 0.634 HD22 ' HB2' ' A' ' 88' ' ' PHE . 0.3 OUTLIER -94.12 162.92 13.68 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 116.268 -0.424 . . . . 71.44 110.928 179.989 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -88.84 159.74 29.39 Favored Glycine 0 N--CA 1.453 -0.219 0 C-N-CA 120.705 -0.76 . . . . 61.33 112.477 179.9 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 107' ' ' ARG . . . . . 0.554 ' HA ' ' CD1' ' A' ' 88' ' ' PHE . 4.3 ptp180 -66.84 157.29 33.42 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.847 0.356 . . . . 74.13 110.883 -179.882 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -173.1 111.61 0.39 Allowed Glycine 0 N--CA 1.452 -0.272 0 C-N-CA 120.717 -0.754 . . . . 42.4 112.468 -179.916 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 109' ' ' VAL . . . . . 0.448 HG23 ' HD2' ' A' ' 110' ' ' PRO . 7.2 p -86.42 133.96 39.2 Favored Pre-proline 0 C--N 1.33 -0.264 0 CA-C-O 121.567 0.698 . . . . 64.44 111.157 179.999 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 110' ' ' PRO . . . . . 0.448 ' HD2' HG23 ' A' ' 109' ' ' VAL . 53.1 Cg_endo -69.76 167.53 24.17 Favored 'Trans proline' 0 C--O 1.232 0.175 0 C-N-CA 122.635 2.224 . . . . 72.32 112.328 179.987 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 111' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.8 -18.08 37.04 Favored 'Trans proline' 0 C--N 1.342 0.201 0 C-N-CA 122.685 2.256 . . . . 45.44 112.312 179.963 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -75.42 138.33 41.61 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.221 -0.445 . . . . 74.42 111.068 179.955 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 8.4 p -125.04 139.03 52.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.207 -0.451 . . . . 74.33 111.111 -179.951 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 114' ' ' ASN . . . . . . . . . . . . . 16.7 t30 -107.29 122.94 47.57 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.169 -0.469 . . . . 65.51 110.95 179.986 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 3.2 ptm180 -107.65 140.47 40.63 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.207 -0.452 . . . . 72.25 110.929 -179.992 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 116' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -114.47 135.37 54.18 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.221 -0.445 . . . . 75.23 110.894 -179.886 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 3.9 tmm_? . . . . . 0 C--N 1.329 -0.296 0 CA-C-N 116.156 -0.475 . . . . 70.55 110.894 -179.883 . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 2.0 mpt? . . . . . 0 C--O 1.23 0.065 0 CA-C-O 120.824 0.345 . . . . 73.23 110.857 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -166.25 163.26 17.74 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.196 -0.456 . . . . 71.24 111.123 179.961 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 3' ' ' ASP . . . . . . . . . . . . . 14.7 m-20 -137.57 -178.64 5.32 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.305 -0.407 . . . . 71.35 110.886 179.914 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 4' ' ' PHE . . . . . . . . . . . . . 66.2 m-85 -152.04 -175.72 5.36 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.194 -0.457 . . . . 70.44 110.862 -179.915 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 6.4 t0 -162.81 177.59 9.17 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.152 -0.476 . . . . 41.24 110.89 -179.985 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 6' ' ' ASN . . . . . . . . . . . . . 2.2 p30 -152.83 176.02 12.26 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.156 -0.475 . . . . 70.2 110.89 -179.898 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 7' ' ' LEU . . . . . . . . . . . . . 4.8 mp -127.15 -67.63 0.83 Allowed 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.178 -0.465 . . . . 72.42 110.976 179.948 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 8' ' ' PHE . . . . . . . . . . . . . 8.2 m-85 57.17 51.74 9.89 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.192 -0.458 . . . . 62.44 110.922 179.92 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 77.1 m-20 -75.23 -175.05 2.54 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.166 -0.47 . . . . 64.55 110.866 179.984 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -150.39 177.28 10.13 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.138 -0.483 . . . . 54.04 111.074 179.921 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -160.11 177.8 10.32 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.171 -0.468 . . . . 31.44 111.099 -179.993 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -132.25 -154.67 0.14 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.23 -0.441 . . . . 72.4 111.139 -179.98 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -173.68 178.34 2.29 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.194 -0.457 . . . . 64.54 111.081 179.842 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -155.85 -176.33 5.9 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.158 -0.474 . . . . 75.54 110.861 -179.944 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -138.18 179.1 6.65 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.16 -0.473 . . . . 51.41 111.159 179.882 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 21.9 m-20 -153.28 -174.05 4.8 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.246 -0.434 . . . . 74.32 110.879 179.969 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 49.6 mt-10 -125.11 177.66 5.97 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.157 -0.474 . . . . 72.54 110.83 -179.853 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -129.39 171.34 12.62 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.132 -0.485 . . . . 43.15 111.144 -179.986 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 61.5 mt -144.41 110.38 1.3 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.168 -0.469 . . . . 51.0 111.116 179.971 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 20' ' ' ARG . . . . . . . . . . . . . 25.5 mtp180 -98.91 179.06 4.76 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.163 -0.471 . . . . 72.41 110.837 179.974 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 120.61 120.31 2.76 Favored Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.748 -0.739 . . . . 60.25 112.499 -179.967 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 22' ' ' TYR . . . . . . . . . . . . . 52.7 t80 -162.24 107.0 1.2 Allowed 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.897 0.379 . . . . 74.34 110.973 -179.796 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 23' ' ' MET . . . . . . . . . . . . . 0.9 OUTLIER -175.02 145.31 0.8 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.113 -0.494 . . . . 64.32 110.845 179.939 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 102.76 -128.29 9.49 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.73 -0.748 . . . . 72.14 112.435 179.942 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 25' ' ' THR . . . . . 0.482 ' O ' ' HA ' ' A' ' 40' ' ' ARG . 1.3 t -111.67 111.71 22.89 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.746 0.308 . . . . 70.32 111.196 -179.828 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 20.6 p -72.86 123.46 23.44 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.258 -0.428 . . . . 63.2 110.799 -179.811 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 27' ' ' ALA . . . . . 0.783 ' HB3' HG23 ' A' ' 39' ' ' ILE . . . -146.79 162.83 37.78 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.109 -0.496 . . . . 63.11 111.079 179.882 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 28' ' ' THR . . . . . 0.505 HG22 ' O ' ' A' ' 28' ' ' THR . 14.4 m -130.69 89.6 2.79 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.164 -0.471 . . . . 75.31 111.183 -179.89 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 29' ' ' ILE . . . . . 0.856 HG21 HD21 ' A' ' 75' ' ' LEU . 2.2 pt -43.69 134.5 1.21 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.364 0 CA-C-N 116.239 -0.437 . . . . 72.52 111.167 179.936 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 30' ' ' THR . . . . . 0.593 HG23 ' O ' ' A' ' 35' ' ' SER . 26.7 m -155.29 98.24 1.97 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.183 -0.462 . . . . 72.12 111.104 179.979 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 96.8 p -134.7 70.14 1.45 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.146 -0.479 . . . . 71.43 110.859 -179.868 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -179.27 168.86 39.79 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.733 -0.746 . . . . 74.11 112.476 179.988 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 16.7 pt-20 -48.72 -24.2 1.31 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.731 0.301 . . . . 74.32 110.863 -179.799 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 29.9 tt0 -173.97 95.55 0.1 Allowed 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.14 -0.482 . . . . 64.31 110.956 -179.888 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 35' ' ' SER . . . . . 0.593 ' O ' HG23 ' A' ' 30' ' ' THR . 2.1 m -144.29 165.07 28.92 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.223 -0.444 . . . . 73.34 110.836 -179.751 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 179.59 89.43 0.08 OUTLIER Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.796 -0.716 . . . . 72.41 112.51 -179.954 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 37' ' ' ALA . . . . . 0.642 ' HB3' ' CD1' ' A' ' 29' ' ' ILE . . . -109.15 -170.71 1.71 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.83 0.348 . . . . 53.44 111.107 179.949 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 51.1 t -98.31 119.89 46.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.133 -0.485 . . . . 75.54 111.161 179.956 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 39' ' ' ILE . . . . . 0.787 HD12 HD13 ' A' ' 81' ' ' LEU . 0.0 OUTLIER -137.72 150.53 25.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.262 -0.426 . . . . 71.1 111.157 179.884 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 40' ' ' ARG . . . . . 0.482 ' HA ' ' O ' ' A' ' 25' ' ' THR . 19.2 mtt-85 -109.56 80.53 1.32 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.2 -0.455 . . . . 75.32 110.893 179.95 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 41' ' ' GLY . . . . . 0.437 ' N ' HD13 ' A' ' 39' ' ' ILE . . . -133.76 141.17 12.48 Favored Glycine 0 N--CA 1.452 -0.252 0 C-N-CA 120.77 -0.729 . . . . 42.43 112.478 -179.911 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 42' ' ' VAL . . . . . 0.445 HG23 ' OG1' ' A' ' 25' ' ' THR . 0.4 OUTLIER -124.22 139.01 51.89 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-O 120.818 0.342 . . . . 73.2 111.117 -179.935 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 43' ' ' PHE . . . . . 0.536 ' H ' HD11 ' A' ' 83' ' ' ILE . 2.4 p90 -96.15 132.21 41.79 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.199 -0.455 . . . . 54.1 110.87 179.981 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 12.9 t70 -114.6 124.29 51.49 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.141 -0.482 . . . . 52.33 110.899 179.918 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -105.62 153.09 40.13 Favored Pre-proline 0 C--N 1.328 -0.345 0 CA-C-O 121.624 0.726 . . . . 65.43 110.834 -179.97 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 46' ' ' PRO . . . . . . . . . . . . . 54.9 Cg_endo -69.71 -36.21 11.35 Favored 'Trans proline' 0 C--N 1.342 0.187 0 C-N-CA 122.699 2.266 . . . . 72.52 112.379 179.96 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 38.5 mt-10 -59.67 -20.44 56.21 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.221 -0.445 . . . . 62.2 110.894 -179.984 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 10.4 m-20 -76.52 64.34 2.19 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.158 -0.474 . . . . 75.54 110.847 -179.943 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 9.6 pt -143.22 -40.42 0.17 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.215 -0.448 . . . . 64.33 111.135 179.899 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 13.1 m -82.78 -169.85 2.7 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.132 -0.485 . . . . 72.35 110.927 -179.946 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 7.9 m-85 -95.59 40.65 1.11 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.123 -0.489 . . . . 73.33 110.883 -179.878 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -167.97 143.65 3.84 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.105 -0.498 . . . . 61.54 111.14 179.798 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -159.34 88.19 0.11 Allowed Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.692 -0.766 . . . . 53.15 112.466 -179.952 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 54' ' ' GLN . . . . . . . . . . . . . 16.2 tt0 -174.94 109.82 0.12 Allowed 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.822 0.344 . . . . 43.34 110.948 -179.918 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 169.2 81.9 0.05 OUTLIER Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.827 -0.702 . . . . 53.51 112.541 -179.962 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 46.3 t -93.42 87.18 2.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-O 120.792 0.329 . . . . 42.33 111.136 -179.971 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 30.8 mtt180 -105.93 71.23 0.89 Allowed 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.17 -0.468 . . . . 72.03 110.862 -179.972 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 58' ' ' VAL . . . . . 0.595 HG22 ' O ' ' A' ' 58' ' ' VAL . 12.6 p 39.78 38.02 0.21 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.143 -0.481 . . . . 74.45 111.121 179.953 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 9.0 tt0 -92.59 156.7 16.94 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.194 -0.457 . . . . 73.53 110.877 -179.992 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -129.23 128.72 5.87 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.762 -0.732 . . . . 34.43 112.533 -179.972 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -147.38 153.41 39.6 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.882 0.372 . . . . 52.32 110.804 -179.718 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 1.1 m -106.04 97.63 16.19 Favored Pre-proline 0 C--N 1.329 -0.325 0 CA-C-O 121.611 0.719 . . . . 73.41 110.878 -179.838 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 63' ' ' PRO . . . . . 0.408 ' HG2' HD11 ' A' ' 105' ' ' LEU . 53.9 Cg_endo -69.78 -177.96 2.13 Favored 'Trans proline' 0 C--O 1.231 0.164 0 C-N-CA 122.636 2.224 . . . . 73.33 112.378 179.958 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 64' ' ' SER . . . . . 0.52 ' O ' ' HA ' ' A' ' 43' ' ' PHE . 0.5 OUTLIER -105.95 151.21 24.89 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.237 -0.438 . . . . 74.35 110.87 -179.854 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 65' ' ' LEU . . . . . 0.78 HD21 HD11 ' A' ' 81' ' ' LEU . 3.2 tm? -113.52 139.21 49.15 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.119 -0.491 . . . . 64.12 110.951 179.998 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 66' ' ' PHE . . . . . 0.697 ' N ' HD13 ' A' ' 65' ' ' LEU . 2.8 t80 -120.54 106.25 11.61 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.235 -0.439 . . . . 74.31 110.923 179.906 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 67' ' ' VAL . . . . . 0.477 HG22 ' N ' ' A' ' 68' ' ' ARG . 8.2 p -144.03 161.46 15.59 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 116.144 -0.48 . . . . 70.43 111.124 179.992 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 68' ' ' ARG . . . . . 0.49 ' HG3' ' HA2' ' A' ' 99' ' ' GLY . 7.0 ttm180 -96.09 145.38 25.53 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.148 -0.478 . . . . 62.34 110.878 -179.976 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 69' ' ' THR . . . . . 0.459 ' HB ' ' HG3' ' A' ' 95' ' ' PRO . 3.0 t -40.22 -45.43 2.06 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.227 -0.442 . . . . 74.22 111.209 -179.98 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 70' ' ' ASP . . . . . 0.407 ' N ' HG23 ' A' ' 69' ' ' THR . 4.8 m-20 -65.81 -53.97 33.08 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.191 -0.459 . . . . 72.24 110.91 179.884 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 71' ' ' GLU . . . . . 0.484 ' O ' HD13 ' A' ' 75' ' ' LEU . 1.1 mp0 -53.74 -39.24 65.14 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.17 -0.468 . . . . 70.13 110.897 -179.964 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 7.2 p -82.63 -24.35 8.73 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.225 -0.443 . . . . 71.43 111.115 179.991 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 73' ' ' ARG . . . . . . . . . . . . . 51.0 ttt180 -63.97 -37.22 86.62 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.16 -0.473 . . . . 63.45 110.887 -179.989 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 15.2 mm-40 -67.62 -10.96 56.85 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.179 -0.464 . . . . 71.31 110.877 -179.95 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 75' ' ' LEU . . . . . 0.856 HD21 HG21 ' A' ' 29' ' ' ILE . 8.7 mp -103.39 -176.4 3.07 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.234 -0.439 . . . . 64.33 110.95 179.995 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 76' ' ' ARG . . . . . . . . . . . . . 16.5 ttm180 -123.64 150.0 44.71 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.231 -0.441 . . . . 61.2 110.873 -179.986 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -50.34 105.43 0.09 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.218 -0.446 . . . . 61.53 110.918 -179.9 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 113.97 16.14 8.1 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.745 -0.741 . . . . 64.55 112.441 -179.974 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 79' ' ' ASP . . . . . 0.73 ' HB3' HD23 ' A' ' 75' ' ' LEU . 0.4 OUTLIER -79.88 106.27 11.78 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-O 120.898 0.38 . . . . 73.12 110.852 -179.976 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 80' ' ' THR . . . . . 0.728 ' HA ' ' HA ' ' A' ' 89' ' ' TRP . 0.7 OUTLIER -85.46 110.24 19.03 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.226 -0.443 . . . . 21.43 111.167 -179.929 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 81' ' ' LEU . . . . . 0.787 HD13 HD12 ' A' ' 39' ' ' ILE . 0.3 OUTLIER -96.38 132.2 42.14 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.226 -0.443 . . . . 71.51 110.961 179.955 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 82' ' ' THR . . . . . 0.743 ' CA ' ' HA ' ' A' ' 87' ' ' ASN . 3.4 t -93.82 102.5 14.63 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.205 -0.452 . . . . 72.1 111.18 179.973 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 83' ' ' ILE . . . . . 0.722 ' CG2' HD12 ' A' ' 81' ' ' LEU . 0.1 OUTLIER -138.52 131.66 39.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.211 -0.45 . . . . 73.43 111.105 179.966 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 74.59 -53.17 2.39 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.741 -0.742 . . . . 65.42 112.517 179.941 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 4.1 mm-40 -117.76 -82.2 0.63 Allowed 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.834 0.35 . . . . 74.23 110.865 -179.91 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 86' ' ' GLU . . . . . 0.404 ' HB2' ' CE1' ' A' ' 88' ' ' PHE . 6.9 mp0 -149.7 160.3 43.64 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.163 -0.471 . . . . 75.34 110.92 -179.915 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 87' ' ' ASN . . . . . 0.751 ' HA ' ' C ' ' A' ' 81' ' ' LEU . 1.9 p-10 -50.91 123.81 9.95 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.193 -0.458 . . . . 73.04 110.893 -179.913 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 88' ' ' PHE . . . . . 0.779 ' HB2' HD22 ' A' ' 105' ' ' LEU . 14.9 m-85 -131.81 118.32 19.73 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.199 -0.455 . . . . 74.13 110.893 -179.955 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 89' ' ' TRP . . . . . 0.728 ' HA ' ' HA ' ' A' ' 80' ' ' THR . 62.2 p-90 -81.53 135.1 35.59 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.196 -0.456 . . . . 65.3 110.854 -179.963 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 90' ' ' VAL . . . . . 0.48 ' HA ' ' HB3' ' A' ' 105' ' ' LEU . 4.9 p -91.52 136.8 23.38 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.193 -0.458 . . . . 74.41 111.131 179.881 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -63.06 -72.3 0.14 Allowed 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.219 -0.446 . . . . 71.42 110.919 179.87 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 92' ' ' ARG . . . . . 0.597 ' O ' ' HG ' ' A' ' 103' ' ' LEU . 12.3 ttm-85 -159.17 120.66 3.35 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.185 -0.461 . . . . 72.04 110.861 -179.962 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 93' ' ' VAL . . . . . 0.645 HG12 ' HB2' ' A' ' 103' ' ' LEU . 24.4 m -111.8 133.01 58.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.188 -0.46 . . . . 73.3 111.127 179.994 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 94' ' ' SER . . . . . 0.442 ' HA ' ' HD2' ' A' ' 95' ' ' PRO . 11.5 t -125.72 100.29 31.44 Favored Pre-proline 0 C--N 1.329 -0.291 0 CA-C-O 121.692 0.758 . . . . 75.12 110.824 -179.78 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 95' ' ' PRO . . . . . 0.459 ' HG3' ' HB ' ' A' ' 69' ' ' THR . 53.9 Cg_endo -69.79 169.96 17.73 Favored 'Trans proline' 0 C--N 1.343 0.26 0 C-N-CA 122.634 2.222 . . . . 75.32 112.383 179.977 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 8.8 m-20 -131.68 4.74 4.25 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.221 -0.445 . . . . 74.45 110.871 179.97 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 12.1 t0 -140.95 30.45 1.82 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.13 -0.486 . . . . 65.52 110.918 179.957 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 49.27 60.21 6.4 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.701 -0.762 . . . . 71.31 112.442 -179.957 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 99' ' ' GLY . . . . . 0.49 ' HA2' ' HG3' ' A' ' 68' ' ' ARG . . . 138.42 35.13 0.17 Allowed Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.712 -0.756 . . . . 52.21 112.462 -179.964 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 28.8 t -152.22 72.12 0.98 Allowed 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 120.785 0.326 . . . . 74.41 110.859 -179.747 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 101' ' ' CYS . . . . . 0.475 ' CB ' ' HB ' ' A' ' 93' ' ' VAL . 0.0 OUTLIER -108.47 149.77 28.34 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.126 -0.488 . . . . 75.23 110.887 -179.975 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 102' ' ' HIS . . . . . 0.656 ' HA ' ' O ' ' A' ' 65' ' ' LEU . 28.6 p-80 -158.88 125.42 4.64 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.145 -0.48 . . . . 71.44 110.862 179.968 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 103' ' ' LEU . . . . . 0.923 HD13 ' N ' ' A' ' 104' ' ' TRP . 2.8 tm? -151.92 148.02 27.28 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.199 -0.455 . . . . 53.54 110.952 -179.955 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 104' ' ' TRP . . . . . 0.923 ' N ' HD13 ' A' ' 103' ' ' LEU . 28.0 p90 -64.79 113.69 3.97 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.24 -0.436 . . . . 73.25 110.964 179.839 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 105' ' ' LEU . . . . . 0.779 HD22 ' HB2' ' A' ' 88' ' ' PHE . 0.3 OUTLIER -92.6 162.62 14.11 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.219 -0.446 . . . . 65.34 110.898 179.998 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -89.27 159.16 28.4 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.811 -0.709 . . . . 61.24 112.459 179.92 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 107' ' ' ARG . . . . . 0.539 ' HA ' ' CD1' ' A' ' 88' ' ' PHE . 0.0 OUTLIER -69.74 158.32 35.64 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.852 0.358 . . . . 53.52 110.891 -179.875 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -172.9 109.13 0.29 Allowed Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.715 -0.755 . . . . 41.12 112.442 -179.987 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 109' ' ' VAL . . . . . 0.487 HG23 ' HD2' ' A' ' 110' ' ' PRO . 7.4 p -92.31 134.34 28.45 Favored Pre-proline 0 C--N 1.329 -0.312 0 CA-C-O 121.604 0.716 . . . . 71.51 111.09 -179.951 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 110' ' ' PRO . . . . . 0.487 ' HD2' HG23 ' A' ' 109' ' ' VAL . 53.9 Cg_endo -69.75 168.34 21.83 Favored 'Trans proline' 0 C--O 1.232 0.198 0 C-N-CA 122.678 2.252 . . . . 70.25 112.347 179.948 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 111' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.79 -8.39 23.48 Favored 'Trans proline' 0 C--N 1.341 0.164 0 C-N-CA 122.723 2.282 . . . . 62.45 112.304 179.967 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -60.81 161.39 8.11 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.249 -0.432 . . . . 75.33 111.144 179.86 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 113' ' ' VAL . . . . . 0.425 ' O ' HG13 ' A' ' 113' ' ' VAL . 5.6 p -93.08 119.86 41.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.168 -0.469 . . . . 61.34 111.129 179.999 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 114' ' ' ASN . . . . . . . . . . . . . 1.6 m-80 -129.11 145.88 51.19 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.217 -0.447 . . . . 73.33 110.884 -179.993 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -83.49 125.96 32.28 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.13 -0.487 . . . . 74.41 110.824 -179.935 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 116' ' ' ARG . . . . . . . . . . . . . 6.9 ptp85 -115.01 138.21 51.12 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.172 -0.467 . . . . 71.22 110.924 -179.956 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 46.0 ttt180 . . . . . 0 C--N 1.329 -0.29 0 CA-C-N 116.202 -0.454 . . . . 75.0 110.86 -179.891 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 27.1 mtt . . . . . 0 C--O 1.231 0.088 0 CA-C-O 120.779 0.324 . . . . 73.43 110.91 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . 62.5 53.79 2.61 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.323 -0.399 . . . . 63.11 111.07 179.901 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 3' ' ' ASP . . . . . . . . . . . . . 11.1 t70 -121.84 149.46 43.33 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.207 -0.452 . . . . 71.22 110.8 -179.977 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 4' ' ' PHE . . . . . . . . . . . . . 31.4 m-85 -153.0 178.98 9.11 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.181 -0.463 . . . . 63.41 110.938 -179.968 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 5.7 m-20 -160.63 178.96 8.97 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 116.147 -0.479 . . . . 73.04 110.906 -179.975 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 6' ' ' ASN . . . . . . . . . . . . . 30.8 t30 -159.34 171.57 19.55 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.213 -0.448 . . . . 52.25 110.868 -179.918 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 7' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -164.85 178.7 6.99 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.138 -0.483 . . . . 74.35 110.864 179.954 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 8' ' ' PHE . . . . . . . . . . . . . 45.6 m-85 -139.73 -178.65 5.51 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.156 -0.474 . . . . 73.23 110.856 179.979 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 3.3 t70 -175.96 177.43 1.63 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.165 -0.471 . . . . 53.44 110.834 179.932 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -154.79 177.55 11.14 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.238 -0.437 . . . . 75.42 111.149 179.98 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -125.16 -72.33 0.67 Allowed 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.243 -0.435 . . . . 74.31 111.042 179.972 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 41.9 mt 59.96 71.64 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.268 -0.424 . . . . 70.31 111.102 -179.993 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -150.87 168.88 23.13 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.194 -0.457 . . . . 52.13 111.108 179.832 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 22.6 mmm180 -139.71 -176.01 4.41 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.272 -0.422 . . . . 73.2 110.871 -179.855 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -145.0 -172.48 3.85 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.165 -0.47 . . . . 20.24 111.048 179.918 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 1.8 p-10 -152.48 -174.04 4.76 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.171 -0.468 . . . . 65.1 110.861 179.933 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 17' ' ' GLU . . . . . 0.502 ' O ' HG23 ' A' ' 18' ' ' THR . 0.4 OUTLIER -146.68 176.94 9.47 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.212 -0.449 . . . . 70.54 110.883 -179.942 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 18' ' ' THR . . . . . 0.502 HG23 ' O ' ' A' ' 17' ' ' GLU . 0.9 OUTLIER -159.71 151.09 19.81 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.108 -0.496 . . . . 74.54 111.136 -179.932 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 38.7 mm -136.92 103.73 3.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.196 -0.456 . . . . 72.11 111.09 179.93 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 20' ' ' ARG . . . . . . . . . . . . . 8.4 ttm-85 -137.14 167.88 20.7 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.148 -0.478 . . . . 63.12 110.886 179.943 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -107.25 -125.13 5.32 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.696 -0.764 . . . . 63.01 112.478 -179.947 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 22' ' ' TYR . . . . . . . . . . . . . 33.7 p90 -165.69 134.34 3.17 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.894 0.378 . . . . 73.33 110.901 -179.786 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 23' ' ' MET . . . . . . . . . . . . . 2.6 ptt? -169.14 156.41 7.1 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.112 -0.495 . . . . 65.3 110.903 179.85 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 75.7 -99.2 1.22 Allowed Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.761 -0.733 . . . . 74.32 112.451 179.985 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 25' ' ' THR . . . . . 0.597 ' O ' ' HA ' ' A' ' 40' ' ' ARG . 46.6 p -99.51 108.19 20.56 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.814 0.34 . . . . 53.11 111.172 -179.905 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -76.27 121.77 23.43 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.275 -0.42 . . . . 45.01 110.884 -179.878 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 27' ' ' ALA . . . . . 0.798 ' HB3' HG23 ' A' ' 39' ' ' ILE . . . -151.39 161.12 43.27 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.168 -0.469 . . . . 73.32 111.102 179.877 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 28' ' ' THR . . . . . 0.529 HG22 ' O ' ' A' ' 28' ' ' THR . 16.0 m -131.98 87.99 2.5 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.203 -0.453 . . . . 74.34 111.144 -179.856 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 29' ' ' ILE . . . . . 0.778 HG23 ' CB ' ' A' ' 39' ' ' ILE . 2.5 pt -43.23 128.55 1.0 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 CA-C-N 116.189 -0.46 . . . . 71.45 111.171 179.893 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 30' ' ' THR . . . . . 0.687 HG23 ' O ' ' A' ' 35' ' ' SER . 11.8 m -153.18 101.11 2.52 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.177 -0.465 . . . . 75.42 111.141 -179.998 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 85.2 p -141.09 72.56 1.39 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.217 -0.447 . . . . 73.32 110.879 -179.853 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -178.42 166.91 37.13 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.764 -0.731 . . . . 61.43 112.529 -179.981 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 8.5 pt-20 -49.14 -23.51 1.3 Allowed 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.812 0.339 . . . . 70.13 110.874 -179.915 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -174.47 93.49 0.08 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.192 -0.458 . . . . 72.52 110.971 -179.91 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 35' ' ' SER . . . . . 0.687 ' O ' HG23 ' A' ' 30' ' ' THR . 1.9 m -145.22 165.34 28.64 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.241 -0.436 . . . . 75.12 110.914 -179.823 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -179.61 86.99 0.07 OUTLIER Glycine 0 N--CA 1.452 -0.273 0 C-N-CA 120.689 -0.767 . . . . 71.05 112.491 -179.999 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 37' ' ' ALA . . . . . 0.631 ' HB3' ' CD1' ' A' ' 29' ' ' ILE . . . -106.23 -173.56 2.33 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.771 0.32 . . . . 73.43 111.184 179.933 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 65.9 t -100.02 122.87 52.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.301 -0.408 . . . . 63.4 111.139 -179.996 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 39' ' ' ILE . . . . . 0.798 HG23 ' HB3' ' A' ' 27' ' ' ALA . 0.0 OUTLIER -136.88 147.63 27.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.158 -0.473 . . . . 71.13 111.097 179.979 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 40' ' ' ARG . . . . . 0.691 ' O ' HG12 ' A' ' 67' ' ' VAL . 0.2 OUTLIER -108.8 81.78 1.51 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.166 -0.47 . . . . 72.13 110.913 179.914 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 41' ' ' GLY . . . . . 0.594 ' O ' ' HB2' ' A' ' 27' ' ' ALA . . . -143.07 141.96 11.0 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.715 -0.755 . . . . 75.2 112.503 -179.989 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 42' ' ' VAL . . . . . 0.533 HG12 HG21 ' A' ' 25' ' ' THR . 9.8 p -127.8 142.39 43.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-O 120.882 0.373 . . . . 70.31 111.102 -179.904 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 43' ' ' PHE . . . . . 0.769 ' H ' HD11 ' A' ' 83' ' ' ILE . 1.7 p90 -90.08 137.6 32.21 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.142 -0.481 . . . . 62.42 110.878 -179.969 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 9.9 t70 -123.52 125.0 44.11 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.142 -0.481 . . . . 72.14 110.777 -179.992 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 2.6 p30 -120.15 153.06 55.34 Favored Pre-proline 0 C--N 1.329 -0.322 0 CA-C-O 121.618 0.723 . . . . 65.54 110.868 179.941 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 46' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.73 -37.63 8.99 Favored 'Trans proline' 0 C--N 1.34 0.121 0 C-N-CA 122.725 2.283 . . . . 65.35 112.308 -179.958 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 3.7 tt0 -146.16 89.08 1.84 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.255 -0.43 . . . . 72.3 110.877 -179.938 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 18.4 p-10 -54.96 161.89 1.48 Allowed 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.136 -0.483 . . . . 72.23 110.89 -179.907 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 49' ' ' ILE . . . . . 1.044 HD11 HG22 ' A' ' 58' ' ' VAL . 52.9 mt -52.13 140.02 7.87 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.202 -0.454 . . . . 64.21 111.138 179.956 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 54.4 p -124.02 61.6 1.1 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.158 -0.473 . . . . 75.1 110.863 -179.883 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 36.2 m-85 -156.7 175.98 13.33 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.131 -0.486 . . . . 74.43 110.917 -179.868 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -57.1 113.69 1.82 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.106 -0.497 . . . . 71.31 111.119 179.875 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -81.05 -138.74 2.36 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.704 -0.76 . . . . 74.31 112.465 -179.927 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 54' ' ' GLN . . . . . . . . . . . . . 11.8 mm-40 62.87 25.71 15.21 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.907 0.384 . . . . 74.04 110.955 -179.849 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 128.57 53.09 0.12 Allowed Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.726 -0.749 . . . . 45.04 112.507 -179.947 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 11.1 p -115.88 151.36 17.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-O 120.832 0.349 . . . . 41.41 111.083 -179.926 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 52.9 mtp180 -75.22 -177.06 3.3 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.143 -0.48 . . . . 73.24 110.909 179.995 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 58' ' ' VAL . . . . . 1.044 HG22 HD11 ' A' ' 49' ' ' ILE . 58.1 t -137.38 143.54 34.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.19 -0.459 . . . . 73.23 111.117 179.948 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 11.9 mt-10 -75.07 -171.13 1.28 Allowed 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.117 -0.492 . . . . 70.51 110.939 -179.981 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -91.33 100.27 2.66 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.746 -0.74 . . . . 61.4 112.481 -179.952 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -150.14 152.88 35.4 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.852 0.358 . . . . 73.11 110.861 -179.704 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 62' ' ' SER . . . . . 0.427 ' HA ' ' HD2' ' A' ' 63' ' ' PRO . 0.3 OUTLIER -120.35 97.52 48.94 Favored Pre-proline 0 C--N 1.33 -0.277 0 CA-C-O 121.689 0.757 . . . . 71.12 110.882 -179.852 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 63' ' ' PRO . . . . . 0.427 ' HD2' ' HA ' ' A' ' 62' ' ' SER . 53.5 Cg_endo -69.78 171.22 14.89 Favored 'Trans proline' 0 C--N 1.341 0.164 0 C-N-CA 122.722 2.281 . . . . 75.42 112.298 -179.985 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 64' ' ' SER . . . . . 0.444 ' O ' ' HA ' ' A' ' 43' ' ' PHE . 8.0 t -105.6 147.04 28.88 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.21 -0.45 . . . . 63.24 110.854 -179.877 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 65' ' ' LEU . . . . . 0.94 HD11 HG13 ' A' ' 67' ' ' VAL . 0.9 OUTLIER -113.62 119.41 37.37 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.141 -0.481 . . . . 75.02 110.932 -179.986 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 66' ' ' PHE . . . . . 0.433 ' N ' HD12 ' A' ' 65' ' ' LEU . 6.4 t80 -94.63 111.28 23.05 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.242 -0.435 . . . . 73.2 110.844 179.981 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 67' ' ' VAL . . . . . 0.94 HG13 HD11 ' A' ' 65' ' ' LEU . 0.8 OUTLIER -141.38 170.49 13.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.096 -0.502 . . . . 72.32 111.197 179.961 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 10.1 ttm180 -100.74 143.86 30.39 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.24 -0.436 . . . . 60.3 110.934 -179.999 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 69' ' ' THR . . . . . 0.421 HG23 ' N ' ' A' ' 70' ' ' ASP . 4.7 t -42.9 -44.61 4.62 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.219 -0.446 . . . . 65.43 111.191 -179.901 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 70' ' ' ASP . . . . . 0.421 ' N ' HG23 ' A' ' 69' ' ' THR . 21.1 t0 -65.67 -46.32 79.56 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.233 -0.44 . . . . 71.51 110.903 179.862 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 71' ' ' GLU . . . . . . . . . . . . . 67.1 mm-40 -53.93 -39.66 66.05 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.116 -0.493 . . . . 72.42 110.928 -179.921 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 19.0 m -86.72 -25.51 6.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.103 -0.498 . . . . 72.12 111.151 179.966 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 73' ' ' ARG . . . . . . . . . . . . . 0.8 OUTLIER -60.0 -41.24 91.67 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.139 -0.482 . . . . 64.21 110.895 -179.999 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 32.3 mt-30 -62.07 -16.59 53.15 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.169 -0.469 . . . . 73.35 110.899 -179.959 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 75' ' ' LEU . . . . . 0.648 HD21 HG21 ' A' ' 29' ' ' ILE . 5.3 mp -108.89 -175.51 2.79 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.246 -0.434 . . . . 73.13 110.85 -179.921 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 76' ' ' ARG . . . . . . . . . . . . . 5.0 ptp85 -115.56 -173.83 2.41 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.135 -0.484 . . . . 71.2 110.934 179.954 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 7.0 ptp180 -79.99 131.38 35.79 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.253 -0.43 . . . . 64.0 110.89 -179.951 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 92.31 25.79 20.33 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.74 -0.743 . . . . 71.14 112.56 -179.924 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -89.24 105.33 17.72 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.911 0.386 . . . . 75.12 110.852 -179.949 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 80' ' ' THR . . . . . 0.776 ' HA ' ' HA ' ' A' ' 89' ' ' TRP . 0.8 OUTLIER -87.28 110.57 20.29 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.196 -0.456 . . . . 41.34 111.101 -179.89 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 81' ' ' LEU . . . . . 0.777 HD13 HD12 ' A' ' 39' ' ' ILE . 0.3 OUTLIER -95.41 131.91 41.04 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.153 -0.476 . . . . 75.23 110.897 179.935 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 82' ' ' THR . . . . . 0.741 ' CA ' ' HA ' ' A' ' 87' ' ' ASN . 5.0 t -94.01 102.03 14.1 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.18 -0.464 . . . . 74.12 111.133 179.932 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 83' ' ' ILE . . . . . 0.769 HD11 ' H ' ' A' ' 43' ' ' PHE . 0.1 OUTLIER -132.46 130.26 59.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.184 -0.462 . . . . 73.42 111.116 179.92 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 68.19 -62.73 0.39 Allowed Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.707 -0.758 . . . . 73.24 112.508 179.911 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 85' ' ' GLU . . . . . 0.404 ' N ' ' O ' ' A' ' 83' ' ' ILE . 29.2 mm-40 -98.66 -83.7 0.41 Allowed 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.766 0.317 . . . . 65.44 110.949 -179.924 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 86' ' ' GLU . . . . . 0.414 ' C ' ' HA ' ' A' ' 82' ' ' THR . 70.1 mt-10 -154.22 160.97 42.09 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.129 -0.487 . . . . 52.15 110.844 -179.96 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 87' ' ' ASN . . . . . 0.747 ' HA ' ' C ' ' A' ' 81' ' ' LEU . 0.8 OUTLIER -50.55 123.73 9.37 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.156 -0.475 . . . . 73.35 110.871 -179.89 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 88' ' ' PHE . . . . . 0.784 ' HB2' HD22 ' A' ' 105' ' ' LEU . 15.1 m-85 -131.51 119.48 21.6 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.239 -0.437 . . . . 73.14 110.889 -179.974 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 89' ' ' TRP . . . . . 0.776 ' HA ' ' HA ' ' A' ' 80' ' ' THR . 4.6 p90 -80.12 138.05 36.85 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.166 -0.47 . . . . 72.15 110.856 -179.915 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 90' ' ' VAL . . . . . 0.552 HG23 HD12 ' A' ' 103' ' ' LEU . 2.2 p -94.59 135.84 27.6 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 116.156 -0.474 . . . . 63.13 111.129 179.942 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -65.28 -75.25 0.09 Allowed 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.173 -0.467 . . . . 72.12 110.879 179.892 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 92' ' ' ARG . . . . . 0.587 ' O ' ' HG ' ' A' ' 103' ' ' LEU . 0.0 OUTLIER -153.23 117.45 4.87 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.166 -0.47 . . . . 75.13 110.818 -179.944 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 93' ' ' VAL . . . . . 0.491 ' CG2' ' N ' ' A' ' 102' ' ' HIS . 0.3 OUTLIER -111.45 139.82 33.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.171 -0.468 . . . . 72.44 111.173 179.906 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 1.4 p -140.78 103.94 6.32 Favored Pre-proline 0 C--N 1.329 -0.293 0 CA-C-O 121.713 0.768 . . . . 53.11 110.857 -179.807 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 95' ' ' PRO . . . . . 0.418 ' HG3' ' HB ' ' A' ' 69' ' ' THR . 54.4 Cg_endo -69.68 173.61 10.65 Favored 'Trans proline' 0 C--N 1.342 0.199 0 C-N-CA 122.729 2.286 . . . . 75.32 112.365 179.908 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 21.2 m-20 -107.26 -6.28 17.34 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.197 -0.456 . . . . 74.02 110.854 179.95 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 46.5 p-10 -151.78 32.81 0.55 Allowed 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.236 -0.438 . . . . 74.14 110.906 179.981 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 45.25 68.8 0.88 Allowed Glycine 0 N--CA 1.452 -0.235 0 C-N-CA 120.696 -0.764 . . . . 64.4 112.437 -179.97 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . 173.08 -28.13 0.09 OUTLIER Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.74 -0.743 . . . . 71.34 112.467 179.991 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 1.5 m -122.04 101.03 7.3 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.775 0.321 . . . . 74.53 110.831 -179.741 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 101' ' ' CYS . . . . . 0.433 ' HB3' HG22 ' A' ' 93' ' ' VAL . 0.0 OUTLIER -122.95 154.43 38.39 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.212 -0.449 . . . . 75.22 110.839 -179.954 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 102' ' ' HIS . . . . . 0.491 ' N ' ' CG2' ' A' ' 93' ' ' VAL . 13.5 p80 -156.94 123.34 4.96 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.161 -0.472 . . . . 74.23 110.853 -179.972 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 103' ' ' LEU . . . . . 0.814 HD13 ' N ' ' A' ' 104' ' ' TRP . 3.4 tm? -148.25 144.57 27.74 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.211 -0.45 . . . . 75.32 110.856 -179.916 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 104' ' ' TRP . . . . . 0.814 ' N ' HD13 ' A' ' 103' ' ' LEU . 4.2 m-90 -69.29 108.54 3.72 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.225 -0.443 . . . . 62.33 110.924 179.831 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 105' ' ' LEU . . . . . 0.784 HD22 ' HB2' ' A' ' 88' ' ' PHE . 0.3 OUTLIER -89.6 161.8 15.97 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.266 -0.424 . . . . 73.1 110.985 179.945 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -89.69 159.92 28.5 Favored Glycine 0 N--CA 1.45 -0.379 0 C-N-CA 120.713 -0.756 . . . . 53.21 112.537 179.891 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 107' ' ' ARG . . . . . 0.585 ' HA ' ' CD1' ' A' ' 88' ' ' PHE . 0.1 OUTLIER -68.94 157.55 36.46 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.88 0.372 . . . . 73.34 110.832 -179.807 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -172.05 112.38 0.44 Allowed Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.78 -0.724 . . . . 73.55 112.538 -179.998 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 109' ' ' VAL . . . . . 0.454 HG23 ' HD2' ' A' ' 110' ' ' PRO . 7.3 p -85.56 133.78 41.35 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-O 121.599 0.714 . . . . 71.52 111.176 -179.975 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 110' ' ' PRO . . . . . 0.454 ' HD2' HG23 ' A' ' 109' ' ' VAL . 54.8 Cg_endo -69.63 168.14 22.26 Favored 'Trans proline' 0 C--O 1.233 0.232 0 C-N-CA 122.693 2.262 . . . . 72.55 112.394 179.9 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 111' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.77 -8.48 23.7 Favored 'Trans proline' 0 C--O 1.231 0.174 0 C-N-CA 122.708 2.272 . . . . 73.21 112.365 179.896 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -59.15 161.22 5.47 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.244 -0.435 . . . . 52.14 111.156 179.769 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 17.2 m -92.97 122.0 44.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.278 -0.419 . . . . 44.12 111.135 179.97 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 114' ' ' ASN . . . . . . . . . . . . . 1.5 m-80 -128.67 146.15 50.95 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.097 -0.501 . . . . 73.34 110.896 179.985 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 6.4 mtp180 -82.46 112.6 19.54 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.159 -0.473 . . . . 74.34 110.804 -179.897 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 116' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -111.79 138.0 48.96 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.159 -0.473 . . . . 62.44 110.889 -179.912 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 C--N 1.328 -0.326 0 CA-C-N 116.173 -0.467 . . . . 75.43 110.873 -179.909 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 10.6 ttp . . . . . 0 C--O 1.23 0.049 0 CA-C-O 120.794 0.33 . . . . 63.4 110.931 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -172.7 158.98 4.18 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.162 -0.472 . . . . 61.13 111.094 179.885 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 3' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -154.57 122.75 5.98 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.262 -0.426 . . . . 62.03 110.867 179.937 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 4' ' ' PHE . . . . . . . . . . . . . 36.8 p90 -141.54 147.56 37.94 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.123 -0.489 . . . . 64.54 110.89 -179.909 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 5.4 m-20 -136.64 151.72 49.62 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.156 -0.475 . . . . 71.23 110.863 -179.968 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 6' ' ' ASN . . . . . . . . . . . . . 64.4 m-80 -101.06 -70.48 0.74 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.239 -0.437 . . . . 71.04 110.916 -179.951 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 7' ' ' LEU . . . . . . . . . . . . . 20.3 mt -101.34 109.66 21.54 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.143 -0.48 . . . . 63.05 110.932 179.91 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 8' ' ' PHE . . . . . . . . . . . . . 10.4 m-85 -63.93 -30.58 71.65 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.172 -0.467 . . . . 74.21 110.899 179.881 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 28.5 t70 -165.95 104.2 0.67 Allowed 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.184 -0.462 . . . . 72.22 110.885 179.994 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -127.39 108.72 11.08 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.232 -0.44 . . . . 71.41 111.07 179.978 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -71.04 97.68 1.5 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.23 -0.441 . . . . 72.23 111.139 179.899 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 32.0 mt -121.82 63.95 0.26 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.21 -0.45 . . . . 74.13 111.102 -179.981 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -175.54 104.82 0.08 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.113 -0.494 . . . . 70.3 111.106 179.786 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 61.4 ttt180 -71.84 125.94 28.46 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.171 -0.468 . . . . 74.21 110.828 -179.88 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -75.53 74.14 2.56 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.152 -0.476 . . . . 45.21 111.078 179.941 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 10.5 p-10 -137.2 58.48 1.71 Allowed 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.17 -0.468 . . . . 73.15 110.83 -179.983 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 10.1 tt0 61.74 52.66 3.44 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.217 -0.447 . . . . 71.12 110.908 -179.91 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 43.0 p -62.17 -176.69 0.1 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.135 -0.484 . . . . 75.31 111.158 -179.882 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 9.5 mt 64.98 46.02 0.17 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.261 -0.427 . . . . 72.02 111.143 179.941 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 20' ' ' ARG . . . . . . . . . . . . . 3.9 ttt180 -106.17 -62.99 1.31 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.172 -0.467 . . . . 74.32 110.855 180.0 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 82.87 176.39 51.47 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.678 -0.772 . . . . 42.32 112.454 -179.957 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 22' ' ' TYR . . . . . . . . . . . . . 20.3 p90 -177.78 123.37 0.12 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.89 0.376 . . . . 75.12 110.905 -179.839 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 23' ' ' MET . . . . . . . . . . . . . 4.2 mmt -150.97 145.21 25.42 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.126 -0.488 . . . . 74.13 110.833 179.883 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 74.51 -99.51 1.11 Allowed Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.711 -0.757 . . . . 63.3 112.519 -179.952 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 25' ' ' THR . . . . . 0.547 ' O ' ' HA ' ' A' ' 40' ' ' ARG . 0.0 OUTLIER -122.22 111.88 17.49 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.867 0.365 . . . . 73.12 111.09 -179.889 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -75.09 123.33 25.03 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.112 -0.495 . . . . 70.21 110.838 -179.856 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 27' ' ' ALA . . . . . 0.832 ' HB3' HG23 ' A' ' 39' ' ' ILE . . . -145.13 163.21 35.02 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.15 -0.477 . . . . 53.12 111.056 179.894 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 28' ' ' THR . . . . . 0.501 HG22 ' O ' ' A' ' 28' ' ' THR . 19.1 m -130.46 87.2 2.47 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.173 -0.467 . . . . 62.05 111.164 -179.874 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 29' ' ' ILE . . . . . 0.744 HG23 ' CB ' ' A' ' 39' ' ' ILE . 2.2 pt -44.27 132.15 1.55 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.213 -0.448 . . . . 71.21 111.161 179.926 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 30' ' ' THR . . . . . 0.636 HG23 ' O ' ' A' ' 35' ' ' SER . 23.4 m -153.89 101.17 2.42 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.183 -0.462 . . . . 64.14 111.176 179.983 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 1.8 t -137.12 71.04 1.4 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.265 -0.425 . . . . 71.21 110.843 -179.856 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -179.4 168.1 38.51 Favored Glycine 0 N--CA 1.45 -0.422 0 C-N-CA 120.72 -0.752 . . . . 54.23 112.458 -179.968 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 6.7 pt-20 -49.24 -23.4 1.33 Allowed 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.793 0.33 . . . . 74.45 110.894 -179.896 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 3.5 tt0 -174.69 94.93 0.08 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.12 -0.491 . . . . 65.31 110.971 -179.97 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 35' ' ' SER . . . . . 0.636 ' O ' HG23 ' A' ' 30' ' ' THR . 0.1 OUTLIER -145.11 165.33 28.59 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.232 -0.44 . . . . 52.14 110.801 -179.789 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -179.22 88.86 0.07 OUTLIER Glycine 0 N--CA 1.452 -0.254 0 C-N-CA 120.723 -0.751 . . . . 44.24 112.449 179.995 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 37' ' ' ALA . . . . . 0.649 ' HB3' ' CD1' ' A' ' 29' ' ' ILE . . . -106.26 -172.45 2.09 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.798 0.332 . . . . 54.33 111.116 179.942 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 23.5 t -99.66 120.01 48.47 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.232 -0.44 . . . . 71.23 111.117 179.998 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 39' ' ' ILE . . . . . 0.832 HG23 ' HB3' ' A' ' 27' ' ' ALA . 0.0 OUTLIER -137.28 151.03 26.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.227 -0.442 . . . . 73.03 111.177 179.918 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 40' ' ' ARG . . . . . 0.598 ' O ' HG12 ' A' ' 67' ' ' VAL . 28.0 mmt180 -112.87 82.03 1.59 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.193 -0.458 . . . . 72.2 110.845 179.988 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 41' ' ' GLY . . . . . 0.51 ' HA3' HD21 ' A' ' 65' ' ' LEU . . . -140.18 138.21 8.92 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.794 -0.717 . . . . 72.01 112.451 -179.966 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 42' ' ' VAL . . . . . 0.517 HG12 HG21 ' A' ' 25' ' ' THR . 1.7 p -123.59 137.81 55.53 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-O 120.817 0.341 . . . . 64.42 111.17 179.943 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 43' ' ' PHE . . . . . 0.58 ' H ' HD11 ' A' ' 83' ' ' ILE . 2.1 p90 -93.22 137.82 32.19 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.198 -0.455 . . . . 74.51 110.88 -179.91 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 3.4 t70 -117.96 125.43 50.41 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.147 -0.479 . . . . 64.31 110.853 179.986 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 45' ' ' ASP . . . . . 0.437 ' HA ' ' HD2' ' A' ' 46' ' ' PRO . 1.2 p30 -109.63 106.2 58.13 Favored Pre-proline 0 C--N 1.329 -0.323 0 CA-C-O 121.548 0.69 . . . . 71.54 110.913 179.951 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 46' ' ' PRO . . . . . 0.437 ' HD2' ' HA ' ' A' ' 45' ' ' ASP . 53.9 Cg_endo -69.81 -37.74 8.63 Favored 'Trans proline' 0 C--O 1.231 0.126 0 C-N-CA 122.673 2.248 . . . . 73.03 112.335 -179.949 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 35.8 mt-10 -133.98 84.03 2.09 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.296 -0.411 . . . . 63.24 110.917 179.999 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 28.4 m-80 -59.21 164.77 2.96 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.171 -0.468 . . . . 54.15 110.932 -179.963 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 7.3 tt -98.11 23.17 1.08 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.373 0 CA-C-N 116.187 -0.461 . . . . 73.03 111.129 179.948 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -69.02 100.1 1.18 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.162 -0.472 . . . . 72.12 110.837 -179.923 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 8.4 t80 -164.97 158.3 16.9 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.11 -0.495 . . . . 72.44 110.878 -179.858 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -116.95 116.13 26.8 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.086 -0.507 . . . . 61.24 111.102 179.838 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 112.11 71.07 0.59 Allowed Glycine 0 N--CA 1.452 -0.257 0 C-N-CA 120.791 -0.718 . . . . 51.32 112.487 -179.913 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 54' ' ' GLN . . . . . . . . . . . . . 5.2 pm0 -163.28 142.54 8.49 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.884 0.373 . . . . 75.44 110.885 -179.915 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -177.33 31.81 0.08 OUTLIER Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.78 -0.724 . . . . 63.03 112.523 -179.991 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 25.0 t -89.3 -67.23 0.77 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-O 120.855 0.36 . . . . 45.33 111.085 -179.899 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -176.94 122.14 0.13 Allowed 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.194 -0.457 . . . . 63.4 110.874 -179.94 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 11.3 p -51.71 132.28 13.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.258 -0.428 . . . . 42.31 111.097 179.986 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 1.3 mt-10 -81.7 -74.7 0.32 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.196 -0.456 . . . . 72.43 110.904 -179.999 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -149.99 136.1 5.55 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.747 -0.74 . . . . 60.02 112.476 -179.974 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 22.3 m -145.13 105.51 4.08 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.87 0.367 . . . . 64.12 110.883 -179.811 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -147.99 97.82 3.87 Favored Pre-proline 0 C--N 1.329 -0.289 0 CA-C-O 121.661 0.744 . . . . 75.11 110.822 -179.766 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.78 175.77 7.67 Favored 'Trans proline' 0 C--N 1.342 0.199 0 C-N-CA 122.727 2.285 . . . . 72.1 112.326 179.986 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 1.3 t -111.29 138.29 47.94 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.211 -0.45 . . . . 75.21 110.834 -179.863 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 65' ' ' LEU . . . . . 0.781 HD11 HG13 ' A' ' 67' ' ' VAL . 1.7 tm? -117.1 135.67 53.57 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.19 -0.459 . . . . 74.21 110.962 -179.974 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 66' ' ' PHE . . . . . 0.664 ' N ' HD22 ' A' ' 65' ' ' LEU . 35.7 t80 -117.94 110.28 17.53 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.244 -0.435 . . . . 74.24 110.87 179.966 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 67' ' ' VAL . . . . . 0.781 HG13 HD11 ' A' ' 65' ' ' LEU . 24.1 m -140.13 168.12 17.85 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.092 -0.504 . . . . 71.15 111.11 179.993 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 68' ' ' ARG . . . . . 0.436 ' HG2' ' H ' ' A' ' 71' ' ' GLU . 1.5 ptm180 -102.83 146.18 28.66 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.191 -0.459 . . . . 73.23 110.859 179.982 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 69' ' ' THR . . . . . 0.457 HG22 ' HA2' ' A' ' 99' ' ' GLY . 0.2 OUTLIER -37.75 -60.96 0.67 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.153 -0.476 . . . . 73.4 111.139 -179.895 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 3.4 m-20 -46.11 -43.92 15.24 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.198 -0.455 . . . . 70.1 110.887 179.886 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 71' ' ' GLU . . . . . 0.436 ' H ' ' HG2' ' A' ' 68' ' ' ARG . 8.7 tp10 -59.77 -42.81 94.15 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.198 -0.456 . . . . 72.5 110.858 -179.873 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 72' ' ' VAL . . . . . 0.503 HG22 ' O ' ' A' ' 72' ' ' VAL . 14.3 p -87.27 -3.86 9.38 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.172 -0.467 . . . . 73.11 111.106 -179.978 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 73' ' ' ARG . . . . . . . . . . . . . 57.6 ttt180 -85.27 -41.93 15.11 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.165 -0.47 . . . . 70.22 110.884 -179.965 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 71.8 mt-30 -53.26 -25.25 13.74 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.188 -0.46 . . . . 71.55 110.907 -179.944 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 75' ' ' LEU . . . . . 0.74 HD21 ' CD1' ' A' ' 29' ' ' ILE . 3.9 mp -107.74 -169.63 1.56 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.204 -0.453 . . . . 72.53 110.956 179.963 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 76' ' ' ARG . . . . . . . . . . . . . 8.5 ttp180 -116.6 136.84 52.64 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.212 -0.449 . . . . 72.14 110.85 179.978 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -47.34 102.01 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.211 -0.45 . . . . 72.15 110.884 -179.899 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 133.19 25.73 0.64 Allowed Glycine 0 N--CA 1.453 -0.231 0 C-N-CA 120.701 -0.762 . . . . 74.33 112.427 -179.967 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 79' ' ' ASP . . . . . 0.724 ' OD2' HD22 ' A' ' 75' ' ' LEU . 5.4 p-10 -114.13 119.84 38.48 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.871 0.367 . . . . 55.42 110.91 179.963 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 80' ' ' THR . . . . . 0.831 HG22 ' HB3' ' A' ' 89' ' ' TRP . 13.6 p -83.11 123.05 29.14 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.195 -0.457 . . . . 71.22 111.123 -179.825 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 81' ' ' LEU . . . . . 0.794 ' C ' ' HA ' ' A' ' 87' ' ' ASN . 0.2 OUTLIER -94.37 124.47 38.42 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.243 -0.435 . . . . 61.22 110.921 179.956 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 82' ' ' THR . . . . . 0.802 ' N ' ' HA ' ' A' ' 87' ' ' ASN . 3.5 t -91.47 104.42 16.93 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.214 -0.448 . . . . 74.44 111.164 179.947 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 83' ' ' ILE . . . . . 0.725 HD13 ' O ' ' A' ' 83' ' ' ILE . 0.1 OUTLIER -141.17 126.45 18.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.177 -0.465 . . . . 72.25 111.062 179.97 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 74.36 -52.74 2.27 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.692 -0.766 . . . . 65.0 112.495 179.908 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 8.1 tp10 -112.91 -82.73 0.59 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.809 0.338 . . . . 74.13 110.903 -179.896 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 86' ' ' GLU . . . . . 0.468 ' C ' ' HA ' ' A' ' 82' ' ' THR . 86.9 mt-10 -152.17 160.86 43.31 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.171 -0.468 . . . . 74.14 110.884 -179.937 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 87' ' ' ASN . . . . . 0.802 ' HA ' ' N ' ' A' ' 82' ' ' THR . 9.2 p30 -51.32 121.66 6.6 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.168 -0.469 . . . . 64.33 110.938 -179.949 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 88' ' ' PHE . . . . . 0.661 ' HB2' HD22 ' A' ' 105' ' ' LEU . 15.9 m-85 -132.16 121.36 23.61 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.172 -0.467 . . . . 74.14 110.938 -179.958 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 89' ' ' TRP . . . . . 0.831 ' HB3' HG22 ' A' ' 80' ' ' THR . 3.7 t-105 -81.38 130.53 35.07 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.14 -0.482 . . . . 70.12 110.906 -179.923 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 90' ' ' VAL . . . . . 0.505 ' O ' ' CH2' ' A' ' 89' ' ' TRP . 6.1 p -80.93 114.58 22.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.215 -0.448 . . . . 72.21 111.172 179.912 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -41.9 -65.21 0.48 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.208 -0.451 . . . . 52.51 110.945 179.953 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 92' ' ' ARG . . . . . 0.488 ' O ' ' HG ' ' A' ' 103' ' ' LEU . 69.5 ttt180 -160.15 125.65 4.03 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.197 -0.456 . . . . 71.31 110.902 -179.967 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 93' ' ' VAL . . . . . 0.507 HG12 ' N ' ' A' ' 102' ' ' HIS . 0.0 OUTLIER -115.49 111.55 36.12 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 116.203 -0.453 . . . . 75.23 111.135 179.954 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 94' ' ' SER . . . . . 0.451 ' C ' ' HB3' ' A' ' 101' ' ' CYS . 4.4 p -105.8 106.16 55.61 Favored Pre-proline 0 C--N 1.33 -0.255 0 CA-C-O 121.666 0.746 . . . . 73.12 110.833 -179.78 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 95' ' ' PRO . . . . . 0.432 ' HG3' ' HB ' ' A' ' 69' ' ' THR . 53.3 Cg_endo -69.83 159.19 54.28 Favored 'Trans proline' 0 C--N 1.341 0.18 0 C-N-CA 122.633 2.222 . . . . 65.2 112.363 179.984 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 4.5 m-20 -123.14 -3.3 8.53 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.23 -0.441 . . . . 64.51 110.884 179.982 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 14.9 t70 -145.54 40.81 1.21 Allowed 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.148 -0.478 . . . . 75.52 110.955 179.992 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 51.02 60.95 6.57 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.713 -0.756 . . . . 24.54 112.47 -179.922 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 99' ' ' GLY . . . . . 0.457 ' HA2' HG22 ' A' ' 69' ' ' THR . . . 124.21 46.58 0.25 Allowed Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.697 -0.763 . . . . 73.25 112.438 -179.948 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 2.0 p -159.74 77.61 0.68 Allowed 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 120.831 0.348 . . . . 70.41 110.861 -179.736 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 101' ' ' CYS . . . . . 0.451 ' HB3' ' C ' ' A' ' 94' ' ' SER . 0.3 OUTLIER -129.21 167.47 17.6 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.168 -0.469 . . . . 73.24 110.898 -179.95 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 102' ' ' HIS . . . . . 0.507 ' N ' HG12 ' A' ' 93' ' ' VAL . 37.0 p-80 -167.41 128.28 1.5 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.137 -0.483 . . . . 74.0 110.842 -179.928 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 103' ' ' LEU . . . . . 0.824 HD13 ' N ' ' A' ' 104' ' ' TRP . 2.5 tm? -150.19 147.17 27.38 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.181 -0.463 . . . . 71.14 110.938 -179.928 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 104' ' ' TRP . . . . . 0.824 ' N ' HD13 ' A' ' 103' ' ' LEU . 29.7 p90 -63.92 118.25 8.15 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.261 -0.427 . . . . 71.31 110.95 179.893 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 105' ' ' LEU . . . . . 0.661 HD22 ' HB2' ' A' ' 88' ' ' PHE . 0.2 OUTLIER -88.45 163.58 15.89 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 116.245 -0.434 . . . . 72.2 110.924 -179.998 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -88.15 160.26 30.66 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.751 -0.737 . . . . 74.42 112.523 179.919 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 107' ' ' ARG . . . . . 0.486 ' HA ' ' CD1' ' A' ' 88' ' ' PHE . 0.7 OUTLIER -66.17 157.5 31.14 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.864 0.364 . . . . 74.42 110.923 -179.941 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -176.58 108.16 0.25 Allowed Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.733 -0.746 . . . . 74.24 112.425 179.984 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 109' ' ' VAL . . . . . 0.416 HG23 ' HD2' ' A' ' 110' ' ' PRO . 10.8 p -100.06 133.6 21.46 Favored Pre-proline 0 C--N 1.329 -0.296 0 CA-C-O 121.543 0.687 . . . . 53.25 111.091 -179.938 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 110' ' ' PRO . . . . . 0.416 ' HD2' HG23 ' A' ' 109' ' ' VAL . 54.0 Cg_endo -69.75 167.62 23.9 Favored 'Trans proline' 0 C--O 1.23 0.123 0 C-N-CA 122.652 2.235 . . . . 75.31 112.319 179.934 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 111' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.8 -15.41 36.94 Favored 'Trans proline' 0 C--N 1.342 0.214 0 C-N-CA 122.672 2.248 . . . . 73.14 112.284 179.993 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -117.97 121.25 40.17 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.198 -0.455 . . . . 63.52 111.079 179.881 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 7.4 m -118.61 129.14 75.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.166 -0.47 . . . . 74.25 111.055 -179.957 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 114' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -128.31 118.99 24.21 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.151 -0.477 . . . . 72.21 110.884 179.976 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 5.5 ptm180 -112.12 130.44 55.89 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-N 116.126 -0.488 . . . . 52.33 110.837 -179.93 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 116' ' ' ARG . . . . . . . . . . . . . 12.3 ptp180 -114.2 137.81 51.29 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.167 -0.47 . . . . 70.11 110.899 -179.913 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 C--N 1.329 -0.307 0 CA-C-N 116.24 -0.436 . . . . 74.25 110.89 -179.981 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 19.8 ptt? . . . . . 0 C--O 1.231 0.1 0 CA-C-O 120.831 0.348 . . . . 72.21 110.919 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -119.84 -45.42 2.49 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.237 -0.438 . . . . 61.15 111.096 179.948 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 3' ' ' ASP . . . . . . . . . . . . . 22.5 t70 -52.37 144.71 12.52 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.22 -0.446 . . . . 70.33 110.791 -179.978 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 4' ' ' PHE . . . . . . . . . . . . . 12.1 m-85 -114.89 -73.57 0.65 Allowed 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.147 -0.478 . . . . 73.2 110.916 -179.927 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 3.9 m-20 -166.33 119.79 1.09 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.104 -0.498 . . . . 63.11 110.892 179.955 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 6' ' ' ASN . . . . . . . . . . . . . 4.4 t-20 -176.92 133.43 0.19 Allowed 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.227 -0.442 . . . . 65.4 110.858 -179.842 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 7' ' ' LEU . . . . . . . . . . . . . 5.1 mp -124.37 -72.97 0.65 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.215 -0.448 . . . . 73.41 110.938 179.931 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 8' ' ' PHE . . . . . . . . . . . . . 3.7 m-85 -163.26 178.27 8.32 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.211 -0.45 . . . . 75.31 110.924 179.898 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 4.4 m-20 -122.13 -176.69 3.41 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.162 -0.472 . . . . 54.25 110.846 179.98 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -144.27 177.36 8.67 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.198 -0.455 . . . . 61.31 111.095 179.967 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 11' ' ' ALA . . . . . 0.587 ' O ' HD13 ' A' ' 12' ' ' ILE . . . -136.74 150.63 48.51 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.193 -0.458 . . . . 75.43 111.066 179.915 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 12' ' ' ILE . . . . . 0.587 HD13 ' O ' ' A' ' 11' ' ' ALA . 26.6 mm -133.69 69.37 0.33 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.237 -0.438 . . . . 74.42 111.097 -179.993 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -147.54 142.25 26.69 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.19 -0.459 . . . . 62.24 111.128 179.77 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 1.8 tpt180 -175.34 117.07 0.16 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.222 -0.445 . . . . 71.51 110.849 -179.946 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -177.68 138.86 0.22 Allowed 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.233 -0.44 . . . . 64.04 111.1 179.895 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 6.1 p-10 -174.29 169.44 3.84 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.21 -0.45 . . . . 74.33 110.967 179.963 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 9.9 mp0 -114.19 -174.06 2.4 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.247 -0.433 . . . . 64.11 110.913 -179.917 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 94.1 m -88.84 -72.97 0.52 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.171 -0.468 . . . . 72.23 111.128 -179.906 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 31.5 mt 54.82 77.42 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.229 -0.441 . . . . 64.5 111.166 179.945 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 20' ' ' ARG . . . . . . . . . . . . . 9.6 tpt180 -71.54 149.15 46.0 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.136 -0.484 . . . . 75.11 110.879 179.971 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -158.23 -162.34 11.73 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.787 -0.72 . . . . 42.22 112.548 -179.945 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 22' ' ' TYR . . . . . . . . . . . . . 34.7 t80 -158.92 -45.92 0.06 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.869 0.366 . . . . 73.01 110.907 -179.843 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 23' ' ' MET . . . . . . . . . . . . . 9.4 ptt? -52.1 145.93 9.66 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.171 -0.468 . . . . 74.42 110.856 179.953 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 103.75 -156.61 17.6 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.696 -0.764 . . . . 64.13 112.496 179.998 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 25' ' ' THR . . . . . 0.496 HG21 HG23 ' A' ' 42' ' ' VAL . 8.4 m -110.69 137.69 48.03 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.742 0.306 . . . . 71.21 111.192 -179.911 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -72.5 122.08 20.71 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.207 -0.451 . . . . 50.25 110.866 -179.855 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 27' ' ' ALA . . . . . 0.823 ' HB3' HG23 ' A' ' 39' ' ' ILE . . . -142.05 162.29 35.86 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.047 -0.524 . . . . 42.21 111.119 179.89 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 28' ' ' THR . . . . . 0.505 HG22 ' O ' ' A' ' 28' ' ' THR . 16.9 m -129.23 88.65 2.73 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.242 -0.436 . . . . 74.44 111.184 -179.883 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 29' ' ' ILE . . . . . 0.764 HG23 ' CB ' ' A' ' 39' ' ' ILE . 1.8 pt -44.64 130.99 1.7 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.218 -0.446 . . . . 74.45 111.135 179.917 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 30' ' ' THR . . . . . 0.695 HG23 ' O ' ' A' ' 35' ' ' SER . 7.3 m -153.73 97.98 2.16 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.167 -0.47 . . . . 71.12 111.15 179.934 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 87.1 p -137.76 70.92 1.39 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.229 -0.441 . . . . 63.2 110.921 -179.858 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -178.61 167.52 38.01 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.779 -0.724 . . . . 55.2 112.511 -179.924 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 3.6 pt-20 -49.45 -23.01 1.34 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.798 0.332 . . . . 71.22 110.851 -179.935 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -174.6 94.22 0.08 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.228 -0.442 . . . . 75.22 110.919 -179.913 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 35' ' ' SER . . . . . 0.695 ' O ' HG23 ' A' ' 30' ' ' THR . 3.1 m -144.71 165.77 27.12 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.161 -0.472 . . . . 72.51 110.821 -179.81 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 178.6 87.6 0.07 OUTLIER Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.78 -0.724 . . . . 75.41 112.497 -179.975 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 37' ' ' ALA . . . . . 0.676 ' HB3' ' CD1' ' A' ' 29' ' ' ILE . . . -109.03 -172.49 2.06 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.904 0.383 . . . . 74.42 111.078 179.983 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 4.0 p -97.97 123.04 50.22 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.209 -0.451 . . . . 72.34 111.12 179.969 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 39' ' ' ILE . . . . . 0.823 HG23 ' HB3' ' A' ' 27' ' ' ALA . 0.0 OUTLIER -138.53 149.9 24.1 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.137 -0.483 . . . . 65.31 111.165 179.906 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 40' ' ' ARG . . . . . 0.548 ' O ' HG12 ' A' ' 67' ' ' VAL . 6.6 mtm-85 -109.1 80.05 1.28 Allowed 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.159 -0.473 . . . . 72.43 110.879 -179.962 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 41' ' ' GLY . . . . . 0.52 ' HA2' HG12 ' A' ' 67' ' ' VAL . . . -128.38 148.78 18.03 Favored Glycine 0 N--CA 1.45 -0.374 0 C-N-CA 120.814 -0.708 . . . . 70.23 112.577 -179.937 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 42' ' ' VAL . . . . . 0.573 HG12 ' CB ' ' A' ' 66' ' ' PHE . 3.4 p -127.53 138.79 53.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-O 120.837 0.351 . . . . 72.44 111.148 -179.986 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 43' ' ' PHE . . . . . 0.613 ' H ' HD11 ' A' ' 83' ' ' ILE . 2.5 p90 -98.36 128.76 44.92 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.175 -0.466 . . . . 61.14 110.887 -179.966 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -107.75 124.0 49.38 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.12 -0.491 . . . . 74.43 110.812 180.0 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -120.33 106.13 40.89 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-O 121.61 0.719 . . . . 61.42 110.854 179.976 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 46' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.73 -41.64 4.14 Favored 'Trans proline' 0 C--N 1.343 0.238 0 C-N-CA 122.582 2.188 . . . . 75.44 112.415 179.987 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 20.7 mt-10 -146.78 89.95 1.87 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.227 -0.442 . . . . 63.34 110.904 -179.992 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 2.2 t-20 -62.84 99.74 0.17 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.123 -0.489 . . . . 75.24 110.894 -179.963 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 4.9 pt -148.96 179.82 0.63 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.207 -0.451 . . . . 75.21 111.136 179.929 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -122.36 154.72 37.3 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.145 -0.479 . . . . 71.02 110.823 -179.91 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 9.3 m-85 -127.28 -72.89 0.62 Allowed 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.086 -0.506 . . . . 74.12 110.951 -179.848 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 52' ' ' ALA . . . . . 0.883 ' HB1' HG21 ' A' ' 56' ' ' VAL . . . -52.73 169.56 0.09 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.057 -0.52 . . . . 75.21 111.137 179.835 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -152.34 -113.63 0.56 Allowed Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.685 -0.769 . . . . 53.14 112.463 -179.951 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 54' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -53.83 147.26 12.26 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.796 0.331 . . . . 51.01 110.891 -179.888 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 78.23 -59.31 3.99 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.736 -0.745 . . . . 51.45 112.514 -179.971 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 56' ' ' VAL . . . . . 0.883 HG21 ' HB1' ' A' ' 52' ' ' ALA . 43.4 t -53.84 147.41 2.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-O 120.856 0.36 . . . . 70.22 111.079 -179.93 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 22.0 ptt180 -90.38 -32.83 16.29 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.104 -0.498 . . . . 72.12 110.838 -179.931 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 58' ' ' VAL . . . . . 0.435 ' H ' HG12 ' A' ' 56' ' ' VAL . 38.4 t -144.0 138.64 24.73 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.206 -0.452 . . . . 72.12 111.101 -179.979 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 6.6 pt-20 -54.38 173.51 0.07 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.12 -0.491 . . . . 63.24 110.934 179.983 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -100.0 100.95 2.27 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.717 -0.754 . . . . 34.41 112.475 -179.947 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 1.4 m -148.03 129.73 15.09 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.859 0.361 . . . . 71.54 110.911 -179.768 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 62' ' ' SER . . . . . 0.418 ' HA ' ' HD2' ' A' ' 63' ' ' PRO . 1.1 t -137.06 97.59 10.82 Favored Pre-proline 0 C--N 1.328 -0.332 0 CA-C-O 121.626 0.727 . . . . 61.02 110.831 -179.755 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 63' ' ' PRO . . . . . 0.418 ' HD2' ' HA ' ' A' ' 62' ' ' SER . 53.6 Cg_endo -69.78 -172.9 0.63 Allowed 'Trans proline' 0 C--O 1.231 0.15 0 C-N-CA 122.613 2.209 . . . . 73.12 112.359 179.946 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 64' ' ' SER . . . . . 0.516 ' O ' ' HA ' ' A' ' 43' ' ' PHE . 0.1 OUTLIER -106.54 148.39 28.29 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.203 -0.453 . . . . 65.13 110.865 -179.832 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 65' ' ' LEU . . . . . 0.558 HD11 ' CG1' ' A' ' 67' ' ' VAL . 2.8 tm? -114.55 129.29 56.65 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.134 -0.484 . . . . 75.01 110.924 -179.96 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 66' ' ' PHE . . . . . 0.573 ' CB ' HG12 ' A' ' 42' ' ' VAL . 1.7 t80 -119.03 105.68 11.67 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.257 -0.428 . . . . 74.21 110.889 179.937 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 67' ' ' VAL . . . . . 0.558 ' CG1' HD11 ' A' ' 65' ' ' LEU . 33.7 m -141.04 172.51 10.85 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-N 116.148 -0.478 . . . . 74.04 111.126 -179.968 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 68' ' ' ARG . . . . . 0.447 ' HG2' ' H ' ' A' ' 71' ' ' GLU . 1.1 ptp180 -109.23 144.47 37.3 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.194 -0.457 . . . . 64.4 110.849 -179.986 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 69' ' ' THR . . . . . 0.759 HG22 ' HA2' ' A' ' 99' ' ' GLY . 0.0 OUTLIER -38.01 -56.88 1.1 Allowed 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.202 -0.454 . . . . 73.14 111.189 -179.927 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 70' ' ' ASP . . . . . 0.46 ' H ' HG23 ' A' ' 69' ' ' THR . 7.8 t70 -44.28 -59.43 2.38 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.155 -0.475 . . . . 70.21 110.865 179.908 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 71' ' ' GLU . . . . . 0.447 ' H ' ' HG2' ' A' ' 68' ' ' ARG . 1.2 tm-20 -59.35 -42.1 90.74 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.217 -0.447 . . . . 74.22 110.92 -179.966 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 72' ' ' VAL . . . . . 0.651 HG12 ' HA ' ' A' ' 69' ' ' THR . 0.3 OUTLIER -82.98 4.42 2.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.117 -0.492 . . . . 74.13 111.073 -179.948 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 73' ' ' ARG . . . . . 0.521 ' N ' ' O ' ' A' ' 69' ' ' THR . 16.1 ttt180 -98.31 -37.98 9.44 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.168 -0.469 . . . . 75.14 110.86 -179.993 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 48.7 mt-30 -65.67 -12.36 52.85 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.252 -0.431 . . . . 74.4 110.956 -179.978 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 75' ' ' LEU . . . . . 0.651 HD21 HG21 ' A' ' 29' ' ' ILE . 3.1 mp -107.99 -174.46 2.53 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.157 -0.474 . . . . 70.11 110.877 -179.964 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 76' ' ' ARG . . . . . . . . . . . . . 10.5 ptp180 -117.91 154.37 32.02 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.164 -0.471 . . . . 75.34 110.941 179.965 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 3.7 ptt180 -51.21 131.91 28.15 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.24 -0.436 . . . . 70.03 110.87 -179.909 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 86.77 42.97 6.21 Favored Glycine 0 N--CA 1.452 -0.24 0 C-N-CA 120.735 -0.745 . . . . 60.23 112.397 179.944 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -103.43 110.74 22.88 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.909 0.385 . . . . 74.01 110.85 -179.963 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 80' ' ' THR . . . . . 0.733 ' HA ' ' HA ' ' A' ' 89' ' ' TRP . 0.0 OUTLIER -88.62 108.59 19.52 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.119 -0.491 . . . . 62.12 111.209 -179.886 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 81' ' ' LEU . . . . . 0.787 ' C ' ' HA ' ' A' ' 87' ' ' ASN . 0.0 OUTLIER -98.18 135.24 40.12 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.272 -0.422 . . . . 71.21 110.928 -179.986 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 82' ' ' THR . . . . . 0.7 ' N ' ' HA ' ' A' ' 87' ' ' ASN . 8.0 t -93.63 101.59 13.75 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.204 -0.453 . . . . 63.4 111.145 179.968 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 83' ' ' ILE . . . . . 0.714 HD13 ' O ' ' A' ' 83' ' ' ILE . 0.1 OUTLIER -136.18 131.11 48.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.22 -0.446 . . . . 75.01 111.184 179.861 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 73.0 -54.59 1.78 Allowed Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.785 -0.722 . . . . 64.14 112.507 179.936 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 10.7 mm-40 -113.55 -80.65 0.59 Allowed 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 120.86 0.362 . . . . 64.4 110.875 -179.922 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 86' ' ' GLU . . . . . 0.46 ' C ' ' HA ' ' A' ' 82' ' ' THR . 96.1 mt-10 -154.54 161.06 41.82 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 116.159 -0.473 . . . . 64.42 110.823 -179.939 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 87' ' ' ASN . . . . . 0.787 ' HA ' ' C ' ' A' ' 81' ' ' LEU . 1.6 p-10 -50.7 121.98 6.63 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.156 -0.474 . . . . 74.5 110.921 -179.957 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 88' ' ' PHE . . . . . 0.747 ' CB ' HD13 ' A' ' 105' ' ' LEU . 14.7 m-85 -131.08 120.86 24.02 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.155 -0.475 . . . . 75.14 110.903 -179.972 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 89' ' ' TRP . . . . . 0.733 ' HA ' ' HA ' ' A' ' 80' ' ' THR . 0.9 OUTLIER -80.11 135.77 36.39 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.12 -0.491 . . . . 64.12 110.913 -179.951 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 90' ' ' VAL . . . . . 0.464 ' HA ' ' HB3' ' A' ' 105' ' ' LEU . 0.3 OUTLIER -92.58 138.23 20.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.264 -0.426 . . . . 71.01 111.101 179.925 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -65.61 -71.19 0.2 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.186 -0.461 . . . . 75.21 110.85 179.935 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 92' ' ' ARG . . . . . 0.526 ' O ' ' HG ' ' A' ' 103' ' ' LEU . 0.0 OUTLIER -152.58 120.89 6.3 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.251 -0.432 . . . . 74.24 110.838 -179.882 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 93' ' ' VAL . . . . . 0.617 HG12 ' CB ' ' A' ' 103' ' ' LEU . 8.8 m -121.45 137.28 55.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.254 -0.43 . . . . 65.14 111.121 179.928 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 12.6 t -137.14 128.4 16.44 Favored Pre-proline 0 C--N 1.328 -0.337 0 CA-C-O 121.714 0.769 . . . . 73.01 110.862 -179.856 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 95' ' ' PRO . . . . . 0.479 ' HG3' ' HB ' ' A' ' 69' ' ' THR . 53.2 Cg_endo -69.85 160.51 49.42 Favored 'Trans proline' 0 C--N 1.342 0.198 0 C-N-CA 122.681 2.254 . . . . 71.31 112.322 -179.946 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 9.4 t0 -118.23 -25.35 6.64 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.256 -0.429 . . . . 74.34 110.844 179.945 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER 177.9 85.5 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.277 -0.419 . . . . 75.31 110.909 -179.96 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 99.71 55.42 1.01 Allowed Glycine 0 N--CA 1.452 -0.267 0 C-N-CA 120.726 -0.75 . . . . 40.14 112.508 -179.959 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 99' ' ' GLY . . . . . 0.759 ' HA2' HG22 ' A' ' 69' ' ' THR . . . 40.29 77.53 0.07 OUTLIER Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.769 -0.729 . . . . 72.43 112.461 -179.918 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 20.1 t -125.81 12.12 7.87 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.91 0.386 . . . . 75.14 110.842 -179.745 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 101' ' ' CYS . . . . . 0.571 ' HB2' ' HB ' ' A' ' 93' ' ' VAL . 19.6 p -47.23 142.31 3.98 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.16 -0.473 . . . . 73.45 110.882 -179.98 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 102' ' ' HIS . . . . . 0.437 ' HA ' ' O ' ' A' ' 65' ' ' LEU . 43.4 p-80 -159.97 129.38 5.2 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.241 -0.436 . . . . 75.43 110.836 -179.934 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 103' ' ' LEU . . . . . 0.874 HD13 ' N ' ' A' ' 104' ' ' TRP . 2.8 tm? -150.8 148.4 28.45 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 116.239 -0.437 . . . . 72.24 110.943 -179.998 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 104' ' ' TRP . . . . . 0.874 ' N ' HD13 ' A' ' 103' ' ' LEU . 56.3 p-90 -64.34 118.02 8.08 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.174 -0.466 . . . . 64.3 110.855 179.946 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 105' ' ' LEU . . . . . 0.747 HD13 ' CB ' ' A' ' 88' ' ' PHE . 0.4 OUTLIER -93.92 162.8 13.76 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.266 -0.425 . . . . 71.42 110.866 179.978 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -91.0 160.39 27.26 Favored Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.712 -0.756 . . . . 65.44 112.498 179.892 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 107' ' ' ARG . . . . . 0.544 ' HA ' ' CD1' ' A' ' 88' ' ' PHE . 0.0 OUTLIER -65.73 157.39 30.31 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.856 0.36 . . . . 74.43 110.925 -179.895 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -173.1 110.18 0.33 Allowed Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.644 -0.789 . . . . 32.31 112.454 179.984 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 109' ' ' VAL . . . . . 0.453 HG23 ' HD2' ' A' ' 110' ' ' PRO . 7.1 p -84.19 133.89 44.38 Favored Pre-proline 0 C--N 1.33 -0.28 0 CA-C-O 121.687 0.756 . . . . 74.1 111.084 -179.93 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 110' ' ' PRO . . . . . 0.453 ' HD2' HG23 ' A' ' 109' ' ' VAL . 53.8 Cg_endo -69.68 168.22 22.08 Favored 'Trans proline' 0 C--N 1.342 0.222 0 C-N-CA 122.644 2.229 . . . . 61.33 112.328 179.928 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 111' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.77 -8.94 24.87 Favored 'Trans proline' 0 C--N 1.342 0.189 0 C-N-CA 122.66 2.24 . . . . 72.02 112.358 179.905 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -59.67 161.08 6.49 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.231 -0.44 . . . . 74.0 111.072 179.891 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 6.4 p -93.69 124.2 46.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.209 -0.45 . . . . 74.03 111.073 -179.986 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 114' ' ' ASN . . . . . . . . . . . . . 2.6 m-20 -128.71 145.54 51.14 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.132 -0.485 . . . . 74.43 110.849 179.994 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 13.3 mtt180 -82.91 103.31 12.28 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.109 -0.496 . . . . 54.02 110.9 179.983 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 116' ' ' ARG . . . . . . . . . . . . . 2.7 mmp_? -115.24 138.1 51.31 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.171 -0.468 . . . . 65.22 110.804 -179.85 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 15.7 tpt180 . . . . . 0 C--N 1.329 -0.293 0 CA-C-N 116.173 -0.467 . . . . 64.23 110.866 -179.922 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 1.3 mpt? . . . . . 0 C--O 1.231 0.09 0 CA-C-O 120.749 0.309 . . . . 32.3 110.86 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . 52.9 47.04 25.54 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.218 -0.447 . . . . 73.13 111.122 179.939 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 3' ' ' ASP . . . . . . . . . . . . . 6.2 p-10 -117.11 150.13 39.19 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.176 -0.465 . . . . 63.12 110.881 179.968 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 4' ' ' PHE . . . . . . . . . . . . . 47.7 t80 -170.42 150.77 3.56 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.233 -0.44 . . . . 74.14 110.886 -179.913 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 33.5 m-20 -153.74 157.24 39.18 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.162 -0.472 . . . . 64.51 110.864 -179.988 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 6' ' ' ASN . . . . . . . . . . . . . 6.7 p30 -173.76 141.2 0.81 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.242 -0.435 . . . . 63.2 110.921 -179.92 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 7' ' ' LEU . . . . . . . . . . . . . 20.1 mt -107.33 171.39 7.41 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.173 -0.467 . . . . 71.44 110.957 179.941 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 8' ' ' PHE . . . . . . . . . . . . . 11.9 t80 -129.64 58.06 1.65 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.207 -0.451 . . . . 71.54 110.94 179.934 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 3.0 m-20 -118.74 127.06 53.2 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.141 -0.481 . . . . 54.53 110.892 179.992 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -68.55 133.53 48.69 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.253 -0.431 . . . . 75.22 111.057 179.946 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -164.05 164.39 23.0 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.172 -0.467 . . . . 64.24 111.086 179.942 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 3.4 mp -125.31 64.76 0.3 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.244 -0.434 . . . . 71.4 111.188 179.901 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -145.87 56.44 1.2 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.173 -0.467 . . . . 72.12 111.095 179.847 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 31.8 mmm-85 -104.72 -179.53 3.97 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.27 -0.423 . . . . 64.14 110.866 -179.902 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -171.01 130.67 0.78 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.179 -0.464 . . . . 74.44 111.057 179.903 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 4.3 p-10 -93.58 47.4 1.23 Allowed 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.179 -0.464 . . . . 54.24 110.874 -179.988 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 6.8 mm-40 -117.83 -172.27 2.21 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.202 -0.454 . . . . 74.12 110.875 -179.848 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 39.7 p -74.04 -178.35 3.29 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.143 -0.481 . . . . 72.02 111.135 -179.923 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 2.7 pt -114.35 74.36 0.39 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.242 -0.435 . . . . 73.23 111.065 179.933 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 20' ' ' ARG . . . . . . . . . . . . . 9.0 tpp180 -110.06 -64.28 1.28 Allowed 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.157 -0.474 . . . . 73.33 110.88 179.924 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -71.36 140.5 30.92 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.755 -0.736 . . . . 52.11 112.494 -179.965 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 22' ' ' TYR . . . . . . . . . . . . . 5.9 t80 -121.7 -67.47 0.96 Allowed 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.842 0.353 . . . . 75.54 110.923 -179.824 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 23' ' ' MET . . . . . . . . . . . . . 10.4 ptm -175.81 173.48 2.32 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.147 -0.478 . . . . 70.33 110.899 179.888 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 138.59 -142.95 13.6 Favored Glycine 0 N--CA 1.452 -0.239 0 C-N-CA 120.727 -0.749 . . . . 70.43 112.448 -179.973 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 25' ' ' THR . . . . . 0.821 ' HB ' HG22 ' A' ' 42' ' ' VAL . 98.6 m -96.74 126.7 42.09 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.804 0.335 . . . . 65.13 111.107 -179.815 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 3.0 p -70.81 123.5 22.11 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.173 -0.467 . . . . 75.4 110.823 -179.844 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 27' ' ' ALA . . . . . 0.84 ' HB3' HG23 ' A' ' 39' ' ' ILE . . . -135.24 162.42 32.61 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.074 -0.512 . . . . 63.51 111.104 179.884 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 28' ' ' THR . . . . . 0.503 HG22 ' O ' ' A' ' 28' ' ' THR . 21.7 m -129.33 85.8 2.36 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.216 -0.447 . . . . 73.22 111.09 -179.902 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 29' ' ' ILE . . . . . 0.682 HG23 HG21 ' A' ' 39' ' ' ILE . 1.9 pt -44.92 126.93 1.3 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.182 -0.463 . . . . 73.44 111.137 179.884 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 30' ' ' THR . . . . . 0.669 HG23 ' O ' ' A' ' 35' ' ' SER . 17.6 m -151.93 97.87 2.39 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.119 -0.491 . . . . 74.42 111.143 -179.983 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 31' ' ' SER . . . . . 0.517 ' OG ' HG22 ' A' ' 80' ' ' THR . 5.1 t -136.5 70.53 1.41 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.161 -0.472 . . . . 73.54 110.913 -179.853 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -178.88 168.8 39.92 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.771 -0.728 . . . . 74.42 112.536 -179.93 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 5.8 pt-20 -49.31 -23.25 1.33 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.809 0.338 . . . . 64.03 110.9 -179.906 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -174.76 95.29 0.08 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.204 -0.453 . . . . 53.23 110.913 -179.908 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 35' ' ' SER . . . . . 0.669 ' O ' HG23 ' A' ' 30' ' ' THR . 2.3 m -145.24 165.41 28.46 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.148 -0.478 . . . . 72.15 110.84 -179.794 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 176.36 88.42 0.07 OUTLIER Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 120.756 -0.735 . . . . 44.13 112.515 -179.988 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 37' ' ' ALA . . . . . 0.667 ' HB3' ' CD1' ' A' ' 29' ' ' ILE . . . -108.11 -170.53 1.7 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.809 0.337 . . . . 73.35 111.161 179.994 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 38' ' ' VAL . . . . . 0.413 ' O ' HG13 ' A' ' 38' ' ' VAL . 4.4 p -99.03 119.64 47.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.293 -0.412 . . . . 41.14 111.112 179.983 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 39' ' ' ILE . . . . . 0.84 HG23 ' HB3' ' A' ' 27' ' ' ALA . 0.0 OUTLIER -139.1 151.56 23.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.059 -0.518 . . . . 73.33 111.096 179.938 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 40' ' ' ARG . . . . . . . . . . . . . 1.4 ptp85 -113.59 82.86 1.75 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.191 -0.459 . . . . 75.04 110.879 179.964 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 41' ' ' GLY . . . . . 0.434 ' N ' HD13 ' A' ' 39' ' ' ILE . . . -111.92 146.46 18.0 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.723 -0.751 . . . . 61.44 112.436 -179.923 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 42' ' ' VAL . . . . . 0.821 HG22 ' HB ' ' A' ' 25' ' ' THR . 2.2 t -124.58 112.57 32.68 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-O 120.882 0.372 . . . . 72.41 111.08 -179.937 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 43' ' ' PHE . . . . . 0.526 ' HA ' ' O ' ' A' ' 64' ' ' SER . 2.4 p90 -87.29 131.38 34.26 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.141 -0.481 . . . . 74.12 110.89 -179.976 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 2.8 t70 -129.78 125.34 35.56 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.129 -0.487 . . . . 74.12 110.811 -179.965 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 2.5 p-10 -102.46 152.97 38.43 Favored Pre-proline 0 C--N 1.33 -0.276 0 CA-C-O 121.567 0.698 . . . . 64.14 110.862 -179.928 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 46' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.89 -37.89 8.25 Favored 'Trans proline' 0 C--N 1.341 0.161 0 C-N-CA 122.724 2.283 . . . . 54.44 112.307 -179.907 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 1.2 mp0 -91.92 64.98 4.81 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.249 -0.432 . . . . 73.2 110.887 179.97 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 2.8 t30 -92.78 124.86 37.08 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.107 -0.497 . . . . 72.31 110.959 179.98 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 12.6 tt -146.98 137.81 17.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.194 -0.457 . . . . 72.21 111.163 179.91 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 2.8 p 46.29 39.36 6.19 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.191 -0.459 . . . . 61.24 110.831 -179.893 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 15.9 p90 -55.15 -27.75 47.78 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.151 -0.477 . . . . 64.42 110.969 -179.951 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -97.35 41.31 1.12 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.099 -0.5 . . . . 71.24 111.135 179.872 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -147.18 -86.37 0.06 OUTLIER Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.8 -0.714 . . . . 73.52 112.486 -179.903 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 54' ' ' GLN . . . . . . . . . . . . . 3.8 tt0 -176.11 126.75 0.21 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.783 0.325 . . . . 74.35 110.918 -179.945 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -144.3 89.97 0.16 Allowed Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.706 -0.759 . . . . 73.1 112.539 -179.963 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 21.8 t -85.71 71.52 0.79 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 CA-C-O 120.798 0.333 . . . . 74.31 111.104 -179.922 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 29.3 ptt-85 -177.17 145.24 0.45 Allowed 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.194 -0.457 . . . . 75.32 110.909 179.962 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 74.7 t -148.04 144.68 19.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.16 -0.473 . . . . 70.0 111.162 179.95 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 11.2 mt-10 -113.01 -171.78 1.93 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.122 -0.49 . . . . 71.54 110.937 179.976 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -90.09 100.42 2.67 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.75 -0.738 . . . . 53.13 112.447 -179.92 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -149.83 159.24 44.52 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.846 0.355 . . . . 71.2 110.881 -179.815 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 62' ' ' SER . . . . . 0.425 ' HA ' ' HD2' ' A' ' 63' ' ' PRO . 1.1 p -105.82 97.31 14.66 Favored Pre-proline 0 C--N 1.33 -0.277 0 CA-C-O 121.613 0.721 . . . . 74.11 110.858 -179.774 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 63' ' ' PRO . . . . . 0.425 ' HD2' ' HA ' ' A' ' 62' ' ' SER . 54.1 Cg_endo -69.82 169.41 19.05 Favored 'Trans proline' 0 C--N 1.342 0.207 0 C-N-CA 122.706 2.271 . . . . 45.22 112.37 179.984 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 64' ' ' SER . . . . . 0.526 ' O ' ' HA ' ' A' ' 43' ' ' PHE . 1.3 t -106.19 142.51 35.77 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.259 -0.428 . . . . 71.12 110.906 -179.816 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 65' ' ' LEU . . . . . 1.031 HD11 HG13 ' A' ' 67' ' ' VAL . 0.4 OUTLIER -110.75 123.72 50.59 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.178 -0.464 . . . . 52.12 110.942 179.982 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 66' ' ' PHE . . . . . 0.571 ' N ' HD12 ' A' ' 65' ' ' LEU . 0.2 OUTLIER -94.05 111.83 23.59 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.23 -0.441 . . . . 74.34 110.924 179.961 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 67' ' ' VAL . . . . . 1.031 HG13 HD11 ' A' ' 65' ' ' LEU . 0.4 OUTLIER -140.92 167.28 17.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.227 -0.442 . . . . 64.35 111.109 -179.998 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 68' ' ' ARG . . . . . 0.4 ' HB3' ' HG2' ' A' ' 71' ' ' GLU . 3.5 ttp85 -96.84 132.42 42.6 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.174 -0.466 . . . . 71.23 110.91 -179.952 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 69' ' ' THR . . . . . 0.414 ' O ' HG12 ' A' ' 72' ' ' VAL . 1.4 m -44.67 -36.81 3.29 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.246 -0.433 . . . . 74.03 111.126 -179.825 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 33.2 t0 -59.02 -71.88 0.11 Allowed 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.199 -0.455 . . . . 71.52 110.872 179.868 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 71' ' ' GLU . . . . . 0.473 ' O ' HD12 ' A' ' 75' ' ' LEU . 3.1 pt-20 -56.37 -37.73 70.45 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.176 -0.466 . . . . 51.13 110.875 -179.849 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 72' ' ' VAL . . . . . 0.414 HG12 ' O ' ' A' ' 69' ' ' THR . 0.4 OUTLIER -68.74 -25.39 30.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.157 -0.474 . . . . 71.0 111.148 179.982 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 73' ' ' ARG . . . . . . . . . . . . . 24.7 ttm-85 -75.9 -39.3 56.62 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.107 -0.497 . . . . 71.35 110.869 -179.996 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 12.4 mt-30 -54.73 -29.09 52.59 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.214 -0.448 . . . . 62.5 110.895 -179.936 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 75' ' ' LEU . . . . . 0.517 HD23 ' CG ' ' A' ' 79' ' ' ASP . 3.4 mp -87.26 -175.82 5.43 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.182 -0.463 . . . . 72.53 110.944 -179.973 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 76' ' ' ARG . . . . . . . . . . . . . 6.8 ttt-85 -109.47 139.33 44.59 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.192 -0.458 . . . . 74.43 110.866 179.962 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 3.3 ptt85 -48.65 108.31 0.17 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.224 -0.443 . . . . 74.32 110.844 -179.92 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 119.55 9.96 8.15 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.663 -0.78 . . . . 63.33 112.536 -179.932 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 79' ' ' ASP . . . . . 0.517 ' CG ' HD23 ' A' ' 75' ' ' LEU . 0.4 OUTLIER -73.09 109.12 6.38 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.945 0.402 . . . . 72.11 110.914 -179.994 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 80' ' ' THR . . . . . 0.716 ' HA ' ' HA ' ' A' ' 89' ' ' TRP . 0.0 OUTLIER -85.51 110.34 19.13 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.17 -0.468 . . . . 74.45 111.118 -179.828 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 81' ' ' LEU . . . . . 0.758 ' C ' ' HA ' ' A' ' 87' ' ' ASN . 0.3 OUTLIER -97.63 132.43 43.29 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.222 -0.445 . . . . 71.42 110.887 179.97 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 82' ' ' THR . . . . . 0.762 ' CA ' ' HA ' ' A' ' 87' ' ' ASN . 6.7 t -91.57 102.35 15.0 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.189 -0.46 . . . . 73.41 111.139 179.925 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 83' ' ' ILE . . . . . 0.733 ' CG2' HD12 ' A' ' 81' ' ' LEU . 0.1 OUTLIER -139.24 131.2 35.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.223 -0.444 . . . . 74.31 111.119 179.923 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 76.74 -51.67 3.1 Favored Glycine 0 N--CA 1.452 -0.264 0 C-N-CA 120.715 -0.755 . . . . 40.34 112.471 179.9 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 6.7 tp10 -121.37 -77.83 0.59 Allowed 'General case' 0 C--N 1.331 -0.229 0 CA-C-O 120.818 0.342 . . . . 62.54 110.876 -179.876 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 86' ' ' GLU . . . . . 0.472 ' C ' ' HA ' ' A' ' 82' ' ' THR . 98.8 mt-10 -152.76 162.29 41.46 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.12 -0.491 . . . . 73.22 110.923 -179.977 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 87' ' ' ASN . . . . . 0.762 ' HA ' ' CA ' ' A' ' 82' ' ' THR . 2.6 p-10 -51.5 122.02 7.31 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.183 -0.462 . . . . 73.41 110.899 -179.975 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 88' ' ' PHE . . . . . 0.776 ' HB2' HD22 ' A' ' 105' ' ' LEU . 13.9 m-85 -131.77 119.4 21.23 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.184 -0.462 . . . . 70.55 110.935 179.95 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 89' ' ' TRP . . . . . 0.716 ' HA ' ' HA ' ' A' ' 80' ' ' THR . 65.4 p-90 -82.21 132.87 35.23 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.164 -0.471 . . . . 71.31 110.96 179.983 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 90' ' ' VAL . . . . . 0.515 ' HA ' ' HB3' ' A' ' 105' ' ' LEU . 4.0 p -95.39 139.11 19.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.231 -0.441 . . . . 75.31 111.156 179.92 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 91' ' ' ASP . . . . . 0.476 ' HB2' HD21 ' A' ' 103' ' ' LEU . 1.9 t70 -58.84 -73.82 0.08 Allowed 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.208 -0.451 . . . . 63.44 110.877 179.959 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 92' ' ' ARG . . . . . 0.684 ' O ' HD13 ' A' ' 103' ' ' LEU . 8.2 ttt180 -170.15 121.39 0.64 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.215 -0.448 . . . . 73.21 110.898 -179.908 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 93' ' ' VAL . . . . . 0.532 ' HB ' ' HB3' ' A' ' 101' ' ' CYS . 2.6 m -104.83 139.0 27.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.217 -0.447 . . . . 72.41 111.176 179.917 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 12.1 t -130.1 96.53 25.18 Favored Pre-proline 0 C--N 1.33 -0.278 0 CA-C-O 121.577 0.703 . . . . 63.52 110.826 -179.766 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 95' ' ' PRO . . . . . 0.428 ' CB ' ' H ' ' A' ' 100' ' ' SER . 52.6 Cg_endo -69.8 -167.39 0.22 Allowed 'Trans proline' 0 C--N 1.341 0.152 0 C-N-CA 122.655 2.237 . . . . 72.03 112.319 179.97 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 5.8 t0 -135.57 5.99 3.21 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.226 -0.443 . . . . 70.01 110.871 179.971 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 8.7 t70 -159.56 105.46 1.65 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.224 -0.444 . . . . 74.4 110.795 -179.946 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 63.39 -90.03 0.07 OUTLIER Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.768 -0.73 . . . . 70.14 112.515 -179.996 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -163.57 87.81 0.1 Allowed Glycine 0 N--CA 1.45 -0.38 0 C-N-CA 120.752 -0.737 . . . . 44.24 112.511 -179.961 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 100' ' ' SER . . . . . 0.428 ' H ' ' CB ' ' A' ' 95' ' ' PRO . 12.0 t -155.07 79.22 1.05 Allowed 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.809 0.338 . . . . 72.44 110.774 -179.71 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 101' ' ' CYS . . . . . 0.532 ' HB3' ' HB ' ' A' ' 93' ' ' VAL . 1.8 t -132.12 -172.83 2.98 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.185 -0.462 . . . . 54.4 110.849 -179.955 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 102' ' ' HIS . . . . . 0.408 ' HB3' ' HA ' ' A' ' 66' ' ' PHE . 0.3 OUTLIER -169.53 138.91 1.99 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.183 -0.462 . . . . 73.12 110.91 -179.933 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 103' ' ' LEU . . . . . 0.684 HD13 ' O ' ' A' ' 92' ' ' ARG . 6.2 tt -139.26 155.79 47.51 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.267 -0.424 . . . . 61.1 110.945 -179.943 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 104' ' ' TRP . . . . . 0.451 ' O ' HD23 ' A' ' 103' ' ' LEU . 48.4 p-90 -64.21 110.27 2.15 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 116.18 -0.464 . . . . 65.12 110.871 179.92 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 105' ' ' LEU . . . . . 0.776 HD22 ' HB2' ' A' ' 88' ' ' PHE . 0.4 OUTLIER -91.24 163.05 14.38 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.218 -0.446 . . . . 65.24 110.958 179.957 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -89.13 157.64 27.21 Favored Glycine 0 N--CA 1.452 -0.266 0 C-N-CA 120.732 -0.747 . . . . 74.42 112.456 179.888 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 107' ' ' ARG . . . . . 0.516 ' HA ' ' CD1' ' A' ' 88' ' ' PHE . 65.5 ttp85 -69.99 156.91 38.43 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.784 0.326 . . . . 75.03 110.895 -179.856 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -169.77 108.15 0.29 Allowed Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.736 -0.745 . . . . 43.23 112.549 179.999 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 109' ' ' VAL . . . . . 0.471 HG23 ' HD2' ' A' ' 110' ' ' PRO . 7.3 p -90.14 134.16 32.08 Favored Pre-proline 0 C--N 1.329 -0.295 0 CA-C-O 121.566 0.698 . . . . 72.15 111.121 -179.906 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 110' ' ' PRO . . . . . 0.471 ' HD2' HG23 ' A' ' 109' ' ' VAL . 53.2 Cg_endo -69.76 169.65 18.42 Favored 'Trans proline' 0 C--O 1.232 0.217 0 C-N-CA 122.737 2.291 . . . . 72.54 112.308 179.995 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 111' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.73 -8.9 24.78 Favored 'Trans proline' 0 C--N 1.342 0.197 0 C-N-CA 122.727 2.285 . . . . 73.42 112.355 179.923 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -102.67 102.29 12.47 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.216 -0.447 . . . . 72.43 111.126 179.868 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 32.0 m -130.5 140.11 49.62 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.182 -0.463 . . . . 62.42 111.11 179.985 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 114' ' ' ASN . . . . . . . . . . . . . 7.3 t-20 -100.31 113.16 25.65 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.158 -0.474 . . . . 72.02 110.858 179.986 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 14.1 mtm180 -113.09 147.97 36.22 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.155 -0.475 . . . . 65.34 110.848 -179.998 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 116' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -115.12 138.14 51.23 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.19 -0.459 . . . . 74.02 110.907 -179.948 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 12.2 ptm180 . . . . . 0 C--N 1.328 -0.33 0 CA-C-N 116.24 -0.436 . . . . 74.43 110.8 -179.865 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 13.9 mtt . . . . . 0 C--O 1.23 0.041 0 CA-C-O 120.755 0.312 . . . . 74.33 110.889 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -95.36 131.5 41.4 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.168 -0.469 . . . . 74.42 111.097 179.897 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 3' ' ' ASP . . . . . . . . . . . . . 24.9 t70 -120.01 -33.94 3.83 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 116.274 -0.421 . . . . 62.34 110.845 179.931 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 4' ' ' PHE . . . . . . . . . . . . . 41.9 t80 -128.17 141.05 51.59 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.26 -0.427 . . . . 74.13 110.836 -179.874 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 17.0 m-20 -138.0 179.34 6.49 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.134 -0.484 . . . . 73.43 110.86 179.928 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 6' ' ' ASN . . . . . . . . . . . . . 7.6 t-20 -164.38 163.54 22.36 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.191 -0.459 . . . . 73.31 110.83 -179.894 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 7' ' ' LEU . . . . . . . . . . . . . 2.1 mp -144.61 -174.93 4.46 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.097 -0.501 . . . . 73.54 110.999 179.942 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 8' ' ' PHE . . . . . . . . . . . . . 2.7 t80 -159.95 175.37 13.11 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.247 -0.433 . . . . 65.31 110.894 179.924 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 5.9 t0 -109.27 -179.72 3.92 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.199 -0.455 . . . . 54.21 110.867 179.999 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -144.83 -170.9 3.51 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.229 -0.442 . . . . 63.01 111.1 179.984 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -94.43 156.69 16.36 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.231 -0.44 . . . . 75.51 111.154 179.854 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 3.8 mp -139.64 73.16 0.25 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.233 -0.439 . . . . 70.43 111.166 179.991 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -151.04 159.43 44.54 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.219 -0.446 . . . . 74.11 111.088 179.865 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 6.8 ttp180 -171.01 179.25 3.15 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.194 -0.457 . . . . 72.25 110.844 -179.893 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -137.62 -174.88 3.89 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.149 -0.478 . . . . 71.51 111.056 179.933 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -162.64 -178.15 6.02 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.156 -0.474 . . . . 62.14 110.846 179.948 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 13.3 tp10 -104.14 139.63 38.93 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.248 -0.433 . . . . 72.21 110.883 -179.861 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -54.07 169.28 0.17 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.213 -0.448 . . . . 74.53 111.097 -179.932 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 19' ' ' ILE . . . . . 0.432 HG22 ' O ' ' A' ' 19' ' ' ILE . 14.4 mm -118.99 0.35 8.0 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.166 -0.47 . . . . 74.25 111.107 179.862 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 20' ' ' ARG . . . . . . . . . . . . . 24.9 mtt-85 61.0 95.78 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.197 -0.456 . . . . 73.24 110.907 179.949 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 157.96 123.8 0.76 Allowed Glycine 0 N--CA 1.452 -0.262 0 C-N-CA 120.751 -0.738 . . . . 64.41 112.489 -179.908 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 22' ' ' TYR . . . . . . . . . . . . . 7.6 p90 -178.76 140.25 0.18 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.915 0.388 . . . . 71.32 110.87 -179.849 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 23' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -179.25 136.92 0.13 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.07 -0.514 . . . . 75.23 110.853 179.854 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 130.53 -91.53 0.3 Allowed Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.674 -0.774 . . . . 52.43 112.489 -179.954 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 25' ' ' THR . . . . . 0.611 ' O ' ' HA ' ' A' ' 40' ' ' ARG . 69.8 p -93.23 108.69 20.27 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.737 0.303 . . . . 74.2 111.156 -179.884 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -76.3 122.47 24.48 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.268 -0.424 . . . . 54.42 110.838 -179.838 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 27' ' ' ALA . . . . . 0.788 ' HB3' HG23 ' A' ' 39' ' ' ILE . . . -151.56 161.78 42.1 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.184 -0.462 . . . . 74.13 111.104 179.882 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 28' ' ' THR . . . . . 0.514 HG22 ' O ' ' A' ' 28' ' ' THR . 12.9 m -131.46 89.74 2.76 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.215 -0.448 . . . . 71.21 111.167 -179.97 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 29' ' ' ILE . . . . . 0.792 HG23 ' CB ' ' A' ' 39' ' ' ILE . 2.1 pt -44.22 130.23 1.48 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 116.186 -0.461 . . . . 73.11 111.12 179.932 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 30' ' ' THR . . . . . 0.716 HG23 ' O ' ' A' ' 35' ' ' SER . 9.1 m -153.61 99.26 2.3 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.218 -0.447 . . . . 75.55 111.137 179.924 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 8.1 t -139.34 72.41 1.4 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.184 -0.462 . . . . 64.31 110.856 -179.819 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -178.96 166.95 36.9 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.796 -0.716 . . . . 73.05 112.512 179.999 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 17.1 pt-20 -49.24 -23.58 1.41 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.743 0.306 . . . . 70.41 110.829 -179.901 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 1.1 mt-30 -174.4 93.65 0.08 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.193 -0.458 . . . . 62.54 110.948 -179.829 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 35' ' ' SER . . . . . 0.716 ' O ' HG23 ' A' ' 30' ' ' THR . 3.2 m -145.95 165.71 28.16 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.196 -0.456 . . . . 72.43 110.885 -179.793 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 179.46 86.97 0.07 OUTLIER Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.788 -0.72 . . . . 55.21 112.542 -179.966 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 37' ' ' ALA . . . . . 0.657 ' HB3' ' CD1' ' A' ' 29' ' ' ILE . . . -105.79 -171.82 1.98 Allowed 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.81 0.338 . . . . 53.51 111.056 -179.955 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 73.5 t -99.74 122.79 52.0 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.15 -0.477 . . . . 73.51 111.131 -179.985 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 39' ' ' ILE . . . . . 0.792 ' CB ' HG23 ' A' ' 29' ' ' ILE . 0.0 OUTLIER -136.82 150.24 26.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.189 -0.459 . . . . 75.03 111.093 179.882 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 40' ' ' ARG . . . . . 0.701 ' O ' HG12 ' A' ' 67' ' ' VAL . 10.1 mmt-85 -110.82 82.23 1.56 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.17 -0.468 . . . . 63.51 110.88 179.987 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 41' ' ' GLY . . . . . 0.546 ' O ' ' HB2' ' A' ' 27' ' ' ALA . . . -141.5 142.95 12.49 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.78 -0.724 . . . . 72.15 112.485 -179.965 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 42' ' ' VAL . . . . . 0.515 HG12 HG21 ' A' ' 25' ' ' THR . 8.8 p -127.46 142.34 43.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-O 120.912 0.387 . . . . 71.41 111.091 -179.95 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 43' ' ' PHE . . . . . 0.743 ' H ' HD11 ' A' ' 83' ' ' ILE . 2.0 p90 -90.05 135.19 33.8 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.205 -0.452 . . . . 55.52 110.937 179.905 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 11.5 t0 -120.17 125.23 47.68 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.134 -0.485 . . . . 74.01 110.869 179.965 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -101.59 153.64 37.76 Favored Pre-proline 0 C--N 1.328 -0.339 0 CA-C-O 121.646 0.736 . . . . 70.01 110.854 179.988 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 46' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.78 -35.76 11.98 Favored 'Trans proline' 0 C--N 1.341 0.172 0 C-N-CA 122.629 2.22 . . . . 73.24 112.337 -179.905 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 40.1 tt0 63.92 57.93 1.28 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.204 -0.453 . . . . 72.2 110.807 179.966 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -146.8 -169.77 3.37 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.143 -0.48 . . . . 74.2 110.939 179.996 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 1.3 pp -140.17 22.3 0.55 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.19 -0.459 . . . . 70.34 111.084 179.9 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 11.0 t -77.06 108.17 9.94 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.201 -0.454 . . . . 64.31 110.856 -179.938 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 4.3 m-85 -160.88 178.56 9.29 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.112 -0.495 . . . . 75.01 110.865 -179.912 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -152.0 172.85 15.64 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.108 -0.496 . . . . 43.34 111.073 179.874 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 131.22 -171.73 20.97 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.746 -0.74 . . . . 72.11 112.523 -179.94 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 54' ' ' GLN . . . . . . . . . . . . . 4.7 mp0 -80.07 -43.11 22.37 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.874 0.369 . . . . 75.24 110.975 -179.911 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 114.19 -32.11 6.11 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.719 -0.753 . . . . 63.14 112.508 -179.98 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 48.1 t -52.58 -36.71 22.84 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-O 120.863 0.363 . . . . 72.41 111.178 179.953 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 23.2 mtm180 -104.78 162.13 13.57 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.146 -0.479 . . . . 74.5 110.889 -179.974 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 24.9 t -135.55 144.82 32.81 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.194 -0.457 . . . . 40.24 111.131 179.944 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 3.4 tt0 -112.0 -179.53 3.71 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.217 -0.447 . . . . 64.42 110.864 179.999 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -110.3 155.45 16.09 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.743 -0.741 . . . . 62.53 112.429 -179.909 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 29.7 t -91.65 149.94 21.39 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.861 0.362 . . . . 52.23 110.834 -179.705 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 37.2 m -126.58 97.35 33.76 Favored Pre-proline 0 C--N 1.328 -0.33 0 CA-C-O 121.667 0.746 . . . . 71.24 110.829 -179.832 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.81 179.99 3.33 Favored 'Trans proline' 0 C--N 1.341 0.181 0 C-N-CA 122.689 2.26 . . . . 61.34 112.337 179.993 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 64' ' ' SER . . . . . 0.426 ' O ' ' HA ' ' A' ' 43' ' ' PHE . 1.1 t -110.7 144.42 39.66 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.214 -0.448 . . . . 63.05 110.817 -179.798 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 65' ' ' LEU . . . . . 0.627 ' O ' HD23 ' A' ' 65' ' ' LEU . 0.0 OUTLIER -112.97 123.39 50.22 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.142 -0.481 . . . . 72.45 110.869 -179.943 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 66' ' ' PHE . . . . . 0.426 ' HA ' ' HB3' ' A' ' 102' ' ' HIS . 15.3 t80 -102.88 110.31 22.18 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.235 -0.439 . . . . 73.22 110.972 179.857 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 67' ' ' VAL . . . . . 0.701 HG12 ' O ' ' A' ' 40' ' ' ARG . 28.0 m -141.16 172.09 11.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.135 -0.484 . . . . 64.0 111.089 -179.93 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 68' ' ' ARG . . . . . 0.483 ' HG2' ' H ' ' A' ' 71' ' ' GLU . 0.9 OUTLIER -104.95 142.19 35.22 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.126 -0.488 . . . . 71.3 110.885 179.989 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 69' ' ' THR . . . . . 0.665 HG22 ' HA2' ' A' ' 99' ' ' GLY . 0.1 OUTLIER -36.03 -69.59 0.1 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.18 -0.464 . . . . 42.41 111.128 -179.91 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 70' ' ' ASP . . . . . 0.463 ' H ' HG23 ' A' ' 69' ' ' THR . 30.9 t70 -44.06 -50.24 8.5 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.183 -0.462 . . . . 73.21 110.922 179.917 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 71' ' ' GLU . . . . . 0.483 ' H ' ' HG2' ' A' ' 68' ' ' ARG . 7.4 tp10 -55.49 -40.69 72.02 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.199 -0.455 . . . . 54.13 110.978 -179.976 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 72' ' ' VAL . . . . . 0.766 ' HA ' HD11 ' A' ' 75' ' ' LEU . 6.1 p -101.09 16.55 4.25 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.244 0 CA-C-N 116.134 -0.485 . . . . 71.41 111.052 179.998 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 73' ' ' ARG . . . . . 0.445 ' N ' ' O ' ' A' ' 69' ' ' THR . 0.6 OUTLIER -103.58 -32.19 9.55 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.18 -0.464 . . . . 72.24 110.87 -179.95 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -64.57 -23.46 67.28 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.143 -0.481 . . . . 75.32 110.983 -179.936 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 75' ' ' LEU . . . . . 0.766 HD11 ' HA ' ' A' ' 72' ' ' VAL . 0.0 OUTLIER -103.99 -177.56 3.4 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.149 -0.478 . . . . 54.12 110.888 179.968 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 76' ' ' ARG . . . . . . . . . . . . . 33.4 ttt180 -97.35 146.55 25.05 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.162 -0.472 . . . . 75.42 110.85 179.977 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 5.6 ptm180 -51.79 154.89 1.87 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.203 -0.453 . . . . 72.23 110.848 -179.919 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 72.46 18.9 78.66 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.734 -0.746 . . . . 32.43 112.538 -179.943 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 58.5 t0 -76.5 115.18 16.01 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.866 0.365 . . . . 63.03 110.81 -179.95 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 80' ' ' THR . . . . . 0.715 ' HA ' ' HA ' ' A' ' 89' ' ' TRP . 0.0 OUTLIER -88.15 109.1 19.63 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.148 -0.478 . . . . 75.25 111.197 -179.957 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 81' ' ' LEU . . . . . 0.785 ' C ' ' HA ' ' A' ' 87' ' ' ASN . 0.0 OUTLIER -97.24 134.46 40.51 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.246 -0.433 . . . . 63.42 110.943 179.93 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 82' ' ' THR . . . . . 0.71 ' CA ' ' HA ' ' A' ' 87' ' ' ASN . 5.0 t -92.77 101.36 13.74 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.186 -0.461 . . . . 74.41 111.112 179.981 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 83' ' ' ILE . . . . . 0.782 HD13 ' O ' ' A' ' 83' ' ' ILE . 0.1 OUTLIER -132.99 130.66 58.61 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 116.246 -0.434 . . . . 72.03 111.111 179.938 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 71.97 -57.92 1.41 Allowed Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.721 -0.752 . . . . 74.44 112.502 179.931 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 7.6 tp10 -109.54 -82.37 0.57 Allowed 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.838 0.352 . . . . 71.13 110.893 -179.92 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 86' ' ' GLU . . . . . 0.448 ' C ' ' HA ' ' A' ' 82' ' ' THR . 5.8 mm-40 -151.09 162.02 41.64 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.162 -0.472 . . . . 64.22 110.896 -179.955 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 87' ' ' ASN . . . . . 0.785 ' HA ' ' C ' ' A' ' 81' ' ' LEU . 12.1 p30 -51.43 125.31 14.09 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.14 -0.482 . . . . 73.31 110.9 -179.933 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 88' ' ' PHE . . . . . 0.682 ' HB2' HD22 ' A' ' 105' ' ' LEU . 15.3 m-85 -132.55 118.5 19.3 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.166 -0.47 . . . . 73.2 110.846 -179.958 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 89' ' ' TRP . . . . . 0.715 ' HA ' ' HA ' ' A' ' 80' ' ' THR . 53.9 p-90 -82.62 136.3 34.83 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.12 -0.491 . . . . 74.42 110.91 -179.976 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 90' ' ' VAL . . . . . 0.679 HG21 ' CG1' ' A' ' 93' ' ' VAL . 4.5 p -93.36 139.6 17.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.197 -0.456 . . . . 72.44 111.158 179.915 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 91' ' ' ASP . . . . . 0.412 ' HB2' HD21 ' A' ' 103' ' ' LEU . 0.2 OUTLIER -62.71 -63.77 1.12 Allowed 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.157 -0.474 . . . . 55.33 110.869 179.933 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 92' ' ' ARG . . . . . 0.67 ' O ' HD13 ' A' ' 103' ' ' LEU . 11.5 mtm180 -159.2 123.9 4.06 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.145 -0.479 . . . . 73.13 110.858 -179.869 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 93' ' ' VAL . . . . . 0.679 ' CG1' HG21 ' A' ' 90' ' ' VAL . 18.6 m -123.37 136.01 61.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.155 -0.475 . . . . 73.14 111.086 179.985 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 21.0 m -136.36 130.45 18.14 Favored Pre-proline 0 C--N 1.33 -0.244 0 CA-C-O 121.618 0.723 . . . . 74.12 110.854 -179.855 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 95' ' ' PRO . . . . . 0.428 ' HB3' ' HA2' ' A' ' 99' ' ' GLY . 53.8 Cg_endo -69.75 155.55 65.7 Favored 'Trans proline' 0 C--O 1.232 0.178 0 C-N-CA 122.667 2.244 . . . . 71.42 112.385 179.931 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 14.1 t0 -117.31 -24.62 7.35 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.198 -0.455 . . . . 54.05 110.914 179.909 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 20.1 t70 -179.77 76.27 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.197 -0.456 . . . . 73.05 110.835 -179.976 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 98' ' ' GLY . . . . . 0.419 ' O ' ' C ' ' A' ' 99' ' ' GLY . . . 103.59 64.93 0.7 Allowed Glycine 0 N--CA 1.452 -0.263 0 C-N-CA 120.701 -0.761 . . . . 24.1 112.504 -179.921 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 99' ' ' GLY . . . . . 0.665 ' HA2' HG22 ' A' ' 69' ' ' THR . . . 36.69 75.18 0.08 OUTLIER Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.79 -0.719 . . . . 55.12 112.434 -179.928 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 3.3 m -119.93 5.96 10.89 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 120.8 0.333 . . . . 71.12 110.845 -179.759 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 101' ' ' CYS . . . . . 0.592 ' HB2' ' HB ' ' A' ' 93' ' ' VAL . 25.4 p -47.3 132.66 12.82 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.144 -0.48 . . . . 62.15 110.939 179.996 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 102' ' ' HIS . . . . . 0.426 ' HB3' ' HA ' ' A' ' 66' ' ' PHE . 1.7 p80 -163.28 130.3 3.45 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.221 -0.445 . . . . 71.22 110.887 -179.968 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 103' ' ' LEU . . . . . 0.67 HD13 ' O ' ' A' ' 92' ' ' ARG . 7.1 tt -147.78 157.1 43.38 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.211 -0.449 . . . . 75.34 110.942 179.978 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 104' ' ' TRP . . . . . 0.509 ' O ' HD23 ' A' ' 103' ' ' LEU . 8.4 m-90 -64.0 110.08 2.02 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.195 -0.457 . . . . 75.31 110.939 179.898 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 105' ' ' LEU . . . . . 0.682 HD22 ' HB2' ' A' ' 88' ' ' PHE . 0.3 OUTLIER -88.75 163.06 15.9 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.231 -0.44 . . . . 63.54 110.922 179.986 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -92.41 161.37 26.26 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.749 -0.738 . . . . 54.43 112.455 179.956 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 107' ' ' ARG . . . . . 0.606 ' HA ' ' CD1' ' A' ' 88' ' ' PHE . 4.8 ptt180 -68.07 158.57 32.7 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.835 0.35 . . . . 73.31 110.841 -179.832 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -171.49 112.38 0.44 Allowed Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.673 -0.775 . . . . 52.41 112.469 -179.998 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 109' ' ' VAL . . . . . 0.455 HG23 ' HD2' ' A' ' 110' ' ' PRO . 7.2 p -101.3 134.09 20.52 Favored Pre-proline 0 C--N 1.328 -0.332 0 CA-C-O 121.619 0.723 . . . . 71.5 111.157 179.999 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 110' ' ' PRO . . . . . 0.455 ' HD2' HG23 ' A' ' 109' ' ' VAL . 53.7 Cg_endo -69.76 167.89 23.13 Favored 'Trans proline' 0 C--O 1.232 0.199 0 C-N-CA 122.731 2.288 . . . . 64.53 112.321 179.956 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 111' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.76 -8.23 23.08 Favored 'Trans proline' 0 C--N 1.342 0.19 0 C-N-CA 122.717 2.278 . . . . 75.35 112.321 179.912 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -61.94 161.01 11.23 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.262 -0.426 . . . . 62.44 111.064 179.929 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 33.8 t -93.84 127.99 45.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.176 -0.465 . . . . 74.13 111.215 179.934 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 114' ' ' ASN . . . . . . . . . . . . . 6.5 m-20 -127.83 145.79 50.82 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.275 -0.42 . . . . 74.01 110.942 -179.987 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -83.78 103.25 12.92 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.162 -0.472 . . . . 65.15 110.895 -179.986 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 116' ' ' ARG . . . . . . . . . . . . . 19.3 mmt85 -115.34 114.37 25.05 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.15 -0.477 . . . . 71.24 110.799 -179.858 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 11.9 ptp180 . . . . . 0 C--N 1.33 -0.277 0 CA-C-N 116.172 -0.467 . . . . 75.34 110.883 -179.966 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 25' ' ' THR . . . . . 0.485 HG21 HG23 ' A' ' 42' ' ' VAL . 11.7 m . . . . . 0 C--O 1.232 0.15 0 CA-C-O 120.765 0.317 . . . . 60.23 111.237 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -71.95 122.45 20.85 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.286 -0.415 . . . . 74.12 110.842 -179.836 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 27' ' ' ALA . . . . . 0.81 ' HB3' HG23 ' A' ' 39' ' ' ILE . . . -141.95 162.18 36.13 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.09 -0.505 . . . . 73.02 111.134 179.904 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 28' ' ' THR . . . . . 0.464 HG22 ' O ' ' A' ' 28' ' ' THR . 21.2 m -129.99 87.95 2.59 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.224 -0.444 . . . . 73.24 111.143 -179.918 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . 0.858 HG21 HD21 ' A' ' 75' ' ' LEU . 2.3 pt -45.15 130.9 1.97 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.277 -0.419 . . . . 75.42 111.08 179.931 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . 0.667 HG23 ' O ' ' A' ' 35' ' ' SER . 19.8 m -153.14 97.51 2.19 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.133 -0.485 . . . . 74.12 111.155 179.974 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 31' ' ' SER . . . . . 0.402 ' OG ' HG22 ' A' ' 80' ' ' THR . 8.5 t -135.1 70.86 1.43 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.213 -0.449 . . . . 61.23 110.829 -179.858 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -178.95 167.92 38.47 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.76 -0.733 . . . . 72.11 112.449 179.984 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 4.1 pt-20 -49.12 -23.36 1.22 Allowed 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.828 0.346 . . . . 64.41 110.89 -179.878 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 9.6 tt0 -174.44 94.64 0.08 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.129 -0.487 . . . . 71.3 110.879 -179.938 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 35' ' ' SER . . . . . 0.667 ' O ' HG23 ' A' ' 30' ' ' THR . 0.1 OUTLIER -144.9 165.49 27.98 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.992 0.425 . . . . 55.32 110.832 -179.831 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 178.17 87.84 0.07 OUTLIER Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.752 -0.737 . . . . 61.32 112.48 -179.97 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 37' ' ' ALA . . . . . 0.601 ' HB3' ' CD1' ' A' ' 29' ' ' ILE . . . -107.06 -170.67 1.75 Allowed 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.881 0.372 . . . . 63.42 111.087 179.984 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 4.1 p -99.15 120.74 48.9 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.227 -0.442 . . . . 74.22 111.185 179.913 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 39' ' ' ILE . . . . . 0.81 HG23 ' HB3' ' A' ' 27' ' ' ALA . 0.0 OUTLIER -137.85 148.69 25.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.199 -0.455 . . . . 74.1 111.106 179.951 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 40' ' ' ARG . . . . . 0.575 ' O ' HG12 ' A' ' 67' ' ' VAL . 18.5 mtt180 -109.66 80.76 1.35 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.189 -0.459 . . . . 70.22 110.887 179.9 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . 0.479 ' N ' HD13 ' A' ' 39' ' ' ILE . . . -128.71 148.9 18.21 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.738 -0.744 . . . . 72.52 112.454 -179.928 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 42' ' ' VAL . . . . . 0.664 HG12 ' HB3' ' A' ' 66' ' ' PHE . 3.4 p -127.16 135.04 64.64 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-O 120.851 0.357 . . . . 73.22 111.102 179.972 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 43' ' ' PHE . . . . . 0.58 ' H ' HD11 ' A' ' 83' ' ' ILE . 3.2 p90 -92.84 128.2 38.62 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.134 -0.485 . . . . 73.14 110.915 179.945 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 46.8 m-20 -114.88 124.52 51.93 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 116.133 -0.485 . . . . 64.13 110.861 179.944 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--N 1.329 -0.314 0 CA-C-O 121.624 0.726 . . . . 63.24 110.854 179.95 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 63' ' ' PRO . . . . . 0.536 ' HG2' HD11 ' A' ' 105' ' ' LEU . 54.2 Cg_endo . . . . . 0 C--O 1.231 0.159 0 CA-C-O 120.775 0.24 . . . . 64.21 112.354 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . 0.488 ' O ' ' HA ' ' A' ' 43' ' ' PHE . 2.2 t -106.46 146.8 30.1 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.271 -0.422 . . . . 74.44 110.821 -179.879 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 65' ' ' LEU . . . . . 0.788 HD11 HG13 ' A' ' 67' ' ' VAL . 0.2 OUTLIER -113.36 123.66 50.63 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.07 -0.513 . . . . 54.13 110.899 -179.989 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 66' ' ' PHE . . . . . 0.664 ' HB3' HG12 ' A' ' 42' ' ' VAL . 15.2 t80 -102.48 110.87 22.94 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.185 -0.461 . . . . 72.14 110.873 179.956 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 67' ' ' VAL . . . . . 0.788 HG13 HD11 ' A' ' 65' ' ' LEU . 0.3 OUTLIER -140.99 168.73 15.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.193 -0.458 . . . . 52.41 111.237 179.954 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 8.9 ttm180 -98.36 143.18 29.1 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.202 -0.454 . . . . 73.52 110.8 -179.935 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 69' ' ' THR . . . . . 0.421 ' HB ' ' HG3' ' A' ' 95' ' ' PRO . 0.0 OUTLIER -41.17 -44.51 2.58 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.156 -0.475 . . . . 74.41 111.172 -179.932 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 29.0 m-20 -65.69 -52.64 49.92 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.236 -0.438 . . . . 70.51 110.891 179.888 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 71' ' ' GLU . . . . . . . . . . . . . 2.1 mm-40 -55.0 -39.49 69.1 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.22 -0.445 . . . . 73.11 110.906 -179.947 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 11.1 p -82.6 -22.13 9.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.132 -0.485 . . . . 63.43 111.075 -179.993 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 73' ' ' ARG . . . . . . . . . . . . . 1.5 tmt_? -67.59 -41.52 83.95 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.194 -0.457 . . . . 75.23 110.869 179.984 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 59.1 mt-30 -57.78 -20.45 35.45 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.198 -0.456 . . . . 71.12 110.969 -179.957 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 75' ' ' LEU . . . . . 0.858 HD21 HG21 ' A' ' 29' ' ' ILE . 5.8 mp -104.95 -175.87 2.92 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.199 -0.455 . . . . 73.43 110.899 -179.999 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 76' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -111.76 -179.45 3.7 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.197 -0.456 . . . . 75.24 110.937 179.944 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -81.21 116.25 21.01 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.225 -0.443 . . . . 71.15 110.888 -179.913 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 107.92 20.14 8.61 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.77 -0.729 . . . . 70.23 112.453 -179.991 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . 0.409 ' OD2' HD23 ' A' ' 75' ' ' LEU . 0.2 OUTLIER -84.41 111.58 19.58 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.881 0.372 . . . . 74.23 110.886 179.996 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . 0.711 ' HA ' ' HA ' ' A' ' 89' ' ' TRP . 0.0 OUTLIER -86.62 111.6 20.8 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.198 -0.455 . . . . 71.14 111.148 -179.91 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 81' ' ' LEU . . . . . 0.755 ' C ' ' HA ' ' A' ' 87' ' ' ASN . 0.3 OUTLIER -97.22 131.82 43.58 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.194 -0.457 . . . . 64.43 110.921 179.917 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 82' ' ' THR . . . . . 0.748 ' CA ' ' HA ' ' A' ' 87' ' ' ASN . 2.4 t -92.48 101.42 13.87 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.13 -0.486 . . . . 61.15 111.156 179.946 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 83' ' ' ILE . . . . . 0.713 ' CG2' HD12 ' A' ' 81' ' ' LEU . 0.1 OUTLIER -137.24 131.84 45.67 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.282 -0.417 . . . . 73.34 111.081 179.979 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 74.9 -53.86 2.56 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.7 -0.762 . . . . 65.25 112.537 179.929 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 85' ' ' GLU . . . . . 0.41 ' C ' ' HG3' ' A' ' 86' ' ' GLU . 84.5 tt0 -117.94 -81.31 0.62 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.766 0.317 . . . . 73.34 110.879 -179.951 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 86' ' ' GLU . . . . . 0.695 ' OE1' HG22 ' A' ' 109' ' ' VAL . 61.7 mt-10 -149.35 161.4 42.13 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.233 -0.439 . . . . 73.23 110.931 -179.903 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 87' ' ' ASN . . . . . 0.755 ' HA ' ' C ' ' A' ' 81' ' ' LEU . 13.0 p30 -51.92 123.99 11.66 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.188 -0.46 . . . . 70.12 110.877 -179.932 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 88' ' ' PHE . . . . . 0.795 ' HB3' HD13 ' A' ' 105' ' ' LEU . 14.3 m-85 -132.2 118.18 19.21 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.184 -0.462 . . . . 73.52 110.869 -179.957 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 89' ' ' TRP . . . . . 0.711 ' HA ' ' HA ' ' A' ' 80' ' ' THR . 64.0 p-90 -82.15 135.35 35.3 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.185 -0.461 . . . . 74.34 110.922 -179.963 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 90' ' ' VAL . . . . . 0.731 ' HB ' HD23 ' A' ' 65' ' ' LEU . 0.4 OUTLIER -92.88 139.58 17.8 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.257 -0.429 . . . . 71.24 111.163 179.893 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -62.71 -71.0 0.17 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.183 -0.462 . . . . 74.32 110.89 179.867 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 92' ' ' ARG . . . . . 0.569 ' O ' ' HG ' ' A' ' 103' ' ' LEU . 7.0 mtm180 -159.9 120.89 3.1 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.172 -0.467 . . . . 54.31 110.894 -179.878 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 93' ' ' VAL . . . . . 0.758 HG12 ' HB2' ' A' ' 103' ' ' LEU . 17.4 m -112.51 135.43 51.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.197 -0.456 . . . . 75.04 111.164 179.942 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 2.1 m -130.22 101.62 17.69 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-O 121.661 0.743 . . . . 72.34 110.827 -179.811 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 95' ' ' PRO . . . . . 0.421 ' HG3' ' HB ' ' A' ' 69' ' ' THR . 54.0 Cg_endo -69.74 177.27 5.74 Favored 'Trans proline' 0 C--N 1.341 0.155 0 C-N-CA 122.682 2.254 . . . . 73.22 112.319 179.977 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 37.2 t70 . . . . . 0 C--N 1.329 -0.31 0 CA-C-N 116.203 -0.453 . . . . 74.12 110.848 179.928 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 1.7 m . . . . . 0 C--O 1.232 0.158 0 CA-C-O 120.922 0.392 . . . . 44.42 110.881 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 101' ' ' CYS . . . . . 0.425 ' CB ' ' HB ' ' A' ' 93' ' ' VAL . 0.0 OUTLIER -105.02 148.38 26.82 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.104 -0.498 . . . . 72.13 110.87 -179.996 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 102' ' ' HIS . . . . . 0.579 ' HA ' ' O ' ' A' ' 65' ' ' LEU . 6.7 p80 -157.65 123.69 4.74 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.142 -0.481 . . . . 64.53 110.865 -179.947 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 103' ' ' LEU . . . . . 0.931 HD13 ' N ' ' A' ' 104' ' ' TRP . 2.4 tm? -151.53 146.73 26.09 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.256 -0.429 . . . . 55.14 110.959 -180.0 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 104' ' ' TRP . . . . . 0.931 ' N ' HD13 ' A' ' 103' ' ' LEU . 30.4 p90 -65.81 110.52 2.87 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.15 -0.477 . . . . 73.11 110.928 179.937 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 105' ' ' LEU . . . . . 0.795 HD13 ' HB3' ' A' ' 88' ' ' PHE . 0.4 OUTLIER -91.23 161.84 14.89 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.169 -0.469 . . . . 72.42 110.944 179.99 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -89.43 159.52 28.5 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.692 -0.766 . . . . 61.04 112.477 179.911 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 107' ' ' ARG . . . . . 0.574 ' HA ' ' CD1' ' A' ' 88' ' ' PHE . 0.4 OUTLIER -69.33 158.47 34.99 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.845 0.355 . . . . 73.33 110.863 -179.83 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -174.56 111.12 0.35 Allowed Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.758 -0.734 . . . . 60.14 112.525 -179.969 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 109' ' ' VAL . . . . . 0.695 HG22 ' OE1' ' A' ' 86' ' ' GLU . 10.6 t -100.23 132.44 22.6 Favored Pre-proline 0 C--N 1.33 -0.251 0 CA-C-O 121.632 0.729 . . . . 64.42 111.15 -179.961 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 110' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo . . . . . 0 C--N 1.341 0.161 0 C-N-CA 122.718 2.279 . . . . 64.1 112.335 179.955 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 25' ' ' THR . . . . . 0.49 HG21 HG23 ' A' ' 42' ' ' VAL . 9.6 m . . . . . 0 C--O 1.232 0.138 0 CA-C-O 120.816 0.341 . . . . 72.33 111.218 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 7.7 m -72.39 122.37 21.08 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.287 -0.415 . . . . 74.51 110.818 -179.833 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 27' ' ' ALA . . . . . 0.816 ' HB3' HG23 ' A' ' 39' ' ' ILE . . . -143.06 162.37 35.7 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.109 -0.496 . . . . 75.11 111.133 179.831 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 28' ' ' THR . . . . . 0.49 HG22 ' O ' ' A' ' 28' ' ' THR . 18.0 m -129.86 88.17 2.63 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.243 -0.435 . . . . 43.33 111.155 -179.846 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . 0.766 HG23 ' CB ' ' A' ' 39' ' ' ILE . 2.1 pt -43.87 131.08 1.39 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.19 -0.459 . . . . 71.11 111.162 179.978 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . 0.698 HG23 ' O ' ' A' ' 35' ' ' SER . 11.3 m -152.98 97.33 2.19 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.229 -0.441 . . . . 53.11 111.183 -179.998 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 86.3 p -135.96 70.79 1.42 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.193 -0.458 . . . . 71.34 110.945 -179.867 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -179.29 167.52 37.65 Favored Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.72 -0.752 . . . . 71.22 112.499 -179.982 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 16.8 pt-20 -48.95 -23.43 1.12 Allowed 'General case' 0 C--N 1.33 -0.283 0 CA-C-O 120.856 0.36 . . . . 73.33 110.885 -179.9 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -174.06 94.63 0.09 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.155 -0.475 . . . . 41.33 110.954 -179.937 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 35' ' ' SER . . . . . 0.698 ' O ' HG23 ' A' ' 30' ' ' THR . 2.9 m -145.23 165.45 28.35 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.191 -0.459 . . . . 70.41 110.81 -179.783 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 177.8 88.5 0.07 OUTLIER Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.799 -0.715 . . . . 74.4 112.52 -179.923 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 37' ' ' ALA . . . . . 0.648 ' HB3' ' CD1' ' A' ' 29' ' ' ILE . . . -108.43 -170.75 1.73 Allowed 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 120.893 0.378 . . . . 53.51 111.078 179.977 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 64.6 t -98.57 120.23 47.63 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-N 116.211 -0.449 . . . . 72.11 111.146 179.958 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 39' ' ' ILE . . . . . 0.816 HG23 ' HB3' ' A' ' 27' ' ' ALA . 0.0 OUTLIER -137.08 149.93 26.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.177 -0.465 . . . . 71.3 111.124 179.956 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 40' ' ' ARG . . . . . 0.434 ' HA ' ' O ' ' A' ' 25' ' ' THR . 19.3 mtt85 -109.46 80.47 1.32 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.213 -0.448 . . . . 73.53 110.849 179.934 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . 0.591 ' HA2' HG12 ' A' ' 67' ' ' VAL . . . -127.47 147.93 17.29 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.797 -0.716 . . . . 74.42 112.527 179.998 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 42' ' ' VAL . . . . . 0.56 HG12 ' CB ' ' A' ' 66' ' ' PHE . 3.1 p -127.19 138.86 53.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-O 120.851 0.358 . . . . 72.41 111.126 -179.942 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 43' ' ' PHE . . . . . 0.51 ' H ' HD11 ' A' ' 83' ' ' ILE . 2.8 p90 -101.05 128.71 46.98 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.166 -0.47 . . . . 73.13 110.873 -179.982 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 1.5 t0 -104.38 124.67 49.63 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.106 -0.497 . . . . 75.13 110.835 179.956 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 C--N 1.328 -0.356 0 CA-C-O 121.608 0.718 . . . . 73.42 110.88 179.97 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_endo . . . . . 0 C--O 1.231 0.169 0 CA-C-O 120.779 0.241 . . . . 72.32 112.315 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . 0.492 ' O ' ' HA ' ' A' ' 43' ' ' PHE . 0.2 OUTLIER -107.02 146.38 31.2 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.228 -0.442 . . . . 43.53 110.894 -179.891 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 65' ' ' LEU . . . . . 0.55 HD11 ' CG1' ' A' ' 67' ' ' VAL . 2.7 tm? -114.93 131.48 56.87 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.126 -0.488 . . . . 74.24 110.919 -179.957 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 66' ' ' PHE . . . . . 0.56 ' CB ' HG12 ' A' ' 42' ' ' VAL . 1.2 t80 -120.38 106.17 11.59 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.261 -0.427 . . . . 73.24 110.846 179.951 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 67' ' ' VAL . . . . . 0.591 HG12 ' HA2' ' A' ' 41' ' ' GLY . 23.2 m -144.69 172.71 5.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.167 -0.469 . . . . 75.24 111.148 179.921 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 1.4 ttt180 -105.62 143.48 33.71 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.128 -0.487 . . . . 72.12 110.896 -179.992 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 69' ' ' THR . . . . . 0.415 ' HB ' ' HG3' ' A' ' 95' ' ' PRO . 0.0 OUTLIER -41.17 -49.4 3.53 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.168 -0.469 . . . . 72.33 111.135 -179.908 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 14.8 t70 -53.39 -51.29 63.01 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.231 -0.44 . . . . 74.4 110.862 179.918 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 71' ' ' GLU . . . . . . . . . . . . . 31.2 mt-10 -53.3 -39.07 63.71 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.164 -0.471 . . . . 64.22 110.905 -179.932 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 72' ' ' VAL . . . . . 0.838 HG11 HG21 ' A' ' 93' ' ' VAL . 3.3 t -78.6 -32.43 16.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.156 -0.474 . . . . 74.05 111.148 179.952 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 73' ' ' ARG . . . . . . . . . . . . . 1.8 tmt_? -57.32 -39.18 75.3 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.149 -0.478 . . . . 63.11 110.841 -179.94 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 39.9 mt-30 -56.22 -22.02 26.86 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.188 -0.46 . . . . 63.25 110.87 -179.897 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 75' ' ' LEU . . . . . 0.784 HD22 ' CG ' ' A' ' 79' ' ' ASP . 2.3 mp -119.23 -165.29 1.13 Allowed 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.252 -0.431 . . . . 54.05 110.918 -180.0 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 76' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -116.15 171.94 7.49 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.219 -0.446 . . . . 73.23 110.86 179.969 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -62.41 132.05 51.26 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.174 -0.466 . . . . 75.25 110.899 -179.917 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 92.5 18.11 43.03 Favored Glycine 0 N--CA 1.452 -0.252 0 C-N-CA 120.746 -0.74 . . . . 70.23 112.477 179.998 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . 0.784 ' CG ' HD22 ' A' ' 75' ' ' LEU . 0.1 OUTLIER -74.23 106.33 5.82 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.883 0.373 . . . . 74.34 110.896 -179.976 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . 0.718 ' HA ' ' HA ' ' A' ' 89' ' ' TRP . 0.6 OUTLIER -85.78 109.14 18.44 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.185 -0.461 . . . . 72.22 111.155 -179.857 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 81' ' ' LEU . . . . . 0.756 ' C ' ' HA ' ' A' ' 87' ' ' ASN . 0.3 OUTLIER -97.07 133.11 42.16 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.188 -0.46 . . . . 71.24 110.9 -179.992 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 82' ' ' THR . . . . . 0.741 ' CA ' ' HA ' ' A' ' 87' ' ' ASN . 9.8 t -93.51 102.27 14.48 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.193 -0.458 . . . . 73.32 111.123 179.949 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 83' ' ' ILE . . . . . 0.734 ' CG2' HD12 ' A' ' 81' ' ' LEU . 0.1 OUTLIER -138.46 131.78 40.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.208 -0.451 . . . . 64.45 111.147 179.882 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 74.43 -50.51 2.08 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.663 -0.779 . . . . 55.43 112.548 179.96 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 11.4 mm-40 -119.77 -80.68 0.62 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.831 0.348 . . . . 74.12 110.929 -179.885 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 86' ' ' GLU . . . . . 0.458 ' C ' ' HA ' ' A' ' 82' ' ' THR . 69.0 mt-10 -153.01 161.29 42.71 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.143 -0.48 . . . . 72.11 110.901 -179.908 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 87' ' ' ASN . . . . . 0.756 ' HA ' ' C ' ' A' ' 81' ' ' LEU . 1.6 p30 -49.59 122.15 5.99 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.198 -0.455 . . . . 75.12 110.871 -179.99 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 88' ' ' PHE . . . . . 0.857 ' HB2' HD22 ' A' ' 105' ' ' LEU . 15.9 m-85 -131.83 120.01 22.02 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.196 -0.457 . . . . 74.41 110.859 -179.96 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 89' ' ' TRP . . . . . 0.718 ' HA ' ' HA ' ' A' ' 80' ' ' THR . 59.9 p-90 -83.94 136.79 33.94 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.226 -0.443 . . . . 65.01 110.869 -179.972 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 90' ' ' VAL . . . . . 0.556 HG21 HG13 ' A' ' 93' ' ' VAL . 10.1 p -86.92 138.75 18.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.246 -0.434 . . . . 70.42 111.074 179.966 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 91' ' ' ASP . . . . . 0.416 ' H ' HD22 ' A' ' 103' ' ' LEU . 0.7 OUTLIER -70.15 -41.78 73.39 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.177 -0.465 . . . . 61.11 110.76 179.934 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 92' ' ' ARG . . . . . 0.508 ' HB3' HD13 ' A' ' 103' ' ' LEU . 20.0 tpp180 -160.26 138.59 10.16 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.265 -0.425 . . . . 62.53 110.912 -179.826 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 93' ' ' VAL . . . . . 0.838 HG21 HG11 ' A' ' 72' ' ' VAL . 0.0 OUTLIER -126.81 111.9 27.41 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.258 -0.428 . . . . 52.32 111.148 179.936 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 4.0 t -127.25 109.35 21.4 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-O 121.694 0.759 . . . . 64.25 110.88 -179.914 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 95' ' ' PRO . . . . . 0.415 ' HG3' ' HB ' ' A' ' 69' ' ' THR . 53.3 Cg_endo -69.77 156.64 62.8 Favored 'Trans proline' 0 C--O 1.232 0.18 0 C-N-CA 122.649 2.232 . . . . 55.24 112.356 179.983 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 44.4 m-20 . . . . . 0 C--N 1.329 -0.322 0 CA-C-N 116.187 -0.46 . . . . 74.42 110.873 179.911 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 C--O 1.232 0.14 0 CA-C-O 120.832 0.349 . . . . 73.1 110.881 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 101' ' ' CYS . . . . . 0.406 ' HB2' ' CB ' ' A' ' 93' ' ' VAL . 1.6 p -42.37 142.85 0.71 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.145 -0.479 . . . . 73.31 110.868 -179.99 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 102' ' ' HIS . . . . . 0.491 ' HA ' ' O ' ' A' ' 65' ' ' LEU . 46.1 p-80 -161.2 125.55 3.47 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.188 -0.46 . . . . 65.21 110.87 -179.944 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 103' ' ' LEU . . . . . 0.571 HD23 ' N ' ' A' ' 104' ' ' TRP . 9.8 tt -152.04 155.85 38.77 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.201 -0.454 . . . . 71.3 110.873 -179.993 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 104' ' ' TRP . . . . . 0.571 ' N ' HD23 ' A' ' 103' ' ' LEU . 50.2 p-90 -66.23 112.0 3.74 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.136 -0.484 . . . . 74.42 110.981 179.865 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 105' ' ' LEU . . . . . 0.857 HD22 ' HB2' ' A' ' 88' ' ' PHE . 0.3 OUTLIER -87.58 162.24 17.29 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.319 -0.4 . . . . 74.32 110.934 -179.983 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -88.36 160.43 30.54 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.724 -0.75 . . . . 62.0 112.53 179.894 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 107' ' ' ARG . . . . . 0.52 ' HA ' ' CD1' ' A' ' 88' ' ' PHE . 2.5 ptm180 -68.89 158.46 34.5 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.799 0.333 . . . . 64.41 110.845 -179.816 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -173.64 106.79 0.23 Allowed Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.694 -0.765 . . . . 45.2 112.436 -179.966 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 109' ' ' VAL . . . . . 0.443 HG23 ' HD2' ' A' ' 110' ' ' PRO . 8.7 p -91.04 134.01 30.9 Favored Pre-proline 0 C--N 1.33 -0.275 0 CA-C-O 121.644 0.735 . . . . 64.35 111.103 180.0 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 110' ' ' PRO . . . . . 0.552 ' N ' HD21 ' A' ' 87' ' ' ASN . 53.9 Cg_endo . . . . . 0 C--N 1.341 0.153 0 C-N-CA 122.659 2.239 . . . . 74.12 112.358 179.929 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 25' ' ' THR . . . . . 0.718 HG21 HG23 ' A' ' 42' ' ' VAL . 85.8 m . . . . . 0 N--CA 1.457 -0.115 0 CA-C-O 120.829 0.347 . . . . 61.22 111.147 . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -71.41 123.17 21.76 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.212 -0.449 . . . . 75.31 110.898 -179.861 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 27' ' ' ALA . . . . . 0.827 ' HB3' HG23 ' A' ' 39' ' ' ILE . . . -140.03 162.74 34.5 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.122 -0.49 . . . . 63.0 111.113 179.921 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 28' ' ' THR . . . . . 0.501 HG22 ' O ' ' A' ' 28' ' ' THR . 16.9 m -129.6 88.54 2.7 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.246 -0.434 . . . . 73.21 111.116 -179.913 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . 0.766 HG23 ' CB ' ' A' ' 39' ' ' ILE . 2.0 pt -45.12 129.75 1.83 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.385 0 CA-C-N 116.264 -0.425 . . . . 75.51 111.123 179.876 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . 0.711 HG23 ' O ' ' A' ' 35' ' ' SER . 7.0 m -152.97 98.53 2.32 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.24 -0.437 . . . . 74.05 111.179 179.917 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 31' ' ' SER . . . . . 0.441 ' OG ' HG22 ' A' ' 80' ' ' THR . 12.1 t -138.38 71.11 1.39 Allowed 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.246 -0.434 . . . . 71.44 110.817 -179.854 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -178.72 168.17 38.99 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.751 -0.738 . . . . 74.23 112.508 179.959 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 15.4 pt-20 -49.38 -23.46 1.49 Allowed 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.781 0.324 . . . . 53.42 110.835 -179.844 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 4.8 tt0 -174.68 94.84 0.08 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.166 -0.47 . . . . 52.13 110.907 -179.916 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 35' ' ' SER . . . . . 0.711 ' O ' HG23 ' A' ' 30' ' ' THR . 3.3 m -144.97 165.71 27.4 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.214 -0.448 . . . . 70.14 110.891 -179.834 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 178.35 88.21 0.07 OUTLIER Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.811 -0.709 . . . . 63.42 112.505 -179.977 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 37' ' ' ALA . . . . . 0.666 ' HB3' ' CD1' ' A' ' 29' ' ' ILE . . . -109.6 -172.81 2.12 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.849 0.357 . . . . 44.03 111.088 -179.984 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 61.9 t -97.75 121.9 48.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.238 -0.437 . . . . 62.4 111.123 179.962 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 39' ' ' ILE . . . . . 0.827 HG23 ' HB3' ' A' ' 27' ' ' ALA . 0.0 OUTLIER -137.62 150.12 25.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.126 -0.488 . . . . 74.32 111.157 179.898 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 40' ' ' ARG . . . . . 0.657 ' O ' HG12 ' A' ' 67' ' ' VAL . 5.4 ttm180 -109.69 80.3 1.3 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.24 -0.436 . . . . 73.0 110.873 179.987 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . 0.499 ' N ' HD13 ' A' ' 39' ' ' ILE . . . -129.18 147.44 17.75 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.774 -0.727 . . . . 74.14 112.46 -179.955 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 42' ' ' VAL . . . . . 0.718 HG23 HG21 ' A' ' 25' ' ' THR . 2.8 p -126.49 136.59 60.37 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-O 120.845 0.355 . . . . 74.12 111.072 -179.971 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 43' ' ' PHE . . . . . 0.658 ' H ' HD11 ' A' ' 83' ' ' ILE . 1.3 p90 -93.72 130.77 39.57 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.218 -0.446 . . . . 73.12 110.872 179.96 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 12.6 t70 -117.04 124.76 50.08 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.121 -0.49 . . . . 61.12 110.87 179.956 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 C--N 1.328 -0.327 0 CA-C-O 121.575 0.702 . . . . 73.33 110.877 179.999 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_endo . . . . . 0 C--O 1.232 0.181 0 CA-C-O 120.841 0.267 . . . . 55.25 112.315 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . 0.502 ' O ' ' HA ' ' A' ' 43' ' ' PHE . 1.5 t -106.32 148.15 28.36 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.222 -0.444 . . . . 62.24 110.915 -179.922 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 65' ' ' LEU . . . . . 0.666 ' O ' HD23 ' A' ' 65' ' ' LEU . 0.0 OUTLIER -112.68 140.45 47.44 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.118 -0.492 . . . . 63.01 110.901 179.996 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 66' ' ' PHE . . . . . 0.63 ' HB3' HG12 ' A' ' 42' ' ' VAL . 17.8 t80 -118.47 107.97 14.45 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.156 -0.475 . . . . 70.55 110.896 179.904 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 67' ' ' VAL . . . . . 0.657 HG12 ' O ' ' A' ' 40' ' ' ARG . 4.3 m -141.98 166.79 16.4 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.18 -0.463 . . . . 75.54 111.057 -179.949 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 68' ' ' ARG . . . . . 0.619 ' O ' HG23 ' A' ' 72' ' ' VAL . 2.8 ttm180 -103.23 144.19 31.66 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.156 -0.475 . . . . 72.15 110.921 179.984 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 69' ' ' THR . . . . . 0.403 ' HB ' ' HG3' ' A' ' 95' ' ' PRO . 2.0 t -40.32 -47.3 2.48 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.245 -0.434 . . . . 73.0 111.138 -179.92 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 46.8 m-20 -52.97 -62.03 1.92 Allowed 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.224 -0.444 . . . . 72.4 110.859 179.924 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 71' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -53.39 -40.44 65.04 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.235 -0.439 . . . . 64.44 110.903 -179.915 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 72' ' ' VAL . . . . . 0.619 HG23 ' O ' ' A' ' 68' ' ' ARG . 14.4 t -69.39 -33.84 59.49 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.125 -0.489 . . . . 70.52 111.12 179.946 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 73' ' ' ARG . . . . . . . . . . . . . 18.9 ttm180 -62.17 -39.89 94.19 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.205 -0.452 . . . . 73.05 110.836 -179.96 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 29.9 mt-30 -55.04 -22.58 16.28 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.219 -0.446 . . . . 72.12 110.874 -179.932 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 75' ' ' LEU . . . . . 0.511 HD21 HG21 ' A' ' 29' ' ' ILE . 4.5 mp -113.03 -168.73 1.36 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.234 -0.439 . . . . 73.41 110.912 -179.969 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 76' ' ' ARG . . . . . . . . . . . . . 11.1 ptp180 -124.12 -178.96 4.24 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.182 -0.463 . . . . 74.22 110.871 179.974 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 4.7 mtp180 -70.05 130.56 42.48 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.155 -0.475 . . . . 74.33 110.926 -179.957 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . 0.401 ' HA2' ' CD1' ' A' ' 89' ' ' TRP . . . 92.42 36.47 6.2 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.767 -0.73 . . . . 33.52 112.453 -179.976 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . 0.486 ' OD1' HD23 ' A' ' 75' ' ' LEU . 0.6 OUTLIER -99.13 105.46 17.55 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.859 0.362 . . . . 71.15 110.926 179.994 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . 0.742 ' HA ' ' HA ' ' A' ' 89' ' ' TRP . 0.8 OUTLIER -89.61 108.56 19.74 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.199 -0.455 . . . . 70.44 111.102 -179.851 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 81' ' ' LEU . . . . . 0.768 ' C ' ' HA ' ' A' ' 87' ' ' ASN . 0.0 OUTLIER -96.05 135.42 37.85 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.132 -0.485 . . . . 71.24 110.93 179.956 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 82' ' ' THR . . . . . 0.714 ' CA ' ' HA ' ' A' ' 87' ' ' ASN . 8.9 t -94.99 101.64 13.41 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.267 -0.424 . . . . 73.45 111.124 179.958 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 83' ' ' ILE . . . . . 0.732 HD13 ' O ' ' A' ' 83' ' ' ILE . 0.1 OUTLIER -135.58 132.58 51.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.236 -0.438 . . . . 73.14 111.128 179.913 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 73.08 -54.37 1.81 Allowed Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.761 -0.733 . . . . 65.53 112.486 179.936 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 3.0 mm-40 -115.54 -83.18 0.62 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.787 0.327 . . . . 54.43 110.837 -179.829 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 7.6 mp0 -150.02 159.45 44.39 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.195 -0.457 . . . . 61.43 110.883 -179.946 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 87' ' ' ASN . . . . . 0.768 ' HA ' ' C ' ' A' ' 81' ' ' LEU . 0.7 OUTLIER -50.28 124.05 9.66 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.152 -0.476 . . . . 63.13 110.876 -179.868 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 88' ' ' PHE . . . . . 0.748 ' HB3' HD13 ' A' ' 105' ' ' LEU . 15.9 m-85 -131.09 119.61 22.2 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.113 -0.494 . . . . 73.55 110.857 -179.956 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 89' ' ' TRP . . . . . 0.742 ' HA ' ' HA ' ' A' ' 80' ' ' THR . 0.0 OUTLIER -79.23 135.55 36.81 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 116.121 -0.491 . . . . 72.01 110.921 -179.993 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 90' ' ' VAL . . . . . 0.682 HG21 HG13 ' A' ' 93' ' ' VAL . 3.0 p -91.55 136.08 25.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.207 -0.451 . . . . 72.34 111.161 179.951 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -63.24 -72.35 0.14 Allowed 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.185 -0.461 . . . . 71.21 110.888 179.926 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 92' ' ' ARG . . . . . 0.569 ' O ' ' HG ' ' A' ' 103' ' ' LEU . 9.0 ptm180 -159.71 122.12 3.43 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.164 -0.471 . . . . 74.32 110.954 -179.936 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 93' ' ' VAL . . . . . 0.699 HG12 ' HB2' ' A' ' 103' ' ' LEU . 26.0 m -113.63 136.88 48.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.191 -0.459 . . . . 72.42 111.083 -179.956 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 94' ' ' SER . . . . . 0.423 ' HA ' ' HD2' ' A' ' 95' ' ' PRO . 7.0 t -129.32 100.31 20.31 Favored Pre-proline 0 C--N 1.329 -0.307 0 CA-C-O 121.673 0.749 . . . . 41.05 110.821 -179.84 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 95' ' ' PRO . . . . . 0.423 ' HD2' ' HA ' ' A' ' 94' ' ' SER . 53.5 Cg_endo -69.81 169.59 18.62 Favored 'Trans proline' 0 C--N 1.342 0.186 0 C-N-CA 122.629 2.22 . . . . 75.43 112.312 179.958 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 11.7 t0 . . . . . 0 C--N 1.329 -0.302 0 CA-C-N 116.186 -0.461 . . . . 75.2 110.837 179.923 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 46.7 t . . . . . 0 C--O 1.231 0.131 0 CA-C-O 120.791 0.329 . . . . 73.53 110.878 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 101' ' ' CYS . . . . . 0.463 ' CB ' ' HB ' ' A' ' 93' ' ' VAL . 0.0 OUTLIER -110.16 148.54 31.59 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.131 -0.486 . . . . 75.21 110.931 -179.976 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 102' ' ' HIS . . . . . 0.613 ' HA ' ' O ' ' A' ' 65' ' ' LEU . 24.8 p80 -160.37 126.28 4.06 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.225 -0.443 . . . . 64.24 110.953 179.99 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 103' ' ' LEU . . . . . 0.926 HD13 ' N ' ' A' ' 104' ' ' TRP . 2.5 tm? -151.22 147.55 27.14 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.272 -0.422 . . . . 62.45 110.926 -179.96 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 104' ' ' TRP . . . . . 0.926 ' N ' HD13 ' A' ' 103' ' ' LEU . 22.2 m-90 -63.43 114.45 3.88 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 116.208 -0.451 . . . . 71.24 110.922 179.91 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 105' ' ' LEU . . . . . 0.748 HD13 ' HB3' ' A' ' 88' ' ' PHE . 0.3 OUTLIER -93.7 162.0 14.11 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.255 -0.43 . . . . 63.22 110.912 -179.987 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -88.83 160.63 30.12 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.741 -0.743 . . . . 75.5 112.523 179.878 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 107' ' ' ARG . . . . . 0.57 ' HA ' ' CD1' ' A' ' 88' ' ' PHE . 3.1 ptt85 -67.9 157.31 35.23 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.858 0.361 . . . . 74.24 110.893 -179.887 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -173.97 110.52 0.33 Allowed Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.756 -0.735 . . . . 72.14 112.478 -179.979 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 109' ' ' VAL . . . . . 0.475 HG13 ' HD2' ' A' ' 110' ' ' PRO . 58.1 t -84.72 134.46 41.92 Favored Pre-proline 0 C--N 1.33 -0.276 0 CA-C-O 121.629 0.728 . . . . 72.4 111.135 -179.988 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 110' ' ' PRO . . . . . 0.475 ' HD2' HG13 ' A' ' 109' ' ' VAL . 52.6 Cg_endo . . . . . 0 C--N 1.341 0.173 0 C-N-CA 122.675 2.25 . . . . 63.15 112.263 -179.971 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 25' ' ' THR . . . . . 0.594 ' O ' ' HA ' ' A' ' 40' ' ' ARG . 60.7 p . . . . . 0 C--O 1.232 0.136 0 CA-C-O 120.785 0.326 . . . . 74.32 111.139 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -77.53 121.76 24.32 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.227 -0.442 . . . . 62.44 110.849 -179.822 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 27' ' ' ALA . . . . . 0.793 ' HB3' HG23 ' A' ' 39' ' ' ILE . . . -151.7 161.46 42.64 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.123 -0.489 . . . . 63.51 111.132 179.891 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 28' ' ' THR . . . . . 0.537 HG22 ' O ' ' A' ' 28' ' ' THR . 11.0 m -130.84 88.87 2.67 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.177 -0.465 . . . . 75.24 111.117 -179.852 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . 0.798 HG23 ' CB ' ' A' ' 39' ' ' ILE . 1.7 pt -43.49 128.75 1.11 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.198 -0.456 . . . . 72.43 111.133 179.902 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . 0.688 HG23 ' O ' ' A' ' 35' ' ' SER . 7.1 m -153.76 99.0 2.25 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.199 -0.455 . . . . 70.31 111.148 179.949 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 18.7 t -140.8 72.94 1.4 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.222 -0.444 . . . . 62.43 110.845 -179.84 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -178.53 166.57 36.51 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.72 -0.753 . . . . 70.14 112.512 -179.968 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 10.6 pt-20 -48.96 -23.72 1.23 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.738 0.304 . . . . 74.11 110.873 -179.892 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 4.1 tt0 -174.1 93.5 0.09 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.15 -0.477 . . . . 62.41 110.944 -179.949 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 35' ' ' SER . . . . . 0.688 ' O ' HG23 ' A' ' 30' ' ' THR . 2.0 m -144.87 165.53 27.87 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.243 -0.435 . . . . 73.51 110.84 -179.791 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -179.86 85.21 0.06 OUTLIER Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.746 -0.74 . . . . 74.31 112.513 179.936 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 37' ' ' ALA . . . . . 0.619 ' HB3' ' CD1' ' A' ' 29' ' ' ILE . . . -106.93 -173.83 2.39 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.886 0.374 . . . . 54.05 111.1 -179.996 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 57.5 t -99.36 124.85 52.92 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.171 -0.468 . . . . 74.04 111.124 179.99 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 39' ' ' ILE . . . . . 0.798 ' CB ' HG23 ' A' ' 29' ' ' ILE . 0.0 OUTLIER -137.15 149.35 26.05 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 116.223 -0.444 . . . . 73.24 111.111 179.97 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 40' ' ' ARG . . . . . 0.665 ' O ' HG12 ' A' ' 67' ' ' VAL . 0.2 OUTLIER -107.84 82.02 1.59 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.192 -0.458 . . . . 74.33 110.907 179.931 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . 0.608 ' O ' ' HB2' ' A' ' 27' ' ' ALA . . . -141.6 142.75 12.26 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.685 -0.769 . . . . 43.24 112.482 -179.94 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 42' ' ' VAL . . . . . 0.545 ' O ' ' HA ' ' A' ' 65' ' ' LEU . 9.0 p -128.57 141.3 46.91 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-O 120.815 0.34 . . . . 74.43 111.144 -179.939 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 43' ' ' PHE . . . . . 0.784 ' H ' HD11 ' A' ' 83' ' ' ILE . 1.8 p90 -90.28 135.88 33.4 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.228 -0.442 . . . . 73.24 110.938 179.964 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 11.4 t70 -126.15 125.27 42.21 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.221 -0.445 . . . . 71.14 110.852 179.99 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 . . . . . 0 C--N 1.329 -0.315 0 CA-C-O 121.619 0.723 . . . . 75.32 110.855 179.943 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo . . . . . 0 C--O 1.23 0.112 0 CA-C-O 120.83 0.263 . . . . 71.05 112.327 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 3.5 t -106.92 142.87 35.85 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.196 -0.456 . . . . 75.22 110.842 -179.839 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 65' ' ' LEU . . . . . 0.613 ' O ' HD23 ' A' ' 65' ' ' LEU . 0.0 OUTLIER -114.88 119.76 37.67 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.163 -0.471 . . . . 60.25 110.926 -179.991 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 56.0 t80 -101.76 109.81 21.66 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.226 -0.443 . . . . 54.24 110.85 179.98 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 67' ' ' VAL . . . . . 0.665 HG12 ' O ' ' A' ' 40' ' ' ARG . 22.3 m -138.13 169.2 18.9 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.159 -0.473 . . . . 64.43 111.163 179.895 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 68' ' ' ARG . . . . . 0.469 ' O ' HG23 ' A' ' 72' ' ' VAL . 1.1 ttp180 -93.43 143.82 25.92 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.191 -0.459 . . . . 64.22 110.919 -179.983 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 69' ' ' THR . . . . . 0.411 HG23 ' N ' ' A' ' 70' ' ' ASP . 2.4 t -45.47 -47.74 13.95 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.241 -0.436 . . . . 74.53 111.039 -179.868 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 70' ' ' ASP . . . . . 0.411 ' N ' HG23 ' A' ' 69' ' ' THR . 30.5 t70 -52.18 -52.84 49.56 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.197 -0.456 . . . . 75.13 110.923 179.928 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 71' ' ' GLU . . . . . . . . . . . . . 66.0 mm-40 -54.41 -39.29 67.16 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.246 -0.434 . . . . 75.24 110.909 -179.947 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 72' ' ' VAL . . . . . 0.469 HG23 ' O ' ' A' ' 68' ' ' ARG . 4.4 t -73.49 -38.45 52.7 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.16 -0.473 . . . . 74.22 111.172 179.925 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 73' ' ' ARG . . . . . . . . . . . . . 2.6 tmt_? -55.69 -40.02 71.79 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.187 -0.46 . . . . 74.12 110.907 -179.985 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 41.7 mt-30 -52.64 -25.86 12.0 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.245 -0.434 . . . . 71.24 110.962 -179.995 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 75' ' ' LEU . . . . . 0.496 HD21 ' CD1' ' A' ' 29' ' ' ILE . 2.5 mp -116.25 -166.64 1.17 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.163 -0.472 . . . . 62.3 110.951 179.942 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 76' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -112.35 -178.67 3.47 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.204 -0.453 . . . . 74.34 110.845 179.925 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -76.05 125.89 29.97 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.184 -0.462 . . . . 72.31 110.925 -179.929 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 99.77 23.94 10.39 Favored Glycine 0 N--CA 1.45 -0.383 0 C-N-CA 120.768 -0.729 . . . . 34.42 112.505 -179.912 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -82.63 109.31 16.7 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.876 0.369 . . . . 73.02 110.916 179.968 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . 0.737 ' HA ' ' HA ' ' A' ' 89' ' ' TRP . 0.5 OUTLIER -88.37 109.64 20.15 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.209 -0.45 . . . . 71.34 111.16 -179.906 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 81' ' ' LEU . . . . . 0.806 ' C ' ' HA ' ' A' ' 87' ' ' ASN . 0.0 OUTLIER -96.82 134.37 40.21 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 116.227 -0.442 . . . . 55.44 110.956 179.949 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 82' ' ' THR . . . . . 0.729 ' CA ' ' HA ' ' A' ' 87' ' ' ASN . 4.9 t -92.63 101.79 14.21 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.187 -0.461 . . . . 72.12 111.183 179.975 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 83' ' ' ILE . . . . . 0.784 HD11 ' H ' ' A' ' 43' ' ' PHE . 0.1 OUTLIER -132.92 130.45 58.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.219 -0.446 . . . . 74.12 111.118 179.975 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 70.42 -62.37 0.83 Allowed Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.749 -0.739 . . . . 75.03 112.458 179.924 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 10.1 tp10 -103.07 -81.83 0.5 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.806 0.336 . . . . 75.45 110.908 -179.891 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 86' ' ' GLU . . . . . 0.427 ' C ' ' HA ' ' A' ' 82' ' ' THR . 95.7 mt-10 -152.91 160.7 43.07 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.143 -0.48 . . . . 73.43 110.923 -179.923 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 87' ' ' ASN . . . . . 0.806 ' HA ' ' C ' ' A' ' 81' ' ' LEU . 1.3 p-10 -51.55 124.64 12.62 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.153 -0.476 . . . . 60.32 110.893 -179.908 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 88' ' ' PHE . . . . . 0.634 ' HB2' HD22 ' A' ' 105' ' ' LEU . 15.3 m-85 -132.77 120.27 21.4 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.176 -0.465 . . . . 74.42 110.932 179.999 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 89' ' ' TRP . . . . . 0.737 ' HA ' ' HA ' ' A' ' 80' ' ' THR . 7.1 p90 -80.01 137.0 36.72 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.179 -0.464 . . . . 64.43 111.005 -179.981 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 90' ' ' VAL . . . . . 0.569 HG21 ' CG1' ' A' ' 93' ' ' VAL . 7.2 p -89.64 135.97 24.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.318 -0.401 . . . . 62.44 111.161 179.893 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 91' ' ' ASP . . . . . 0.422 ' HB3' HD12 ' A' ' 103' ' ' LEU . 0.0 OUTLIER -64.28 -67.76 0.41 Allowed 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.155 -0.475 . . . . 73.2 110.907 179.891 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 92' ' ' ARG . . . . . 0.646 ' O ' ' HG ' ' A' ' 103' ' ' LEU . 13.3 ttm-85 -162.76 122.26 2.25 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.238 -0.437 . . . . 75.24 110.897 -179.939 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 93' ' ' VAL . . . . . 0.741 HG12 ' HB2' ' A' ' 103' ' ' LEU . 22.7 m -117.9 135.42 58.37 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.144 -0.48 . . . . 73.13 111.111 179.966 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 94' ' ' SER . . . . . 0.425 ' HA ' ' HD2' ' A' ' 95' ' ' PRO . 1.1 p -129.36 103.24 18.12 Favored Pre-proline 0 C--N 1.329 -0.285 0 CA-C-O 121.585 0.707 . . . . 65.45 110.856 -179.823 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 95' ' ' PRO . . . . . 0.425 ' HD2' ' HA ' ' A' ' 94' ' ' SER . 53.6 Cg_endo -69.76 -176.15 1.39 Allowed 'Trans proline' 0 C--O 1.231 0.142 0 C-N-CA 122.657 2.238 . . . . 74.3 112.31 -179.947 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 66.5 m-20 . . . . . 0 C--N 1.328 -0.332 0 CA-C-N 116.185 -0.461 . . . . 74.42 110.853 179.962 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 1.7 m . . . . . 0 C--O 1.233 0.203 0 CA-C-O 120.89 0.376 . . . . 74.25 110.874 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 101' ' ' CYS . . . . . 0.485 ' CB ' ' HB ' ' A' ' 93' ' ' VAL . 0.0 OUTLIER -106.0 150.02 26.1 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.128 -0.487 . . . . 65.52 110.886 -179.939 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 102' ' ' HIS . . . . . 0.526 ' HA ' ' O ' ' A' ' 65' ' ' LEU . 19.6 p-80 -160.92 123.54 3.19 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.198 -0.456 . . . . 74.11 110.89 -179.951 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 103' ' ' LEU . . . . . 0.841 HD13 ' N ' ' A' ' 104' ' ' TRP . 2.1 tm? -152.91 147.67 26.25 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.203 -0.453 . . . . 73.15 110.918 -179.964 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 104' ' ' TRP . . . . . 0.841 ' N ' HD13 ' A' ' 103' ' ' LEU . 30.9 p90 -63.99 117.52 7.15 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 116.178 -0.465 . . . . 74.21 110.891 179.951 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 105' ' ' LEU . . . . . 0.634 HD22 ' HB2' ' A' ' 88' ' ' PHE . 0.3 OUTLIER -94.12 162.92 13.68 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 116.268 -0.424 . . . . 71.44 110.928 179.989 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -88.84 159.74 29.39 Favored Glycine 0 N--CA 1.453 -0.219 0 C-N-CA 120.705 -0.76 . . . . 61.33 112.477 179.9 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 107' ' ' ARG . . . . . 0.554 ' HA ' ' CD1' ' A' ' 88' ' ' PHE . 4.3 ptp180 -66.84 157.29 33.42 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.847 0.356 . . . . 74.13 110.883 -179.882 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -173.1 111.61 0.39 Allowed Glycine 0 N--CA 1.452 -0.272 0 C-N-CA 120.717 -0.754 . . . . 42.4 112.468 -179.916 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 109' ' ' VAL . . . . . 0.448 HG23 ' HD2' ' A' ' 110' ' ' PRO . 7.2 p -86.42 133.96 39.2 Favored Pre-proline 0 C--N 1.33 -0.264 0 CA-C-O 121.567 0.698 . . . . 64.44 111.157 179.999 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 110' ' ' PRO . . . . . 0.448 ' HD2' HG23 ' A' ' 109' ' ' VAL . 53.1 Cg_endo . . . . . 0 C--O 1.232 0.175 0 C-N-CA 122.635 2.224 . . . . 72.32 112.328 179.987 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 25' ' ' THR . . . . . 0.482 ' O ' ' HA ' ' A' ' 40' ' ' ARG . 1.3 t . . . . . 0 C--O 1.231 0.121 0 CA-C-O 120.746 0.308 . . . . 70.32 111.196 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 20.6 p -72.86 123.46 23.44 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.258 -0.428 . . . . 63.2 110.799 -179.811 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 27' ' ' ALA . . . . . 0.783 ' HB3' HG23 ' A' ' 39' ' ' ILE . . . -146.79 162.83 37.78 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.109 -0.496 . . . . 63.11 111.079 179.882 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 28' ' ' THR . . . . . 0.505 HG22 ' O ' ' A' ' 28' ' ' THR . 14.4 m -130.69 89.6 2.79 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.164 -0.471 . . . . 75.31 111.183 -179.89 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . 0.856 HG21 HD21 ' A' ' 75' ' ' LEU . 2.2 pt -43.69 134.5 1.21 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.364 0 CA-C-N 116.239 -0.437 . . . . 72.52 111.167 179.936 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . 0.593 HG23 ' O ' ' A' ' 35' ' ' SER . 26.7 m -155.29 98.24 1.97 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.183 -0.462 . . . . 72.12 111.104 179.979 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 96.8 p -134.7 70.14 1.45 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.146 -0.479 . . . . 71.43 110.859 -179.868 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -179.27 168.86 39.79 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.733 -0.746 . . . . 74.11 112.476 179.988 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 16.7 pt-20 -48.72 -24.2 1.31 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.731 0.301 . . . . 74.32 110.863 -179.799 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 29.9 tt0 -173.97 95.55 0.1 Allowed 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.14 -0.482 . . . . 64.31 110.956 -179.888 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 35' ' ' SER . . . . . 0.593 ' O ' HG23 ' A' ' 30' ' ' THR . 2.1 m -144.29 165.07 28.92 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.223 -0.444 . . . . 73.34 110.836 -179.751 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 179.59 89.43 0.08 OUTLIER Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.796 -0.716 . . . . 72.41 112.51 -179.954 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 37' ' ' ALA . . . . . 0.642 ' HB3' ' CD1' ' A' ' 29' ' ' ILE . . . -109.15 -170.71 1.71 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.83 0.348 . . . . 53.44 111.107 179.949 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 51.1 t -98.31 119.89 46.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.133 -0.485 . . . . 75.54 111.161 179.956 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 39' ' ' ILE . . . . . 0.787 HD12 HD13 ' A' ' 81' ' ' LEU . 0.0 OUTLIER -137.72 150.53 25.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.262 -0.426 . . . . 71.1 111.157 179.884 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 40' ' ' ARG . . . . . 0.482 ' HA ' ' O ' ' A' ' 25' ' ' THR . 19.2 mtt-85 -109.56 80.53 1.32 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.2 -0.455 . . . . 75.32 110.893 179.95 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . 0.437 ' N ' HD13 ' A' ' 39' ' ' ILE . . . -133.76 141.17 12.48 Favored Glycine 0 N--CA 1.452 -0.252 0 C-N-CA 120.77 -0.729 . . . . 42.43 112.478 -179.911 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 42' ' ' VAL . . . . . 0.445 HG23 ' OG1' ' A' ' 25' ' ' THR . 0.4 OUTLIER -124.22 139.01 51.89 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-O 120.818 0.342 . . . . 73.2 111.117 -179.935 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 43' ' ' PHE . . . . . 0.536 ' H ' HD11 ' A' ' 83' ' ' ILE . 2.4 p90 -96.15 132.21 41.79 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.199 -0.455 . . . . 54.1 110.87 179.981 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 12.9 t70 -114.6 124.29 51.49 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.141 -0.482 . . . . 52.33 110.899 179.918 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--N 1.328 -0.345 0 CA-C-O 121.624 0.726 . . . . 65.43 110.834 -179.97 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 63' ' ' PRO . . . . . 0.408 ' HG2' HD11 ' A' ' 105' ' ' LEU . 53.9 Cg_endo . . . . . 0 C--O 1.231 0.164 0 CA-C-O 120.741 0.226 . . . . 73.33 112.378 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . 0.52 ' O ' ' HA ' ' A' ' 43' ' ' PHE . 0.5 OUTLIER -105.95 151.21 24.89 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.237 -0.438 . . . . 74.35 110.87 -179.854 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 65' ' ' LEU . . . . . 0.78 HD21 HD11 ' A' ' 81' ' ' LEU . 3.2 tm? -113.52 139.21 49.15 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.119 -0.491 . . . . 64.12 110.951 179.998 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 66' ' ' PHE . . . . . 0.697 ' N ' HD13 ' A' ' 65' ' ' LEU . 2.8 t80 -120.54 106.25 11.61 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.235 -0.439 . . . . 74.31 110.923 179.906 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 67' ' ' VAL . . . . . 0.477 HG22 ' N ' ' A' ' 68' ' ' ARG . 8.2 p -144.03 161.46 15.59 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 116.144 -0.48 . . . . 70.43 111.124 179.992 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 68' ' ' ARG . . . . . 0.477 ' N ' HG22 ' A' ' 67' ' ' VAL . 7.0 ttm180 -96.09 145.38 25.53 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.148 -0.478 . . . . 62.34 110.878 -179.976 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 69' ' ' THR . . . . . 0.459 ' HB ' ' HG3' ' A' ' 95' ' ' PRO . 3.0 t -40.22 -45.43 2.06 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.227 -0.442 . . . . 74.22 111.209 -179.98 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 70' ' ' ASP . . . . . 0.407 ' N ' HG23 ' A' ' 69' ' ' THR . 4.8 m-20 -65.81 -53.97 33.08 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.191 -0.459 . . . . 72.24 110.91 179.884 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 71' ' ' GLU . . . . . 0.484 ' O ' HD13 ' A' ' 75' ' ' LEU . 1.1 mp0 -53.74 -39.24 65.14 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.17 -0.468 . . . . 70.13 110.897 -179.964 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 7.2 p -82.63 -24.35 8.73 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.225 -0.443 . . . . 71.43 111.115 179.991 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 73' ' ' ARG . . . . . . . . . . . . . 51.0 ttt180 -63.97 -37.22 86.62 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.16 -0.473 . . . . 63.45 110.887 -179.989 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 15.2 mm-40 -67.62 -10.96 56.85 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.179 -0.464 . . . . 71.31 110.877 -179.95 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 75' ' ' LEU . . . . . 0.856 HD21 HG21 ' A' ' 29' ' ' ILE . 8.7 mp -103.39 -176.4 3.07 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.234 -0.439 . . . . 64.33 110.95 179.995 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 76' ' ' ARG . . . . . . . . . . . . . 16.5 ttm180 -123.64 150.0 44.71 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.231 -0.441 . . . . 61.2 110.873 -179.986 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -50.34 105.43 0.09 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.218 -0.446 . . . . 61.53 110.918 -179.9 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 113.97 16.14 8.1 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.745 -0.741 . . . . 64.55 112.441 -179.974 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . 0.73 ' HB3' HD23 ' A' ' 75' ' ' LEU . 0.4 OUTLIER -79.88 106.27 11.78 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-O 120.898 0.38 . . . . 73.12 110.852 -179.976 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . 0.728 ' HA ' ' HA ' ' A' ' 89' ' ' TRP . 0.7 OUTLIER -85.46 110.24 19.03 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.226 -0.443 . . . . 21.43 111.167 -179.929 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 81' ' ' LEU . . . . . 0.787 HD13 HD12 ' A' ' 39' ' ' ILE . 0.3 OUTLIER -96.38 132.2 42.14 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.226 -0.443 . . . . 71.51 110.961 179.955 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 82' ' ' THR . . . . . 0.743 ' CA ' ' HA ' ' A' ' 87' ' ' ASN . 3.4 t -93.82 102.5 14.63 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.205 -0.452 . . . . 72.1 111.18 179.973 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 83' ' ' ILE . . . . . 0.722 ' CG2' HD12 ' A' ' 81' ' ' LEU . 0.1 OUTLIER -138.52 131.66 39.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.211 -0.45 . . . . 73.43 111.105 179.966 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 74.59 -53.17 2.39 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.741 -0.742 . . . . 65.42 112.517 179.941 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 4.1 mm-40 -117.76 -82.2 0.63 Allowed 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.834 0.35 . . . . 74.23 110.865 -179.91 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 86' ' ' GLU . . . . . 0.404 ' HB2' ' CE1' ' A' ' 88' ' ' PHE . 6.9 mp0 -149.7 160.3 43.64 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.163 -0.471 . . . . 75.34 110.92 -179.915 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 87' ' ' ASN . . . . . 0.751 ' HA ' ' C ' ' A' ' 81' ' ' LEU . 1.4 p30 -50.91 123.81 9.95 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.193 -0.458 . . . . 73.04 110.893 -179.913 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 88' ' ' PHE . . . . . 0.779 ' HB2' HD22 ' A' ' 105' ' ' LEU . 14.9 m-85 -131.81 118.32 19.73 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.199 -0.455 . . . . 74.13 110.893 -179.955 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 89' ' ' TRP . . . . . 0.728 ' HA ' ' HA ' ' A' ' 80' ' ' THR . 62.2 p-90 -81.53 135.1 35.59 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.196 -0.456 . . . . 65.3 110.854 -179.963 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 90' ' ' VAL . . . . . 0.48 ' HA ' ' HB3' ' A' ' 105' ' ' LEU . 4.9 p -91.52 136.8 23.38 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.193 -0.458 . . . . 74.41 111.131 179.881 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -63.06 -72.3 0.14 Allowed 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.219 -0.446 . . . . 71.42 110.919 179.87 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 92' ' ' ARG . . . . . 0.597 ' O ' ' HG ' ' A' ' 103' ' ' LEU . 12.3 ttm-85 -159.17 120.66 3.35 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.185 -0.461 . . . . 72.04 110.861 -179.962 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 93' ' ' VAL . . . . . 0.645 HG12 ' HB2' ' A' ' 103' ' ' LEU . 24.4 m -111.8 133.01 58.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.188 -0.46 . . . . 73.3 111.127 179.994 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 94' ' ' SER . . . . . 0.442 ' HA ' ' HD2' ' A' ' 95' ' ' PRO . 11.5 t -125.72 100.29 31.44 Favored Pre-proline 0 C--N 1.329 -0.291 0 CA-C-O 121.692 0.758 . . . . 75.12 110.824 -179.78 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 95' ' ' PRO . . . . . 0.459 ' HG3' ' HB ' ' A' ' 69' ' ' THR . 53.9 Cg_endo -69.79 169.96 17.73 Favored 'Trans proline' 0 C--N 1.343 0.26 0 C-N-CA 122.634 2.222 . . . . 75.32 112.383 179.977 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 8.8 m-20 . . . . . 0 C--N 1.329 -0.32 0 CA-C-N 116.221 -0.445 . . . . 74.45 110.871 179.97 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 28.8 t . . . . . 0 C--O 1.232 0.135 0 CA-C-O 120.785 0.326 . . . . 74.41 110.859 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 101' ' ' CYS . . . . . 0.475 ' CB ' ' HB ' ' A' ' 93' ' ' VAL . 0.0 OUTLIER -108.47 149.77 28.34 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.126 -0.488 . . . . 75.23 110.887 -179.975 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 102' ' ' HIS . . . . . 0.656 ' HA ' ' O ' ' A' ' 65' ' ' LEU . 28.6 p-80 -158.88 125.42 4.64 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.145 -0.48 . . . . 71.44 110.862 179.968 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 103' ' ' LEU . . . . . 0.923 HD13 ' N ' ' A' ' 104' ' ' TRP . 2.8 tm? -151.92 148.02 27.28 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.199 -0.455 . . . . 53.54 110.952 -179.955 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 104' ' ' TRP . . . . . 0.923 ' N ' HD13 ' A' ' 103' ' ' LEU . 28.0 p90 -64.79 113.69 3.97 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.24 -0.436 . . . . 73.25 110.964 179.839 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 105' ' ' LEU . . . . . 0.779 HD22 ' HB2' ' A' ' 88' ' ' PHE . 0.3 OUTLIER -92.6 162.62 14.11 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.219 -0.446 . . . . 65.34 110.898 179.998 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -89.27 159.16 28.4 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.811 -0.709 . . . . 61.24 112.459 179.92 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 107' ' ' ARG . . . . . 0.539 ' HA ' ' CD1' ' A' ' 88' ' ' PHE . 0.0 OUTLIER -69.74 158.32 35.64 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.852 0.358 . . . . 53.52 110.891 -179.875 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -172.9 109.13 0.29 Allowed Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.715 -0.755 . . . . 41.12 112.442 -179.987 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 109' ' ' VAL . . . . . 0.487 HG23 ' HD2' ' A' ' 110' ' ' PRO . 7.4 p -92.31 134.34 28.45 Favored Pre-proline 0 C--N 1.329 -0.312 0 CA-C-O 121.604 0.716 . . . . 71.51 111.09 -179.951 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 110' ' ' PRO . . . . . 0.541 ' N ' HD21 ' A' ' 87' ' ' ASN . 53.9 Cg_endo . . . . . 0 C--O 1.232 0.198 0 C-N-CA 122.678 2.252 . . . . 70.25 112.347 179.948 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 25' ' ' THR . . . . . 0.597 ' O ' ' HA ' ' A' ' 40' ' ' ARG . 46.6 p . . . . . 0 N--CA 1.457 -0.1 0 CA-C-O 120.814 0.34 . . . . 53.11 111.172 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -76.27 121.77 23.43 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.275 -0.42 . . . . 45.01 110.884 -179.878 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 27' ' ' ALA . . . . . 0.798 ' HB3' HG23 ' A' ' 39' ' ' ILE . . . -151.39 161.12 43.27 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.168 -0.469 . . . . 73.32 111.102 179.877 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 28' ' ' THR . . . . . 0.529 HG22 ' O ' ' A' ' 28' ' ' THR . 16.0 m -131.98 87.99 2.5 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.203 -0.453 . . . . 74.34 111.144 -179.856 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . 0.778 HG23 ' CB ' ' A' ' 39' ' ' ILE . 2.5 pt -43.23 128.55 1.0 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 CA-C-N 116.189 -0.46 . . . . 71.45 111.171 179.893 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . 0.687 HG23 ' O ' ' A' ' 35' ' ' SER . 11.8 m -153.18 101.11 2.52 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.177 -0.465 . . . . 75.42 111.141 -179.998 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 85.2 p -141.09 72.56 1.39 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.217 -0.447 . . . . 73.32 110.879 -179.853 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -178.42 166.91 37.13 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.764 -0.731 . . . . 61.43 112.529 -179.981 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 8.5 pt-20 -49.14 -23.51 1.3 Allowed 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.812 0.339 . . . . 70.13 110.874 -179.915 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -174.47 93.49 0.08 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.192 -0.458 . . . . 72.52 110.971 -179.91 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 35' ' ' SER . . . . . 0.687 ' O ' HG23 ' A' ' 30' ' ' THR . 1.9 m -145.22 165.34 28.64 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.241 -0.436 . . . . 75.12 110.914 -179.823 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -179.61 86.99 0.07 OUTLIER Glycine 0 N--CA 1.452 -0.273 0 C-N-CA 120.689 -0.767 . . . . 71.05 112.491 -179.999 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 37' ' ' ALA . . . . . 0.631 ' HB3' ' CD1' ' A' ' 29' ' ' ILE . . . -106.23 -173.56 2.33 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.771 0.32 . . . . 73.43 111.184 179.933 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 65.9 t -100.02 122.87 52.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.301 -0.408 . . . . 63.4 111.139 -179.996 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 39' ' ' ILE . . . . . 0.798 HG23 ' HB3' ' A' ' 27' ' ' ALA . 0.0 OUTLIER -136.88 147.63 27.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.158 -0.473 . . . . 71.13 111.097 179.979 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 40' ' ' ARG . . . . . 0.691 ' O ' HG12 ' A' ' 67' ' ' VAL . 0.2 OUTLIER -108.8 81.78 1.51 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.166 -0.47 . . . . 72.13 110.913 179.914 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . 0.594 ' O ' ' HB2' ' A' ' 27' ' ' ALA . . . -143.07 141.96 11.0 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.715 -0.755 . . . . 75.2 112.503 -179.989 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 42' ' ' VAL . . . . . 0.533 HG12 HG21 ' A' ' 25' ' ' THR . 9.8 p -127.8 142.39 43.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-O 120.882 0.373 . . . . 70.31 111.102 -179.904 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 43' ' ' PHE . . . . . 0.769 ' H ' HD11 ' A' ' 83' ' ' ILE . 1.7 p90 -90.08 137.6 32.21 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.142 -0.481 . . . . 62.42 110.878 -179.969 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 9.9 t70 -123.52 125.0 44.11 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.142 -0.481 . . . . 72.14 110.777 -179.992 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 2.6 p30 . . . . . 0 C--N 1.329 -0.322 0 CA-C-O 121.618 0.723 . . . . 65.54 110.868 179.941 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo . . . . . 0 C--O 1.23 0.123 0 CA-C-O 120.823 0.26 . . . . 75.42 112.298 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . 0.444 ' O ' ' HA ' ' A' ' 43' ' ' PHE . 8.0 t -105.6 147.04 28.88 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.21 -0.45 . . . . 63.24 110.854 -179.877 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 65' ' ' LEU . . . . . 0.94 HD11 HG13 ' A' ' 67' ' ' VAL . 0.9 OUTLIER -113.62 119.41 37.37 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.141 -0.481 . . . . 75.02 110.932 -179.986 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 66' ' ' PHE . . . . . 0.433 ' N ' HD12 ' A' ' 65' ' ' LEU . 6.4 t80 -94.63 111.28 23.05 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.242 -0.435 . . . . 73.2 110.844 179.981 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 67' ' ' VAL . . . . . 0.94 HG13 HD11 ' A' ' 65' ' ' LEU . 0.8 OUTLIER -141.38 170.49 13.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.096 -0.502 . . . . 72.32 111.197 179.961 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 10.1 ttm180 -100.74 143.86 30.39 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.24 -0.436 . . . . 60.3 110.934 -179.999 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 69' ' ' THR . . . . . 0.421 HG23 ' N ' ' A' ' 70' ' ' ASP . 4.7 t -42.9 -44.61 4.62 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.219 -0.446 . . . . 65.43 111.191 -179.901 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 70' ' ' ASP . . . . . 0.421 ' N ' HG23 ' A' ' 69' ' ' THR . 21.1 t0 -65.67 -46.32 79.56 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.233 -0.44 . . . . 71.51 110.903 179.862 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 71' ' ' GLU . . . . . . . . . . . . . 67.1 mm-40 -53.93 -39.66 66.05 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.116 -0.493 . . . . 72.42 110.928 -179.921 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 19.0 m -86.72 -25.51 6.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.103 -0.498 . . . . 72.12 111.151 179.966 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 73' ' ' ARG . . . . . . . . . . . . . 0.8 OUTLIER -60.0 -41.24 91.67 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.139 -0.482 . . . . 64.21 110.895 -179.999 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 32.3 mt-30 -62.07 -16.59 53.15 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.169 -0.469 . . . . 73.35 110.899 -179.959 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 75' ' ' LEU . . . . . 0.648 HD21 HG21 ' A' ' 29' ' ' ILE . 5.3 mp -108.89 -175.51 2.79 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.246 -0.434 . . . . 73.13 110.85 -179.921 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 76' ' ' ARG . . . . . . . . . . . . . 5.0 ptp85 -115.56 -173.83 2.41 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.135 -0.484 . . . . 71.2 110.934 179.954 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 7.0 ptp180 -79.99 131.38 35.79 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.253 -0.43 . . . . 64.0 110.89 -179.951 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 92.31 25.79 20.33 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.74 -0.743 . . . . 71.14 112.56 -179.924 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -89.24 105.33 17.72 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.911 0.386 . . . . 75.12 110.852 -179.949 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . 0.776 ' HA ' ' HA ' ' A' ' 89' ' ' TRP . 0.8 OUTLIER -87.28 110.57 20.29 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.196 -0.456 . . . . 41.34 111.101 -179.89 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 81' ' ' LEU . . . . . 0.777 HD13 HD12 ' A' ' 39' ' ' ILE . 0.3 OUTLIER -95.41 131.91 41.04 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.153 -0.476 . . . . 75.23 110.897 179.935 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 82' ' ' THR . . . . . 0.741 ' CA ' ' HA ' ' A' ' 87' ' ' ASN . 5.0 t -94.01 102.03 14.1 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.18 -0.464 . . . . 74.12 111.133 179.932 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 83' ' ' ILE . . . . . 0.769 HD11 ' H ' ' A' ' 43' ' ' PHE . 0.1 OUTLIER -132.46 130.26 59.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.184 -0.462 . . . . 73.42 111.116 179.92 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 68.19 -62.73 0.39 Allowed Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.707 -0.758 . . . . 73.24 112.508 179.911 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 85' ' ' GLU . . . . . 0.404 ' N ' ' O ' ' A' ' 83' ' ' ILE . 29.2 mm-40 -98.66 -83.7 0.41 Allowed 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.766 0.317 . . . . 65.44 110.949 -179.924 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 86' ' ' GLU . . . . . 0.414 ' C ' ' HA ' ' A' ' 82' ' ' THR . 70.1 mt-10 -154.22 160.97 42.09 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.129 -0.487 . . . . 52.15 110.844 -179.96 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 87' ' ' ASN . . . . . 0.747 ' HA ' ' C ' ' A' ' 81' ' ' LEU . 0.8 OUTLIER -50.55 123.73 9.37 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.156 -0.475 . . . . 73.35 110.871 -179.89 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 88' ' ' PHE . . . . . 0.784 ' HB2' HD22 ' A' ' 105' ' ' LEU . 15.1 m-85 -131.51 119.48 21.6 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.239 -0.437 . . . . 73.14 110.889 -179.974 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 89' ' ' TRP . . . . . 0.776 ' HA ' ' HA ' ' A' ' 80' ' ' THR . 4.6 p90 -80.12 138.05 36.85 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.166 -0.47 . . . . 72.15 110.856 -179.915 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 90' ' ' VAL . . . . . 0.552 HG23 HD12 ' A' ' 103' ' ' LEU . 2.2 p -94.59 135.84 27.6 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 116.156 -0.474 . . . . 63.13 111.129 179.942 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -65.28 -75.25 0.09 Allowed 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.173 -0.467 . . . . 72.12 110.879 179.892 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 92' ' ' ARG . . . . . 0.587 ' O ' ' HG ' ' A' ' 103' ' ' LEU . 0.0 OUTLIER -153.23 117.45 4.87 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.166 -0.47 . . . . 75.13 110.818 -179.944 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 93' ' ' VAL . . . . . 0.491 ' CG2' ' N ' ' A' ' 102' ' ' HIS . 0.3 OUTLIER -111.45 139.82 33.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.171 -0.468 . . . . 72.44 111.173 179.906 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 1.4 p -140.78 103.94 6.32 Favored Pre-proline 0 C--N 1.329 -0.293 0 CA-C-O 121.713 0.768 . . . . 53.11 110.857 -179.807 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 95' ' ' PRO . . . . . 0.418 ' HG3' ' HB ' ' A' ' 69' ' ' THR . 54.4 Cg_endo -69.68 173.61 10.65 Favored 'Trans proline' 0 C--N 1.342 0.199 0 C-N-CA 122.729 2.286 . . . . 75.32 112.365 179.908 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 21.2 m-20 . . . . . 0 C--N 1.328 -0.337 0 CA-C-N 116.197 -0.456 . . . . 74.02 110.854 179.95 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 1.5 m . . . . . 0 C--O 1.232 0.176 0 CA-C-O 120.775 0.321 . . . . 74.53 110.831 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 101' ' ' CYS . . . . . 0.433 ' HB3' HG22 ' A' ' 93' ' ' VAL . 0.0 OUTLIER -122.95 154.43 38.39 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.212 -0.449 . . . . 75.22 110.839 -179.954 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 102' ' ' HIS . . . . . 0.491 ' N ' ' CG2' ' A' ' 93' ' ' VAL . 13.5 p80 -156.94 123.34 4.96 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.161 -0.472 . . . . 74.23 110.853 -179.972 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 103' ' ' LEU . . . . . 0.814 HD13 ' N ' ' A' ' 104' ' ' TRP . 3.4 tm? -148.25 144.57 27.74 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.211 -0.45 . . . . 75.32 110.856 -179.916 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 104' ' ' TRP . . . . . 0.814 ' N ' HD13 ' A' ' 103' ' ' LEU . 4.2 m-90 -69.29 108.54 3.72 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.225 -0.443 . . . . 62.33 110.924 179.831 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 105' ' ' LEU . . . . . 0.784 HD22 ' HB2' ' A' ' 88' ' ' PHE . 0.3 OUTLIER -89.6 161.8 15.97 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.266 -0.424 . . . . 73.1 110.985 179.945 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -89.69 159.92 28.5 Favored Glycine 0 N--CA 1.45 -0.379 0 C-N-CA 120.713 -0.756 . . . . 53.21 112.537 179.891 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 107' ' ' ARG . . . . . 0.585 ' HA ' ' CD1' ' A' ' 88' ' ' PHE . 0.1 OUTLIER -68.94 157.55 36.46 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.88 0.372 . . . . 73.34 110.832 -179.807 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -172.05 112.38 0.44 Allowed Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.78 -0.724 . . . . 73.55 112.538 -179.998 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 109' ' ' VAL . . . . . 0.454 HG23 ' HD2' ' A' ' 110' ' ' PRO . 7.3 p -85.56 133.78 41.35 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-O 121.599 0.714 . . . . 71.52 111.176 -179.975 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 110' ' ' PRO . . . . . 0.454 ' HD2' HG23 ' A' ' 109' ' ' VAL . 54.8 Cg_endo . . . . . 0 C--O 1.233 0.232 0 C-N-CA 122.693 2.262 . . . . 72.55 112.394 179.9 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 25' ' ' THR . . . . . 0.547 ' O ' ' HA ' ' A' ' 40' ' ' ARG . 0.0 OUTLIER . . . . . 0 N--CA 1.458 -0.072 0 CA-C-O 120.867 0.365 . . . . 73.12 111.09 . . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -75.09 123.33 25.03 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.112 -0.495 . . . . 70.21 110.838 -179.856 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 27' ' ' ALA . . . . . 0.832 ' HB3' HG23 ' A' ' 39' ' ' ILE . . . -145.13 163.21 35.02 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.15 -0.477 . . . . 53.12 111.056 179.894 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 28' ' ' THR . . . . . 0.501 HG22 ' O ' ' A' ' 28' ' ' THR . 19.1 m -130.46 87.2 2.47 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.173 -0.467 . . . . 62.05 111.164 -179.874 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . 0.744 HG23 ' CB ' ' A' ' 39' ' ' ILE . 2.2 pt -44.27 132.15 1.55 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.213 -0.448 . . . . 71.21 111.161 179.926 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . 0.636 HG23 ' O ' ' A' ' 35' ' ' SER . 23.4 m -153.89 101.17 2.42 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.183 -0.462 . . . . 64.14 111.176 179.983 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 1.8 t -137.12 71.04 1.4 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.265 -0.425 . . . . 71.21 110.843 -179.856 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -179.4 168.1 38.51 Favored Glycine 0 N--CA 1.45 -0.422 0 C-N-CA 120.72 -0.752 . . . . 54.23 112.458 -179.968 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 6.7 pt-20 -49.24 -23.4 1.33 Allowed 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.793 0.33 . . . . 74.45 110.894 -179.896 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 3.5 tt0 -174.69 94.93 0.08 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.12 -0.491 . . . . 65.31 110.971 -179.97 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 35' ' ' SER . . . . . 0.636 ' O ' HG23 ' A' ' 30' ' ' THR . 0.1 OUTLIER -145.11 165.33 28.59 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.232 -0.44 . . . . 52.14 110.801 -179.789 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -179.22 88.86 0.07 OUTLIER Glycine 0 N--CA 1.452 -0.254 0 C-N-CA 120.723 -0.751 . . . . 44.24 112.449 179.995 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 37' ' ' ALA . . . . . 0.649 ' HB3' ' CD1' ' A' ' 29' ' ' ILE . . . -106.26 -172.45 2.09 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.798 0.332 . . . . 54.33 111.116 179.942 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 23.5 t -99.66 120.01 48.47 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.232 -0.44 . . . . 71.23 111.117 179.998 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 39' ' ' ILE . . . . . 0.832 HG23 ' HB3' ' A' ' 27' ' ' ALA . 0.0 OUTLIER -137.28 151.03 26.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.227 -0.442 . . . . 73.03 111.177 179.918 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 40' ' ' ARG . . . . . 0.598 ' O ' HG12 ' A' ' 67' ' ' VAL . 28.0 mmt180 -112.87 82.03 1.59 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.193 -0.458 . . . . 72.2 110.845 179.988 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . 0.51 ' HA3' HD21 ' A' ' 65' ' ' LEU . . . -140.18 138.21 8.92 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.794 -0.717 . . . . 72.01 112.451 -179.966 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 42' ' ' VAL . . . . . 0.517 HG12 HG21 ' A' ' 25' ' ' THR . 1.7 p -123.59 137.81 55.53 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-O 120.817 0.341 . . . . 64.42 111.17 179.943 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 43' ' ' PHE . . . . . 0.58 ' H ' HD11 ' A' ' 83' ' ' ILE . 2.1 p90 -93.22 137.82 32.19 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.198 -0.455 . . . . 74.51 110.88 -179.91 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 3.4 t70 -117.96 125.43 50.41 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.147 -0.479 . . . . 64.31 110.853 179.986 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 1.2 p30 . . . . . 0 C--N 1.329 -0.323 0 CA-C-O 121.548 0.69 . . . . 71.54 110.913 179.951 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo . . . . . 0 N--CA 1.465 -0.149 0 CA-C-O 120.776 0.24 . . . . 72.1 112.326 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 1.3 t -111.29 138.29 47.94 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.211 -0.45 . . . . 75.21 110.834 -179.863 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 65' ' ' LEU . . . . . 0.781 HD11 HG13 ' A' ' 67' ' ' VAL . 1.7 tm? -117.1 135.67 53.57 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.19 -0.459 . . . . 74.21 110.962 -179.974 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 66' ' ' PHE . . . . . 0.664 ' N ' HD22 ' A' ' 65' ' ' LEU . 35.7 t80 -117.94 110.28 17.53 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.244 -0.435 . . . . 74.24 110.87 179.966 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 67' ' ' VAL . . . . . 0.781 HG13 HD11 ' A' ' 65' ' ' LEU . 24.1 m -140.13 168.12 17.85 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.092 -0.504 . . . . 71.15 111.11 179.993 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 68' ' ' ARG . . . . . 0.436 ' HG2' ' H ' ' A' ' 71' ' ' GLU . 1.5 ptm180 -102.83 146.18 28.66 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.191 -0.459 . . . . 73.23 110.859 179.982 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 69' ' ' THR . . . . . 0.432 ' HB ' ' HG3' ' A' ' 95' ' ' PRO . 0.2 OUTLIER -37.75 -60.96 0.67 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.153 -0.476 . . . . 73.4 111.139 -179.895 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 3.4 m-20 -46.11 -43.92 15.24 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.198 -0.455 . . . . 70.1 110.887 179.886 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 71' ' ' GLU . . . . . 0.436 ' H ' ' HG2' ' A' ' 68' ' ' ARG . 8.7 tp10 -59.77 -42.81 94.15 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.198 -0.456 . . . . 72.5 110.858 -179.873 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 72' ' ' VAL . . . . . 0.503 HG22 ' O ' ' A' ' 72' ' ' VAL . 14.3 p -87.27 -3.86 9.38 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.172 -0.467 . . . . 73.11 111.106 -179.978 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 73' ' ' ARG . . . . . . . . . . . . . 57.6 ttt180 -85.27 -41.93 15.11 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.165 -0.47 . . . . 70.22 110.884 -179.965 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 71.8 mt-30 -53.26 -25.25 13.74 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.188 -0.46 . . . . 71.55 110.907 -179.944 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 75' ' ' LEU . . . . . 0.74 HD21 ' CD1' ' A' ' 29' ' ' ILE . 3.9 mp -107.74 -169.63 1.56 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.204 -0.453 . . . . 72.53 110.956 179.963 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 76' ' ' ARG . . . . . . . . . . . . . 8.5 ttp180 -116.6 136.84 52.64 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.212 -0.449 . . . . 72.14 110.85 179.978 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -47.34 102.01 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.211 -0.45 . . . . 72.15 110.884 -179.899 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 133.19 25.73 0.64 Allowed Glycine 0 N--CA 1.453 -0.231 0 C-N-CA 120.701 -0.762 . . . . 74.33 112.427 -179.967 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . 0.724 ' OD2' HD22 ' A' ' 75' ' ' LEU . 5.4 p-10 -114.13 119.84 38.48 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.871 0.367 . . . . 55.42 110.91 179.963 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . 0.831 HG22 ' HB3' ' A' ' 89' ' ' TRP . 13.6 p -83.11 123.05 29.14 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.195 -0.457 . . . . 71.22 111.123 -179.825 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 81' ' ' LEU . . . . . 0.794 ' C ' ' HA ' ' A' ' 87' ' ' ASN . 0.2 OUTLIER -94.37 124.47 38.42 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.243 -0.435 . . . . 61.22 110.921 179.956 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 82' ' ' THR . . . . . 0.802 ' N ' ' HA ' ' A' ' 87' ' ' ASN . 3.5 t -91.47 104.42 16.93 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.214 -0.448 . . . . 74.44 111.164 179.947 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 83' ' ' ILE . . . . . 0.725 HD13 ' O ' ' A' ' 83' ' ' ILE . 0.1 OUTLIER -141.17 126.45 18.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.177 -0.465 . . . . 72.25 111.062 179.97 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 74.36 -52.74 2.27 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.692 -0.766 . . . . 65.0 112.495 179.908 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 8.1 tp10 -112.91 -82.73 0.59 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.809 0.338 . . . . 74.13 110.903 -179.896 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 86' ' ' GLU . . . . . 0.468 ' C ' ' HA ' ' A' ' 82' ' ' THR . 86.9 mt-10 -152.17 160.86 43.31 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.171 -0.468 . . . . 74.14 110.884 -179.937 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 87' ' ' ASN . . . . . 0.802 ' HA ' ' N ' ' A' ' 82' ' ' THR . 9.2 p30 -51.32 121.66 6.6 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.168 -0.469 . . . . 64.33 110.938 -179.949 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 88' ' ' PHE . . . . . 0.661 ' HB2' HD22 ' A' ' 105' ' ' LEU . 15.9 m-85 -132.16 121.36 23.61 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.172 -0.467 . . . . 74.14 110.938 -179.958 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 89' ' ' TRP . . . . . 0.831 ' HB3' HG22 ' A' ' 80' ' ' THR . 3.7 t-105 -81.38 130.53 35.07 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.14 -0.482 . . . . 70.12 110.906 -179.923 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 90' ' ' VAL . . . . . 0.505 ' O ' ' CH2' ' A' ' 89' ' ' TRP . 6.1 p -80.93 114.58 22.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.215 -0.448 . . . . 72.21 111.172 179.912 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -41.9 -65.21 0.48 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.208 -0.451 . . . . 52.51 110.945 179.953 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 92' ' ' ARG . . . . . 0.488 ' O ' ' HG ' ' A' ' 103' ' ' LEU . 69.5 ttt180 -160.15 125.65 4.03 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.197 -0.456 . . . . 71.31 110.902 -179.967 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 93' ' ' VAL . . . . . 0.507 HG12 ' N ' ' A' ' 102' ' ' HIS . 0.0 OUTLIER -115.49 111.55 36.12 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 116.203 -0.453 . . . . 75.23 111.135 179.954 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 94' ' ' SER . . . . . 0.451 ' C ' ' HB3' ' A' ' 101' ' ' CYS . 4.4 p -105.8 106.16 55.61 Favored Pre-proline 0 C--N 1.33 -0.255 0 CA-C-O 121.666 0.746 . . . . 73.12 110.833 -179.78 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 95' ' ' PRO . . . . . 0.432 ' HG3' ' HB ' ' A' ' 69' ' ' THR . 53.3 Cg_endo -69.83 159.19 54.28 Favored 'Trans proline' 0 C--N 1.341 0.18 0 C-N-CA 122.633 2.222 . . . . 65.2 112.363 179.984 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 4.5 m-20 . . . . . 0 C--N 1.329 -0.32 0 CA-C-N 116.23 -0.441 . . . . 64.51 110.884 179.982 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 2.0 p . . . . . 0 C--O 1.233 0.194 0 CA-C-O 120.831 0.348 . . . . 70.41 110.861 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 101' ' ' CYS . . . . . 0.451 ' HB3' ' C ' ' A' ' 94' ' ' SER . 0.3 OUTLIER -129.21 167.47 17.6 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.168 -0.469 . . . . 73.24 110.898 -179.95 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 102' ' ' HIS . . . . . 0.507 ' N ' HG12 ' A' ' 93' ' ' VAL . 37.0 p-80 -167.41 128.28 1.5 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.137 -0.483 . . . . 74.0 110.842 -179.928 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 103' ' ' LEU . . . . . 0.824 HD13 ' N ' ' A' ' 104' ' ' TRP . 2.5 tm? -150.19 147.17 27.38 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.181 -0.463 . . . . 71.14 110.938 -179.928 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 104' ' ' TRP . . . . . 0.824 ' N ' HD13 ' A' ' 103' ' ' LEU . 29.7 p90 -63.92 118.25 8.15 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.261 -0.427 . . . . 71.31 110.95 179.893 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 105' ' ' LEU . . . . . 0.661 HD22 ' HB2' ' A' ' 88' ' ' PHE . 0.2 OUTLIER -88.45 163.58 15.89 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 116.245 -0.434 . . . . 72.2 110.924 -179.998 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -88.15 160.26 30.66 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.751 -0.737 . . . . 74.42 112.523 179.919 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 107' ' ' ARG . . . . . 0.486 ' HA ' ' CD1' ' A' ' 88' ' ' PHE . 0.7 OUTLIER -66.17 157.5 31.14 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.864 0.364 . . . . 74.42 110.923 -179.941 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -176.58 108.16 0.25 Allowed Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.733 -0.746 . . . . 74.24 112.425 179.984 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 109' ' ' VAL . . . . . 0.416 HG23 ' HD2' ' A' ' 110' ' ' PRO . 10.8 p -100.06 133.6 21.46 Favored Pre-proline 0 C--N 1.329 -0.296 0 CA-C-O 121.543 0.687 . . . . 53.25 111.091 -179.938 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 110' ' ' PRO . . . . . 0.416 ' HD2' HG23 ' A' ' 109' ' ' VAL . 54.0 Cg_endo . . . . . 0 C--O 1.23 0.123 0 C-N-CA 122.652 2.235 . . . . 75.31 112.319 179.934 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 25' ' ' THR . . . . . 0.496 HG21 HG23 ' A' ' 42' ' ' VAL . 8.4 m . . . . . 0 N--CA 1.457 -0.107 0 CA-C-O 120.742 0.306 . . . . 71.21 111.192 . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -72.5 122.08 20.71 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.207 -0.451 . . . . 50.25 110.866 -179.855 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 27' ' ' ALA . . . . . 0.823 ' HB3' HG23 ' A' ' 39' ' ' ILE . . . -142.05 162.29 35.86 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.047 -0.524 . . . . 42.21 111.119 179.89 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 28' ' ' THR . . . . . 0.505 HG22 ' O ' ' A' ' 28' ' ' THR . 16.9 m -129.23 88.65 2.73 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.242 -0.436 . . . . 74.44 111.184 -179.883 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . 0.764 HG23 ' CB ' ' A' ' 39' ' ' ILE . 1.8 pt -44.64 130.99 1.7 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.218 -0.446 . . . . 74.45 111.135 179.917 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . 0.695 HG23 ' O ' ' A' ' 35' ' ' SER . 7.3 m -153.73 97.98 2.16 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.167 -0.47 . . . . 71.12 111.15 179.934 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 87.1 p -137.76 70.92 1.39 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.229 -0.441 . . . . 63.2 110.921 -179.858 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -178.61 167.52 38.01 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.779 -0.724 . . . . 55.2 112.511 -179.924 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 3.6 pt-20 -49.45 -23.01 1.34 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.798 0.332 . . . . 71.22 110.851 -179.935 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -174.6 94.22 0.08 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.228 -0.442 . . . . 75.22 110.919 -179.913 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 35' ' ' SER . . . . . 0.695 ' O ' HG23 ' A' ' 30' ' ' THR . 3.1 m -144.71 165.77 27.12 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.161 -0.472 . . . . 72.51 110.821 -179.81 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 178.6 87.6 0.07 OUTLIER Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.78 -0.724 . . . . 75.41 112.497 -179.975 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 37' ' ' ALA . . . . . 0.676 ' HB3' ' CD1' ' A' ' 29' ' ' ILE . . . -109.03 -172.49 2.06 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.904 0.383 . . . . 74.42 111.078 179.983 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 4.0 p -97.97 123.04 50.22 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.209 -0.451 . . . . 72.34 111.12 179.969 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 39' ' ' ILE . . . . . 0.823 HG23 ' HB3' ' A' ' 27' ' ' ALA . 0.0 OUTLIER -138.53 149.9 24.1 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.137 -0.483 . . . . 65.31 111.165 179.906 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 40' ' ' ARG . . . . . 0.548 ' O ' HG12 ' A' ' 67' ' ' VAL . 6.6 mtm-85 -109.1 80.05 1.28 Allowed 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.159 -0.473 . . . . 72.43 110.879 -179.962 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . 0.52 ' HA2' HG12 ' A' ' 67' ' ' VAL . . . -128.38 148.78 18.03 Favored Glycine 0 N--CA 1.45 -0.374 0 C-N-CA 120.814 -0.708 . . . . 70.23 112.577 -179.937 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 42' ' ' VAL . . . . . 0.573 HG12 ' CB ' ' A' ' 66' ' ' PHE . 3.4 p -127.53 138.79 53.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-O 120.837 0.351 . . . . 72.44 111.148 -179.986 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 43' ' ' PHE . . . . . 0.613 ' H ' HD11 ' A' ' 83' ' ' ILE . 2.5 p90 -98.36 128.76 44.92 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.175 -0.466 . . . . 61.14 110.887 -179.966 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -107.75 124.0 49.38 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.12 -0.491 . . . . 74.43 110.812 180.0 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 C--N 1.329 -0.315 0 CA-C-O 121.61 0.719 . . . . 61.42 110.854 179.976 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo . . . . . 0 C--O 1.231 0.15 0 CA-C-O 120.81 0.254 . . . . 73.12 112.359 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . 0.516 ' O ' ' HA ' ' A' ' 43' ' ' PHE . 0.1 OUTLIER -106.54 148.39 28.29 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.203 -0.453 . . . . 65.13 110.865 -179.832 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 65' ' ' LEU . . . . . 0.558 HD11 ' CG1' ' A' ' 67' ' ' VAL . 2.8 tm? -114.55 129.29 56.65 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.134 -0.484 . . . . 75.01 110.924 -179.96 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 66' ' ' PHE . . . . . 0.573 ' CB ' HG12 ' A' ' 42' ' ' VAL . 1.7 t80 -119.03 105.68 11.67 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.257 -0.428 . . . . 74.21 110.889 179.937 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 67' ' ' VAL . . . . . 0.558 ' CG1' HD11 ' A' ' 65' ' ' LEU . 33.7 m -141.04 172.51 10.85 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-N 116.148 -0.478 . . . . 74.04 111.126 -179.968 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 68' ' ' ARG . . . . . 0.447 ' HG2' ' H ' ' A' ' 71' ' ' GLU . 1.1 ptp180 -109.23 144.47 37.3 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.194 -0.457 . . . . 64.4 110.849 -179.986 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 69' ' ' THR . . . . . 0.651 ' HA ' HG12 ' A' ' 72' ' ' VAL . 0.0 OUTLIER -38.01 -56.88 1.1 Allowed 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.202 -0.454 . . . . 73.14 111.189 -179.927 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 70' ' ' ASP . . . . . 0.46 ' H ' HG23 ' A' ' 69' ' ' THR . 7.8 t70 -44.28 -59.43 2.38 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.155 -0.475 . . . . 70.21 110.865 179.908 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 71' ' ' GLU . . . . . 0.447 ' H ' ' HG2' ' A' ' 68' ' ' ARG . 1.2 tm-20 -59.35 -42.1 90.74 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.217 -0.447 . . . . 74.22 110.92 -179.966 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 72' ' ' VAL . . . . . 0.651 HG12 ' HA ' ' A' ' 69' ' ' THR . 0.3 OUTLIER -82.98 4.42 2.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.117 -0.492 . . . . 74.13 111.073 -179.948 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 73' ' ' ARG . . . . . 0.521 ' N ' ' O ' ' A' ' 69' ' ' THR . 16.1 ttt180 -98.31 -37.98 9.44 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.168 -0.469 . . . . 75.14 110.86 -179.993 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 48.7 mt-30 -65.67 -12.36 52.85 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.252 -0.431 . . . . 74.4 110.956 -179.978 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 75' ' ' LEU . . . . . 0.651 HD21 HG21 ' A' ' 29' ' ' ILE . 3.1 mp -107.99 -174.46 2.53 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.157 -0.474 . . . . 70.11 110.877 -179.964 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 76' ' ' ARG . . . . . . . . . . . . . 10.5 ptp180 -117.91 154.37 32.02 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.164 -0.471 . . . . 75.34 110.941 179.965 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 3.7 ptt180 -51.21 131.91 28.15 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.24 -0.436 . . . . 70.03 110.87 -179.909 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 86.77 42.97 6.21 Favored Glycine 0 N--CA 1.452 -0.24 0 C-N-CA 120.735 -0.745 . . . . 60.23 112.397 179.944 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -103.43 110.74 22.88 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.909 0.385 . . . . 74.01 110.85 -179.963 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . 0.733 ' HA ' ' HA ' ' A' ' 89' ' ' TRP . 0.0 OUTLIER -88.62 108.59 19.52 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.119 -0.491 . . . . 62.12 111.209 -179.886 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 81' ' ' LEU . . . . . 0.787 ' C ' ' HA ' ' A' ' 87' ' ' ASN . 0.0 OUTLIER -98.18 135.24 40.12 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.272 -0.422 . . . . 71.21 110.928 -179.986 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 82' ' ' THR . . . . . 0.7 ' N ' ' HA ' ' A' ' 87' ' ' ASN . 8.0 t -93.63 101.59 13.75 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.204 -0.453 . . . . 63.4 111.145 179.968 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 83' ' ' ILE . . . . . 0.714 HD13 ' O ' ' A' ' 83' ' ' ILE . 0.1 OUTLIER -136.18 131.11 48.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.22 -0.446 . . . . 75.01 111.184 179.861 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 73.0 -54.59 1.78 Allowed Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.785 -0.722 . . . . 64.14 112.507 179.936 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 10.7 mm-40 -113.55 -80.65 0.59 Allowed 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 120.86 0.362 . . . . 64.4 110.875 -179.922 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 86' ' ' GLU . . . . . 0.46 ' C ' ' HA ' ' A' ' 82' ' ' THR . 96.1 mt-10 -154.54 161.06 41.82 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 116.159 -0.473 . . . . 64.42 110.823 -179.939 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 87' ' ' ASN . . . . . 0.787 ' HA ' ' C ' ' A' ' 81' ' ' LEU . 1.6 p-10 -50.7 121.98 6.63 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.156 -0.474 . . . . 74.5 110.921 -179.957 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 88' ' ' PHE . . . . . 0.747 ' CB ' HD13 ' A' ' 105' ' ' LEU . 14.7 m-85 -131.08 120.86 24.02 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.155 -0.475 . . . . 75.14 110.903 -179.972 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 89' ' ' TRP . . . . . 0.733 ' HA ' ' HA ' ' A' ' 80' ' ' THR . 0.9 OUTLIER -80.11 135.77 36.39 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.12 -0.491 . . . . 64.12 110.913 -179.951 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 90' ' ' VAL . . . . . 0.464 ' HA ' ' HB3' ' A' ' 105' ' ' LEU . 0.3 OUTLIER -92.58 138.23 20.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.264 -0.426 . . . . 71.01 111.101 179.925 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -65.61 -71.19 0.2 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.186 -0.461 . . . . 75.21 110.85 179.935 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 92' ' ' ARG . . . . . 0.526 ' O ' ' HG ' ' A' ' 103' ' ' LEU . 0.0 OUTLIER -152.58 120.89 6.3 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.251 -0.432 . . . . 74.24 110.838 -179.882 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 93' ' ' VAL . . . . . 0.617 HG12 ' CB ' ' A' ' 103' ' ' LEU . 8.8 m -121.45 137.28 55.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.254 -0.43 . . . . 65.14 111.121 179.928 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 12.6 t -137.14 128.4 16.44 Favored Pre-proline 0 C--N 1.328 -0.337 0 CA-C-O 121.714 0.769 . . . . 73.01 110.862 -179.856 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 95' ' ' PRO . . . . . 0.479 ' HG3' ' HB ' ' A' ' 69' ' ' THR . 53.2 Cg_endo -69.85 160.51 49.42 Favored 'Trans proline' 0 C--N 1.342 0.198 0 C-N-CA 122.681 2.254 . . . . 71.31 112.322 -179.946 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 9.4 t0 . . . . . 0 C--N 1.329 -0.307 0 CA-C-N 116.256 -0.429 . . . . 74.34 110.844 179.945 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 20.1 t . . . . . 0 C--O 1.232 0.153 0 CA-C-O 120.91 0.386 . . . . 75.14 110.842 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 101' ' ' CYS . . . . . 0.571 ' HB2' ' HB ' ' A' ' 93' ' ' VAL . 19.6 p -47.23 142.31 3.98 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.16 -0.473 . . . . 73.45 110.882 -179.98 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 102' ' ' HIS . . . . . 0.437 ' HA ' ' O ' ' A' ' 65' ' ' LEU . 43.4 p-80 -159.97 129.38 5.2 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.241 -0.436 . . . . 75.43 110.836 -179.934 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 103' ' ' LEU . . . . . 0.874 HD13 ' N ' ' A' ' 104' ' ' TRP . 2.8 tm? -150.8 148.4 28.45 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 116.239 -0.437 . . . . 72.24 110.943 -179.998 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 104' ' ' TRP . . . . . 0.874 ' N ' HD13 ' A' ' 103' ' ' LEU . 56.3 p-90 -64.34 118.02 8.08 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.174 -0.466 . . . . 64.3 110.855 179.946 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 105' ' ' LEU . . . . . 0.747 HD13 ' CB ' ' A' ' 88' ' ' PHE . 0.4 OUTLIER -93.92 162.8 13.76 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.266 -0.425 . . . . 71.42 110.866 179.978 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -91.0 160.39 27.26 Favored Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.712 -0.756 . . . . 65.44 112.498 179.892 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 107' ' ' ARG . . . . . 0.544 ' HA ' ' CD1' ' A' ' 88' ' ' PHE . 0.0 OUTLIER -65.73 157.39 30.31 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.856 0.36 . . . . 74.43 110.925 -179.895 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -173.1 110.18 0.33 Allowed Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.644 -0.789 . . . . 32.31 112.454 179.984 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 109' ' ' VAL . . . . . 0.453 HG23 ' HD2' ' A' ' 110' ' ' PRO . 7.1 p -84.19 133.89 44.38 Favored Pre-proline 0 C--N 1.33 -0.28 0 CA-C-O 121.687 0.756 . . . . 74.1 111.084 -179.93 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 110' ' ' PRO . . . . . 0.453 ' HD2' HG23 ' A' ' 109' ' ' VAL . 53.8 Cg_endo . . . . . 0 C--N 1.342 0.222 0 C-N-CA 122.644 2.229 . . . . 61.33 112.328 179.928 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 25' ' ' THR . . . . . 0.821 ' HB ' HG22 ' A' ' 42' ' ' VAL . 98.6 m . . . . . 0 C--O 1.231 0.081 0 CA-C-O 120.804 0.335 . . . . 65.13 111.107 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 3.0 p -70.81 123.5 22.11 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.173 -0.467 . . . . 75.4 110.823 -179.844 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 27' ' ' ALA . . . . . 0.84 ' HB3' HG23 ' A' ' 39' ' ' ILE . . . -135.24 162.42 32.61 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.074 -0.512 . . . . 63.51 111.104 179.884 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 28' ' ' THR . . . . . 0.503 HG22 ' O ' ' A' ' 28' ' ' THR . 21.7 m -129.33 85.8 2.36 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.216 -0.447 . . . . 73.22 111.09 -179.902 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . 0.682 HG23 HG21 ' A' ' 39' ' ' ILE . 1.9 pt -44.92 126.93 1.3 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.182 -0.463 . . . . 73.44 111.137 179.884 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . 0.669 HG23 ' O ' ' A' ' 35' ' ' SER . 17.6 m -151.93 97.87 2.39 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.119 -0.491 . . . . 74.42 111.143 -179.983 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 31' ' ' SER . . . . . 0.517 ' OG ' HG22 ' A' ' 80' ' ' THR . 5.1 t -136.5 70.53 1.41 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.161 -0.472 . . . . 73.54 110.913 -179.853 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -178.88 168.8 39.92 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.771 -0.728 . . . . 74.42 112.536 -179.93 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 5.8 pt-20 -49.31 -23.25 1.33 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.809 0.338 . . . . 64.03 110.9 -179.906 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -174.76 95.29 0.08 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.204 -0.453 . . . . 53.23 110.913 -179.908 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 35' ' ' SER . . . . . 0.669 ' O ' HG23 ' A' ' 30' ' ' THR . 2.3 m -145.24 165.41 28.46 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.148 -0.478 . . . . 72.15 110.84 -179.794 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 176.36 88.42 0.07 OUTLIER Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 120.756 -0.735 . . . . 44.13 112.515 -179.988 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 37' ' ' ALA . . . . . 0.667 ' HB3' ' CD1' ' A' ' 29' ' ' ILE . . . -108.11 -170.53 1.7 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.809 0.337 . . . . 73.35 111.161 179.994 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . 0.413 ' O ' HG13 ' A' ' 38' ' ' VAL . 4.4 p -99.03 119.64 47.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.293 -0.412 . . . . 41.14 111.112 179.983 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 39' ' ' ILE . . . . . 0.84 HG23 ' HB3' ' A' ' 27' ' ' ALA . 0.0 OUTLIER -139.1 151.56 23.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.059 -0.518 . . . . 73.33 111.096 179.938 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 40' ' ' ARG . . . . . . . . . . . . . 1.4 ptp85 -113.59 82.86 1.75 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.191 -0.459 . . . . 75.04 110.879 179.964 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . 0.434 ' N ' HD13 ' A' ' 39' ' ' ILE . . . -111.92 146.46 18.0 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.723 -0.751 . . . . 61.44 112.436 -179.923 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 42' ' ' VAL . . . . . 0.821 HG22 ' HB ' ' A' ' 25' ' ' THR . 2.2 t -124.58 112.57 32.68 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-O 120.882 0.372 . . . . 72.41 111.08 -179.937 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 43' ' ' PHE . . . . . 0.526 ' HA ' ' O ' ' A' ' 64' ' ' SER . 2.4 p90 -87.29 131.38 34.26 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.141 -0.481 . . . . 74.12 110.89 -179.976 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 2.8 t70 -129.78 125.34 35.56 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.129 -0.487 . . . . 74.12 110.811 -179.965 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 2.5 p-10 . . . . . 0 C--N 1.33 -0.276 0 CA-C-O 121.567 0.698 . . . . 64.14 110.862 -179.928 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo . . . . . 0 C--O 1.231 0.17 0 CA-C-O 120.753 0.23 . . . . 45.22 112.37 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . 0.526 ' O ' ' HA ' ' A' ' 43' ' ' PHE . 1.3 t -106.19 142.51 35.77 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.259 -0.428 . . . . 71.12 110.906 -179.816 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 65' ' ' LEU . . . . . 1.031 HD11 HG13 ' A' ' 67' ' ' VAL . 0.4 OUTLIER -110.75 123.72 50.59 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.178 -0.464 . . . . 52.12 110.942 179.982 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 66' ' ' PHE . . . . . 0.571 ' N ' HD12 ' A' ' 65' ' ' LEU . 0.2 OUTLIER -94.05 111.83 23.59 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.23 -0.441 . . . . 74.34 110.924 179.961 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 67' ' ' VAL . . . . . 1.031 HG13 HD11 ' A' ' 65' ' ' LEU . 0.4 OUTLIER -140.92 167.28 17.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.227 -0.442 . . . . 64.35 111.109 -179.998 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 68' ' ' ARG . . . . . 0.4 ' HB3' ' HG2' ' A' ' 71' ' ' GLU . 3.5 ttp85 -96.84 132.42 42.6 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.174 -0.466 . . . . 71.23 110.91 -179.952 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 69' ' ' THR . . . . . 0.414 ' O ' HG12 ' A' ' 72' ' ' VAL . 1.4 m -44.67 -36.81 3.29 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.246 -0.433 . . . . 74.03 111.126 -179.825 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 33.2 t0 -59.02 -71.88 0.11 Allowed 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.199 -0.455 . . . . 71.52 110.872 179.868 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 71' ' ' GLU . . . . . 0.473 ' O ' HD12 ' A' ' 75' ' ' LEU . 3.1 pt-20 -56.37 -37.73 70.45 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.176 -0.466 . . . . 51.13 110.875 -179.849 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 72' ' ' VAL . . . . . 0.414 HG12 ' O ' ' A' ' 69' ' ' THR . 0.4 OUTLIER -68.74 -25.39 30.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.157 -0.474 . . . . 71.0 111.148 179.982 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 73' ' ' ARG . . . . . . . . . . . . . 24.7 ttm-85 -75.9 -39.3 56.62 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.107 -0.497 . . . . 71.35 110.869 -179.996 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 12.4 mt-30 -54.73 -29.09 52.59 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.214 -0.448 . . . . 62.5 110.895 -179.936 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 75' ' ' LEU . . . . . 0.517 HD23 ' CG ' ' A' ' 79' ' ' ASP . 3.4 mp -87.26 -175.82 5.43 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.182 -0.463 . . . . 72.53 110.944 -179.973 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 76' ' ' ARG . . . . . . . . . . . . . 6.8 ttt-85 -109.47 139.33 44.59 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.192 -0.458 . . . . 74.43 110.866 179.962 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 3.3 ptt85 -48.65 108.31 0.17 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.224 -0.443 . . . . 74.32 110.844 -179.92 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 119.55 9.96 8.15 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.663 -0.78 . . . . 63.33 112.536 -179.932 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . 0.517 ' CG ' HD23 ' A' ' 75' ' ' LEU . 0.4 OUTLIER -73.09 109.12 6.38 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.945 0.402 . . . . 72.11 110.914 -179.994 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . 0.716 ' HA ' ' HA ' ' A' ' 89' ' ' TRP . 0.0 OUTLIER -85.51 110.34 19.13 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.17 -0.468 . . . . 74.45 111.118 -179.828 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 81' ' ' LEU . . . . . 0.758 ' C ' ' HA ' ' A' ' 87' ' ' ASN . 0.3 OUTLIER -97.63 132.43 43.29 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.222 -0.445 . . . . 71.42 110.887 179.97 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 82' ' ' THR . . . . . 0.762 ' CA ' ' HA ' ' A' ' 87' ' ' ASN . 6.7 t -91.57 102.35 15.0 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.189 -0.46 . . . . 73.41 111.139 179.925 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 83' ' ' ILE . . . . . 0.733 ' CG2' HD12 ' A' ' 81' ' ' LEU . 0.1 OUTLIER -139.24 131.2 35.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.223 -0.444 . . . . 74.31 111.119 179.923 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 76.74 -51.67 3.1 Favored Glycine 0 N--CA 1.452 -0.264 0 C-N-CA 120.715 -0.755 . . . . 40.34 112.471 179.9 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 6.7 tp10 -121.37 -77.83 0.59 Allowed 'General case' 0 C--N 1.331 -0.229 0 CA-C-O 120.818 0.342 . . . . 62.54 110.876 -179.876 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 86' ' ' GLU . . . . . 0.472 ' C ' ' HA ' ' A' ' 82' ' ' THR . 98.8 mt-10 -152.76 162.29 41.46 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.12 -0.491 . . . . 73.22 110.923 -179.977 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 87' ' ' ASN . . . . . 0.762 ' HA ' ' CA ' ' A' ' 82' ' ' THR . 2.4 p30 -51.5 122.02 7.31 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.183 -0.462 . . . . 73.41 110.899 -179.975 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 88' ' ' PHE . . . . . 0.776 ' HB2' HD22 ' A' ' 105' ' ' LEU . 13.9 m-85 -131.77 119.4 21.23 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.184 -0.462 . . . . 70.55 110.935 179.95 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 89' ' ' TRP . . . . . 0.716 ' HA ' ' HA ' ' A' ' 80' ' ' THR . 65.4 p-90 -82.21 132.87 35.23 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.164 -0.471 . . . . 71.31 110.96 179.983 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 90' ' ' VAL . . . . . 0.515 ' HA ' ' HB3' ' A' ' 105' ' ' LEU . 4.0 p -95.39 139.11 19.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.231 -0.441 . . . . 75.31 111.156 179.92 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 91' ' ' ASP . . . . . 0.476 ' HB2' HD21 ' A' ' 103' ' ' LEU . 1.9 t70 -58.84 -73.82 0.08 Allowed 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.208 -0.451 . . . . 63.44 110.877 179.959 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 92' ' ' ARG . . . . . 0.684 ' O ' HD13 ' A' ' 103' ' ' LEU . 8.2 ttt180 -170.15 121.39 0.64 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.215 -0.448 . . . . 73.21 110.898 -179.908 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 93' ' ' VAL . . . . . 0.532 ' HB ' ' HB3' ' A' ' 101' ' ' CYS . 2.6 m -104.83 139.0 27.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.217 -0.447 . . . . 72.41 111.176 179.917 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 12.1 t -130.1 96.53 25.18 Favored Pre-proline 0 C--N 1.33 -0.278 0 CA-C-O 121.577 0.703 . . . . 63.52 110.826 -179.766 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 95' ' ' PRO . . . . . . . . . . . . . 52.6 Cg_endo -69.8 -167.39 0.22 Allowed 'Trans proline' 0 C--N 1.341 0.152 0 C-N-CA 122.655 2.237 . . . . 72.03 112.319 179.97 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 5.8 t0 . . . . . 0 C--N 1.328 -0.345 0 CA-C-N 116.226 -0.443 . . . . 70.01 110.871 179.971 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 12.0 t . . . . . 0 C--O 1.232 0.168 0 CA-C-O 120.809 0.338 . . . . 72.44 110.774 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 101' ' ' CYS . . . . . 0.532 ' HB3' ' HB ' ' A' ' 93' ' ' VAL . 1.8 t -132.12 -172.83 2.98 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.185 -0.462 . . . . 54.4 110.849 -179.955 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 102' ' ' HIS . . . . . 0.408 ' HB3' ' HA ' ' A' ' 66' ' ' PHE . 2.6 p-80 -169.53 138.91 1.99 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.183 -0.462 . . . . 73.12 110.91 -179.933 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 103' ' ' LEU . . . . . 0.684 HD13 ' O ' ' A' ' 92' ' ' ARG . 6.2 tt -139.26 155.79 47.51 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.267 -0.424 . . . . 61.1 110.945 -179.943 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 104' ' ' TRP . . . . . 0.451 ' O ' HD23 ' A' ' 103' ' ' LEU . 48.4 p-90 -64.21 110.27 2.15 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 116.18 -0.464 . . . . 65.12 110.871 179.92 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 105' ' ' LEU . . . . . 0.776 HD22 ' HB2' ' A' ' 88' ' ' PHE . 0.4 OUTLIER -91.24 163.05 14.38 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.218 -0.446 . . . . 65.24 110.958 179.957 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -89.13 157.64 27.21 Favored Glycine 0 N--CA 1.452 -0.266 0 C-N-CA 120.732 -0.747 . . . . 74.42 112.456 179.888 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 107' ' ' ARG . . . . . 0.516 ' HA ' ' CD1' ' A' ' 88' ' ' PHE . 65.5 ttp85 -69.99 156.91 38.43 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.784 0.326 . . . . 75.03 110.895 -179.856 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -169.77 108.15 0.29 Allowed Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.736 -0.745 . . . . 43.23 112.549 179.999 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 109' ' ' VAL . . . . . 0.471 HG23 ' HD2' ' A' ' 110' ' ' PRO . 7.3 p -90.14 134.16 32.08 Favored Pre-proline 0 C--N 1.329 -0.295 0 CA-C-O 121.566 0.698 . . . . 72.15 111.121 -179.906 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 110' ' ' PRO . . . . . 0.518 ' N ' HD21 ' A' ' 87' ' ' ASN . 53.2 Cg_endo . . . . . 0 C--O 1.232 0.217 0 C-N-CA 122.737 2.291 . . . . 72.54 112.308 179.995 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 25' ' ' THR . . . . . 0.611 ' O ' ' HA ' ' A' ' 40' ' ' ARG . 69.8 p . . . . . 0 N--CA 1.456 -0.14 0 CA-C-O 120.737 0.303 . . . . 74.2 111.156 . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -76.3 122.47 24.48 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.268 -0.424 . . . . 54.42 110.838 -179.838 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 27' ' ' ALA . . . . . 0.788 ' HB3' HG23 ' A' ' 39' ' ' ILE . . . -151.56 161.78 42.1 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.184 -0.462 . . . . 74.13 111.104 179.882 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 28' ' ' THR . . . . . 0.514 HG22 ' O ' ' A' ' 28' ' ' THR . 12.9 m -131.46 89.74 2.76 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.215 -0.448 . . . . 71.21 111.167 -179.97 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . 0.792 HG23 ' CB ' ' A' ' 39' ' ' ILE . 2.1 pt -44.22 130.23 1.48 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 116.186 -0.461 . . . . 73.11 111.12 179.932 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 30' ' ' THR . . . . . 0.716 HG23 ' O ' ' A' ' 35' ' ' SER . 9.1 m -153.61 99.26 2.3 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.218 -0.447 . . . . 75.55 111.137 179.924 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 8.1 t -139.34 72.41 1.4 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.184 -0.462 . . . . 64.31 110.856 -179.819 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -178.96 166.95 36.9 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.796 -0.716 . . . . 73.05 112.512 179.999 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 17.1 pt-20 -49.24 -23.58 1.41 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.743 0.306 . . . . 70.41 110.829 -179.901 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 1.1 mt-30 -174.4 93.65 0.08 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.193 -0.458 . . . . 62.54 110.948 -179.829 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 35' ' ' SER . . . . . 0.716 ' O ' HG23 ' A' ' 30' ' ' THR . 3.2 m -145.95 165.71 28.16 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.196 -0.456 . . . . 72.43 110.885 -179.793 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 179.46 86.97 0.07 OUTLIER Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.788 -0.72 . . . . 55.21 112.542 -179.966 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 37' ' ' ALA . . . . . 0.657 ' HB3' ' CD1' ' A' ' 29' ' ' ILE . . . -105.79 -171.82 1.98 Allowed 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.81 0.338 . . . . 53.51 111.056 -179.955 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 73.5 t -99.74 122.79 52.0 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.15 -0.477 . . . . 73.51 111.131 -179.985 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 39' ' ' ILE . . . . . 0.792 ' CB ' HG23 ' A' ' 29' ' ' ILE . 0.0 OUTLIER -136.82 150.24 26.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.189 -0.459 . . . . 75.03 111.093 179.882 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 40' ' ' ARG . . . . . 0.701 ' O ' HG12 ' A' ' 67' ' ' VAL . 10.1 mmt-85 -110.82 82.23 1.56 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.17 -0.468 . . . . 63.51 110.88 179.987 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . 0.546 ' O ' ' HB2' ' A' ' 27' ' ' ALA . . . -141.5 142.95 12.49 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.78 -0.724 . . . . 72.15 112.485 -179.965 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 42' ' ' VAL . . . . . 0.515 HG12 HG21 ' A' ' 25' ' ' THR . 8.8 p -127.46 142.34 43.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-O 120.912 0.387 . . . . 71.41 111.091 -179.95 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 43' ' ' PHE . . . . . 0.743 ' H ' HD11 ' A' ' 83' ' ' ILE . 2.0 p90 -90.05 135.19 33.8 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.205 -0.452 . . . . 55.52 110.937 179.905 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 11.5 t0 -120.17 125.23 47.68 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.134 -0.485 . . . . 74.01 110.869 179.965 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--N 1.328 -0.339 0 CA-C-O 121.646 0.736 . . . . 70.01 110.854 179.988 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo . . . . . 0 C--O 1.231 0.156 0 CA-C-O 120.74 0.225 . . . . 61.34 112.337 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 64' ' ' SER . . . . . 0.426 ' O ' ' HA ' ' A' ' 43' ' ' PHE . 1.1 t -110.7 144.42 39.66 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.214 -0.448 . . . . 63.05 110.817 -179.798 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 65' ' ' LEU . . . . . 0.627 ' O ' HD23 ' A' ' 65' ' ' LEU . 0.0 OUTLIER -112.97 123.39 50.22 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.142 -0.481 . . . . 72.45 110.869 -179.943 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 66' ' ' PHE . . . . . 0.426 ' HA ' ' HB3' ' A' ' 102' ' ' HIS . 15.3 t80 -102.88 110.31 22.18 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.235 -0.439 . . . . 73.22 110.972 179.857 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 67' ' ' VAL . . . . . 0.701 HG12 ' O ' ' A' ' 40' ' ' ARG . 28.0 m -141.16 172.09 11.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.135 -0.484 . . . . 64.0 111.089 -179.93 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 68' ' ' ARG . . . . . 0.483 ' HG2' ' H ' ' A' ' 71' ' ' GLU . 0.9 OUTLIER -104.95 142.19 35.22 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.126 -0.488 . . . . 71.3 110.885 179.989 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 69' ' ' THR . . . . . 0.463 HG23 ' H ' ' A' ' 70' ' ' ASP . 0.1 OUTLIER -36.03 -69.59 0.1 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.18 -0.464 . . . . 42.41 111.128 -179.91 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 70' ' ' ASP . . . . . 0.463 ' H ' HG23 ' A' ' 69' ' ' THR . 30.9 t70 -44.06 -50.24 8.5 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.183 -0.462 . . . . 73.21 110.922 179.917 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 71' ' ' GLU . . . . . 0.483 ' H ' ' HG2' ' A' ' 68' ' ' ARG . 7.4 tp10 -55.49 -40.69 72.02 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.199 -0.455 . . . . 54.13 110.978 -179.976 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 72' ' ' VAL . . . . . 0.766 ' HA ' HD11 ' A' ' 75' ' ' LEU . 6.1 p -101.09 16.55 4.25 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.244 0 CA-C-N 116.134 -0.485 . . . . 71.41 111.052 179.998 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 73' ' ' ARG . . . . . 0.445 ' N ' ' O ' ' A' ' 69' ' ' THR . 0.6 OUTLIER -103.58 -32.19 9.55 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.18 -0.464 . . . . 72.24 110.87 -179.95 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -64.57 -23.46 67.28 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.143 -0.481 . . . . 75.32 110.983 -179.936 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 75' ' ' LEU . . . . . 0.766 HD11 ' HA ' ' A' ' 72' ' ' VAL . 0.0 OUTLIER -103.99 -177.56 3.4 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.149 -0.478 . . . . 54.12 110.888 179.968 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 76' ' ' ARG . . . . . . . . . . . . . 33.4 ttt180 -97.35 146.55 25.05 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.162 -0.472 . . . . 75.42 110.85 179.977 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 5.6 ptm180 -51.79 154.89 1.87 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.203 -0.453 . . . . 72.23 110.848 -179.919 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 72.46 18.9 78.66 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.734 -0.746 . . . . 32.43 112.538 -179.943 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 58.5 t0 -76.5 115.18 16.01 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.866 0.365 . . . . 63.03 110.81 -179.95 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . 0.715 ' HA ' ' HA ' ' A' ' 89' ' ' TRP . 0.0 OUTLIER -88.15 109.1 19.63 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.148 -0.478 . . . . 75.25 111.197 -179.957 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 81' ' ' LEU . . . . . 0.785 ' C ' ' HA ' ' A' ' 87' ' ' ASN . 0.0 OUTLIER -97.24 134.46 40.51 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.246 -0.433 . . . . 63.42 110.943 179.93 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 82' ' ' THR . . . . . 0.71 ' CA ' ' HA ' ' A' ' 87' ' ' ASN . 5.0 t -92.77 101.36 13.74 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.186 -0.461 . . . . 74.41 111.112 179.981 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 83' ' ' ILE . . . . . 0.782 HD13 ' O ' ' A' ' 83' ' ' ILE . 0.1 OUTLIER -132.99 130.66 58.61 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 116.246 -0.434 . . . . 72.03 111.111 179.938 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 71.97 -57.92 1.41 Allowed Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.721 -0.752 . . . . 74.44 112.502 179.931 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 7.6 tp10 -109.54 -82.37 0.57 Allowed 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.838 0.352 . . . . 71.13 110.893 -179.92 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 86' ' ' GLU . . . . . 0.448 ' C ' ' HA ' ' A' ' 82' ' ' THR . 5.8 mm-40 -151.09 162.02 41.64 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.162 -0.472 . . . . 64.22 110.896 -179.955 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 87' ' ' ASN . . . . . 0.785 ' HA ' ' C ' ' A' ' 81' ' ' LEU . 12.1 p30 -51.43 125.31 14.09 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.14 -0.482 . . . . 73.31 110.9 -179.933 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 88' ' ' PHE . . . . . 0.682 ' HB2' HD22 ' A' ' 105' ' ' LEU . 15.3 m-85 -132.55 118.5 19.3 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.166 -0.47 . . . . 73.2 110.846 -179.958 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 89' ' ' TRP . . . . . 0.715 ' HA ' ' HA ' ' A' ' 80' ' ' THR . 53.9 p-90 -82.62 136.3 34.83 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.12 -0.491 . . . . 74.42 110.91 -179.976 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 90' ' ' VAL . . . . . 0.679 HG21 ' CG1' ' A' ' 93' ' ' VAL . 4.5 p -93.36 139.6 17.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.197 -0.456 . . . . 72.44 111.158 179.915 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 91' ' ' ASP . . . . . 0.412 ' HB2' HD21 ' A' ' 103' ' ' LEU . 0.2 OUTLIER -62.71 -63.77 1.12 Allowed 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.157 -0.474 . . . . 55.33 110.869 179.933 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 92' ' ' ARG . . . . . 0.67 ' O ' HD13 ' A' ' 103' ' ' LEU . 11.5 mtm180 -159.2 123.9 4.06 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.145 -0.479 . . . . 73.13 110.858 -179.869 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 93' ' ' VAL . . . . . 0.679 ' CG1' HG21 ' A' ' 90' ' ' VAL . 18.6 m -123.37 136.01 61.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.155 -0.475 . . . . 73.14 111.086 179.985 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 21.0 m -136.36 130.45 18.14 Favored Pre-proline 0 C--N 1.33 -0.244 0 CA-C-O 121.618 0.723 . . . . 74.12 110.854 -179.855 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 95' ' ' PRO . . . . . 0.421 ' HG3' ' HB ' ' A' ' 69' ' ' THR . 53.8 Cg_endo -69.75 155.55 65.7 Favored 'Trans proline' 0 C--O 1.232 0.178 0 C-N-CA 122.667 2.244 . . . . 71.42 112.385 179.931 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 14.1 t0 . . . . . 0 C--N 1.328 -0.34 0 CA-C-N 116.198 -0.455 . . . . 54.05 110.914 179.909 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 3.3 m . . . . . 0 C--O 1.232 0.163 0 CA-C-O 120.8 0.333 . . . . 71.12 110.845 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 101' ' ' CYS . . . . . 0.592 ' HB2' ' HB ' ' A' ' 93' ' ' VAL . 25.4 p -47.3 132.66 12.82 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.144 -0.48 . . . . 62.15 110.939 179.996 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 102' ' ' HIS . . . . . 0.426 ' HB3' ' HA ' ' A' ' 66' ' ' PHE . 1.7 p80 -163.28 130.3 3.45 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.221 -0.445 . . . . 71.22 110.887 -179.968 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 103' ' ' LEU . . . . . 0.67 HD13 ' O ' ' A' ' 92' ' ' ARG . 7.1 tt -147.78 157.1 43.38 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.211 -0.449 . . . . 75.34 110.942 179.978 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 104' ' ' TRP . . . . . 0.509 ' O ' HD23 ' A' ' 103' ' ' LEU . 8.4 m-90 -64.0 110.08 2.02 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.195 -0.457 . . . . 75.31 110.939 179.898 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 105' ' ' LEU . . . . . 0.682 HD22 ' HB2' ' A' ' 88' ' ' PHE . 0.3 OUTLIER -88.75 163.06 15.9 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.231 -0.44 . . . . 63.54 110.922 179.986 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -92.41 161.37 26.26 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.749 -0.738 . . . . 54.43 112.455 179.956 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 107' ' ' ARG . . . . . 0.606 ' HA ' ' CD1' ' A' ' 88' ' ' PHE . 4.8 ptt180 -68.07 158.57 32.7 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.835 0.35 . . . . 73.31 110.841 -179.832 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -171.49 112.38 0.44 Allowed Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.673 -0.775 . . . . 52.41 112.469 -179.998 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 109' ' ' VAL . . . . . 0.455 HG23 ' HD2' ' A' ' 110' ' ' PRO . 7.2 p -101.3 134.09 20.52 Favored Pre-proline 0 C--N 1.328 -0.332 0 CA-C-O 121.619 0.723 . . . . 71.5 111.157 179.999 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 110' ' ' PRO . . . . . 0.455 ' HD2' HG23 ' A' ' 109' ' ' VAL . 53.7 Cg_endo . . . . . 0 C--O 1.232 0.199 0 C-N-CA 122.731 2.288 . . . . 64.53 112.321 179.956 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--O 1.231 0.115 0 CA-C-O 120.766 0.317 . . . . 72.21 110.887 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -156.36 178.35 10.41 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.22 -0.446 . . . . 60.41 111.151 179.833 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 3' ' ' ASP . . . . . . . . . . . . . 9.3 m-20 -159.6 -178.56 7.19 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.234 -0.439 . . . . 72.32 110.837 -179.997 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 4' ' ' PHE . . . . . . . . . . . . . 3.8 t80 -170.12 161.03 8.36 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.173 -0.467 . . . . 72.33 110.892 -179.878 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 8.5 m-20 -157.9 -177.25 6.43 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.154 -0.476 . . . . 72.32 110.838 179.933 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 6' ' ' ASN . . . . . . . . . . . . . 24.4 t30 -151.68 173.7 14.38 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.15 -0.477 . . . . 74.23 110.82 -179.903 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 7' ' ' LEU . . . . . 0.403 HD12 ' C ' ' A' ' 7' ' ' LEU . 3.4 pp -171.81 -176.87 1.83 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.168 -0.469 . . . . 55.02 110.926 179.945 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 8' ' ' PHE . . . . . . . . . . . . . 30.6 p90 -140.33 178.54 7.22 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.16 -0.473 . . . . 74.43 110.884 179.9 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 4.0 m-20 -164.04 179.14 7.16 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.146 -0.479 . . . . 50.15 110.834 179.979 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -132.85 -173.18 3.11 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.148 -0.478 . . . . 74.34 111.092 179.967 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -149.15 133.15 17.15 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.206 -0.452 . . . . 61.44 111.078 179.953 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -132.68 -153.68 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.141 -0.481 . . . . 62.34 111.175 179.927 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -144.37 144.42 31.42 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.261 -0.427 . . . . 73.43 111.135 179.824 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 22.3 mmm180 -145.45 -176.85 5.28 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.262 -0.426 . . . . 73.04 110.875 -179.936 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -124.79 -172.47 2.58 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.187 -0.461 . . . . 74.11 111.029 179.95 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 8.8 t0 -140.43 176.53 8.7 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.136 -0.484 . . . . 54.4 110.842 -179.996 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -175.02 176.3 2.15 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.192 -0.458 . . . . 75.33 110.971 -179.91 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 18' ' ' THR . . . . . 0.523 ' O ' HD13 ' A' ' 19' ' ' ILE . 1.1 p -139.59 150.39 44.96 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.189 -0.46 . . . . 63.12 111.142 -179.919 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . 0.523 HD13 ' O ' ' A' ' 18' ' ' THR . 45.0 mm -140.12 103.59 1.65 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.251 -0.432 . . . . 55.23 111.081 179.953 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 20' ' ' ARG . . . . . . . . . . . . . 5.4 tmm_? -167.47 132.61 1.97 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.179 -0.464 . . . . 72.22 110.863 179.963 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 155.89 92.19 0.09 OUTLIER Glycine 0 N--CA 1.452 -0.283 0 C-N-CA 120.721 -0.752 . . . . 75.21 112.45 -179.97 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 22' ' ' TYR . . . . . . . . . . . . . 72.7 t80 -150.09 93.93 2.08 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.921 0.391 . . . . 63.01 110.91 -179.883 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 23' ' ' MET . . . . . . . . . . . . . 11.1 ttm -134.37 -55.8 0.85 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.08 -0.509 . . . . 75.32 110.921 179.913 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -112.19 -112.39 3.21 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.699 -0.763 . . . . 73.41 112.473 -179.999 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 25' ' ' THR . . . . . 0.485 HG21 HG23 ' A' ' 42' ' ' VAL . 11.7 m -98.65 137.41 37.33 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.765 0.317 . . . . 60.23 111.237 -179.913 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -71.95 122.45 20.85 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.286 -0.415 . . . . 74.12 110.842 -179.836 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 27' ' ' ALA . . . . . 0.81 ' HB3' HG23 ' A' ' 39' ' ' ILE . . . -141.95 162.18 36.13 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.09 -0.505 . . . . 73.02 111.134 179.904 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 28' ' ' THR . . . . . 0.464 HG22 ' O ' ' A' ' 28' ' ' THR . 21.2 m -129.99 87.95 2.59 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.224 -0.444 . . . . 73.24 111.143 -179.918 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . 0.858 HG21 HD21 ' A' ' 75' ' ' LEU . 2.3 pt -45.15 130.9 1.97 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.277 -0.419 . . . . 75.42 111.08 179.931 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . 0.667 HG23 ' O ' ' A' ' 35' ' ' SER . 19.8 m -153.14 97.51 2.19 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.133 -0.485 . . . . 74.12 111.155 179.974 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . 0.402 ' OG ' HG22 ' A' ' 80' ' ' THR . 8.5 t -135.1 70.86 1.43 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.213 -0.449 . . . . 61.23 110.829 -179.858 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -178.95 167.92 38.47 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.76 -0.733 . . . . 72.11 112.449 179.984 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 4.1 pt-20 -49.12 -23.36 1.22 Allowed 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.828 0.346 . . . . 64.41 110.89 -179.878 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 9.6 tt0 -174.44 94.64 0.08 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.129 -0.487 . . . . 71.3 110.879 -179.938 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 35' ' ' SER . . . . . 0.667 ' O ' HG23 ' A' ' 30' ' ' THR . 0.1 OUTLIER -144.9 165.49 27.98 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.992 0.425 . . . . 55.32 110.832 -179.831 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 178.17 87.84 0.07 OUTLIER Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.752 -0.737 . . . . 61.32 112.48 -179.97 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . 0.601 ' HB3' ' CD1' ' A' ' 29' ' ' ILE . . . -107.06 -170.67 1.75 Allowed 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.881 0.372 . . . . 63.42 111.087 179.984 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 4.1 p -99.15 120.74 48.9 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.227 -0.442 . . . . 74.22 111.185 179.913 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 39' ' ' ILE . . . . . 0.81 HG23 ' HB3' ' A' ' 27' ' ' ALA . 0.0 OUTLIER -137.85 148.69 25.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.199 -0.455 . . . . 74.1 111.106 179.951 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 40' ' ' ARG . . . . . 0.575 ' O ' HG12 ' A' ' 67' ' ' VAL . 18.5 mtt180 -109.66 80.76 1.35 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.189 -0.459 . . . . 70.22 110.887 179.9 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . 0.479 ' N ' HD13 ' A' ' 39' ' ' ILE . . . -128.71 148.9 18.21 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.738 -0.744 . . . . 72.52 112.454 -179.928 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 42' ' ' VAL . . . . . 0.664 HG12 ' HB3' ' A' ' 66' ' ' PHE . 3.4 p -127.16 135.04 64.64 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-O 120.851 0.357 . . . . 73.22 111.102 179.972 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 43' ' ' PHE . . . . . 0.58 ' H ' HD11 ' A' ' 83' ' ' ILE . 3.2 p90 -92.84 128.2 38.62 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.134 -0.485 . . . . 73.14 110.915 179.945 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 46.8 m-20 -114.88 124.52 51.93 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 116.133 -0.485 . . . . 64.13 110.861 179.944 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -105.63 153.0 40.19 Favored Pre-proline 0 C--N 1.329 -0.314 0 CA-C-O 121.624 0.726 . . . . 63.24 110.854 179.95 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 46' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.78 -41.31 4.36 Favored 'Trans proline' 0 C--N 1.342 0.186 0 C-N-CA 122.636 2.224 . . . . 54.33 112.355 179.991 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 28.9 tt0 -169.74 103.97 0.33 Allowed 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.225 -0.443 . . . . 70.42 110.898 179.989 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 4.0 t-20 -51.57 -30.5 21.06 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.213 -0.449 . . . . 74.23 110.861 -179.853 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 28.6 mt -88.69 100.16 10.18 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.192 -0.458 . . . . 54.12 111.104 179.911 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 1.4 t -153.83 147.3 24.99 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.149 -0.478 . . . . 75.35 110.864 -179.923 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 7.6 m-85 -148.72 178.62 8.49 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.13 -0.487 . . . . 74.44 110.854 -179.82 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -125.96 -75.79 0.59 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.105 -0.498 . . . . 72.2 111.043 179.875 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 147.13 39.91 0.04 OUTLIER Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.764 -0.731 . . . . 54.44 112.457 -179.921 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 54' ' ' GLN . . . . . . . . . . . . . 42.8 mt-30 53.26 29.55 8.69 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.818 0.342 . . . . 73.34 110.914 -179.866 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -103.96 -65.75 0.7 Allowed Glycine 0 N--CA 1.452 -0.271 0 C-N-CA 120.752 -0.737 . . . . 73.24 112.434 -179.946 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 43.8 t -68.17 147.18 12.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-O 120.79 0.329 . . . . 72.2 111.126 -179.916 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 15.6 ptm180 -94.95 -31.34 13.69 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.126 -0.488 . . . . 65.04 110.871 -179.961 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 7.1 p -134.44 126.89 49.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.209 -0.45 . . . . 74.43 111.142 179.972 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 2.6 tt0 -104.81 172.56 6.72 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.165 -0.47 . . . . 72.14 110.885 -179.981 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -131.83 131.99 6.54 Favored Glycine 0 N--CA 1.452 -0.262 0 C-N-CA 120.706 -0.759 . . . . 32.03 112.496 -179.991 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 1.7 p -148.11 123.64 10.41 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.885 0.374 . . . . 41.44 110.888 -179.77 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . 0.409 ' HA ' ' HD2' ' A' ' 63' ' ' PRO . 16.7 p -133.01 97.81 16.39 Favored Pre-proline 0 C--N 1.329 -0.322 0 CA-C-O 121.689 0.757 . . . . 45.42 110.84 -179.796 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 63' ' ' PRO . . . . . 0.536 ' HG2' HD11 ' A' ' 105' ' ' LEU . 54.2 Cg_endo -69.76 -178.46 2.35 Favored 'Trans proline' 0 C--N 1.341 0.183 0 C-N-CA 122.684 2.256 . . . . 64.21 112.354 179.975 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . 0.488 ' O ' ' HA ' ' A' ' 43' ' ' PHE . 2.2 t -106.46 146.8 30.1 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.271 -0.422 . . . . 74.44 110.821 -179.879 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 65' ' ' LEU . . . . . 0.788 HD11 HG13 ' A' ' 67' ' ' VAL . 0.2 OUTLIER -113.36 123.66 50.63 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.07 -0.513 . . . . 54.13 110.899 -179.989 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 66' ' ' PHE . . . . . 0.664 ' HB3' HG12 ' A' ' 42' ' ' VAL . 15.2 t80 -102.48 110.87 22.94 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.185 -0.461 . . . . 72.14 110.873 179.956 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 67' ' ' VAL . . . . . 0.788 HG13 HD11 ' A' ' 65' ' ' LEU . 0.3 OUTLIER -140.99 168.73 15.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.193 -0.458 . . . . 52.41 111.237 179.954 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 68' ' ' ARG . . . . . 0.427 ' HG3' ' HA3' ' A' ' 99' ' ' GLY . 8.9 ttm180 -98.36 143.18 29.1 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.202 -0.454 . . . . 73.52 110.8 -179.935 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 69' ' ' THR . . . . . 0.722 HG22 ' HA2' ' A' ' 99' ' ' GLY . 0.0 OUTLIER -41.17 -44.51 2.58 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.156 -0.475 . . . . 74.41 111.172 -179.932 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 29.0 m-20 -65.69 -52.64 49.92 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.236 -0.438 . . . . 70.51 110.891 179.888 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 71' ' ' GLU . . . . . . . . . . . . . 2.1 mm-40 -55.0 -39.49 69.1 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.22 -0.445 . . . . 73.11 110.906 -179.947 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 11.1 p -82.6 -22.13 9.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.132 -0.485 . . . . 63.43 111.075 -179.993 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 73' ' ' ARG . . . . . . . . . . . . . 1.5 tmt_? -67.59 -41.52 83.95 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.194 -0.457 . . . . 75.23 110.869 179.984 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 59.1 mt-30 -57.78 -20.45 35.45 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.198 -0.456 . . . . 71.12 110.969 -179.957 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 75' ' ' LEU . . . . . 0.858 HD21 HG21 ' A' ' 29' ' ' ILE . 5.8 mp -104.95 -175.87 2.92 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.199 -0.455 . . . . 73.43 110.899 -179.999 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 76' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -111.76 -179.45 3.7 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.197 -0.456 . . . . 75.24 110.937 179.944 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -81.21 116.25 21.01 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.225 -0.443 . . . . 71.15 110.888 -179.913 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 107.92 20.14 8.61 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.77 -0.729 . . . . 70.23 112.453 -179.991 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . 0.409 ' OD2' HD23 ' A' ' 75' ' ' LEU . 0.2 OUTLIER -84.41 111.58 19.58 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.881 0.372 . . . . 74.23 110.886 179.996 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . 0.711 ' HA ' ' HA ' ' A' ' 89' ' ' TRP . 0.0 OUTLIER -86.62 111.6 20.8 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.198 -0.455 . . . . 71.14 111.148 -179.91 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 81' ' ' LEU . . . . . 0.755 ' C ' ' HA ' ' A' ' 87' ' ' ASN . 0.3 OUTLIER -97.22 131.82 43.58 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.194 -0.457 . . . . 64.43 110.921 179.917 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 82' ' ' THR . . . . . 0.748 ' CA ' ' HA ' ' A' ' 87' ' ' ASN . 2.4 t -92.48 101.42 13.87 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.13 -0.486 . . . . 61.15 111.156 179.946 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 83' ' ' ILE . . . . . 0.713 ' CG2' HD12 ' A' ' 81' ' ' LEU . 0.1 OUTLIER -137.24 131.84 45.67 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.282 -0.417 . . . . 73.34 111.081 179.979 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 74.9 -53.86 2.56 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.7 -0.762 . . . . 65.25 112.537 179.929 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . 0.41 ' C ' ' HG3' ' A' ' 86' ' ' GLU . 84.5 tt0 -117.94 -81.31 0.62 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.766 0.317 . . . . 73.34 110.879 -179.951 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 86' ' ' GLU . . . . . 0.695 ' OE1' HG22 ' A' ' 109' ' ' VAL . 61.7 mt-10 -149.35 161.4 42.13 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.233 -0.439 . . . . 73.23 110.931 -179.903 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 87' ' ' ASN . . . . . 0.755 ' HA ' ' C ' ' A' ' 81' ' ' LEU . 13.0 p30 -51.92 123.99 11.66 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.188 -0.46 . . . . 70.12 110.877 -179.932 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 88' ' ' PHE . . . . . 0.795 ' HB3' HD13 ' A' ' 105' ' ' LEU . 14.3 m-85 -132.2 118.18 19.21 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.184 -0.462 . . . . 73.52 110.869 -179.957 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 89' ' ' TRP . . . . . 0.711 ' HA ' ' HA ' ' A' ' 80' ' ' THR . 64.0 p-90 -82.15 135.35 35.3 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.185 -0.461 . . . . 74.34 110.922 -179.963 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 90' ' ' VAL . . . . . 0.731 ' HB ' HD23 ' A' ' 65' ' ' LEU . 0.4 OUTLIER -92.88 139.58 17.8 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.257 -0.429 . . . . 71.24 111.163 179.893 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -62.71 -71.0 0.17 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.183 -0.462 . . . . 74.32 110.89 179.867 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 92' ' ' ARG . . . . . 0.569 ' O ' ' HG ' ' A' ' 103' ' ' LEU . 7.0 mtm180 -159.9 120.89 3.1 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.172 -0.467 . . . . 54.31 110.894 -179.878 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 93' ' ' VAL . . . . . 0.758 HG12 ' HB2' ' A' ' 103' ' ' LEU . 17.4 m -112.51 135.43 51.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.197 -0.456 . . . . 75.04 111.164 179.942 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 2.1 m -130.22 101.62 17.69 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-O 121.661 0.743 . . . . 72.34 110.827 -179.811 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 95' ' ' PRO . . . . . 0.421 ' HG3' ' HB ' ' A' ' 69' ' ' THR . 54.0 Cg_endo -69.74 177.27 5.74 Favored 'Trans proline' 0 C--N 1.341 0.155 0 C-N-CA 122.682 2.254 . . . . 73.22 112.319 179.977 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 37.2 t70 -121.21 -31.82 4.03 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.203 -0.453 . . . . 74.12 110.848 179.928 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 5.8 t70 177.96 134.64 0.07 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.244 -0.435 . . . . 74.42 110.781 -179.942 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 75.53 41.55 29.52 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.692 -0.766 . . . . 74.13 112.45 -179.994 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 99' ' ' GLY . . . . . 0.722 ' HA2' HG22 ' A' ' 69' ' ' THR . . . 42.7 74.31 0.19 Allowed Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.723 -0.751 . . . . 73.0 112.533 -179.901 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 1.7 m -131.66 76.98 1.74 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.922 0.392 . . . . 44.42 110.881 -179.748 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 101' ' ' CYS . . . . . 0.425 ' CB ' ' HB ' ' A' ' 93' ' ' VAL . 0.0 OUTLIER -105.02 148.38 26.82 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.104 -0.498 . . . . 72.13 110.87 -179.996 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 102' ' ' HIS . . . . . 0.579 ' HA ' ' O ' ' A' ' 65' ' ' LEU . 6.7 p80 -157.65 123.69 4.74 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.142 -0.481 . . . . 64.53 110.865 -179.947 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 103' ' ' LEU . . . . . 0.931 HD13 ' N ' ' A' ' 104' ' ' TRP . 2.4 tm? -151.53 146.73 26.09 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.256 -0.429 . . . . 55.14 110.959 -180.0 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 104' ' ' TRP . . . . . 0.931 ' N ' HD13 ' A' ' 103' ' ' LEU . 30.4 p90 -65.81 110.52 2.87 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.15 -0.477 . . . . 73.11 110.928 179.937 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 105' ' ' LEU . . . . . 0.795 HD13 ' HB3' ' A' ' 88' ' ' PHE . 0.4 OUTLIER -91.23 161.84 14.89 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.169 -0.469 . . . . 72.42 110.944 179.99 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -89.43 159.52 28.5 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.692 -0.766 . . . . 61.04 112.477 179.911 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 107' ' ' ARG . . . . . 0.574 ' HA ' ' CD1' ' A' ' 88' ' ' PHE . 0.4 OUTLIER -69.33 158.47 34.99 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.845 0.355 . . . . 73.33 110.863 -179.83 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -174.56 111.12 0.35 Allowed Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.758 -0.734 . . . . 60.14 112.525 -179.969 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 109' ' ' VAL . . . . . 0.695 HG22 ' OE1' ' A' ' 86' ' ' GLU . 10.6 t -100.23 132.44 22.6 Favored Pre-proline 0 C--N 1.33 -0.251 0 CA-C-O 121.632 0.729 . . . . 64.42 111.15 -179.961 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 110' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.7 168.2 22.17 Favored 'Trans proline' 0 C--N 1.341 0.161 0 C-N-CA 122.718 2.279 . . . . 64.1 112.335 179.955 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 111' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.77 -8.01 22.51 Favored 'Trans proline' 0 C--N 1.341 0.149 0 C-N-CA 122.661 2.241 . . . . 75.23 112.318 179.905 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -59.31 161.54 5.46 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.221 -0.445 . . . . 44.41 111.128 179.87 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 19.7 m -93.26 124.24 45.63 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.244 -0.435 . . . . 74.54 111.134 179.941 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 114' ' ' ASN . . . . . . . . . . . . . 6.0 t-20 -128.35 146.13 50.86 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.168 -0.469 . . . . 74.41 110.919 179.99 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -82.56 133.46 35.19 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.155 -0.475 . . . . 75.42 110.901 -179.95 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 116' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -106.71 138.1 43.51 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.201 -0.454 . . . . 75.54 110.919 -179.904 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 1.6 tpm_? . . . . . 0 C--N 1.329 -0.299 0 CA-C-N 116.239 -0.437 . . . . 73.34 110.823 -179.857 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 6.8 ttp . . . . . 0 C--O 1.231 0.082 0 CA-C-O 120.829 0.347 . . . . 63.41 110.928 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -174.71 176.08 2.33 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.199 -0.455 . . . . 53.24 111.101 179.866 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 3' ' ' ASP . . . . . . . . . . . . . 3.0 p-10 -174.96 170.15 3.29 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.178 -0.464 . . . . 64.25 110.822 -179.983 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 4' ' ' PHE . . . . . . . . . . . . . 10.3 m-85 -160.74 177.58 10.31 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.267 -0.424 . . . . 41.23 110.9 -179.959 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -174.98 178.07 1.85 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.149 -0.478 . . . . 63.44 110.912 179.983 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 6' ' ' ASN . . . . . . . . . . . . . 18.0 m-80 -161.63 173.4 14.78 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.245 -0.434 . . . . 62.51 110.89 -179.94 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 7' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -164.48 172.08 13.79 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.157 -0.474 . . . . 52.23 110.967 179.927 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 8' ' ' PHE . . . . . . . . . . . . . 25.6 p90 -174.36 150.12 1.43 Allowed 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.185 -0.462 . . . . 72.41 110.915 -179.984 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 3.9 m-20 -153.86 157.07 38.76 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.192 -0.458 . . . . 53.14 110.842 179.978 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -175.39 158.54 2.32 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.152 -0.476 . . . . 73.55 111.061 179.893 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -70.33 173.93 6.24 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.177 -0.465 . . . . 51.32 111.082 179.967 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 32.5 mt -54.3 -74.99 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.239 -0.437 . . . . 63.24 111.144 -179.999 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . 52.64 49.69 19.81 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.14 -0.482 . . . . 61.43 111.118 179.786 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 3.3 tpm_? -55.02 105.0 0.13 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.297 -0.41 . . . . 74.42 110.914 -179.926 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -172.7 170.09 4.8 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.208 -0.451 . . . . 53.24 111.062 179.907 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 2.0 t70 -61.96 173.76 1.01 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.142 -0.481 . . . . 72.11 110.815 -179.929 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 3.7 tt0 -136.45 171.45 14.47 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.192 -0.458 . . . . 61.33 110.899 -179.886 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -154.93 178.03 10.64 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.213 -0.448 . . . . 75.33 111.231 -179.932 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . 0.457 ' O ' HG23 ' A' ' 19' ' ' ILE . 4.1 tp -160.38 110.86 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.263 -0.426 . . . . 74.24 111.11 179.907 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 20' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -145.93 -176.23 5.06 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.13 -0.487 . . . . 74.13 110.839 179.931 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 141.52 87.72 0.11 Allowed Glycine 0 N--CA 1.452 -0.264 0 C-N-CA 120.685 -0.769 . . . . 62.32 112.471 179.972 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 22' ' ' TYR . . . . . . . . . . . . . 56.8 m-85 -153.93 -175.9 5.6 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.885 0.374 . . . . 70.33 110.913 -179.818 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 23' ' ' MET . . . . . . . . . . . . . 1.8 ptt? -61.11 -172.19 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.129 -0.487 . . . . 61.0 110.844 179.892 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 59.42 -159.56 20.04 Favored Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 120.756 -0.735 . . . . 72.21 112.474 -179.967 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 25' ' ' THR . . . . . 0.49 HG21 HG23 ' A' ' 42' ' ' VAL . 9.6 m -97.89 137.77 36.23 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.816 0.341 . . . . 72.33 111.218 -179.943 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 7.7 m -72.39 122.37 21.08 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.287 -0.415 . . . . 74.51 110.818 -179.833 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 27' ' ' ALA . . . . . 0.816 ' HB3' HG23 ' A' ' 39' ' ' ILE . . . -143.06 162.37 35.7 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.109 -0.496 . . . . 75.11 111.133 179.831 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 28' ' ' THR . . . . . 0.49 HG22 ' O ' ' A' ' 28' ' ' THR . 18.0 m -129.86 88.17 2.63 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.243 -0.435 . . . . 43.33 111.155 -179.846 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . 0.766 HG23 ' CB ' ' A' ' 39' ' ' ILE . 2.1 pt -43.87 131.08 1.39 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.19 -0.459 . . . . 71.11 111.162 179.978 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . 0.698 HG23 ' O ' ' A' ' 35' ' ' SER . 11.3 m -152.98 97.33 2.19 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.229 -0.441 . . . . 53.11 111.183 -179.998 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 86.3 p -135.96 70.79 1.42 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.193 -0.458 . . . . 71.34 110.945 -179.867 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -179.29 167.52 37.65 Favored Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.72 -0.752 . . . . 71.22 112.499 -179.982 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 16.8 pt-20 -48.95 -23.43 1.12 Allowed 'General case' 0 C--N 1.33 -0.283 0 CA-C-O 120.856 0.36 . . . . 73.33 110.885 -179.9 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -174.06 94.63 0.09 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.155 -0.475 . . . . 41.33 110.954 -179.937 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 35' ' ' SER . . . . . 0.698 ' O ' HG23 ' A' ' 30' ' ' THR . 2.9 m -145.23 165.45 28.35 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.191 -0.459 . . . . 70.41 110.81 -179.783 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 177.8 88.5 0.07 OUTLIER Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.799 -0.715 . . . . 74.4 112.52 -179.923 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . 0.648 ' HB3' ' CD1' ' A' ' 29' ' ' ILE . . . -108.43 -170.75 1.73 Allowed 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 120.893 0.378 . . . . 53.51 111.078 179.977 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 64.6 t -98.57 120.23 47.63 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-N 116.211 -0.449 . . . . 72.11 111.146 179.958 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 39' ' ' ILE . . . . . 0.816 HG23 ' HB3' ' A' ' 27' ' ' ALA . 0.0 OUTLIER -137.08 149.93 26.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.177 -0.465 . . . . 71.3 111.124 179.956 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 40' ' ' ARG . . . . . 0.434 ' HA ' ' O ' ' A' ' 25' ' ' THR . 19.3 mtt85 -109.46 80.47 1.32 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.213 -0.448 . . . . 73.53 110.849 179.934 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . 0.591 ' HA2' HG12 ' A' ' 67' ' ' VAL . . . -127.47 147.93 17.29 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.797 -0.716 . . . . 74.42 112.527 179.998 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 42' ' ' VAL . . . . . 0.56 HG12 ' CB ' ' A' ' 66' ' ' PHE . 3.1 p -127.19 138.86 53.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-O 120.851 0.358 . . . . 72.41 111.126 -179.942 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 43' ' ' PHE . . . . . 0.51 ' H ' HD11 ' A' ' 83' ' ' ILE . 2.8 p90 -101.05 128.71 46.98 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.166 -0.47 . . . . 73.13 110.873 -179.982 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 1.5 t0 -104.38 124.67 49.63 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.106 -0.497 . . . . 75.13 110.835 179.956 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 45' ' ' ASP . . . . . 0.415 ' HA ' ' HD2' ' A' ' 46' ' ' PRO . 0.4 OUTLIER -114.1 105.79 53.85 Favored Pre-proline 0 C--N 1.328 -0.356 0 CA-C-O 121.608 0.718 . . . . 73.42 110.88 179.97 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 46' ' ' PRO . . . . . 0.415 ' HD2' ' HA ' ' A' ' 45' ' ' ASP . 53.2 Cg_endo -69.76 -46.3 1.27 Allowed 'Trans proline' 0 C--N 1.34 0.107 0 C-N-CA 122.678 2.252 . . . . 72.54 112.346 -179.979 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 1.9 tp10 -158.76 95.83 1.33 Allowed 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.155 -0.475 . . . . 71.24 110.868 -179.993 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 48.2 t30 -69.88 88.79 0.57 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.141 -0.481 . . . . 64.34 110.928 -179.988 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 10.4 tp -173.2 136.99 0.24 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.146 -0.479 . . . . 63.23 111.108 179.974 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 11.2 p -95.48 120.37 35.61 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.132 -0.486 . . . . 74.2 110.881 -179.933 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 10.8 m-85 -66.88 -74.34 0.11 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.118 -0.492 . . . . 65.05 110.971 -179.878 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -178.04 -179.85 0.78 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.175 -0.466 . . . . 72.41 111.058 179.915 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 178.32 136.29 2.51 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.763 -0.732 . . . . 35.34 112.533 -179.986 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 54' ' ' GLN . . . . . . . . . . . . . 9.7 pt20 -166.01 158.15 14.38 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.888 0.375 . . . . 65.34 110.886 -179.911 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 66.37 -91.61 0.17 Allowed Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.684 -0.769 . . . . 53.42 112.456 -179.976 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 80.0 t -111.34 111.6 36.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-O 120.868 0.366 . . . . 72.31 111.084 -179.921 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -102.4 102.33 12.65 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.156 -0.475 . . . . 73.25 110.856 -179.939 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 58' ' ' VAL . . . . . 0.44 HG22 ' O ' ' A' ' 58' ' ' VAL . 6.8 p -128.32 23.72 2.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.201 -0.454 . . . . 75.51 111.103 -179.964 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 3.8 tp10 -120.46 141.3 50.3 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.154 -0.476 . . . . 64.54 110.903 179.948 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -135.13 142.92 14.41 Favored Glycine 0 N--CA 1.452 -0.246 0 C-N-CA 120.744 -0.741 . . . . 74.12 112.478 -179.91 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 2.5 m -131.88 112.67 12.65 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.884 0.373 . . . . 53.34 110.848 -179.798 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -131.0 160.17 68.11 Favored Pre-proline 0 C--N 1.329 -0.295 0 CA-C-O 121.67 0.748 . . . . 55.42 110.836 -179.792 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_endo -69.76 -179.25 2.78 Favored 'Trans proline' 0 C--O 1.231 0.169 0 C-N-CA 122.754 2.303 . . . . 72.32 112.315 179.987 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . 0.492 ' O ' ' HA ' ' A' ' 43' ' ' PHE . 0.2 OUTLIER -107.02 146.38 31.2 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.228 -0.442 . . . . 43.53 110.894 -179.891 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 65' ' ' LEU . . . . . 0.55 HD11 ' CG1' ' A' ' 67' ' ' VAL . 2.7 tm? -114.93 131.48 56.87 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.126 -0.488 . . . . 74.24 110.919 -179.957 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 66' ' ' PHE . . . . . 0.56 ' CB ' HG12 ' A' ' 42' ' ' VAL . 1.2 t80 -120.38 106.17 11.59 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.261 -0.427 . . . . 73.24 110.846 179.951 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 67' ' ' VAL . . . . . 0.591 HG12 ' HA2' ' A' ' 41' ' ' GLY . 23.2 m -144.69 172.71 5.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.167 -0.469 . . . . 75.24 111.148 179.921 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 1.4 ttt180 -105.62 143.48 33.71 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.128 -0.487 . . . . 72.12 110.896 -179.992 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 69' ' ' THR . . . . . 0.672 HG22 ' HA2' ' A' ' 99' ' ' GLY . 0.0 OUTLIER -41.17 -49.4 3.53 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.168 -0.469 . . . . 72.33 111.135 -179.908 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 14.8 t70 -53.39 -51.29 63.01 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.231 -0.44 . . . . 74.4 110.862 179.918 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 71' ' ' GLU . . . . . . . . . . . . . 31.2 mt-10 -53.3 -39.07 63.71 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.164 -0.471 . . . . 64.22 110.905 -179.932 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 72' ' ' VAL . . . . . 0.838 HG11 HG21 ' A' ' 93' ' ' VAL . 3.3 t -78.6 -32.43 16.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.156 -0.474 . . . . 74.05 111.148 179.952 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 73' ' ' ARG . . . . . . . . . . . . . 1.8 tmt_? -57.32 -39.18 75.3 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.149 -0.478 . . . . 63.11 110.841 -179.94 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 39.9 mt-30 -56.22 -22.02 26.86 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.188 -0.46 . . . . 63.25 110.87 -179.897 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 75' ' ' LEU . . . . . 0.784 HD22 ' CG ' ' A' ' 79' ' ' ASP . 2.3 mp -119.23 -165.29 1.13 Allowed 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.252 -0.431 . . . . 54.05 110.918 -180.0 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 76' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -116.15 171.94 7.49 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.219 -0.446 . . . . 73.23 110.86 179.969 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -62.41 132.05 51.26 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.174 -0.466 . . . . 75.25 110.899 -179.917 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 92.5 18.11 43.03 Favored Glycine 0 N--CA 1.452 -0.252 0 C-N-CA 120.746 -0.74 . . . . 70.23 112.477 179.998 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . 0.784 ' CG ' HD22 ' A' ' 75' ' ' LEU . 0.1 OUTLIER -74.23 106.33 5.82 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.883 0.373 . . . . 74.34 110.896 -179.976 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . 0.718 ' HA ' ' HA ' ' A' ' 89' ' ' TRP . 0.6 OUTLIER -85.78 109.14 18.44 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.185 -0.461 . . . . 72.22 111.155 -179.857 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 81' ' ' LEU . . . . . 0.756 ' C ' ' HA ' ' A' ' 87' ' ' ASN . 0.3 OUTLIER -97.07 133.11 42.16 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.188 -0.46 . . . . 71.24 110.9 -179.992 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 82' ' ' THR . . . . . 0.741 ' CA ' ' HA ' ' A' ' 87' ' ' ASN . 9.8 t -93.51 102.27 14.48 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.193 -0.458 . . . . 73.32 111.123 179.949 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 83' ' ' ILE . . . . . 0.734 ' CG2' HD12 ' A' ' 81' ' ' LEU . 0.1 OUTLIER -138.46 131.78 40.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.208 -0.451 . . . . 64.45 111.147 179.882 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 74.43 -50.51 2.08 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.663 -0.779 . . . . 55.43 112.548 179.96 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 11.4 mm-40 -119.77 -80.68 0.62 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.831 0.348 . . . . 74.12 110.929 -179.885 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 86' ' ' GLU . . . . . 0.458 ' C ' ' HA ' ' A' ' 82' ' ' THR . 69.0 mt-10 -153.01 161.29 42.71 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.143 -0.48 . . . . 72.11 110.901 -179.908 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 87' ' ' ASN . . . . . 0.756 ' HA ' ' C ' ' A' ' 81' ' ' LEU . 1.6 p30 -49.59 122.15 5.99 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.198 -0.455 . . . . 75.12 110.871 -179.99 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 88' ' ' PHE . . . . . 0.857 ' HB2' HD22 ' A' ' 105' ' ' LEU . 15.9 m-85 -131.83 120.01 22.02 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.196 -0.457 . . . . 74.41 110.859 -179.96 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 89' ' ' TRP . . . . . 0.718 ' HA ' ' HA ' ' A' ' 80' ' ' THR . 59.9 p-90 -83.94 136.79 33.94 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.226 -0.443 . . . . 65.01 110.869 -179.972 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 90' ' ' VAL . . . . . 0.556 HG21 HG13 ' A' ' 93' ' ' VAL . 10.1 p -86.92 138.75 18.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.246 -0.434 . . . . 70.42 111.074 179.966 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 91' ' ' ASP . . . . . 0.416 ' H ' HD22 ' A' ' 103' ' ' LEU . 0.7 OUTLIER -70.15 -41.78 73.39 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.177 -0.465 . . . . 61.11 110.76 179.934 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 92' ' ' ARG . . . . . 0.508 ' HB3' HD13 ' A' ' 103' ' ' LEU . 20.0 tpp180 -160.26 138.59 10.16 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.265 -0.425 . . . . 62.53 110.912 -179.826 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 93' ' ' VAL . . . . . 0.838 HG21 HG11 ' A' ' 72' ' ' VAL . 0.0 OUTLIER -126.81 111.9 27.41 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.258 -0.428 . . . . 52.32 111.148 179.936 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 4.0 t -127.25 109.35 21.4 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-O 121.694 0.759 . . . . 64.25 110.88 -179.914 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 95' ' ' PRO . . . . . 0.415 ' HG3' ' HB ' ' A' ' 69' ' ' THR . 53.3 Cg_endo -69.77 156.64 62.8 Favored 'Trans proline' 0 C--O 1.232 0.18 0 C-N-CA 122.649 2.232 . . . . 55.24 112.356 179.983 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 44.4 m-20 -113.67 -24.55 9.14 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.187 -0.46 . . . . 74.42 110.873 179.911 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 3.6 t0 179.04 92.46 0.02 OUTLIER 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 116.229 -0.441 . . . . 72.42 110.9 179.992 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 87.21 58.9 1.81 Allowed Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.705 -0.76 . . . . 75.43 112.491 180.0 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 99' ' ' GLY . . . . . 0.672 ' HA2' HG22 ' A' ' 69' ' ' THR . . . 42.7 81.68 0.03 OUTLIER Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.764 -0.731 . . . . 50.32 112.478 -179.873 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -127.53 6.55 6.27 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.832 0.349 . . . . 73.1 110.881 -179.81 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 101' ' ' CYS . . . . . 0.406 ' HB2' ' CB ' ' A' ' 93' ' ' VAL . 1.6 p -42.37 142.85 0.71 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.145 -0.479 . . . . 73.31 110.868 -179.99 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 102' ' ' HIS . . . . . 0.491 ' HA ' ' O ' ' A' ' 65' ' ' LEU . 46.1 p-80 -161.2 125.55 3.47 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.188 -0.46 . . . . 65.21 110.87 -179.944 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 103' ' ' LEU . . . . . 0.571 HD23 ' N ' ' A' ' 104' ' ' TRP . 9.8 tt -152.04 155.85 38.77 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.201 -0.454 . . . . 71.3 110.873 -179.993 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 104' ' ' TRP . . . . . 0.571 ' N ' HD23 ' A' ' 103' ' ' LEU . 50.2 p-90 -66.23 112.0 3.74 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.136 -0.484 . . . . 74.42 110.981 179.865 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 105' ' ' LEU . . . . . 0.857 HD22 ' HB2' ' A' ' 88' ' ' PHE . 0.3 OUTLIER -87.58 162.24 17.29 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.319 -0.4 . . . . 74.32 110.934 -179.983 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -88.36 160.43 30.54 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.724 -0.75 . . . . 62.0 112.53 179.894 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 107' ' ' ARG . . . . . 0.52 ' HA ' ' CD1' ' A' ' 88' ' ' PHE . 2.5 ptm180 -68.89 158.46 34.5 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.799 0.333 . . . . 64.41 110.845 -179.816 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -173.64 106.79 0.23 Allowed Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.694 -0.765 . . . . 45.2 112.436 -179.966 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 109' ' ' VAL . . . . . 0.443 HG23 ' HD2' ' A' ' 110' ' ' PRO . 8.7 p -91.04 134.01 30.9 Favored Pre-proline 0 C--N 1.33 -0.275 0 CA-C-O 121.644 0.735 . . . . 64.35 111.103 180.0 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 110' ' ' PRO . . . . . 0.552 ' N ' HD21 ' A' ' 87' ' ' ASN . 53.9 Cg_endo -69.75 167.84 23.27 Favored 'Trans proline' 0 C--N 1.341 0.153 0 C-N-CA 122.659 2.239 . . . . 74.12 112.358 179.929 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 111' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.7 -48.64 0.69 Allowed 'Trans proline' 0 C--N 1.341 0.174 0 C-N-CA 122.714 2.276 . . . . 71.31 112.374 179.939 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -109.85 160.98 15.9 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.247 -0.433 . . . . 71.35 111.114 179.881 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 13.6 p -93.63 138.67 19.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.243 -0.435 . . . . 64.14 111.146 179.969 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 114' ' ' ASN . . . . . . . . . . . . . 2.2 p30 -128.4 146.21 50.85 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.247 -0.433 . . . . 73.12 110.934 179.965 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -82.22 103.19 11.63 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.121 -0.491 . . . . 65.23 110.889 -179.953 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 116' ' ' ARG . . . . . . . . . . . . . 16.9 mmm180 -95.44 132.61 40.33 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.24 -0.437 . . . . 63.15 110.843 -179.894 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 8.5 ttt-85 . . . . . 0 C--N 1.33 -0.278 0 CA-C-N 116.241 -0.436 . . . . 74.51 110.884 -179.921 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 29.4 mmm . . . . . 0 C--O 1.231 0.091 0 CA-C-O 120.732 0.301 . . . . 75.31 110.873 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -174.1 -178.66 1.52 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.205 -0.452 . . . . 64.13 111.089 179.976 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 3' ' ' ASP . . . . . . . . . . . . . 3.0 t0 59.75 57.56 3.13 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.185 -0.461 . . . . 74.35 110.901 179.968 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 4' ' ' PHE . . . . . . . . . . . . . 12.3 t80 -72.82 162.09 29.92 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.153 -0.476 . . . . 73.11 110.887 -179.881 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 1.8 t70 -140.14 169.1 18.31 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.238 -0.437 . . . . 75.25 110.944 179.946 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 6' ' ' ASN . . . . . . . . . . . . . 24.7 m120 -133.29 -175.52 3.83 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.244 -0.435 . . . . 65.3 110.897 -179.895 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 7' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -107.73 -179.13 3.82 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.254 -0.43 . . . . 75.23 110.904 179.918 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 8' ' ' PHE . . . . . . . . . . . . . 10.6 p90 -167.14 -175.05 2.83 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.16 -0.473 . . . . 53.25 110.921 179.923 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 6.5 t0 -104.16 171.44 7.34 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.185 -0.461 . . . . 73.32 110.879 -179.996 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . 0.468 ' HB2' ' CE2' ' A' ' 89' ' ' TRP . . . -113.86 -170.41 1.7 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.186 -0.461 . . . . 70.21 111.064 -179.98 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -111.16 177.58 4.62 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.262 -0.426 . . . . 62.43 111.111 179.934 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 4.0 mp -140.07 73.65 0.24 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.242 -0.436 . . . . 62.34 111.153 179.989 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . 0.47 ' HB3' ' HD3' ' A' ' 77' ' ' ARG . . . -153.01 146.72 25.17 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.174 -0.466 . . . . 53.41 111.052 179.881 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -128.39 176.45 7.71 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.2 -0.454 . . . . 73.25 110.835 -179.902 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -154.35 -171.02 3.72 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.172 -0.467 . . . . 75.52 111.067 179.985 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 16.5 p-10 -62.0 -171.49 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.195 -0.457 . . . . 73.1 110.862 -179.99 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 4.8 pt-20 -142.38 176.84 8.69 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.189 -0.459 . . . . 62.32 110.9 -179.906 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 18' ' ' THR . . . . . 0.595 HG21 ' NH2' ' A' ' 20' ' ' ARG . 1.4 p -148.98 175.56 11.19 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.141 -0.481 . . . . 65.44 111.174 -179.924 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 59.5 mt -131.05 96.72 2.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.258 -0.428 . . . . 62.3 111.119 179.872 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 20' ' ' ARG . . . . . 0.595 ' NH2' HG21 ' A' ' 18' ' ' THR . 14.7 ptt180 -176.83 -179.08 0.91 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.182 -0.463 . . . . 72.43 110.845 179.94 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -176.36 -172.24 40.87 Favored Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.706 -0.759 . . . . 44.44 112.482 -179.997 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 22' ' ' TYR . . . . . . . . . . . . . 0.4 OUTLIER -164.08 -169.65 1.9 Allowed 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 120.843 0.354 . . . . 73.13 110.96 -179.844 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 23' ' ' MET . . . . . . . . . . . . . 33.0 mmt -82.34 148.93 28.02 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.112 -0.494 . . . . 73.01 110.913 179.867 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 171.29 -121.94 0.93 Allowed Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.78 -0.724 . . . . 70.5 112.479 -179.972 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 25' ' ' THR . . . . . 0.718 HG21 HG23 ' A' ' 42' ' ' VAL . 85.8 m -122.24 133.29 54.71 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.829 0.347 . . . . 61.22 111.147 -179.858 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -71.41 123.17 21.76 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.212 -0.449 . . . . 75.31 110.898 -179.861 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 27' ' ' ALA . . . . . 0.827 ' HB3' HG23 ' A' ' 39' ' ' ILE . . . -140.03 162.74 34.5 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.122 -0.49 . . . . 63.0 111.113 179.921 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 28' ' ' THR . . . . . 0.501 HG22 ' O ' ' A' ' 28' ' ' THR . 16.9 m -129.6 88.54 2.7 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.246 -0.434 . . . . 73.21 111.116 -179.913 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . 0.766 HG23 ' CB ' ' A' ' 39' ' ' ILE . 2.0 pt -45.12 129.75 1.83 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.385 0 CA-C-N 116.264 -0.425 . . . . 75.51 111.123 179.876 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . 0.711 HG23 ' O ' ' A' ' 35' ' ' SER . 7.0 m -152.97 98.53 2.32 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.24 -0.437 . . . . 74.05 111.179 179.917 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . 0.441 ' OG ' HG22 ' A' ' 80' ' ' THR . 12.1 t -138.38 71.11 1.39 Allowed 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.246 -0.434 . . . . 71.44 110.817 -179.854 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -178.72 168.17 38.99 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.751 -0.738 . . . . 74.23 112.508 179.959 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 15.4 pt-20 -49.38 -23.46 1.49 Allowed 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.781 0.324 . . . . 53.42 110.835 -179.844 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 4.8 tt0 -174.68 94.84 0.08 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.166 -0.47 . . . . 52.13 110.907 -179.916 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 35' ' ' SER . . . . . 0.711 ' O ' HG23 ' A' ' 30' ' ' THR . 3.3 m -144.97 165.71 27.4 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.214 -0.448 . . . . 70.14 110.891 -179.834 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 178.35 88.21 0.07 OUTLIER Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.811 -0.709 . . . . 63.42 112.505 -179.977 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . 0.666 ' HB3' ' CD1' ' A' ' 29' ' ' ILE . . . -109.6 -172.81 2.12 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.849 0.357 . . . . 44.03 111.088 -179.984 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 61.9 t -97.75 121.9 48.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.238 -0.437 . . . . 62.4 111.123 179.962 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 39' ' ' ILE . . . . . 0.827 HG23 ' HB3' ' A' ' 27' ' ' ALA . 0.0 OUTLIER -137.62 150.12 25.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.126 -0.488 . . . . 74.32 111.157 179.898 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 40' ' ' ARG . . . . . 0.657 ' O ' HG12 ' A' ' 67' ' ' VAL . 5.4 ttm180 -109.69 80.3 1.3 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.24 -0.436 . . . . 73.0 110.873 179.987 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . 0.499 ' N ' HD13 ' A' ' 39' ' ' ILE . . . -129.18 147.44 17.75 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.774 -0.727 . . . . 74.14 112.46 -179.955 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 42' ' ' VAL . . . . . 0.718 HG23 HG21 ' A' ' 25' ' ' THR . 2.8 p -126.49 136.59 60.37 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-O 120.845 0.355 . . . . 74.12 111.072 -179.971 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 43' ' ' PHE . . . . . 0.658 ' H ' HD11 ' A' ' 83' ' ' ILE . 1.3 p90 -93.72 130.77 39.57 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.218 -0.446 . . . . 73.12 110.872 179.96 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 12.6 t70 -117.04 124.76 50.08 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.121 -0.49 . . . . 61.12 110.87 179.956 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -122.51 149.94 56.59 Favored Pre-proline 0 C--N 1.328 -0.327 0 CA-C-O 121.575 0.702 . . . . 73.33 110.877 179.999 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 46' ' ' PRO . . . . . . . . . . . . . 52.5 Cg_endo -69.93 -39.03 6.65 Favored 'Trans proline' 0 C--O 1.232 0.186 0 C-N-CA 122.689 2.259 . . . . 73.5 112.297 -179.94 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 17.1 tt0 -161.76 95.92 1.01 Allowed 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.29 -0.414 . . . . 73.14 110.891 179.96 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 19.8 t-20 -52.47 106.84 0.17 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.116 -0.493 . . . . 73.24 110.908 -179.913 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 26.0 mm -70.03 149.96 10.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.117 -0.492 . . . . 72.13 111.143 179.942 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 20.4 t -112.15 131.39 55.48 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.241 -0.436 . . . . 72.4 110.776 -179.855 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 45.7 p90 -75.35 177.28 6.71 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.11 -0.495 . . . . 62.34 110.964 -179.934 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -111.27 -67.22 1.01 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.137 -0.483 . . . . 75.55 111.133 179.854 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -170.26 -116.16 0.37 Allowed Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.797 -0.716 . . . . 65.43 112.574 -179.993 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 54' ' ' GLN . . . . . . . . . . . . . 5.2 tt0 -82.56 57.93 3.96 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.872 0.368 . . . . 72.41 110.952 -179.959 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -164.91 100.69 0.18 Allowed Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.665 -0.778 . . . . 50.02 112.46 -179.993 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . 0.71 HG12 ' H ' ' A' ' 58' ' ' VAL . 39.2 t -63.31 124.58 18.22 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-O 120.758 0.313 . . . . 61.33 111.213 -179.998 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -59.88 -23.0 63.09 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.204 -0.453 . . . . 64.23 110.884 -179.936 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 58' ' ' VAL . . . . . 0.71 ' H ' HG12 ' A' ' 56' ' ' VAL . 21.0 t 64.31 63.16 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-N 116.19 -0.459 . . . . 71.13 111.122 179.955 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 46.4 tt0 -170.37 147.51 3.04 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.122 -0.49 . . . . 74.22 110.891 -179.992 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -145.98 120.72 1.36 Allowed Glycine 0 N--CA 1.45 -0.433 0 C-N-CA 120.786 -0.721 . . . . 71.24 112.499 -179.923 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 1.7 t -89.95 155.4 19.14 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.869 0.366 . . . . 41.44 110.907 -179.758 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . 0.413 ' HA ' ' HD2' ' A' ' 63' ' ' PRO . 1.9 p -106.14 97.72 16.7 Favored Pre-proline 0 C--N 1.33 -0.267 0 CA-C-O 121.669 0.747 . . . . 73.52 110.886 -179.804 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 63' ' ' PRO . . . . . 0.413 ' HD2' ' HA ' ' A' ' 62' ' ' SER . 53.1 Cg_endo -69.78 -178.0 2.15 Favored 'Trans proline' 0 C--N 1.342 0.198 0 C-N-CA 122.679 2.253 . . . . 55.25 112.315 -179.988 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . 0.502 ' O ' ' HA ' ' A' ' 43' ' ' PHE . 1.5 t -106.32 148.15 28.36 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.222 -0.444 . . . . 62.24 110.915 -179.922 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 65' ' ' LEU . . . . . 0.666 ' O ' HD23 ' A' ' 65' ' ' LEU . 0.0 OUTLIER -112.68 140.45 47.44 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.118 -0.492 . . . . 63.01 110.901 179.996 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 66' ' ' PHE . . . . . 0.63 ' HB3' HG12 ' A' ' 42' ' ' VAL . 17.8 t80 -118.47 107.97 14.45 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.156 -0.475 . . . . 70.55 110.896 179.904 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 67' ' ' VAL . . . . . 0.657 HG12 ' O ' ' A' ' 40' ' ' ARG . 4.3 m -141.98 166.79 16.4 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.18 -0.463 . . . . 75.54 111.057 -179.949 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 68' ' ' ARG . . . . . 0.619 ' O ' HG23 ' A' ' 72' ' ' VAL . 2.8 ttm180 -103.23 144.19 31.66 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.156 -0.475 . . . . 72.15 110.921 179.984 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 69' ' ' THR . . . . . 0.403 ' HB ' ' HG3' ' A' ' 95' ' ' PRO . 2.0 t -40.32 -47.3 2.48 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.245 -0.434 . . . . 73.0 111.138 -179.92 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 46.8 m-20 -52.97 -62.03 1.92 Allowed 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.224 -0.444 . . . . 72.4 110.859 179.924 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 71' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -53.39 -40.44 65.04 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.235 -0.439 . . . . 64.44 110.903 -179.915 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 72' ' ' VAL . . . . . 0.619 HG23 ' O ' ' A' ' 68' ' ' ARG . 14.4 t -69.39 -33.84 59.49 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.125 -0.489 . . . . 70.52 111.12 179.946 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 73' ' ' ARG . . . . . . . . . . . . . 18.9 ttm180 -62.17 -39.89 94.19 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.205 -0.452 . . . . 73.05 110.836 -179.96 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 29.9 mt-30 -55.04 -22.58 16.28 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.219 -0.446 . . . . 72.12 110.874 -179.932 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 75' ' ' LEU . . . . . 0.511 HD21 HG21 ' A' ' 29' ' ' ILE . 4.5 mp -113.03 -168.73 1.36 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.234 -0.439 . . . . 73.41 110.912 -179.969 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 76' ' ' ARG . . . . . . . . . . . . . 11.1 ptp180 -124.12 -178.96 4.24 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.182 -0.463 . . . . 74.22 110.871 179.974 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 77' ' ' ARG . . . . . 0.47 ' HD3' ' HB3' ' A' ' 13' ' ' ALA . 4.7 mtp180 -70.05 130.56 42.48 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.155 -0.475 . . . . 74.33 110.926 -179.957 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . 0.401 ' HA2' ' CD1' ' A' ' 89' ' ' TRP . . . 92.42 36.47 6.2 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.767 -0.73 . . . . 33.52 112.453 -179.976 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . 0.486 ' OD1' HD23 ' A' ' 75' ' ' LEU . 0.6 OUTLIER -99.13 105.46 17.55 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.859 0.362 . . . . 71.15 110.926 179.994 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . 0.742 ' HA ' ' HA ' ' A' ' 89' ' ' TRP . 0.8 OUTLIER -89.61 108.56 19.74 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.199 -0.455 . . . . 70.44 111.102 -179.851 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 81' ' ' LEU . . . . . 0.768 ' C ' ' HA ' ' A' ' 87' ' ' ASN . 0.0 OUTLIER -96.05 135.42 37.85 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.132 -0.485 . . . . 71.24 110.93 179.956 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 82' ' ' THR . . . . . 0.714 ' CA ' ' HA ' ' A' ' 87' ' ' ASN . 8.9 t -94.99 101.64 13.41 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.267 -0.424 . . . . 73.45 111.124 179.958 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 83' ' ' ILE . . . . . 0.732 HD13 ' O ' ' A' ' 83' ' ' ILE . 0.1 OUTLIER -135.58 132.58 51.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.236 -0.438 . . . . 73.14 111.128 179.913 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 73.08 -54.37 1.81 Allowed Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.761 -0.733 . . . . 65.53 112.486 179.936 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 3.0 mm-40 -115.54 -83.18 0.62 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.787 0.327 . . . . 54.43 110.837 -179.829 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 86' ' ' GLU . . . . . . . . . . . . . 7.6 mp0 -150.02 159.45 44.39 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.195 -0.457 . . . . 61.43 110.883 -179.946 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 87' ' ' ASN . . . . . 0.768 ' HA ' ' C ' ' A' ' 81' ' ' LEU . 0.7 OUTLIER -50.28 124.05 9.66 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.152 -0.476 . . . . 63.13 110.876 -179.868 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 88' ' ' PHE . . . . . 0.748 ' HB3' HD13 ' A' ' 105' ' ' LEU . 15.9 m-85 -131.09 119.61 22.2 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.113 -0.494 . . . . 73.55 110.857 -179.956 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 89' ' ' TRP . . . . . 0.742 ' HA ' ' HA ' ' A' ' 80' ' ' THR . 0.0 OUTLIER -79.23 135.55 36.81 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 116.121 -0.491 . . . . 72.01 110.921 -179.993 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 90' ' ' VAL . . . . . 0.682 HG21 HG13 ' A' ' 93' ' ' VAL . 3.0 p -91.55 136.08 25.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.207 -0.451 . . . . 72.34 111.161 179.951 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -63.24 -72.35 0.14 Allowed 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.185 -0.461 . . . . 71.21 110.888 179.926 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 92' ' ' ARG . . . . . 0.569 ' O ' ' HG ' ' A' ' 103' ' ' LEU . 9.0 ptm180 -159.71 122.12 3.43 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.164 -0.471 . . . . 74.32 110.954 -179.936 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 93' ' ' VAL . . . . . 0.699 HG12 ' HB2' ' A' ' 103' ' ' LEU . 26.0 m -113.63 136.88 48.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.191 -0.459 . . . . 72.42 111.083 -179.956 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 94' ' ' SER . . . . . 0.423 ' HA ' ' HD2' ' A' ' 95' ' ' PRO . 7.0 t -129.32 100.31 20.31 Favored Pre-proline 0 C--N 1.329 -0.307 0 CA-C-O 121.673 0.749 . . . . 41.05 110.821 -179.84 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 95' ' ' PRO . . . . . 0.423 ' HD2' ' HA ' ' A' ' 94' ' ' SER . 53.5 Cg_endo -69.81 169.59 18.62 Favored 'Trans proline' 0 C--N 1.342 0.186 0 C-N-CA 122.629 2.22 . . . . 75.43 112.312 179.958 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 11.7 t0 -129.64 1.58 4.96 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.186 -0.461 . . . . 75.2 110.837 179.923 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 4.5 p30 -139.27 29.29 2.22 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.196 -0.457 . . . . 72.01 110.859 179.98 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 51.04 55.95 16.42 Favored Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.759 -0.734 . . . . 53.4 112.469 -179.953 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 99' ' ' GLY . . . . . 0.426 ' HA2' ' HG3' ' A' ' 68' ' ' ARG . . . 145.05 35.21 0.07 OUTLIER Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.655 -0.783 . . . . 72.21 112.495 -179.904 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 46.7 t -151.61 71.31 0.98 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.791 0.329 . . . . 73.53 110.878 -179.675 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 101' ' ' CYS . . . . . 0.463 ' CB ' ' HB ' ' A' ' 93' ' ' VAL . 0.0 OUTLIER -110.16 148.54 31.59 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.131 -0.486 . . . . 75.21 110.931 -179.976 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 102' ' ' HIS . . . . . 0.613 ' HA ' ' O ' ' A' ' 65' ' ' LEU . 24.8 p80 -160.37 126.28 4.06 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.225 -0.443 . . . . 64.24 110.953 179.99 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 103' ' ' LEU . . . . . 0.926 HD13 ' N ' ' A' ' 104' ' ' TRP . 2.5 tm? -151.22 147.55 27.14 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.272 -0.422 . . . . 62.45 110.926 -179.96 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 104' ' ' TRP . . . . . 0.926 ' N ' HD13 ' A' ' 103' ' ' LEU . 22.2 m-90 -63.43 114.45 3.88 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 116.208 -0.451 . . . . 71.24 110.922 179.91 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 105' ' ' LEU . . . . . 0.748 HD13 ' HB3' ' A' ' 88' ' ' PHE . 0.3 OUTLIER -93.7 162.0 14.11 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.255 -0.43 . . . . 63.22 110.912 -179.987 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -88.83 160.63 30.12 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.741 -0.743 . . . . 75.5 112.523 179.878 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 107' ' ' ARG . . . . . 0.57 ' HA ' ' CD1' ' A' ' 88' ' ' PHE . 3.1 ptt85 -67.9 157.31 35.23 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.858 0.361 . . . . 74.24 110.893 -179.887 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -173.97 110.52 0.33 Allowed Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.756 -0.735 . . . . 72.14 112.478 -179.979 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 109' ' ' VAL . . . . . 0.475 HG13 ' HD2' ' A' ' 110' ' ' PRO . 58.1 t -84.72 134.46 41.92 Favored Pre-proline 0 C--N 1.33 -0.276 0 CA-C-O 121.629 0.728 . . . . 72.4 111.135 -179.988 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 110' ' ' PRO . . . . . 0.475 ' HD2' HG13 ' A' ' 109' ' ' VAL . 52.6 Cg_endo -69.85 170.0 17.71 Favored 'Trans proline' 0 C--N 1.341 0.173 0 C-N-CA 122.675 2.25 . . . . 63.15 112.263 -179.971 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 111' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.77 -4.47 14.11 Favored 'Trans proline' 0 C--N 1.342 0.232 0 C-N-CA 122.697 2.265 . . . . 72.02 112.289 -179.98 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -58.16 162.16 3.68 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.246 -0.434 . . . . 40.22 111.082 179.899 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 113' ' ' VAL . . . . . 0.422 ' O ' HG13 ' A' ' 113' ' ' VAL . 5.3 p -91.81 119.62 39.49 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 CA-C-N 116.165 -0.471 . . . . 70.25 111.117 -179.984 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 114' ' ' ASN . . . . . . . . . . . . . 5.5 t30 -128.75 146.82 50.79 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.145 -0.479 . . . . 71.34 110.863 179.974 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 5.2 mmt180 -81.66 101.95 10.38 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.141 -0.481 . . . . 74.25 110.881 -179.985 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 116' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -116.3 139.5 50.32 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.198 -0.455 . . . . 71.42 110.811 -179.918 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 3.3 mtt180 . . . . . 0 C--N 1.329 -0.295 0 CA-C-N 116.186 -0.461 . . . . 74.54 110.852 -179.898 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 12.0 mmt . . . . . 0 N--CA 1.458 -0.04 0 CA-C-O 120.78 0.324 . . . . 64.32 110.861 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -171.69 173.68 4.53 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.226 -0.443 . . . . 54.31 111.101 179.941 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 3' ' ' ASP . . . . . . . . . . . . . 3.7 p-10 -161.11 179.84 8.08 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.202 -0.454 . . . . 72.32 110.841 179.977 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 4' ' ' PHE . . . . . . . . . . . . . 51.1 p90 -174.26 156.38 2.57 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.157 -0.474 . . . . 75.24 110.857 -179.907 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 3.7 m-20 -142.81 153.09 42.89 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.159 -0.473 . . . . 74.43 110.894 179.993 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 6' ' ' ASN . . . . . . . . . . . . . 3.5 p-10 -138.24 111.73 8.13 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.239 -0.437 . . . . 72.12 110.87 -179.916 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 7' ' ' LEU . . . . . . . . . . . . . 3.5 mm? -51.5 163.35 0.28 Allowed 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.106 -0.497 . . . . 53.25 110.835 179.99 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 8' ' ' PHE . . . . . . . . . . . . . 67.4 m-85 -125.9 115.01 19.28 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.152 -0.477 . . . . 62.42 110.876 179.966 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 9.1 m-20 -71.01 83.45 0.68 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.17 -0.468 . . . . 60.51 110.886 179.966 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -114.89 148.47 38.58 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.13 -0.486 . . . . 72.43 111.064 179.99 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -79.31 104.34 9.86 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.251 -0.431 . . . . 62.23 111.133 179.925 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 29.9 mt -123.83 64.9 0.29 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.356 0 CA-C-N 116.229 -0.441 . . . . 71.51 111.161 179.96 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -171.32 124.63 0.61 Allowed 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.177 -0.465 . . . . 64.31 111.093 179.835 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 9.7 mpt_? -92.87 62.0 3.61 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.151 -0.477 . . . . 72.21 110.876 -179.884 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -134.63 -176.33 4.19 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.11 -0.496 . . . . 71.34 111.077 179.996 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 11.2 p-10 -104.52 112.38 25.42 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.192 -0.458 . . . . 72.14 110.88 179.984 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 5.5 pt-20 -134.04 158.65 43.01 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.21 -0.45 . . . . 75.42 110.966 -179.962 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -156.81 173.99 16.15 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.193 -0.458 . . . . 73.1 111.165 -179.912 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . 0.442 ' O ' HG23 ' A' ' 19' ' ' ILE . 8.5 tt -134.29 109.71 12.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.241 -0.436 . . . . 65.53 111.115 179.914 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 20' ' ' ARG . . . . . 0.508 HH12 HG21 ' A' ' 38' ' ' VAL . 52.5 mtp180 -96.14 143.8 26.94 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.117 -0.492 . . . . 70.32 110.836 -179.989 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 161.37 118.45 0.48 Allowed Glycine 0 C--N 1.33 0.238 0 C-N-CA 120.728 -0.748 . . . . 50.15 112.416 -179.983 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 22' ' ' TYR . . . . . . . . . . . . . 0.5 OUTLIER -136.16 -53.39 0.74 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.849 0.356 . . . . 74.42 110.873 -179.822 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 23' ' ' MET . . . . . . . . . . . . . 2.3 tpt -80.71 -59.73 2.57 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.156 -0.475 . . . . 73.32 110.869 179.916 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 126.53 -17.53 6.5 Favored Glycine 0 N--CA 1.452 -0.279 0 C-N-CA 120.685 -0.769 . . . . 51.35 112.482 -179.935 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 25' ' ' THR . . . . . 0.594 ' O ' ' HA ' ' A' ' 40' ' ' ARG . 60.7 p -94.42 107.49 19.46 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.785 0.326 . . . . 74.32 111.139 -179.85 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -77.53 121.76 24.32 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.227 -0.442 . . . . 62.44 110.849 -179.822 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 27' ' ' ALA . . . . . 0.793 ' HB3' HG23 ' A' ' 39' ' ' ILE . . . -151.7 161.46 42.64 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.123 -0.489 . . . . 63.51 111.132 179.891 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 28' ' ' THR . . . . . 0.537 HG22 ' O ' ' A' ' 28' ' ' THR . 11.0 m -130.84 88.87 2.67 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.177 -0.465 . . . . 75.24 111.117 -179.852 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . 0.798 HG23 ' CB ' ' A' ' 39' ' ' ILE . 1.7 pt -43.49 128.75 1.11 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.198 -0.456 . . . . 72.43 111.133 179.902 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . 0.688 HG23 ' O ' ' A' ' 35' ' ' SER . 7.1 m -153.76 99.0 2.25 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.199 -0.455 . . . . 70.31 111.148 179.949 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 18.7 t -140.8 72.94 1.4 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.222 -0.444 . . . . 62.43 110.845 -179.84 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -178.53 166.57 36.51 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.72 -0.753 . . . . 70.14 112.512 -179.968 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 10.6 pt-20 -48.96 -23.72 1.23 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.738 0.304 . . . . 74.11 110.873 -179.892 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 4.1 tt0 -174.1 93.5 0.09 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.15 -0.477 . . . . 62.41 110.944 -179.949 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 35' ' ' SER . . . . . 0.688 ' O ' HG23 ' A' ' 30' ' ' THR . 2.0 m -144.87 165.53 27.87 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.243 -0.435 . . . . 73.51 110.84 -179.791 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -179.86 85.21 0.06 OUTLIER Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.746 -0.74 . . . . 74.31 112.513 179.936 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . 0.619 ' HB3' ' CD1' ' A' ' 29' ' ' ILE . . . -106.93 -173.83 2.39 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.886 0.374 . . . . 54.05 111.1 -179.996 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . 0.508 HG21 HH12 ' A' ' 20' ' ' ARG . 57.5 t -99.36 124.85 52.92 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.171 -0.468 . . . . 74.04 111.124 179.99 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 39' ' ' ILE . . . . . 0.798 ' CB ' HG23 ' A' ' 29' ' ' ILE . 0.0 OUTLIER -137.15 149.35 26.05 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 116.223 -0.444 . . . . 73.24 111.111 179.97 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 40' ' ' ARG . . . . . 0.665 ' O ' HG12 ' A' ' 67' ' ' VAL . 0.2 OUTLIER -107.84 82.02 1.59 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.192 -0.458 . . . . 74.33 110.907 179.931 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . 0.608 ' O ' ' HB2' ' A' ' 27' ' ' ALA . . . -141.6 142.75 12.26 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.685 -0.769 . . . . 43.24 112.482 -179.94 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 42' ' ' VAL . . . . . 0.545 ' O ' ' HA ' ' A' ' 65' ' ' LEU . 9.0 p -128.57 141.3 46.91 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-O 120.815 0.34 . . . . 74.43 111.144 -179.939 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 43' ' ' PHE . . . . . 0.784 ' H ' HD11 ' A' ' 83' ' ' ILE . 1.8 p90 -90.28 135.88 33.4 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.228 -0.442 . . . . 73.24 110.938 179.964 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 11.4 t70 -126.15 125.27 42.21 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.221 -0.445 . . . . 71.14 110.852 179.99 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -101.17 153.27 37.88 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-O 121.619 0.723 . . . . 75.32 110.855 179.943 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 46' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_endo -69.73 -48.15 0.79 Allowed 'Trans proline' 0 C--N 1.341 0.158 0 C-N-CA 122.715 2.277 . . . . 63.32 112.334 179.991 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 25.0 tt0 -178.86 105.91 0.04 OUTLIER 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.247 -0.433 . . . . 74.33 110.881 -179.95 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 11.2 t30 -51.86 105.35 0.11 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.228 -0.442 . . . . 73.14 110.883 -179.936 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 10.1 tp -72.25 143.48 14.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.145 -0.48 . . . . 63.42 111.139 179.923 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 3.0 t -107.79 -170.61 1.72 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.157 -0.474 . . . . 75.44 110.904 -179.917 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 43.9 t80 -52.54 158.41 1.27 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.165 -0.47 . . . . 74.25 110.912 -179.865 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -123.46 -74.48 0.61 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.159 -0.473 . . . . 55.32 111.099 179.907 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 111.8 38.83 1.37 Allowed Glycine 0 N--CA 1.452 -0.249 0 C-N-CA 120.723 -0.751 . . . . 62.44 112.437 -179.985 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 54' ' ' GLN . . . . . . . . . . . . . 24.8 mt-30 -126.1 -37.77 2.22 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.927 0.394 . . . . 61.41 110.948 -179.919 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 120.33 19.39 3.88 Favored Glycine 0 N--CA 1.452 -0.272 0 C-N-CA 120.674 -0.774 . . . . 74.44 112.502 -179.938 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 22.3 t -137.33 92.28 0.88 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-O 120.839 0.352 . . . . 70.25 111.097 -179.857 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 8.8 mpt_? -57.68 170.66 0.55 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.208 -0.451 . . . . 74.03 110.797 -179.968 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 11.2 p -51.63 147.06 1.6 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.136 -0.484 . . . . 71.02 111.124 179.978 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -80.27 -75.18 0.27 Allowed 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.174 -0.467 . . . . 65.1 110.886 179.99 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -150.14 149.19 21.05 Favored Glycine 0 N--CA 1.452 -0.267 0 C-N-CA 120.677 -0.773 . . . . 33.23 112.477 -179.945 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -124.48 125.42 44.21 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.853 0.358 . . . . 74.52 110.855 -179.732 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 89.3 p -129.19 97.88 24.85 Favored Pre-proline 0 C--N 1.328 -0.328 0 CA-C-O 121.666 0.746 . . . . 73.23 110.895 -179.886 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.74 166.18 28.44 Favored 'Trans proline' 0 C--N 1.341 0.162 0 C-N-CA 122.638 2.225 . . . . 71.05 112.327 -179.994 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 3.5 t -106.92 142.87 35.85 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.196 -0.456 . . . . 75.22 110.842 -179.839 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 65' ' ' LEU . . . . . 0.613 ' O ' HD23 ' A' ' 65' ' ' LEU . 0.0 OUTLIER -114.88 119.76 37.67 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.163 -0.471 . . . . 60.25 110.926 -179.991 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 56.0 t80 -101.76 109.81 21.66 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.226 -0.443 . . . . 54.24 110.85 179.98 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 67' ' ' VAL . . . . . 0.665 HG12 ' O ' ' A' ' 40' ' ' ARG . 22.3 m -138.13 169.2 18.9 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.159 -0.473 . . . . 64.43 111.163 179.895 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 68' ' ' ARG . . . . . 0.469 ' O ' HG23 ' A' ' 72' ' ' VAL . 1.1 ttp180 -93.43 143.82 25.92 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.191 -0.459 . . . . 64.22 110.919 -179.983 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 69' ' ' THR . . . . . 0.442 HG22 ' HA2' ' A' ' 99' ' ' GLY . 2.4 t -45.47 -47.74 13.95 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.241 -0.436 . . . . 74.53 111.039 -179.868 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 70' ' ' ASP . . . . . 0.411 ' N ' HG23 ' A' ' 69' ' ' THR . 30.5 t70 -52.18 -52.84 49.56 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.197 -0.456 . . . . 75.13 110.923 179.928 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 71' ' ' GLU . . . . . . . . . . . . . 66.0 mm-40 -54.41 -39.29 67.16 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.246 -0.434 . . . . 75.24 110.909 -179.947 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 72' ' ' VAL . . . . . 0.469 HG23 ' O ' ' A' ' 68' ' ' ARG . 4.4 t -73.49 -38.45 52.7 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.16 -0.473 . . . . 74.22 111.172 179.925 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 73' ' ' ARG . . . . . . . . . . . . . 2.6 tmt_? -55.69 -40.02 71.79 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.187 -0.46 . . . . 74.12 110.907 -179.985 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 41.7 mt-30 -52.64 -25.86 12.0 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.245 -0.434 . . . . 71.24 110.962 -179.995 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 75' ' ' LEU . . . . . 0.496 HD21 ' CD1' ' A' ' 29' ' ' ILE . 2.5 mp -116.25 -166.64 1.17 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.163 -0.472 . . . . 62.3 110.951 179.942 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 76' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -112.35 -178.67 3.47 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.204 -0.453 . . . . 74.34 110.845 179.925 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -76.05 125.89 29.97 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.184 -0.462 . . . . 72.31 110.925 -179.929 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 99.77 23.94 10.39 Favored Glycine 0 N--CA 1.45 -0.383 0 C-N-CA 120.768 -0.729 . . . . 34.42 112.505 -179.912 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -82.63 109.31 16.7 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.876 0.369 . . . . 73.02 110.916 179.968 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . 0.737 ' HA ' ' HA ' ' A' ' 89' ' ' TRP . 0.5 OUTLIER -88.37 109.64 20.15 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.209 -0.45 . . . . 71.34 111.16 -179.906 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 81' ' ' LEU . . . . . 0.806 ' C ' ' HA ' ' A' ' 87' ' ' ASN . 0.0 OUTLIER -96.82 134.37 40.21 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 116.227 -0.442 . . . . 55.44 110.956 179.949 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 82' ' ' THR . . . . . 0.729 ' CA ' ' HA ' ' A' ' 87' ' ' ASN . 4.9 t -92.63 101.79 14.21 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.187 -0.461 . . . . 72.12 111.183 179.975 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 83' ' ' ILE . . . . . 0.784 HD11 ' H ' ' A' ' 43' ' ' PHE . 0.1 OUTLIER -132.92 130.45 58.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.219 -0.446 . . . . 74.12 111.118 179.975 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 70.42 -62.37 0.83 Allowed Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.749 -0.739 . . . . 75.03 112.458 179.924 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 10.1 tp10 -103.07 -81.83 0.5 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.806 0.336 . . . . 75.45 110.908 -179.891 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 86' ' ' GLU . . . . . 0.427 ' C ' ' HA ' ' A' ' 82' ' ' THR . 95.7 mt-10 -152.91 160.7 43.07 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.143 -0.48 . . . . 73.43 110.923 -179.923 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 87' ' ' ASN . . . . . 0.806 ' HA ' ' C ' ' A' ' 81' ' ' LEU . 1.3 p-10 -51.55 124.64 12.62 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.153 -0.476 . . . . 60.32 110.893 -179.908 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 88' ' ' PHE . . . . . 0.634 ' HB2' HD22 ' A' ' 105' ' ' LEU . 15.3 m-85 -132.77 120.27 21.4 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.176 -0.465 . . . . 74.42 110.932 179.999 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 89' ' ' TRP . . . . . 0.737 ' HA ' ' HA ' ' A' ' 80' ' ' THR . 7.1 p90 -80.01 137.0 36.72 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.179 -0.464 . . . . 64.43 111.005 -179.981 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 90' ' ' VAL . . . . . 0.569 HG21 ' CG1' ' A' ' 93' ' ' VAL . 7.2 p -89.64 135.97 24.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.318 -0.401 . . . . 62.44 111.161 179.893 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 91' ' ' ASP . . . . . 0.422 ' HB3' HD12 ' A' ' 103' ' ' LEU . 0.0 OUTLIER -64.28 -67.76 0.41 Allowed 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.155 -0.475 . . . . 73.2 110.907 179.891 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 92' ' ' ARG . . . . . 0.646 ' O ' ' HG ' ' A' ' 103' ' ' LEU . 13.3 ttm-85 -162.76 122.26 2.25 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.238 -0.437 . . . . 75.24 110.897 -179.939 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 93' ' ' VAL . . . . . 0.741 HG12 ' HB2' ' A' ' 103' ' ' LEU . 22.7 m -117.9 135.42 58.37 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.144 -0.48 . . . . 73.13 111.111 179.966 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 94' ' ' SER . . . . . 0.425 ' HA ' ' HD2' ' A' ' 95' ' ' PRO . 1.1 p -129.36 103.24 18.12 Favored Pre-proline 0 C--N 1.329 -0.285 0 CA-C-O 121.585 0.707 . . . . 65.45 110.856 -179.823 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 95' ' ' PRO . . . . . 0.425 ' HD2' ' HA ' ' A' ' 94' ' ' SER . 53.6 Cg_endo -69.76 -176.15 1.39 Allowed 'Trans proline' 0 C--O 1.231 0.142 0 C-N-CA 122.657 2.238 . . . . 74.3 112.31 -179.947 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 66.5 m-20 -124.66 -36.25 2.62 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.185 -0.461 . . . . 74.42 110.853 179.962 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 4.5 t70 177.7 117.65 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.199 -0.455 . . . . 72.14 110.858 179.959 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 93.22 39.74 5.02 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.724 -0.75 . . . . 61.15 112.516 -179.894 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 99' ' ' GLY . . . . . 0.442 ' HA2' HG22 ' A' ' 69' ' ' THR . . . 46.62 68.4 1.12 Allowed Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.699 -0.762 . . . . 74.15 112.5 -179.889 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 1.7 m -125.29 71.67 1.21 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.89 0.376 . . . . 74.25 110.874 -179.755 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 101' ' ' CYS . . . . . 0.485 ' CB ' ' HB ' ' A' ' 93' ' ' VAL . 0.0 OUTLIER -106.0 150.02 26.1 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.128 -0.487 . . . . 65.52 110.886 -179.939 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 102' ' ' HIS . . . . . 0.526 ' HA ' ' O ' ' A' ' 65' ' ' LEU . 19.6 p-80 -160.92 123.54 3.19 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.198 -0.456 . . . . 74.11 110.89 -179.951 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 103' ' ' LEU . . . . . 0.841 HD13 ' N ' ' A' ' 104' ' ' TRP . 2.1 tm? -152.91 147.67 26.25 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.203 -0.453 . . . . 73.15 110.918 -179.964 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 104' ' ' TRP . . . . . 0.841 ' N ' HD13 ' A' ' 103' ' ' LEU . 30.9 p90 -63.99 117.52 7.15 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 116.178 -0.465 . . . . 74.21 110.891 179.951 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 105' ' ' LEU . . . . . 0.634 HD22 ' HB2' ' A' ' 88' ' ' PHE . 0.3 OUTLIER -94.12 162.92 13.68 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 116.268 -0.424 . . . . 71.44 110.928 179.989 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -88.84 159.74 29.39 Favored Glycine 0 N--CA 1.453 -0.219 0 C-N-CA 120.705 -0.76 . . . . 61.33 112.477 179.9 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 107' ' ' ARG . . . . . 0.554 ' HA ' ' CD1' ' A' ' 88' ' ' PHE . 4.3 ptp180 -66.84 157.29 33.42 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.847 0.356 . . . . 74.13 110.883 -179.882 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -173.1 111.61 0.39 Allowed Glycine 0 N--CA 1.452 -0.272 0 C-N-CA 120.717 -0.754 . . . . 42.4 112.468 -179.916 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 109' ' ' VAL . . . . . 0.448 HG23 ' HD2' ' A' ' 110' ' ' PRO . 7.2 p -86.42 133.96 39.2 Favored Pre-proline 0 C--N 1.33 -0.264 0 CA-C-O 121.567 0.698 . . . . 64.44 111.157 179.999 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 110' ' ' PRO . . . . . 0.448 ' HD2' HG23 ' A' ' 109' ' ' VAL . 53.1 Cg_endo -69.76 167.53 24.17 Favored 'Trans proline' 0 C--O 1.232 0.175 0 C-N-CA 122.635 2.224 . . . . 72.32 112.328 179.987 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 111' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.8 -18.08 37.04 Favored 'Trans proline' 0 C--N 1.342 0.201 0 C-N-CA 122.685 2.256 . . . . 45.44 112.312 179.963 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -75.42 138.33 41.61 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.221 -0.445 . . . . 74.42 111.068 179.955 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 8.4 p -125.04 139.03 52.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.207 -0.451 . . . . 74.33 111.111 -179.951 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 114' ' ' ASN . . . . . . . . . . . . . 16.7 t30 -107.29 122.94 47.57 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.169 -0.469 . . . . 65.51 110.95 179.986 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 3.2 ptm180 -107.65 140.47 40.63 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.207 -0.452 . . . . 72.25 110.929 -179.992 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 116' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -114.47 135.37 54.18 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.221 -0.445 . . . . 75.23 110.894 -179.886 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 3.9 tmm_? . . . . . 0 C--N 1.329 -0.296 0 CA-C-N 116.156 -0.475 . . . . 70.55 110.894 -179.883 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 2.0 mpt? . . . . . 0 C--O 1.23 0.065 0 CA-C-O 120.824 0.345 . . . . 73.23 110.857 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -166.25 163.26 17.74 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.196 -0.456 . . . . 71.24 111.123 179.961 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 3' ' ' ASP . . . . . . . . . . . . . 14.7 m-20 -137.57 -178.64 5.32 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.305 -0.407 . . . . 71.35 110.886 179.914 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 4' ' ' PHE . . . . . . . . . . . . . 66.2 m-85 -152.04 -175.72 5.36 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.194 -0.457 . . . . 70.44 110.862 -179.915 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 6.4 t0 -162.81 177.59 9.17 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.152 -0.476 . . . . 41.24 110.89 -179.985 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 6' ' ' ASN . . . . . . . . . . . . . 2.2 p30 -152.83 176.02 12.26 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.156 -0.475 . . . . 70.2 110.89 -179.898 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 7' ' ' LEU . . . . . . . . . . . . . 4.8 mp -127.15 -67.63 0.83 Allowed 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.178 -0.465 . . . . 72.42 110.976 179.948 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 8' ' ' PHE . . . . . . . . . . . . . 8.2 m-85 57.17 51.74 9.89 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.192 -0.458 . . . . 62.44 110.922 179.92 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 77.1 m-20 -75.23 -175.05 2.54 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.166 -0.47 . . . . 64.55 110.866 179.984 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -150.39 177.28 10.13 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.138 -0.483 . . . . 54.04 111.074 179.921 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -160.11 177.8 10.32 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.171 -0.468 . . . . 31.44 111.099 -179.993 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -132.25 -154.67 0.14 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.23 -0.441 . . . . 72.4 111.139 -179.98 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -173.68 178.34 2.29 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.194 -0.457 . . . . 64.54 111.081 179.842 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -155.85 -176.33 5.9 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.158 -0.474 . . . . 75.54 110.861 -179.944 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -138.18 179.1 6.65 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.16 -0.473 . . . . 51.41 111.159 179.882 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 21.9 m-20 -153.28 -174.05 4.8 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.246 -0.434 . . . . 74.32 110.879 179.969 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 49.6 mt-10 -125.11 177.66 5.97 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.157 -0.474 . . . . 72.54 110.83 -179.853 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -129.39 171.34 12.62 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.132 -0.485 . . . . 43.15 111.144 -179.986 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 61.5 mt -144.41 110.38 1.3 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.168 -0.469 . . . . 51.0 111.116 179.971 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 20' ' ' ARG . . . . . . . . . . . . . 25.5 mtp180 -98.91 179.06 4.76 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.163 -0.471 . . . . 72.41 110.837 179.974 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 120.61 120.31 2.76 Favored Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.748 -0.739 . . . . 60.25 112.499 -179.967 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 22' ' ' TYR . . . . . . . . . . . . . 52.7 t80 -162.24 107.0 1.2 Allowed 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.897 0.379 . . . . 74.34 110.973 -179.796 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 23' ' ' MET . . . . . . . . . . . . . 0.9 OUTLIER -175.02 145.31 0.8 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.113 -0.494 . . . . 64.32 110.845 179.939 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 102.76 -128.29 9.49 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.73 -0.748 . . . . 72.14 112.435 179.942 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 25' ' ' THR . . . . . 0.482 ' O ' ' HA ' ' A' ' 40' ' ' ARG . 1.3 t -111.67 111.71 22.89 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.746 0.308 . . . . 70.32 111.196 -179.828 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 20.6 p -72.86 123.46 23.44 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.258 -0.428 . . . . 63.2 110.799 -179.811 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 27' ' ' ALA . . . . . 0.783 ' HB3' HG23 ' A' ' 39' ' ' ILE . . . -146.79 162.83 37.78 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.109 -0.496 . . . . 63.11 111.079 179.882 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 28' ' ' THR . . . . . 0.505 HG22 ' O ' ' A' ' 28' ' ' THR . 14.4 m -130.69 89.6 2.79 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.164 -0.471 . . . . 75.31 111.183 -179.89 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . 0.856 HG21 HD21 ' A' ' 75' ' ' LEU . 2.2 pt -43.69 134.5 1.21 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.364 0 CA-C-N 116.239 -0.437 . . . . 72.52 111.167 179.936 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . 0.593 HG23 ' O ' ' A' ' 35' ' ' SER . 26.7 m -155.29 98.24 1.97 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.183 -0.462 . . . . 72.12 111.104 179.979 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 96.8 p -134.7 70.14 1.45 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.146 -0.479 . . . . 71.43 110.859 -179.868 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -179.27 168.86 39.79 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.733 -0.746 . . . . 74.11 112.476 179.988 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 16.7 pt-20 -48.72 -24.2 1.31 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.731 0.301 . . . . 74.32 110.863 -179.799 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 29.9 tt0 -173.97 95.55 0.1 Allowed 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.14 -0.482 . . . . 64.31 110.956 -179.888 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 35' ' ' SER . . . . . 0.593 ' O ' HG23 ' A' ' 30' ' ' THR . 2.1 m -144.29 165.07 28.92 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.223 -0.444 . . . . 73.34 110.836 -179.751 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 179.59 89.43 0.08 OUTLIER Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.796 -0.716 . . . . 72.41 112.51 -179.954 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . 0.642 ' HB3' ' CD1' ' A' ' 29' ' ' ILE . . . -109.15 -170.71 1.71 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.83 0.348 . . . . 53.44 111.107 179.949 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 51.1 t -98.31 119.89 46.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.133 -0.485 . . . . 75.54 111.161 179.956 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 39' ' ' ILE . . . . . 0.787 HD12 HD13 ' A' ' 81' ' ' LEU . 0.0 OUTLIER -137.72 150.53 25.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.262 -0.426 . . . . 71.1 111.157 179.884 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 40' ' ' ARG . . . . . 0.482 ' HA ' ' O ' ' A' ' 25' ' ' THR . 19.2 mtt-85 -109.56 80.53 1.32 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.2 -0.455 . . . . 75.32 110.893 179.95 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . 0.437 ' N ' HD13 ' A' ' 39' ' ' ILE . . . -133.76 141.17 12.48 Favored Glycine 0 N--CA 1.452 -0.252 0 C-N-CA 120.77 -0.729 . . . . 42.43 112.478 -179.911 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 42' ' ' VAL . . . . . 0.445 HG23 ' OG1' ' A' ' 25' ' ' THR . 0.4 OUTLIER -124.22 139.01 51.89 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-O 120.818 0.342 . . . . 73.2 111.117 -179.935 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 43' ' ' PHE . . . . . 0.536 ' H ' HD11 ' A' ' 83' ' ' ILE . 2.4 p90 -96.15 132.21 41.79 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.199 -0.455 . . . . 54.1 110.87 179.981 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 12.9 t70 -114.6 124.29 51.49 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.141 -0.482 . . . . 52.33 110.899 179.918 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -105.62 153.09 40.13 Favored Pre-proline 0 C--N 1.328 -0.345 0 CA-C-O 121.624 0.726 . . . . 65.43 110.834 -179.97 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 46' ' ' PRO . . . . . . . . . . . . . 54.9 Cg_endo -69.71 -36.21 11.35 Favored 'Trans proline' 0 C--N 1.342 0.187 0 C-N-CA 122.699 2.266 . . . . 72.52 112.379 179.96 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 38.5 mt-10 -59.67 -20.44 56.21 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.221 -0.445 . . . . 62.2 110.894 -179.984 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 10.4 m-20 -76.52 64.34 2.19 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.158 -0.474 . . . . 75.54 110.847 -179.943 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 9.6 pt -143.22 -40.42 0.17 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.215 -0.448 . . . . 64.33 111.135 179.899 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 13.1 m -82.78 -169.85 2.7 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.132 -0.485 . . . . 72.35 110.927 -179.946 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 7.9 m-85 -95.59 40.65 1.11 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.123 -0.489 . . . . 73.33 110.883 -179.878 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -167.97 143.65 3.84 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.105 -0.498 . . . . 61.54 111.14 179.798 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -159.34 88.19 0.11 Allowed Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.692 -0.766 . . . . 53.15 112.466 -179.952 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 54' ' ' GLN . . . . . . . . . . . . . 16.2 tt0 -174.94 109.82 0.12 Allowed 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.822 0.344 . . . . 43.34 110.948 -179.918 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 169.2 81.9 0.05 OUTLIER Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.827 -0.702 . . . . 53.51 112.541 -179.962 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 46.3 t -93.42 87.18 2.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-O 120.792 0.329 . . . . 42.33 111.136 -179.971 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 30.8 mtt180 -105.93 71.23 0.89 Allowed 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.17 -0.468 . . . . 72.03 110.862 -179.972 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 58' ' ' VAL . . . . . 0.595 HG22 ' O ' ' A' ' 58' ' ' VAL . 12.6 p 39.78 38.02 0.21 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.143 -0.481 . . . . 74.45 111.121 179.953 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 9.0 tt0 -92.59 156.7 16.94 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.194 -0.457 . . . . 73.53 110.877 -179.992 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -129.23 128.72 5.87 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.762 -0.732 . . . . 34.43 112.533 -179.972 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -147.38 153.41 39.6 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.882 0.372 . . . . 52.32 110.804 -179.718 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 1.1 m -106.04 97.63 16.19 Favored Pre-proline 0 C--N 1.329 -0.325 0 CA-C-O 121.611 0.719 . . . . 73.41 110.878 -179.838 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 63' ' ' PRO . . . . . 0.408 ' HG2' HD11 ' A' ' 105' ' ' LEU . 53.9 Cg_endo -69.78 -177.96 2.13 Favored 'Trans proline' 0 C--O 1.231 0.164 0 C-N-CA 122.636 2.224 . . . . 73.33 112.378 179.958 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . 0.52 ' O ' ' HA ' ' A' ' 43' ' ' PHE . 0.5 OUTLIER -105.95 151.21 24.89 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.237 -0.438 . . . . 74.35 110.87 -179.854 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 65' ' ' LEU . . . . . 0.78 HD21 HD11 ' A' ' 81' ' ' LEU . 3.2 tm? -113.52 139.21 49.15 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.119 -0.491 . . . . 64.12 110.951 179.998 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 66' ' ' PHE . . . . . 0.697 ' N ' HD13 ' A' ' 65' ' ' LEU . 2.8 t80 -120.54 106.25 11.61 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.235 -0.439 . . . . 74.31 110.923 179.906 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 67' ' ' VAL . . . . . 0.477 HG22 ' N ' ' A' ' 68' ' ' ARG . 8.2 p -144.03 161.46 15.59 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 116.144 -0.48 . . . . 70.43 111.124 179.992 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 68' ' ' ARG . . . . . 0.49 ' HG3' ' HA2' ' A' ' 99' ' ' GLY . 7.0 ttm180 -96.09 145.38 25.53 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.148 -0.478 . . . . 62.34 110.878 -179.976 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 69' ' ' THR . . . . . 0.459 ' HB ' ' HG3' ' A' ' 95' ' ' PRO . 3.0 t -40.22 -45.43 2.06 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.227 -0.442 . . . . 74.22 111.209 -179.98 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 70' ' ' ASP . . . . . 0.407 ' N ' HG23 ' A' ' 69' ' ' THR . 4.8 m-20 -65.81 -53.97 33.08 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.191 -0.459 . . . . 72.24 110.91 179.884 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 71' ' ' GLU . . . . . 0.484 ' O ' HD13 ' A' ' 75' ' ' LEU . 1.1 mp0 -53.74 -39.24 65.14 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.17 -0.468 . . . . 70.13 110.897 -179.964 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 7.2 p -82.63 -24.35 8.73 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.225 -0.443 . . . . 71.43 111.115 179.991 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 73' ' ' ARG . . . . . . . . . . . . . 51.0 ttt180 -63.97 -37.22 86.62 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.16 -0.473 . . . . 63.45 110.887 -179.989 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 15.2 mm-40 -67.62 -10.96 56.85 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.179 -0.464 . . . . 71.31 110.877 -179.95 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 75' ' ' LEU . . . . . 0.856 HD21 HG21 ' A' ' 29' ' ' ILE . 8.7 mp -103.39 -176.4 3.07 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.234 -0.439 . . . . 64.33 110.95 179.995 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 76' ' ' ARG . . . . . . . . . . . . . 16.5 ttm180 -123.64 150.0 44.71 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.231 -0.441 . . . . 61.2 110.873 -179.986 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -50.34 105.43 0.09 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.218 -0.446 . . . . 61.53 110.918 -179.9 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 113.97 16.14 8.1 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.745 -0.741 . . . . 64.55 112.441 -179.974 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . 0.73 ' HB3' HD23 ' A' ' 75' ' ' LEU . 0.4 OUTLIER -79.88 106.27 11.78 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-O 120.898 0.38 . . . . 73.12 110.852 -179.976 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . 0.728 ' HA ' ' HA ' ' A' ' 89' ' ' TRP . 0.7 OUTLIER -85.46 110.24 19.03 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.226 -0.443 . . . . 21.43 111.167 -179.929 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 81' ' ' LEU . . . . . 0.787 HD13 HD12 ' A' ' 39' ' ' ILE . 0.3 OUTLIER -96.38 132.2 42.14 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.226 -0.443 . . . . 71.51 110.961 179.955 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 82' ' ' THR . . . . . 0.743 ' CA ' ' HA ' ' A' ' 87' ' ' ASN . 3.4 t -93.82 102.5 14.63 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.205 -0.452 . . . . 72.1 111.18 179.973 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 83' ' ' ILE . . . . . 0.722 ' CG2' HD12 ' A' ' 81' ' ' LEU . 0.1 OUTLIER -138.52 131.66 39.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.211 -0.45 . . . . 73.43 111.105 179.966 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 74.59 -53.17 2.39 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.741 -0.742 . . . . 65.42 112.517 179.941 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 4.1 mm-40 -117.76 -82.2 0.63 Allowed 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.834 0.35 . . . . 74.23 110.865 -179.91 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 86' ' ' GLU . . . . . 0.404 ' HB2' ' CE1' ' A' ' 88' ' ' PHE . 6.9 mp0 -149.7 160.3 43.64 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.163 -0.471 . . . . 75.34 110.92 -179.915 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 87' ' ' ASN . . . . . 0.751 ' HA ' ' C ' ' A' ' 81' ' ' LEU . 1.4 p30 -50.91 123.81 9.95 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.193 -0.458 . . . . 73.04 110.893 -179.913 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 88' ' ' PHE . . . . . 0.779 ' HB2' HD22 ' A' ' 105' ' ' LEU . 14.9 m-85 -131.81 118.32 19.73 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.199 -0.455 . . . . 74.13 110.893 -179.955 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 89' ' ' TRP . . . . . 0.728 ' HA ' ' HA ' ' A' ' 80' ' ' THR . 62.2 p-90 -81.53 135.1 35.59 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.196 -0.456 . . . . 65.3 110.854 -179.963 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 90' ' ' VAL . . . . . 0.48 ' HA ' ' HB3' ' A' ' 105' ' ' LEU . 4.9 p -91.52 136.8 23.38 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.193 -0.458 . . . . 74.41 111.131 179.881 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -63.06 -72.3 0.14 Allowed 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.219 -0.446 . . . . 71.42 110.919 179.87 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 92' ' ' ARG . . . . . 0.597 ' O ' ' HG ' ' A' ' 103' ' ' LEU . 12.3 ttm-85 -159.17 120.66 3.35 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.185 -0.461 . . . . 72.04 110.861 -179.962 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 93' ' ' VAL . . . . . 0.645 HG12 ' HB2' ' A' ' 103' ' ' LEU . 24.4 m -111.8 133.01 58.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.188 -0.46 . . . . 73.3 111.127 179.994 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 94' ' ' SER . . . . . 0.442 ' HA ' ' HD2' ' A' ' 95' ' ' PRO . 11.5 t -125.72 100.29 31.44 Favored Pre-proline 0 C--N 1.329 -0.291 0 CA-C-O 121.692 0.758 . . . . 75.12 110.824 -179.78 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 95' ' ' PRO . . . . . 0.459 ' HG3' ' HB ' ' A' ' 69' ' ' THR . 53.9 Cg_endo -69.79 169.96 17.73 Favored 'Trans proline' 0 C--N 1.343 0.26 0 C-N-CA 122.634 2.222 . . . . 75.32 112.383 179.977 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 8.8 m-20 -131.68 4.74 4.25 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.221 -0.445 . . . . 74.45 110.871 179.97 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 12.1 t0 -140.95 30.45 1.82 Allowed 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.13 -0.486 . . . . 65.52 110.918 179.957 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 49.27 60.21 6.4 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.701 -0.762 . . . . 71.31 112.442 -179.957 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 99' ' ' GLY . . . . . 0.49 ' HA2' ' HG3' ' A' ' 68' ' ' ARG . . . 138.42 35.13 0.17 Allowed Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.712 -0.756 . . . . 52.21 112.462 -179.964 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 28.8 t -152.22 72.12 0.98 Allowed 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 120.785 0.326 . . . . 74.41 110.859 -179.747 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 101' ' ' CYS . . . . . 0.475 ' CB ' ' HB ' ' A' ' 93' ' ' VAL . 0.0 OUTLIER -108.47 149.77 28.34 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.126 -0.488 . . . . 75.23 110.887 -179.975 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 102' ' ' HIS . . . . . 0.656 ' HA ' ' O ' ' A' ' 65' ' ' LEU . 28.6 p-80 -158.88 125.42 4.64 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.145 -0.48 . . . . 71.44 110.862 179.968 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 103' ' ' LEU . . . . . 0.923 HD13 ' N ' ' A' ' 104' ' ' TRP . 2.8 tm? -151.92 148.02 27.28 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.199 -0.455 . . . . 53.54 110.952 -179.955 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 104' ' ' TRP . . . . . 0.923 ' N ' HD13 ' A' ' 103' ' ' LEU . 28.0 p90 -64.79 113.69 3.97 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.24 -0.436 . . . . 73.25 110.964 179.839 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 105' ' ' LEU . . . . . 0.779 HD22 ' HB2' ' A' ' 88' ' ' PHE . 0.3 OUTLIER -92.6 162.62 14.11 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.219 -0.446 . . . . 65.34 110.898 179.998 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -89.27 159.16 28.4 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.811 -0.709 . . . . 61.24 112.459 179.92 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 107' ' ' ARG . . . . . 0.539 ' HA ' ' CD1' ' A' ' 88' ' ' PHE . 0.0 OUTLIER -69.74 158.32 35.64 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.852 0.358 . . . . 53.52 110.891 -179.875 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -172.9 109.13 0.29 Allowed Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.715 -0.755 . . . . 41.12 112.442 -179.987 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 109' ' ' VAL . . . . . 0.487 HG23 ' HD2' ' A' ' 110' ' ' PRO . 7.4 p -92.31 134.34 28.45 Favored Pre-proline 0 C--N 1.329 -0.312 0 CA-C-O 121.604 0.716 . . . . 71.51 111.09 -179.951 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 110' ' ' PRO . . . . . 0.541 ' N ' HD21 ' A' ' 87' ' ' ASN . 53.9 Cg_endo -69.75 168.34 21.83 Favored 'Trans proline' 0 C--O 1.232 0.198 0 C-N-CA 122.678 2.252 . . . . 70.25 112.347 179.948 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 111' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.79 -8.39 23.48 Favored 'Trans proline' 0 C--N 1.341 0.164 0 C-N-CA 122.723 2.282 . . . . 62.45 112.304 179.967 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -60.81 161.39 8.11 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.249 -0.432 . . . . 75.33 111.144 179.86 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 113' ' ' VAL . . . . . 0.425 ' O ' HG13 ' A' ' 113' ' ' VAL . 5.6 p -93.08 119.86 41.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.168 -0.469 . . . . 61.34 111.129 179.999 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 114' ' ' ASN . . . . . . . . . . . . . 1.6 m-80 -129.11 145.88 51.19 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.217 -0.447 . . . . 73.33 110.884 -179.993 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -83.49 125.96 32.28 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.13 -0.487 . . . . 74.41 110.824 -179.935 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 116' ' ' ARG . . . . . . . . . . . . . 6.9 ptp85 -115.01 138.21 51.12 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.172 -0.467 . . . . 71.22 110.924 -179.956 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 46.0 ttt180 . . . . . 0 C--N 1.329 -0.29 0 CA-C-N 116.202 -0.454 . . . . 75.0 110.86 -179.891 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 27.1 mtt . . . . . 0 C--O 1.231 0.088 0 CA-C-O 120.779 0.324 . . . . 73.43 110.91 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . 62.5 53.79 2.61 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.323 -0.399 . . . . 63.11 111.07 179.901 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 3' ' ' ASP . . . . . . . . . . . . . 11.1 t70 -121.84 149.46 43.33 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.207 -0.452 . . . . 71.22 110.8 -179.977 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 4' ' ' PHE . . . . . . . . . . . . . 31.4 m-85 -153.0 178.98 9.11 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.181 -0.463 . . . . 63.41 110.938 -179.968 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 5.7 m-20 -160.63 178.96 8.97 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 116.147 -0.479 . . . . 73.04 110.906 -179.975 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 6' ' ' ASN . . . . . . . . . . . . . 30.8 t30 -159.34 171.57 19.55 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.213 -0.448 . . . . 52.25 110.868 -179.918 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 7' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -164.85 178.7 6.99 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.138 -0.483 . . . . 74.35 110.864 179.954 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 8' ' ' PHE . . . . . . . . . . . . . 45.6 m-85 -139.73 -178.65 5.51 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.156 -0.474 . . . . 73.23 110.856 179.979 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 3.3 t70 -175.96 177.43 1.63 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.165 -0.471 . . . . 53.44 110.834 179.932 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -154.79 177.55 11.14 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.238 -0.437 . . . . 75.42 111.149 179.98 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -125.16 -72.33 0.67 Allowed 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.243 -0.435 . . . . 74.31 111.042 179.972 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 41.9 mt 59.96 71.64 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.268 -0.424 . . . . 70.31 111.102 -179.993 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -150.87 168.88 23.13 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.194 -0.457 . . . . 52.13 111.108 179.832 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 22.6 mmm180 -139.71 -176.01 4.41 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.272 -0.422 . . . . 73.2 110.871 -179.855 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -145.0 -172.48 3.85 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.165 -0.47 . . . . 20.24 111.048 179.918 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 1.8 p-10 -152.48 -174.04 4.76 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.171 -0.468 . . . . 65.1 110.861 179.933 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . 0.502 ' O ' HG23 ' A' ' 18' ' ' THR . 0.4 OUTLIER -146.68 176.94 9.47 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.212 -0.449 . . . . 70.54 110.883 -179.942 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 18' ' ' THR . . . . . 0.502 HG23 ' O ' ' A' ' 17' ' ' GLU . 0.9 OUTLIER -159.71 151.09 19.81 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.108 -0.496 . . . . 74.54 111.136 -179.932 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 38.7 mm -136.92 103.73 3.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.196 -0.456 . . . . 72.11 111.09 179.93 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 20' ' ' ARG . . . . . . . . . . . . . 8.4 ttm-85 -137.14 167.88 20.7 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.148 -0.478 . . . . 63.12 110.886 179.943 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -107.25 -125.13 5.32 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.696 -0.764 . . . . 63.01 112.478 -179.947 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 22' ' ' TYR . . . . . . . . . . . . . 33.7 p90 -165.69 134.34 3.17 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.894 0.378 . . . . 73.33 110.901 -179.786 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 23' ' ' MET . . . . . . . . . . . . . 2.6 ptt? -169.14 156.41 7.1 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.112 -0.495 . . . . 65.3 110.903 179.85 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 75.7 -99.2 1.22 Allowed Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.761 -0.733 . . . . 74.32 112.451 179.985 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 25' ' ' THR . . . . . 0.597 ' O ' ' HA ' ' A' ' 40' ' ' ARG . 46.6 p -99.51 108.19 20.56 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.814 0.34 . . . . 53.11 111.172 -179.905 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -76.27 121.77 23.43 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.275 -0.42 . . . . 45.01 110.884 -179.878 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 27' ' ' ALA . . . . . 0.798 ' HB3' HG23 ' A' ' 39' ' ' ILE . . . -151.39 161.12 43.27 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.168 -0.469 . . . . 73.32 111.102 179.877 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 28' ' ' THR . . . . . 0.529 HG22 ' O ' ' A' ' 28' ' ' THR . 16.0 m -131.98 87.99 2.5 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.203 -0.453 . . . . 74.34 111.144 -179.856 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . 0.778 HG23 ' CB ' ' A' ' 39' ' ' ILE . 2.5 pt -43.23 128.55 1.0 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 CA-C-N 116.189 -0.46 . . . . 71.45 111.171 179.893 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . 0.687 HG23 ' O ' ' A' ' 35' ' ' SER . 11.8 m -153.18 101.11 2.52 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.177 -0.465 . . . . 75.42 111.141 -179.998 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 85.2 p -141.09 72.56 1.39 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.217 -0.447 . . . . 73.32 110.879 -179.853 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -178.42 166.91 37.13 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.764 -0.731 . . . . 61.43 112.529 -179.981 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 8.5 pt-20 -49.14 -23.51 1.3 Allowed 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.812 0.339 . . . . 70.13 110.874 -179.915 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -174.47 93.49 0.08 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.192 -0.458 . . . . 72.52 110.971 -179.91 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 35' ' ' SER . . . . . 0.687 ' O ' HG23 ' A' ' 30' ' ' THR . 1.9 m -145.22 165.34 28.64 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.241 -0.436 . . . . 75.12 110.914 -179.823 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -179.61 86.99 0.07 OUTLIER Glycine 0 N--CA 1.452 -0.273 0 C-N-CA 120.689 -0.767 . . . . 71.05 112.491 -179.999 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . 0.631 ' HB3' ' CD1' ' A' ' 29' ' ' ILE . . . -106.23 -173.56 2.33 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.771 0.32 . . . . 73.43 111.184 179.933 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 65.9 t -100.02 122.87 52.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.301 -0.408 . . . . 63.4 111.139 -179.996 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 39' ' ' ILE . . . . . 0.798 HG23 ' HB3' ' A' ' 27' ' ' ALA . 0.0 OUTLIER -136.88 147.63 27.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.158 -0.473 . . . . 71.13 111.097 179.979 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 40' ' ' ARG . . . . . 0.691 ' O ' HG12 ' A' ' 67' ' ' VAL . 0.2 OUTLIER -108.8 81.78 1.51 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.166 -0.47 . . . . 72.13 110.913 179.914 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . 0.594 ' O ' ' HB2' ' A' ' 27' ' ' ALA . . . -143.07 141.96 11.0 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.715 -0.755 . . . . 75.2 112.503 -179.989 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 42' ' ' VAL . . . . . 0.533 HG12 HG21 ' A' ' 25' ' ' THR . 9.8 p -127.8 142.39 43.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-O 120.882 0.373 . . . . 70.31 111.102 -179.904 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 43' ' ' PHE . . . . . 0.769 ' H ' HD11 ' A' ' 83' ' ' ILE . 1.7 p90 -90.08 137.6 32.21 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.142 -0.481 . . . . 62.42 110.878 -179.969 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 9.9 t70 -123.52 125.0 44.11 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.142 -0.481 . . . . 72.14 110.777 -179.992 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 2.6 p30 -120.15 153.06 55.34 Favored Pre-proline 0 C--N 1.329 -0.322 0 CA-C-O 121.618 0.723 . . . . 65.54 110.868 179.941 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 46' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.73 -37.63 8.99 Favored 'Trans proline' 0 C--N 1.34 0.121 0 C-N-CA 122.725 2.283 . . . . 65.35 112.308 -179.958 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 3.7 tt0 -146.16 89.08 1.84 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.255 -0.43 . . . . 72.3 110.877 -179.938 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 18.4 p-10 -54.96 161.89 1.48 Allowed 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.136 -0.483 . . . . 72.23 110.89 -179.907 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 49' ' ' ILE . . . . . 1.044 HD11 HG22 ' A' ' 58' ' ' VAL . 52.9 mt -52.13 140.02 7.87 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.202 -0.454 . . . . 64.21 111.138 179.956 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 54.4 p -124.02 61.6 1.1 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.158 -0.473 . . . . 75.1 110.863 -179.883 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 36.2 m-85 -156.7 175.98 13.33 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.131 -0.486 . . . . 74.43 110.917 -179.868 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -57.1 113.69 1.82 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.106 -0.497 . . . . 71.31 111.119 179.875 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -81.05 -138.74 2.36 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.704 -0.76 . . . . 74.31 112.465 -179.927 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 54' ' ' GLN . . . . . . . . . . . . . 11.8 mm-40 62.87 25.71 15.21 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.907 0.384 . . . . 74.04 110.955 -179.849 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 128.57 53.09 0.12 Allowed Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.726 -0.749 . . . . 45.04 112.507 -179.947 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 11.1 p -115.88 151.36 17.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-O 120.832 0.349 . . . . 41.41 111.083 -179.926 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 52.9 mtp180 -75.22 -177.06 3.3 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.143 -0.48 . . . . 73.24 110.909 179.995 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 58' ' ' VAL . . . . . 1.044 HG22 HD11 ' A' ' 49' ' ' ILE . 58.1 t -137.38 143.54 34.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.19 -0.459 . . . . 73.23 111.117 179.948 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 11.9 mt-10 -75.07 -171.13 1.28 Allowed 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.117 -0.492 . . . . 70.51 110.939 -179.981 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -91.33 100.27 2.66 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.746 -0.74 . . . . 61.4 112.481 -179.952 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -150.14 152.88 35.4 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.852 0.358 . . . . 73.11 110.861 -179.704 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . 0.427 ' HA ' ' HD2' ' A' ' 63' ' ' PRO . 0.3 OUTLIER -120.35 97.52 48.94 Favored Pre-proline 0 C--N 1.33 -0.277 0 CA-C-O 121.689 0.757 . . . . 71.12 110.882 -179.852 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 63' ' ' PRO . . . . . 0.427 ' HD2' ' HA ' ' A' ' 62' ' ' SER . 53.5 Cg_endo -69.78 171.22 14.89 Favored 'Trans proline' 0 C--N 1.341 0.164 0 C-N-CA 122.722 2.281 . . . . 75.42 112.298 -179.985 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . 0.444 ' O ' ' HA ' ' A' ' 43' ' ' PHE . 8.0 t -105.6 147.04 28.88 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.21 -0.45 . . . . 63.24 110.854 -179.877 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 65' ' ' LEU . . . . . 0.94 HD11 HG13 ' A' ' 67' ' ' VAL . 0.9 OUTLIER -113.62 119.41 37.37 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.141 -0.481 . . . . 75.02 110.932 -179.986 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 66' ' ' PHE . . . . . 0.433 ' N ' HD12 ' A' ' 65' ' ' LEU . 6.4 t80 -94.63 111.28 23.05 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.242 -0.435 . . . . 73.2 110.844 179.981 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 67' ' ' VAL . . . . . 0.94 HG13 HD11 ' A' ' 65' ' ' LEU . 0.8 OUTLIER -141.38 170.49 13.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.096 -0.502 . . . . 72.32 111.197 179.961 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 10.1 ttm180 -100.74 143.86 30.39 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.24 -0.436 . . . . 60.3 110.934 -179.999 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 69' ' ' THR . . . . . 0.421 HG23 ' N ' ' A' ' 70' ' ' ASP . 4.7 t -42.9 -44.61 4.62 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.219 -0.446 . . . . 65.43 111.191 -179.901 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 70' ' ' ASP . . . . . 0.421 ' N ' HG23 ' A' ' 69' ' ' THR . 21.1 t0 -65.67 -46.32 79.56 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.233 -0.44 . . . . 71.51 110.903 179.862 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 71' ' ' GLU . . . . . . . . . . . . . 67.1 mm-40 -53.93 -39.66 66.05 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.116 -0.493 . . . . 72.42 110.928 -179.921 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 72' ' ' VAL . . . . . . . . . . . . . 19.0 m -86.72 -25.51 6.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.103 -0.498 . . . . 72.12 111.151 179.966 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 73' ' ' ARG . . . . . . . . . . . . . 0.8 OUTLIER -60.0 -41.24 91.67 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.139 -0.482 . . . . 64.21 110.895 -179.999 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 32.3 mt-30 -62.07 -16.59 53.15 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.169 -0.469 . . . . 73.35 110.899 -179.959 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 75' ' ' LEU . . . . . 0.648 HD21 HG21 ' A' ' 29' ' ' ILE . 5.3 mp -108.89 -175.51 2.79 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.246 -0.434 . . . . 73.13 110.85 -179.921 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 76' ' ' ARG . . . . . . . . . . . . . 5.0 ptp85 -115.56 -173.83 2.41 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.135 -0.484 . . . . 71.2 110.934 179.954 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 7.0 ptp180 -79.99 131.38 35.79 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.253 -0.43 . . . . 64.0 110.89 -179.951 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 92.31 25.79 20.33 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.74 -0.743 . . . . 71.14 112.56 -179.924 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -89.24 105.33 17.72 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.911 0.386 . . . . 75.12 110.852 -179.949 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . 0.776 ' HA ' ' HA ' ' A' ' 89' ' ' TRP . 0.8 OUTLIER -87.28 110.57 20.29 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.196 -0.456 . . . . 41.34 111.101 -179.89 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 81' ' ' LEU . . . . . 0.777 HD13 HD12 ' A' ' 39' ' ' ILE . 0.3 OUTLIER -95.41 131.91 41.04 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.153 -0.476 . . . . 75.23 110.897 179.935 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 82' ' ' THR . . . . . 0.741 ' CA ' ' HA ' ' A' ' 87' ' ' ASN . 5.0 t -94.01 102.03 14.1 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.18 -0.464 . . . . 74.12 111.133 179.932 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 83' ' ' ILE . . . . . 0.769 HD11 ' H ' ' A' ' 43' ' ' PHE . 0.1 OUTLIER -132.46 130.26 59.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.184 -0.462 . . . . 73.42 111.116 179.92 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 68.19 -62.73 0.39 Allowed Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.707 -0.758 . . . . 73.24 112.508 179.911 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . 0.404 ' N ' ' O ' ' A' ' 83' ' ' ILE . 29.2 mm-40 -98.66 -83.7 0.41 Allowed 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.766 0.317 . . . . 65.44 110.949 -179.924 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 86' ' ' GLU . . . . . 0.414 ' C ' ' HA ' ' A' ' 82' ' ' THR . 70.1 mt-10 -154.22 160.97 42.09 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.129 -0.487 . . . . 52.15 110.844 -179.96 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 87' ' ' ASN . . . . . 0.747 ' HA ' ' C ' ' A' ' 81' ' ' LEU . 0.8 OUTLIER -50.55 123.73 9.37 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.156 -0.475 . . . . 73.35 110.871 -179.89 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 88' ' ' PHE . . . . . 0.784 ' HB2' HD22 ' A' ' 105' ' ' LEU . 15.1 m-85 -131.51 119.48 21.6 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.239 -0.437 . . . . 73.14 110.889 -179.974 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 89' ' ' TRP . . . . . 0.776 ' HA ' ' HA ' ' A' ' 80' ' ' THR . 4.6 p90 -80.12 138.05 36.85 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.166 -0.47 . . . . 72.15 110.856 -179.915 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 90' ' ' VAL . . . . . 0.552 HG23 HD12 ' A' ' 103' ' ' LEU . 2.2 p -94.59 135.84 27.6 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 116.156 -0.474 . . . . 63.13 111.129 179.942 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -65.28 -75.25 0.09 Allowed 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.173 -0.467 . . . . 72.12 110.879 179.892 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 92' ' ' ARG . . . . . 0.587 ' O ' ' HG ' ' A' ' 103' ' ' LEU . 0.0 OUTLIER -153.23 117.45 4.87 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.166 -0.47 . . . . 75.13 110.818 -179.944 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 93' ' ' VAL . . . . . 0.491 ' CG2' ' N ' ' A' ' 102' ' ' HIS . 0.3 OUTLIER -111.45 139.82 33.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.171 -0.468 . . . . 72.44 111.173 179.906 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 1.4 p -140.78 103.94 6.32 Favored Pre-proline 0 C--N 1.329 -0.293 0 CA-C-O 121.713 0.768 . . . . 53.11 110.857 -179.807 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 95' ' ' PRO . . . . . 0.418 ' HG3' ' HB ' ' A' ' 69' ' ' THR . 54.4 Cg_endo -69.68 173.61 10.65 Favored 'Trans proline' 0 C--N 1.342 0.199 0 C-N-CA 122.729 2.286 . . . . 75.32 112.365 179.908 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 21.2 m-20 -107.26 -6.28 17.34 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.197 -0.456 . . . . 74.02 110.854 179.95 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 46.5 p-10 -151.78 32.81 0.55 Allowed 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.236 -0.438 . . . . 74.14 110.906 179.981 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 45.25 68.8 0.88 Allowed Glycine 0 N--CA 1.452 -0.235 0 C-N-CA 120.696 -0.764 . . . . 64.4 112.437 -179.97 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . 173.08 -28.13 0.09 OUTLIER Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.74 -0.743 . . . . 71.34 112.467 179.991 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 1.5 m -122.04 101.03 7.3 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.775 0.321 . . . . 74.53 110.831 -179.741 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 101' ' ' CYS . . . . . 0.433 ' HB3' HG22 ' A' ' 93' ' ' VAL . 0.0 OUTLIER -122.95 154.43 38.39 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.212 -0.449 . . . . 75.22 110.839 -179.954 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 102' ' ' HIS . . . . . 0.491 ' N ' ' CG2' ' A' ' 93' ' ' VAL . 13.5 p80 -156.94 123.34 4.96 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.161 -0.472 . . . . 74.23 110.853 -179.972 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 103' ' ' LEU . . . . . 0.814 HD13 ' N ' ' A' ' 104' ' ' TRP . 3.4 tm? -148.25 144.57 27.74 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.211 -0.45 . . . . 75.32 110.856 -179.916 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 104' ' ' TRP . . . . . 0.814 ' N ' HD13 ' A' ' 103' ' ' LEU . 4.2 m-90 -69.29 108.54 3.72 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.225 -0.443 . . . . 62.33 110.924 179.831 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 105' ' ' LEU . . . . . 0.784 HD22 ' HB2' ' A' ' 88' ' ' PHE . 0.3 OUTLIER -89.6 161.8 15.97 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.266 -0.424 . . . . 73.1 110.985 179.945 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -89.69 159.92 28.5 Favored Glycine 0 N--CA 1.45 -0.379 0 C-N-CA 120.713 -0.756 . . . . 53.21 112.537 179.891 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 107' ' ' ARG . . . . . 0.585 ' HA ' ' CD1' ' A' ' 88' ' ' PHE . 0.1 OUTLIER -68.94 157.55 36.46 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.88 0.372 . . . . 73.34 110.832 -179.807 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -172.05 112.38 0.44 Allowed Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.78 -0.724 . . . . 73.55 112.538 -179.998 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 109' ' ' VAL . . . . . 0.454 HG23 ' HD2' ' A' ' 110' ' ' PRO . 7.3 p -85.56 133.78 41.35 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-O 121.599 0.714 . . . . 71.52 111.176 -179.975 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 110' ' ' PRO . . . . . 0.454 ' HD2' HG23 ' A' ' 109' ' ' VAL . 54.8 Cg_endo -69.63 168.14 22.26 Favored 'Trans proline' 0 C--O 1.233 0.232 0 C-N-CA 122.693 2.262 . . . . 72.55 112.394 179.9 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 111' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.77 -8.48 23.7 Favored 'Trans proline' 0 C--O 1.231 0.174 0 C-N-CA 122.708 2.272 . . . . 73.21 112.365 179.896 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -59.15 161.22 5.47 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.244 -0.435 . . . . 52.14 111.156 179.769 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 17.2 m -92.97 122.0 44.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.278 -0.419 . . . . 44.12 111.135 179.97 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 114' ' ' ASN . . . . . . . . . . . . . 1.5 m-80 -128.67 146.15 50.95 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.097 -0.501 . . . . 73.34 110.896 179.985 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 6.4 mtp180 -82.46 112.6 19.54 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.159 -0.473 . . . . 74.34 110.804 -179.897 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 116' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -111.79 138.0 48.96 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.159 -0.473 . . . . 62.44 110.889 -179.912 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 C--N 1.328 -0.326 0 CA-C-N 116.173 -0.467 . . . . 75.43 110.873 -179.909 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 10.6 ttp . . . . . 0 C--O 1.23 0.049 0 CA-C-O 120.794 0.33 . . . . 63.4 110.931 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -172.7 158.98 4.18 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.162 -0.472 . . . . 61.13 111.094 179.885 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 3' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -154.57 122.75 5.98 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.262 -0.426 . . . . 62.03 110.867 179.937 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 4' ' ' PHE . . . . . . . . . . . . . 36.8 p90 -141.54 147.56 37.94 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.123 -0.489 . . . . 64.54 110.89 -179.909 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 5.4 m-20 -136.64 151.72 49.62 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.156 -0.475 . . . . 71.23 110.863 -179.968 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 6' ' ' ASN . . . . . . . . . . . . . 64.4 m-80 -101.06 -70.48 0.74 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.239 -0.437 . . . . 71.04 110.916 -179.951 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 7' ' ' LEU . . . . . . . . . . . . . 20.3 mt -101.34 109.66 21.54 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.143 -0.48 . . . . 63.05 110.932 179.91 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 8' ' ' PHE . . . . . . . . . . . . . 10.4 m-85 -63.93 -30.58 71.65 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.172 -0.467 . . . . 74.21 110.899 179.881 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 28.5 t70 -165.95 104.2 0.67 Allowed 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.184 -0.462 . . . . 72.22 110.885 179.994 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -127.39 108.72 11.08 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.232 -0.44 . . . . 71.41 111.07 179.978 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -71.04 97.68 1.5 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.23 -0.441 . . . . 72.23 111.139 179.899 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 32.0 mt -121.82 63.95 0.26 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.21 -0.45 . . . . 74.13 111.102 -179.981 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -175.54 104.82 0.08 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.113 -0.494 . . . . 70.3 111.106 179.786 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 61.4 ttt180 -71.84 125.94 28.46 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.171 -0.468 . . . . 74.21 110.828 -179.88 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -75.53 74.14 2.56 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.152 -0.476 . . . . 45.21 111.078 179.941 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 10.5 p-10 -137.2 58.48 1.71 Allowed 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.17 -0.468 . . . . 73.15 110.83 -179.983 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 10.1 tt0 61.74 52.66 3.44 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.217 -0.447 . . . . 71.12 110.908 -179.91 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 43.0 p -62.17 -176.69 0.1 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.135 -0.484 . . . . 75.31 111.158 -179.882 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 9.5 mt 64.98 46.02 0.17 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.261 -0.427 . . . . 72.02 111.143 179.941 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 20' ' ' ARG . . . . . . . . . . . . . 3.9 ttt180 -106.17 -62.99 1.31 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.172 -0.467 . . . . 74.32 110.855 180.0 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 82.87 176.39 51.47 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.678 -0.772 . . . . 42.32 112.454 -179.957 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 22' ' ' TYR . . . . . . . . . . . . . 20.3 p90 -177.78 123.37 0.12 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.89 0.376 . . . . 75.12 110.905 -179.839 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 23' ' ' MET . . . . . . . . . . . . . 4.2 mmt -150.97 145.21 25.42 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.126 -0.488 . . . . 74.13 110.833 179.883 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 74.51 -99.51 1.11 Allowed Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.711 -0.757 . . . . 63.3 112.519 -179.952 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 25' ' ' THR . . . . . 0.547 ' O ' ' HA ' ' A' ' 40' ' ' ARG . 0.0 OUTLIER -122.22 111.88 17.49 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.867 0.365 . . . . 73.12 111.09 -179.889 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -75.09 123.33 25.03 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.112 -0.495 . . . . 70.21 110.838 -179.856 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 27' ' ' ALA . . . . . 0.832 ' HB3' HG23 ' A' ' 39' ' ' ILE . . . -145.13 163.21 35.02 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.15 -0.477 . . . . 53.12 111.056 179.894 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 28' ' ' THR . . . . . 0.501 HG22 ' O ' ' A' ' 28' ' ' THR . 19.1 m -130.46 87.2 2.47 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.173 -0.467 . . . . 62.05 111.164 -179.874 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . 0.744 HG23 ' CB ' ' A' ' 39' ' ' ILE . 2.2 pt -44.27 132.15 1.55 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.213 -0.448 . . . . 71.21 111.161 179.926 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . 0.636 HG23 ' O ' ' A' ' 35' ' ' SER . 23.4 m -153.89 101.17 2.42 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.183 -0.462 . . . . 64.14 111.176 179.983 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 1.8 t -137.12 71.04 1.4 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.265 -0.425 . . . . 71.21 110.843 -179.856 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -179.4 168.1 38.51 Favored Glycine 0 N--CA 1.45 -0.422 0 C-N-CA 120.72 -0.752 . . . . 54.23 112.458 -179.968 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 6.7 pt-20 -49.24 -23.4 1.33 Allowed 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.793 0.33 . . . . 74.45 110.894 -179.896 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 3.5 tt0 -174.69 94.93 0.08 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.12 -0.491 . . . . 65.31 110.971 -179.97 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 35' ' ' SER . . . . . 0.636 ' O ' HG23 ' A' ' 30' ' ' THR . 0.1 OUTLIER -145.11 165.33 28.59 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.232 -0.44 . . . . 52.14 110.801 -179.789 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -179.22 88.86 0.07 OUTLIER Glycine 0 N--CA 1.452 -0.254 0 C-N-CA 120.723 -0.751 . . . . 44.24 112.449 179.995 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . 0.649 ' HB3' ' CD1' ' A' ' 29' ' ' ILE . . . -106.26 -172.45 2.09 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.798 0.332 . . . . 54.33 111.116 179.942 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 23.5 t -99.66 120.01 48.47 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.232 -0.44 . . . . 71.23 111.117 179.998 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 39' ' ' ILE . . . . . 0.832 HG23 ' HB3' ' A' ' 27' ' ' ALA . 0.0 OUTLIER -137.28 151.03 26.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.227 -0.442 . . . . 73.03 111.177 179.918 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 40' ' ' ARG . . . . . 0.598 ' O ' HG12 ' A' ' 67' ' ' VAL . 28.0 mmt180 -112.87 82.03 1.59 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.193 -0.458 . . . . 72.2 110.845 179.988 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . 0.51 ' HA3' HD21 ' A' ' 65' ' ' LEU . . . -140.18 138.21 8.92 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.794 -0.717 . . . . 72.01 112.451 -179.966 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 42' ' ' VAL . . . . . 0.517 HG12 HG21 ' A' ' 25' ' ' THR . 1.7 p -123.59 137.81 55.53 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-O 120.817 0.341 . . . . 64.42 111.17 179.943 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 43' ' ' PHE . . . . . 0.58 ' H ' HD11 ' A' ' 83' ' ' ILE . 2.1 p90 -93.22 137.82 32.19 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.198 -0.455 . . . . 74.51 110.88 -179.91 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 3.4 t70 -117.96 125.43 50.41 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.147 -0.479 . . . . 64.31 110.853 179.986 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 45' ' ' ASP . . . . . 0.437 ' HA ' ' HD2' ' A' ' 46' ' ' PRO . 1.2 p30 -109.63 106.2 58.13 Favored Pre-proline 0 C--N 1.329 -0.323 0 CA-C-O 121.548 0.69 . . . . 71.54 110.913 179.951 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 46' ' ' PRO . . . . . 0.437 ' HD2' ' HA ' ' A' ' 45' ' ' ASP . 53.9 Cg_endo -69.81 -37.74 8.63 Favored 'Trans proline' 0 C--O 1.231 0.126 0 C-N-CA 122.673 2.248 . . . . 73.03 112.335 -179.949 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 35.8 mt-10 -133.98 84.03 2.09 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.296 -0.411 . . . . 63.24 110.917 179.999 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 28.4 m-80 -59.21 164.77 2.96 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.171 -0.468 . . . . 54.15 110.932 -179.963 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 7.3 tt -98.11 23.17 1.08 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.373 0 CA-C-N 116.187 -0.461 . . . . 73.03 111.129 179.948 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -69.02 100.1 1.18 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.162 -0.472 . . . . 72.12 110.837 -179.923 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 8.4 t80 -164.97 158.3 16.9 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.11 -0.495 . . . . 72.44 110.878 -179.858 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -116.95 116.13 26.8 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.086 -0.507 . . . . 61.24 111.102 179.838 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 112.11 71.07 0.59 Allowed Glycine 0 N--CA 1.452 -0.257 0 C-N-CA 120.791 -0.718 . . . . 51.32 112.487 -179.913 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 54' ' ' GLN . . . . . . . . . . . . . 5.2 pm0 -163.28 142.54 8.49 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.884 0.373 . . . . 75.44 110.885 -179.915 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -177.33 31.81 0.08 OUTLIER Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.78 -0.724 . . . . 63.03 112.523 -179.991 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 25.0 t -89.3 -67.23 0.77 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-O 120.855 0.36 . . . . 45.33 111.085 -179.899 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -176.94 122.14 0.13 Allowed 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.194 -0.457 . . . . 63.4 110.874 -179.94 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 11.3 p -51.71 132.28 13.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.258 -0.428 . . . . 42.31 111.097 179.986 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 1.3 mt-10 -81.7 -74.7 0.32 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.196 -0.456 . . . . 72.43 110.904 -179.999 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -149.99 136.1 5.55 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.747 -0.74 . . . . 60.02 112.476 -179.974 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 22.3 m -145.13 105.51 4.08 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.87 0.367 . . . . 64.12 110.883 -179.811 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -147.99 97.82 3.87 Favored Pre-proline 0 C--N 1.329 -0.289 0 CA-C-O 121.661 0.744 . . . . 75.11 110.822 -179.766 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.78 175.77 7.67 Favored 'Trans proline' 0 C--N 1.342 0.199 0 C-N-CA 122.727 2.285 . . . . 72.1 112.326 179.986 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . . . . . . . . . 1.3 t -111.29 138.29 47.94 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.211 -0.45 . . . . 75.21 110.834 -179.863 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 65' ' ' LEU . . . . . 0.781 HD11 HG13 ' A' ' 67' ' ' VAL . 1.7 tm? -117.1 135.67 53.57 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.19 -0.459 . . . . 74.21 110.962 -179.974 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 66' ' ' PHE . . . . . 0.664 ' N ' HD22 ' A' ' 65' ' ' LEU . 35.7 t80 -117.94 110.28 17.53 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.244 -0.435 . . . . 74.24 110.87 179.966 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 67' ' ' VAL . . . . . 0.781 HG13 HD11 ' A' ' 65' ' ' LEU . 24.1 m -140.13 168.12 17.85 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.092 -0.504 . . . . 71.15 111.11 179.993 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 68' ' ' ARG . . . . . 0.436 ' HG2' ' H ' ' A' ' 71' ' ' GLU . 1.5 ptm180 -102.83 146.18 28.66 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.191 -0.459 . . . . 73.23 110.859 179.982 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 69' ' ' THR . . . . . 0.457 HG22 ' HA2' ' A' ' 99' ' ' GLY . 0.2 OUTLIER -37.75 -60.96 0.67 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.153 -0.476 . . . . 73.4 111.139 -179.895 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 3.4 m-20 -46.11 -43.92 15.24 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.198 -0.455 . . . . 70.1 110.887 179.886 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 71' ' ' GLU . . . . . 0.436 ' H ' ' HG2' ' A' ' 68' ' ' ARG . 8.7 tp10 -59.77 -42.81 94.15 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.198 -0.456 . . . . 72.5 110.858 -179.873 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 72' ' ' VAL . . . . . 0.503 HG22 ' O ' ' A' ' 72' ' ' VAL . 14.3 p -87.27 -3.86 9.38 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.172 -0.467 . . . . 73.11 111.106 -179.978 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 73' ' ' ARG . . . . . . . . . . . . . 57.6 ttt180 -85.27 -41.93 15.11 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.165 -0.47 . . . . 70.22 110.884 -179.965 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 71.8 mt-30 -53.26 -25.25 13.74 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.188 -0.46 . . . . 71.55 110.907 -179.944 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 75' ' ' LEU . . . . . 0.74 HD21 ' CD1' ' A' ' 29' ' ' ILE . 3.9 mp -107.74 -169.63 1.56 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.204 -0.453 . . . . 72.53 110.956 179.963 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 76' ' ' ARG . . . . . . . . . . . . . 8.5 ttp180 -116.6 136.84 52.64 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.212 -0.449 . . . . 72.14 110.85 179.978 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -47.34 102.01 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.211 -0.45 . . . . 72.15 110.884 -179.899 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 133.19 25.73 0.64 Allowed Glycine 0 N--CA 1.453 -0.231 0 C-N-CA 120.701 -0.762 . . . . 74.33 112.427 -179.967 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . 0.724 ' OD2' HD22 ' A' ' 75' ' ' LEU . 5.4 p-10 -114.13 119.84 38.48 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.871 0.367 . . . . 55.42 110.91 179.963 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . 0.831 HG22 ' HB3' ' A' ' 89' ' ' TRP . 13.6 p -83.11 123.05 29.14 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.195 -0.457 . . . . 71.22 111.123 -179.825 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 81' ' ' LEU . . . . . 0.794 ' C ' ' HA ' ' A' ' 87' ' ' ASN . 0.2 OUTLIER -94.37 124.47 38.42 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.243 -0.435 . . . . 61.22 110.921 179.956 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 82' ' ' THR . . . . . 0.802 ' N ' ' HA ' ' A' ' 87' ' ' ASN . 3.5 t -91.47 104.42 16.93 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.214 -0.448 . . . . 74.44 111.164 179.947 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 83' ' ' ILE . . . . . 0.725 HD13 ' O ' ' A' ' 83' ' ' ILE . 0.1 OUTLIER -141.17 126.45 18.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.177 -0.465 . . . . 72.25 111.062 179.97 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 74.36 -52.74 2.27 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.692 -0.766 . . . . 65.0 112.495 179.908 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 8.1 tp10 -112.91 -82.73 0.59 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.809 0.338 . . . . 74.13 110.903 -179.896 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 86' ' ' GLU . . . . . 0.468 ' C ' ' HA ' ' A' ' 82' ' ' THR . 86.9 mt-10 -152.17 160.86 43.31 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.171 -0.468 . . . . 74.14 110.884 -179.937 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 87' ' ' ASN . . . . . 0.802 ' HA ' ' N ' ' A' ' 82' ' ' THR . 9.2 p30 -51.32 121.66 6.6 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.168 -0.469 . . . . 64.33 110.938 -179.949 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 88' ' ' PHE . . . . . 0.661 ' HB2' HD22 ' A' ' 105' ' ' LEU . 15.9 m-85 -132.16 121.36 23.61 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.172 -0.467 . . . . 74.14 110.938 -179.958 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 89' ' ' TRP . . . . . 0.831 ' HB3' HG22 ' A' ' 80' ' ' THR . 3.7 t-105 -81.38 130.53 35.07 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.14 -0.482 . . . . 70.12 110.906 -179.923 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 90' ' ' VAL . . . . . 0.505 ' O ' ' CH2' ' A' ' 89' ' ' TRP . 6.1 p -80.93 114.58 22.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.215 -0.448 . . . . 72.21 111.172 179.912 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -41.9 -65.21 0.48 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.208 -0.451 . . . . 52.51 110.945 179.953 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 92' ' ' ARG . . . . . 0.488 ' O ' ' HG ' ' A' ' 103' ' ' LEU . 69.5 ttt180 -160.15 125.65 4.03 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.197 -0.456 . . . . 71.31 110.902 -179.967 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 93' ' ' VAL . . . . . 0.507 HG12 ' N ' ' A' ' 102' ' ' HIS . 0.0 OUTLIER -115.49 111.55 36.12 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 116.203 -0.453 . . . . 75.23 111.135 179.954 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 94' ' ' SER . . . . . 0.451 ' C ' ' HB3' ' A' ' 101' ' ' CYS . 4.4 p -105.8 106.16 55.61 Favored Pre-proline 0 C--N 1.33 -0.255 0 CA-C-O 121.666 0.746 . . . . 73.12 110.833 -179.78 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 95' ' ' PRO . . . . . 0.432 ' HG3' ' HB ' ' A' ' 69' ' ' THR . 53.3 Cg_endo -69.83 159.19 54.28 Favored 'Trans proline' 0 C--N 1.341 0.18 0 C-N-CA 122.633 2.222 . . . . 65.2 112.363 179.984 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 4.5 m-20 -123.14 -3.3 8.53 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.23 -0.441 . . . . 64.51 110.884 179.982 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 14.9 t70 -145.54 40.81 1.21 Allowed 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.148 -0.478 . . . . 75.52 110.955 179.992 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 51.02 60.95 6.57 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.713 -0.756 . . . . 24.54 112.47 -179.922 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 99' ' ' GLY . . . . . 0.457 ' HA2' HG22 ' A' ' 69' ' ' THR . . . 124.21 46.58 0.25 Allowed Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.697 -0.763 . . . . 73.25 112.438 -179.948 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 2.0 p -159.74 77.61 0.68 Allowed 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 120.831 0.348 . . . . 70.41 110.861 -179.736 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 101' ' ' CYS . . . . . 0.451 ' HB3' ' C ' ' A' ' 94' ' ' SER . 0.3 OUTLIER -129.21 167.47 17.6 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.168 -0.469 . . . . 73.24 110.898 -179.95 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 102' ' ' HIS . . . . . 0.507 ' N ' HG12 ' A' ' 93' ' ' VAL . 37.0 p-80 -167.41 128.28 1.5 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.137 -0.483 . . . . 74.0 110.842 -179.928 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 103' ' ' LEU . . . . . 0.824 HD13 ' N ' ' A' ' 104' ' ' TRP . 2.5 tm? -150.19 147.17 27.38 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.181 -0.463 . . . . 71.14 110.938 -179.928 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 104' ' ' TRP . . . . . 0.824 ' N ' HD13 ' A' ' 103' ' ' LEU . 29.7 p90 -63.92 118.25 8.15 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.261 -0.427 . . . . 71.31 110.95 179.893 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 105' ' ' LEU . . . . . 0.661 HD22 ' HB2' ' A' ' 88' ' ' PHE . 0.2 OUTLIER -88.45 163.58 15.89 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 116.245 -0.434 . . . . 72.2 110.924 -179.998 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -88.15 160.26 30.66 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.751 -0.737 . . . . 74.42 112.523 179.919 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 107' ' ' ARG . . . . . 0.486 ' HA ' ' CD1' ' A' ' 88' ' ' PHE . 0.7 OUTLIER -66.17 157.5 31.14 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.864 0.364 . . . . 74.42 110.923 -179.941 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -176.58 108.16 0.25 Allowed Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.733 -0.746 . . . . 74.24 112.425 179.984 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 109' ' ' VAL . . . . . 0.416 HG23 ' HD2' ' A' ' 110' ' ' PRO . 10.8 p -100.06 133.6 21.46 Favored Pre-proline 0 C--N 1.329 -0.296 0 CA-C-O 121.543 0.687 . . . . 53.25 111.091 -179.938 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 110' ' ' PRO . . . . . 0.416 ' HD2' HG23 ' A' ' 109' ' ' VAL . 54.0 Cg_endo -69.75 167.62 23.9 Favored 'Trans proline' 0 C--O 1.23 0.123 0 C-N-CA 122.652 2.235 . . . . 75.31 112.319 179.934 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 111' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.8 -15.41 36.94 Favored 'Trans proline' 0 C--N 1.342 0.214 0 C-N-CA 122.672 2.248 . . . . 73.14 112.284 179.993 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -117.97 121.25 40.17 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.198 -0.455 . . . . 63.52 111.079 179.881 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 7.4 m -118.61 129.14 75.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.166 -0.47 . . . . 74.25 111.055 -179.957 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 114' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -128.31 118.99 24.21 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.151 -0.477 . . . . 72.21 110.884 179.976 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 5.5 ptm180 -112.12 130.44 55.89 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-N 116.126 -0.488 . . . . 52.33 110.837 -179.93 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 116' ' ' ARG . . . . . . . . . . . . . 12.3 ptp180 -114.2 137.81 51.29 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.167 -0.47 . . . . 70.11 110.899 -179.913 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 C--N 1.329 -0.307 0 CA-C-N 116.24 -0.436 . . . . 74.25 110.89 -179.981 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 19.8 ptt? . . . . . 0 C--O 1.231 0.1 0 CA-C-O 120.831 0.348 . . . . 72.21 110.919 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -119.84 -45.42 2.49 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.237 -0.438 . . . . 61.15 111.096 179.948 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 3' ' ' ASP . . . . . . . . . . . . . 22.5 t70 -52.37 144.71 12.52 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.22 -0.446 . . . . 70.33 110.791 -179.978 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 4' ' ' PHE . . . . . . . . . . . . . 12.1 m-85 -114.89 -73.57 0.65 Allowed 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.147 -0.478 . . . . 73.2 110.916 -179.927 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 3.9 m-20 -166.33 119.79 1.09 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.104 -0.498 . . . . 63.11 110.892 179.955 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 6' ' ' ASN . . . . . . . . . . . . . 4.4 t-20 -176.92 133.43 0.19 Allowed 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.227 -0.442 . . . . 65.4 110.858 -179.842 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 7' ' ' LEU . . . . . . . . . . . . . 5.1 mp -124.37 -72.97 0.65 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.215 -0.448 . . . . 73.41 110.938 179.931 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 8' ' ' PHE . . . . . . . . . . . . . 3.7 m-85 -163.26 178.27 8.32 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.211 -0.45 . . . . 75.31 110.924 179.898 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 4.4 m-20 -122.13 -176.69 3.41 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.162 -0.472 . . . . 54.25 110.846 179.98 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -144.27 177.36 8.67 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.198 -0.455 . . . . 61.31 111.095 179.967 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . 0.587 ' O ' HD13 ' A' ' 12' ' ' ILE . . . -136.74 150.63 48.51 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.193 -0.458 . . . . 75.43 111.066 179.915 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 12' ' ' ILE . . . . . 0.587 HD13 ' O ' ' A' ' 11' ' ' ALA . 26.6 mm -133.69 69.37 0.33 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.237 -0.438 . . . . 74.42 111.097 -179.993 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -147.54 142.25 26.69 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.19 -0.459 . . . . 62.24 111.128 179.77 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 1.8 tpt180 -175.34 117.07 0.16 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.222 -0.445 . . . . 71.51 110.849 -179.946 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -177.68 138.86 0.22 Allowed 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.233 -0.44 . . . . 64.04 111.1 179.895 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 6.1 p-10 -174.29 169.44 3.84 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.21 -0.45 . . . . 74.33 110.967 179.963 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 9.9 mp0 -114.19 -174.06 2.4 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.247 -0.433 . . . . 64.11 110.913 -179.917 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 94.1 m -88.84 -72.97 0.52 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.171 -0.468 . . . . 72.23 111.128 -179.906 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 31.5 mt 54.82 77.42 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.229 -0.441 . . . . 64.5 111.166 179.945 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 20' ' ' ARG . . . . . . . . . . . . . 9.6 tpt180 -71.54 149.15 46.0 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.136 -0.484 . . . . 75.11 110.879 179.971 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -158.23 -162.34 11.73 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.787 -0.72 . . . . 42.22 112.548 -179.945 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 22' ' ' TYR . . . . . . . . . . . . . 34.7 t80 -158.92 -45.92 0.06 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.869 0.366 . . . . 73.01 110.907 -179.843 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 23' ' ' MET . . . . . . . . . . . . . 9.4 ptt? -52.1 145.93 9.66 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.171 -0.468 . . . . 74.42 110.856 179.953 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 103.75 -156.61 17.6 Favored Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.696 -0.764 . . . . 64.13 112.496 179.998 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 25' ' ' THR . . . . . 0.496 HG21 HG23 ' A' ' 42' ' ' VAL . 8.4 m -110.69 137.69 48.03 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.742 0.306 . . . . 71.21 111.192 -179.911 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -72.5 122.08 20.71 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.207 -0.451 . . . . 50.25 110.866 -179.855 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 27' ' ' ALA . . . . . 0.823 ' HB3' HG23 ' A' ' 39' ' ' ILE . . . -142.05 162.29 35.86 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.047 -0.524 . . . . 42.21 111.119 179.89 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 28' ' ' THR . . . . . 0.505 HG22 ' O ' ' A' ' 28' ' ' THR . 16.9 m -129.23 88.65 2.73 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.242 -0.436 . . . . 74.44 111.184 -179.883 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . 0.764 HG23 ' CB ' ' A' ' 39' ' ' ILE . 1.8 pt -44.64 130.99 1.7 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.218 -0.446 . . . . 74.45 111.135 179.917 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . 0.695 HG23 ' O ' ' A' ' 35' ' ' SER . 7.3 m -153.73 97.98 2.16 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.167 -0.47 . . . . 71.12 111.15 179.934 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 87.1 p -137.76 70.92 1.39 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.229 -0.441 . . . . 63.2 110.921 -179.858 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -178.61 167.52 38.01 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.779 -0.724 . . . . 55.2 112.511 -179.924 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 3.6 pt-20 -49.45 -23.01 1.34 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.798 0.332 . . . . 71.22 110.851 -179.935 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -174.6 94.22 0.08 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.228 -0.442 . . . . 75.22 110.919 -179.913 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 35' ' ' SER . . . . . 0.695 ' O ' HG23 ' A' ' 30' ' ' THR . 3.1 m -144.71 165.77 27.12 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.161 -0.472 . . . . 72.51 110.821 -179.81 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 178.6 87.6 0.07 OUTLIER Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.78 -0.724 . . . . 75.41 112.497 -179.975 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . 0.676 ' HB3' ' CD1' ' A' ' 29' ' ' ILE . . . -109.03 -172.49 2.06 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.904 0.383 . . . . 74.42 111.078 179.983 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 4.0 p -97.97 123.04 50.22 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.209 -0.451 . . . . 72.34 111.12 179.969 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 39' ' ' ILE . . . . . 0.823 HG23 ' HB3' ' A' ' 27' ' ' ALA . 0.0 OUTLIER -138.53 149.9 24.1 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.137 -0.483 . . . . 65.31 111.165 179.906 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 40' ' ' ARG . . . . . 0.548 ' O ' HG12 ' A' ' 67' ' ' VAL . 6.6 mtm-85 -109.1 80.05 1.28 Allowed 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.159 -0.473 . . . . 72.43 110.879 -179.962 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . 0.52 ' HA2' HG12 ' A' ' 67' ' ' VAL . . . -128.38 148.78 18.03 Favored Glycine 0 N--CA 1.45 -0.374 0 C-N-CA 120.814 -0.708 . . . . 70.23 112.577 -179.937 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 42' ' ' VAL . . . . . 0.573 HG12 ' CB ' ' A' ' 66' ' ' PHE . 3.4 p -127.53 138.79 53.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-O 120.837 0.351 . . . . 72.44 111.148 -179.986 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 43' ' ' PHE . . . . . 0.613 ' H ' HD11 ' A' ' 83' ' ' ILE . 2.5 p90 -98.36 128.76 44.92 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.175 -0.466 . . . . 61.14 110.887 -179.966 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -107.75 124.0 49.38 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.12 -0.491 . . . . 74.43 110.812 180.0 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -120.33 106.13 40.89 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-O 121.61 0.719 . . . . 61.42 110.854 179.976 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 46' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.73 -41.64 4.14 Favored 'Trans proline' 0 C--N 1.343 0.238 0 C-N-CA 122.582 2.188 . . . . 75.44 112.415 179.987 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 20.7 mt-10 -146.78 89.95 1.87 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.227 -0.442 . . . . 63.34 110.904 -179.992 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 2.2 t-20 -62.84 99.74 0.17 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.123 -0.489 . . . . 75.24 110.894 -179.963 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 4.9 pt -148.96 179.82 0.63 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.207 -0.451 . . . . 75.21 111.136 179.929 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -122.36 154.72 37.3 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.145 -0.479 . . . . 71.02 110.823 -179.91 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 9.3 m-85 -127.28 -72.89 0.62 Allowed 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.086 -0.506 . . . . 74.12 110.951 -179.848 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . 0.883 ' HB1' HG21 ' A' ' 56' ' ' VAL . . . -52.73 169.56 0.09 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.057 -0.52 . . . . 75.21 111.137 179.835 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -152.34 -113.63 0.56 Allowed Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.685 -0.769 . . . . 53.14 112.463 -179.951 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 54' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -53.83 147.26 12.26 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.796 0.331 . . . . 51.01 110.891 -179.888 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 78.23 -59.31 3.99 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.736 -0.745 . . . . 51.45 112.514 -179.971 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . 0.883 HG21 ' HB1' ' A' ' 52' ' ' ALA . 43.4 t -53.84 147.41 2.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-O 120.856 0.36 . . . . 70.22 111.079 -179.93 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 22.0 ptt180 -90.38 -32.83 16.29 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.104 -0.498 . . . . 72.12 110.838 -179.931 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 58' ' ' VAL . . . . . 0.435 ' H ' HG12 ' A' ' 56' ' ' VAL . 38.4 t -144.0 138.64 24.73 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.206 -0.452 . . . . 72.12 111.101 -179.979 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 6.6 pt-20 -54.38 173.51 0.07 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.12 -0.491 . . . . 63.24 110.934 179.983 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -100.0 100.95 2.27 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.717 -0.754 . . . . 34.41 112.475 -179.947 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 1.4 m -148.03 129.73 15.09 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.859 0.361 . . . . 71.54 110.911 -179.768 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . 0.418 ' HA ' ' HD2' ' A' ' 63' ' ' PRO . 1.1 t -137.06 97.59 10.82 Favored Pre-proline 0 C--N 1.328 -0.332 0 CA-C-O 121.626 0.727 . . . . 61.02 110.831 -179.755 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 63' ' ' PRO . . . . . 0.418 ' HD2' ' HA ' ' A' ' 62' ' ' SER . 53.6 Cg_endo -69.78 -172.9 0.63 Allowed 'Trans proline' 0 C--O 1.231 0.15 0 C-N-CA 122.613 2.209 . . . . 73.12 112.359 179.946 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . 0.516 ' O ' ' HA ' ' A' ' 43' ' ' PHE . 0.1 OUTLIER -106.54 148.39 28.29 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.203 -0.453 . . . . 65.13 110.865 -179.832 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 65' ' ' LEU . . . . . 0.558 HD11 ' CG1' ' A' ' 67' ' ' VAL . 2.8 tm? -114.55 129.29 56.65 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.134 -0.484 . . . . 75.01 110.924 -179.96 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 66' ' ' PHE . . . . . 0.573 ' CB ' HG12 ' A' ' 42' ' ' VAL . 1.7 t80 -119.03 105.68 11.67 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.257 -0.428 . . . . 74.21 110.889 179.937 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 67' ' ' VAL . . . . . 0.558 ' CG1' HD11 ' A' ' 65' ' ' LEU . 33.7 m -141.04 172.51 10.85 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-N 116.148 -0.478 . . . . 74.04 111.126 -179.968 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 68' ' ' ARG . . . . . 0.447 ' HG2' ' H ' ' A' ' 71' ' ' GLU . 1.1 ptp180 -109.23 144.47 37.3 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.194 -0.457 . . . . 64.4 110.849 -179.986 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 69' ' ' THR . . . . . 0.759 HG22 ' HA2' ' A' ' 99' ' ' GLY . 0.0 OUTLIER -38.01 -56.88 1.1 Allowed 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.202 -0.454 . . . . 73.14 111.189 -179.927 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 70' ' ' ASP . . . . . 0.46 ' H ' HG23 ' A' ' 69' ' ' THR . 7.8 t70 -44.28 -59.43 2.38 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.155 -0.475 . . . . 70.21 110.865 179.908 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 71' ' ' GLU . . . . . 0.447 ' H ' ' HG2' ' A' ' 68' ' ' ARG . 1.2 tm-20 -59.35 -42.1 90.74 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.217 -0.447 . . . . 74.22 110.92 -179.966 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 72' ' ' VAL . . . . . 0.651 HG12 ' HA ' ' A' ' 69' ' ' THR . 0.3 OUTLIER -82.98 4.42 2.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.117 -0.492 . . . . 74.13 111.073 -179.948 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 73' ' ' ARG . . . . . 0.521 ' N ' ' O ' ' A' ' 69' ' ' THR . 16.1 ttt180 -98.31 -37.98 9.44 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.168 -0.469 . . . . 75.14 110.86 -179.993 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 48.7 mt-30 -65.67 -12.36 52.85 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.252 -0.431 . . . . 74.4 110.956 -179.978 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 75' ' ' LEU . . . . . 0.651 HD21 HG21 ' A' ' 29' ' ' ILE . 3.1 mp -107.99 -174.46 2.53 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.157 -0.474 . . . . 70.11 110.877 -179.964 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 76' ' ' ARG . . . . . . . . . . . . . 10.5 ptp180 -117.91 154.37 32.02 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.164 -0.471 . . . . 75.34 110.941 179.965 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 3.7 ptt180 -51.21 131.91 28.15 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.24 -0.436 . . . . 70.03 110.87 -179.909 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 86.77 42.97 6.21 Favored Glycine 0 N--CA 1.452 -0.24 0 C-N-CA 120.735 -0.745 . . . . 60.23 112.397 179.944 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -103.43 110.74 22.88 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.909 0.385 . . . . 74.01 110.85 -179.963 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . 0.733 ' HA ' ' HA ' ' A' ' 89' ' ' TRP . 0.0 OUTLIER -88.62 108.59 19.52 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.119 -0.491 . . . . 62.12 111.209 -179.886 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 81' ' ' LEU . . . . . 0.787 ' C ' ' HA ' ' A' ' 87' ' ' ASN . 0.0 OUTLIER -98.18 135.24 40.12 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.272 -0.422 . . . . 71.21 110.928 -179.986 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 82' ' ' THR . . . . . 0.7 ' N ' ' HA ' ' A' ' 87' ' ' ASN . 8.0 t -93.63 101.59 13.75 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.204 -0.453 . . . . 63.4 111.145 179.968 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 83' ' ' ILE . . . . . 0.714 HD13 ' O ' ' A' ' 83' ' ' ILE . 0.1 OUTLIER -136.18 131.11 48.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.22 -0.446 . . . . 75.01 111.184 179.861 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 73.0 -54.59 1.78 Allowed Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.785 -0.722 . . . . 64.14 112.507 179.936 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 10.7 mm-40 -113.55 -80.65 0.59 Allowed 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 120.86 0.362 . . . . 64.4 110.875 -179.922 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 86' ' ' GLU . . . . . 0.46 ' C ' ' HA ' ' A' ' 82' ' ' THR . 96.1 mt-10 -154.54 161.06 41.82 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 116.159 -0.473 . . . . 64.42 110.823 -179.939 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 87' ' ' ASN . . . . . 0.787 ' HA ' ' C ' ' A' ' 81' ' ' LEU . 1.6 p-10 -50.7 121.98 6.63 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.156 -0.474 . . . . 74.5 110.921 -179.957 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 88' ' ' PHE . . . . . 0.747 ' CB ' HD13 ' A' ' 105' ' ' LEU . 14.7 m-85 -131.08 120.86 24.02 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.155 -0.475 . . . . 75.14 110.903 -179.972 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 89' ' ' TRP . . . . . 0.733 ' HA ' ' HA ' ' A' ' 80' ' ' THR . 0.9 OUTLIER -80.11 135.77 36.39 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.12 -0.491 . . . . 64.12 110.913 -179.951 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 90' ' ' VAL . . . . . 0.464 ' HA ' ' HB3' ' A' ' 105' ' ' LEU . 0.3 OUTLIER -92.58 138.23 20.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.264 -0.426 . . . . 71.01 111.101 179.925 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -65.61 -71.19 0.2 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.186 -0.461 . . . . 75.21 110.85 179.935 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 92' ' ' ARG . . . . . 0.526 ' O ' ' HG ' ' A' ' 103' ' ' LEU . 0.0 OUTLIER -152.58 120.89 6.3 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.251 -0.432 . . . . 74.24 110.838 -179.882 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 93' ' ' VAL . . . . . 0.617 HG12 ' CB ' ' A' ' 103' ' ' LEU . 8.8 m -121.45 137.28 55.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.254 -0.43 . . . . 65.14 111.121 179.928 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 12.6 t -137.14 128.4 16.44 Favored Pre-proline 0 C--N 1.328 -0.337 0 CA-C-O 121.714 0.769 . . . . 73.01 110.862 -179.856 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 95' ' ' PRO . . . . . 0.479 ' HG3' ' HB ' ' A' ' 69' ' ' THR . 53.2 Cg_endo -69.85 160.51 49.42 Favored 'Trans proline' 0 C--N 1.342 0.198 0 C-N-CA 122.681 2.254 . . . . 71.31 112.322 -179.946 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 9.4 t0 -118.23 -25.35 6.64 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.256 -0.429 . . . . 74.34 110.844 179.945 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER 177.9 85.5 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.277 -0.419 . . . . 75.31 110.909 -179.96 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 99.71 55.42 1.01 Allowed Glycine 0 N--CA 1.452 -0.267 0 C-N-CA 120.726 -0.75 . . . . 40.14 112.508 -179.959 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 99' ' ' GLY . . . . . 0.759 ' HA2' HG22 ' A' ' 69' ' ' THR . . . 40.29 77.53 0.07 OUTLIER Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.769 -0.729 . . . . 72.43 112.461 -179.918 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 20.1 t -125.81 12.12 7.87 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.91 0.386 . . . . 75.14 110.842 -179.745 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 101' ' ' CYS . . . . . 0.571 ' HB2' ' HB ' ' A' ' 93' ' ' VAL . 19.6 p -47.23 142.31 3.98 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.16 -0.473 . . . . 73.45 110.882 -179.98 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 102' ' ' HIS . . . . . 0.437 ' HA ' ' O ' ' A' ' 65' ' ' LEU . 43.4 p-80 -159.97 129.38 5.2 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.241 -0.436 . . . . 75.43 110.836 -179.934 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 103' ' ' LEU . . . . . 0.874 HD13 ' N ' ' A' ' 104' ' ' TRP . 2.8 tm? -150.8 148.4 28.45 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 116.239 -0.437 . . . . 72.24 110.943 -179.998 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 104' ' ' TRP . . . . . 0.874 ' N ' HD13 ' A' ' 103' ' ' LEU . 56.3 p-90 -64.34 118.02 8.08 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.174 -0.466 . . . . 64.3 110.855 179.946 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 105' ' ' LEU . . . . . 0.747 HD13 ' CB ' ' A' ' 88' ' ' PHE . 0.4 OUTLIER -93.92 162.8 13.76 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.266 -0.425 . . . . 71.42 110.866 179.978 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -91.0 160.39 27.26 Favored Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.712 -0.756 . . . . 65.44 112.498 179.892 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 107' ' ' ARG . . . . . 0.544 ' HA ' ' CD1' ' A' ' 88' ' ' PHE . 0.0 OUTLIER -65.73 157.39 30.31 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.856 0.36 . . . . 74.43 110.925 -179.895 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -173.1 110.18 0.33 Allowed Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.644 -0.789 . . . . 32.31 112.454 179.984 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 109' ' ' VAL . . . . . 0.453 HG23 ' HD2' ' A' ' 110' ' ' PRO . 7.1 p -84.19 133.89 44.38 Favored Pre-proline 0 C--N 1.33 -0.28 0 CA-C-O 121.687 0.756 . . . . 74.1 111.084 -179.93 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 110' ' ' PRO . . . . . 0.453 ' HD2' HG23 ' A' ' 109' ' ' VAL . 53.8 Cg_endo -69.68 168.22 22.08 Favored 'Trans proline' 0 C--N 1.342 0.222 0 C-N-CA 122.644 2.229 . . . . 61.33 112.328 179.928 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 111' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.77 -8.94 24.87 Favored 'Trans proline' 0 C--N 1.342 0.189 0 C-N-CA 122.66 2.24 . . . . 72.02 112.358 179.905 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -59.67 161.08 6.49 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.231 -0.44 . . . . 74.0 111.072 179.891 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 6.4 p -93.69 124.2 46.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.209 -0.45 . . . . 74.03 111.073 -179.986 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 114' ' ' ASN . . . . . . . . . . . . . 2.6 m-20 -128.71 145.54 51.14 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.132 -0.485 . . . . 74.43 110.849 179.994 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 13.3 mtt180 -82.91 103.31 12.28 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.109 -0.496 . . . . 54.02 110.9 179.983 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 116' ' ' ARG . . . . . . . . . . . . . 2.7 mmp_? -115.24 138.1 51.31 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.171 -0.468 . . . . 65.22 110.804 -179.85 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 15.7 tpt180 . . . . . 0 C--N 1.329 -0.293 0 CA-C-N 116.173 -0.467 . . . . 64.23 110.866 -179.922 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 1.3 mpt? . . . . . 0 C--O 1.231 0.09 0 CA-C-O 120.749 0.309 . . . . 32.3 110.86 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . 52.9 47.04 25.54 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.218 -0.447 . . . . 73.13 111.122 179.939 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 3' ' ' ASP . . . . . . . . . . . . . 6.2 p-10 -117.11 150.13 39.19 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.176 -0.465 . . . . 63.12 110.881 179.968 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 4' ' ' PHE . . . . . . . . . . . . . 47.7 t80 -170.42 150.77 3.56 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.233 -0.44 . . . . 74.14 110.886 -179.913 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 33.5 m-20 -153.74 157.24 39.18 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.162 -0.472 . . . . 64.51 110.864 -179.988 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 6' ' ' ASN . . . . . . . . . . . . . 6.7 p30 -173.76 141.2 0.81 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.242 -0.435 . . . . 63.2 110.921 -179.92 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 7' ' ' LEU . . . . . . . . . . . . . 20.1 mt -107.33 171.39 7.41 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.173 -0.467 . . . . 71.44 110.957 179.941 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 8' ' ' PHE . . . . . . . . . . . . . 11.9 t80 -129.64 58.06 1.65 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.207 -0.451 . . . . 71.54 110.94 179.934 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 3.0 m-20 -118.74 127.06 53.2 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.141 -0.481 . . . . 54.53 110.892 179.992 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -68.55 133.53 48.69 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.253 -0.431 . . . . 75.22 111.057 179.946 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -164.05 164.39 23.0 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.172 -0.467 . . . . 64.24 111.086 179.942 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 3.4 mp -125.31 64.76 0.3 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.244 -0.434 . . . . 71.4 111.188 179.901 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -145.87 56.44 1.2 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.173 -0.467 . . . . 72.12 111.095 179.847 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 31.8 mmm-85 -104.72 -179.53 3.97 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.27 -0.423 . . . . 64.14 110.866 -179.902 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -171.01 130.67 0.78 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.179 -0.464 . . . . 74.44 111.057 179.903 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 4.3 p-10 -93.58 47.4 1.23 Allowed 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.179 -0.464 . . . . 54.24 110.874 -179.988 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 6.8 mm-40 -117.83 -172.27 2.21 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.202 -0.454 . . . . 74.12 110.875 -179.848 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 39.7 p -74.04 -178.35 3.29 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.143 -0.481 . . . . 72.02 111.135 -179.923 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 2.7 pt -114.35 74.36 0.39 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.242 -0.435 . . . . 73.23 111.065 179.933 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 20' ' ' ARG . . . . . . . . . . . . . 9.0 tpp180 -110.06 -64.28 1.28 Allowed 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.157 -0.474 . . . . 73.33 110.88 179.924 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -71.36 140.5 30.92 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.755 -0.736 . . . . 52.11 112.494 -179.965 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 22' ' ' TYR . . . . . . . . . . . . . 5.9 t80 -121.7 -67.47 0.96 Allowed 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.842 0.353 . . . . 75.54 110.923 -179.824 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 23' ' ' MET . . . . . . . . . . . . . 10.4 ptm -175.81 173.48 2.32 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.147 -0.478 . . . . 70.33 110.899 179.888 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 138.59 -142.95 13.6 Favored Glycine 0 N--CA 1.452 -0.239 0 C-N-CA 120.727 -0.749 . . . . 70.43 112.448 -179.973 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 25' ' ' THR . . . . . 0.821 ' HB ' HG22 ' A' ' 42' ' ' VAL . 98.6 m -96.74 126.7 42.09 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.804 0.335 . . . . 65.13 111.107 -179.815 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 3.0 p -70.81 123.5 22.11 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.173 -0.467 . . . . 75.4 110.823 -179.844 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 27' ' ' ALA . . . . . 0.84 ' HB3' HG23 ' A' ' 39' ' ' ILE . . . -135.24 162.42 32.61 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.074 -0.512 . . . . 63.51 111.104 179.884 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 28' ' ' THR . . . . . 0.503 HG22 ' O ' ' A' ' 28' ' ' THR . 21.7 m -129.33 85.8 2.36 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.216 -0.447 . . . . 73.22 111.09 -179.902 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . 0.682 HG23 HG21 ' A' ' 39' ' ' ILE . 1.9 pt -44.92 126.93 1.3 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.182 -0.463 . . . . 73.44 111.137 179.884 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . 0.669 HG23 ' O ' ' A' ' 35' ' ' SER . 17.6 m -151.93 97.87 2.39 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.119 -0.491 . . . . 74.42 111.143 -179.983 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . 0.517 ' OG ' HG22 ' A' ' 80' ' ' THR . 5.1 t -136.5 70.53 1.41 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.161 -0.472 . . . . 73.54 110.913 -179.853 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -178.88 168.8 39.92 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.771 -0.728 . . . . 74.42 112.536 -179.93 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 5.8 pt-20 -49.31 -23.25 1.33 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.809 0.338 . . . . 64.03 110.9 -179.906 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -174.76 95.29 0.08 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.204 -0.453 . . . . 53.23 110.913 -179.908 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 35' ' ' SER . . . . . 0.669 ' O ' HG23 ' A' ' 30' ' ' THR . 2.3 m -145.24 165.41 28.46 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.148 -0.478 . . . . 72.15 110.84 -179.794 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 176.36 88.42 0.07 OUTLIER Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 120.756 -0.735 . . . . 44.13 112.515 -179.988 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . 0.667 ' HB3' ' CD1' ' A' ' 29' ' ' ILE . . . -108.11 -170.53 1.7 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.809 0.337 . . . . 73.35 111.161 179.994 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . 0.413 ' O ' HG13 ' A' ' 38' ' ' VAL . 4.4 p -99.03 119.64 47.29 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.293 -0.412 . . . . 41.14 111.112 179.983 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 39' ' ' ILE . . . . . 0.84 HG23 ' HB3' ' A' ' 27' ' ' ALA . 0.0 OUTLIER -139.1 151.56 23.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.059 -0.518 . . . . 73.33 111.096 179.938 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 40' ' ' ARG . . . . . . . . . . . . . 1.4 ptp85 -113.59 82.86 1.75 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.191 -0.459 . . . . 75.04 110.879 179.964 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . 0.434 ' N ' HD13 ' A' ' 39' ' ' ILE . . . -111.92 146.46 18.0 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.723 -0.751 . . . . 61.44 112.436 -179.923 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 42' ' ' VAL . . . . . 0.821 HG22 ' HB ' ' A' ' 25' ' ' THR . 2.2 t -124.58 112.57 32.68 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-O 120.882 0.372 . . . . 72.41 111.08 -179.937 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 43' ' ' PHE . . . . . 0.526 ' HA ' ' O ' ' A' ' 64' ' ' SER . 2.4 p90 -87.29 131.38 34.26 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.141 -0.481 . . . . 74.12 110.89 -179.976 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 2.8 t70 -129.78 125.34 35.56 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.129 -0.487 . . . . 74.12 110.811 -179.965 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 2.5 p-10 -102.46 152.97 38.43 Favored Pre-proline 0 C--N 1.33 -0.276 0 CA-C-O 121.567 0.698 . . . . 64.14 110.862 -179.928 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 46' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.89 -37.89 8.25 Favored 'Trans proline' 0 C--N 1.341 0.161 0 C-N-CA 122.724 2.283 . . . . 54.44 112.307 -179.907 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 1.2 mp0 -91.92 64.98 4.81 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.249 -0.432 . . . . 73.2 110.887 179.97 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 2.8 t30 -92.78 124.86 37.08 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.107 -0.497 . . . . 72.31 110.959 179.98 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 12.6 tt -146.98 137.81 17.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.194 -0.457 . . . . 72.21 111.163 179.91 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 2.8 p 46.29 39.36 6.19 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.191 -0.459 . . . . 61.24 110.831 -179.893 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 15.9 p90 -55.15 -27.75 47.78 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.151 -0.477 . . . . 64.42 110.969 -179.951 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -97.35 41.31 1.12 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.099 -0.5 . . . . 71.24 111.135 179.872 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -147.18 -86.37 0.06 OUTLIER Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.8 -0.714 . . . . 73.52 112.486 -179.903 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 54' ' ' GLN . . . . . . . . . . . . . 3.8 tt0 -176.11 126.75 0.21 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.783 0.325 . . . . 74.35 110.918 -179.945 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . -144.3 89.97 0.16 Allowed Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.706 -0.759 . . . . 73.1 112.539 -179.963 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 21.8 t -85.71 71.52 0.79 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 CA-C-O 120.798 0.333 . . . . 74.31 111.104 -179.922 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 29.3 ptt-85 -177.17 145.24 0.45 Allowed 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.194 -0.457 . . . . 75.32 110.909 179.962 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 74.7 t -148.04 144.68 19.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.16 -0.473 . . . . 70.0 111.162 179.95 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 11.2 mt-10 -113.01 -171.78 1.93 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.122 -0.49 . . . . 71.54 110.937 179.976 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -90.09 100.42 2.67 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.75 -0.738 . . . . 53.13 112.447 -179.92 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -149.83 159.24 44.52 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.846 0.355 . . . . 71.2 110.881 -179.815 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . 0.425 ' HA ' ' HD2' ' A' ' 63' ' ' PRO . 1.1 p -105.82 97.31 14.66 Favored Pre-proline 0 C--N 1.33 -0.277 0 CA-C-O 121.613 0.721 . . . . 74.11 110.858 -179.774 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 63' ' ' PRO . . . . . 0.425 ' HD2' ' HA ' ' A' ' 62' ' ' SER . 54.1 Cg_endo -69.82 169.41 19.05 Favored 'Trans proline' 0 C--N 1.342 0.207 0 C-N-CA 122.706 2.271 . . . . 45.22 112.37 179.984 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . 0.526 ' O ' ' HA ' ' A' ' 43' ' ' PHE . 1.3 t -106.19 142.51 35.77 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.259 -0.428 . . . . 71.12 110.906 -179.816 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 65' ' ' LEU . . . . . 1.031 HD11 HG13 ' A' ' 67' ' ' VAL . 0.4 OUTLIER -110.75 123.72 50.59 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.178 -0.464 . . . . 52.12 110.942 179.982 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 66' ' ' PHE . . . . . 0.571 ' N ' HD12 ' A' ' 65' ' ' LEU . 0.2 OUTLIER -94.05 111.83 23.59 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.23 -0.441 . . . . 74.34 110.924 179.961 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 67' ' ' VAL . . . . . 1.031 HG13 HD11 ' A' ' 65' ' ' LEU . 0.4 OUTLIER -140.92 167.28 17.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.227 -0.442 . . . . 64.35 111.109 -179.998 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 68' ' ' ARG . . . . . 0.4 ' HB3' ' HG2' ' A' ' 71' ' ' GLU . 3.5 ttp85 -96.84 132.42 42.6 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.174 -0.466 . . . . 71.23 110.91 -179.952 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 69' ' ' THR . . . . . 0.414 ' O ' HG12 ' A' ' 72' ' ' VAL . 1.4 m -44.67 -36.81 3.29 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.246 -0.433 . . . . 74.03 111.126 -179.825 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 70' ' ' ASP . . . . . . . . . . . . . 33.2 t0 -59.02 -71.88 0.11 Allowed 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.199 -0.455 . . . . 71.52 110.872 179.868 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 71' ' ' GLU . . . . . 0.473 ' O ' HD12 ' A' ' 75' ' ' LEU . 3.1 pt-20 -56.37 -37.73 70.45 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.176 -0.466 . . . . 51.13 110.875 -179.849 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 72' ' ' VAL . . . . . 0.414 HG12 ' O ' ' A' ' 69' ' ' THR . 0.4 OUTLIER -68.74 -25.39 30.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.157 -0.474 . . . . 71.0 111.148 179.982 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 73' ' ' ARG . . . . . . . . . . . . . 24.7 ttm-85 -75.9 -39.3 56.62 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.107 -0.497 . . . . 71.35 110.869 -179.996 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 12.4 mt-30 -54.73 -29.09 52.59 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.214 -0.448 . . . . 62.5 110.895 -179.936 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 75' ' ' LEU . . . . . 0.517 HD23 ' CG ' ' A' ' 79' ' ' ASP . 3.4 mp -87.26 -175.82 5.43 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.182 -0.463 . . . . 72.53 110.944 -179.973 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 76' ' ' ARG . . . . . . . . . . . . . 6.8 ttt-85 -109.47 139.33 44.59 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.192 -0.458 . . . . 74.43 110.866 179.962 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 3.3 ptt85 -48.65 108.31 0.17 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.224 -0.443 . . . . 74.32 110.844 -179.92 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 119.55 9.96 8.15 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.663 -0.78 . . . . 63.33 112.536 -179.932 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . 0.517 ' CG ' HD23 ' A' ' 75' ' ' LEU . 0.4 OUTLIER -73.09 109.12 6.38 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.945 0.402 . . . . 72.11 110.914 -179.994 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . 0.716 ' HA ' ' HA ' ' A' ' 89' ' ' TRP . 0.0 OUTLIER -85.51 110.34 19.13 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.17 -0.468 . . . . 74.45 111.118 -179.828 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 81' ' ' LEU . . . . . 0.758 ' C ' ' HA ' ' A' ' 87' ' ' ASN . 0.3 OUTLIER -97.63 132.43 43.29 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.222 -0.445 . . . . 71.42 110.887 179.97 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 82' ' ' THR . . . . . 0.762 ' CA ' ' HA ' ' A' ' 87' ' ' ASN . 6.7 t -91.57 102.35 15.0 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.189 -0.46 . . . . 73.41 111.139 179.925 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 83' ' ' ILE . . . . . 0.733 ' CG2' HD12 ' A' ' 81' ' ' LEU . 0.1 OUTLIER -139.24 131.2 35.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.223 -0.444 . . . . 74.31 111.119 179.923 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 76.74 -51.67 3.1 Favored Glycine 0 N--CA 1.452 -0.264 0 C-N-CA 120.715 -0.755 . . . . 40.34 112.471 179.9 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 6.7 tp10 -121.37 -77.83 0.59 Allowed 'General case' 0 C--N 1.331 -0.229 0 CA-C-O 120.818 0.342 . . . . 62.54 110.876 -179.876 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 86' ' ' GLU . . . . . 0.472 ' C ' ' HA ' ' A' ' 82' ' ' THR . 98.8 mt-10 -152.76 162.29 41.46 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.12 -0.491 . . . . 73.22 110.923 -179.977 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 87' ' ' ASN . . . . . 0.762 ' HA ' ' CA ' ' A' ' 82' ' ' THR . 2.4 p30 -51.5 122.02 7.31 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.183 -0.462 . . . . 73.41 110.899 -179.975 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 88' ' ' PHE . . . . . 0.776 ' HB2' HD22 ' A' ' 105' ' ' LEU . 13.9 m-85 -131.77 119.4 21.23 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.184 -0.462 . . . . 70.55 110.935 179.95 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 89' ' ' TRP . . . . . 0.716 ' HA ' ' HA ' ' A' ' 80' ' ' THR . 65.4 p-90 -82.21 132.87 35.23 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.164 -0.471 . . . . 71.31 110.96 179.983 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 90' ' ' VAL . . . . . 0.515 ' HA ' ' HB3' ' A' ' 105' ' ' LEU . 4.0 p -95.39 139.11 19.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.231 -0.441 . . . . 75.31 111.156 179.92 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 91' ' ' ASP . . . . . 0.476 ' HB2' HD21 ' A' ' 103' ' ' LEU . 1.9 t70 -58.84 -73.82 0.08 Allowed 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.208 -0.451 . . . . 63.44 110.877 179.959 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 92' ' ' ARG . . . . . 0.684 ' O ' HD13 ' A' ' 103' ' ' LEU . 8.2 ttt180 -170.15 121.39 0.64 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.215 -0.448 . . . . 73.21 110.898 -179.908 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 93' ' ' VAL . . . . . 0.532 ' HB ' ' HB3' ' A' ' 101' ' ' CYS . 2.6 m -104.83 139.0 27.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.217 -0.447 . . . . 72.41 111.176 179.917 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 12.1 t -130.1 96.53 25.18 Favored Pre-proline 0 C--N 1.33 -0.278 0 CA-C-O 121.577 0.703 . . . . 63.52 110.826 -179.766 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 95' ' ' PRO . . . . . 0.428 ' CB ' ' H ' ' A' ' 100' ' ' SER . 52.6 Cg_endo -69.8 -167.39 0.22 Allowed 'Trans proline' 0 C--N 1.341 0.152 0 C-N-CA 122.655 2.237 . . . . 72.03 112.319 179.97 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 5.8 t0 -135.57 5.99 3.21 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.226 -0.443 . . . . 70.01 110.871 179.971 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 8.7 t70 -159.56 105.46 1.65 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.224 -0.444 . . . . 74.4 110.795 -179.946 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . 63.39 -90.03 0.07 OUTLIER Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.768 -0.73 . . . . 70.14 112.515 -179.996 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 99' ' ' GLY . . . . . . . . . . . . . . . -163.57 87.81 0.1 Allowed Glycine 0 N--CA 1.45 -0.38 0 C-N-CA 120.752 -0.737 . . . . 44.24 112.511 -179.961 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 100' ' ' SER . . . . . 0.428 ' H ' ' CB ' ' A' ' 95' ' ' PRO . 12.0 t -155.07 79.22 1.05 Allowed 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.809 0.338 . . . . 72.44 110.774 -179.71 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 101' ' ' CYS . . . . . 0.532 ' HB3' ' HB ' ' A' ' 93' ' ' VAL . 1.8 t -132.12 -172.83 2.98 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.185 -0.462 . . . . 54.4 110.849 -179.955 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 102' ' ' HIS . . . . . 0.408 ' HB3' ' HA ' ' A' ' 66' ' ' PHE . 2.6 p-80 -169.53 138.91 1.99 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.183 -0.462 . . . . 73.12 110.91 -179.933 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 103' ' ' LEU . . . . . 0.684 HD13 ' O ' ' A' ' 92' ' ' ARG . 6.2 tt -139.26 155.79 47.51 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.267 -0.424 . . . . 61.1 110.945 -179.943 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 104' ' ' TRP . . . . . 0.451 ' O ' HD23 ' A' ' 103' ' ' LEU . 48.4 p-90 -64.21 110.27 2.15 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 116.18 -0.464 . . . . 65.12 110.871 179.92 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 105' ' ' LEU . . . . . 0.776 HD22 ' HB2' ' A' ' 88' ' ' PHE . 0.4 OUTLIER -91.24 163.05 14.38 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.218 -0.446 . . . . 65.24 110.958 179.957 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -89.13 157.64 27.21 Favored Glycine 0 N--CA 1.452 -0.266 0 C-N-CA 120.732 -0.747 . . . . 74.42 112.456 179.888 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 107' ' ' ARG . . . . . 0.516 ' HA ' ' CD1' ' A' ' 88' ' ' PHE . 65.5 ttp85 -69.99 156.91 38.43 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.784 0.326 . . . . 75.03 110.895 -179.856 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -169.77 108.15 0.29 Allowed Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.736 -0.745 . . . . 43.23 112.549 179.999 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 109' ' ' VAL . . . . . 0.471 HG23 ' HD2' ' A' ' 110' ' ' PRO . 7.3 p -90.14 134.16 32.08 Favored Pre-proline 0 C--N 1.329 -0.295 0 CA-C-O 121.566 0.698 . . . . 72.15 111.121 -179.906 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 110' ' ' PRO . . . . . 0.518 ' N ' HD21 ' A' ' 87' ' ' ASN . 53.2 Cg_endo -69.76 169.65 18.42 Favored 'Trans proline' 0 C--O 1.232 0.217 0 C-N-CA 122.737 2.291 . . . . 72.54 112.308 179.995 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 111' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.73 -8.9 24.78 Favored 'Trans proline' 0 C--N 1.342 0.197 0 C-N-CA 122.727 2.285 . . . . 73.42 112.355 179.923 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -102.67 102.29 12.47 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.216 -0.447 . . . . 72.43 111.126 179.868 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 32.0 m -130.5 140.11 49.62 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.182 -0.463 . . . . 62.42 111.11 179.985 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 114' ' ' ASN . . . . . . . . . . . . . 7.3 t-20 -100.31 113.16 25.65 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.158 -0.474 . . . . 72.02 110.858 179.986 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 14.1 mtm180 -113.09 147.97 36.22 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.155 -0.475 . . . . 65.34 110.848 -179.998 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 116' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -115.12 138.14 51.23 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.19 -0.459 . . . . 74.02 110.907 -179.948 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 12.2 ptm180 . . . . . 0 C--N 1.328 -0.33 0 CA-C-N 116.24 -0.436 . . . . 74.43 110.8 -179.865 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 13.9 mtt . . . . . 0 C--O 1.23 0.041 0 CA-C-O 120.755 0.312 . . . . 74.33 110.889 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 2' ' ' ALA . . . . . . . . . . . . . . . -95.36 131.5 41.4 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.168 -0.469 . . . . 74.42 111.097 179.897 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 3' ' ' ASP . . . . . . . . . . . . . 24.9 t70 -120.01 -33.94 3.83 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 116.274 -0.421 . . . . 62.34 110.845 179.931 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 4' ' ' PHE . . . . . . . . . . . . . 41.9 t80 -128.17 141.05 51.59 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.26 -0.427 . . . . 74.13 110.836 -179.874 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 17.0 m-20 -138.0 179.34 6.49 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.134 -0.484 . . . . 73.43 110.86 179.928 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 6' ' ' ASN . . . . . . . . . . . . . 7.6 t-20 -164.38 163.54 22.36 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.191 -0.459 . . . . 73.31 110.83 -179.894 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 7' ' ' LEU . . . . . . . . . . . . . 2.1 mp -144.61 -174.93 4.46 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.097 -0.501 . . . . 73.54 110.999 179.942 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 8' ' ' PHE . . . . . . . . . . . . . 2.7 t80 -159.95 175.37 13.11 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.247 -0.433 . . . . 65.31 110.894 179.924 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 5.9 t0 -109.27 -179.72 3.92 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.199 -0.455 . . . . 54.21 110.867 179.999 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 10' ' ' ALA . . . . . . . . . . . . . . . -144.83 -170.9 3.51 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.229 -0.442 . . . . 63.01 111.1 179.984 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -94.43 156.69 16.36 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.231 -0.44 . . . . 75.51 111.154 179.854 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 3.8 mp -139.64 73.16 0.25 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.233 -0.439 . . . . 70.43 111.166 179.991 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -151.04 159.43 44.54 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.219 -0.446 . . . . 74.11 111.088 179.865 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 14' ' ' ARG . . . . . . . . . . . . . 6.8 ttp180 -171.01 179.25 3.15 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.194 -0.457 . . . . 72.25 110.844 -179.893 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -137.62 -174.88 3.89 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.149 -0.478 . . . . 71.51 111.056 179.933 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -162.64 -178.15 6.02 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.156 -0.474 . . . . 62.14 110.846 179.948 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 17' ' ' GLU . . . . . . . . . . . . . 13.3 tp10 -104.14 139.63 38.93 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.248 -0.433 . . . . 72.21 110.883 -179.861 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -54.07 169.28 0.17 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.213 -0.448 . . . . 74.53 111.097 -179.932 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . 0.432 HG22 ' O ' ' A' ' 19' ' ' ILE . 14.4 mm -118.99 0.35 8.0 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.166 -0.47 . . . . 74.25 111.107 179.862 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 20' ' ' ARG . . . . . . . . . . . . . 24.9 mtt-85 61.0 95.78 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.197 -0.456 . . . . 73.24 110.907 179.949 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 157.96 123.8 0.76 Allowed Glycine 0 N--CA 1.452 -0.262 0 C-N-CA 120.751 -0.738 . . . . 64.41 112.489 -179.908 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 22' ' ' TYR . . . . . . . . . . . . . 7.6 p90 -178.76 140.25 0.18 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.915 0.388 . . . . 71.32 110.87 -179.849 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 23' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -179.25 136.92 0.13 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.07 -0.514 . . . . 75.23 110.853 179.854 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . 130.53 -91.53 0.3 Allowed Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.674 -0.774 . . . . 52.43 112.489 -179.954 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 25' ' ' THR . . . . . 0.611 ' O ' ' HA ' ' A' ' 40' ' ' ARG . 69.8 p -93.23 108.69 20.27 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.737 0.303 . . . . 74.2 111.156 -179.884 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -76.3 122.47 24.48 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.268 -0.424 . . . . 54.42 110.838 -179.838 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 27' ' ' ALA . . . . . 0.788 ' HB3' HG23 ' A' ' 39' ' ' ILE . . . -151.56 161.78 42.1 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.184 -0.462 . . . . 74.13 111.104 179.882 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 28' ' ' THR . . . . . 0.514 HG22 ' O ' ' A' ' 28' ' ' THR . 12.9 m -131.46 89.74 2.76 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.215 -0.448 . . . . 71.21 111.167 -179.97 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . 0.792 HG23 ' CB ' ' A' ' 39' ' ' ILE . 2.1 pt -44.22 130.23 1.48 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 116.186 -0.461 . . . . 73.11 111.12 179.932 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 30' ' ' THR . . . . . 0.716 HG23 ' O ' ' A' ' 35' ' ' SER . 9.1 m -153.61 99.26 2.3 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.218 -0.447 . . . . 75.55 111.137 179.924 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 8.1 t -139.34 72.41 1.4 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.184 -0.462 . . . . 64.31 110.856 -179.819 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -178.96 166.95 36.9 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.796 -0.716 . . . . 73.05 112.512 179.999 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 33' ' ' GLU . . . . . . . . . . . . . 17.1 pt-20 -49.24 -23.58 1.41 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.743 0.306 . . . . 70.41 110.829 -179.901 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 1.1 mt-30 -174.4 93.65 0.08 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.193 -0.458 . . . . 62.54 110.948 -179.829 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 35' ' ' SER . . . . . 0.716 ' O ' HG23 ' A' ' 30' ' ' THR . 3.2 m -145.95 165.71 28.16 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.196 -0.456 . . . . 72.43 110.885 -179.793 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 179.46 86.97 0.07 OUTLIER Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.788 -0.72 . . . . 55.21 112.542 -179.966 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 37' ' ' ALA . . . . . 0.657 ' HB3' ' CD1' ' A' ' 29' ' ' ILE . . . -105.79 -171.82 1.98 Allowed 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.81 0.338 . . . . 53.51 111.056 -179.955 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 38' ' ' VAL . . . . . . . . . . . . . 73.5 t -99.74 122.79 52.0 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-N 116.15 -0.477 . . . . 73.51 111.131 -179.985 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 39' ' ' ILE . . . . . 0.792 ' CB ' HG23 ' A' ' 29' ' ' ILE . 0.0 OUTLIER -136.82 150.24 26.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.189 -0.459 . . . . 75.03 111.093 179.882 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 40' ' ' ARG . . . . . 0.701 ' O ' HG12 ' A' ' 67' ' ' VAL . 10.1 mmt-85 -110.82 82.23 1.56 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.17 -0.468 . . . . 63.51 110.88 179.987 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . 0.546 ' O ' ' HB2' ' A' ' 27' ' ' ALA . . . -141.5 142.95 12.49 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.78 -0.724 . . . . 72.15 112.485 -179.965 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 42' ' ' VAL . . . . . 0.515 HG12 HG21 ' A' ' 25' ' ' THR . 8.8 p -127.46 142.34 43.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-O 120.912 0.387 . . . . 71.41 111.091 -179.95 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 43' ' ' PHE . . . . . 0.743 ' H ' HD11 ' A' ' 83' ' ' ILE . 2.0 p90 -90.05 135.19 33.8 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.205 -0.452 . . . . 55.52 110.937 179.905 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 44' ' ' ASP . . . . . . . . . . . . . 11.5 t0 -120.17 125.23 47.68 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.134 -0.485 . . . . 74.01 110.869 179.965 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 45' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -101.59 153.64 37.76 Favored Pre-proline 0 C--N 1.328 -0.339 0 CA-C-O 121.646 0.736 . . . . 70.01 110.854 179.988 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 46' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.78 -35.76 11.98 Favored 'Trans proline' 0 C--N 1.341 0.172 0 C-N-CA 122.629 2.22 . . . . 73.24 112.337 -179.905 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 40.1 tt0 63.92 57.93 1.28 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.204 -0.453 . . . . 72.2 110.807 179.966 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 48' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -146.8 -169.77 3.37 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.143 -0.48 . . . . 74.2 110.939 179.996 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 49' ' ' ILE . . . . . . . . . . . . . 1.3 pp -140.17 22.3 0.55 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.19 -0.459 . . . . 70.34 111.084 179.9 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 11.0 t -77.06 108.17 9.94 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.201 -0.454 . . . . 64.31 110.856 -179.938 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 51' ' ' TYR . . . . . . . . . . . . . 4.3 m-85 -160.88 178.56 9.29 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.112 -0.495 . . . . 75.01 110.865 -179.912 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -152.0 172.85 15.64 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.108 -0.496 . . . . 43.34 111.073 179.874 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 131.22 -171.73 20.97 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.746 -0.74 . . . . 72.11 112.523 -179.94 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 54' ' ' GLN . . . . . . . . . . . . . 4.7 mp0 -80.07 -43.11 22.37 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.874 0.369 . . . . 75.24 110.975 -179.911 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 114.19 -32.11 6.11 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.719 -0.753 . . . . 63.14 112.508 -179.98 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 48.1 t -52.58 -36.71 22.84 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-O 120.863 0.363 . . . . 72.41 111.178 179.953 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 23.2 mtm180 -104.78 162.13 13.57 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.146 -0.479 . . . . 74.5 110.889 -179.974 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 24.9 t -135.55 144.82 32.81 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.194 -0.457 . . . . 40.24 111.131 179.944 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 59' ' ' GLU . . . . . . . . . . . . . 3.4 tt0 -112.0 -179.53 3.71 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.217 -0.447 . . . . 64.42 110.864 179.999 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -110.3 155.45 16.09 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.743 -0.741 . . . . 62.53 112.429 -179.909 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 61' ' ' SER . . . . . . . . . . . . . 29.7 t -91.65 149.94 21.39 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.861 0.362 . . . . 52.23 110.834 -179.705 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 37.2 m -126.58 97.35 33.76 Favored Pre-proline 0 C--N 1.328 -0.33 0 CA-C-O 121.667 0.746 . . . . 71.24 110.829 -179.832 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.81 179.99 3.33 Favored 'Trans proline' 0 C--N 1.341 0.181 0 C-N-CA 122.689 2.26 . . . . 61.34 112.337 179.993 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 64' ' ' SER . . . . . 0.426 ' O ' ' HA ' ' A' ' 43' ' ' PHE . 1.1 t -110.7 144.42 39.66 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.214 -0.448 . . . . 63.05 110.817 -179.798 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 65' ' ' LEU . . . . . 0.627 ' O ' HD23 ' A' ' 65' ' ' LEU . 0.0 OUTLIER -112.97 123.39 50.22 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.142 -0.481 . . . . 72.45 110.869 -179.943 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 66' ' ' PHE . . . . . 0.426 ' HA ' ' HB3' ' A' ' 102' ' ' HIS . 15.3 t80 -102.88 110.31 22.18 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.235 -0.439 . . . . 73.22 110.972 179.857 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 67' ' ' VAL . . . . . 0.701 HG12 ' O ' ' A' ' 40' ' ' ARG . 28.0 m -141.16 172.09 11.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.135 -0.484 . . . . 64.0 111.089 -179.93 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 68' ' ' ARG . . . . . 0.483 ' HG2' ' H ' ' A' ' 71' ' ' GLU . 0.9 OUTLIER -104.95 142.19 35.22 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.126 -0.488 . . . . 71.3 110.885 179.989 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 69' ' ' THR . . . . . 0.665 HG22 ' HA2' ' A' ' 99' ' ' GLY . 0.1 OUTLIER -36.03 -69.59 0.1 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.18 -0.464 . . . . 42.41 111.128 -179.91 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 70' ' ' ASP . . . . . 0.463 ' H ' HG23 ' A' ' 69' ' ' THR . 30.9 t70 -44.06 -50.24 8.5 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.183 -0.462 . . . . 73.21 110.922 179.917 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 71' ' ' GLU . . . . . 0.483 ' H ' ' HG2' ' A' ' 68' ' ' ARG . 7.4 tp10 -55.49 -40.69 72.02 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.199 -0.455 . . . . 54.13 110.978 -179.976 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 72' ' ' VAL . . . . . 0.766 ' HA ' HD11 ' A' ' 75' ' ' LEU . 6.1 p -101.09 16.55 4.25 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.244 0 CA-C-N 116.134 -0.485 . . . . 71.41 111.052 179.998 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 73' ' ' ARG . . . . . 0.445 ' N ' ' O ' ' A' ' 69' ' ' THR . 0.6 OUTLIER -103.58 -32.19 9.55 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.18 -0.464 . . . . 72.24 110.87 -179.95 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 74' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -64.57 -23.46 67.28 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.143 -0.481 . . . . 75.32 110.983 -179.936 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 75' ' ' LEU . . . . . 0.766 HD11 ' HA ' ' A' ' 72' ' ' VAL . 0.0 OUTLIER -103.99 -177.56 3.4 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.149 -0.478 . . . . 54.12 110.888 179.968 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 76' ' ' ARG . . . . . . . . . . . . . 33.4 ttt180 -97.35 146.55 25.05 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.162 -0.472 . . . . 75.42 110.85 179.977 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 77' ' ' ARG . . . . . . . . . . . . . 5.6 ptm180 -51.79 154.89 1.87 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.203 -0.453 . . . . 72.23 110.848 -179.919 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 72.46 18.9 78.66 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.734 -0.746 . . . . 32.43 112.538 -179.943 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 58.5 t0 -76.5 115.18 16.01 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.866 0.365 . . . . 63.03 110.81 -179.95 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . 0.715 ' HA ' ' HA ' ' A' ' 89' ' ' TRP . 0.0 OUTLIER -88.15 109.1 19.63 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.148 -0.478 . . . . 75.25 111.197 -179.957 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 81' ' ' LEU . . . . . 0.785 ' C ' ' HA ' ' A' ' 87' ' ' ASN . 0.0 OUTLIER -97.24 134.46 40.51 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.246 -0.433 . . . . 63.42 110.943 179.93 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 82' ' ' THR . . . . . 0.71 ' CA ' ' HA ' ' A' ' 87' ' ' ASN . 5.0 t -92.77 101.36 13.74 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.186 -0.461 . . . . 74.41 111.112 179.981 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 83' ' ' ILE . . . . . 0.782 HD13 ' O ' ' A' ' 83' ' ' ILE . 0.1 OUTLIER -132.99 130.66 58.61 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 116.246 -0.434 . . . . 72.03 111.111 179.938 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 71.97 -57.92 1.41 Allowed Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.721 -0.752 . . . . 74.44 112.502 179.931 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 7.6 tp10 -109.54 -82.37 0.57 Allowed 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.838 0.352 . . . . 71.13 110.893 -179.92 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 86' ' ' GLU . . . . . 0.448 ' C ' ' HA ' ' A' ' 82' ' ' THR . 5.8 mm-40 -151.09 162.02 41.64 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.162 -0.472 . . . . 64.22 110.896 -179.955 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 87' ' ' ASN . . . . . 0.785 ' HA ' ' C ' ' A' ' 81' ' ' LEU . 12.1 p30 -51.43 125.31 14.09 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.14 -0.482 . . . . 73.31 110.9 -179.933 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 88' ' ' PHE . . . . . 0.682 ' HB2' HD22 ' A' ' 105' ' ' LEU . 15.3 m-85 -132.55 118.5 19.3 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.166 -0.47 . . . . 73.2 110.846 -179.958 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 89' ' ' TRP . . . . . 0.715 ' HA ' ' HA ' ' A' ' 80' ' ' THR . 53.9 p-90 -82.62 136.3 34.83 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.12 -0.491 . . . . 74.42 110.91 -179.976 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 90' ' ' VAL . . . . . 0.679 HG21 ' CG1' ' A' ' 93' ' ' VAL . 4.5 p -93.36 139.6 17.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.197 -0.456 . . . . 72.44 111.158 179.915 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 91' ' ' ASP . . . . . 0.412 ' HB2' HD21 ' A' ' 103' ' ' LEU . 0.2 OUTLIER -62.71 -63.77 1.12 Allowed 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.157 -0.474 . . . . 55.33 110.869 179.933 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 92' ' ' ARG . . . . . 0.67 ' O ' HD13 ' A' ' 103' ' ' LEU . 11.5 mtm180 -159.2 123.9 4.06 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.145 -0.479 . . . . 73.13 110.858 -179.869 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 93' ' ' VAL . . . . . 0.679 ' CG1' HG21 ' A' ' 90' ' ' VAL . 18.6 m -123.37 136.01 61.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.155 -0.475 . . . . 73.14 111.086 179.985 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 94' ' ' SER . . . . . . . . . . . . . 21.0 m -136.36 130.45 18.14 Favored Pre-proline 0 C--N 1.33 -0.244 0 CA-C-O 121.618 0.723 . . . . 74.12 110.854 -179.855 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 95' ' ' PRO . . . . . 0.428 ' HB3' ' HA2' ' A' ' 99' ' ' GLY . 53.8 Cg_endo -69.75 155.55 65.7 Favored 'Trans proline' 0 C--O 1.232 0.178 0 C-N-CA 122.667 2.244 . . . . 71.42 112.385 179.931 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 14.1 t0 -117.31 -24.62 7.35 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.198 -0.455 . . . . 54.05 110.914 179.909 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 20.1 t70 -179.77 76.27 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.197 -0.456 . . . . 73.05 110.835 -179.976 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 98' ' ' GLY . . . . . 0.419 ' O ' ' C ' ' A' ' 99' ' ' GLY . . . 103.59 64.93 0.7 Allowed Glycine 0 N--CA 1.452 -0.263 0 C-N-CA 120.701 -0.761 . . . . 24.1 112.504 -179.921 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 99' ' ' GLY . . . . . 0.665 ' HA2' HG22 ' A' ' 69' ' ' THR . . . 36.69 75.18 0.08 OUTLIER Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.79 -0.719 . . . . 55.12 112.434 -179.928 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 3.3 m -119.93 5.96 10.89 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 120.8 0.333 . . . . 71.12 110.845 -179.759 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 101' ' ' CYS . . . . . 0.592 ' HB2' ' HB ' ' A' ' 93' ' ' VAL . 25.4 p -47.3 132.66 12.82 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.144 -0.48 . . . . 62.15 110.939 179.996 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 102' ' ' HIS . . . . . 0.426 ' HB3' ' HA ' ' A' ' 66' ' ' PHE . 1.7 p80 -163.28 130.3 3.45 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.221 -0.445 . . . . 71.22 110.887 -179.968 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 103' ' ' LEU . . . . . 0.67 HD13 ' O ' ' A' ' 92' ' ' ARG . 7.1 tt -147.78 157.1 43.38 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.211 -0.449 . . . . 75.34 110.942 179.978 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 104' ' ' TRP . . . . . 0.509 ' O ' HD23 ' A' ' 103' ' ' LEU . 8.4 m-90 -64.0 110.08 2.02 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.195 -0.457 . . . . 75.31 110.939 179.898 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 105' ' ' LEU . . . . . 0.682 HD22 ' HB2' ' A' ' 88' ' ' PHE . 0.3 OUTLIER -88.75 163.06 15.9 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.231 -0.44 . . . . 63.54 110.922 179.986 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 106' ' ' GLY . . . . . . . . . . . . . . . -92.41 161.37 26.26 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.749 -0.738 . . . . 54.43 112.455 179.956 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 107' ' ' ARG . . . . . 0.606 ' HA ' ' CD1' ' A' ' 88' ' ' PHE . 4.8 ptt180 -68.07 158.57 32.7 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.835 0.35 . . . . 73.31 110.841 -179.832 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -171.49 112.38 0.44 Allowed Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.673 -0.775 . . . . 52.41 112.469 -179.998 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 109' ' ' VAL . . . . . 0.455 HG23 ' HD2' ' A' ' 110' ' ' PRO . 7.2 p -101.3 134.09 20.52 Favored Pre-proline 0 C--N 1.328 -0.332 0 CA-C-O 121.619 0.723 . . . . 71.5 111.157 179.999 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 110' ' ' PRO . . . . . 0.455 ' HD2' HG23 ' A' ' 109' ' ' VAL . 53.7 Cg_endo -69.76 167.89 23.13 Favored 'Trans proline' 0 C--O 1.232 0.199 0 C-N-CA 122.731 2.288 . . . . 64.53 112.321 179.956 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 111' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.76 -8.23 23.08 Favored 'Trans proline' 0 C--N 1.342 0.19 0 C-N-CA 122.717 2.278 . . . . 75.35 112.321 179.912 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -61.94 161.01 11.23 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.262 -0.426 . . . . 62.44 111.064 179.929 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 33.8 t -93.84 127.99 45.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.176 -0.465 . . . . 74.13 111.215 179.934 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 114' ' ' ASN . . . . . . . . . . . . . 6.5 m-20 -127.83 145.79 50.82 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.275 -0.42 . . . . 74.01 110.942 -179.987 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -83.78 103.25 12.92 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.162 -0.472 . . . . 65.15 110.895 -179.986 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 116' ' ' ARG . . . . . . . . . . . . . 19.3 mmt85 -115.34 114.37 25.05 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.15 -0.477 . . . . 71.24 110.799 -179.858 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 117' ' ' ARG . . . . . . . . . . . . . 11.9 ptp180 . . . . . 0 C--N 1.33 -0.277 0 CA-C-N 116.172 -0.467 . . . . 75.34 110.883 -179.966 . . . . . . . . 0 0 . 1 stop_ save_